
<html lang="en"     class="pb-page"  data-request-id="c35ebf69-8c73-4264-83c7-bf01ba4d9f90"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/jm9002395;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2009.52.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach" /></meta><meta name="dc.Creator" content="Rongshi  Li" /></meta><meta name="dc.Creator" content="Alan  Pourpak" /></meta><meta name="dc.Creator" content="Stephan W.  Morris" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 17, 2009" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm9002395" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm9002395" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm9002395" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm9002395" /></link>
        
    
    

<title>Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm9002395" /></meta><meta property="og:title" content="Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm9002395"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm9002395">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm9002395&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm9002395&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm9002395&amp;href=/doi/10.1021/jm9002395" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2009</span><span class="cit-fg-volume">, 52</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 4981-5004</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/52/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm9009229" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rongshi++Li">Rongshi Li</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Pourpak">Alan Pourpak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephan+W.++Morris">Stephan W. Morris</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Departments of Pathology and Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105-3678</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. For R.L.: phone, (813) 745-6485; fax, (813) 745-7264; e-mail, <a href="/cdn-cgi/l/email-protection#e5b78a8b82968d8ccba98ca5888a83838c9191cb8a9782"><span class="__cf_email__" data-cfemail="a0f2cfcec7d3c8c98eecc9e0cdcfc6c6c9d4d48ecfd2c7">[email protected]</span></a>. For S.W.M.: phone, (901) 595-3616; fax, (901) 595-2032; e-mail, <a href="/cdn-cgi/l/email-protection#7f0c0b1a091a5112100d0d160c3f0c0b150a1b1a51100d18"><span class="__cf_email__" data-cfemail="e19295849784cf8c8e93938892a192958b948584cf8e9386">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm9002395&amp;href=/doi/10.1021%2Fjm9002395" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2009</span></span><span class="cit-volume">, 52</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 4981–5004</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 17, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 February 2009</li><li><span class="item_label"><b>Published</b> online</span>17 July 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 August 2009</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm9002395" title="DOI URL">https://doi.org/10.1021/jm9002395</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4981%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRongshi%2BLi%252C%2BAlan%2BPourpak%252C%2BStephan%2BW.%2BMorris%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D52%26issueNum%3D16%26contentID%3Djm9002395%26title%3DInhibition%2Bof%2Bthe%2BInsulin-like%2BGrowth%2BFactor-1%2BReceptor%2B%2528IGF1R%2529%2BTyrosine%2BKinase%2Bas%2Ba%2BNovel%2BCancer%2BTherapy%2BApproach%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5004%26publicationDate%3DAugust%2B2009">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm9002395"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4796</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">79</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm9002395" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rongshi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Pourpak&quot;},{&quot;first_name&quot;:&quot;Stephan&quot;,&quot;last_name&quot;:&quot;W. Morris&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;52&quot;,&quot;pages&quot;:&quot;4981-5004&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm9002395&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9002395&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9002395" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9002395&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9002395" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9002395&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9002395" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm9002395&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9002395&amp;href=/doi/10.1021/jm9002395" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm9002395" /></input><a href="/doi/pdf/10.1021/jm9002395" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm9002395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm9002395%26sid%3Dliteratum%253Aachs%26pmid%3D19610618%26genre%3Darticle%26aulast%3DLi%26date%3D2009%26atitle%3DInhibition%2Bof%2Bthe%2BInsulin-like%2BGrowth%2BFactor-1%2BReceptor%2B%2528IGF1R%2529%2BTyrosine%2BKinase%2Bas%2Ba%2BNovel%2BCancer%2BTherapy%2BApproach%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D52%26issue%3D16%26spage%3D4981%26epage%3D5004%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/52/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The initial experimental evidence for insulin-like growth factor (IGF,<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a><div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: ER, estrogen receptor; HSP90, heat shock protein 90; IC<sub><b>50</b></sub>, inhibitory concentration at 50% control growth; IGF, insulin-like growth factor; IGF1R, insulin-like growth factor 1 receptor; IGFBP, insulin-like growth factor binding protein; IR, insulin receptor; mTOR, mammalian target of rapamycin.</p></div> originally referred to as sulfation factor or somatomedin) bioactivity was demonstrated just over 50 years ago by Salmon and Daughaday.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The genes encoding the ligands insulin-like growth factor-1 and -2 (IGF1, IGF2) as well as insulin, and their receptors, were cloned in the 1980s,<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2-7)</a> and mitogenic activity of IGF1 for breast carcinoma cells was first demonstrated in 1984.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> IGF1R expression was demonstrated on human cancers, and the possibility of therapeutically targeting cellular signaling mediated by the receptor suggested in 1987,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and antitumor activity of an IGF1R-specific antibody was demonstrated only 2 years later in a human breast cancer xenograft mouse model by Arteaga and colleagues.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In the 1990s and during the first half of the current decade, both epidemiological population-based studies, which showed a correlation between circulating IGF1 levels and cancer risk (for example, see ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">11</a>), and laboratory-based research performed by a number of investigators, which showed that IGFs can promote the growth of multiple types of cancer (for example, see refs <a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16">12−16</a>), provided validation for the relevance of IGF signaling in oncogenesis. Since 2000, a number of agents that target IGF1−IGF1R signaling have been shown to possess antitumor activity in preclinical studies (for example, see refs <a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23">17−23</a>), and this research has led to the evaluation currently of more than 10 different drug candidates targeting IGF1 signaling in clinical trials.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Initial results from this expanding clinical trial activity were reported in 2007, with the release of results from phase I trials of IGF1R-antagonistic monoclonal antibodies (for example, see refs <a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29 ref30">25−30</a>), and the clinical development has now progressed to include several phase II trials as well as the recent launch of a phase III trial (the latter with the fully human monoclonal antibody CP-751,871 from Pfizer) for several of these antibodies.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Although antibody-based anti-IGF1 signaling therapeutic development has been in the forefront to date, considerable work has also been undertaken on other modalities as well.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39">(-31-39)</a> In this Perspective, we focus primarily on efforts to design and develop small-molecule IGF1R kinase inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Physiological Functions of the IGF1R</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.a Background Regarding the IGF1R/IGF-1 and IGF-2/IGFBP Signaling Axes</h3><div class="NLM_p">The IGF signaling system comprises two ligands (IGF1 and IGF2), three cellular membrane-spanning receptors (the IGF1 receptor (IGF1R), the insulin receptor (IR), and the IGF2 receptor (IGF2R)), and six high-affinity IGF-binding proteins (IGFBP1−6) (reviewed in detail in refs <a onclick="showRef(event, 'ref31 ref32 ref35 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref35 ref37 ref38 ref39">31, 32, 35, 37−39</a>). The central component of the IGF system and the main focus of this review is the IGF1R, a type 2 tyrosine kinase receptor that shares 60% homology at the amino acid level with the IR.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(-6, 7)</a> The IGF1R is synthesized as a single-chain 1367-amino acid pre-propeptide that possesses a 30-amino acid signal peptide, which is cleaved after translation. This propeptide is then glycosylated, dimerized, and transported to the Golgi apparatus, where it is processed at a furin cleavage site to yield α and β subunits. These subunits form a tetramer (β−α−α−β), linked through disulfide bonds, that is transported to the plasma membrane.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The fully mature cell membrane-bound IGF1R consists of two 130−135 kDa α chains and two 90−95 kDa β chains, with several α−α and α−β disulfide bridges.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The α subunits are entirely extracellular and form the ligand-binding domain,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which binds one ligand molecule.</div><div class="NLM_p">IGF1 and IGF2 share 62% amino acid homology. In addition, there is 40% homology between the IGFs and proinsulin.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> IGF2 concentrations are normally higher than IGF1 levels in both the human fetus and adult sera (5- and 3.5-fold higher, respectively).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Experimental evidence suggests that the binding sites for IGF1 and IGF2 on the IGF1R may be distinct.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> Ligand-binding affinities of IGF1 and IGF2 for the IGF1R have been shown to vary somewhat depending upon cell type and experimental conditions; for example, in cultured adult bovine chromaffin cells, the IGF1R bound the two ligands with identical affinities (<i>K</i><sub>d</sub> ≈ 1 nM) whereas recent experiments using recombinant IGF1R protein in surface plasmon resonance-based studies as well as cell-based assays suggested a difference of 4-fold in affinities, with IGF1 exhibiting a higher affinity (4.45 nM) than IGF2 (17.8 nM).<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> IGF2 and, with a much lower affinity, IGF1 can also bind to a second receptor, IGF2R, which is identical to the cation-independent mannose-6-phosphate receptor and functions as a scavenger receptor.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Furthermore, IGF2 can also bind the insulin receptor subtype A (IR-A) with an affinity similar to that of insulin.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The IR-A (a short isoform of the IR generated by the skipping of exon 11, which encodes for 12 amino acids at the C-terminal end of the IR α subunit) is more mitogenic than the B subtype, the latter possessing a more metabolic function. The IR-A is the predominant form expressed in normal fetal tissues and malignant cells.<a onclick="showRef(event, 'ref50 ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52 ref53 ref54 ref55">(50-55)</a> For example, IR-A increased expression has been described in breast, colon, and lung tumor specimens and on primary cultures and cell lines established from other tumors such as ovarian and thyroid carcinomas.<a onclick="showRef(event, 'ref50 ref51 ref54 ref56'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref54 ref56">(50, 51, 54, 56)</a></div><div class="NLM_p">The complexity of signaling mediated by the IGF system is further complicated by the existence of hybrid heterodimeric receptors in cells consisting of IGF1R and insulin receptor subunits. The basis and full significance of the preferential expression of the IR-A isoform and of IGF1R/IR-A heterodimers in malignant cells are not yet completely clear and are a topic of ongoing investigations.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> However, currently available data do suggest signaling generated from these heterodimeric receptors to be of pathogenic importance; for instance, in the human breast cancer cell line MDA-MB-157, hybrid IGF1R/IR receptors have been shown to undergo autophosphorylation in response to IGF1, and this response exceeds the autophosphorylation of nonhybrid IGF1Rs and promotes increased cellular proliferation, suggesting that hybrid receptors are the major transducers of IGF signaling in these cells.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Clinical data also support a role for these hybrid receptors during carcinogenesis; for example, the expression of hybrid receptors was found to exceed that of nonhybrid IGF1R in over 75% of 39 human breast cancer specimens examined.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Since IGF2 is the predominant IGF in the circulation of adults, it may be that the interaction of IGF2 (rather than IGF1) with hybrid IGF1R/IR-A receptors contributes most substantively to cancer cell growth in such settings. It also seems clear that the ability of insulin to increase the growth of neoplastic cells, an effect noted more than 30 years ago<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> and recently revisited and confirmed by several studies, is mediated at least in part via the activation of IGF1R/IR heterodimers.<a onclick="showRef(event, 'ref60 ref61 ref62 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62 ref63 ref64 ref65">(60-65)</a></div><div class="NLM_p">The IGF1R has also been reported to form heterodimers with the HER2/ERBB2/NEU (hereafter simply HER2) tyrosine kinase and to contribute to the development of resistance to HER2 inhibition with the monoclonal antibody trastuzumab.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The IGF1R physically interacts with HER2 in breast cancer cells that have acquired resistance to trastuzumab but not in parental, trastuzumab-sensitive cells. Stimulation of the IGF1R results in increased phosphorylation of HER2 in resistant (but not parental) cells, and the inhibition of IGF1R kinase activity leads to decreased HER2 phosphorylation in only trastuzumab-resistant cells. Disruption of IGF1R/HER2 heterodimer formation experimentally using the anti-IGF1R antibody α-IR3 dramatically restored the sensitivity of trastuzumab-resistant breast cancer cells to the anti-HER2 antibody, emphasizing the pathophysiologic relevance of the association of the two kinases.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p last">The physiological activities of the IGFs are regulated in part by their physical association with the IGF-binding proteins (IGFBPs), a six-member family of secreted proteins (IGFBP1−6) that bind both IGF1 and IGF2 with high (although varied) affinities.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> The IGFBPs can either potentiate or inhibit IGF function, in part by maintaining a reservoir of IGFs in the circulation (a function mainly of IGFBP3) and by transporting IGFs from the circulation to peripheral tissues (IGFBP1, -2, and -4). In addition, the IGFBPs mediate IGF-independent biological effects that will not be discussed in this review (for a detailed discussion and specific example of this role for the IGFBPs, see refs <a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">67</a> and <a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">69</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.b Signal Transduction Downstream of the IGF1R</h3><div class="NLM_p">Ligand binding and subsequent activation of the IGF1R initiates the propagation of cell survival and proliferative signals through intracellular signaling cascades.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70, 71)</a> An illustration of the major signaling pathways activated by the IGF1R is provided in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>. Activation of these intracellular pathways begins by ligand binding to the extracellular α subunits of the IGF1R.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Ligand binding induces a conformational change and autophosphorylation of the key tyrosine (Y) triplet residues Y1131, Y1135, and Y1136 in the activation loop of the IGF1R, leading to transphosphorylation of the opposing β subunit. The inactive, non-ligand-bound form of the IGF1R sterically hinders the ATP-binding pocket of the kinase catalytic domain, thus preventing ready access of the receptor to ATP.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> The intracellular portion of the β subunit contains other domains critical for receptor activation and subsequent initiation of signaling pathways. After phosphorylation of the key triplet tyrosines in the activation loop, other tyrosine residues in the juxtamembrane region, kinase domain, and carboxy terminus of the β subunits are autophosphorylated, thereby generating docking sites for adaptor proteins that recognize specific sequences containing the phosphorylated tyrosines.<a onclick="showRef(event, 'ref32 ref70'); return false;" href="javascript:void(0);" class="ref ref32 ref70">(32, 70)</a> In addition to the tyrosine residues, mutations in serine (S) residues 1280−1283 (S1283 being phosphorylated during the signaling process) have been shown to abrogate the transforming ability of the IGF1R but still maintain mitogenicity.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> This serine quartet is involved in the activation of ERK1/2, especially in cells that do not express IRS-1.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Major signaling pathways activated by the IGF1R. The RAS/RAF/MEK/ERK and PI3K/AKT pathways are depicted above. The IGF1R is activated by binding of either IGF1 or IGF2. Binding of ligand induces a conformational change and autophosphorylation of key residues in the β subunits of the receptor, and docking proteins then interact with the phosphorylated residues of the activated receptor. Activation of the receptor and transduction of the intracellular signaling kinase cascades culminates in cell proliferation and antiapoptotic effects. Detailed descriptions of the regulation of IGF1R activation and of these signaling pathways can be found in sections <a class="ref internalNav" href="#sec2_1" aria-label=""></a> and <a class="ref internalNav" href="#sec2_2" aria-label=""></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The engagement of the various downstream signaling cascades is mediated through the interactions of the activated IGF1R with adaptor proteins. As an example, phosphorylation of Y950 in the juxtamembrane domain of the IGF1R forms a docking site to recruit and phosphorylate the Src homology 2 domain-containing SHC (for Src homologous and collagen) adaptor protein.<a onclick="showRef(event, 'ref32 ref74'); return false;" href="javascript:void(0);" class="ref ref32 ref74">(32, 74)</a> SHC recruitment and phosphorylation in turn lead to activation of the RAS/RAF/MEK/ERK pathway through recruitment of the adaptor protein growth factor receptor-bound protein 2 (GRB2).<a onclick="showRef(event, 'ref70 ref75'); return false;" href="javascript:void(0);" class="ref ref70 ref75">(70, 75)</a> In addition to SHC, GRB2 can also be recruited by the insulin receptor substrate (IRS)-1, another IGF1R adaptor protein.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Following GRB2 recruitment to the IGF1R, the guanine nucleotide exchange factor Son of Sevenless (SOS) is recruited and aids in the exchange of GDP for GTP on the membrane-bound small GTP-binding protein RAS.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> GTP binding leads to a conformational change of RAS and creates a high-affinity binding site for RAF, leading ultimately to the phosphorylation and activation of the RAF serine/threonine kinase.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Activated RAF in turn phosphorylates the MEK dual-specificity serine/threonine and tyrosine kinases, which then phosphorylate and activate the serine/threonine kinases ERK-1 and ERK-2.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Activation of the ERKs leads to both phosphorylation of cytoplasmic substrates and nuclear translocation and activation of various transcription factors (e.g., c-Myc, Ets factors, CREB, AP1) that control the expression of many genes. Ultimately, this signaling cascade culminates in the generation of proproliferative and antiapoptotic effects in many cell types.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> For example, one of the cytoplasmic substrates of ERK includes procaspase-9, the zymogen form of the proapoptotic caspase-9 protein. The phosphorylation of procaspase-9 at threonine 125 by ERK has been demonstrated to prevent the conformational change of the proenzyme to active caspase-9, thus enhancing cellular survival.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The complexity of these signaling pathways is further amplified by the finding that different isoforms of RAS can preferentially activate different kinase signal transduction cascades. Specifically, it has been reported that Ki-RAS activates the RAS/RAF/MEK/ERK pathway, while Ha-RAS is a more potent activator of the PI3K/AKT pathway.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In addition to the role of RAF in the aforementioned signaling cascade, mitochondrial-associated RAF has been reported to have an antiapoptotic effect, although the precise regulation and overall physiological relevance of the mitochondrial translocation of RAF remain to be fully elucidated.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><div class="NLM_p">The activation of the RAS/RAF/MEK/ERK pathway plays a vital role in the development and progression of cancer, with either RAS or RAF being mutated in a substantial percentage and variety of malignancies.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Inhibition of RAS activation, by interference with its farnesylation and subsequent membrane localization, has been shown to induce cell death in vitro, but pharmacological farnesylation inhibitors have proven to have less than optimal efficacy in clinical cancer trials performed to date.<a onclick="showRef(event, 'ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84">(82-84)</a> By contrast, the inhibition of RAF has been proven to be more promising in the clinic, as exemplified by the RAF kinase inhibitor sorafenib, <b>1</b> (BAY 43-9006, Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals), which has recently been approved for the treatment of patients with certain malignancies such as renal cell and hepatocellular carcinomas.<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85-87)</a> Importantly, recent data suggest that inhibition of the IGF1R (using a human IgG1 monoclonal antibody) potentiates the anticancer activity of pharmacological interference with the RAS/RAF/MEK/ERK pathway. Similarly, abrogation of IGF1R activation appears to potentiate the antitumor efficacy of inhibitors of PI3K/AKT/mTOR pathway signaling (vide infra; see also section <a class="ref internalNav" href="#sec3_2" aria-label=""></a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Therefore, to fully inhibit aberrant activity of these signaling pathways in malignancies, it may be necessary to target both upstream receptor tyrosine kinases, such as the IGF1R, and components within the downstream intracellular signaling cascades.</div><div class="NLM_p last">In addition to the RAS/RAF/MEK/ERK signaling cascade, activation of the IGF1R can engage the PI3K/AKT pathway. Docking of IRS-1 to either phosphorylated Y950 or the Y1131, Y1135, and Y1136 triplet motif of the IGF1R recruits the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K), which then activates its p110 catalytic subunit.<a onclick="showRef(event, 'ref70 ref74 ref76 ref89'); return false;" href="javascript:void(0);" class="ref ref70 ref74 ref76 ref89">(70, 74, 76, 89)</a> Activated PI3K phosphorylates membrane-associated phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP<sub>3</sub>), in turn resulting in membrane localization of phosphatidylinositol-dependent kinase (PDK)-1.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The conversion of PIP<sub>2</sub> to PIP<sub>3</sub> also recruits AKT to the membrane, leading to its phosphorylation and subsequent activation by PDK1 and PDK2.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The AKT serine/threonine kinase itself can phosphorylate a number of targets that ultimately contribute to cellular antiapoptotic and proliferation-enhancing effects.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> For example, the proapoptotic BH3-only BCL2 family member BAD, which can bind and inhibit the antiapoptotic BCL2 family proteins BCL2 and BCL-XL<sub>,</sub> is phosphorylated by AKT.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Phosphorylated BAD is sequestered by binding to 14−3−3 proteins rather than BCL2 and BCL-XL, in turn allowing the two antiapoptotic proteins to efficiently associate with and neutralize other apoptosis-promoting molecules and thus abrogate the prodeath signals.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Activated AKT can also affect cellular metabolism by phosphorylating and inactivating GSK (glycogen synthase kinase)-3β.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The inactivation of GSK-3β promotes the dephosphorylation and activation of glycogen synthase (GS), which up-regulates glycogen synthesis. Activated AKT plays a pivotal role as well in the regulation of translation via phosphorylation and activation of the serine/threonine kinase mammalian target of rapamycin (mTOR).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Activation of mTOR is accomplished by phosphorylation and subsequent inactivation of the GTPase-activating heterodimeric protein tuberous sclerosis complex 1/2 (TSC1/2, also known as hamartin/tuberin, respectively) on TSC2.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93, 94)</a> The inactivation of TSC1/2 relieves inhibition on the RAS-family GTP-binding protein RHEB, which subsequently activates mTOR by antagonizing the endogenous mTOR inhibitor FKBP38.<a onclick="showRef(event, 'ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref95 ref96 ref97">(95-97)</a> Key targets of mTOR affecting protein synthesis are the family of binding proteins termed eIF4E-binding proteins (4E-BPs) and the ribosomal S6 family of kinases (S6K1 and S6K2). The function of 4E-BP is to sequester and inhibit the eukaryotic initiation factor (eIF) 4E.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Phosphorylation of 4E-BP proteins by mTOR causes disassociation from them of eIF4E and allows eIF4E to bind the 5′ cap of mRNA and to cooperate in the formation of the translational initiation complex, thereby enhancing protein translation.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Several groups have demonstrated that eIF4E can function as an oncogene and possesses antiapoptotic capabilities.<a onclick="showRef(event, 'ref92 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref92 ref98 ref99">(92, 98, 99)</a> The S6 kinases are also involved in the formation of the translation initiation complex. Phosphorylation of S6K releases it from eIF3, and S6K is then phosphorylated and fully activated by PDK1.<a onclick="showRef(event, 'ref92 ref100'); return false;" href="javascript:void(0);" class="ref ref92 ref100">(92, 100)</a> The fully activated S6K phosphorylates eIF4B, which then associates with eIF3 in the translation initiation complex.<a onclick="showRef(event, 'ref92 ref100'); return false;" href="javascript:void(0);" class="ref ref92 ref100">(92, 100)</a> Other targets of mTOR play a role in the regulation of protein translation as well, as described in recent reviews.<a onclick="showRef(event, 'ref92 ref101'); return false;" href="javascript:void(0);" class="ref ref92 ref101">(92, 101)</a> Inhibition of mTOR has also been investigated as an attractive target for antitumor agents. Analogues of the mTOR inhibitor rapamycin have demonstrated activity in clinical trials for a number of tumor types, and the first mTOR inhibitor temsirolimus (Wyeth Pharmaceuticals) for clinical use as an anticancer agent was approved by the FDA in 2007 for the treatment of advanced renal cell carcinoma.<a onclick="showRef(event, 'ref102 ref103 ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref102 ref103 ref104 ref105">(102-105)</a> Recent data suggest that the inhibition of mTOR relieves negative feedback regulation of IRS-1, resulting in increased IRS-1 expression and activation of AKT.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This increased AKT activation may lead to decreased sensitivity to mTOR inhibitors, and simultaneous inhibition of the IGF1R and mTOR may be an effective combination for overcoming resistance to mTOR inhibitors (see also section <a class="ref internalNav" href="#sec3_2" aria-label=""></a>).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In addition, recent studies have demonstrated that the combination of mTOR and inhibitors of other receptor tyrosine kinase inhibitors induces synergistic cell death in vitro and in vivo.<a onclick="showRef(event, 'ref107 ref108 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109 ref110">(107-110)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.c Function of IGF1R in Normal Development and Growth and Potential Negative Consequences of Inhibiting IGF1R Function</h3><div class="NLM_p">The IGF axis fulfills critical functions during normal growth and development. Mice with deletion of either the <i>Igf1</i> or <i>Igf1r</i> genes have severe growth abnormalities,<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111, 112)</a> and humans with functional disruption of IGF1 or the IGF1R suffer similar growth abnormalities.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113, 114)</a> Igf1 knockout mice have a complex phenotype, with their birth weight averaging approximately 60% of normal and with some mice dying shortly after birth. In addition, surviving Igf1 knockout mice suffer multiple abnormalities including underdeveloped muscles and lungs, delayed ossification, and infertility. Igf1r knockout mice exhibit even more severe developmental retardation than Igf1-null animals, with death occurring invariably at birth, severe in utero growth retardation with average weights only approximately 45% of normal controls, and multiple organ abnormalities (e.g., hypoplasia, abnormal skin formation, delayed bone development, anomalous central nervous system morphology). As a result of the importance of signaling by the IGF axis during growth and development, it is therefore possible that children and adolescents could have poor growth and perhaps other developmental delays if they were treated with IGF1R inhibitors, especially for prolonged periods. These data also suggest that the administration of IGF1R inhibitors may be contraindicated during pregnancy.</div><div class="NLM_p">While the functional importance of signaling by the IGF1R in the adult is not fully clear, aggressive and extended blockade of signaling by the receptor could potentially produce clinical signs and symptoms similar to those of severe untreated growth hormone deficiency including osteoporosis, hyperlipidemia, visceral adiposity, cardiac events, impaired physical performance, and psychological complaints.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> It might also be expected that inhibition of normal physiologic feedback loops mediated by the IGF1R in the hypothalamus could result in an abnormal increase in growth hormone secretion. The metabolic consequences of excessive growth hormone production in the absence of IGF1R function are unknown, but one might predict that IGF1-independent effects of growth hormone (e.g., lipolysis) could be increased under such circumstances.</div><div class="NLM_p">Specific organ systems could be especially predisposed to toxicities as a result of IGF1R inhibition. For example, on the basis of data generated using genetically engineered mice, it is now established that skeletal expression of IGF1 is critical for differentiative bone cell function, and it may also be essential for the full anabolic effects of parathyroid hormone on trabecular bone and for some aspects of biomineralization.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116, 117)</a> In addition, low circulating levels of IGF1 in people have been associated with decreased bone mineral density (osteoporosis) and increased risk of fractures in various ethnic groups, and osteoblasts from patients with osteoporosis exhibit dysregulated IGF1R signaling.<a onclick="showRef(event, 'ref116 ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref116 ref117 ref118">(116-118)</a> Furthermore, the development and extent of peak bone density during puberty in both mouse and man appear to be highly dependent upon serum IGF1 levels.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Thus, IGF1R inhibition (especially for prolonged periods) may be relatively contraindicated in adolescents during the pubertal growth period or in adult patients with pre-existing severe osteoporosis. IGF signaling also plays important roles in neuronal survival throughout life,<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119, 120)</a> and inhibition of IGF1R function could thus have negative effects on the central and peripheral nervous systems. IGF1 functions in the brain as a pleiotropic factor that promotes the proliferation of oligodendrocytes, myelination, neurite outgrowth, and the survival of neurons and glial cells.<a onclick="showRef(event, 'ref70 ref121'); return false;" href="javascript:void(0);" class="ref ref70 ref121">(70, 121)</a> IGF1 treatment within the initial hours following brain injury has been shown to be beneficial in limiting the extent of pathological apoptosis in experimental animal models of hypoxic/ischemic stoke; for example, ventricular infusion of IGF1 substantially reduced the infarction rate and neuronal loss induced by unilateral hypoperfusion in an adult rat stroke model.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Conversely, one might predict that inhibition of IGF1 signaling via blockade of the IGF1R would potentially increase the severity of ischemic brain injury. As such, a relative contraindication to the administration of IGF1R inhibitors to specific patients might be a history of severe cerebrovascular disease and prior stroke. Similarly, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), Huntington’s disease, and Alzheimer’s disease, which are characterized in part by pathological apoptosis, could potentially be adversely affected by IGF1R inhibition.<a onclick="showRef(event, 'ref70 ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref70 ref122 ref123">(70, 122, 123)</a></div><div class="NLM_p">Signaling by the IGF1R has also been suggested to play a role in cardiac myocyte survival.<a onclick="showRef(event, 'ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref124 ref125">(124, 125)</a> In addition, IGF axis signals participate in the physiological cardiac hypertrophic responses to exercise and play a role as well in the hypertrophic responses to hypertension.<a onclick="showRef(event, 'ref124 ref126 ref127 ref128 ref129 ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref124 ref126 ref127 ref128 ref129 ref130 ref131">(124, 126-131)</a> The importance of IGF axis signals in normal cardiac function has been elegantly demonstrated by recent studies in mice with inactivation of both the insulin and Igf1 receptors in their cardiac and skeletal muscles.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> These double knockout mice suffer early onset dilated cardiomyopathy and lethal heart failure within their first month of life despite having normal glucose homeostasis. Mice lacking the insulin receptor alone showed impaired cardiac performance at 6 months of age, and mice lacking the insulin receptor and one Igf1r allele had slightly increased mortality. In contrast, animals that lacked the Igf1r or the Igf1r plus one insulin receptor allele appeared normal. These data suggest that neither the insulin receptor nor the IGF1R in muscle is essential for normal glucose control, at least during early postnatal life, but signaling by the two receptors (especially the insulin receptor) appears to be essential for normal cardiac function.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Other tyrosine kinases, such as HER2 and ABL, also seem to be critical for normal cardiac function, and down-regulation of signaling by these kinases in cancer patients treated with the HER2 inhibitor trastuzumab or the BCR-ABL inhibitor imatinib, <b>2</b> (STI-571, Novartis), has been associated with heart failure in occasional cases.<a onclick="showRef(event, 'ref133 ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref133 ref134 ref135">(133-135)</a> Signaling by phosphoinositide 3-kinase (p110α) may be a common feature that explains at least in part the cardiac toxicity that can occur following tyrosine kinase inhibitor therapy. PI3K (p110α), which phosphorylates serine/threonine residues on its substrates and is activated by the aforementioned and many other tyrosine kinases, is known to be protective of cardiac function; for example, mice deficient in PI3K (p110α) display accelerated heart failure in response to hypertrophic or dilated cardiomyopathies.<a onclick="showRef(event, 'ref124 ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref124 ref136 ref137">(124, 136, 137)</a> Collectively, these observations suggest that special care regarding cardiac health could possibly be warranted during the clinical use of IGF1R inhibitors, especially in patients with pre-existing cardiac disease and those treated with chemotherapeutic agents known to have heart toxicities associated with them (e.g., doxorubicin).</div><div class="NLM_p last">Adverse effects upon metabolism and homeostasis are also potential negative consequences of inhibition of IGF axis signals. Disruption of Igf1r signaling in mice with tissue-specific deletion of the <i>Igf1</i>, <i>Irs-2</i>, or <i>Igf1r</i> genes has led to some degree of insulin resistance in most model systems examined (reviewed in ref <a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">138</a>). It is not fully certain whether insulin resistance in these animal models is due to growth hormone overproduction or due to an IGF-dependent event. Clearly, however, liver-specific deletion of Igf1 has been shown to cause an insulin resistance phenotype.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Inactivation of the Igf1r, Irs-1, or Irs-2 in pancreatic β cells (the insulin-producing endocrine cells of the pancreas) has been shown to decrease β cell mass and increase apoptotic death of these cells.<a onclick="showRef(event, 'ref140 ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref140 ref141 ref142">(140-142)</a> Insulin resistance, together with possible reductions of β cell numbers and function, as a result of treatment with IGF1R inhibitors could potentially cause clinically evident diabetes. Indeed, hyperglycemia has been encountered in patients occasionally with treatment using IGF1R-specific antibodies, probably as a consequence of insulin resistance induced by high levels of growth hormone (rather than direct inhibiton of the insulin receptor).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Treatment-induced hyperinsulinemia has also been observed.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In addition, because many small-molecule ATP-competitive IGF1R inhibitors discriminate poorly between the IGF1R and the insulin receptor (due to the high homology shared by the catalytic domains of the two kinases), both hyperglycemia and hyperinsulinemia have been observed in preclinical studies using them (for example, see ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">19</a>). It is important to note that such iatrogenic perturbations in glucose/insulin metabolism are likely to be transient and either self-limited or amenable to medical intervention; for example, the most extreme consequences of insulin resistance such as those observed in individuals with leprechaunism associated with insulin receptor mutations (severe insulin-resistant diabetes, acanthosis nigricans, lipodystrophy, hypertrichosis, acral hypertrophy [enlargement of the ears, nose, chin, and fingertips])<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> would not be expected with the intermittent and relatively short-term inhibition associated with therapeutic IGF1R blockade during antitumor therapy.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3 Role of the IGF1R in Oncogenesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.a Clinical and Epidemiological Evidence for IGF1R Signaling in Tumorigenesis</h3><div class="NLM_p">The importance of the IGF signaling axis to cancer development, progression, and metastatic spread cannot be fully appreciated by simple analysis of the expression levels of the IGF1R and its ligands alone. Furthermore, the significance of IGF and IGF1R expression levels as indicators of tumor stage or disease prognosis tends to track in a tumor-specific fashion. Nevertheless, some generalizations are made below.</div><div class="NLM_p">A wide variety of malignancies have been documented to contain increased expression of the IGF1R, IGF1, and/or IGF2 including breast cancers, cancer of the prostate, gastrointestinal tract malignancies (e.g., colorectal, hepatocellular, and pancreatic carcinomas), ovarian and endometrial cancers, glioblastomas, medulloblastomas, and neuroblastomas (see ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a> for a comprehensive review). These reports have suggested a consistent correlation between IGF1/IGF2 expression levels and tumor progression in some malignancies (e.g., colorectal, hepatocellular, and pancreatic) but not others (e.g., breast cancers). In other cases (e.g., gliomas), conflicting results have been reported in different studies. However, considered as a whole, the above-noted studies suggest that the IGF signaling axis can play a paracrine and/or autocrine role in promoting tumor progression but that the role may differ depending on the specific tumor type, as illustrated in more detail below for the two most common malignancies, breast cancer and prostate cancer.</div><div class="NLM_p">In the case of breast cancer, conflicting data exist regarding the clinical and prognostic significance of IGF1R expression. For example, a study of 126 breast cancer specimens showed 39% to be IGF1R-positive. A significant correlation between IGF1R expression and estrogen receptor (ER) status was noted, and the expression of the IGF1R was found to correlate with disease-free survival.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Specifically, this study suggested that patients with ER-negative/IGF1R-positive tumors suffer a worse prognosis compared to patients with ER-negative/IGF1R-negative disease. In a study of 150 breast cancer samples,<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> 47% of the tumors were shown to express increased levels of the IGF1R, and this increased expression was correlated with positive ER and/or progesterone receptor (Pgr) status and lower nuclear grade. In this analysis, breast cancer cases with IGF1R overexpression tended to have a better prognosis than cases without receptor overexpression among hormone receptor-positive tumors (although the difference was not statistically significant; <i>P</i> = 0.09), while IGF1R expression status was not correlated with prognosis in ER-negative and PgR-negative cases. In another study that examined 210 formalin-fixed paraffin-embedded primary breast cancers using immunohistochemistry, IGF1R overexpression was observed in 43.8% of the specimens, but no correlation with prognosis, tumor size, lymph node status, histological grade, hormone receptor status, or HER2 status could be made.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">With respect to prostate cancer as well, conflicting evidence for the role of IGF signaling in disease progression has been published. For example, a 2002 study showed a significant up-regulation of the IGF1R mRNA and protein in primary prostate cancers and bone metastases compared with benign prostatic epithelium.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> By contrast, an earlier study published in 1996 described decreased IGF1R mRNA expression in both high-grade prostatic intraepithelial neoplasia (PIN) and prostate cancer compared to benign tissue, thus implying that IGF1R expression was actually inversely correlated with disease progression.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> In another study in which the expression of IGF1, IGF2, and their receptors was determined in 23 paired benign and neoplastic specimens, no correlation was identified between their expression and tumor grade, stage, perineural invasion, or extraprostatic involvement.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> At least a partial explanation (an explanation that reflects the aforementioned complexity of signaling mediated via the IGF axis) for these conflicting data in prostate cancer has recently been described: among various markers analyzed including serum prostate-specific antigen (PSA), IGF1/PSA ratios, and conventional TNM staging, the ratio of IGFBP3/PSA was identified as the only significant variable for relapse-free survival and was an independent predictor of survival in advanced prostate cancer patients.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> In other malignancies, recent data suggest that more refined analyses of several components of the IGF axis (e.g., IGF1/IGFBP ratios) may better predict disease progression than determination of one factor alone. For example, in bladder cancer, plasma IGF1 and IGFBP3 levels were not significantly different from those found in healthy individuals when compared separately. By contrast, when adjusted for serum IGF1 level, lower preoperative IGFBP3 plasma levels were found to be associated with a higher incidence of lymph node metastases and a poorer clinical outcome in these patients.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div><div class="NLM_p">Most of the data from the epidemiology literature do support a role for the IGF axis in tumor development (reviewed in refs <a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">37−39</a>). For example, an increased risk for the development of multiple malignancies (bladder cancer, premenopausal breast carcinoma, colorectal carcinoma, endometrial cancer, lung cancer, and prostate cancer), presumably through paracrine activation of receptors, has been associated with elevated serum IGF concentrations (i.e., levels in the highest quartile within the normal range) and/or lower levels of serum IGFBPs. Furthermore, an elevated incidence of precancerous colonic adenomas, as well as cervical squamous intraepithelial lesions, has been linked to higher levels of circulating IGF1, supporting a role for the IGF axis in the early stages of carcinogenesis.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(-153, 154)</a> Increased expression of IGF2 due to the loss of imprinting (LOI) also appears to be an epidemiologic risk factor for the development of certain malignancies.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The <i>IGF2</i> gene is normally maternally imprinted in humans, but biallelic expression can occur due to LOI. LOI has been reported in colorectal carcinomas, childhood acute lymphoblastic leukemias, juvenile nasopharyngeal angiofibromas, and Wilm’s tumors. Epidemiologically, LOI of the <i>IGF2</i> gene can be frequently observed in the colonic mucosa of colorectal carcinoma patients and may be an independent risk factor for developing this carcinoma. Interestingly, the same genetic alterations leading to LOI found in cells of the colon are also found in peripheral lymphocytes of colorectal cancer patients, suggesting the possibility of a DNA-based blood test to follow individuals for cancer development.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Mouse modeling of IGF2 LOI and overexpression also implicate a role for IGF2 as a tumor initiator/promoter in intestinal cancers.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><div class="NLM_p last">A number of animal models strongly support a role for aberrant IGF axis signaling in the genesis, progression, and metastasis of cancer (reviewed in ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a>). Arguably, the most compelling support from animal models for a substantive role of signaling mediated by the IGF1R itself in oncogenesis has been provided by human xenograft studies examining the efficacy of receptor inhibition. As an example, Kolb and colleagues studied the activity of a fully human anti-IGF1R neutralizing antibody against a number of pediatric tumor xenografts (including specimens representing rhabdoid tumor, Wilm’s tumor, Ewing’s sarcoma, rhabdomyosarcoma, medulloblastoma, ependymoma, glioblastoma, neuroblastoma, osteosarcoma, and acute lymphoblastic leukemia).<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Although the antibody did not substantively retard the growth of cell lines in vitro, significantly increased event-free survivals were observed in vivo in 20 of 35 (57%) of the solid tumor xenografts with complete responses observed in one Ewing’s sarcoma and two osteosarcoma models. By contrast, little activity was observed against eight different xenografts of acute lymphoblastic leukemia cases. Overall, this study revealed major effects in controlling tumor growth in approximately one-third of the solid tumor xenografts tested (although the objective response rate was modest given the occurrence of only three complete responses, suggesting that rationally designed combinations of IGF1R inhibitors with other anticancer agents is likely to provide optimal treatment efficacy).</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.b Role of the IGF1R in Mediating Resistance to Various Cancer Therapies</h3><div class="NLM_p">Cancers treated with conventional radiotherapy and/or chemotherapy frequently develop resistance to these treatments, ultimately leading to recurrent disease that often has a more aggressive phenotype than that observed at the time of the original diagnosis. Multiple lines of evidence suggest that the IGF signaling axis contributes to the acquisition of tumor resistance to therapy. Several studies, for example, have supported a function for signaling via the IGF1R in the protection of cells from DNA-damaging agents such as ionizing and ultraviolet B irradiation and chemotherapeutic drugs. Mechanistically, this protection involves IGF1R-mediated inhibition of apoptotic cell death via activation of the PI3K/AKT pathway as well as rescue from drug-induced cytostasis through the activation of MAPK pathway signals.<a onclick="showRef(event, 'ref159 ref160 ref161 ref162 ref163 ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref159 ref160 ref161 ref162 ref163 ref164 ref165">(159-165)</a></div><div class="NLM_p">IGF signaling also appears to directly interfere with the normal cell growth arrest and proapoptotic responses triggered by activation of the p53 tumor suppressor upon the treatment of tumor cells with anticancer agents. In cells experimentally subjected to chemically induced DNA damage, the IGF1R has been demonstrated to up-regulate expression of the mRNA encoding the p53 ubiquitin ligase protein MDM2 via activation of p38 MAPK. Under such circumstances, this excess MDM2 protein translocates to the nucleus and facilitates p53 ubiquitination, thus targeting p53 for proteasome-mediated degradation.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><div class="NLM_p">Signaling mediated by the IGF system may also confer a multidrug-resistance (MDR) phenotype to cancer cells by the induction of MDR-related genes including <i>Mdr-1</i> (with increased expression of the p-glycoprotein drug efflux pump encoded by the <i>Mdr-1</i> gene) and manganese superoxide dismutase (MnSOD), a mitochondrial antioxidant enzyme that catalyzes the conversion of toxic superoxide radicals to hydrogen peroxide and molecular oxygen, thus leading to tumor cell protection.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Experiments using a mouse colon cancer cell line revealed that incubation of the cells with IGF1 rendered them significantly less sensitive to cell death associated with cytotoxic agents such as actinomycin D and doxorubicin, and this decreased death was accompanied by concomitant induction of Mdr-1, MnSOD, and c-H-ras gene expression.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">IGF1R signaling has been demonstrated to increase the survival of breast cancer cells treated with 5-fluorouracil, methotrexate, tamoxifen, or camptothecin because of its ability to inhibit apoptosis.<a onclick="showRef(event, 'ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref169 ref170">(169, 170)</a> Conversely, IGF1R inhibition using antibodies or small-molecule kinase inhibitors has been reported to enhance the cytotoxic effects of a number of conventional chemotherapy agents including gemcitabine, irinotecan, etoposide, carboplatin, adriamycin, ifosfamide, navelbine, 5-fluorouracil, and vincristine, both in vitro and in vivo (reviewed in ref <a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">39</a>). IGF1R signaling is also involved in radioresistance, in part by modulating ataxia telangiectasia mutated (ATM) function, which regulates the cellular response to DNA damage induced by radiation by triggering cell cycle arrest and apoptosis as well as DNA repair.<a onclick="showRef(event, 'ref171 ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref171 ref172 ref173">(171-173)</a> Inhibition of IGF1R signaling has been shown to enhance tumor responses to radiation in breast, gastric, colon, and lung cancer models among others,<a onclick="showRef(event, 'ref174 ref175 ref176 ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref174 ref175 ref176 ref177 ref178">(174-178)</a> and down-regulation of IGF1R signals may potentially be a means to render intrinsically radioresistant tumors such as melanoma more sensitive to therapy.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Thus, IGF1R inhibition may be helpful to augment the effectiveness of conventional chemotherapeutic and/or radiation therapies.</div><div class="NLM_p">IGF1R signaling has also been found to correlate with resistance to therapies that target other kinases including the EGFR, HER2, mTOR, and others. Resistance to anti-EGFR therapies has been observed in both preclinical studies (e.g., in pancreas and prostate cancer cell lines) as well as in clinical studies of lung cancer and glioblastoma patients.<a onclick="showRef(event, 'ref179 ref180 ref181 ref182 ref183 ref184 ref185 ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref179 ref180 ref181 ref182 ref183 ref184 ref185 ref186 ref187">(179-187)</a> IGF1R overexpression correlates with decreased effectiveness of EGFR targeting at least in part due to continued activation of PI3K/AKT signaling.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Cancers such as lung tumors appear to remain dependent upon EGFR signals despite the development of resistance to EGFR inhibition.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188, 189)</a> Thus, co-targeting of the IGF1R and EGFR could be a potentially important means to address the problem of anti-EGFR inhibitor resistance. Indeed, bispecific antibodies that inhibit both kinases have been reported to cause more inhibition of tumor growth in preclinical models than predicted with a simple additive effect.<a onclick="showRef(event, 'ref190 ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref190 ref191 ref192">(190-192)</a></div><div class="NLM_p">As mentioned above (section <a class="ref internalNav" href="#sec2_1" aria-label=""></a>), the IGF1R can form heterodimers with the HER2 tyrosine kinase and contribute to the development of resistance to HER2 inhibition with the monoclonal antibody trastuzumab.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Substantial additional preclinical data support a role for IGF1R signaling in mediating resistance of tumors to HER2 inhibition.<a onclick="showRef(event, 'ref193 ref194 ref195 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref193 ref194 ref195 ref196 ref197">(193-197)</a> For example, studies by Chakraborty and co-workers using breast cancer cell lines with variable levels of HER2 and IGF1R expression showed no single receptor-targeting drug to be capable of inducing apoptosis whereas combining antagonists of both receptors resulted in a marked degree of apoptosis even in cells in which one of the receptors was not overexpressed. Specific inhibitors of one of the receptors were shown to cross-inhibit the other (because of coassociation of HER2 and IGF1R in the cells), with targeting of both providing the maximal inhibition of downstream MAP kinase and AKT signaling.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Thus, these and similar data from others suggest that drug combinations that inhibit both IGF1R and HER2 could be useful even in tumors in which single drugs produce minimal antineoplastic effects.<a onclick="showRef(event, 'ref193 ref194 ref195 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref193 ref194 ref195 ref196 ref197">(193-197)</a></div><div class="NLM_p last">IGF1R inhibition may also enhance the efficacy of inhibitors of other kinases such as KIT and mTOR. Martins et al. found IGF1R blockade using the small-molecule inhibitor <b>3</b> (NVP-ADW742, Novartis)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to synergistically augment the cytostatic effects of imatinib (which inhibits an SCF-KIT autocrine loop found in a portion of Ewing sarcomas), effectively abrogating AKT/mTOR phosphorylation and reducing VEGF expression especially in Ewing’s tumor cell lines with high IGF1R activation levels. The combination of <b>3</b> with <b>2</b> was associated with a significant reduction in tumor cell growth and increased apoptosis that correlated with the extent of IGF1R activation of the lines.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Importantly, the antitumor effectiveness of mTOR inhibitors such as rapamycin, temsirolimus, everolimus, and others has recently been suggested to be compromised by an induction of PI3K/AKT phosphorylation/activation caused by up-regulation of IGF1R-mediated signaling,<a onclick="showRef(event, 'ref106 ref199 ref200 ref201'); return false;" href="javascript:void(0);" class="ref ref106 ref199 ref200 ref201">(106, 199-201)</a> although one study has suggested that this diminished effectiveness of mTOR inhibition may also occur independent of IGF1R signaling in at least some contexts.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> This enhanced IGF1R signaling has been attributed to autocrine growth loops involving IGF1 as well as increased association of the IRS-1 substrate with the IGF1R and decreased IRS-1 protein degradation. Preclinical studies indicate that IGF1R inhibition prevents the induction of PI3K/AKT by mTOR inhibitors, thus sensitizing tumor cells for growth inhibition and death and providing a strong rationale for the combination of IGF1R and mTOR inhibitors in the clinic.<a onclick="showRef(event, 'ref106 ref199 ref200 ref201'); return false;" href="javascript:void(0);" class="ref ref106 ref199 ref200 ref201">(106, 199-201)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">4 Inhibition of the IGF1R by Small Molecules</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16058" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16058" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Diverse human diseases including cancer,<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> inflammatory conditions,<a onclick="showRef(event, 'ref204 ref205'); return false;" href="javascript:void(0);" class="ref ref204 ref205">(204, 205)</a> diabetes,<a onclick="showRef(event, 'ref206 ref207'); return false;" href="javascript:void(0);" class="ref ref206 ref207">(206, 207)</a> and Alzheimer’s disease<a onclick="showRef(event, 'ref208 ref209 ref210'); return false;" href="javascript:void(0);" class="ref ref208 ref209 ref210">(208-210)</a> have become important indications for kinase-targeted drug discovery and development. Since the 2001 FDA approval of the kinase inhibitor <b>2</b>,<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> for the treatment of chronic myeloid leukemia, the widely held notion within the pharmaceutical industry that selective kinase inhibition was impossible to achieve was dispelled. By February 2009, despite the challenges in identification of novel and selective kinase inhibitors against a family of 518 proteins, pharmaceutical research and development efforts had already resulted in seven additional launched small-molecule inhibitor products for targeted cancer therapy, validating the protein kinases as a highly meaningful and tractable class of drug targets for therapeutic intervention. Gefitinib (<b>4</b>, AstraZeneca),<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> erlotinib (<b>5</b>, Genentech/OSI),<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> sorafenib (<b>1</b>, Bayer/Onyx),<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> sunitinib (<b>6</b>, Pfizer),<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> dasatinib (<b>7</b>, Bristol-Myers Squibb),<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> lapatinib (<b>8</b>, GlaxoSmithKline),<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> and nilotinib (<b>9</b>, Novartis)<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) have already brought substantial clinical benefit to patients with various types of cancers. Moreover, there are approximately over 100 protein kinase inhibitors currently at various stages of clinical investigation.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Protein kinases comprise the largest enzyme family, being encoded by 1.7% of the genes in the human genome.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> The vast majority of reported kinase inhibitors bind to the highly conserved catalytic domain essential for kinase activity, competing with ATP for association with the ATP-binding pocket. As a result, selectivity is a crucial issue in the design of these inhibitors as potential drugs.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of kinase inhibitors approved for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the background provided above, the complexity of the IGF signaling system and the challenges this complexity poses to the discovery and development of selective IGF1R inhibitors have been reviewed recently by others as well.<a onclick="showRef(event, 'ref35 ref220 ref221 ref222 ref223 ref224'); return false;" href="javascript:void(0);" class="ref ref35 ref220 ref221 ref222 ref223 ref224">(35, 220-224)</a> Further, Sarma and colleagues have summarized the patent literature from 2000 to early 2006 regarding the development of small-molecule inhibitors of the IGF1R.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> In addition, ongoing clinical trials for IGF1R-targeted therapeutics in cancer were recently discussed by Ryan and colleagues.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In the following text, we attempt to provide a comprehensive review and update of both the biomedical and patent literature concerning the current state of IGF1R small-molecule inhibitor development.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.a ATP-Competitive Inhibitors</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">4.a.i Tyrphostins</h4><div class="NLM_p">The tyrphostins are derived from a benzylidene malononitrile scaffold and were first reported as kinase inhibitors and potential antiproliferative agents in the late 1980s and early 1990s.<a onclick="showRef(event, 'ref226 ref227 ref228 ref229 ref230'); return false;" href="javascript:void(0);" class="ref ref226 ref227 ref228 ref229 ref230">(226-230)</a> Subsequently in 1997, compounds from this series of kinase inhibitors were shown to possess inhibitory effects on IGF1R and insulin receptor-stimulated cellular proliferation of NIH-3T3 fibroblasts overexpressing either receptor and to inhibit ligand-stimulated receptor autophosphorylation and tyrosine kinase activity toward exogenous substrates.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> Among the tyrphostins tested, <b>10</b> (AG1024) and <b>11</b> (AG1034) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) showed significant selectivity against the IGF1R compared to the insulin receptor.<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> It was recognized early that a potential liability of different tyrphostins was their inhibition of a variety of non-kinase enzymes. For instance, <b>12</b> (AG82), an analogue of compounds <b>10</b> and <b>11</b> in which the <i>tert-</i>butyl group of R2 in compound <b>11</b> is replaced with a hydroxyl, demonstrates inhibitory activity on guanylyl and adenylyl cyclases.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> Studies of tyrophostins have yielded valuable information regarding the goal of achieving selective inhibition of closely related kinases. For example, 3D-QSAR studies of 50 benzylidene malonitrile tyrphostins as inhibitors of the EGFR and the homologous HER2 kinase revealed that subtle chemical differences could markedly alter kinase selectivity. Representative of these studies, <b>13</b> was shown to be about 100-fold more selective against the EGFR compared to HER2 while <b>14</b> was demonstrated to be almost 1000-fold selective against HER2 compared to the EGFR.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> To date, the tyrphostins have served mainly as molecular tools for studying protein kinase inhibition and providing proof-of-principle concepts for the potential therapeutic feasibility of this approach.<a onclick="showRef(event, 'ref234 ref235'); return false;" href="javascript:void(0);" class="ref ref234 ref235">(234, 235)</a></div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of ATP-competitive inhibitors (I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">4.a.ii Pyrrolopyrimidines and Pyrazolopyrimidines</h4><div class="NLM_p">Selected pyrrolo[2,3-<i>d</i>]pyrimidines were recently disclosed as novel, potent, and selective inhibitors of the IGF1R kinase.<a onclick="showRef(event, 'ref17 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref22">(17, 22)</a> The general structure of this series is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> as represented by <b>3</b>. Warshamana-Greene and colleagues showed compound <b>3</b> to be a potent and selective IGF1R kinase inhibitor that could efficiently inhibit the growth of cells that are highly dependent on IGF1 signaling such as certain small-cell lung cancer (SCLC) derived lines.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> In addition, synergistic antitumor responses were observed in other SCLC cell lines that possess autocrine growth loops involving stem cell factor (SCF) and the SCF/KIT receptor tyrosine kinase when they were treated with the combination of <b>3</b> and an inhibitor of KIT such as <b>2</b>, a finding consistent with previous data suggesting that IGF1R-mediated signaling could protect such cells from apoptosis induced by KIT receptor inhibition.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> Cellular kinase activity assays demonstrated <b>3</b> to be a >16-fold more potent inhibitor against the IGF1R than the IR (cellular IC<sub>50</sub> values of 0.17 and 2.8 μM, respectively)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> even though the amino acid sequence identity between the IGF1R and IR kinase domains is high (84%)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and the ATP-binding site homology is close to 100%.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> In addition, compound <b>3</b> was shown to have much higher IC<sub>50</sub> values against other kinases (e.g., >10 μM for HER2, PDGFR, VEGFR2, or BCR-ABL p210 and >5 μM for c-KIT).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In these studies, reported by Mitsiades and colleagues, the effect of <b>3</b> on the viability of 58 hematologic and solid tumor cell lines was assayed, with multiple myeloma lines being the most sensitive to the compound. Furthermore, <b>3</b> inhibited multiple myeloma cell growth and enhanced the survival of tumor-bearing mice and, when combined with the alkylating agent melphalan at a subtherapeutic dose, the two compounds synergistically reduced tumor burden. Compound <b>3</b> also inhibited the proliferation of Ewing’s sarcoma cell lines alone and in combination with imatinib, vincristine, or doxorubicin.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><div class="NLM_p">Closely related to compound <b>3</b>, <b>15</b> (NVP-AEW541, Novartis, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) achieved 27-fold cellular selectivity against IGF1R over the IR (IC<sub>50</sub> of 0.086 and 2.3 μM, respectively) even though the in vitro inhibitory activity against both of the kinases was equally potent (IC<sub>50</sub> of 0.15 and 0.14 μM, respectively). The reason for this unique cellular selectivity was not determined in this report, but the suggestion is that there are conformational differences between the native forms of the two receptor tyrosine kinases that are not present in the recombinant kinase domains used for in vitro kinase assays.<a onclick="showRef(event, 'ref17 ref238'); return false;" href="javascript:void(0);" class="ref ref17 ref238">(17, 238)</a> Cellular selectivity over other kinases was at least 50- or 100-fold higher (e.g., >10 μM for HER1 (EGFR), PDGFR, or BCR-ABL p210 and >5 μM for c-KIT).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Compound <b>15</b> was also subsequently shown to possess significant in vitro and in vivo antiproliferative activity in neuroblastoma cancer cell lines.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> In the same study, compound <b>15</b> also inhibited angiogenesis in vivo, presumptively because of the down-regulation of <i>VEGF</i> mRNA, and decreased tumor invasiveness in vivo and in vitro.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> Similarly, compound <b>15</b> inhibited the migration, metastasis, and angiogenesis associated with the growth of Ewing’s sarcoma cancer cell lines.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> Recently, the anticancer activity of compound <b>15</b> has also been described in several other cancer types, including hematologic malignancies and pancreatic cancer.<a onclick="showRef(event, 'ref241 ref242 ref243 ref244'); return false;" href="javascript:void(0);" class="ref ref241 ref242 ref243 ref244">(241-244)</a></div><div class="NLM_p">A high-throughput screen of Abbott’s compound repository discovered a pyrazolo[3,4-<i>d</i>]pyrimidine class of compounds (which contain insertion of a nitrogen atom at the 2-position of the NVP-ADW series, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) as moderately potent IGF1R inhibitors.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> Optimization of this series led to the discovery of a compound demonstrating in vivo IGF1R inhibitory activity after oral administration.</div><div class="NLM_p">A series of pyrrolopyrimidines with different substitution patterns from the Novartis series (vide supra) has also been designed and synthesized.<a onclick="showRef(event, 'ref245'); return false;" href="javascript:void(0);" class="ref ref245">(245)</a> As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, <b>16</b> and <b>17</b> demonstrated modest activity against IGF1R with a slight selectivity over the IR. On the basis of the general pharmacophore model and molecular modeling, two binding modes to the active site by these molecules were proposed.<a onclick="showRef(event, 'ref245 ref246'); return false;" href="javascript:void(0);" class="ref ref245 ref246">(245, 246)</a></div><div class="NLM_p last">4,6-Bis-anilinopyrrolopyrimidines from GSK have been reported recently.<a onclick="showRef(event, 'ref247 ref248 ref249'); return false;" href="javascript:void(0);" class="ref ref247 ref248 ref249">(247-249)</a> In that series, substitutions varied at both the 4- and 6-positions while there was no substituent at the 2-position (refer to Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for positions). The most potent compounds exhibited single-digit nanomolar IC<sub>50</sub> values against the IGF1R with 1000-fold selectivity over JNK1 and JNK3.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> A further optimization of the series yielded both potent and acid-stable inhibitors.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> The optimized compounds demonstrated nanomolar potencies in both enzymatic and cellular assays as well as promising in vivo pharmacokinetics in the rat.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">4.a.iii Benzimidazole-pyridones</h4><div class="NLM_p">Another chemotype of IGF1R inhibitors was disclosed by Bristol-Myers Squibb.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, the initial “hit” <b>18</b> was identified as an ATP-competitive inhibitor of the IGF1R kinase with an in vitro IC<sub>50</sub> of 3.5 μM.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Cocrystallization of <b>18</b> with a truncated IGF1R containing the kinase domain confirmed that the inhibitor bound in the ATP binding site.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Further scrutinization of the crystallographic information revealed potential new interactions to explore via the 4-position of the pyridone ring and the benzimidazole methyl group, leading to a key breakthrough after a focused study of the SAR that yielded a <b>19</b> in vitro IC<sub>50</sub> of 180 nM.<a onclick="showRef(event, 'ref250 ref251 ref252'); return false;" href="javascript:void(0);" class="ref ref250 ref251 ref252">(250-252)</a> In order to improve the cytochrome P450 profile of compound <b>19</b>, the pendent imidazole moiety was replaced by imidazole bioisosteres including amides, amidines, imidazolines, and saturated and unsaturated heterocycles. The morpholine group substitution yielded <b>20</b> (BMS-536924) and <b>21</b>, which are enantiomers of each other, that both possessed low inhibitory activity toward a panel of cytochrome P450 enzymes.<a onclick="showRef(event, 'ref250 ref253'); return false;" href="javascript:void(0);" class="ref ref250 ref253">(250, 253)</a> The difference in potency between the enantiomers was about 8-fold, as the <i>S</i>-OH isomer <b>20</b> showed an IC<sub>50</sub> of 100 nM and the <i>R</i>-OH isomer <b>21</b> had an IC<sub>50</sub> of 830 nM.<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> Further optimization resulted in <b>22</b> (BMS-554417) that had an in vitro IC<sub>50</sub> of 67.9 nM against IGF1R.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The only structural difference between <b>20</b> and <b>22</b> is the R1 pendant (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Both BMS compounds demonstrated very similar kinase selectivity and cellular activity against several kinases and tumor cell lines, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.<a onclick="showRef(event, 'ref19 ref250'); return false;" href="javascript:void(0);" class="ref ref19 ref250">(19, 250)</a> To address issues of CYP3A4 inhibition, poor aqueous solubility, and high plasma protein binding of compound <b>20</b>, <b>23</b> (BMS-695735) was synthesized and reported to exhibit improved ADME properties, a low risk for drug−drug interactions, and in vivo efficacy in several xenograft models.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzyme and Cellular Activity of <b>20</b>−<b>23</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="center"> </th><th class="colsep1" colspan="3" align="center" char=".">enzyme or cellular activity, IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="rowsep1"><th class="rowsep1" align="center"> </th><th class="rowsep1" align="center" char="."><b>20</b> (BMS-536924)<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a></th><th class="rowsep1" align="center" char="."><b>22</b> (BMS-554417)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></th><th class="rowsep1" align="center" char="."><b>23</b> (BMS-695735)<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a></th></tr></thead><tbody><tr valign="top"><td align="left">IGF1R</td><td align="char" char=".">100</td><td align="char" char=".">68</td><td align="char" char=".">34</td></tr><tr valign="top"><td align="left">IR</td><td align="char" char=".">73</td><td align="char" char=".">51</td><td align="char" char=".">72</td></tr><tr valign="top"><td align="left">FAK</td><td align="char" char=".">150</td><td align="char" char=".">94</td><td align="char" char=".">165</td></tr><tr valign="top"><td align="left">MEK</td><td align="char" char=".">182</td><td align="char" char=".">356</td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">Lck</td><td align="char" char=".">341</td><td align="char" char=".">>1500</td><td align="char" char=".">140</td></tr><tr valign="top"><td align="left">RD-1 (sarcoma)</td><td align="char" char=".">202</td><td align="char" char=".">146</td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">MDA PCa-2b  (prostate)</td><td align="char" char=".">194</td><td align="char" char=".">188</td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">Colo205 (colon)</td><td align="char" char=".">212</td><td align="char" char=".">120</td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">MCF-7 (breast)</td><td align="char" char=".">460</td><td align="char" char=".">234</td><td align="char" char="."> </td></tr></tbody></table></div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">4.a.iv Imidazopyrazines</h4><div class="NLM_p">A novel 6/5 heteroaryl scaffold containing key pharmacophoric donor/acceptor interactions with the kinase hinge region was reported recently by OSI Pharmaceuticals.<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> Additional advantages of the imidazo[1,5-<i>a</i>]pyrazine core over the conventional pyrrolo[2,3-<i>d</i>]pyrimidine scaffold included a slightly lower polar surface area (PSA), log <i>P</i>, and log <i>D</i>; higher basicity for potentially greater hinge-binding affinity; improved predicted solubilities; and stable attachment of both carbon and heteroatoms to C3 directly or with a methylene linker.<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, <b>24</b> was found to have a biochemical IC<sub>50</sub> value of 0.606 μM. It was discovered that, in general, a 3-substitution in aromatic ring A is preferred over a 4-substitution, in terms of activity. Studies have shown that the 8-NH<sub>2</sub> and N<sub>7</sub> nitrogens of the imidazopyrazine core are involved in a conventional hinge-binding interaction with the protein, and the C3 groups project toward the P-loop, a solvent-exposed region of the protein as suggested by structural hypotheses from IGF1R models. Although the difference in biochemical activity against IGF1R between C3-cyclohexyl of <b>25</b> and C3-cyclobutyl of <b>24</b> is 6-fold, there is only about a 2-fold difference in cellular activity for <b>26</b> and <b>27</b>. <b>28</b> and <b>29</b> demonstrated approximately a 2-fold difference in both their biochemical and cellular activity with amide and free amine functionality, respectively. Both compounds <b>28</b> and <b>29</b> were orally bioavailable with the major pharmacokinetic parameters being performed in mice.<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a> Compound <b>29</b> demonstrated selectivity against the IGF1R over 15 other protein kinases (ABL, CDK2/cyclin A, CDK2/cyclin E, CHK2, CK2, c-RAF, Fes, IKK-β, MAPK2, p70S6K, PDGFR-β, PDK1, PKA, PKAα, and PKCα).<a onclick="showRef(event, 'ref255'); return false;" href="javascript:void(0);" class="ref ref255">(255)</a></div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of ATP-competitive inhibitors (II).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Through structure-based design efforts utilizing IGF1R and IR cocrystal structures, the benzyloxyphenyl substituent was replaced with a bioactive, conformationally constrained 2-phenylquinolinyl moiety, resulting in a 10-fold increase in cellular potency. As a result, <b>30</b> (OSI-906, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) proved to be a potent, selective, and orally bioavailable IGF1R inhibitor.<a onclick="showRef(event, 'ref256'); return false;" href="javascript:void(0);" class="ref ref256">(256)</a><b>31</b> (PQIP, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), an analogue of compound <b>30</b> bearing a methylpiperazine side chain, displayed a cellular IC<sub>50</sub> of 19 nM for the IGF1R with 14-fold selectivity over the IR. This compound showed minimal activity against a panel of 32 other protein kinases, and it abolished the ligand-induced activation of downstream phosphorylated AKT and ERK1/2 in a cell line engineered to exogenously express IGF1R cell line and endogenous IGF1R in the GEO human colorectal cancer line.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Most recently, Wu and colleagues reported the crystal structure of the tyrosine kinase domain of IGF1R complexed with compound <b>31</b>.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> This structure revealed that compound <b>31</b> interacts with residues in the ATP-binding pocket and in the activation loop, which confers specificity for the IGF1R and the IR.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a><b>32</b> (AQIP) was reported to exhibit strong cellular potency against IGF1R (IC<sub>50</sub> of 20 nM) with 5-fold IR selectivity and to exhibit minimal inhibition against a panel of 28 other kinases in assays performed at ATP concentrations approximating their respective <i>K</i><sub>m</sub> values. Once-per-day oral dosing of <b>32</b> in mouse xenograft efficacy studies led to tumor growth inhibition at a 25 mg/kg dose and tumor regression at a 75 mg/kg dosing level.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">4.a.v Pyrazolotetrahydropyridines and Pyrrolopyrazoles</h4><div class="NLM_p">A series of pyrazolotetrahydropyridines was recently patented as IGF1R inhibitors.<a onclick="showRef(event, 'ref259 ref260 ref261'); return false;" href="javascript:void(0);" class="ref ref259 ref260 ref261">(259-261)</a> As a representative of this series, <b>33</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) inhibited the IGF1R and IGF1R-induced S6 kinase phosphorylation with IC<sub>50</sub> values of 0.34 and 3.05 μM, respectively.<a onclick="showRef(event, 'ref259'); return false;" href="javascript:void(0);" class="ref ref259">(259)</a> Incorporation of pyrolecarboxamide in the phenyl ring affording <b>34</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) led to a 7-fold improvement of potency in a biochemical assay against IGF1R (IC<sub>50</sub> = 0.049 μM). Compound <b>34</b> also demonstrated a cellular IC<sub>50</sub> value of 0.08 μM.<a onclick="showRef(event, 'ref260'); return false;" href="javascript:void(0);" class="ref ref260">(260)</a></div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of ATP-competitive inhibitors (III).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The five-member ring analogues <b>35</b> and <b>36</b>, created by the same research group, led to the pyrrolopyrazoles. Compound <b>35</b> was reported to have an inhibitory activity against IGF1R similar to compound <b>33</b>.<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> Modifications on <b>33</b> included the change from six-member to five-member ring, removal of a sulfonamide, masking of the pyrazole nitrogen with carbamate, and the addition of a solubilizing group to the phenyl ring. Further modification of <b>35</b> yielded compound <b>36</b>, which had IC<sub>50</sub> values of 0.09 μM in a biochemical assay against IGF1R and 0.30 μM in a cell-based assay.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">4.a.vi Epigallocatechin 3-Gallate</h4><div class="NLM_p last">It has been reported recently that the tea polyphenol <b>37</b> (EGCG, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) is a small-molecule inhibitor of the IGF1R with an IC<sub>50</sub> of 14 μM.<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a> A possible mechanism of action of compound <b>37</b> proposed that the compound may fit into the ATP-binding pocket through hydrogen-bonding interactions with residues Gln977, Lys1003, Met1052, Thr1053, and Asp1123, as suggested by a molecular modeling study. It was reported that compound <b>37</b> abrogates anchorage-independent growth induced by IGF1R overexpression and activation, including growth of the human MCF7 breast and HeLa cervical cancer cell lines, through inhibition of IGF1R downstream signaling.<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a></div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">4.a.vii Pyrrolecarboxaldehydes</h4><div class="NLM_p last">Another class of IGF1R inhibitors discovered has been a pyrrole-5-carboxaldehyde series.<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a> As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, <b>38</b> and <b>39</b> demonstrated inhibitory activity through ATP competition, forming a reversible, covalent adduct between the aldehyde moiety and a lysine residue within the IGF1R ATP-binding pocket. Crystal structure analysis confirmed the modification of the active site lysine side chain and revealed details of the key interactions between the inhibitor and enzyme. These compounds show modest selectivity for inhibition of IGF1R over the IR.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">4.a.viii Cyanoquinolines</h4><div class="NLM_p last">In early 2009, Miller et al. from Wyeth disclosed a series of 3-cyanoquinolines as low nanomolar inhibitors of IGF1R.<a onclick="showRef(event, 'ref264'); return false;" href="javascript:void(0);" class="ref ref264">(264)</a> This series originated from Wyeth’s in-house high-throughput screening and was optimized on the basis of input from structural biology and data mining. The strategies, syntheses, and SARs of the cyanoquinolines were discussed in this report. These cyanoquinoline compounds had better potency overall than a previously reported series of isoquinolinedione inhibitors of the IGF1R reported by Wyeth as potential anticancer agents,<a onclick="showRef(event, 'ref265'); return false;" href="javascript:void(0);" class="ref ref265">(265)</a> but neither series showed selectivity for the IGF1R relative to the IR.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.b ATP-Noncompetitive Inhibitors</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">4.b.i Picropodophyllin</h4><div class="NLM_p">A class of compounds called cyclolignans has been found to interfere with autophosphorylation of the IGF1R. This inhibition does not involve competition with ATP and has been suggested to occur at the substrate level.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> One of these cyclolignan compounds, <b>40</b> (PPP, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), was shown to induce apoptosis in cultured IGF1R-positive tumor cells and to cause complete tumor regression in mice bearing several different xenografted human tumor cell lines (e.g., ES-1 Ewing’s sarcoma cells, BE malignant melanoma cells, and PC3 prostate carcinoma cells). Importantly, compound <b>40</b> does not appear to affect insulin receptor function and thus would not be expected to cause iatrogenic diabetes. Unlike ATP-competitive small-molecule kinase inhibitors, <b>40</b> has been suggested to cause only minimal resistance in tumor cells exposed to the agent.<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a> In addition, <b>40</b> down-regulates the receptor protein (but not several other receptor tyrosine kinases including the IR, VEGFR, EGFR, KIT, PDGFRα, or PDGFRβ).<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> Strategies that lead not only to inhibition of the tyrosine kinase activity but also to down-regulation of the IGF1R (such as many antibody-based therapies) have typically been associated with the strongest antitumor effects.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a></div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of ATP-noncompetitive or “mechanism unknown” inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">4.b.ii <b>41</b> (AG538)</h4><div class="NLM_p last">Another series of ATP-noncompetitive inhibitors is represented by <b>41</b> in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. Compound <b>41</b> belongs to the tyrphostin group of compounds with catechol functionality on both sides of the molecule and has an IC<sub>50</sub> against IGF1R of 61 nM in a cell-free kinase assay.<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> To circumvent the sensitivity of catechol rings to oxidation, a series of <b>41</b> analogues with catechol bioisosteres have been synthesized.<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a> Studies showed that these metabolically more stable <b>41</b> bioisosteres possessed biological properties similar to those of <b>41</b> and inhibited IGF1R by a substrate-competitive mechanism with inhibitory activity in the submicromolar concentration range in cell-free assays and low micromolar concentration in intact cells.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">4.b.iii <b>42</b> (SBL02)</h4><div class="NLM_p last">A series of secondary or tertiary amines branched out with at least one catechol ring has been identified as ATP noncompetitive IGF1R inhibitors.<a onclick="showRef(event, 'ref272'); return false;" href="javascript:void(0);" class="ref ref272">(272)</a> Within the combinatorial chemical libraries synthesized, one of most potent compounds, <b>42</b> shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, demonstrated inhibitory activity against the IGF1R with an IC<sub>50</sub> of 170 nM in a cell-free kinase assay. Compound <b>42</b> was found to inhibit IGF1R autophosphorylation and substrate phosphorylation at the low micromolar range in cellular assays.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.c Miscellaneous</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">4.c.i Diarylureas</h4><div class="NLM_p last">After screening of a chemical library against the IGF1R in the human MCF7 breast cancer cell line, <b>43</b> (PQ401, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) was identified as a potent inhibitor of IGF1R signaling.<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> Although the mechanism of kinase inhibition has not been elucidated, compound <b>43</b> might act as an indirect inhibitor of ATP binding, similar to heterocyclic urea inhibitors of the p38 mitogen-activated protein serine−threonine kinase.<a onclick="showRef(event, 'ref274 ref275'); return false;" href="javascript:void(0);" class="ref ref274 ref275">(274, 275)</a> Compound <b>43</b> inhibited autophosphorylation of the IGF1R in cultured human MCF7 cells with an IC<sub>50</sub> of 12 μM and autophosphorylation of the isolated kinase domain of the IGF1R with IC<sub>50</sub> < 1 μM.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">4.c.ii Lapatinib</h4><div class="NLM_p last">The dual EGFR/HER2 kinase inhibitor <b>8</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) was approved to treat metastatic HER2-positive breast cancer that has progressed following standard therapy, to be used in combination with capectabine (Roche), in March 2007 by the FDA.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Recently, compound <b>8</b> was reported to also inhibit some of the functional consequences of IGF1R signaling, an effect thought to contribute to its ability to induce apoptosis in trastuzumab-resistant breast cancer cells.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> This study showed that compound <b>8</b> induces apoptosis in HER2-overexpressing breast cancer cells that are either naive or refractory to trastuzumab. In addition to blocking HER2 and EGFR signaling, <b>8</b> reduced IGF1R signaling in HER2-overexpressing breast cancer cells, and co-treatment with an IGF1R-targeted antibody increased <b>8</b>-mediated growth inhibition yet further. It is important to emphasize that lapatinib is very selective for EGFR and HER2 and does not directly inhibit the IGF1R.<a onclick="showRef(event, 'ref277'); return false;" href="javascript:void(0);" class="ref ref277">(277)</a> Rather, these effects occur because of inhibition of EGFR/HER2 signaling, which can undergo cross-talk with the IGF1R.<a onclick="showRef(event, 'ref278 ref279'); return false;" href="javascript:void(0);" class="ref ref278 ref279">(278, 279)</a> These results help to explain the mechanisms that enable compound <b>8</b> to be an effective therapy in trastuzumab-resistant cancers and suggest that <b>8</b>-mediated cytotoxicity may be due in part to its indirect effects on the IGF1 signaling pathway.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">4.c.iii <b>44</b> (NDGA)</h4><div class="NLM_p last">It has recently been reported that nordihydroguaiaretic acid <b>44</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), a naturally occurring compound isolated from creosote bush (<i>Larrea divaricata</i>), inhibits IGF1R and HER2 kinase activity.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a> Compound <b>44</b> inhibited IGF1R kinase activity at an IC<sub>50</sub> of 0.9 μM and also inhibited lipoxygenase activity at an IC<sub>50</sub> of 3.8 μM.<a onclick="showRef(event, 'ref281'); return false;" href="javascript:void(0);" class="ref ref281">(281)</a> Analogues of <b>44</b> with increased specificity for IGF1R over lipoxygenase have been described. It is currently unknown whether <b>44</b> competitively inhibits the ATP-binding pocket of IGF1R.<a onclick="showRef(event, 'ref280'); return false;" href="javascript:void(0);" class="ref ref280">(280)</a> The anticancer activity of <b>44</b> and its analogues is being investigated in clinical trials.<a onclick="showRef(event, 'ref282 ref283'); return false;" href="javascript:void(0);" class="ref ref282 ref283">(282, 283)</a></div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">4.c.iv Simvastatin</h4><div class="NLM_p last">Recently, a group of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors known as statins, e.g., simvastatin <b>45</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), have been found to decrease IGF1R plasma membrane expression.<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> This effect has been attributed to a decrease in dolichyl phosphate, a nonsterol isoprenoid derivative in the mevalonate pathway, which is decreased following inhibition of HMG-CoA reductase.<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> Dolichyl phosphate plays an important role in the N-glycosylation of several proteins.<a onclick="showRef(event, 'ref285'); return false;" href="javascript:void(0);" class="ref ref285">(285)</a> Glycosylation of the IGF1R is required for targeting of the receptor to the plasma membrane.<a onclick="showRef(event, 'ref284 ref286'); return false;" href="javascript:void(0);" class="ref ref284 ref286">(284, 286)</a> As demonstration of the importance of the isoprenoid pathway in statin-induced cell death, cell death induced by the <b>45</b> in C2C12 mouse myoblast cells can be blocked by co-treatment with mevalonate and other intermediates in the isoprenoid pathway.<a onclick="showRef(event, 'ref287'); return false;" href="javascript:void(0);" class="ref ref287">(287)</a><b>45</b> has been shown to block IGF1-mediated proliferation of PC-3 prostate cancer cells.<a onclick="showRef(event, 'ref288'); return false;" href="javascript:void(0);" class="ref ref288">(288)</a></div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">4.c.v Heat Shock Protein 90 (HSP90) Inhibitors</h4><div class="NLM_p last">Heat shock proteins play a vital role in the chaperoning and trafficking of receptors to the plasma membrane.<a onclick="showRef(event, 'ref289 ref290'); return false;" href="javascript:void(0);" class="ref ref289 ref290">(289, 290)</a> Heat shock proteins have been implicated in mediating the proper folding and membrane targeting of IGF1R.<a onclick="showRef(event, 'ref34 ref291'); return false;" href="javascript:void(0);" class="ref ref34 ref291">(34, 291)</a> Recently, heat shock protein 90 (HSP90) inhibitors have become valuable tools in research and a promising class of anticancer therapeutics.<a onclick="showRef(event, 'ref290'); return false;" href="javascript:void(0);" class="ref ref290">(290)</a> Although not direct inhibitors of IGF1R activity, HSP90 inhibitors may indirectly reduce IGF1R expression and therefore mediate overall activity. As one example of the effectiveness of HSP90 inhibition, treatment of pancreatic cancer cell lines with the HSP90 inhibitor 17-AAG decreased IGF1R phosphorylation and total protein expression and, in an orthotopic model, pancreatic tumor growth and vascularization were both significantly reduced upon Hsp90 inhibtion.<a onclick="showRef(event, 'ref292'); return false;" href="javascript:void(0);" class="ref ref292">(292)</a> In addition to antitumor efficacy, HSP90 inhibitor therapy may be associated with toxicities that involve interference with normal IGF1R-mediated signaling as well; for example, IGF1-induced proliferation of articular chondrocytes has been shown to be decreased by HSP90 inhibitor treatment.<a onclick="showRef(event, 'ref293'); return false;" href="javascript:void(0);" class="ref ref293">(293)</a></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">5 Conclusions and Further Considerations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26741" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26741" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, in addition to other therapeutic modalities that target IGF1 signaling, there are at least a dozen chemotypes of small-molecule inhibitors of the IGF1R (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). These include ATP-competitive or ATP-noncompetitive inhibitors or small molecules that possess a mechanism of inhibition not yet elucidated. As the studies of these IGF1R inhibitors progress, some key issues need to be addressed. For instance, what is the therapeutic window for inhibition of the IGF1R versus the IR? What approaches are required to fully optimize the physicochemical properties of the currently described IGF1R inhibitors to achieve adequate pharmacokinetic and pharmacodynamic profiles? How can potential metabolic liabilities best be addressed?</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IGF1R Signaling Inhibitors at Various Stages of Development<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="rowsep1"><th class="rowsep1" align="center">therapeutic agent</th><th class="rowsep1" align="center">type</th><th class="rowsep1" align="center">company/institution</th><th class="rowsep1" align="center">phase</th><th class="rowsep1" align="center">therapeutic indication</th><th class="rowsep1" align="center">comments</th></tr></thead><tbody><tr valign="top"><td align="left">A-928605<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td align="left">SMI</td><td align="left">Abbott</td><td align="left">PC</td><td align="left">cancer</td><td align="left">ATP-competitive kinase inhibitor</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>10</b></td><td align="left">SMI</td><td align="left">Calbiochem/ The Hebrew  University of Jerusalem</td><td align="left">ND</td><td align="left">RT</td><td align="left">ATP-noncompetitive kinase  inhibitor</td></tr><tr valign="top"><td align="left"><b>41</b></td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">AMG 479</td><td align="left">mAb</td><td align="left">Amgen</td><td align="left">I, II</td><td align="left">solid tumors, NHL, sarcoma</td><td align="left">fully human monoclonal antibody</td></tr><tr valign="top"><td align="left">AMG 655</td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">ANT-429<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="f">f</a></td><td align="left">Peptide</td><td align="left">Antyra</td><td align="left">PC</td><td align="left">pancreatic cancer</td><td align="left">receptor ligand antagonist</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">anti-IGF-1R/BIIBO22</td><td align="left">mAb</td><td align="left">Biogen Idec</td><td align="left">PC</td><td align="left">solid tumors</td><td align="left">fully human monoclonal antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">ATL1101</td><td align="left">AS</td><td align="left">Antisense Therapeutics  Ltd.</td><td align="left">I</td><td align="left">psoriasis, HRPC</td><td align="left">blocks translation of the IGF1R</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">AVE1642</td><td align="left">mAb</td><td align="left">Immunogen, Sanofi- Aventis</td><td align="left">I, II</td><td align="left">solid tumors</td><td align="left">humanized antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>20</b></td><td align="left">SMI</td><td align="left">Bristol-Myers Squibb</td><td align="left">PC</td><td align="left">cancer</td><td align="left">ATP-competitive kinase inhibitors,  inhibit several kinases</td></tr><tr valign="top"><td align="left"><b>22</b></td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td></tr><tr valign="top"><td align="left"><b>23</b></td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">CP-751,871</td><td align="left">mAb</td><td align="left">Pfizer</td><td align="left">I, II, III</td><td align="left">breast and prostate cancers,  NSCLC, rheumatoid arthritis</td><td align="left">fully human monoclonal antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>37</b></td><td align="left">SMI</td><td align="left">various companies/ institutions</td><td align="left">I, II, III</td><td align="left">diabetes, cancer</td><td align="left">natural product. Focus of clinical  trials is on prevention.</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">F50035</td><td align="left">mAb</td><td align="left">Merck, Pierre Fabre  Medicament</td><td align="left">PC</td><td align="left">cancer</td><td align="left">recombinant humanized  monoclonal antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">IMC-A12</td><td align="left">mAb</td><td align="left">Imclone Systems</td><td align="left">I, II</td><td align="left">colorectal cancer, prostate  cancer, solid tumors</td><td align="left">fully human monoclonal antibody  and exists as a di-diabody with  the EGFR antibody IMC-11F8</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>44</b></td><td align="left">SMI</td><td align="left">Insmed, University of  California—San Francisco</td><td align="left">II</td><td align="left">breast and prostate cancers,  and neuroblastomas</td><td align="left">kinase inhibitor, also inhibits  human epidermal growth factor  receptor (HER2/neu)</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">GSK 621659A<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a><sup>,</sup><a class="ref internalNav" href="#t2fn3" aria-label="d">d</a></td><td align="left">SMI</td><td align="left">GlaxoSmithKline</td><td align="left">PC</td><td align="left">cancer</td><td align="left">kinase inhibitor</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">MK-0646</td><td align="left">mAb</td><td align="left">Merck</td><td align="left">I, II</td><td align="left">breast, pancreatic, and  prostate cancers and MM</td><td align="left">monoclonal antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>3</b></td><td align="left">SMI</td><td align="left">Novartis Pharma AG</td><td align="left">PC</td><td align="left">cancer</td><td align="left">ATP-competitive kinase inhibitor</td></tr><tr valign="top"><td align="left"><b>15</b></td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td><td align="left"> </td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>30</b></td><td align="left">SMI</td><td align="left">OSI Pharmaceuticals</td><td align="left">I</td><td align="left">solid tumors</td><td align="left">ATP-competitive kinase inhibitor</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>40</b></td><td align="left">SMI</td><td align="left">Axelar</td><td align="left">I, II</td><td align="left">cancer</td><td align="left">ATP-noncompetitve kinase  inhibitor, natural product</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>31</b></td><td align="left">SMI</td><td align="left">OSI Pharmaceuticals</td><td align="left">PC</td><td align="left">cancer</td><td align="left">ATP-competitive kinase inhibitor</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">R1507</td><td align="left">mAb</td><td align="left">Genmab A/S, Roche  Holdings Ltd.</td><td align="left">I, II</td><td align="left">lymphoma, NHL, sarcoma,  solid tumors</td><td align="left">fully human IgG<sub>1</sub> recombinant  antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>42</b></td><td align="left">SMI</td><td align="left">The Hebrew University  of Jerusalem</td><td align="left">ND</td><td align="left">RT</td><td align="left">ATP-noncompetitive kinase  inhibitor</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">SCH-717454 (19D12)/ robatumumab</td><td align="left">mAb</td><td align="left">Schering-Plough/Medarex</td><td align="left">II</td><td align="left">osteosarcoma, Ewing’s sarcoma,  colorectal cancer</td><td align="left">fully human monoclonal antibody</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left"><b>45</b></td><td align="left">SMI</td><td align="left">various companies/ institutions</td><td align="left">II</td><td align="left">breast and prostate cancers,  NSCLC, SCLC, multiple  sclerosis</td><td align="left">indirect inhibition of IGF1R by  inhibition of the HMG-CoA  pathway</td></tr><tr valign="top"><td colspan="6" align="left"> </td></tr><tr valign="top"><td align="left">XL228<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td align="left">SMI</td><td align="left">Exelixis</td><td align="left">I</td><td align="left">hematologic and solid tumors</td><td align="left">ATP-competitive kinase inhibitor;  also inhibits BCR-ABL,  including drug-resistant T315I  mutant, as well as SRC, FGFR  1−3, and Aurora kinases<a class="ref internalNav" href="#t2fn4" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Abbreviations: mAb, monoclonal antibody; SMI, small-molecule inhibitor; AS, antisense; NA, not applicable; RT, research tool; PC, preclinical; ND, not currently in clinical development; MM, multiple myeloma; HRPC, hormone-refractory prostate cancer; NSCLC, non-small-cell lung cancer; NHL, non-Hodgkin’s lymphoma.</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">References <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">31</a> and <a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">301</a> also contain further information regarding these and other novel therapies targeting the IGF signaling axis, as well as completed, current, or planned clinical trials testing these agents.</p></div><div class="footnote" id="t2fn2"><sup>c</sup><p class="last">Structures not disclosed.</p></div><div class="footnote" id="t2fn3"><sup>d</sup><p class="last">These inhibitors have been reported to be in development by the designated companies, but minimal data are currently available.</p></div><div class="footnote" id="t2fn4"><sup>e</sup><p class="last">Minimal information (see refs <a onclick="showRef(event, 'ref303'); return false;" href="javascript:void(0);" class="ref ref303">303</a> and <a onclick="showRef(event, 'ref304'); return false;" href="javascript:void(0);" class="ref ref304">304</a>) is presently available on this compound.</p></div><div class="footnote" id="t2fn5"><sup>f</sup><p class="last">See ref <a onclick="showRef(event, 'ref305'); return false;" href="javascript:void(0);" class="ref ref305">305</a>.</p></div></div></div><div class="NLM_p">Notably, the majority of kinase inhibitors reported to date have been identified from high-throughput screens of libraries containing large molecular weight compounds. Hit-to-lead and lead optimization performed around “hits” identified in this manner usually add, rather than remove, more functional groups or rings to increase the binding affinity of the inhibitors. With advances in technologies such as X-ray crystallography, NMR-based screening, surface plasmon resonance, mass spectrometry, and isothermal calorimetry, fragment-based and structure-guided approaches are becoming increasingly common.<a onclick="showRef(event, 'ref294'); return false;" href="javascript:void(0);" class="ref ref294">(294)</a> Compounds obtained from fragment-based and structure-guided approaches may result in novel kinase inhibitors characterized by a greater “fine-tuning” of their selectivity and more optimal physicochemical properties; thus, the authors (as well as others) favor these approaches to improve new kinase inhibitor discovery and development in the future.<a onclick="showRef(event, 'ref295 ref296'); return false;" href="javascript:void(0);" class="ref ref295 ref296">(295, 296)</a></div><div class="NLM_p">With regard to IGF1R small-molecule inhibitor design, the authors predict that optimal clinical utility may actually be obtained with compounds that are not necessarily highly selective for the IGF1R but that also inhibit other kinases such as the EGFR that can signal in parallel (since tumor cells can switch in their “preference” for a given upstream kinase) and/or kinases such as mTOR that signal downstream of IGF1R (since IGF1R signaling can diminish the antitumor effects of mTOR inhibition). Efforts toward the design and preclinical testing of such “dirty” inhibitors are warranted to assess the effectiveness of the simultaneous inhibition of the IGF1R with these and other kinases (see ref <a onclick="showRef(event, 'ref297'); return false;" href="javascript:void(0);" class="ref ref297">297</a> for a recent review concerning kinase inhibitor selectivity). With respect to the design and optimization of future IGF1R inhibitors regarding their pharmacokinetic/pharmacodynamic characteristics, it may also be relevant to take into account experimental and clinical data suggesting that compounds associated with long half-lives and near-continuous kinase inhibition in vivo are not necessarily required (nor perhaps preferred) for clinical effectiveness.<a onclick="showRef(event, 'ref298'); return false;" href="javascript:void(0);" class="ref ref298">(298)</a> These recent findings run counter to the general prevailing assumption that continuous kinase inhibition is a requirement for clinical anticancer success, and they suggest that high-dose pulse therapy with a kinase inhibitor might still be effective while also allowing one to minimize toxicities (e.g., iatrogenic diabetes in the case of a dual IGF1R/IR small-molecule inhibitor) that could complicate or preclude continuous therapy.</div><div class="NLM_p">There are also questions to be addressed from the biology/oncology viewpoint. For example, is IGF1R down-regulation (which occurs with certain therapeutic antibodies but not with small-molecule inhibitors, a notable exception being the cyclolignan compound <b>40</b>)<a onclick="showRef(event, 'ref268'); return false;" href="javascript:void(0);" class="ref ref268">(268)</a> required for optimal antitumor responses in the clinical setting? This question will be answered only upon the entry of small-molecule IGF1R inhibitors into clinical trials. Nonetheless, considerable experimental data indicate that IGF1R down-regulation is probably necessary to induce tumor cell apoptosis; without down-regulation, growth inhibition but no apoptosis occurs (reviewed in ref <a onclick="showRef(event, 'ref299'); return false;" href="javascript:void(0);" class="ref ref299">299</a>). Whether these preclinical observations hold true in the clinc remains to be seen, but the authors consider this to be a point that could be a relative “make or break” issue for the overall clinical applicability of small-molecule inhibitors of the IGF1R. Does the optimal strategy for IGF1R-targeted therapy involve the use of small molecules that specifically target the IGF1R alone or rather less selective compounds that show concomitant IR inhibition (in a trade-off for the possible enhancement of antitumor efficacy against increased toxicity)? What are the optimal combinations and sequencing of IGF1R-targeted agents with other targeted therapies (e.g., EGFR and/or HER2 inhibitors, inhibitors of the downstream RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways) and with conventional chemotherapy and radiotherapy? As described above in this Perspective, experimental results suggest an important role for the IR, especially the IR-A in the form of hybrid receptors with the IGF1R, in transducing tumor growth-promoting signals. Likewise, substantial experimental data support the combination of IGF1R-targeted therapy with other treatments as a means to enhance antitumor responses, especially due to inhibition of the strong antiapoptotic signaling that is normally mediated by the IGF1R. Unfortunately, these experimental results provide only general guidance, and definitive answers for these last two questions must await actual clinical experience with small-molecule IGF1R inhibitors; however, results from ongoing and future trials examining anti-IGF1R antibodies may help to presage at least some of the possible clinical characteristics of anti-IGF1R small molecules.</div><div class="NLM_p">Another consideration for the clinical development of anti-IGF1R therapies is the following: Which tumors are most likely to respond to treatment? With the exception of selected malignancies (such as Ewing’s sarcomas, in which the IGF1R is constitutively activated by autocrine production of IGF1), the majority of primary tumors may exhibit only minimal-to-modest antitumor responses to IGF1R-directed therapy (at least when administered as monotherapy without other concomitant treatments). The IGF1R is required for anchorage-independent growth of tumor cells (scored experimentally as colony formation in soft agar), which is considered by investigators to be an in vitro biological counterpart in at least certain respects of metastatic capability and the occurrence of metastatic spread (reviewed in ref <a onclick="showRef(event, 'ref299'); return false;" href="javascript:void(0);" class="ref ref299">299</a>). Furthermore, experimental targeting of the IGF1R has much greater effects on the viability of cells in anchorage-independent compared to adherent growth conditions, and several in vivo cancer models have demonstrated metastases to be very susceptible to IGF1R targeting (reviewed in ref <a onclick="showRef(event, 'ref299'); return false;" href="javascript:void(0);" class="ref ref299">299</a>). These observations argue that IGF1R-targeted therapies (especially administered as monotherapy) could have a substantive role in the prevention and/or treatment of metastatic cancer (perhaps being of greater efficacy in this setting than for the monotherapy of most primary cancers). In the opinion of the authors, serious consideration should be given to the performance of clinical trials that address this hypothesis. One very common clinical setting that could be employed to test this possibility would be for the prevention of liver metastases in colon cancer patients after resection of their primary tumors. Metastatic colon tumors in the liver are the main cause of mortality in patients with colon cancer, and cancer cells in the liver are awash in IGF1 (which is produced in large amounts by the liver) and may be addicted to it for their viability, especially before they are established as discrete metastatic tumor masses.</div><div class="NLM_p">Yet another clinically relevant question concerns identification of the most informative biomarkers that allow prediction of the robustness of antitumor efficacy of IGF1R inhibition, as well as the clinical monitoring of antitumor responses.<a onclick="showRef(event, 'ref300'); return false;" href="javascript:void(0);" class="ref ref300">(300)</a> Rather than overexpression, expression (even at low levels) of the IGF1R is the requirement for cellular transformation in general; thus, the amount of IGF1R in a given tumor cannot be used as a reliable predictor of response to IGF1R-targeted therapy. Baserga has suggested that the status of IRS1 in a particular tumor may possibly presage responsiveness to anti-IGF1R therapy, given that without IRS1, the IGF1R does not send a mitogenic signal but rather a differentiation signal in cells.<a onclick="showRef(event, 'ref300'); return false;" href="javascript:void(0);" class="ref ref300">(300)</a> Thus, expression of IRS1 (especially nuclear IRS1, which can function as a transcriptional cofactor) may be a requirement for IGF1R-driven tumorigenesis and could potentially serve as a biomarker for sensitivity to IGF1R targeting. As such, in the authors’ opinion, assessments of IRS1 status should be considered for incorporation into clinical trial designs.</div><div class="NLM_p last">Despite a number of unanswered questions, it does now appear clear that the IGF1R signaling system is an important component of the development, progression, and therapeutic responsiveness of a number of cancer types.<a onclick="showRef(event, 'ref32 ref34 ref36 ref37 ref38 ref39 ref56 ref221 ref222 ref224 ref279 ref301 ref302'); return false;" href="javascript:void(0);" class="ref ref32 ref34 ref36 ref37 ref38 ref39 ref56 ref221 ref222 ref224 ref279 ref301 ref302">(32, 34, 36-39, 56, 221, 222, 224, 279, 301, 302)</a> Furthermore, experience from early stage clinical trials has thus far suggested that the toxicities associated with IGF1R inhibition can be managed effectively and tolerated by the patient.<a onclick="showRef(event, 'ref301'); return false;" href="javascript:void(0);" class="ref ref301">(301)</a> Now, slightly more than 50 years after the initial recognition of signaling by the IGF1 pathway and roughly 20 years following the initial suggestions of possible antitumor efficacy of the targeting of this pathway, we are finally poised to fully test the clinical usefulness of IGF1R-inhibitory agents for cancer therapy.</div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rongshi Li</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Oncologic Sciences, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#21734e4f465249480f6d48614c4e47474855550f4e53460152554457440f4c4e535348526152554b5445440f4e5346"><span class="__cf_email__" data-cfemail="5c0e33323b2f34357210351c31333a3a35282872332e3b">[email protected]</span> <span class="__cf_email__" data-cfemail="b1c2c5d4c7d49fdcdec3c3d8c2f1c2c5dbc4d5d49fdec3d6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephan W. Morris</span> - <span class="hlFld-Affiliation affiliation">Departments of Pathology and Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105-3678</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8fdde0e1e8fce7e6a1c3e6cfe2e0e9e9e6fbfba1e0fde8affcfbeaf9eaa1e2e0fdfde6fccffcfbe5faebeaa1e0fde8"><span class="__cf_email__" data-cfemail="d98bb6b7beaab1b0f795b099b4b6bfbfb0adadf7b6abbe">[email protected]</span> <span class="__cf_email__" data-cfemail="ec9f98899a89c281839e9e859fac9f9886998889c2839e8b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Pourpak</span> - <span class="hlFld-Affiliation affiliation">Departments of Pathology and Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee 38105-3678</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm9002395" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rongshi Li</b> is Associate Member of the Drug Discovery Department at H. Lee Moffitt Cancer Center and Research Institute and is Associate Professor in Oncologic Sciences at the University of South Florida. Dr. Li previously held positions as Senior Vice President, Discovery Chemistry, at Pharmaron, and as Senior Director of Chemistry at ChemBridge Research Laboratories. Dr. Li started his industrial career at IRORI, founded by Professor K. C. Nicolaou. He received his Ph.D. in Medicinal Chemistry as a Killam Scholar from Dalhousie University in Canada and obtained his postdoctoral training under the guidance of Professor George L. Kenyon in the Department of Pharmaceutical Chemistry, University of California—San Francisco. His current research focuses on fragment-based and structure-guided design of enzyme inhibitors and inhibitors of protein−protein interactions.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Alan Pourpak</b> received his undergraduate degree in Biology from the University of Utah (Salt Lake City, UT) in 2001 and a Ph.D. in Pharmacology and Toxicology from the University of Arizona (Tucson, AZ) in 2006 under the direction of Dr. Robert T. Dorr. His dissertation focused on the mechanism of action of an anthracene-containing anticancer agent called ethonafide. Dr. Pourpak is currently a Postdoctoral Research Associate at St. Jude Children’s Research Hospital (Memphis, TN) in the laboratory of Dr. Stephan W. Morris. His research interests lie in identifying pathways deregulated in cancer and developing new agents to abrogate the oncogenic activity of those pathways. He is currently focusing his efforts on identifying new molecular targets, along with novel therapies, for the management of childhood hematologic cancers.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Stephan W. Morris</b> is a Full Member in the Departments of Pathology and Oncology, St. Jude Children’s Research Hospital (Memphis, TN) and is an internationally recognized physician−scientist and translational investigator whose work focuses on molecular oncology. The Morris laboratory has discovered and characterized a number of oncogenes including the NPM-ALK fusion and BCL10 oncogene found in non-Hodgkin’s lymphomas, and the NPM-MLF1 and RBM15-MKL1 fusion genes of acute nonlymphocytic leukemias. Dr. Morris has published over 120 peer-reviewed manuscripts and currently holds seven patents. He earned his M.D. from Louisiana State University School of Medicine—Shreveport (LA), completed an Internal Medicine residency at the University of Texas Southwestern Health Science Center (Dallas, TX), and trained in Medical Oncology at Yale University School of Medicine (New Haven, CT).</p></figure></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Alan Pourpak and Stephan W. Morris are supported in part by NIH Grant R01 CA69129 (to S.W.M.) and Cancer Center CORE Grant CA21765 and by the American Lebanese Syrian Associated Charities, St. Jude Children’s Research Hospital.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 305 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Salmon, W. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daughaday, W. H.</span><span> </span><span class="NLM_article-title">A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro</span> <span class="citation_source-journal">J. Lab. Clin. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1957</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1957&pages=825-836&author=W.+D.+Salmonauthor=W.+H.+Daughaday&title=A+hormonally+controlled+serum+factor+which+stimulates+sulfate+incorporation+by+cartilage+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DW.%2BD.%26aulast%3DDaughaday%26aufirst%3DW.%2BH.%26atitle%3DA%2520hormonally%2520controlled%2520serum%2520factor%2520which%2520stimulates%2520sulfate%2520incorporation%2520by%2520cartilage%2520in%2520vitro%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1957%26volume%3D49%26spage%3D825%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bell, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pictet, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, H. M.</span><span> </span><span class="NLM_article-title">Sequence of the human insulin gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1980&pages=26-32&author=G.+I.+Bellauthor=R.+L.+Pictetauthor=W.+J.+Rutterauthor=B.+Cordellauthor=E.+Tischerauthor=H.+M.+Goodman&title=Sequence+of+the+human+insulin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DG.%2BI.%26aulast%3DPictet%26aufirst%3DR.%2BL.%26aulast%3DRutter%26aufirst%3DW.%2BJ.%26aulast%3DCordell%26aufirst%3DB.%26aulast%3DTischer%26aufirst%3DE.%26aulast%3DGoodman%26aufirst%3DH.%2BM.%26atitle%3DSequence%2520of%2520the%2520human%2520insulin%2520gene%26jtitle%3DNature%26date%3D1980%26volume%3D284%26spage%3D26%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayflick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor II precursor gene organization in relation to insulin gene family</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">310</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=1984&pages=777-781&author=T.+J.+Dullauthor=A.+Grayauthor=J.+S.+Hayflickauthor=A.+Ullrich&title=Insulin-like+growth+factor+II+precursor+gene+organization+in+relation+to+insulin+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DHayflick%26aufirst%3DJ.%2BS.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DInsulin-like%2520growth%2520factor%2520II%2520precursor%2520gene%2520organization%2520in%2520relation%2520to%2520insulin%2520gene%2520family%26jtitle%3DNature%26date%3D1984%26volume%3D310%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Jansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schaik, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabbay, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussbaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussenbach, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Brande, J. L.</span><span> </span><span class="NLM_article-title">Sequence of cDNA encoding human insulin-like growth factor I precursor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1983&pages=609-611&author=M.+Jansenauthor=F.+M.+van+Schaikauthor=A.+T.+Rickerauthor=B.+Bullockauthor=D.+E.+Woodsauthor=K.+H.+Gabbayauthor=A.+L.+Nussbaumauthor=J.+S.+Sussenbachauthor=J.+L.+Van+den+Brande&title=Sequence+of+cDNA+encoding+human+insulin-like+growth+factor+I+precursor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DM.%26aulast%3Dvan%2BSchaik%26aufirst%3DF.%2BM.%26aulast%3DRicker%26aufirst%3DA.%2BT.%26aulast%3DBullock%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DD.%2BE.%26aulast%3DGabbay%26aufirst%3DK.%2BH.%26aulast%3DNussbaum%26aufirst%3DA.%2BL.%26aulast%3DSussenbach%26aufirst%3DJ.%2BS.%26aulast%3DVan%2Bden%2BBrande%26aufirst%3DJ.%2BL.%26atitle%3DSequence%2520of%2520cDNA%2520encoding%2520human%2520insulin-like%2520growth%2520factor%2520I%2520precursor%26jtitle%3DNature%26date%3D1983%26volume%3D306%26spage%3D609%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sures, I.</span><span> </span><span class="NLM_article-title">Genetic variation in the human insulin gene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=1980&pages=612-615&author=A.+Ullrichauthor=T.+J.+Dullauthor=A.+Grayauthor=J.+Brosiusauthor=I.+Sures&title=Genetic+variation+in+the+human+insulin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DBrosius%26aufirst%3DJ.%26aulast%3DSures%26aufirst%3DI.%26atitle%3DGenetic%2520variation%2520in%2520the%2520human%2520insulin%2520gene%26jtitle%3DScience%26date%3D1980%26volume%3D209%26spage%3D612%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzzelli, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coussens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubokawa, M.</span><span> </span><span class="NLM_article-title">Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">761</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=756-761&author=A.+Ullrichauthor=J.+R.+Bellauthor=E.+Y.+Chenauthor=R.+Herreraauthor=L.+M.+Petruzzelliauthor=T.+J.+Dullauthor=A.+Grayauthor=L.+Coussensauthor=Y.+C.+Liaoauthor=M.+Tsubokawa&title=Human+insulin+receptor+and+its+relationship+to+the+tyrosine+kinase+family+of+oncogenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DBell%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DE.%2BY.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DPetruzzelli%26aufirst%3DL.%2BM.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DCoussens%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DY.%2BC.%26aulast%3DTsubokawa%26aufirst%3DM.%26atitle%3DHuman%2520insulin%2520receptor%2520and%2520its%2520relationship%2520to%2520the%2520tyrosine%2520kinase%2520family%2520of%2520oncogenes%26jtitle%3DNature%26date%3D1985%26volume%3D313%26spage%3D756%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang-Feng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henzel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2503</span><span class="NLM_x">–</span> <span class="NLM_lpage">2512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1986&pages=2503-2512&author=A.+Ullrichauthor=A.+Grayauthor=A.+W.+Tamauthor=T.+Yang-Fengauthor=M.+Tsubokawaauthor=C.+Collinsauthor=W.+Henzelauthor=B.+T.+Leauthor=S.+Kathuriaauthor=E.+Chen&title=Insulin-like+growth+factor+I+receptor+primary+structure%3A+comparison+with+insulin+receptor+suggests+structural+determinants+that+define+functional+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DA.%2BW.%26aulast%3DYang-Feng%26aufirst%3DT.%26aulast%3DTsubokawa%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DHenzel%26aufirst%3DW.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DE.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520primary%2520structure%253A%2520comparison%2520with%2520insulin%2520receptor%2520suggests%2520structural%2520determinants%2520that%2520define%2520functional%2520specificity%26jtitle%3DEMBO%2520J.%26date%3D1986%26volume%3D5%26spage%3D2503%26epage%3D2512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Myal, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiu, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhaumick, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bala, M.</span><span> </span><span class="NLM_article-title">Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">5486</span><span class="NLM_x">–</span> <span class="NLM_lpage">5490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1984&pages=5486-5490&author=Y.+Myalauthor=R.+P.+Shiuauthor=B.+Bhaumickauthor=M.+Bala&title=Receptor+binding+and+growth-promoting+activity+of+insulin-like+growth+factors+in+human+breast+cancer+cells+%28T-47D%29+in+culture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMyal%26aufirst%3DY.%26aulast%3DShiu%26aufirst%3DR.%2BP.%26aulast%3DBhaumick%26aufirst%3DB.%26aulast%3DBala%26aufirst%3DM.%26atitle%3DReceptor%2520binding%2520and%2520growth-promoting%2520activity%2520of%2520insulin-like%2520growth%2520factors%2520in%2520human%2520breast%2520cancer%2520cells%2520%2528T-47D%2529%2520in%2520culture%26jtitle%3DCancer%2520Res.%26date%3D1984%26volume%3D44%26spage%3D5486%26epage%3D5490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolese, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M.</span><span> </span><span class="NLM_article-title">Presence of somatomedin receptors on primary human breast and colon carcinomas</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0304-3835%2887%2990218-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=2961436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaL1cXpt1Citg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1987&pages=223-230&author=M.+N.+Pollakauthor=J.+F.+Perdueauthor=R.+G.+Margoleseauthor=K.+Baerauthor=M.+Richard&title=Presence+of+somatomedin+receptors+on+primary+human+breast+and+colon+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Presence of somatomedin receptors on primary human breast and colon carcinomas</span></div><div class="casAuthors">Pollak, Michael N.; Perdue, James F.; Margolese, Richard G.; Baer, Kathy; Richard, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">223-30</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">Competitive binding techniques were used to study the interaction of insulin-like growth factor I (IGF-I) with a plasma membrane-enriched subcellular fraction purified from primary breast and colon carcinoma specimens obtained at surgery.  The presence of specific binding sites for IGF-I was detected in all tumor specimens studied.  Scatchard anal. and competition studies with insulin and insulin-like growth factor-II (IGF-II) revealed the presence of specific IGF-I receptors, with a Kd of ∼2 nM.  These results are consistent with the hypothesis that somatomedins play a role in detg. the proliferative behavior of human breast and colon tumors, and suggest that recent lab. studies showing dependence of neoplastic cells on somatomedins (insulin-like growth factors) for optimum proliferation may have clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodS2tABEEBO7Vg90H21EOLACvtfcHk0lgID58b-NOE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXpt1Citg%253D%253D&md5=db53dd74a8ea856c46bd508836d7694d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2887%2990218-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252887%252990218-7%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DPerdue%26aufirst%3DJ.%2BF.%26aulast%3DMargolese%26aufirst%3DR.%2BG.%26aulast%3DBaer%26aufirst%3DK.%26aulast%3DRichard%26aufirst%3DM.%26atitle%3DPresence%2520of%2520somatomedin%2520receptors%2520on%2520primary%2520human%2520breast%2520and%2520colon%2520carcinomas%26jtitle%3DCancer%2520Lett.%26date%3D1987%26volume%3D38%26spage%3D223%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitten, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coronado, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, F. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">–</span> <span class="NLM_lpage">1423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1989&pages=1418-1423&author=C.+L.+Arteagaauthor=L.+J.+Kittenauthor=E.+B.+Coronadoauthor=S.+Jacobsauthor=F.+C.+Kullauthor=D.+C.+Allredauthor=C.+K.+Osborne&title=Blockade+of+the+type+I+somatomedin+receptor+inhibits+growth+of+human+breast+cancer+cells+in+athymic+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DKitten%26aufirst%3DL.%2BJ.%26aulast%3DCoronado%26aufirst%3DE.%2BB.%26aulast%3DJacobs%26aufirst%3DS.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DBlockade%2520of%2520the%2520type%2520I%2520somatomedin%2520receptor%2520inhibits%2520growth%2520of%2520human%2520breast%2520cancer%2520cells%2520in%2520athymic%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D1989%26volume%3D84%26spage%3D1418%26epage%3D1423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Chan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannucci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.279.5350.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9438850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=563-566&author=J.+M.+Chanauthor=M.+J.+Stampferauthor=E.+Giovannucciauthor=P.+H.+Gannauthor=J.+Maauthor=P.+Wilkinsonauthor=C.+H.+Hennekensauthor=M.+Pollak&title=Plasma+insulin-like+growth+factor-I+and+prostate+cancer+risk%3A+a+prospective+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span></div><div class="casAuthors">Chan, June M.; Stempfer, Meir J.; Giovannucci, Edward; Gann, Peter H.; Ma, Jing; Wilkinson, Peter; Hennekens, Charles H.; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">563-566</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells.  To investigate assocns. between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' health Study was conducted on prospectively collected plasma from 152 cases and 152 controls.  A strong pos. assocn. was obsd. between IGF-I levels and prostate cancer risk.  Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 % confidence interval 1.8 to 10.6) compared with men in the lowest quartile.  This assocn. was independent of baseline prostate-specific antigen levels.  Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk redn. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8T4rIgzxMLVg90H21EOLACvtfcHk0lgID58b-NOE3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D&md5=43c076479c5fb946f61a42758043bd92</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.563%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DGann%26aufirst%3DP.%2BH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPlasma%2520insulin-like%2520growth%2520factor-I%2520and%2520prostate%2520cancer%2520risk%253A%2520a%2520prospective%2520study%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D563%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Majeed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry-Shaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismar, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4736</span><span class="NLM_x">–</span> <span class="NLM_lpage">4740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=4736-4740&author=N.+Majeedauthor=M.+J.+Blouinauthor=P.+J.+Kaplan-Lefkoauthor=J.+Barry-Shawauthor=N.+M.+Greenbergauthor=P.+Gaudreauauthor=T.+A.+Bismarauthor=M.+Pollak&title=A+germ+line+mutation+that+delays+prostate+cancer+progression+and+prolongs+survival+in+a+murine+prostate+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMajeed%26aufirst%3DN.%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%2BJ.%26aulast%3DBarry-Shaw%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DN.%2BM.%26aulast%3DGaudreau%26aufirst%3DP.%26aulast%3DBismar%26aufirst%3DT.%2BA.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DA%2520germ%2520line%2520mutation%2520that%2520delays%2520prostate%2520cancer%2520progression%2520and%2520prolongs%2520survival%2520in%2520a%2520murine%2520prostate%2520cancer%2520model%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D4736%26epage%3D4740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span> </span><span class="NLM_article-title">Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fbjoc.2001.1895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11487276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=428-430&author=M.+Pollakauthor=M.+J.+Blouinauthor=J.+C.+Zhangauthor=J.+J.+Kopchick&title=Reduced+mammary+gland+carcinogenesis+in+transgenic+mice+expressing+a+growth+hormone+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist</span></div><div class="casAuthors">Pollak, M.; Blouin, M.-J.; Zhang, J.-C.; Kopchick, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-430</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Several reports have provided evidence that body size early in life is pos. correlated with risk of subsequent breast cancer, but the biol. basis for this relationship is unclear.  We examd. tumor incidence in transgenic mice expressing a growth hormone (GH) antagonist and in non-transgenic littermates following exposure to dimethylbenz[a]anthracene (DMBA), a well characterized murine mammary gland carcinogen.  The transgenic animals had lower IGF-I levels, were smaller in terms of body size and wt., and exhibited decreased tumor incidence relative to controls.  The demonstration that both body size early in life and breast cancer incidence are influenced by exptl. perturbation of the GH-IGF-I axis in a transgenic model provides evidence that variability between individuals with respect to these hormones underlies the relationship between body size early in life and breast cancer risk obsd. in epidemiol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoem3KP3bi6qbVg90H21EOLACvtfcHk0likuJmBWMAPCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslSgt7o%253D&md5=2c353440324684e27bfeed56cc8090f1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.1895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.1895%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%2BC.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26atitle%3DReduced%2520mammary%2520gland%2520carcinogenesis%2520in%2520transgenic%2520mice%2520expressing%2520a%2520growth%2520hormone%2520antagonist%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D428%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efstratiadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">11217</span><span class="NLM_x">–</span> <span class="NLM_lpage">11221</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=11217-11221&author=C.+Sellauthor=M.+Rubiniauthor=R.+Rubinauthor=J.+P.+Liuauthor=A.+Efstratiadisauthor=R.+Baserga&title=Simian+virus+40+large+tumor+antigen+is+unable+to+transform+mouse+embryonic+fibroblasts+lacking+type+1+insulin-like+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSell%26aufirst%3DC.%26aulast%3DRubini%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DEfstratiadis%26aufirst%3DA.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DSimian%2520virus%252040%2520large%2520tumor%2520antigen%2520is%2520unable%2520to%2520transform%2520mouse%2520embryonic%2520fibroblasts%2520lacking%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D11217%26epage%3D11221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennighausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakar, S.</span><span> </span><span class="NLM_article-title">Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">4384</span><span class="NLM_x">–</span> <span class="NLM_lpage">4388</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=4384-4388&author=Y.+Wuauthor=K.+Cuiauthor=K.+Miyoshiauthor=L.+Hennighausenauthor=J.+E.+Greenauthor=J.+Setserauthor=D.+LeRoithauthor=S.+Yakar&title=Reduced+circulating+insulin-like+growth+factor+I+levels+delay+the+onset+of+chemically+and+genetically+induced+mammary+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DK.%26aulast%3DHennighausen%26aufirst%3DL.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DYakar%26aufirst%3DS.%26atitle%3DReduced%2520circulating%2520insulin-like%2520growth%2520factor%2520I%2520levels%2520delay%2520the%2520onset%2520of%2520chemically%2520and%2520genetically%2520induced%2520mammary%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D4384%26epage%3D4388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Yang, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beamer, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1509</span><span class="NLM_x">–</span> <span class="NLM_lpage">1511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=1509-1511&author=X.+F.+Yangauthor=W.+G.+Beamerauthor=H.+Huynhauthor=M.+Pollak&title=Reduced+growth+of+human+breast+cancer+xenografts+in+hosts+homozygous+for+the+lit+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BF.%26aulast%3DBeamer%26aufirst%3DW.%2BG.%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DReduced%2520growth%2520of%2520human%2520breast%2520cancer%2520xenografts%2520in%2520hosts%2520homozygous%2520for%2520the%2520lit%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D1509%26epage%3D1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capraro, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span> </span><span class="NLM_article-title">In vivo antitumor activity of NVP-AEW541, a novel, potent, and selective inhibitor of the IGF-IR kinase</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=231-239&author=C.+Garcia-Echeverriaauthor=M.+A.+Pearsonauthor=A.+Martiauthor=T.+Meyerauthor=J.+Mestanauthor=J.+Zimmermannauthor=J.+Gaoauthor=J.+Brueggenauthor=H.+G.+Capraroauthor=R.+Cozensauthor=D.+B.+Evansauthor=D.+Fabbroauthor=P.+Furetauthor=D.+G.+Portaauthor=J.+Liebetanzauthor=G.+Martiny-Baronauthor=S.+Ruetzauthor=F.+Hofmann&title=In+vivo+antitumor+activity+of+NVP-AEW541%2C+a+novel%2C+potent%2C+and+selective+inhibitor+of+the+IGF-IR+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPearson%26aufirst%3DM.%2BA.%26aulast%3DMarti%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCapraro%26aufirst%3DH.%2BG.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%2520NVP-AEW541%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520IGF-IR%2520kinase%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D231%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Goya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shitara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasebe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiai, A.</span><span> </span><span class="NLM_article-title">Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6252</span><span class="NLM_x">–</span> <span class="NLM_lpage">6258</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6252-6258&author=M.+Goyaauthor=S.+Miyamotoauthor=K.+Nagaiauthor=Y.+Ohkiauthor=K.+Nakamuraauthor=K.+Shitaraauthor=H.+Maedaauthor=T.+Sangaiauthor=K.+Kodamaauthor=Y.+Endohauthor=G.+Ishiiauthor=T.+Hasebeauthor=H.+Yonouauthor=T.+Hatanoauthor=Y.+Ogawaauthor=A.+Ochiai&title=Growth+inhibition+of+human+prostate+cancer+cells+in+human+adult+bone+implanted+into+nonobese+diabetic%2Fsevere+combined+immunodeficient+mice+by+a+ligand-specific+antibody+to+human+insulin-like+growth+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoya%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DOhki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DSangai%26aufirst%3DT.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DEndoh%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DHasebe%26aufirst%3DT.%26aulast%3DYonou%26aufirst%3DH.%26aulast%3DHatano%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DGrowth%2520inhibition%2520of%2520human%2520prostate%2520cancer%2520cells%2520in%2520human%2520adult%2520bone%2520implanted%2520into%2520nonobese%2520diabetic%252Fsevere%2520combined%2520immunodeficient%2520mice%2520by%2520a%2520ligand-specific%2520antibody%2520to%2520human%2520insulin-like%2520growth%2520factors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6252%26epage%3D6258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frennesson, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalli, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conover, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=362-371&author=P.+Haluskaauthor=J.+M.+Carboniauthor=D.+A.+Loegeringauthor=F.+Y.+Leeauthor=M.+Wittmanauthor=M.+G.+Saulnierauthor=D.+B.+Frennessonauthor=K.+R.+Kalliauthor=C.+A.+Conoverauthor=R.+M.+Attarauthor=S.+H.+Kaufmannauthor=M.+Gottardisauthor=C.+Erlichman&title=In+vitro+and+in+vivo+antitumor+effects+of+the+dual+insulin-like+growth+factor-I%2Finsulin+receptor+inhibitor%2C+BMS-554417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DFrennesson%26aufirst%3DD.%2BB.%26aulast%3DKalli%26aufirst%3DK.%2BR.%26aulast%3DConover%26aufirst%3DC.%2BA.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520effects%2520of%2520the%2520dual%2520insulin-like%2520growth%2520factor-I%252Finsulin%2520receptor%2520inhibitor%252C%2520BMS-554417%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D362%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld-Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirritt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyzaguirre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2158</span><span class="NLM_x">–</span> <span class="NLM_lpage">2167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-07-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17671083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2158-2167&author=Q.+S.+Jiauthor=M.+J.+Mulvihillauthor=M.+Rosenfeld-Franklinauthor=A.+Cookeauthor=L.+Fengauthor=G.+Makauthor=M.+O%27Connorauthor=Y.+Yaoauthor=C.+Pirrittauthor=E.+Buckauthor=A.+Eyzaguirreauthor=L.+D.+Arnoldauthor=N.+W.+Gibsonauthor=J.+A.+Pachter&title=A+novel%2C+potent%2C+and+selective+insulin-like+growth+factor-I+receptor+kinase+inhibitor+blocks+insulin-like+growth+factor-I+receptor+signaling+in+vitro+and+inhibits+insulin-like+growth+factor-I+receptor+dependent+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo</span></div><div class="casAuthors">Ji, Qun-sheng; Mulvihill, Mark J.; Rosenfeld-Franklin, Maryland; Cooke, Andrew; Feng, Lixin; Mak, Gilda; O'Connor, Matthew; Yao, Yan; Pirritt, Caroline; Buck, Elizabeth; Eyzaguirre, Alexandra; Arnold, Lee D.; Gibson, Neil W.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2158-2167</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and IGF-II, are up-regulated in a variety of human cancers.  In tumors, such as colorectal, non-small cell lung, ovarian, and pediatric cancers, which may drive their own growth and survival through autocrine IGF-II expression, the role of IGF-IR is esp. crit.  Here, we present a novel small-mol. IGF-IR kinase inhibitor, cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine (PQIP), which displayed a cellular IC50 of 19 nmol/L for inhibition of ligand-dependent autophosphorylation of human IGF-IR with 14-fold cellular selectivity relative to the human insulin receptor.  PQIP showed minimal activity against a panel of 32 other protein kinases.  It also abolished the ligand-induced activation of downstream phosphorylated AKT and phosphorylated extracellular signal-regulated kinase 1/2 in both IGF-IR transfectant cells and a GEO human colorectal cancer cell line.  Anal. of GEO cells revealed a significant level of both phosphorylated IGF-IR and IGF-II expression.  Furthermore, inactivation of IGF-II in conditioned GEO culture medium by a neutralizing antibody diminished IGF-IR activation, indicating the presence of a functional IGF-II/IGF-IR autocrine loop in GEO cells.  Once daily oral dosing of PQIP induced robust antitumor efficacy in GEO xenografts.  The antitumor efficacy correlated with the degree and duration of inhibition of tumor IGF-IR phosphorylation in vivo by this compd.  Moreover, when mice were treated for 3 days with a dose of PQIP that maximally inhibited tumor growth, only minor changes in blood glucose were obsd.  Thus, PQIP represents a potent and selective IGF-IR kinase inhibitor that is esp. efficacious in an IGF-II-driven human tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUljsbsd3CzbVg90H21EOLACvtfcHk0liIU9cd-M0b0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltLg%253D&md5=d0d7c5cb6b4ec09893b3ff178f4613d7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0070%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPirritt%26aufirst%3DC.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DEyzaguirre%26aufirst%3DA.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%252C%2520potent%252C%2520and%2520selective%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520blocks%2520insulin-like%2520growth%2520factor-I%2520receptor%2520signaling%2520in%2520vitro%2520and%2520inhibits%2520insulin-like%2520growth%2520factor-I%2520receptor%2520dependent%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2158%26epage%3D2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L.</span><span> </span><span class="NLM_article-title">The new kid on the block(ade) of the IGF-1 receptor</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=201-202&author=D.+LeRoithauthor=L.+Helman&title=The+new+kid+on+the+block%28ade%29+of+the+IGF-1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DHelman%26aufirst%3DL.%26atitle%3DThe%2520new%2520kid%2520on%2520the%2520block%2528ade%2529%2520of%2520the%2520IGF-1%2520receptor%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D201%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMullan, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulaki, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shringarpure, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libermann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span> </span><span class="NLM_article-title">Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=221-230&author=C.+S.+Mitsiadesauthor=N.+S.+Mitsiadesauthor=C.+J.+McMullanauthor=V.+Poulakiauthor=R.+Shringarpureauthor=M.+Akiyamaauthor=T.+Hideshimaauthor=D.+Chauhanauthor=M.+Josephauthor=T.+A.+Libermannauthor=C.+Garcia-Echeverriaauthor=M.+A.+Pearsonauthor=F.+Hofmannauthor=K.+C.+Andersonauthor=A.+L.+Kung&title=Inhibition+of+the+insulin-like+growth+factor+receptor-1+tyrosine+kinase+activity+as+a+therapeutic+strategy+for+multiple+myeloma%2C+other+hematologic+malignancies%2C+and+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%2BS.%26aulast%3DMcMullan%26aufirst%3DC.%2BJ.%26aulast%3DPoulaki%26aufirst%3DV.%26aulast%3DShringarpure%26aufirst%3DR.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DLibermann%26aufirst%3DT.%2BA.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPearson%26aufirst%3DM.%2BA.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26atitle%3DInhibition%2520of%2520the%2520insulin-like%2520growth%2520factor%2520receptor-1%2520tyrosine%2520kinase%2520activity%2520as%2520a%2520therapeutic%2520strategy%2520for%2520multiple%2520myeloma%252C%2520other%2520hematologic%2520malignancies%252C%2520and%2520solid%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D221%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvaia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetsch, L.</span><span> </span><span class="NLM_article-title">Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=1318-1327&author=G.+Pandiniauthor=T.+Wurchauthor=B.+Aklaauthor=N.+Corvaiaauthor=A.+Belfioreauthor=L.+Goetsch&title=Functional+responses+and+in+vivo+anti-tumour+activity+of+h7C10%3A+a+humanised+monoclonal+antibody+with+neutralising+activity+against+the+insulin-like+growth+factor-1+%28IGF-1%29+receptor+and+insulin%2FIGF-1+hybrid+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DWurch%26aufirst%3DT.%26aulast%3DAkla%26aufirst%3DB.%26aulast%3DCorvaia%26aufirst%3DN.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26atitle%3DFunctional%2520responses%2520and%2520in%2520vivo%2520anti-tumour%2520activity%2520of%2520h7C10%253A%2520a%2520humanised%2520monoclonal%2520antibody%2520with%2520neutralising%2520activity%2520against%2520the%2520insulin-like%2520growth%2520factor-1%2520%2528IGF-1%2529%2520receptor%2520and%2520insulin%252FIGF-1%2520hybrid%2520receptors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D1318%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Osborne, R.</span><span> </span><span class="NLM_article-title">Commercial interest waxes for IGF-1 blockers</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=719-720&author=R.+Osborne&title=Commercial+interest+waxes+for+IGF-1+blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DR.%26atitle%3DCommercial%2520interest%2520waxes%2520for%2520IGF-1%2520blockers%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D719%26epage%3D720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batzel, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molife, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualberto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5834</span><span class="NLM_x">–</span> <span class="NLM_lpage">5840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17908976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSntLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=5834-5840&author=P.+Haluskaauthor=H.+M.+Shawauthor=G.+N.+Batzelauthor=D.+Yinauthor=J.+R.+Molinaauthor=L.+R.+Molifeauthor=T.+A.+Yapauthor=M.+L.+Robertsauthor=A.+Sharmaauthor=A.+Gualbertoauthor=A.+A.+Adjeiauthor=J.+S.+de+Bono&title=Phase+I+dose+escalation+study+of+the+anti-insulin-like+growth+factor-I+receptor+monoclonal+antibody+CP-751%2C871+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Dose Escalation Study of the Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors</span></div><div class="casAuthors">Haluska, Paul; Shaw, Heather M.; Batzel, Gretchen N.; Yin, Donghua; Molina, Julian R.; Molife, L. Rhoda; Yap, Timothy A.; Roberts, M. Luisa; Sharma, Amarnath; Gualberto, Antonio; Adjei, Alex A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5834-5840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This phase I study was undertaken to define the max. tolerated dose, safety, and pharmacokinetic profile of CP-751,871.  Exptl. Design: Using a rapid dose escalation design, patients with advanced nonhematol. malignancies were treated with CP-751,871 in four dose escalation cohorts.  CP-751,871 was administered i.v. on day 1 of each 21-day cycle.  Pharmacokinetic evaluation was done in all treatment cohorts during cycles 1 and 4.  RESULTS: Twenty-four patients received 110 cycles at four dose levels.  The max. tolerated dose exceeded the maximal feasible dose of 20 mg/kg and, thus, was not identified.  Treatment-related toxicities were generally mild.  The most common adverse events were hyperglycemia, anorexia, nausea, elevated aspartate aminotransferase, elevated γ-glutamyltransferase, diarrhea, hyperuracemia, and fatigue.  At 20 mg/kg, 10 of 15 patients experienced stability of disease.  Two of these patients experienced long-term stability.  There were no objective responses.  Pharmacokinetic anal. revealed a dose-dependent increase in CP-751,871 exposure and ∼2-fold accumulation on repeated dosing in 21-day cycles.  Plasma concns. of CP-751,871 attained were several log-fold greater than the biol. active concn.  Treatment with CP-751,871 increased serum insulin and human growth hormone levels, with modest increases in serum glucose levels.  CONCLUSIONS: CP-751,871 has a favorable safety profile and was well tolerated when given in continuous cycles.  At the maximal feasible dose of 20 mg/kg, there was a moderate accumulation in plasma exposure, and most of the treated patients experienced stability of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2fKATmHTVIbVg90H21EOLACvtfcHk0liJ3yX6uPHgSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSntLrE&md5=e86e9de9cf2f9d8cea5e32376c8c5f18</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1118%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DShaw%26aufirst%3DH.%2BM.%26aulast%3DBatzel%26aufirst%3DG.%2BN.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DRoberts%26aufirst%3DM.%2BL.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DGualberto%26aufirst%3DA.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520study%2520of%2520the%2520anti-insulin-like%2520growth%2520factor-I%2520receptor%2520monoclonal%2520antibody%2520CP-751%252C871%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D5834%26epage%3D5840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayburn, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picozzi, V. J.</span><span> </span><span class="NLM_article-title">A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3520&author=M.+Hidalgoauthor=M.+Tirado+Gomezauthor=N.+Lewisauthor=J.+L.+Vukyauthor=G.+Taylorauthor=J.+L.+Hayburnauthor=K.+Hsuauthor=M.+Koshauthor=V.+J.+Picozzi&title=A+phase+I+study+of+MK-0646%2C+a+humanized+monoclonal+antibody+against+the+insulin-like+growth+factor+receptor+type+1+%28IGF1R%29+in+advanced+solid+tumor+patients+in+a+q2+wk+schedule"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DTirado%2BGomez%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DN.%26aulast%3DVuky%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DG.%26aulast%3DHayburn%26aufirst%3DJ.%2BL.%26aulast%3DHsu%26aufirst%3DK.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DPicozzi%26aufirst%3DV.%2BJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520MK-0646%252C%2520a%2520humanized%2520monoclonal%2520antibody%2520against%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520type%25201%2520%2528IGF1R%2529%2520in%2520advanced%2520solid%2520tumor%2520patients%2520in%2520a%2520q2%2520wk%2520schedule%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Higano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssoufian, H.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer</span> <span class="citation_source-journal">Eur. J. Cancer, Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1359-6349%2806%2970653-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=195&author=C.+Higanoauthor=M.+Gordonauthor=R.+LoRussoauthor=F.+Foxauthor=T.+Katzauthor=J.+Roeckerauthor=E.+Rowinskyauthor=H.+Youssoufian&title=A+phase+I+dose-escalation+study+of+weekly+IMC-A12%2C+a+fully+human+insulin+like+growth+factor-1+receptor+%28IGF-IR%29+IgG1+monoclonal+antibody+%28Mab%29%2C+in+patients+%28pts%29+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2806%2970653-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252806%252970653-X%26sid%3Dliteratum%253Aachs%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DLoRusso%26aufirst%3DR.%26aulast%3DFox%26aufirst%3DF.%26aulast%3DKatz%26aufirst%3DT.%26aulast%3DRoecker%26aufirst%3DJ.%26aulast%3DRowinsky%26aufirst%3DE.%26aulast%3DYoussoufian%26aufirst%3DH.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520weekly%2520IMC-A12%252C%2520a%2520fully%2520human%2520insulin%2520like%2520growth%2520factor-1%2520receptor%2520%2528IGF-IR%2529%2520IgG1%2520monoclonal%2520antibody%2520%2528Mab%2529%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%252C%2520Suppl.%26date%3D2006%26volume%3D4%26spage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mery-Mignard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deslandes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span> </span><span class="NLM_article-title">Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1166&author=P.+Moreauauthor=C.+Hulinauthor=T.+Faconauthor=M.+Boccadoroauthor=D.+Mery-Mignardauthor=A.+Deslandesauthor=J.+L.+Harousseau&title=Phase+I+Study+of+AVE1642+Anti+IGF-1R+Monoclonal+Antibody+in+Patients+with+Advanced+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DHulin%26aufirst%3DC.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DMery-Mignard%26aufirst%3DD.%26aulast%3DDeslandes%26aufirst%3DA.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26atitle%3DPhase%2520I%2520Study%2520of%2520AVE1642%2520Anti%2520IGF-1R%2520Monoclonal%2520Antibody%2520in%2520Patients%2520with%2520Advanced%2520Multiple%2520Myeloma%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Rothenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poplin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssoufian, H.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span><span class="NLM_elocation-id">C84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Rothenbergauthor=E.+Poplinauthor=A.+Sandlerauthor=E.+Rubinauthor=F.+Foxauthor=J.+Schwartzauthor=W.+Vermeulenauthor=H.+Youssoufian&title=Phase+I+dose-escalation+study+of+the+anti-IGF-IR+recombinant+human+IgG1+monoclonal+antibody+%28Mab%29+IMC-A12%2C+administered+every+other+week+to+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothenberg%26aufirst%3DM.%26aulast%3DPoplin%26aufirst%3DE.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%26aulast%3DFox%26aufirst%3DF.%26aulast%3DSchwartz%26aufirst%3DJ.%26aulast%3DVermeulen%26aufirst%3DW.%26aulast%3DYoussoufian%26aufirst%3DH.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520anti-IGF-IR%2520recombinant%2520human%2520IgG1%2520monoclonal%2520antibody%2520%2528Mab%2529%2520IMC-A12%252C%2520administered%2520every%2520other%2520week%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbeke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haqq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2006.08.8898" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3002&author=A.+W.+Tolcherauthor=M.+L.+Rothenbergauthor=J.+Rodonauthor=D.+Delbekeauthor=A.+Patnaikauthor=L.+Nguyenauthor=F.+Youngauthor=Y.+Hwangauthor=C.+Haqqauthor=I.+Puzanov&title=A+phase+I+pharmacokinetic+and+pharmacodynamic+study+of+AMG+479%2C+a+fully+human+monoclonal+antibody+against+insulin-like+growth+factor+type+1+receptor+%28IGF-1R%29%2C+in+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.08.8898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.08.8898%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDelbeke%26aufirst%3DD.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DF.%26aulast%3DHwang%26aufirst%3DY.%26aulast%3DHaqq%26aufirst%3DC.%26aulast%3DPuzanov%26aufirst%3DI.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520AMG%2520479%252C%2520a%2520fully%2520human%2520monoclonal%2520antibody%2520against%2520insulin-like%2520growth%2520factor%2520type%25201%2520receptor%2520%2528IGF-1R%2529%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Chitnis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">The type 1 insulin-like growth factor receptor pathway</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6364</span><span class="NLM_x">–</span> <span class="NLM_lpage">6370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-4879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18927274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6364-6370&author=M.+M.+Chitnisauthor=J.+S.+Yuenauthor=A.+S.+Protheroeauthor=M.+Pollakauthor=V.+M.+Macaulay&title=The+type+1+insulin-like+growth+factor+receptor+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Type 1 Insulin-Like Growth Factor Receptor Pathway</span></div><div class="casAuthors">Chitnis, Meenali M.; Yuen, John S. P.; Protheroe, Andrew S.; Pollak, Michael; Macaulay, Valentine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6364-6370</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Research conducted over the past two decades has shown the importance of the type 1 insulin-like growth factor receptor (IGF1R) in tumorigenesis, metastasis, and resistance to existing forms of cancer therapy.  The IGF1R itself has only recently been accepted as a credible treatment target, however, perhaps reflecting the potential problems for drug design posed by normal tissue IGF1R expression, and close homol. with the insulin receptor.  Currently ∼12 anti-IGF1R therapeutics are undergoing clin. evaluation, including blocking antibodies and tyrosine kinase inhibitors.  This review will summarize the principal signaling pathways activated by IGF1R and the preclin. data that validated this receptor as a treatment target.  We will review clin. progress in the testing of IGF1R inhibitory drug candidates, the relative benefits and potential toxicities of coinhibition of the insulin receptor, and the rationale for combining IGF1R blockade with other cancer treatments.  An understanding of IGF1R signaling is important because it will guide the incorporation of appropriate mol. markers into clin. trial design.  This will be key to the identification of patients most likely to benefit, and so will influence the ability of IGF1R inhibition to make the transition from exptl. intervention to clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gRwsJwfjNbVg90H21EOLACvtfcHk0lhl7VDWaWy7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrP&md5=2596cc57323f1aa5eee0b87e4554a0fe</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4879%26sid%3Dliteratum%253Aachs%26aulast%3DChitnis%26aufirst%3DM.%2BM.%26aulast%3DYuen%26aufirst%3DJ.%2BS.%26aulast%3DProtheroe%26aufirst%3DA.%2BS.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DThe%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520pathway%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6364%26epage%3D6370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kurmasheva, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">IGF-I mediated survival pathways in normal and malignant cells</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1766</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1766&publication_year=2006&pages=1-22&author=R.+T.+Kurmashevaauthor=P.+J.+Houghton&title=IGF-I+mediated+survival+pathways+in+normal+and+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DIGF-I%2520mediated%2520survival%2520pathways%2520in%2520normal%2520and%2520malignant%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2006%26volume%3D1766%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mateos, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandiella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San-Miguel, J. F.</span><span> </span><span class="NLM_article-title">New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1470-2045%2808%2970304-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19038762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1157-1165&author=E.+M.+Ocioauthor=M.+V.+Mateosauthor=P.+Maisoauthor=A.+Pandiellaauthor=J.+F.+San-Miguel&title=New+drugs+in+multiple+myeloma%3A+mechanisms+of+action+and+phase+I%2FII+clinical+findings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings</span></div><div class="casAuthors">Ocio, Enrique M.; Mateos, Maria-Victoria; Maiso, Patricia; Pandiella, Atanasio; San-Miguel, Jesus F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib.  Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance.  In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclin. and clin. studies in multiple myeloma.  Unfortunately, the single-agent clin. activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1keNCrAvODbVg90H21EOLACvtfcHk0lhqkSf8aX_Bkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7K&md5=6f48bee7ba0f1278bc174352a6be08e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2808%2970304-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252808%252970304-8%26sid%3Dliteratum%253Aachs%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26atitle%3DNew%2520drugs%2520in%2520multiple%2520myeloma%253A%2520mechanisms%2520of%2520action%2520and%2520phase%2520I%252FII%2520clinical%2520findings%26jtitle%3DLancet%2520Oncol.%26date%3D2008%26volume%3D9%26spage%3D1157%26epage%3D1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor signalling in neoplasia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrc2536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19029956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=915-928&author=M.+Pollak&title=Insulin+and+insulin-like+growth+factor+signalling+in+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor signalling in neoplasia</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metab. and growth.  There is now considerable evidence that these hormones and the signal transduction networks they regulate have important roles in neoplasia.  Epidermiol., clin. and lab. research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signaling.  Pharmacol. strategies under study include the use of novel receptor-specific antibodies, receptor kinase inhibitors and AMP-activated protein kinase activators such as metformin.  There is evidence that insulin and IGF signaling may also be relevant to dietary and lifestyle factors that influence cancer risk and cancer prognosis.  Recent results are encouraging and have justified the expansion of many translational research programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Q6Nlh1d68rVg90H21EOLACvtfcHk0lhqkSf8aX_Bkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL&md5=9a7b5e7c67599c7396033f83276f2cb0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrc2536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2536%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor%2520signalling%2520in%2520neoplasia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D915%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Riedemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">IGF1R signalling and its inhibition</span> <span class="citation_source-journal">Endocr.-Relat Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S33</span><span class="NLM_x">–</span> <span class="NLM_lpage">S43</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=S33-S43&issue=Suppl.+1&author=J.+Riedemannauthor=V.+M.+Macaulay&title=IGF1R+signalling+and+its+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiedemann%26aufirst%3DJ.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DIGF1R%2520signalling%2520and%2520its%2520inhibition%26jtitle%3DEndocr.-Relat%2520Cancer%26date%3D2006%26volume%3D13%26issue%3DSuppl.%25201%26spage%3DS33%26epage%3DS43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Ryan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, P. E.</span><span> </span><span class="NLM_article-title">The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=16-24&author=P.+D.+Ryanauthor=P.+E.+Goss&title=The+emerging+role+of+the+insulin-like+growth+factor+pathway+as+a+therapeutic+target+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DP.%2BD.%26aulast%3DGoss%26aufirst%3DP.%2BE.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520insulin-like%2520growth%2520factor%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D16%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Sachdev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Disrupting insulin-like growth factor signaling as a potential cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17237261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVantg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1-12&author=D.+Sachdevauthor=D.+Yee&title=Disrupting+insulin-like+growth+factor+signaling+as+a+potential+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting insulin-like growth factor signaling as a potential cancer therapy</span></div><div class="casAuthors">Sachdev, Deepali; Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of insulin-like growth factor-I (IGF-I) are assocd. with increased risk of breast, colon, and prostate cancers.  Because IGF-II and insulin signal via the insulin receptor (IR) to stimulate the growth of cancer cells, inhibition of IR might be necessary to totally disrupt the action of IGFs and their receptors.  This review describes the well-recognized roles of IGF-IR in driving the malignant phenotype, examines the evidence that perhaps IR should also be targeted to inhibit the effects of the IGF ligands and insulin in cancer, describes the strategies to disrupt IGF signaling in cancer, and highlights some key issues that need to be considered as clin. trials targeting IGF-IR proceed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDCcpW1cNYXbVg90H21EOLACvtfcHk0ljgSFlN8VHJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVantg%253D%253D&md5=90c2e9e9ea4eeac9a1b458b097442284</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0080%26sid%3Dliteratum%253Aachs%26aulast%3DSachdev%26aufirst%3DD.%26aulast%3DYee%26aufirst%3DD.%26atitle%3DDisrupting%2520insulin-like%2520growth%2520factor%2520signaling%2520as%2520a%2520potential%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Samani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodt, P.</span><span> </span><span class="NLM_article-title">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2006-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16931767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=20-47&author=A.+A.+Samaniauthor=S.+Yakarauthor=D.+LeRoithauthor=P.+Brodt&title=The+role+of+the+IGF+system+in+cancer+growth+and+metastasis%3A+overview+and+recent+insights"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span></div><div class="casAuthors">Samani, Amir Abbas; Yakar, Shoshana; LeRoith, Derek; Brodt, Pnina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-47</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  IGF-I receptor (IGF-IR) signaling and functions are mediated through the activities of a complex mol. network of pos. (e.g., type I IGF) and neg. (e.g., the type II IGF receptor, IGF-IIR) effectors.  Under normal physiol. conditions, the balance between the expression and activities of these mols. is tightly controlled.  Changes in this delicate balance (e.g., overexpression of one effector) may trigger a cascade of mol. events that can ultimately lead to malignancy.  In recent years, evidence has been mounting that the IGF axis may be involved in human cancer progression and can be targeted for therapeutic intervention.  Here we review old and more recent evidence on the role the IGF system in malignancy and highlight exptl. and clin. studies that provide novel insights into the complex mechanisms that contribute to its oncogenic potential.  Controversies arising from conflicting evidence on the relevance of IGF-IR and its ligands to human cancer are discussed.  Our review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression levels, state of activation, accessibility, and functionality of other interacting components.  Because IGF targeting for anticancer therapy is rapidly becoming a clin. reality, an understanding of this complexity is timely because it is likely to have an impact on the design, mode of action, and clin. outcomes of newly developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaVO8jlyh3LVg90H21EOLACvtfcHk0ljgSFlN8VHJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D&md5=f900044e75292ad8c7797407fe500025</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1210%2Fer.2006-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2006-0001%26sid%3Dliteratum%253Aachs%26aulast%3DSamani%26aufirst%3DA.%2BA.%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DBrodt%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%2520growth%2520and%2520metastasis%253A%2520overview%2520and%2520recent%2520insights%26jtitle%3DEndocr.%2520Rev.%26date%3D2007%26volume%3D28%26spage%3D20%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Tao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncponc0934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17898809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2isLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=591-602&author=Y.+Taoauthor=V.+Pinziauthor=J.+Bourhisauthor=E.+Deutsch&title=Mechanisms+of+disease%3A+signaling+of+the+insulin-like+growth+factor+1+receptor+pathway%E2%80%94therapeutic+perspectives+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer</span></div><div class="casAuthors">Tao, Yungan; Pinzi, Valentina; Bourhis, Jean; Deutsch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">591-602</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer.  IGF1R signaling has been found to correlate with resistance to anti-EGFR and HER2-based therapies in exptl. systems.  This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of the IGF1R in the resistance of other receptor-targeted therapies.  The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer.  High levels of circulating IGF1 and certain genetic polymorphisms of IGF1 and IGFBP3 are assocd. with an increased risk of several common cancers.  The IGF1 receptor (IGF1R) has been shown to be expressed in a wide range of tumors, and IGF1R signaling is crucial for tumor transformation and the survival of malignant cells.  Several monoclonal antibodies and small-mol. inhibitors have been tested in preclin. studies and early-phase clin. studies.  IGF1R signaling interferes with numerous growth factors and receptors such as VEGF and EGFR.  In the exptl. system, IGF1R signaling has been found to correlate with resistance to therapies based on the inhibition of EGFR and HER2.  This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of IGF1R in resistance to other receptor-targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxL4VL6f6eMrVg90H21EOLACvtfcHk0ljLcr_LXQthQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2isLfE&md5=89dcfab09c26f07e2f0da1bd23c06d5f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fncponc0934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0934%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%26aulast%3DPinzi%26aufirst%3DV.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DMechanisms%2520of%2520disease%253A%2520signaling%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520pathway%25E2%2580%2594therapeutic%2520perspectives%2520in%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2007%26volume%3D4%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Jansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, B.</span><span> </span><span class="NLM_article-title">Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">8189</span><span class="NLM_x">–</span> <span class="NLM_lpage">8197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1074%2Fjbc.272.13.8189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9079636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK2sXitF2nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=8189-8197&author=M.+Janssonauthor=D.+Hallenauthor=H.+Kohoauthor=G.+Anderssonauthor=L.+Berghardauthor=J.+Heidrichauthor=E.+Nybergauthor=M.+Uhlenauthor=J.+Kordelauthor=B.+Nilsson&title=Characterization+of+ligand+binding+of+a+soluble+human+insulin-like+growth+factor+I+receptor+variant+suggests+a+ligand-induced+conformational+change"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change</span></div><div class="casAuthors">Jansson, Magnus; Hallen, Dan; Koho, Hannu; Andersson, Gunilla; Berghard, Lotta; Heidrich, Jessica; Nyberg, Elisabeth; Uhlen, Mathias; Koerdel, Johan; Nilsson, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8189-8197</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Details of the signal transduction mechanisms of the tyrosine kinase family of growth factor receptors remain elusive.  The authors describe an extensive study of kinetic and thermodn. aspects of growth factor binding to a sol. extracellular human insulin-like growth factor-I receptor (sIGF-IR) variant.  The extracellular receptor domains were produced fused to an IgG-binding protein domain (Z) in transfected human 293 cells as a correctly processed secreted α-β'-Z dimer.  The receptor was purified using IgG affinity chromatog., rendering a pure and homogeneous protein in yields from 1 to 5 mg/L of conditioned cell media.  Biosensor technol. (BIAcore) was applied to measure the insulin-like growth factor-I (IGF-I), des(1-3)IGF-I, insulin-like growth factor-II, and insulin ligand binding rate consts. to the immobilized IGF-IR-Z.  The assocn. equil. const., Ka, for the IGF-I interaction is detd. to 2.8 × 108 M-1 (25°).  Microcalorimetric titrns. on IGF-I/IGF-IR-Z were performed at three different temps. (15, 25, and 37°) and in two different buffer systems at 25°.  From these measurements, equil. consts. for the 1:1 (IGF-I:(α-β'-Z)2) receptor complex in soln. are deduced to 0.96 × 108 M-1 (25°).  The detd. heat capacity change for the process is large and neg., -51 kcal (K mol.)-1.  Further, the entropy change (ΔS) at 25° is large and neg.  Far- and near-UV CD measurements display significant changes over the entire wavelength range upon binding of IGF-I to IGF-IR-Z.  These data are all consistent with a significant change in structure of the system upon IGF-I binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVNzbHrKkCbVg90H21EOLACvtfcHk0ljLcr_LXQthQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitF2nsr4%253D&md5=ba0e5756450d1d62d7826cd1e2b83ab3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.13.8189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.13.8189%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DHallen%26aufirst%3DD.%26aulast%3DKoho%26aufirst%3DH.%26aulast%3DAndersson%26aufirst%3DG.%26aulast%3DBerghard%26aufirst%3DL.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DNyberg%26aufirst%3DE.%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DKordel%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DB.%26atitle%3DCharacterization%2520of%2520ligand%2520binding%2520of%2520a%2520soluble%2520human%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520variant%2520suggests%2520a%2520ligand-induced%2520conformational%2520change%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D8189%26epage%3D8197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Massague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, M. P.</span><span> </span><span class="NLM_article-title">The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">5038</span><span class="NLM_x">–</span> <span class="NLM_lpage">5045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=5038-5045&author=J.+Massagueauthor=M.+P.+Czech&title=The+subunit+structures+of+two+distinct+receptors+for+insulin-like+growth+factors+I+and+II+and+their+relationship+to+the+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DCzech%26aufirst%3DM.%2BP.%26atitle%3DThe%2520subunit%2520structures%2520of%2520two%2520distinct%2520receptors%2520for%2520insulin-like%2520growth%2520factors%2520I%2520and%2520II%2520and%2520their%2520relationship%2520to%2520the%2520insulin%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D5038%26epage%3D5045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Garrett, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKern, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenkel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovrecz, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elleman, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span> </span><span class="NLM_article-title">Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=395-399&author=T.+P.+Garrettauthor=N.+M.+McKernauthor=M.+Louauthor=M.+J.+Frenkelauthor=J.+D.+Bentleyauthor=G.+O.+Lovreczauthor=T.+C.+Ellemanauthor=L.+J.+Cosgroveauthor=C.+W.+Ward&title=Crystal+structure+of+the+first+three+domains+of+the+type-1+insulin-like+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DT.%2BP.%26aulast%3DMcKern%26aufirst%3DN.%2BM.%26aulast%3DLou%26aufirst%3DM.%26aulast%3DFrenkel%26aufirst%3DM.%2BJ.%26aulast%3DBentley%26aufirst%3DJ.%2BD.%26aulast%3DLovrecz%26aufirst%3DG.%2BO.%26aulast%3DElleman%26aufirst%3DT.%2BC.%26aulast%3DCosgrove%26aufirst%3DL.%2BJ.%26aulast%3DWard%26aufirst%3DC.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520the%2520first%2520three%2520domains%2520of%2520the%2520type-1%2520insulin-like%2520growth%2520factor%2520receptor%26jtitle%3DNature%26date%3D1998%26volume%3D394%26spage%3D395%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Furstenberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, H. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factors and cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1470-2045%2802%2900731-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12067807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=298-302&author=G.+Furstenbergerauthor=H.+J.+Senn&title=Insulin-like+growth+factors+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factors and cancer</span></div><div class="casAuthors">Furstenberger, Gregor; Senn, Hans-Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">298-302</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interest in insulin-like growth factors (IGFs) and their effect on carcinogenesis has increased recently because high serum concns. of IGF1 are assocd. with an increased risk of breast, prostate, colorectal, and lung cancers.  Physiol., IGF1 is the major mediator of the effects of the growth hormone; it thus has a strong influence on cell proliferation and differentiation and is a potent inhibitor of apoptosis.  The action of IGF1 is predominantly mediated through the IGF1 receptor (IGF1R).  IGF1R is involved in several oncogenic transformation processes.  The availability of unbound IGF1 for interaction with IGF1R is modulated by IGF-binding proteins (IGFBP1-6).  IGFBPs, esp. IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zKKsA1j2FrVg90H21EOLACvtfcHk0lgfm2vw3N5ipA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWhsb0%253D&md5=1000da87e64e46d338826835e84861e7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900731-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900731-3%26sid%3Dliteratum%253Aachs%26aulast%3DFurstenberger%26aufirst%3DG.%26aulast%3DSenn%26aufirst%3DH.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factors%2520and%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D298%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Bennett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagashima, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintz, R. L.</span><span> </span><span class="NLM_article-title">Levels of insulin-like growth factors I and II in human cord blood</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fjcem-57-3-609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=6348065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaL3sXltFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1983&pages=609-612&author=A.+Bennettauthor=D.+M.+Wilsonauthor=F.+Liuauthor=R.+Nagashimaauthor=R.+G.+Rosenfeldauthor=R.+L.+Hintz&title=Levels+of+insulin-like+growth+factors+I+and+II+in+human+cord+blood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Levels of insulin-like growth factors I and II in human cord blood</span></div><div class="casAuthors">Bennett, Ann; Wilson, Darrell M.; Liu, Frances; Nagashima, Raymond; Rosenfeld, Ron G.; Hintz, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-12</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">Levels of insulin-like growth factor I (IGF-I)  [67763-96-6], IGF-II  [67763-97-7], and somatomedin  [9038-70-4] peptide content (SMPC) were measured in 32 normal term and 11 preterm infants.  After acid chromatog. to remove somatomedin-binding protein, SMPC was measured by placental membrane radioreceptor assay, whereas plasma IGF-I and IGF-II concns. were measured by specific RIAs.  SMPC levels in term infants were significantly below normal adult levels [0.49 units/mL for infants compared to 1.30 units/mL for adult males].  IGF-I levels in term infants were also low, averaging 11.3 ng/mL for infants, the normal adult levels is 184 ng/mL.  The IGF-II level was 282 ng/mL for infants and 687 ng/mL for adults.  Both IGF-I and IGF-II levels in preterm infants were lower than those in term infants.  IGF-I, IGF-II, and SMPC levels showed a pos. correlation with birth wt. in term infants.  Both IGF-I and IGF-II levels showed a strong pos. correlation with gestational age in all infants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKyXo_o9YuLVg90H21EOLACvtfcHk0lgfm2vw3N5ipA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltFKrtrw%253D&md5=301207f49082188b174c770d577c6922</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1210%2Fjcem-57-3-609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem-57-3-609%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DNagashima%26aufirst%3DR.%26aulast%3DRosenfeld%26aufirst%3DR.%2BG.%26aulast%3DHintz%26aufirst%3DR.%2BL.%26atitle%3DLevels%2520of%2520insulin-like%2520growth%2520factors%2520I%2520and%2520II%2520in%2520human%2520cord%2520blood%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab%26date%3D1983%26volume%3D57%26spage%3D609%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Germain-Lee, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casella, S. J.</span><span> </span><span class="NLM_article-title">Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x"> (</span><span class="NLM_issue">Part 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1992&pages=413-417&issue=Part+2&author=E.+L.+Germain-Leeauthor=M.+Janicotauthor=R.+Lammersauthor=A.+Ullrichauthor=S.+J.+Casella&title=Expression+of+a+type+I+insulin-like+growth+factor+receptor+with+low+affinity+for+insulin-like+growth+factor+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGermain-Lee%26aufirst%3DE.%2BL.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DCasella%26aufirst%3DS.%2BJ.%26atitle%3DExpression%2520of%2520a%2520type%2520I%2520insulin-like%2520growth%2520factor%2520receptor%2520with%2520low%2520affinity%2520for%2520insulin-like%2520growth%2520factor%2520II%26jtitle%3DBiochem.%2520J.%26date%3D1992%26volume%3D281%26issue%3DPart%25202%26spage%3D413%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Steele-Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1244</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=1990&pages=1244-1251&author=G.+Steele-Perkinsauthor=R.+A.+Roth&title=Monoclonal+antibody+alpha+IR-3+inhibits+the+ability+of+insulin-like+growth+factor+II+to+stimulate+a+signal+from+the+type+I+receptor+without+inhibiting+its+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteele-Perkins%26aufirst%3DG.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DMonoclonal%2520antibody%2520alpha%2520IR-3%2520inhibits%2520the%2520ability%2520of%2520insulin-like%2520growth%2520factor%2520II%2520to%2520stimulate%2520a%2520signal%2520from%2520the%2520type%2520I%2520receptor%2520without%2520inhibiting%2520its%2520binding%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D171%26spage%3D1244%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Danielsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gammeltoft, S.</span><span> </span><span class="NLM_article-title">Chromaffin cells express two types of insulin-like growth factor receptors</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0006-8993%2890%2990958-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=2167752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK3cXltV2qsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=1990&pages=95-100&author=A.+Danielsenauthor=E.+Larsenauthor=S.+Gammeltoft&title=Chromaffin+cells+express+two+types+of+insulin-like+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Chromaffin cells express two types of insulin-like growth factor receptors</span></div><div class="casAuthors">Danielsen, Anne; Larsen, Elisabeth; Gammeltoft, Steen</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The receptor binding, internalization, and tyrosine kinase activation of insulin-like growth factors (IGF) I and II have been investigated in cultured adult bovine chromaffin cells.  IGF-I receptor α-subunits (Mr ∼130,000) bound IGF-I and IGF-II with identical affinity (Kd ∼1 nM) and insulin with about 1000-times lower affinity, IGF-II receptors (Mr ∼250,000) bound IGF-II with a Kd of 0.5 nM, IGF-I with about 10-times lower affinity and insulin with >10,000-times lower affinity.  The amts. of IGF-I and IGF-II receptors on the cell surface were 8 × 104 and 4 × 104 sites per cell, resp.  Insulin bound to a specific receptor with Kd ∼2 nM and the amt. of receptors was 1.5 × 104 sites per cell.  IGF-I and IGF-II stimulated tyrosine kinase activity and autophosphorylation of the IGF-I receptor β-subunit (Mr ∼94,000) with equal potency (ED50 ∼1 nM), whereas insulin was ∼5-times less potent.  Both IGF-I and IGF-II were internalized after their binding to cell surface receptors.  Mannose-6-phosphate, which binds to the IGF-II receptor, did not alter the binding or internalization of IGF-II.  IGF-I and IGF-II can exert their biol. effects in chromaffin cells by activation of the IGF-I receptor tyrosine kinase or by interaction with the IGF-II receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyB6HpbzrblbVg90H21EOLACvtfcHk0lh1HdAch-9K9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltV2qsb4%253D&md5=d51ef6ae5177b1e01b6e7d796c127c51</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2890%2990958-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252890%252990958-E%26sid%3Dliteratum%253Aachs%26aulast%3DDanielsen%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DE.%26aulast%3DGammeltoft%26aufirst%3DS.%26atitle%3DChromaffin%2520cells%2520express%2520two%2520types%2520of%2520insulin-like%2520growth%2520factor%2520receptors%26jtitle%3DBrain%2520Res.%26date%3D1990%26volume%3D518%26spage%3D95%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Forbes, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeil, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surinya, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, J. C.</span><span> </span><span class="NLM_article-title">Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1046%2Fj.0014-2956.2001.02735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11846798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtlKnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2002&pages=961-968&author=B.+E.+Forbesauthor=P.+J.+Hartfieldauthor=K.+A.+McNeilauthor=K.+H.+Surinyaauthor=S.+J.+Milnerauthor=L.+J.+Cosgroveauthor=J.+C.+Wallace&title=Characteristics+of+binding+of+insulin-like+growth+factor+%28IGF%29-I+and+IGF-II+analogues+to+the+type+1+IGF+receptor+determined+by+BIAcore+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis: correlation of binding affinity with ability to prevent apoptosis</span></div><div class="casAuthors">Forbes, Briony E.; Hartfield, Perry J.; McNeil, Kerrie A.; Surinya, Kathy H.; Milner, Steven J.; Cosgrove, Leah J.; Wallace, John C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">961-968</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor (IGF) binding to the type 1 IGF receptor (IGF1R) elicits mitogenic effects, promotion of differentiation and protection from apoptosis.  This study has systematically measured IGF1R binding affinities of IGF-I, IGF-II and 14 IGF analogs to a recombinant high-affinity form of the IGF1R using BIAcore technol.  The analogs assessed could be divided into two groups: (a) those designed to investigate binding of IGF-binding protein, which exhibited IGF1R-binding affinities similar to those of IGF-I or IGF-II; (b) those generated to probe IGF1R interactions with greatly reduced IGF1R-binding affinities.  The relative binding affinities of IGF-I analogs and IGF-I for the IGF1R detd. by BIAcore anal. agreed closely with existing data from receptor-binding assays using cells or tissue membranes, demonstrating that BIAcore technol. is a powerful tool for measuring affinities of IGFs for IGF1R.  In parallel studies, IGF1R-binding affinities were related to ability to protect against serum withdrawal-induced apoptosis in three different assays including Hoechst 33258 staining, cell survival, and DNA fragmentation assays using the rat pheochromocytoma cell line, PC12.  In this model system, IGF-I and IGF-II at low nanomolar concns. are able to prevent apoptosis completely.  The authors conclude that ability to protect against apoptosis is directly related to ability to bind the IGF1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFjO9roFmz8bVg90H21EOLACvtfcHk0lhxpYjyB6cvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtlKnu7g%253D&md5=695e4e4e7354723281ca666b0343daf9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1046%2Fj.0014-2956.2001.02735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0014-2956.2001.02735.x%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DB.%2BE.%26aulast%3DHartfield%26aufirst%3DP.%2BJ.%26aulast%3DMcNeil%26aufirst%3DK.%2BA.%26aulast%3DSurinya%26aufirst%3DK.%2BH.%26aulast%3DMilner%26aufirst%3DS.%2BJ.%26aulast%3DCosgrove%26aufirst%3DL.%2BJ.%26aulast%3DWallace%26aufirst%3DJ.%2BC.%26atitle%3DCharacteristics%2520of%2520binding%2520of%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529-I%2520and%2520IGF-II%2520analogues%2520to%2520the%2520type%25201%2520IGF%2520receptor%2520determined%2520by%2520BIAcore%2520analysis%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2002%26volume%3D269%26spage%3D961%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantzoros, C. S.</span><span> </span><span class="NLM_article-title">The role of the IGF system in cancer: from basic to clinical studies and clinical applications</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2002&pages=317-332&author=S.+J.+Moschosauthor=C.+S.+Mantzoros&title=The+role+of+the+IGF+system+in+cancer%3A+from+basic+to+clinical+studies+and+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DMantzoros%26aufirst%3DC.%2BS.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%253A%2520from%2520basic%2520to%2520clinical%2520studies%2520and%2520clinical%2520applications%26jtitle%3DOncology%26date%3D2002%26volume%3D63%26spage%3D317%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3278</span><span class="NLM_x">–</span> <span class="NLM_lpage">3288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10207053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXislSltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=3278-3288&author=F.+Frascaauthor=G.+Pandiniauthor=P.+Scaliaauthor=L.+Sciaccaauthor=R.+Mineoauthor=A.+Costantinoauthor=I.+D.+Goldfineauthor=A.+Belfioreauthor=R.+Vigneri&title=Insulin+receptor+isoform+A%2C+a+newly+recognized%2C+high-affinity+insulin-like+growth+factor+II+receptor+in+fetal+and+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells</span></div><div class="casAuthors">Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I. D.; Belfiore, A.; Vigneri, R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3278-3288</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Insulin-like growth factor II (IGF-II) is a peptide growth factor that is homologous to both insulin-like growth factor I (IGF-I) and insulin and plays an important role in embryonic development and carcinogenesis.  IGF-II is believed to mediate its cellular signaling via the transmembrane tyrosine kinase type 1 insulin-like growth factor receptor (IGF-I-R), which is also the receptor for IGF-I.  Earlier studies with both cultured cells and transgenic mice, however, have suggested that in the embryo the insulin receptor (IR) may also be a receptor for IGF-II.  In most cells and tissues, IR binds IGF-II with relatively low affinity.  The IR is expressed in two isoforms (IR-A and IR-B) differing by 12 amino acids due to the alternative splicing of exon 11.  In the present study the authors found that IR-A but not IR-B bound IGF-II with an affinity close to that of insulin.  Moreover, IGF-II bound to IR-A with an affinity equal to that of IGF-II binding to the IGF-I-R.  Activation of IR-A by insulin led primarily to metabolic effects, whereas activation of IR-A by IGF-II led primarily to mitogenic effects.  These differences in the biol. effects of IR-A when activated by either IGF-II or insulin were assocd. with differential recruitment and activation of intracellular substrates.  IR-A was preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney and had a relatively increased proportion of isoform A.  IR-A expression was also increased in several tumors including those of the breast and colon.  These data indicate, therefore, that there are two receptors for IGF-II, both IGF-I-R and IR-A.  Further, they suggest that interaction of IGF-II with IR-A may play a role both in fetal growth and cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNrk0Logv4N7Vg90H21EOLACvtfcHk0lhxpYjyB6cvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislSltLk%253D&md5=689c94d9ae9c1e5466517e3b25453aa9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DScalia%26aufirst%3DP.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DInsulin%2520receptor%2520isoform%2520A%252C%2520a%2520newly%2520recognized%252C%2520high-affinity%2520insulin-like%2520growth%2520factor%2520II%2520receptor%2520in%2520fetal%2520and%2520cancer%2520cells%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D3278%26epage%3D3288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzino, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squatrito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">The role of insulin receptors and IGF-I receptors in cancer and other diseases</span> <span class="citation_source-journal">Arch. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1080%2F13813450801969715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18465356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlKls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2008&pages=23-37&author=F.+Frascaauthor=G.+Pandiniauthor=L.+Sciaccaauthor=V.+Pezzinoauthor=S.+Squatritoauthor=A.+Belfioreauthor=R.+Vigneri&title=The+role+of+insulin+receptors+and+IGF-I+receptors+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The role of insulin receptors and IGF-I receptors in cancer and other diseases</span></div><div class="casAuthors">Frasca, Francesco; Pandini, Giuseppe; Sciacca, Laura; Pezzino, Vincenzo; Squatrito, Sebastiano; Belfiore, Antonio; Vigneri, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-37</span>CODEN:
                <span class="NLM_cas:coden">APBIF5</span>;
        ISSN:<span class="NLM_cas:issn">1381-3455</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  There is evidence, both in vitro and in vivo, that receptor tyrosine kinases play a key role in the formation and progression of human cancer.  In particular, the insulin-like growth factor receptor (IGF-IR), a tyrosine kinase receptor for IGF-I and IGF-II, was well documented in cell culture, animal studies, and humans to play a role in malignant transformation, progression, protection from apoptosis, and metastasis.  In addn., the hormone insulin (which is very closely related to the IGFs) and its tyrosine kinase receptor (the IR, which is very closely related to the IGR-IR) were documented both in vitro and in vivo to play a key role in cancer biol.  Indeed, several epidemiol. studies have shown that insulin resistance status, characterized by hyperinsulinemia, is assocd. with an increased risk for a no. of malignancies, including carcinomas of the breast, prostate, colon and kidney.  Recent data have elucidated some mol. mechanisms by which IR is involved in cancer.  IR is over-expressed in several human malignancies.  Interestingly, one of the 2 IR isoform (IR-A) is esp. over-expressed in cancer.  IR-A is the IR fetal isoform and has the peculiar characteristic to bind not only insulin but also IGF-II.  In addn., the IR contributes to formation of hybrid receptors with the IGF-IR (HR).  By binding to hybrid receptors, insulin may stimulate specific IGF-IR signaling pathways.  Over-expression of IR-A is, therefore, a major mechanism of IGF system over-activation in cancer.  In this respect, IR-A isoform and hybrid receptors should be regarded as potential mol. targets, in addn. to IGF-IR, for novel anti-cancer therapy.  These findings may have important implications for both the prevention and treatment of common human malignancies.  They underline the concept that hyperinsulinemia, assocd. with insulin resistance and obesity, should be treated by changes in life style and/or pharmacol. approaches to avoid an increased risk for cancer.  Moreover, native insulin and insulin analog administration should be carefully evaluated in terms of the possible increase in cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGXs0W7l05vLVg90H21EOLACvtfcHk0lizJRMmz8_qaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlKls7s%253D&md5=134ab24a4e7cc0b88d8d4d50c92753c6</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1080%2F13813450801969715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13813450801969715%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DPezzino%26aufirst%3DV.%26aulast%3DSquatrito%26aufirst%3DS.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520insulin%2520receptors%2520and%2520IGF-I%2520receptors%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DArch.%2520Physiol.%2520Biochem.%26date%3D2008%26volume%3D114%26spage%3D23%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">39684</span><span class="NLM_x">–</span> <span class="NLM_lpage">39695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=39684-39695&author=G.+Pandiniauthor=F.+Frascaauthor=R.+Mineoauthor=L.+Sciaccaauthor=R.+Vigneriauthor=A.+Belfiore&title=Insulin%2Finsulin-like+growth+factor+I+hybrid+receptors+have+different+biological+characteristics+depending+on+the+insulin+receptor+isoform+involved"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%252Finsulin-like%2520growth%2520factor%2520I%2520hybrid%2520receptors%2520have%2520different%2520biological%2520characteristics%2520depending%2520on%2520the%2520insulin%2520receptor%2520isoform%2520involved%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D39684%26epage%3D39695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">42178</span><span class="NLM_x">–</span> <span class="NLM_lpage">42189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=42178-42189&author=G.+Pandiniauthor=E.+Medicoauthor=E.+Conteauthor=L.+Sciaccaauthor=R.+Vigneriauthor=A.+Belfiore&title=Differential+gene+expression+induced+by+insulin+and+insulin-like+growth+factor-II+through+the+insulin+receptor+isoform+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DConte%26aufirst%3DE.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DDifferential%2520gene%2520expression%2520induced%2520by%2520insulin%2520and%2520insulin-like%2520growth%2520factor-II%2520through%2520the%2520insulin%2520receptor%2520isoform%2520A%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D42178%26epage%3D42189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbraccia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2479</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=2471-2479&author=L.+Sciaccaauthor=A.+Costantinoauthor=G.+Pandiniauthor=R.+Mineoauthor=F.+Frascaauthor=P.+Scaliaauthor=P.+Sbracciaauthor=I.+D.+Goldfineauthor=R.+Vigneriauthor=A.+Belfiore&title=Insulin+receptor+activation+by+IGF-II+in+breast+cancers%3A+evidence+for+a+new+autocrine%2Fparacrine+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DScalia%26aufirst%3DP.%26aulast%3DSbraccia%26aufirst%3DP.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%2520receptor%2520activation%2520by%2520IGF-II%2520in%2520breast%2520cancers%253A%2520evidence%2520for%2520a%2520new%2520autocrine%252Fparacrine%2520mechanism%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D2471%26epage%3D2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8240</span><span class="NLM_x">–</span> <span class="NLM_lpage">8250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=8240-8250&author=L.+Sciaccaauthor=R.+Mineoauthor=G.+Pandiniauthor=A.+Murabitoauthor=R.+Vigneriauthor=A.+Belfiore&title=In+IGF-I+receptor-deficient+leiomyosarcoma+cells+autocrine+IGF-II+induces+cell+invasion+and+protection+from+apoptosis+via+the+insulin+receptor+isoform+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMurabito%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DIn%2520IGF-I%2520receptor-deficient%2520leiomyosarcoma%2520cells%2520autocrine%2520IGF-II%2520induces%2520cell%2520invasion%2520and%2520protection%2520from%2520apoptosis%2520via%2520the%2520insulin%2520receptor%2520isoform%2520A%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D8240%26epage%3D8250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F138161207780249173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17346183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=671-686&author=A.+Belfiore&title=The+role+of+insulin+receptor+isoforms+and+hybrid+insulin%2FIGF-I+receptors+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer</span></div><div class="casAuthors">Belfiore, Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-686</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review will focus on the emerging role of the insulin receptor (IR) in cancer.  Several epidemiol. studies have shown that insulin resistance states, characterized by hyperinsulinemia, are assocd. with an increased risk for a no. of malignancies, including carcinomas of the breast, prostate, colon and kidney.  Recent data have elucidated some mol. mechanisms by which IR is involved in cancer.  First, IR is overexpressed in several human malignancies.  Interestingly, one of the two IR isoform (IR-A) is esp. overexpressed in cancer.  IR-A is the IR fetal isoform and has the peculiar characteristic to bind not only insulin but also IGF-II.  Second, IR forms hybrid receptors with the homologous IGF-IR, which is also commonly overexpressed in cancer.  These hybrid receptors contg. IR-A hemidimers have broad binding specificity as they bind IGF-I and also IGF-II and insulin.  By binding to hybrid receptors, insulin may stimulate specific IGF-IR signaling pathways.  Overexpression of IR-A is, therefore, a major mechanism of IGF system overactivation in cancer.  These findings may have important implications for both the prevention and treatment of common human malignancies.  They underline the concept that hyperinsulinemia, assocd. with insulin resistance and obesity, should be treated by changes in life style and/or pharmachol. approaches to avoid an increased risk for cancer.  IR-A isoform and hybrid receptors should be regarded, therefore, as potential mol. targets for novel anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzOXo5usLgbVg90H21EOLACvtfcHk0liFR2E2HrmV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVagtr8%253D&md5=7f35c91393d0c0fd34b62467121b1f6e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F138161207780249173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207780249173%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520insulin%2520receptor%2520isoforms%2520and%2520hybrid%2520insulin%252FIGF-I%2520receptors%2520in%2520human%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D671%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita-Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10430101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXltVCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=1935-1944&author=G.+Pandiniauthor=R.+Vigneriauthor=A.+Costantinoauthor=F.+Frascaauthor=A.+Ippolitoauthor=Y.+Fujita-Yamaguchiauthor=K.+Siddleauthor=I.+D.+Goldfineauthor=A.+Belfiore&title=Insulin+and+insulin-like+growth+factor-I+%28IGF-I%29+receptor+overexpression+in+breast+cancers+leads+to+insulin%2FIGF-I+hybrid+receptor+overexpression%3A+evidence+for+a+second+mechanism+of+IGF-I+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling</span></div><div class="casAuthors">Pandini, Giuseppe; Vigneri, Riccardo; Costantino, Angela; Frasca, Francesco; Ippolito, Antonio; Fujita-Yamaguchi, Yoko; Siddle, Kenneth; Goldfine, Ira D.; Belfiore, Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1935-1944</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin receptor (IR) form hybrids with the closely related insulin-like growth factor-I (IGF-I) receptor (IGF-I-R).  Because most human breast carcinomas overexpress both the IR and the IGF-I-R, we evaluated whether the insulin/IGF-I hybrid receptor (Hybrid-R) is also overexpressed in these tumors and what role it plays in breast cancer biol.  Using specific ELISAs and Western blots, we measured Hybrid-R content and function in 8 human cultured breast cancer cell lines and 39 human breast cancer specimens.  Hybrid-R content and function were also compared to the content and function of the IR and the IGF-I-R.  Hybrid-R content exceeded the IGF-I-R content in >75% of breast cancer specimens and was directly related to the molar ratio of both the IR and IGF-I-R content, suggesting that Hybrid-R formation occurred by random assembly of IR and IGF-I-R half-receptors.  Hybrid-Rs became tyrosine autophosphorylated when breast cancer cells were exposed to IGF-I but not when they were exposed to insulin.  In cells with an elevated Hybrid-R content, Hybrid-R autophosphorylation in response to IGF-I exceeded IGF-I-R autophosphorylation, suggesting that most of the IGF-I effect occurred via the Hybrid-R.  Furthermore, Hybrid-Rs mediated growth in response to IGF-I, as indicated by expts. with blocking antibodies to the IGF-I-R.  These data indicated therefore that: (a) Hybrid-Rs are present and play a major role in mediating the IGF-I signal in breast cancer; (b) their expression is directly related to IR overexpression; and (c) potential therapies designed to block IGF-I actions in breast cancer must take into account the role of these Hybrid-Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGFXal6HPgLVg90H21EOLACvtfcHk0liFR2E2HrmV5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVCqtL8%253D&md5=f685d7d1d496c8a08df18da522c719d1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DIppolito%26aufirst%3DA.%26aulast%3DFujita-Yamaguchi%26aufirst%3DY.%26aulast%3DSiddle%26aufirst%3DK.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520overexpression%2520in%2520breast%2520cancers%2520leads%2520to%2520insulin%252FIGF-I%2520hybrid%2520receptor%2520overexpression%253A%2520evidence%2520for%2520a%2520second%2520mechanism%2520of%2520IGF-I%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D1935%26epage%3D1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Heuson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legros, N.</span><span> </span><span class="NLM_article-title">Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1972&pages=226-232&author=J.+C.+Heusonauthor=N.+Legros&title=Influence+of+insulin+deprivation+on+growth+of+the+7%2C12-dimethylbenz%28a%29anthracene-induced+mammary+carcinoma+in+rats+subjected+to+alloxan+diabetes+and+food+restriction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeuson%26aufirst%3DJ.%2BC.%26aulast%3DLegros%26aufirst%3DN.%26atitle%3DInfluence%2520of%2520insulin%2520deprivation%2520on%2520growth%2520of%2520the%25207%252C12-dimethylbenz%2528a%2529anthracene-induced%2520mammary%2520carcinoma%2520in%2520rats%2520subjected%2520to%2520alloxan%2520diabetes%2520and%2520food%2520restriction%26jtitle%3DCancer%2520Res.%26date%3D1972%26volume%3D32%26spage%3D226%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monaco, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, M. E.</span><span> </span><span class="NLM_article-title">Hormone responsive human breast cancer in long-term tissue culture: effect of insulin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4536</span><span class="NLM_x">–</span> <span class="NLM_lpage">4540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4536-4540&author=C.+K.+Osborneauthor=G.+Bolanauthor=M.+E.+Monacoauthor=M.+E.+Lippman&title=Hormone+responsive+human+breast+cancer+in+long-term+tissue+culture%3A+effect+of+insulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBolan%26aufirst%3DG.%26aulast%3DMonaco%26aufirst%3DM.%2BE.%26aulast%3DLippman%26aufirst%3DM.%2BE.%26atitle%3DHormone%2520responsive%2520human%2520breast%2520cancer%2520in%2520long-term%2520tissue%2520culture%253A%2520effect%2520of%2520insulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4536%26epage%3D4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Arcaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doepfner, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerreiro, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span> </span><span class="NLM_article-title">Novel role for insulin as an autocrine growth factor for malignant brain tumour cells</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2007&pages=57-66&author=A.+Arcaroauthor=K.+T.+Doepfnerauthor=D.+Bollerauthor=A.+S.+Guerreiroauthor=T.+Shalabyauthor=S.+P.+Jacksonauthor=S.+M.+Schoenwaelderauthor=O.+Delattreauthor=M.+A.+Grotzerauthor=B.+Fischer&title=Novel+role+for+insulin+as+an+autocrine+growth+factor+for+malignant+brain+tumour+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArcaro%26aufirst%3DA.%26aulast%3DDoepfner%26aufirst%3DK.%2BT.%26aulast%3DBoller%26aufirst%3DD.%26aulast%3DGuerreiro%26aufirst%3DA.%2BS.%26aulast%3DShalaby%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DDelattre%26aufirst%3DO.%26aulast%3DGrotzer%26aufirst%3DM.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26atitle%3DNovel%2520role%2520for%2520insulin%2520as%2520an%2520autocrine%2520growth%2520factor%2520for%2520malignant%2520brain%2520tumour%2520cells%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D406%26spage%3D57%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Cox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakikhani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin receptor expression by human prostate cancers</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=33-40&author=M.+E.+Coxauthor=M.+E.+Gleaveauthor=M.+Zakikhaniauthor=R.+H.+Bellauthor=E.+Piuraauthor=E.+Vickersauthor=M.+Cunninghamauthor=O.+Larssonauthor=L.+Fazliauthor=M.+Pollak&title=Insulin+receptor+expression+by+human+prostate+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DM.%2BE.%26aulast%3DGleave%26aufirst%3DM.%2BE.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DR.%2BH.%26aulast%3DPiura%26aufirst%3DE.%26aulast%3DVickers%26aufirst%3DE.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DFazli%26aufirst%3DL.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520receptor%2520expression%2520by%2520human%2520prostate%2520cancers%26jtitle%3DProstate%26date%3D2009%26volume%3D69%26spage%3D33%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Hede, K.</span><span> </span><span class="NLM_article-title">Doctors seek to prevent breast cancer recurrence by lowering insulin levels</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2Fdjn119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18398091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1c3lt1Wntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=530-532&author=K.+Hede&title=Doctors+seek+to+prevent+breast+cancer+recurrence+by+lowering+insulin+levels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Doctors seek to prevent breast cancer recurrence by lowering insulin levels</span></div><div class="casAuthors">Hede Karyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">530-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRs6BohTJeTws-crCu0nI_sfW6udTcc2eZzf0LJ5Ygh7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3lt1Wntw%253D%253D&md5=a54d69fb501a454e5a9e740888f31386</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjn119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjn119%26sid%3Dliteratum%253Aachs%26aulast%3DHede%26aufirst%3DK.%26atitle%3DDoctors%2520seek%2520to%2520prevent%2520breast%2520cancer%2520recurrence%2520by%2520lowering%2520insulin%2520levels%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D530%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Law, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habibi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. E.</span><span> </span><span class="NLM_article-title">Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">10238</span><span class="NLM_x">–</span> <span class="NLM_lpage">10246</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=10238-10246&author=J.+H.+Lawauthor=G.+Habibiauthor=K.+Huauthor=H.+Masoudiauthor=M.+Y.+Wangauthor=A.+L.+Stratfordauthor=E.+Parkauthor=J.+M.+Geeauthor=P.+Finlayauthor=H.+E.+Jonesauthor=R.+I.+Nicholsonauthor=J.+Carboniauthor=M.+Gottardisauthor=M.+Pollakauthor=S.+E.+Dunn&title=Phosphorylated+insulin-like+growth+factor-i%2Finsulin+receptor+is+present+in+all+breast+cancer+subtypes+and+is+related+to+poor+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaw%26aufirst%3DJ.%2BH.%26aulast%3DHabibi%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DMasoudi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%2BY.%26aulast%3DStratford%26aufirst%3DA.%2BL.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DFinlay%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DH.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DS.%2BE.%26atitle%3DPhosphorylated%2520insulin-like%2520growth%2520factor-i%252Finsulin%2520receptor%2520is%2520present%2520in%2520all%2520breast%2520cancer%2520subtypes%2520and%2520is%2520related%2520to%2520poor%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D10238%26epage%3D10246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Ohsugi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cras-Meneur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal-Mizrachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luciani, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polonsky, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Permutt, M. A.</span><span> </span><span class="NLM_article-title">Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">4992</span><span class="NLM_x">–</span> <span class="NLM_lpage">5003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=4992-5003&author=M.+Ohsugiauthor=C.+Cras-Meneurauthor=Y.+Zhouauthor=E.+Bernal-Mizrachiauthor=J.+D.+Johnsonauthor=D.+S.+Lucianiauthor=K.+S.+Polonskyauthor=M.+A.+Permutt&title=Reduced+expression+of+the+insulin+receptor+in+mouse+insulinoma+%28MIN6%29+cells+reveals+multiple+roles+of+insulin+signaling+in+gene+expression%2C+proliferation%2C+insulin+content%2C+and+secretion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhsugi%26aufirst%3DM.%26aulast%3DCras-Meneur%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DBernal-Mizrachi%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DJ.%2BD.%26aulast%3DLuciani%26aufirst%3DD.%2BS.%26aulast%3DPolonsky%26aufirst%3DK.%2BS.%26aulast%3DPermutt%26aufirst%3DM.%2BA.%26atitle%3DReduced%2520expression%2520of%2520the%2520insulin%2520receptor%2520in%2520mouse%2520insulinoma%2520%2528MIN6%2529%2520cells%2520reveals%2520multiple%2520roles%2520of%2520insulin%2520signaling%2520in%2520gene%2520expression%252C%2520proliferation%252C%2520insulin%2520content%252C%2520and%2520secretion%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D4992%26epage%3D5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Venkateswaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, A. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleshner, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2Fdjm231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18042933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2sjit1SgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2007&pages=1793-1800&author=V.+Venkateswaranauthor=A.+Q.+Haddadauthor=N.+E.+Fleshnerauthor=R.+Fanauthor=L.+M.+Sugarauthor=R.+Namauthor=L.+H.+Klotzauthor=M.+Pollak&title=Association+of+diet-induced+hyperinsulinemia+with+accelerated+growth+of+prostate+cancer+%28LNCaP%29+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts</span></div><div class="casAuthors">Venkateswaran Vasundara; Haddad Ahmed Q; Fleshner Neil E; Fan Rong; Sugar Linda M; Nam Rob; Klotz Laurence H; Pollak Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1793-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Prior research suggested that energy balance and fat intake influence prostate cancer progression, but the influence of dietary carbohydrate on prostate cancer progression has not been well characterized.  We hypothesized that hyperinsulinemia resulting from high intake of refined carbohydrates would lead to more rapid growth of tumors in the murine LNCaP xenograft model of prostate cancer.  METHODS:  Athymic mice were injected subcutaneously with LNCaP human prostate cancer cells and, when tumors were palpable, were randomly assigned (n = 20 per group) to high carbohydrate-high fat or low carbohydrate-high fat diets.  Body weight and tumor volume were measured weekly.  After 9 weeks, serum levels of insulin and insulin-like growth factor 1 (IGF-1) were measured by enzyme immunoassay.  AKT activation and the levels of the insulin receptor in tumor cells were determined by immunoblotting.  The in vitro growth response of LNCaP cells to serum from mice in the two treatment groups was measured based on tetrazolium compound reduction.  All statistical tests were two-sided.  RESULTS:  After 9 weeks on the experimental diets, mice on the high carbohydrate-high fat diet were heavier (mean body weight of mice on the high carbohydrate-high fat diet = 34 g versus 29.1 g on the low carbohydrate-high fat diet, difference = 4.9 g, 95% CI = 3.8 to 6.0 g; P = .003), experienced increased tumor growth (mean tumor volume in mice on high carbohydrate-high fat diet = 1695 versus 980 mm3 on low carbohydrate-high fat diet, difference = 715 mm3, 95% CI = 608 to 822 mm3; P<.001), and experienced a statistically significant increase in serum insulin and IGF-1 levels.  Tumors from mice on the high carbohydrate-high fat diet had higher levels of activated AKT and modestly higher insulin receptor levels than tumors from mice on the low carbohydrate-high fat diet.  Serum from mice on the high carbohydrate-high fat diet was more mitogenic for LNCaP cells in vitro than serum from mice fed the low carbohydrate-high fat diet.  CONCLUSION:  A diet high in refined carbohydrates is associated with increased tumor growth and with activation of signaling pathways distal to the insulin receptor in a murine model of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYgSZZbgBO8kQ0lWbKiCflfW6udTcc2ebIpl9ZXzdgHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjit1SgtQ%253D%253D&md5=be414eb149b66cd784d81dbc3f04e80a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm231%26sid%3Dliteratum%253Aachs%26aulast%3DVenkateswaran%26aufirst%3DV.%26aulast%3DHaddad%26aufirst%3DA.%2BQ.%26aulast%3DFleshner%26aufirst%3DN.%2BE.%26aulast%3DFan%26aufirst%3DR.%26aulast%3DSugar%26aufirst%3DL.%2BM.%26aulast%3DNam%26aufirst%3DR.%26aulast%3DKlotz%26aufirst%3DL.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520diet-induced%2520hyperinsulinemia%2520with%2520accelerated%2520growth%2520of%2520prostate%2520cancer%2520%2528LNCaP%2529%2520xenografts%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2007%26volume%3D99%26spage%3D1793%26epage%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11118</span><span class="NLM_x">–</span> <span class="NLM_lpage">11128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-04-3841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16322262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11118-11128&author=R.+Nahtaauthor=L.+X.+Yuanauthor=B.+Zhangauthor=R.+Kobayashiauthor=F.+J.+Esteva&title=Insulin-like+growth+factor-I+receptor%2Fhuman+epidermal+growth+factor+receptor+2+heterodimerization+contributes+to+trastuzumab+resistance+of+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells</span></div><div class="casAuthors">Nahta, Rita; Yuan, Linda X. H.; Zhang, Bing; Kobayashi, Ryuji; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11118-11128</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of breast cancer patients who achieve an initial therapeutic response to the human epidermal growth factor receptor 2 (HER-2)-targeted antibody trastuzumab will show disease progression within 1 yr.  The authors previously reported the characterization of SKBR3-derived trastuzumab-resistant pools.  In the current study, the authors show that HER-2 interacts with insulin-like growth factor-I receptor (IGF-IR) uniquely in these resistant cells and not in the parental trastuzumab-sensitive cells.  The occurrence of cross talk between IGF-IR and HER-2 exclusively in resistant cells is evidenced by the IGF-I stimulation resulting in increased phosphorylation of HER-2 in resistant cells, but not in parental cells, and by the inhibition of IGF-IR tyrosine kinase activity leading to decreased HER-2 phosphorylation only in resistant cells.  In addn., inhibition of IGF-IR tyrosine kinase activity by I-OMe-AG538 increased sensitivity of resistant cells to trastuzumab.  HER-2/IGF-IR interaction was disrupted on exposure of resistant cells to the anti-IGF-IR antibody α-IR3 and, to a lesser extent, when exposed to the anti-HER-2 antibody pertuzumab.  Heterodimer disruption by α-IR3 dramatically restored sensitivity to trastuzumab and resistant cells showed a slightly increased sensitivity to pertuzumab vs. parental cells.  Neither α-IR3 nor pertuzumab decreased HER-2 phosphorylation, suggesting that addnl. sources of phosphorylation other than IGF-IR exist when HER-2 and IGF-IR are not phys. bound.  Our data support a unique interaction between HER-2 and IGF-IR in trastuzumab-resistant cells such that cross talk occurs between IGF-IR and HER-2.  These data suggest that the IGF-IR/HER-2 heterodimer contributes to trastuzumab resistance and justify the need for further studies examg. this complex as a potential therapeutic target in breast cancers that have progressed while on trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYXv8m9As-bVg90H21EOLACvtfcHk0ljBJJ0cZ5Un0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrrI&md5=305f51b308dbb62d5f7b7de48fecbcea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3841%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DKobayashi%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%252Fhuman%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterodimerization%2520contributes%2520to%2520trastuzumab%2520resistance%2520of%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11118%26epage%3D11128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Firth, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, R. C.</span><span> </span><span class="NLM_article-title">Cellular actions of the insulin-like growth factor binding proteins</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2001-0033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12466191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=824-854&author=S.+M.+Firthauthor=R.+C.+Baxter&title=Cellular+actions+of+the+insulin-like+growth+factor+binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular actions of the insulin-like growth factor binding proteins</span></div><div class="casAuthors">Firth, Sue M.; Baxter, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">824-854</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In addn. to their roles in IGF transport, the 6 IGF-binding proteins (IGFBPs) regulate cell activity in various ways.  By sequestering IGFs away from the type I IGF receptor, they may inhibit mitogenesis, differentiation, survival, and other IGF-stimulated events.  IGFBP proteolysis can reverse this inhibition or generate IGFBP fragments with novel bioactivity.  Alternatively, IGFBP interaction with cell or matrix components may conc. IGFs near their receptor, enhancing IGF activity.  IGF receptor-independent IGFBP actions are also increasingly recognized.  IGFBP-1 interacts with α5β1 integrin, influencing cell adhesion and migration.  IGFBP-2, -3, -5, and -6 have heparin-binding domains and can bind glycosaminoglycans.  IGFBP-3 and -5 have C-terminal basic motifs incorporating heparin-binding and addnl. basic residues that interact with the cell surface and matrix, the nuclear transporter importin-β, and other proteins.  Serine/threonine kinase receptors are proposed for IGFBP-3 and -5, but their signaling functions are poorly understood.  Other cell surface IGFBP-interacting proteins are uncharacterized as functional receptors.  However, IGFBP-3 binds and modulates the retinoid X receptor-α, interacts with TGFβ signaling through Smad proteins, and influences other signaling pathways.  These interactions can modulate cell cycle and apoptosis.  Because IGFBPs regulate cell functions by diverse mechanisms, manipulation of IGFBP-regulated pathways is speculated to offer therapeutic opportunities in cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm_E7z_51hwLVg90H21EOLACvtfcHk0ljBJJ0cZ5Un0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVSntb8%253D&md5=9d90c6ce160d4ad7d2f8babdd036b6f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1210%2Fer.2001-0033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2001-0033%26sid%3Dliteratum%253Aachs%26aulast%3DFirth%26aufirst%3DS.%2BM.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26atitle%3DCellular%2520actions%2520of%2520the%2520insulin-like%2520growth%2520factor%2520binding%2520proteins%26jtitle%3DEndocr.%2520Rev.%26date%3D2002%26volume%3D23%26spage%3D824%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Rosenfeld, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Bermejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minniti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, Y.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor binding protein superfamily: new perspectives</span> <span class="citation_source-journal">Pediatrics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=1018-1021&author=R.+G.+Rosenfeldauthor=V.+Hwaauthor=L.+Wilsonauthor=A.+Lopez-Bermejoauthor=C.+Buckwayauthor=C.+Burrenauthor=W.+K.+Choiauthor=G.+Deviauthor=A.+Ingermannauthor=D.+Grahamauthor=G.+Minnitiauthor=A.+Spagnoliauthor=Y.+Oh&title=The+insulin-like+growth+factor+binding+protein+superfamily%3A+new+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenfeld%26aufirst%3DR.%2BG.%26aulast%3DHwa%26aufirst%3DV.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DLopez-Bermejo%26aufirst%3DA.%26aulast%3DBuckway%26aufirst%3DC.%26aulast%3DBurren%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DW.%2BK.%26aulast%3DDevi%26aufirst%3DG.%26aulast%3DIngermann%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DMinniti%26aufirst%3DG.%26aulast%3DSpagnoli%26aufirst%3DA.%26aulast%3DOh%26aufirst%3DY.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520binding%2520protein%2520superfamily%253A%2520new%2520perspectives%26jtitle%3DPediatrics%26date%3D1999%26volume%3D104%26spage%3D1018%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiojima, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umezawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, I.</span><span> </span><span class="NLM_article-title">IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=345-349&author=W.+Zhuauthor=I.+Shiojimaauthor=Y.+Itoauthor=Z.+Liauthor=H.+Ikedaauthor=M.+Yoshidaauthor=A.+T.+Naitoauthor=J.+Nishiauthor=H.+Uenoauthor=A.+Umezawaauthor=T.+Minaminoauthor=T.+Nagaiauthor=A.+Kikuchiauthor=M.+Asashimaauthor=I.+Komuro&title=IGFBP-4+is+an+inhibitor+of+canonical+Wnt+signalling+required+for+cardiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShiojima%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DA.%2BT.%26aulast%3DNishi%26aufirst%3DJ.%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DUmezawa%26aufirst%3DA.%26aulast%3DMinamino%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DAsashima%26aufirst%3DM.%26aulast%3DKomuro%26aufirst%3DI.%26atitle%3DIGFBP-4%2520is%2520an%2520inhibitor%2520of%2520canonical%2520Wnt%2520signalling%2520required%2520for%2520cardiogenesis%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Kooijman, R.</span><span> </span><span class="NLM_article-title">Regulation of apoptosis by insulin-like growth factor (IGF)-I</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.cytogfr.2006.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16621671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=305-323&author=R.+Kooijman&title=Regulation+of+apoptosis+by+insulin-like+growth+factor+%28IGF%29-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of apoptosis by insulin-like growth factor (IGF)-I</span></div><div class="casAuthors">Kooijman, Ron</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-323</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  IGF-I is important for fetal and post-natal development, but it also controls tissue homeostasis throughout life via regulation of cell proliferation and apoptosis.  This review summarizes our current understanding of how IGF-I receptor signaling interferes with the apoptotic machinery of the cell.  IGF-I acts at different control points of apoptosis, including the Bcl-2 family proteins, inhibitors of caspases and signaling of death-inducing receptors.  The main focal point of IGF-I is the regulation of Bcl-2 family proteins.  Several signaling pathways converge to both the phosphorylation and transcriptional regulation of these proteins.  This phenomenon may explain the efficacy of IGF-I as an inhibitor of apoptosis in many different cell types and in the presence of different apoptogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmTBNxQwZr7Vg90H21EOLACvtfcHk0lg2h0i6jYBXow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSgsbk%253D&md5=02828dfebc553f75dc5b08b5a24ade3b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2006.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2006.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKooijman%26aufirst%3DR.%26atitle%3DRegulation%2520of%2520apoptosis%2520by%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529-I%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2006%26volume%3D17%26spage%3D305%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span> </span><span class="NLM_article-title">Protein tyrosine kinase structure and function</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1146%2Fannurev.biochem.69.1.373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10966463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2000&pages=373-398&author=S.+R.+Hubbardauthor=J.+H.+Till&title=Protein+tyrosine+kinase+structure+and+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine kinase structure and function</span></div><div class="casAuthors">Hubbard, Stevan R.; Till, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-398</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 116 refs.  Tyr-phosphorylation is one of the key covalent modifications that occurs in multicellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues.  The enzymes that carry out this modification are the protein tyrosine kinases (PTKs), which catalyze the transfer of the γ-phosphate of ATP to Tyr residues on protein substrates.  Phosphorylation of Tyr residues modulates enzymic activity and creates binding sites for the recruitment of downstream signaling proteins.  Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs.  Because PTKs are crit. components of cellular signaling pathways, their catalytic activity is strictly regulated.  Over the past several years, high-resoln. structural studies of PTKs have provided a mol. basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated.  This review highlights the important results that have emerged from these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogx8K1IKwbKLVg90H21EOLACvtfcHk0lgFoCLkoQXIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D&md5=2aae3e0c121c9e6652be99030af36af1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.69.1.373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.69.1.373%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26atitle%3DProtein%2520tyrosine%2520kinase%2520structure%2520and%2520function%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2000%26volume%3D69%26spage%3D373%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resnicoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Effect of mutations at serines 1280−1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">12254</span><span class="NLM_x">–</span> <span class="NLM_lpage">12260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=12254-12260&author=S.+Liauthor=M.+Resnicoffauthor=R.+Baserga&title=Effect+of+mutations+at+serines+1280%E2%88%921283+on+the+mitogenic+and+transforming+activities+of+the+insulin-like+growth+factor+I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DResnicoff%26aufirst%3DM.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DEffect%2520of%2520mutations%2520at%2520serines%25201280%25E2%2588%25921283%2520on%2520the%2520mitogenic%2520and%2520transforming%2520activities%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D12254%26epage%3D12260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Dews, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prisco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peruzzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrione, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2000&pages=1289-1300&author=M.+Dewsauthor=M.+Priscoauthor=F.+Peruzziauthor=G.+Romanoauthor=A.+Morrioneauthor=R.+Baserga&title=Domains+of+the+insulin-like+growth+factor+I+receptor+required+for+the+activation+of+extracellular+signal-regulated+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDews%26aufirst%3DM.%26aulast%3DPrisco%26aufirst%3DM.%26aulast%3DPeruzzi%26aufirst%3DF.%26aulast%3DRomano%26aufirst%3DG.%26aulast%3DMorrione%26aufirst%3DA.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DDomains%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520required%2520for%2520the%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinases%26jtitle%3DEndocrinology%26date%3D2000%26volume%3D141%26spage%3D1289%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tartare-Deckert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawka-Verhelle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdaca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, O. E.</span><span> </span><span class="NLM_article-title">Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">23456</span><span class="NLM_x">–</span> <span class="NLM_lpage">23460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=23456-23460&author=S.+Tartare-Deckertauthor=D.+Sawka-Verhelleauthor=J.+Murdacaauthor=O.+E.+Van&title=Evidence+for+a+differential+interaction+of+SHC+and+the+insulin+receptor+substrate-1+%28IRS-1%29+with+the+insulin-like+growth+factor-I+%28IGF-I%29+receptor+in+the+yeast+two-hybrid+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTartare-Deckert%26aufirst%3DS.%26aulast%3DSawka-Verhelle%26aufirst%3DD.%26aulast%3DMurdaca%26aufirst%3DJ.%26aulast%3DVan%26aufirst%3DO.%2BE.%26atitle%3DEvidence%2520for%2520a%2520differential%2520interaction%2520of%2520SHC%2520and%2520the%2520insulin%2520receptor%2520substrate-1%2520%2528IRS-1%2529%2520with%2520the%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520in%2520the%2520yeast%2520two-hybrid%2520system%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D23456%26epage%3D23460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Chang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navolanic, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blalock, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span> </span><span class="NLM_article-title">Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12579299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslKrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=469-480&author=F.+Changauthor=L.+S.+Steelmanauthor=J.+G.+Sheltonauthor=J.+T.+Leeauthor=P.+M.+Navolanicauthor=W.+L.+Blalockauthor=R.+Franklinauthor=J.+A.+McCubrey&title=Regulation+of+cell+cycle+progression+and+apoptosis+by+the+Ras%2FRaf%2FMEK%2FERK+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review)</span></div><div class="casAuthors">Chang, Fumin; Steelman, Linda S.; Shelton, John G.; Lee, John T.; Navolanic, Patrick M.; Blalock, William L.; Franklin, Richard; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-480</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  The Ras/Raf/MEK/ERK signal transduction pathway regulates cell cycle progression and apoptosis in diverse types of cells.  Mutations in this pathway are often obsd. in transformed cell lines and frequently linked with human cancers.  The Ras/Raf/MEK/ERK pathway can induce events both assocd. with cell proliferation and cell cycle arrest.  The particular course chosen may depend on the strength and the particular Raf gene activated by Ras.  This pathway also is involved in maintaining cell survival by modulating the activity of apoptotic mols. including Bad and Bcl-2.  This review will discuss the regulation of the Ras/Raf/MEK/ERK pathway and how it modulates cell cycle progression and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkNzwwNV5N1LVg90H21EOLACvtfcHk0ljSofLkOw9QuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslKrtbo%253D&md5=7edac4057b0506e100b773af70378a3a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DF.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DNavolanic%26aufirst%3DP.%2BM.%26aulast%3DBlalock%26aufirst%3DW.%2BL.%26aulast%3DFranklin%26aufirst%3DR.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DRegulation%2520of%2520cell%2520cycle%2520progression%2520and%2520apoptosis%2520by%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2003%26volume%3D22%26spage%3D469%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">White, M. F.</span><span> </span><span class="NLM_article-title">The IRS-signalling system: a network of docking proteins that mediate insulin action</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=1998&pages=3-11&author=M.+F.+White&title=The+IRS-signalling+system%3A+a+network+of+docking+proteins+that+mediate+insulin+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DM.%2BF.%26atitle%3DThe%2520IRS-signalling%2520system%253A%2520a%2520network%2520of%2520docking%2520proteins%2520that%2520mediate%2520insulin%2520action%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1998%26volume%3D182%26spage%3D3%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x"> (</span><span class="NLM_issue">Part 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=289-305&issue=Part+2&author=W.+Kolch&title=Meaningful+relationships%3A+the+regulation+of+the+Ras%2FRaf%2FMEK%2FERK+pathway+by+protein+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMeaningful%2520relationships%253A%2520the%2520regulation%2520of%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%2520by%2520protein%2520interactions%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26issue%3DPart%25202%26spage%3D289%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Allan, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrice, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. R.</span><span> </span><span class="NLM_article-title">Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncb1005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12792650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFeru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=647-654&author=L.+A.+Allanauthor=N.+Morriceauthor=S.+Bradyauthor=G.+Mageeauthor=S.+Pathakauthor=P.+R.+Clarke&title=Inhibition+of+caspase-9+through+phosphorylation+at+Thr+125+by+ERK+MAPK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK</span></div><div class="casAuthors">Allan, Lindsey A.; Morrice, Nick; Brady, Suzanne; Magee, Gareth; Pathak, Shalini; Clarke, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">647-654</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many pro-apoptotic signals activate caspase-9, an initiator protease that activates caspase-3 and downstream caspases to initiate cellular destruction.  However, survival signals can impinge on this pathway and suppress apoptosis.  Activation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway is assocd. with protection of cells from apoptosis and inhibition of caspase-3 activation, although the targets are unknown.  Here, the authors show that the ERK MAPK pathway inhibits caspase-9 activity by direct phosphorylation.  In mammalian cell exts., cytochrome c-induced activation of caspases-9 and -3 requires okadaic acid-sensitive protein phosphatase activity.  The opposing protein kinase activity is overcome by treatment with the broad-specificity kinase inhibitor staurosporine or with inhibitors of MEK1/2.  Caspase-9 is phosphorylated at Thr 125, a conserved MAPK consensus site targeted by ERK2 in vitro, in a MEK-dependent manner in cells stimulated with epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol-13-acetate (TPA).  Phosphorylation at Thr 125 is sufficient to block caspase-9 processing and subsequent caspase-3 activation.  The authors suggest that phosphorylation and inhibition of caspase-9 by ERK promotes cell survival during development and tissue homeostasis.  This mechanism may also contribute to tumorigenesis when the ERK MAPK pathway is constitutively activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxPQ4IB8G17Vg90H21EOLACvtfcHk0ljSofLkOw9QuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFeru7Y%253D&md5=360d7b1ddf1c1fcee2f958577ac89256</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fncb1005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1005%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DL.%2BA.%26aulast%3DMorrice%26aufirst%3DN.%26aulast%3DBrady%26aufirst%3DS.%26aulast%3DMagee%26aufirst%3DG.%26aulast%3DPathak%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DP.%2BR.%26atitle%3DInhibition%2520of%2520caspase-9%2520through%2520phosphorylation%2520at%2520Thr%2520125%2520by%2520ERK%2520MAPK%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2003%26volume%3D5%26spage%3D647%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apolloni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, J. F.</span><span> </span><span class="NLM_article-title">Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">24052</span><span class="NLM_x">–</span> <span class="NLM_lpage">24056</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=24052-24056&author=J.+Yanauthor=S.+Royauthor=A.+Apolloniauthor=A.+Laneauthor=J.+F.+Hancock&title=Ras+isoforms+vary+in+their+ability+to+activate+Raf-1+and+phosphoinositide+3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DApolloni%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DA.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26atitle%3DRas%2520isoforms%2520vary%2520in%2520their%2520ability%2520to%2520activate%2520Raf-1%2520and%2520phosphoinositide%25203-kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D24052%26epage%3D24056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Galmiche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fueller, J.</span><span> </span><span class="NLM_article-title">RAF kinases and mitochondria</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1773</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1773&publication_year=2007&pages=1256-1262&author=A.+Galmicheauthor=J.+Fueller&title=RAF+kinases+and+mitochondria"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalmiche%26aufirst%3DA.%26aulast%3DFueller%26aufirst%3DJ.%26atitle%3DRAF%2520kinases%2520and%2520mitochondria%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2007%26volume%3D1773%26spage%3D1256%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lgYRbN8BogWqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Macdonald, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, J. L.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span> </span><span class="NLM_article-title">A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=485-487&author=J.+S.+Macdonaldauthor=S.+McCoyauthor=R.+P.+Whiteheadauthor=S.+Iqbalauthor=J.+L.+Wadeauthor=J.+K.+Giguereauthor=J.+L.+Abbruzzese&title=A+phase+II+study+of+farnesyl+transferase+inhibitor+R115777+in+pancreatic+cancer%3A+a+Southwest+oncology+group+%28SWOG+9924%29+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DJ.%2BS.%26aulast%3DMcCoy%26aufirst%3DS.%26aulast%3DWhitehead%26aufirst%3DR.%2BP.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DWade%26aufirst%3DJ.%2BL.%26aulast%3DGiguere%26aufirst%3DJ.%2BK.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520pancreatic%2520cancer%253A%2520a%2520Southwest%2520oncology%2520group%2520%2528SWOG%25209924%2529%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2005%26volume%3D23%26spage%3D485%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von der, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardiak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahasrabudhe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Ruixo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, E. J.</span><span> </span><span class="NLM_article-title">A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2035</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2005&pages=2035-2041&author=J.+E.+Rosenbergauthor=M.+H.+von+derauthor=J.+D.+Seigneauthor=J.+Mardiakauthor=D.+J.+Vaughnauthor=M.+Mooreauthor=D.+Sahasrabudheauthor=P.+A.+Palmerauthor=J.+J.+Perez-Ruixoauthor=E.+J.+Small&title=A+phase+II+trial+of+R115777%2C+an+oral+farnesyl+transferase+inhibitor%2C+in+patients+with+advanced+urothelial+tract+transitional+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3Dvon%2Bder%26aufirst%3DM.%2BH.%26aulast%3DSeigne%26aufirst%3DJ.%2BD.%26aulast%3DMardiak%26aufirst%3DJ.%26aulast%3DVaughn%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DM.%26aulast%3DSahasrabudhe%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DP.%2BA.%26aulast%3DPerez-Ruixo%26aufirst%3DJ.%2BJ.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520R115777%252C%2520an%2520oral%2520farnesyl%2520transferase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520urothelial%2520tract%2520transitional%2520cell%2520carcinoma%26jtitle%3DCancer%26date%3D2005%26volume%3D103%26spage%3D2035%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlabach, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yunus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVore, R. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span><span class="NLM_x">–</span> <span class="NLM_lpage">1193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fannonc%2Fmdh315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15277257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2cznt1Wmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1187-1193&author=J.+V.+Heymachauthor=D.+H.+Johnsonauthor=F.+R.+Khuriauthor=H.+Safranauthor=L.+L.+Schlabachauthor=F.+Yunusauthor=R.+F.+DeVoreauthor=P.+M.+De+Porreauthor=H.+M.+Richardsauthor=X.+Jiaauthor=S.+Zhangauthor=B.+E.+Johnson&title=Phase+II+study+of+the+farnesyl+transferase+inhibitor+R115777+in+patients+with+sensitive+relapse+small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer</span></div><div class="casAuthors">Heymach J V; Johnson D H; Khuri F R; Safran H; Schlabach L L; Yunus F; DeVore R F 3rd; De Porre P M; Richards H M; Jia X; Zhang S; Johnson B E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1187-93</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  R115777 (tipifarnib, Zarnestra) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival.  This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC).  PATIENTS AND METHODS:  Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible.  R115777 was administered in 3-week cycles at a dose of 400 mg orally twice daily for 14 consecutive days followed by 7 days off treatment.  RESULTS:  Twenty-two patients were enrolled.  The median progression-free survival was 1.4 months and median overall survival was 6.8 months.  Non-hematological toxicities were predominantly grade 1-2 and included nausea (64%) and fatigue (60%).  Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27% and 23% of patients, respectively.  Febrile neutropenia was not observed.  Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5 h after oral dosing and no significant drug accumulation.  The trial was terminated because no objective responses were observed in 20 patients evaluable for response.  CONCLUSIONS:  R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIDYFtJj-b8IYPsCkJIw00fW6udTcc2ea7Sbqe4JOqp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cznt1Wmtg%253D%253D&md5=087c6ab3c1c27b87f6fe7d4d77281d24</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdh315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdh315%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSafran%26aufirst%3DH.%26aulast%3DSchlabach%26aufirst%3DL.%2BL.%26aulast%3DYunus%26aufirst%3DF.%26aulast%3DDeVore%26aufirst%3DR.%2BF.%26aulast%3DDe%2BPorre%26aufirst%3DP.%2BM.%26aulast%3DRichards%26aufirst%3DH.%2BM.%26aulast%3DJia%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520patients%2520with%2520sensitive%2520relapse%2520small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2004%26volume%3D15%26spage%3D1187%26epage%3D1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced clear-cell renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowski&title=Sorafenib+in+advanced+clear-cell+renal-cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0lhkJjh1jeFPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DSorafenib%2520in%2520advanced%2520clear-cell%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Elser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agulnik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pond, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheiken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elting, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrenciuc, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. X.</span><span> </span><span class="NLM_article-title">Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3766</span><span class="NLM_x">–</span> <span class="NLM_lpage">3773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2006.10.2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17704426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3766-3773&author=C.+Elserauthor=L.+L.+Siuauthor=E.+Winquistauthor=M.+Agulnikauthor=G.+R.+Pondauthor=S.+F.+Chinauthor=P.+Francisauthor=R.+Cheikenauthor=J.+Eltingauthor=A.+McNabolaauthor=D.+Wilkieauthor=O.+Petrenciucauthor=E.+X.+Chen&title=Phase+II+trial+of+sorafenib+in+patients+with+recurrent+or+metastatic+squamous+cell+carcinoma+of+the+head+and+neck+or+nasopharyngeal+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma</span></div><div class="casAuthors">Elser, Christine; Siu, Lillian L.; Winquist, Eric; Agulnik, Mark; Pond, Gregory R.; Chin, Soo F.; Francis, Peggy; Cheiken, Robin; Elting, James; McNabola, Angela; Wilkie, Dean; Petrenciuc, Oana; Chen, Eric X.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3766-3773</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To det. the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC).  Patients and Methods: In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles.  Patients had ≤ one line of chemotherapy for recurrent and/or metastatic disease, Eastern Cooperative Oncol. Group performance status of ≤ 2, and adequate organ function.  At the end of stage 1, efficacy criteria for further accrual were not met, but the study was amended to enroll an addnl. five patients for paired tumor biopsies.  Results: Twenty-seven and 26 patients were eligible for toxicity and efficacy evaluations, resp.  One patient (3.7%; 95% CI, 0.1% to 19.0%) achieved a partial response.  Disease stabilization was maintained in 10 patients (37.0%; 95% CI, 22.4% to 61.2%).  The median time to progression was 1.8 mo (95% CI, 1.6 to 3.4 mo), and median overall survival time was 4.2 mo (95% CI, 3.6 to 8.7 mo).  Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities.  Biomarker anal. of paired tumor samples before and after treatment with sorafenib revealed a decrease of pERK in all five patients, with a decrease in Ki67 in four patients, consistent with a disruption of ERK signaling.  The antiapoptotic protein Mcl-1 was downregulated in four patients, and there was also evidence of antiangiogenic activity.  Conclusion: Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients.  Further development in combination with radiation or other agents may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XKfUu9hLG7Vg90H21EOLACvtfcHk0lhkJjh1jeFPtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqtL7N&md5=f250b63e9c01bee09330dacafa96d9a2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.10.2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.10.2871%26sid%3Dliteratum%253Aachs%26aulast%3DElser%26aufirst%3DC.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DPond%26aufirst%3DG.%2BR.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DCheiken%26aufirst%3DR.%26aulast%3DElting%26aufirst%3DJ.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DPetrenciuc%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DE.%2BX.%26atitle%3DPhase%2520II%2520trial%2520of%2520sorafenib%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%2520or%2520nasopharyngeal%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3766%26epage%3D3773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Kopec, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamowicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esdaile, J. M.</span><span> </span><span class="NLM_article-title">Randomized discontinuation trials: utility and efficiency</span> <span class="citation_source-journal">J. Clin. Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0895-4356%2893%2990163-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8263581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaK2c%252FoslaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1993&pages=959-971&author=J.+A.+Kopecauthor=M.+Abrahamowiczauthor=J.+M.+Esdaile&title=Randomized+discontinuation+trials%3A+utility+and+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized discontinuation trials: utility and efficiency</span></div><div class="casAuthors">Kopec J A; Abrahamowicz M; Esdaile J M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical epidemiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-71</span>
        ISSN:<span class="NLM_cas:issn">0895-4356</span>.
    </div><div class="casAbstract">The randomized discontinuation trial (RDT) is a two-phase trial.  In phase I all patients are openly treated with the medication being evaluated.  In phase II, those who have responded are randomly assigned to continue the same treatment or switch to placebo.  Usually, non-compliers and "adverse reactors" identified in phase I are excluded from phase II.  To investigate the value of this design, we reviewed the advantages and limitations of discontinuation studies, and compared the RDT design to the classic randomized clinical trial design in terms of clinical utility and efficiency (sample size).  A computer model was used to study the efficiency of the two designs under a broad range of assumptions.  The RDT design is particularly useful in studying the effect of long-term, non-curative therapies, especially when the clinically important effect is relatively small, and the use of placebo should be minimized for ethical or feasibility reasons.  However, its use is limited if the objective of an investigation is to estimate the magnitude of absolute treatment effects and toxic effects in the source population, or to evaluate a potentially curative treatment.  Our results indicate that selecting responders prior to randomization has a very strong effect on the relative efficiency of the trial.  Further improvement may be achieved by excluding non-compliers and adverse reactors.  Under the assumptions tested in our model, the sample size required in phase II of an RDT was only 20-50% of that in a classic trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG5rK8JeajGJ0d-O_J5C0AfW6udTcc2eZbUKeMFquvT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FoslaksA%253D%253D&md5=605cf138d3b553ea9b8fc4464528b4a2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0895-4356%2893%2990163-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0895-4356%252893%252990163-U%26sid%3Dliteratum%253Aachs%26aulast%3DKopec%26aufirst%3DJ.%2BA.%26aulast%3DAbrahamowicz%26aufirst%3DM.%26aulast%3DEsdaile%26aufirst%3DJ.%2BM.%26atitle%3DRandomized%2520discontinuation%2520trials%253A%2520utility%2520and%2520efficiency%26jtitle%3DJ.%2520Clin.%2520Epidemiol.%26date%3D1993%26volume%3D46%26spage%3D959%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Bertrand, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappell, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span> </span><span class="NLM_article-title">Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1254</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1254-1260&author=F.+E.+Bertrandauthor=L.+S.+Steelmanauthor=W.+H.+Chappellauthor=S.+L.+Abramsauthor=J.+G.+Sheltonauthor=E.+R.+Whiteauthor=D.+L.+Ludwigauthor=J.+A.+McCubrey&title=Synergy+between+an+IGF-1R+antibody+and+Raf%2FMEK%2FERK+and+PI3K%2FAkt%2FmTOR+pathway+inhibitors+in+suppressing+IGF-1R-mediated+growth+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DF.%2BE.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DChappell%26aufirst%3DW.%2BH.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DWhite%26aufirst%3DE.%2BR.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DSynergy%2520between%2520an%2520IGF-1R%2520antibody%2520and%2520Raf%252FMEK%252FERK%2520and%2520PI3K%252FAkt%252FmTOR%2520pathway%2520inhibitors%2520in%2520suppressing%2520IGF-1R-mediated%2520growth%2520in%2520hematopoietic%2520cells%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D1254%26epage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT pathway for cancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+pathway+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0li8J4YJ-yPuZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520pathway%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Osaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshimura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span> </span><span class="NLM_article-title">PI3K-Akt pathway: its functions and alterations in human cancer</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=667-676&author=M.+Osakiauthor=M.+Oshimuraauthor=H.+Ito&title=PI3K-Akt+pathway%3A+its+functions+and+alterations+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsaki%26aufirst%3DM.%26aulast%3DOshimura%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPI3K-Akt%2520pathway%253A%2520its%2520functions%2520and%2520alterations%2520in%2520human%2520cancer%26jtitle%3DApoptosis%26date%3D2004%26volume%3D9%26spage%3D667%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span> </span><span class="NLM_article-title">Regulation of protein kinases in insulin, growth factor and Wnt signalling</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0959-440X%2802%2900386-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12504681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=761-767&author=L.+H.+Pearlauthor=D.+Barford&title=Regulation+of+protein+kinases+in+insulin%2C+growth+factor+and+Wnt+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases in insulin, growth factor and Wnt signalling</span></div><div class="casAuthors">Pearl, Laurence H.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-767</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinase cascades provide the regulatory mechanisms for many of the essential processes in eukaryotic cells.  Recent structural and biochem. work has revealed the basis of phosphorylation regulation of three consecutive protein kinases - phosphoinositide-dependent kinase 1 (PDK1), protein kinase B (PKB)/Akt and glycogen synthase kinase 3β (GSK3β) - which transduce signals generated by insulin and/or growth factors binding to cell surface receptors.  PDK1 and PKB are both AGC family kinases.  Whereas PKB is pos. regulated via its phosphorylated C-terminal hydrophobic motif, the activity and specificity of PDK1 are detd. by equiv. hydrophobic motifs of substrate AGC kinases.  In a contrasting mechanism, GSK3β is neg. regulated by competitive autoinhibition by its phosphorylated N terminus.  GSK3β also functions in the developmental Wnt signaling pathway, but without cross-talk with the PDK1-PKB/Akt pathway.  Structural studies of GSK3β complexes are contributing to our understanding of the phosphorylation-independent mechanism that insulates the Wnt and insulin/growth factor pathways.  Structural studies of three consecutive protein kinases in insulin/growth factor signaling (PDK1, PKB/Akt and GSK3b) are revealing complex regulatory mechanisms and beginning to explain how GSK3b also participates in Wnt signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa4IaywapaqbVg90H21EOLACvtfcHk0liuJlibTch2gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslSksL8%253D&md5=b0aab1728b44477af6a2b8bdf2a6d565</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2802%2900386-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252802%252900386-X%26sid%3Dliteratum%253Aachs%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520protein%2520kinases%2520in%2520insulin%252C%2520growth%2520factor%2520and%2520Wnt%2520signalling%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D12%26spage%3D761%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Mamane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petroulakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeBacquer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">mTOR, translation initiation and cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6416</span><span class="NLM_x">–</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6416-6422&author=Y.+Mamaneauthor=E.+Petroulakisauthor=O.+LeBacquerauthor=N.+Sonenberg&title=mTOR%2C+translation+initiation+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamane%26aufirst%3DY.%26aulast%3DPetroulakis%26aufirst%3DE.%26aulast%3DLeBacquer%26aufirst%3DO.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DmTOR%252C%2520translation%2520initiation%2520and%2520cancer%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6416%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Marygold, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leevers, S. J.</span><span> </span><span class="NLM_article-title">Growth signaling: TSC takes its place</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">R785</span><span class="NLM_x">–</span> <span class="NLM_lpage">R787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=R785-R787&author=S.+J.+Marygoldauthor=S.+J.+Leevers&title=Growth+signaling%3A+TSC+takes+its+place"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarygold%26aufirst%3DS.%2BJ.%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26atitle%3DGrowth%2520signaling%253A%2520TSC%2520takes%2520its%2520place%26jtitle%3DCurr.%2520Biol.%26date%3D2002%26volume%3D12%26spage%3DR785%26epage%3DR787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Growing roles for the mTOR pathway</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ceb.2005.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16226444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=596-603&author=D.+D.+Sarbassovauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Growing+roles+for+the+mTOR+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Growing roles for the mTOR pathway</span></div><div class="casAuthors">Sarbassov, Dos D.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">596-603</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian TOR (mTOR; mammalian target of rapamycin) pathway is a key regulator of cell growth and proliferation and increasing evidence suggests that its deregulation is assocd. with human diseases, including cancer and diabetes.  The mTOR pathway integrates signals from nutrients, energy status, and growth factors to regulate many processes, including autophagy, ribosome biogenesis, and metab.  Recent work identifying 2 structurally and functionally distinct mTOR-contg. multiprotein complexes, and TSC1/2, rheb, and AMPK as upstream regulators of mTOR, is beginning to reveal how mTOR can sense diverse signals and produce a myriad of responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMOIIVMYJG0LVg90H21EOLACvtfcHk0liuJlibTch2gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyksL7F&md5=e24e27de16bd9f8e7219b684c7242f8e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DGrowing%2520roles%2520for%2520the%2520mTOR%2520pathway%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26spage%3D596%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=977-980&author=X.+Baiauthor=D.+Maauthor=A.+Liuauthor=X.+Shenauthor=Q.+J.+Wangauthor=Y.+Liuauthor=Y.+Jiang&title=Rheb+activates+mTOR+by+antagonizing+its+endogenous+inhibitor%2C+FKBP38"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DRheb%2520activates%2520mTOR%2520by%2520antagonizing%2520its%2520endogenous%2520inhibitor%252C%2520FKBP38%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D977%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Saucedo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarelli, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, B. A.</span><span> </span><span class="NLM_article-title">Rheb promotes cell growth as a component of the insulin/TOR signalling network</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncb996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12766776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlWnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=566-571&author=L.+J.+Saucedoauthor=X.+Gaoauthor=D.+A.+Chiarelliauthor=L.+Liauthor=D.+Panauthor=B.+A.+Edgar&title=Rheb+promotes+cell+growth+as+a+component+of+the+insulin%2FTOR+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Rheb promotes cell growth as a component of the insulin/TOR signalling network</span></div><div class="casAuthors">Saucedo, Leslie J.; Gao, Xinsheng; Chiarelli, Dominic A.; Li, Ling; Pan, Duoija; Edgar, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">566-571</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insulin signaling is a potent inhibitor of cell growth and has been proposed to function, at least in part, through the conserved protein kinase TOR (target of rapamycin).  Recent studies suggest a that the tuberous sclerosis complex Tsc1-Tsc2 may couple insulin signaling to Tor activity.  However, the regulatory mechanism involved remains unclear, and addnl. components are most probably involved.  In a screen for novel regulators of growth, we identified Rheb (Ras homolog enriched in brain), a member of the Ras superfamily of GTP-binding proteins.  Increased levels of Rheb in D. melanogaster promote cell growth and alter cell cycle kinetics in multiple tissues.  In mitotic tissues, overexpression of Rheb accelerates passage through G1-S phase without affecting rates of cell division, whereas in endoreplicating tissues, Rheb increases DNA ploidy.  Mutation of Rheb suspends larval growth and prevents progression from 1st to 2nd instar.  Genetic and biochem. tests indicate that Rheb functions in the insulin signaling pathway downstream of Tsc1-Tsc2 and upstream of TOR.  Levels of rheb mRNA are rapidly induced in response to protein starvation, and overexpressed Rheb can drive cell growth in starved animals, suggesting a role for Rheb in the nutritional control of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8DM_KyEMljLVg90H21EOLACvtfcHk0ljtVaY9bft9mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlWnsro%253D&md5=f1b291a45a362c0dfe5e92e3212f84ee</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fncb996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb996%26sid%3Dliteratum%253Aachs%26aulast%3DSaucedo%26aufirst%3DL.%2BJ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChiarelli%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DB.%2BA.%26atitle%3DRheb%2520promotes%2520cell%2520growth%2520as%2520a%2520component%2520of%2520the%2520insulin%252FTOR%2520signalling%2520network%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2003%26volume%3D5%26spage%3D566%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Tee, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blenis, J.</span><span> </span><span class="NLM_article-title">Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1259</span><span class="NLM_x">–</span> <span class="NLM_lpage">1268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0960-9822%2803%2900506-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12906785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Kitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1259-1268&author=A.+R.+Teeauthor=B.+D.+Manningauthor=P.+P.+Rouxauthor=L.+C.+Cantleyauthor=J.+Blenis&title=Tuberous+sclerosis+complex+gene+products%2C+tuberin+and+hamartin%2C+control+mTOR+signaling+by+acting+as+a+GTPase-activating+protein+complex+toward+Rheb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb</span></div><div class="casAuthors">Tee, Andrew R.; Manning, Brendan D.; Roux, Philippe P.; Cantley, Lewis C.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Background: Tuberous Sclerosis Complex (TSC) is a genetic disorder that occurs through the loss of heterozygosity of either TSC1 or TSC2, which encode Hamartin or Tuberin, resp.  Tuberin and Hamartin form a tumor suppressor heterodimer that inhibits the mammalian target of rapamycin (mTOR) nutrient signaling input, but how this occurs is unclear.  Results: We show that the small G protein Rheb (Ras homolog enriched in brain) is a mol. target of TSC1/TSC2 that regulates mTOR signaling.  Overexpression of Rheb activates 40S ribosomal protein S6 kinase 1 (S6K1) but not p90 ribosomal S6 kinase 1 (RSK1) or Akt.  Furthermore, Rheb induces phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and causes 4E-BP1 to dissoc. from eIF4E.  This dissocn. is completely sensitive to rapamycin (an mTOR inhibitor) but not wortmannin (a phosphoinositide 3-kinase [PI3K] inhibitor).  Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.  Moreover, Rheb does not activate a S6K1 mutant that is unresponsive to mTOR-mediated signals, confirming that Rheb functions upstream of mTOR.  Overexpression of the Tuberin-Hamartin heterodimer inhibits Rheb-mediated S6K1 activation, suggesting that Tuberin functions as a Rheb GTPase activating protein (GAP).  Supporting this notion, TSC patient-derived Tuberin GAP domain mutants were unable to inactivate Rheb in vivo.  Moreover, in vitro studies reveal that Tuberin, when assocd. with Hamartin, acts as a Rheb GTPase-activating protein.  Finally, we show that membrane localization of Rheb is important for its biol. activity because a farnesylation-defective mutant of Rheb stimulated S6K1 activation less efficiently.  Conclusions: We show that Rheb acts as a novel mediator of the nutrient signaling input to mTOR and is the mol. target of TSC1 and TSC2 within mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKz47uqJPZrVg90H21EOLACvtfcHk0ljtVaY9bft9mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Kitr0%253D&md5=96bcd417af27ed57a88046ff4f7b78de</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2803%2900506-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252803%252900506-2%26sid%3Dliteratum%253Aachs%26aulast%3DTee%26aufirst%3DA.%2BR.%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DTuberous%2520sclerosis%2520complex%2520gene%2520products%252C%2520tuberin%2520and%2520hamartin%252C%2520control%2520mTOR%2520signaling%2520by%2520acting%2520as%2520a%2520GTPase-activating%2520protein%2520complex%2520toward%2520Rheb%26jtitle%3DCurr.%2520Biol.%26date%3D2003%26volume%3D13%26spage%3D1259%26epage%3D1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Lazaris-Karatzas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1990&pages=544-547&author=A.+Lazaris-Karatzasauthor=K.+S.+Montineauthor=N.+Sonenberg&title=Malignant+transformation+by+a+eukaryotic+initiation+factor+subunit+that+binds+to+mRNA+5%E2%80%B2+cap"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DMontine%26aufirst%3DK.%2BS.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMalignant%2520transformation%2520by%2520a%2520eukaryotic%2520initiation%2520factor%2520subunit%2520that%2520binds%2520to%2520mRNA%25205%25E2%2580%25B2%2520cap%26jtitle%3DNature%26date%3D1990%26volume%3D345%26spage%3D544%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Lazaris-Karatzas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1234</span><span class="NLM_x">–</span> <span class="NLM_lpage">1238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=1532049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK38XhslWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=1234-1238&author=A.+Lazaris-Karatzasauthor=N.+Sonenberg&title=The+mRNA+5%E2%80%B2+cap-binding+protein%2C+eIF-4E%2C+cooperates+with+v-myc+or+E1A+in+the+transformation+of+primary+rodent+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts</span></div><div class="casAuthors">Lazaris-Karatzas, Anthoula; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1234-8</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors present evidence that eIF-4E, the mRNA 5' cap-binding protein, cooperates with 2 immortalizing oncogenes, v-myc and E1A, to cause transformation of rat embryo fibroblasts.  EIF-4E alone can transform rat embryo fibroblasts when selection is applied.  The pattern of transformation by eIF-4E is similar to that of p21 Ras, raising the possibility that eIF-4E shares a common signal transduction pathway with p21 Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KEuy5sCzprVg90H21EOLACvtfcHk0lgJNdnzz2E4cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhslWhtL0%253D&md5=59004e6953eea6bf997626b6d2b6a98b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DThe%2520mRNA%25205%25E2%2580%25B2%2520cap-binding%2520protein%252C%2520eIF-4E%252C%2520cooperates%2520with%2520v-myc%2520or%2520E1A%2520in%2520the%2520transformation%2520of%2520primary%2520rodent%2520fibroblasts%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1992%26volume%3D12%26spage%3D1234%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Ruvinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyuhas, O.</span><span> </span><span class="NLM_article-title">Ribosomal protein S6 phosphorylation: from protein synthesis to cell size</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=342-348&author=I.+Ruvinskyauthor=O.+Meyuhas&title=Ribosomal+protein+S6+phosphorylation%3A+from+protein+synthesis+to+cell+size"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuvinsky%26aufirst%3DI.%26aulast%3DMeyuhas%26aufirst%3DO.%26atitle%3DRibosomal%2520protein%2520S6%2520phosphorylation%253A%2520from%2520protein%2520synthesis%2520to%2520cell%2520size%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2006%26volume%3D31%26spage%3D342%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Averous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proud, C. G.</span><span> </span><span class="NLM_article-title">When translation meets transformation: the mTOR story</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6423</span><span class="NLM_x">–</span> <span class="NLM_lpage">6435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.onc.1209887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17041627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6423-6435&author=J.+Averousauthor=C.+G.+Proud&title=When+translation+meets+transformation%3A+the+mTOR+story"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">When translation meets transformation: The mTOR story</span></div><div class="casAuthors">Averous, J.; Proud, C. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6423-6435</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is currently a high level of interest in signaling through the mammalian target of rapamycin (mTOR).  This reflects both its key role in many cell functions and its involvement in disease states such as cancers.  The best understood targets for mTOR signalling are proteins involved in controlling the translational machinery, including the ribosomal protein S6 kinases and proteins that regulate the initiation and elongation phases of translation.  Indeed, there is compelling evidence that at least one of these targets of mTOR (eukaryotic initiation factor eIF4E) plays a key role in tumorigenesis.  It is regulated through the mTOR-dependent phosphorylation of inhibitory proteins such as eIF4E-binding protein 1.  Thus, targeting mTOR signalling may be an effective anticancer strategy, in at least a significant subset of tumors.  Not all effects of mTOR are sensitive to the classical anti-mTOR drug rapamycin, and this compd. also interferes with other processes besides eIF4E function.  Developing new approaches to targeting mTOR for cancer therapy requires more detailed knowledge of signalling downstream of mTOR.  Such advances are likely to come from further work to understand the regulation of mTOR targets such as components of the translational app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsNfzV_sznY7Vg90H21EOLACvtfcHk0liy_4hsxTvjDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrO&md5=4b175aaae5494507cbc43ec08f8da1ac</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209887%26sid%3Dliteratum%253Aachs%26aulast%3DAverous%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DWhen%2520translation%2520meets%2520transformation%253A%2520the%2520mTOR%2520story%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6423%26epage%3D6435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Dancey, J. E.</span><span> </span><span class="NLM_article-title">Therapeutic targets: MTOR and related pathways</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.4161%2Fcbt.5.9.3175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16969122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1065-1073&author=J.+E.+Dancey&title=Therapeutic+targets%3A+MTOR+and+related+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targets. MTOR and related pathways</span></div><div class="casAuthors">Dancey, Janet E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR), a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, has a central role in controlling malignant cellular growth.  As a result, mTOR is viewed as an important target for anticancer drug development.  Inhibitors of mTOR currently under evaluation in cancer clin. trials are rapamycin (also known as sirolimus, Wyeth) and derivs. temsirolimus (CCI-779, Wyeth), everolimus, (RAD001, Novartis Pharma AG), and AP23573 (Ariad Pharmaceuticals).  Preclin. studies suggest that sensitivity to mTOR inhibitors may correlate with activation of the PI3K pathway and/or with aberrant expression of cell cycle regulatory or anti-apoptotic proteins.  Clin. trial results show that mTOR inhibitors are well tolerated and may induce prolonged stable disease and tumor regressions in cancer patients.  Future research should evaluate optimal, schedule, patient selection, and combination strategies for this novel class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz_taiC5i3ALVg90H21EOLACvtfcHk0lhw6xS_yoI8rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlejsQ%253D%253D&md5=be06e2ae7e26fcb0dfe54c3f38011c5e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.4161%2Fcbt.5.9.3175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.5.9.3175%26sid%3Dliteratum%253Aachs%26aulast%3DDancey%26aufirst%3DJ.%2BE.%26atitle%3DTherapeutic%2520targets%253A%2520MTOR%2520and%2520related%2520pathways%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1065%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Easton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">mTOR and cancer therapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6436</span><span class="NLM_x">–</span> <span class="NLM_lpage">6446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6436-6446&author=J.+B.+Eastonauthor=P.+J.+Houghton&title=mTOR+and+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEaston%26aufirst%3DJ.%2BB.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DmTOR%2520and%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6436%26epage%3D6446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Current development of mTOR inhibitors as anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrd2062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16883305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=671-688&author=S.+Faivreauthor=G.+Kroemerauthor=E.+Raymond&title=Current+development+of+mTOR+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Current development of mTOR inhibitors as anticancer agents</span></div><div class="casAuthors">Faivre, Sandrine; Kroemer, Guido; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">671-688</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch between catabolic and anabolic metab. and as such is a target for the design of anticancer agents.  The most established mTOR inhibitors - rapamycin and its derivs. - showed long-lasting objective tumor responses in clin. trials, with CCI-779 being a first-in-class mTOR inhibitor that improved the survival of patients with advanced renal cell carcinoma.  This heralded the beginning of extensive clin. programs to further evaluate mTOR inhibitors in several tumor types.  Here we review the clin. development of this drug class and look at future prospects for incorporating these agents into multitarget or multimodality strategies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajgc4JNPmPrVg90H21EOLACvtfcHk0lhw6xS_yoI8rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkurk%253D&md5=3fe58d7e26bff7c311437ca516584882</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnrd2062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2062%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DCurrent%2520development%2520of%2520mTOR%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D671%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basch, E.</span><span> </span><span class="NLM_article-title">Targeted drugs for metastatic renal cell carcinoma</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=2071-2073&author=R.+J.+Motzerauthor=E.+Basch&title=Targeted+drugs+for+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DBasch%26aufirst%3DE.%26atitle%3DTargeted%2520drugs%2520for%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D2071%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">O'Reilly, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1500</span><span class="NLM_x">–</span> <span class="NLM_lpage">1508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%27Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lhw6xS_yoI8rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Masiello, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubley, G. J.</span><span> </span><span class="NLM_article-title">Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17218776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=195-201&author=D.+Masielloauthor=M.+G.+Mohiauthor=N.+C.+McKnightauthor=B.+Smithauthor=B.+G.+Neelauthor=S.+P.+Balkauthor=G.+J.+Bubley&title=Combining+an+mTOR+antagonist+and+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer</span></div><div class="casAuthors">Masiello, David; Mohi, M. Golam; McKnight, Nicole C.; Smith, Bradley; Neel, Ben G.; Balk, Steven P.; Bubley, Glenn J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-201</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway is a potentially useful therapeutic strategy in the treatment of advanced prostate cancer.  However mTOR antagonists used as single agents are not likely to result in dramatic clin. responses, so that it is useful to identify prospective agents that might be useful in combination.  We treated CWR22Rv1 and LNCaP prostate cancer cells with an mTOR inhibitor, rapamycin, alone, or in combination with either of two receptor protein kinase (RTK) inhibitors.  We assessed the effects of these treatments on cell survival and activation of down-stream mTOR target proteins.  Treatment with either PD16839, an EGFr antagonist, or imatinib mesylate (Gleevec), a PDGFr, c-kit and bcr/abl antagonist, enhanced the anti-proliferative effects of rapamycin.  We therefore assessed the effects of treatment with the RTK antagonist alone and in combination with rapamycin on mTOR targeted proteins.  RTK antagonists alone had no effect or paradoxically increased phosphorylation of the mTOR targeted proteins, p70 S6 kinase and ribosomal S6.  In contrast, when these cells were treated with either RTK antagonist in the presence of rapamycin, there was a dramatic decrease in phosphorylation of these two mTOR-targeted proteins.  These effects were not mediated through phospho-AKT.  Since two sep. RTK antagonists had additive antiproliferative effects in combination with an mTOR antagonist and were assocd. with a dramatic decrease in mTOR targeted proteins in cells with or without PTEN expression, the strategy deserves further evaluation for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfa9_zd3h8drVg90H21EOLACvtfcHk0lhejIr-1yutNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsbzK&md5=5c99f14560ab6c1d7ab8a3ed419a19f4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasiello%26aufirst%3DD.%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DMcKnight%26aufirst%3DN.%2BC.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DBubley%26aufirst%3DG.%2BJ.%26atitle%3DCombining%2520an%2520mTOR%2520antagonist%2520and%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D195%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyzaguirre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, G.</span><span> </span><span class="NLM_article-title">Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2676</span><span class="NLM_x">–</span> <span class="NLM_lpage">2684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17121914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1els7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2676-2684&author=E.+Buckauthor=A.+Eyzaguirreauthor=E.+Brownauthor=F.+Pettiauthor=S.+McCormackauthor=J.+D.+Haleyauthor=K.+K.+Iwataauthor=N.+W.+Gibsonauthor=G.+Griffin&title=Rapamycin+synergizes+with+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+in+non-small-cell+lung%2C+pancreatic%2C+colon%2C+and+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors</span></div><div class="casAuthors">Buck, Elizabeth; Eyzaguirre, Alexandra; Brown, Eric; Petti, Filippo; McCormack, Siobhan; Haley, John D.; Iwata, Kenneth K.; Gibson, Neil W.; Griffin, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2676-2684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers.  One important signaling pathway regulated by EGFR is the phosphatidylinositol 3'-kinase (PI3K)-phosphoinositide-dependent kinase 1-Akt pathway.  Activation of Akt leads to the stimulation of antiapoptotic pathways, promoting cell survival.  Akt also regulates the mammalian target of rapamycin (mTOR)-S6K-S6 pathway to control cell growth in response to growth factors and nutrients.  Recent reports have shown that the sensitivity of non-small-cell lung cancer cell lines to EGFR inhibitors such as erlotinib (Tarceva, OSI Pharmaceuticals) is dependent on inhibition of the phosphatidylinositol 3'-kinase-phosphoinositide-dependent kinase 1-Akt-mTOR pathway.  There can be multiple inputs to this pathway as activity can be regulated by other receptors or upstream mutations.  Therefore, inhibiting EGFR alone may not be sufficient for substantial inhibition of all tumor cells, highlighting the need for multipoint intervention.  Herein, we sought to det. if rapamycin, an inhibitor of mTOR, could enhance erlotinib sensitivity for cell lines derived from a variety of tissue types (non-small-cell lung, pancreatic, colon, and breast).  Erlotinib could inhibit extracellular signal-regulated kinase, Akt, and S6 only in cell lines that were the most sensitive.  Rapamycin could fully inhibit S6 in all cell lines, but this was accompanied by activation of Akt phosphorylation.  However, combination with erlotinib could down-modulate rapamycin-stimulated Akt activity.  Therefore, in select cell lines, inhibition of both S6 and Akt was achieved only with the combination of erlotinib and rapamycin.  This produced a synergistic effect on cell growth inhibition, observations that extended in vivo using xenograft models.  These results suggest that combining rapamycin with erlotinib might be clin. useful to enhance response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrywRO-to2xnbVg90H21EOLACvtfcHk0lhejIr-1yutNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1els7nP&md5=ac5ac416f697a06090869a47975b1f4a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0166%26sid%3Dliteratum%253Aachs%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DEyzaguirre%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DPetti%26aufirst%3DF.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DGriffin%26aufirst%3DG.%26atitle%3DRapamycin%2520synergizes%2520with%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520in%2520non-small-cell%2520lung%252C%2520pancreatic%252C%2520colon%252C%2520and%2520breast%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2676%26epage%3D2684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.+C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+Janneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.+K.+Wong&title=Bronchial+and+peripheral+murine+lung+carcinomas+induced+by+T790M-L858R+mutant+EGFR+respond+to+HKI-272+and+rapamycin+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.%2BC.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBronchial%2520and%2520peripheral%2520murine%2520lung%2520carcinomas%2520induced%2520by%2520T790M-L858R%2520mutant%2520EGFR%2520respond%2520to%2520HKI-272%2520and%2520rapamycin%2520combination%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">Drugging the bad “AKT-TOR” to overcome TKI-resistant lung cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=6-8&author=J.+Settlemanauthor=J.+M.+Kurie&title=Drugging+the+bad+%E2%80%9CAKT-TOR%E2%80%9D+to+overcome+TKI-resistant+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DDrugging%2520the%2520bad%2520%25E2%2580%259CAKT-TOR%25E2%2580%259D%2520to%2520overcome%2520TKI-resistant%2520lung%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D6%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efstratiadis, A.</span><span> </span><span class="NLM_article-title">Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1993&pages=59-72&author=J.+P.+Liuauthor=J.+Bakerauthor=A.+S.+Perkinsauthor=E.+J.+Robertsonauthor=A.+Efstratiadis&title=Mice+carrying+null+mutations+of+the+genes+encoding+insulin-like+growth+factor+I+%28Igf-1%29+and+type+1+IGF+receptor+%28Igf1r%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DE.%2BJ.%26aulast%3DEfstratiadis%26aufirst%3DA.%26atitle%3DMice%2520carrying%2520null%2520mutations%2520of%2520the%2520genes%2520encoding%2520insulin-like%2520growth%2520factor%2520I%2520%2528Igf-1%2529%2520and%2520type%25201%2520IGF%2520receptor%2520%2528Igf1r%2529%26jtitle%3DCell%26date%3D1993%26volume%3D75%26spage%3D59%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Powell-Braxton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warburton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts-Meek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. A.</span><span> </span><span class="NLM_article-title">IGF-I is required for normal embryonic growth in mice</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=2609-2617&author=L.+Powell-Braxtonauthor=P.+Hollingsheadauthor=C.+Warburtonauthor=M.+Dowdauthor=S.+Pitts-Meekauthor=D.+Daltonauthor=N.+Gillettauthor=T.+A.+Stewart&title=IGF-I+is+required+for+normal+embryonic+growth+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowell-Braxton%26aufirst%3DL.%26aulast%3DHollingshead%26aufirst%3DP.%26aulast%3DWarburton%26aufirst%3DC.%26aulast%3DDowd%26aufirst%3DM.%26aulast%3DPitts-Meek%26aufirst%3DS.%26aulast%3DDalton%26aufirst%3DD.%26aulast%3DGillett%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DT.%2BA.%26atitle%3DIGF-I%2520is%2520required%2520for%2520normal%2520embryonic%2520growth%2520in%2520mice%26jtitle%3DGenes%2520Dev.%26date%3D1993%26volume%3D7%26spage%3D2609%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Woods, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camacho-Hubner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, A. J.</span><span> </span><span class="NLM_article-title">Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJM199610313351805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8857020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=1996&pages=1363-1367&author=K.+A.+Woodsauthor=C.+Camacho-Hubnerauthor=M.+O.+Savageauthor=A.+J.+Clark&title=Intrauterine+growth+retardation+and+postnatal+growth+failure+associated+with+deletion+of+the+insulin-like+growth+factor+I+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene</span></div><div class="casAuthors">Woods K A; Camacho-Hubner C; Savage M O; Clark A J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1363-7</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT01tsIhtZ4o6cY7HFp97qMfW6udTcc2eaawGjv2uM3Lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFSnsw%253D%253D&md5=479ba9dbc5bf5f11db26ea67a8d4531b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJM199610313351805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199610313351805%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DK.%2BA.%26aulast%3DCamacho-Hubner%26aufirst%3DC.%26aulast%3DSavage%26aufirst%3DM.%2BO.%26aulast%3DClark%26aufirst%3DA.%2BJ.%26atitle%3DIntrauterine%2520growth%2520retardation%2520and%2520postnatal%2520growth%2520failure%2520associated%2520with%2520deletion%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520gene%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D335%26spage%3D1363%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Abuzzahab, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorescu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiess, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klammt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratzsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaffle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raile, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chernausek, S. D.</span><span> </span><span class="NLM_article-title">IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa010107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14657428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Whs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=2211-2222&author=M.+J.+Abuzzahabauthor=A.+Schneiderauthor=A.+Goddardauthor=F.+Grigorescuauthor=C.+Lautierauthor=E.+Kellerauthor=W.+Kiessauthor=J.+Klammtauthor=J.+Kratzschauthor=D.+Osgoodauthor=R.+Pfaffleauthor=K.+Raileauthor=B.+Seidelauthor=R.+J.+Smithauthor=S.+D.+Chernausek&title=IGF-I+receptor+mutations+resulting+in+intrauterine+and+postnatal+growth+retardation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation</span></div><div class="casAuthors">Abuzzahab, M. Jennifer; Schneider, Anke; Goddard, Audrey; Grigorescu, Florin; Lautier, Corinne; Keller, Eberhard; Kiess, Wieland; Klammt, Juergen; Kratzsch, Juergen; Osgood, Doreen; Pfaeffle, Roland; Raile, Klemens; Seidel, Berthold; Smith, Robert J.; Chernausek, Steven D.; Frank, G. R.; Kaplowitz, P. B.; Pescovitz, O. H.; Smith, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2211-2222</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND-Approx. 10 percent of infants with intrauterine growth retardation remain small, and the causes of their growth deficits are often unclear.  We postulated that mutations in the gene for the insulin-like growth factor I receptor (IGF-IR) might underlie some cases of prenatal and postnatal growth failure.  METHODS-We screened two groups of children for abnormalities in the IGF-IR gene.  In one group of 42 patients with unexplained intrauterine growth retardation and subsequent short stature, we used single-strand conformation polymorphism anal., followed by direct DNA sequencing of any abnormalities found.  A second cohort consisted of 50 children with short stature who had elevated circulating IGF-I concns.  Complete sequencing of the IGF-IR gene was performed with DNA from nine children.  We also studied a control group of 43 children with normal birth wts.  RESULTS-In the first cohort, we identified one girl who was a compd. heterozygote for point mutations in exon 2 of the IGF-IR gene that altered the amino acid sequence to Arg108Gln in one allele and Lys115Asn in the other.  Fibroblasts cultured from the patient had decreased IGF-I-receptor function, as compared with that in control fibroblasts.  No such mutations were found in the 43 controls.  In the second group, we identified one boy with a nonsense mutation (Arg59stop) that reduced the no. of IGF-I receptors on fibroblasts.  Both children had intrauterine growth retardation and poor postnatal growth.  CONCLUSIONS-Mutations in the IGF-IR gene that lead to abnormalities in the function or no. of IGF-I receptors may also retard intrauterine and subsequent growth in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9hG0FbEOBCrVg90H21EOLACvtfcHk0lh9ck7lWYhw6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Whs7w%253D&md5=4292bf2089b400b84d78b640177b67e2</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa010107%26sid%3Dliteratum%253Aachs%26aulast%3DAbuzzahab%26aufirst%3DM.%2BJ.%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DGrigorescu%26aufirst%3DF.%26aulast%3DLautier%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DKiess%26aufirst%3DW.%26aulast%3DKlammt%26aufirst%3DJ.%26aulast%3DKratzsch%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DD.%26aulast%3DPfaffle%26aufirst%3DR.%26aulast%3DRaile%26aufirst%3DK.%26aulast%3DSeidel%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%26aulast%3DChernausek%26aufirst%3DS.%2BD.%26atitle%3DIGF-I%2520receptor%2520mutations%2520resulting%2520in%2520intrauterine%2520and%2520postnatal%2520growth%2520retardation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D2211%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Laursen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, J. S.</span><span> </span><span class="NLM_article-title">The management of adult growth hormone deficiency syndrome</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2435</span><span class="NLM_x">–</span> <span class="NLM_lpage">2450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F14656566.9.14.2435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18778182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVygtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=2435-2450&author=T.+Laursenauthor=J.+O.+Jorgensenauthor=J.+S.+Christiansen&title=The+management+of+adult+growth+hormone+deficiency+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The management of adult growth hormone deficiency syndrome</span></div><div class="casAuthors">Laursen, Torben; Jorgensen, Jens Otto Lunde; Christiansen, Jens Sandahl</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2435-2450</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  In patients with hypopituitarism, growth hormone deficiency (GHD) is almost inevitably present.  Lack of other pituitary hormones may require prompt replacement, but lack of growth hormone (GH) is also assocd. with several abnormalities.  Growth hormone treatment safely improves or normalizes many of these deviations.  The aberrations include low bone mass and increased risk of fractures, abnormal body compn. in terms of increased fat mass, and reduced lean body mass resulting in reduced muscle mass and strength.  The decreased exercise capacity in GHD may be influenced by impaired cardiac performance and heat intolerance.  Increased abdominal fat results in metabolic disturbancies such as reduced insulin sensitivity and hyperlipidemia, leading to an increased risk of cardiovascular diseases.  Patients with hypopituitarism who have had relevant hormones replaced except GH have increased mortality due to, for example, cardiovascular diseases.  Thus, it is important to diagnose GHD, which requires precise diagnostic criteria and methods.  Dynamic testing of GH secretion with insulin tolerance test or arginine + GH releasing hormone can be used.  Patients with childhood onset GHD should be re-evaluated if GH therapy is maintained into adulthood.  Although GH replacement therapy improves the patophysiol. manifestations of GHD and quality of life, it is unclear whether mortality is reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCGpMjMp3097Vg90H21EOLACvtfcHk0lh9ck7lWYhw6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVygtb7N&md5=c90ef5321de25c0e74ccebcf45526db0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1517%2F14656566.9.14.2435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.9.14.2435%26sid%3Dliteratum%253Aachs%26aulast%3DLaursen%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DJ.%2BO.%26aulast%3DChristiansen%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520management%2520of%2520adult%2520growth%2520hormone%2520deficiency%2520syndrome%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2008%26volume%3D9%26spage%3D2435%26epage%3D2450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Baylink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span> </span><span class="NLM_article-title">The role of IGF system in the rise and fall in bone density with age</span> <span class="citation_source-journal">J. Musculoskeletal Neuronal Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18094484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2sjls1Wjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=304-305&author=D.+Baylinkauthor=K.+H.+Lauauthor=S.+Mohan&title=The+role+of+IGF+system+in+the+rise+and+fall+in+bone+density+with+age"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The role of IGF system in the rise and fall in bone density with age</span></div><div class="casAuthors">Baylink D; Lau K H-W; Mohan S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of musculoskeletal & neuronal interactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-5</span>
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIV8rkcnqV_9FxYDaSSP8XfW6udTcc2eao0SnT5d-Iurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjls1Wjug%253D%253D&md5=dee29ba0bf022715dce665e093147d7a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaylink%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DK.%2BH.%26aulast%3DMohan%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520IGF%2520system%2520in%2520the%2520rise%2520and%2520fall%2520in%2520bone%2520density%2520with%2520age%26jtitle%3DJ.%2520Musculoskeletal%2520Neuronal%2520Interact.%26date%3D2007%26volume%3D7%26spage%3D304%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Niu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, C. J.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I gene and osteoporosis: a critical appraisal</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2005&pages=38-56&author=T.+Niuauthor=C.+J.+Rosen&title=The+insulin-like+growth+factor-I+gene+and+osteoporosis%3A+a+critical+appraisal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520gene%2520and%2520osteoporosis%253A%2520a%2520critical%2520appraisal%26jtitle%3DGene%26date%3D2005%26volume%3D361%26spage%3D38%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Perrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalicchio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laviola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cignarelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccioppoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martemucci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belsanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciampolillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantatore, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, F.</span><span> </span><span class="NLM_article-title">Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=1302-1313&author=S.+Perriniauthor=A.+Natalicchioauthor=L.+Laviolaauthor=A.+Cignarelliauthor=M.+Melchiorreauthor=S.+F.+Deauthor=C.+Caccioppoliauthor=A.+Leonardiniauthor=S.+Martemucciauthor=G.+Belsantiauthor=S.+Miccoliauthor=A.+Ciampolilloauthor=A.+Corradoauthor=F.+P.+Cantatoreauthor=R.+Giorginoauthor=F.+Giorgino&title=Abnormalities+of+insulin-like+growth+factor-I+signaling+and+impaired+cell+proliferation+in+osteoblasts+from+subjects+with+osteoporosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerrini%26aufirst%3DS.%26aulast%3DNatalicchio%26aufirst%3DA.%26aulast%3DLaviola%26aufirst%3DL.%26aulast%3DCignarelli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DS.%2BF.%26aulast%3DCaccioppoli%26aufirst%3DC.%26aulast%3DLeonardini%26aufirst%3DA.%26aulast%3DMartemucci%26aufirst%3DS.%26aulast%3DBelsanti%26aufirst%3DG.%26aulast%3DMiccoli%26aufirst%3DS.%26aulast%3DCiampolillo%26aufirst%3DA.%26aulast%3DCorrado%26aufirst%3DA.%26aulast%3DCantatore%26aufirst%3DF.%2BP.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DGiorgino%26aufirst%3DF.%26atitle%3DAbnormalities%2520of%2520insulin-like%2520growth%2520factor-I%2520signaling%2520and%2520impaired%2520cell%2520proliferation%2520in%2520osteoblasts%2520from%2520subjects%2520with%2520osteoporosis%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D1302%26epage%3D1313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Feldman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, J. W.</span><span> </span><span class="NLM_article-title">Insulin-like growth factors regulate neuronal differentiation and survival</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1006%2Fnbdi.1997.0156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9361296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK2sXnsVWjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=201-214&author=E.+L.+Feldmanauthor=K.+A.+Sullivanauthor=B.+Kimauthor=J.+W.+Russell&title=Insulin-like+growth+factors+regulate+neuronal+differentiation+and+survival"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factors regulate neuronal differentiation and survival</span></div><div class="casAuthors">Feldman, Eva L.; Sullivan, Kelli A.; Kim, Bhumsoo; Russell, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3 & 4</span>),
    <span class="NLM_cas:pages">201-214</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with ∼130 refs.  Insulin-like growth factor I (IGF-I) and IGF-II are potent trophic factors for motor and sensory neurons and glial cells.  The actions of IGF-I and IGF-II are mediated via the IGF-I receptor (IGF-IR).  IGF:IGF-IR binding activates distinct signaling cascades, which in turn mediate the trophic-effects of the IGFs.  The authors discuss three main IGF coupled events: growth cone motility, long-term neurite outgrowth, and neuroprotection.  Our data suggest that IGF-I enhances growth cone motility by promoting reorganization of actin and activation of focal adhesion proteins via the phosphatidylinositol-3 kinase (PI-3K) pathway.  Long-term treatment with IGF-I activates the mitogen-activated protein (MAP) kinase cascade and promotes neurite outgrowth.  A separable, but likely linked, action of the IGFs via PI-3K is protection of neurons from apoptosis.  These pleotrophic effects of IGFs suggest that this family of growth factors may have potential clin. utility in the treatment of neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd0EWytNh4nbVg90H21EOLACvtfcHk0ljlsexp3nwX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsVWjtLg%253D&md5=7142a4124534e413723781f442bbfc65</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1006%2Fnbdi.1997.0156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fnbdi.1997.0156%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DE.%2BL.%26aulast%3DSullivan%26aufirst%3DK.%2BA.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DJ.%2BW.%26atitle%3DInsulin-like%2520growth%2520factors%2520regulate%2520neuronal%2520differentiation%2520and%2520survival%26jtitle%3DNeurobiol.%2520Dis.%26date%3D1997%26volume%3D4%26spage%3D201%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Garcia-Segura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardona-Gomez, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azcoitia, I.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection</span> <span class="citation_source-journal">J. Neurocytol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1023%2FA%3A1007125626308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11424959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=425-437&author=L.+M.+Garcia-Seguraauthor=G.+P.+Cardona-Gomezauthor=J.+A.+Chowenauthor=I.+Azcoitia&title=Insulin-like+growth+factor-I+receptors+and+estrogen+receptors+interact+in+the+promotion+of+neuronal+survival+and+neuroprotection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection</span></div><div class="casAuthors">Garcia-Segura, Luis Miguel; Cardona-Gomez, Gloria Patricia; Chowen, Julie Ann; Azcoitia, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurocytology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">425-437</span>CODEN:
                <span class="NLM_cas:coden">JNCYA2</span>;
        ISSN:<span class="NLM_cas:issn">0300-4864</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 120 refs.  Several in vitro and in vivo studies have shown that estrogen has neuroprotective properties.  The neuroprotective effects of estrogen are probably exerted through several mechanisms.  It is established that estrogen can provide neuroprotection by actions that are independent of estrogen receptor activation.  In addn., in several exptl. models, activation of estrogen receptors appears to be indispensable for neuroprotection.  This review focuses on neuroprotection mediated by estrogen receptors.  The interaction of estrogen with growth factor receptor signaling to induce neuroprotection is discussed.  Evidence is presented that estrogen receptors and insulin-like growth factor-I receptors interact in the promotion of neuronal survival and neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEZigIWZjH0rVg90H21EOLACvtfcHk0ljlsexp3nwX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFWqtLs%253D&md5=5027b37a334b3d98b7f2458ab3e1431f</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1023%2FA%3A1007125626308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1007125626308%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Segura%26aufirst%3DL.%2BM.%26aulast%3DCardona-Gomez%26aufirst%3DG.%2BP.%26aulast%3DChowen%26aufirst%3DJ.%2BA.%26aulast%3DAzcoitia%26aufirst%3DI.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptors%2520and%2520estrogen%2520receptors%2520interact%2520in%2520the%2520promotion%2520of%2520neuronal%2520survival%2520and%2520neuroprotection%26jtitle%3DJ.%2520Neurocytol.%26date%3D2000%26volume%3D29%26spage%3D425%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Russo, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gluckman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werther, G. A.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor system and its pleiotropic functions in brain</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2004-0024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16131630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=916-943&author=V.+C.+Russoauthor=P.+D.+Gluckmanauthor=E.+L.+Feldmanauthor=G.+A.+Werther&title=The+insulin-like+growth+factor+system+and+its+pleiotropic+functions+in+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor system and its pleiotropic functions in brain</span></div><div class="casAuthors">Russo, V. C.; Gluckman, P. D.; Feldman, E. L.; Werther, G. A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">916-943</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In recent years, much interest has been devoted to defining the role of the IGF system in the nervous system.  The ubiquitous IGFs, their cell membrane receptors, and their carrier binding proteins, the IGFBPs, are expressed early in the development of the nervous system and are therefore considered to play a key role in these processes.  In vitro studies have demonstrated that the IGF system promotes differentiation and proliferation and sustains survival, preventing apoptosis of neuronal and brain derived cells.  Furthermore, studies of transgenic mice overexpressing components of the IGF system or mice with disruptions of the same genes have clearly shown that the IGF system plays a key role in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK9cGpbNqt_rVg90H21EOLACvtfcHk0ljlsexp3nwX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVygtA%253D%253D&md5=c907190467d50427aae4136067525c6f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1210%2Fer.2004-0024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2004-0024%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DV.%2BC.%26aulast%3DGluckman%26aufirst%3DP.%2BD.%26aulast%3DFeldman%26aufirst%3DE.%2BL.%26aulast%3DWerther%26aufirst%3DG.%2BA.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520system%2520and%2520its%2520pleiotropic%2520functions%2520in%2520brain%26jtitle%3DEndocr.%2520Rev.%26date%3D2005%26volume%3D26%26spage%3D916%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gluckman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, A. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-1 and post-ischemic brain injury</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14568359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVequ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2003&pages=443-462&author=J.+Guanauthor=L.+Bennetauthor=P.+D.+Gluckmanauthor=A.+J.+Gunn&title=Insulin-like+growth+factor-1+and+post-ischemic+brain+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-1 and post-ischemic brain injury</span></div><div class="casAuthors">Guan, J.; Bennet, L.; Gluckman, P. D.; Gunn, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">443-462</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor-1 (IGF-1) is a naturally occurring neurotrophic factor that plays an important role in promoting cell proliferation and differentiation during normal brain development and maturation.  The present review examines recent evidence that endogenous IGF-1 also plays a significant role in recovery from insults such as hypoxia-ischemia and that giving addnl. exogenous IGF-1 can actively ameliorate damage.  It is now well established that neurons and other cell types die many hours or even days after initial injury due to activation of programmed cell death pathways.  IGF-1 and its binding proteins and receptors are intensely induced within damaged brain regions following brain injury, suggesting a possible a role for IGF-1 in brain recovery.  Exogenous administration of IGF-1 within a few hours after brain injury is now known to be protective in both gray and white matter and leads to improved somatic function.  In contrast, pre-treatment is ineffective, likely reflecting limited intracerebral penetration of IGF-1 into the uninjured brain.  The neuroprotective effects of IGF-1 are mediated by IGF-1 receptors and its binding proteins and are specific to particular cellular phenotypes and brain regions.  The window of opportunity for treatment with IGF-1 is limited to a few hours after normothermic brain injury, reflecting its specific actions on early, intracellular events in the apoptotic cascade.  However, injury-assocd. mild post-hypoxic hypothermia, which delays the development of cell death, can shift and dramatically extend the window of opportunity for delayed treatment with IGF-1.  Such a combined approach is likely to be essential for any clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjRH5SsgSwErVg90H21EOLACvtfcHk0lg9pLsX8B0xuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVequ7c%253D&md5=159e576706662df782578610bbd7b68d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBennet%26aufirst%3DL.%26aulast%3DGluckman%26aufirst%3DP.%2BD.%26aulast%3DGunn%26aufirst%3DA.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor-1%2520and%2520post-ischemic%2520brain%2520injury%26jtitle%3DProg.%2520Neurobiol.%26date%3D2003%26volume%3D70%26spage%3D443%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Carro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trejo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Isla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Aleman, I.</span><span> </span><span class="NLM_article-title">Serum insulin-like growth factor I regulates brain amyloid-beta levels</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1390</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12415260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1390-1397&author=E.+Carroauthor=J.+L.+Trejoauthor=T.+Gomez-Islaauthor=D.+LeRoithauthor=I.+Torres-Aleman&title=Serum+insulin-like+growth+factor+I+regulates+brain+amyloid-beta+levels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Serum insulin-like growth factor I regulates brain amyloid-β levels</span></div><div class="casAuthors">Carro, E.; Trejo, J. L.; Gomez-Isla, T.; LeRoith, D.; Torres-Aleman, I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1390-1397</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Levels of insulin-like growth factor I (IGF-I), a neuroprotective hormone, decrease in serum during aging, whereas amyloid-β (Aβ), which is involved in the pathogenesis of Alzheimer disease, accumulates in the brain.  High brain Aβ levels are found at an early age in mutant mice with low circulating IGF-I, and Aβ burden can be reduced in aging rats by increasing serum IGF-I.  This opposing relation between serum IGF-I and brain Aβ levels reflects the ability of IGF-I to induce clearance of brain Aβ, probably by enhancing transport of Aβ carrier proteins such as albumin and transthyretin into the brain.  This effect is antagonized by tumor necrosis factor-α, a pro-inflammatory cytokine putatively involved in dementia and aging.  Because IGF-I treatment of mice overexpressing mutant amyloid markedly reduces their brain Aβ burden, the authors consider that circulating IGF-I is a physiol. regulator of brain amyloid levels with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPwbC1nIXq7Vg90H21EOLACvtfcHk0lg9pLsX8B0xuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVSgsb0%253D&md5=6546487471edc218c63de56606548280</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnm793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm793%26sid%3Dliteratum%253Aachs%26aulast%3DCarro%26aufirst%3DE.%26aulast%3DTrejo%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Isla%26aufirst%3DT.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DTorres-Aleman%26aufirst%3DI.%26atitle%3DSerum%2520insulin-like%2520growth%2520factor%2520I%2520regulates%2520brain%2520amyloid-beta%2520levels%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D1390%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnavski, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisping, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">4782</span><span class="NLM_x">–</span> <span class="NLM_lpage">4793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=4782-4793&author=J.+R.+McMullenauthor=T.+Shioiauthor=W.+Y.+Huangauthor=L.+Zhangauthor=O.+Tarnavskiauthor=E.+Bispingauthor=M.+Schinkeauthor=S.+Kongauthor=M.+C.+Sherwoodauthor=J.+Brownauthor=L.+Riggiauthor=P.+M.+Kangauthor=S.+Izumo&title=The+insulin-like+growth+factor+1+receptor+induces+physiological+heart+growth+via+the+phosphoinositide+3-kinase%28p110alpha%29+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DShioi%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTarnavski%26aufirst%3DO.%26aulast%3DBisping%26aufirst%3DE.%26aulast%3DSchinke%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DSherwood%26aufirst%3DM.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DRiggi%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DP.%2BM.%26aulast%3DIzumo%26aufirst%3DS.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520induces%2520physiological%2520heart%2520growth%2520via%2520the%2520phosphoinositide%25203-kinase%2528p110alpha%2529%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D4782%26epage%3D4793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Suleiman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, C. E.</span><span> </span><span class="NLM_article-title">Apoptosis and the cardiac action of insulin-like growth factor I</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.pharmthera.2007.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17499363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=278-294&author=M.+S.+Suleimanauthor=R.+J.+Singhauthor=C.+E.+Stewart&title=Apoptosis+and+the+cardiac+action+of+insulin-like+growth+factor+I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis and the cardiac action of insulin-like growth factor I</span></div><div class="casAuthors">Suleiman, M.-S.; Singh, R. J. R.; Stewart, C. E. H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">278-294</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In both cardiac surgical and cardiol. settings, clin. interventions used to reperfuse the ischemic heart are assocd. with myocardial damage that is likely to influence long-term functional recovery.  Ischemia and reperfusion trigger cardiomyocyte death by necrosis and apoptosis.  Therefore identifying potent cardioprotective agents remains an important goal in cardiac research.  In a variety of tissues, insulin-like growth factor I (IGF-I) stimulates cellular proliferation, somatic growth, and differentiation.  In addn., IGF-I inhibits apoptotic cell death and therefore plays an important role as a cell survival factor.  This characteristic would provide an opportunity to both protect (rescue) the cardiac myocytes during (after) cardiac insults.  In this review, we shall (i) describe the characteristics of apoptotic cell death with particular emphasis on the heart, (ii) discuss the IGF system with emphasis on the cardiac actions of IGF-I under normal and pathol. conditions, (iii) elaborate on the potential role of IGF-I in myocardial protection, and finally (iv) describe how an improved understanding of the cardiac actions of IGF-I may lead to better protective clin. strategies in the future.  We discuss work by ourselves and others in these areas and also consider recent work describing the cellular signaling assocd. with the IGF-I receptor (IGF-IR) in the heart and its potential role in regulating excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9w-l5jxvPrVg90H21EOLACvtfcHk0lg9pLsX8B0xuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVantrg%253D&md5=c029fdc356b0549a21c0ef7ae0318395</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSuleiman%26aufirst%3DM.%2BS.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DC.%2BE.%26atitle%3DApoptosis%2520and%2520the%2520cardiac%2520action%2520of%2520insulin-like%2520growth%2520factor%2520I%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D114%26spage%3D278%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Delafontaine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brink, M.</span><span> </span><span class="NLM_article-title">The growth hormone and insulin-like growth factor 1 axis in heart failure</span> <span class="citation_source-journal">Ann. Endocrinol. (Paris)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10790588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvV2rtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2000&pages=22-26&author=P.+Delafontaineauthor=M.+Brink&title=The+growth+hormone+and+insulin-like+growth+factor+1+axis+in+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The growth hormone and insulin-like growth factor 1 axis in heart failure</span></div><div class="casAuthors">Delafontaine, P.; Brink, M.</div><div class="citationInfo"><span class="NLM_cas:title">Annales d'Endocrinologie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-26</span>CODEN:
                <span class="NLM_cas:coden">ANENAG</span>;
        ISSN:<span class="NLM_cas:issn">0003-4266</span>.
    
            (<span class="NLM_cas:orgname">Masson Editeur</span>)
        </div><div class="casAbstract">A review is given with 53 refs.  Exptl. data suggests that growth hormone and IGF-1 have beneficial effects on myocardial function in animal models of heart failure.  Preliminary evidence suggests an abnormality in the growth hormone-IGF-1 axis in heart failure with relative growth hormone resistance.  Beneficial effects of growth hormone and IGF-1 include vasodilation, stimulation of cardiac hypertrophy, increase in calcium sensitivity of cardiac myofilaments and prevention of apoptosis.  Recently, cardiac cachexia was shown to be a powerful neg. predictive factor in heart failure.  Cachectic patients have higher angiotensin II levels.  In the rat there is an important interaction between the renin-angiotensin system and IGF-1.  Thus, angiotensin II infusion causes wt. loss in part through a catabolic effect.  This effect results from increased protein degrdn.  Angiotensin II reduces circulating and skeletal muscle IGF-1 but increases IGF-1 and the IGF-IR expression in cardiac muscle.  Preliminary data suggest a potential beneficial effect of growth hormone in heart failure.  Further trials are necessary to test the potential beneficial effect of growth hormone and/or IGF-1 in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOWZZgJOxQbVg90H21EOLACvtfcHk0lgQvm9UUP_GTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvV2rtbY%253D&md5=ba65b135f7cf197ae6403aba49414017</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelafontaine%26aufirst%3DP.%26aulast%3DBrink%26aufirst%3DM.%26atitle%3DThe%2520growth%2520hormone%2520and%2520insulin-like%2520growth%2520factor%25201%2520axis%2520in%2520heart%2520failure%26jtitle%3DAnn.%2520Endocrinol.%2520%2528Paris%2529%26date%3D2000%26volume%3D61%26spage%3D22%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span> </span><span class="NLM_article-title">Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy</span> <span class="citation_source-journal">Novartis Found. Symp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F0470029331.ch7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17019808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslGktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2006&pages=90-111&author=J.+R.+McMullenauthor=S.+Izumo&title=Role+of+the+insulin-like+growth+factor+1+%28IGF1%29%2Fphosphoinositide-3-kinase+%28PI3K%29+pathway+mediating+physiological+cardiac+hypertrophy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy</span></div><div class="casAuthors">McMullen, Julie R.; Izumo, Seigo</div><div class="citationInfo"><span class="NLM_cas:title">Novartis Foundation Symposium</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">Heart Failure</span>),
    <span class="NLM_cas:pages">90-117</span>CODEN:
                <span class="NLM_cas:coden">NFSYF7</span>;
        ISSN:<span class="NLM_cas:issn">1528-2511</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Growth of the heart can be induced by physiol. stimuli (e.g. postnatal development or chronic exercise training: 'the athlete's heart') or pathol. stimuli (e.g. pressure or vol. overload).  Physiol. hypertrophy is characterized by the normal organization of sarcomeres and fibers, normal or enhanced cardiac function and a relatively normal pattern of cardiac gene expression; whereas pathol. hypertrophy is assocd. with an altered pattern of cardiac gene expression, fibrosis, cardiac dysfunction and increased mortality.  Previously, an unresolved question in cardiac biol. was whether distinct signalling pathways are responsible for the development of pathol. and physiol. cardiac hypertrophy.  Recent studies have identified several signalling pathways that play unique roles in the regulation of pathol. and physiol. cardiac hypertrophy.  This review focuses largely on the role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway in mediating physiol. cardiac growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohMnEb_Yxq8rVg90H21EOLACvtfcHk0lgQvm9UUP_GTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslGktb4%253D&md5=9716197e9623c254e32105de5377b5fb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2F0470029331.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0470029331.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DIzumo%26aufirst%3DS.%26atitle%3DRole%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520%2528IGF1%2529%252Fphosphoinositide-3-kinase%2520%2528PI3K%2529%2520pathway%2520mediating%2520physiological%2520cardiac%2520hypertrophy%26jtitle%3DNovartis%2520Found.%2520Symp.%26date%3D2006%26volume%3D274%26spage%3D90%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Neri Serneri, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modesti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecioni, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeletti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanti, G.</span><span> </span><span class="NLM_article-title">Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">982</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2001&pages=977-982&author=G.+G.+Neri+Serneriauthor=M.+Boddiauthor=P.+A.+Modestiauthor=I.+Cecioniauthor=M.+Coppoauthor=L.+Padelettiauthor=A.+Michelucciauthor=A.+Colellaauthor=G.+Galanti&title=Increased+cardiac+sympathetic+activity+and+insulin-like+growth+factor-I+formation+are+associated+with+physiological+hypertrophy+in+athletes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%2BSerneri%26aufirst%3DG.%2BG.%26aulast%3DBoddi%26aufirst%3DM.%26aulast%3DModesti%26aufirst%3DP.%2BA.%26aulast%3DCecioni%26aufirst%3DI.%26aulast%3DCoppo%26aufirst%3DM.%26aulast%3DPadeletti%26aufirst%3DL.%26aulast%3DMichelucci%26aufirst%3DA.%26aulast%3DColella%26aufirst%3DA.%26aulast%3DGalanti%26aufirst%3DG.%26atitle%3DIncreased%2520cardiac%2520sympathetic%2520activity%2520and%2520insulin-like%2520growth%2520factor-I%2520formation%2520are%2520associated%2520with%2520physiological%2520hypertrophy%2520in%2520athletes%26jtitle%3DCirc.%2520Res.%26date%3D2001%26volume%3D89%26spage%3D977%26epage%3D982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Scheinowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler-Icekson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freimann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golomb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savion, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldar, M.</span><span> </span><span class="NLM_article-title">Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression</span> <span class="citation_source-journal">Growth Horm. IGF. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1096-6374%2802%2900137-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12550078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Gkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=19-25&author=M.+Scheinowitzauthor=G.+Kessler-Iceksonauthor=S.+Freimannauthor=R.+Zimmermannauthor=W.+Schaperauthor=E.+Golombauthor=N.+Savionauthor=M.+Eldar&title=Short-+and+long-term+swimming+exercise+training+increases+myocardial+insulin-like+growth+factor-I+gene+expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression</span></div><div class="casAuthors">Scheinowitz, M.; Kessler-Icekson, G.; Freimann, S.; Zimmermann, R.; Schaper, W.; Golomb, E.; Savion, N.; Eldar, M.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Hormone & IGF Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">GHIRF9</span>;
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors investigated the effect of short- and long-term swimming exercise, with or without insulin-like growth factor (IGF)-I administration, on the expression of myocardial IGFs and contractile proteins.  Sprague-Dawley male rats were subjected to swimming exercise for 2 or 6 wk.  IGF-I (0.5 mg/rat) was administered continuously for 1 wk, using Alzet osmotic pumps.  Control groups remained sedentary.  IGF-I, IGF-I receptor (IGF-IR), IGF-II, skeletal α-actin (sk-actin), and β myosin heavy chain (βMHC) mRNAs were measured using Northern blot anal. and RT-PCR.  A significant 2-fold increase in myocardial IGF-I mRNA was found after 2 and 6 wk of swimming in both IGF-I treated and untreated rats.  IGF-IR mRNA was significantly increased after 6 wk of training only in the IGF-I treated animals.  IGF-II mRNA remained unchanged at all time points.  While βMHC mRNA was significantly decreased at 2 and 6 wk, sk-actin mRNA remained unchanged.  Thus, short- and long-term swimming exercise training increase myocardial expression of IGF-I mRNA.  Exogenous administration of IGF-I, during the first week of the exercise session, did not produce any effect on myocardial IGF-I but was assocd. with increased IGF-IR signal after the long-term exercise training.  These data suggest a relationship between IGF-I expression and cardiac adaptation to exercise training.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ3sX-mnwzwLVg90H21EOLACvtfcHk0lgQvm9UUP_GTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Gkuw%253D%253D&md5=405c770630c671b8eb6a156f4e4457a4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS1096-6374%2802%2900137-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1096-6374%252802%252900137-5%26sid%3Dliteratum%253Aachs%26aulast%3DScheinowitz%26aufirst%3DM.%26aulast%3DKessler-Icekson%26aufirst%3DG.%26aulast%3DFreimann%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DR.%26aulast%3DSchaper%26aufirst%3DW.%26aulast%3DGolomb%26aufirst%3DE.%26aulast%3DSavion%26aufirst%3DN.%26aulast%3DEldar%26aufirst%3DM.%26atitle%3DShort-%2520and%2520long-term%2520swimming%2520exercise%2520training%2520increases%2520myocardial%2520insulin-like%2520growth%2520factor-I%2520gene%2520expression%26jtitle%3DGrowth%2520Horm.%2520IGF.%2520Res.%26date%3D2003%26volume%3D13%26spage%3D19%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Verdecchia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboldi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schillaci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgioni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telera, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santeusanio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcellati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, P.</span><span> </span><span class="NLM_article-title">Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1802</span><span class="NLM_x">–</span> <span class="NLM_lpage">1807</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=1802-1807&author=P.+Verdecchiaauthor=G.+Reboldiauthor=G.+Schillaciauthor=C.+Borgioniauthor=A.+Ciucciauthor=M.+P.+Teleraauthor=F.+Santeusanioauthor=C.+Porcellatiauthor=P.+Brunetti&title=Circulating+insulin+and+insulin+growth+factor-1+are+independent+determinants+of+left+ventricular+mass+and+geometry+in+essential+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdecchia%26aufirst%3DP.%26aulast%3DReboldi%26aufirst%3DG.%26aulast%3DSchillaci%26aufirst%3DG.%26aulast%3DBorgioni%26aufirst%3DC.%26aulast%3DCiucci%26aufirst%3DA.%26aulast%3DTelera%26aufirst%3DM.%2BP.%26aulast%3DSanteusanio%26aufirst%3DF.%26aulast%3DPorcellati%26aufirst%3DC.%26aulast%3DBrunetti%26aufirst%3DP.%26atitle%3DCirculating%2520insulin%2520and%2520insulin%2520growth%2520factor-1%2520are%2520independent%2520determinants%2520of%2520left%2520ventricular%2520mass%2520and%2520geometry%2520in%2520essential%2520hypertension%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26spage%3D1802%26epage%3D1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Kuo, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueng, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. Y.</span><span> </span><span class="NLM_article-title">Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats</span> <span class="citation_source-journal">Cell Biochem. Funct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fcbf.1244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15996002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVCgt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=325-331&author=W.+W.+Kuoauthor=C.+Y.+Chuauthor=C.+H.+Wuauthor=J.+A.+Linauthor=J.+Y.+Liuauthor=Y.+H.+Hsiehauthor=K.+C.+Uengauthor=S.+D.+Leeauthor=D.+J.+Hsiehauthor=H.+H.+Hsuauthor=L.+M.+Chenauthor=C.+Y.+Huang&title=Impaired+IGF-I+signalling+of+hypertrophic+hearts+in+the+developmental+phase+of+hypertension+in+genetically+hypertensive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats</span></div><div class="casAuthors">Kuo, Wei-Wen; Chu, Chia-Yih; Wu, Chieh-Hsi; Lin, James A.; Liu, Jer-Yuh; Hsieh, Yi-Hsien; Ueng, Kwo-Chang; Lee, Shin-Da; Hsieh, Dennis Jine-Yuan; Hsu, His-Hsien; Chen, Li-Mien; Huang, Chih-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">325-331</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">0263-6484</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) signaling is reported to contribute to the modulation of blood pressure and set survival and hypertrophic responses in cardiac tissue.  However, whether IGF-I signaling normally acts in cardiac tissues of hypertensive rats is unknown.  In this study, using spontaneously hypertensive rats (SHR) and stroke-prone spontaneously hypertensive rats (SPSHR), both with early blood pressure increases, and Wistar-Kyoto (WKY) rats as controls, we measured the hypertrophic and IGF-I signaling activity changes in rat hearts at 4, 6 and 12 wk of age.  Both SHR and SPSHR were found to have significantly increased blood pressures and ratios of heart- and left ventricle- to body wt. at 12 wk of age.  However, IGF-IR and its downstream signaling, including the protein levels of phosphatidylinositol 3-kinase and phosphorylated Akt, known to maintain physiol. cardiac hypertrophy and cardiomyocyte survival, were downregulated.  The results of dot blotting showed that cardiac mRNA levels of IGF-I in hypertensive rats were higher than those in controls starting from the age of 4 wk.  This difference suggests the increased ligand IGF-I mRNA levels may be a compensatory response caused by the impaired IGF-I signaling.  Moreover, enhanced cardiac cytosolic cytochrome-c, a mitochondria-dependent apoptotic pathway component, tended to occur in both hypertensive rats, although it did not reach a significant level.  These findings indicate that impaired IGF-IR signaling occurs at early stages, and it may contribute, at least partially, to the development of hypertension and pathol. cardiac hypertrophy and to cardiomyocyte apoptosis at later stages in SHR and SPSHR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpbx5jMKI6LVg90H21EOLACvtfcHk0liyeRbeMIGjcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVCgt7vE&md5=c7c7f67feeb4919d6cddcef877ee5e9f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fcbf.1244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.1244%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DW.%2BW.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DLin%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DHsieh%26aufirst%3DY.%2BH.%26aulast%3DUeng%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DHsieh%26aufirst%3DD.%2BJ.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DHuang%26aufirst%3DC.%2BY.%26atitle%3DImpaired%2520IGF-I%2520signalling%2520of%2520hypertrophic%2520hearts%2520in%2520the%2520developmental%2520phase%2520of%2520hypertension%2520in%2520genetically%2520hypertensive%2520rats%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2005%26volume%3D23%26spage%3D325%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Laustsen, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entingh-Pearsall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzenberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span> </span><span class="NLM_article-title">Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.01110-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17189427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1WgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1649-1664&author=P.+G.+Laustsenauthor=S.+J.+Russellauthor=L.+Cuiauthor=A.+Entingh-Pearsallauthor=M.+Holzenbergerauthor=R.+Liaoauthor=C.+R.+Kahn&title=Essential+role+of+insulin+and+insulin-like+growth+factor+1+receptor+signaling+in+cardiac+development+and+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function</span></div><div class="casAuthors">Laustsen, Palle G.; Russell, Steven J.; Cui, Lei; Entingh-Pearsall, Amelia; Holzenberger, Martin; Liao, Ronglih; Kahn, C. Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1649-1664</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cardiovascular disease is the leading cause of death in people with type 2 diabetes and is linked to insulin resistance even in the absence of diabetes.  Here we show that mice with combined deficiency of the insulin receptor and insulin-like growth factor 1 (IGF-1) receptor in cardiac and skeletal muscle develop early-onset dilated cardiomyopathy and die from heart failure within the first month of life despite having a normal glucose homeostasis.  Mice lacking the insulin receptor show impaired cardiac performance at 6 mo, and mice lacking the insulin receptor plus one Igf1r allele have slightly increased mortality.  By contrast, mice lacking the IGF-1 receptor or the IGF-1 receptor plus one Ir allele appear normal.  Morphol. characterization and oligonucleotide array anal. of gene expression demonstrate that prior to development of these physiol. defects, mice with combined deficiency of both insulin and IGF-1 receptors have a coordinated down-regulation of genes encoding components of the electron transport chain and mitochondrial fatty acid β-oxidn. pathways and altered expression of contractile proteins.  Thus, while neither the insulin receptor nor IGF-1 receptor in muscle is crit. for glucose homeostasis during the first month of life, signaling from these receptors, particularly the insulin receptor, is required for normal cardiac metab. and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGD8CFWIVweLVg90H21EOLACvtfcHk0liyeRbeMIGjcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1WgtLc%253D&md5=8c56605c83ace76198ae8b4533d14a10</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1128%2FMCB.01110-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01110-06%26sid%3Dliteratum%253Aachs%26aulast%3DLaustsen%26aufirst%3DP.%2BG.%26aulast%3DRussell%26aufirst%3DS.%2BJ.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DEntingh-Pearsall%26aufirst%3DA.%26aulast%3DHolzenberger%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DR.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26atitle%3DEssential%2520role%2520of%2520insulin%2520and%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signaling%2520in%2520cardiac%2520development%2520and%2520function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D1649%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Crone, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamisawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condorelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. F.</span><span> </span><span class="NLM_article-title">ErbB2 is essential in the prevention of dilated cardiomyopathy</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm0502-459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11984589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Kgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=459-465&author=S.+A.+Croneauthor=Y.+Y.+Zhaoauthor=L.+Fanauthor=Y.+Guauthor=S.+Minamisawaauthor=Y.+Liuauthor=K.+L.+Petersonauthor=J.+Chenauthor=R.+Kahnauthor=G.+Condorelliauthor=J.+Rossauthor=K.+R.+Chienauthor=K.+F.+Lee&title=ErbB2+is+essential+in+the+prevention+of+dilated+cardiomyopathy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB2 is essential in the prevention of dilated cardiomyopathy</span></div><div class="casAuthors">Crone, S. A.; Zhao, Y.-Y.; Fan, L.; Gu, Y.; Minamisawa, S.; Liu, Y.; Peterson, K. L.; Chen, J.; Kahn, R.; Condorelli, G.; Ross, J., Jr.; Chien, K. R.; Lee, K.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-465</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is crit. for the progression of several forms of breast cancer.  In a large-scale clin. trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival.  However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure.  To investigate the physiol. role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2.  These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype.  However, physiol. anal. revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility.  Addnl., cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity.  ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-I76RZDQLVg90H21EOLACvtfcHk0lgGHULT64W_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Kgtbs%253D&md5=902e85bf249c10dfd6540c533ceb267a</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnm0502-459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0502-459%26sid%3Dliteratum%253Aachs%26aulast%3DCrone%26aufirst%3DS.%2BA.%26aulast%3DZhao%26aufirst%3DY.%2BY.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DMinamisawa%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DCondorelli%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DChien%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DK.%2BF.%26atitle%3DErbB2%2520is%2520essential%2520in%2520the%2520prevention%2520of%2520dilated%2520cardiomyopathy%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D459%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Kerkela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacobi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevtsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clubb, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alroy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">908</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm1446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16862153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=908-916&author=R.+Kerkelaauthor=L.+Grazetteauthor=R.+Yacobiauthor=C.+Iliescuauthor=R.+Pattenauthor=C.+Beahmauthor=B.+Waltersauthor=S.+Shevtsovauthor=S.+Pesantauthor=F.+J.+Clubbauthor=A.+Rosenzweigauthor=R.+N.+Salomonauthor=R.+A.+Van+Ettenauthor=J.+Alroyauthor=J.+B.+Durandauthor=T.+Force&title=Cardiotoxicity+of+the+cancer+therapeutic+agent+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span></div><div class="casAuthors">Kerkela Risto; Grazette Luanda; Yacobi Rinat; Iliescu Cezar; Patten Richard; Beahm Cara; Walters Brian; Shevtsov Sergei; Pesant Stephanie; Clubb Fred J; Rosenzweig Anthony; Salomon Robert N; Van Etten Richard A; Alroy Joseph; Durand Jean-Bernard; Force Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">908-16</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.  Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction.  Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy.  With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death.  Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death.  Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGHOTag-dpJhjv2lLSLOxFfW6udTcc2ebcUHnet9xi3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D&md5=4012ddd42a942f1441abb54df1894db8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnm1446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1446%26sid%3Dliteratum%253Aachs%26aulast%3DKerkela%26aufirst%3DR.%26aulast%3DGrazette%26aufirst%3DL.%26aulast%3DYacobi%26aufirst%3DR.%26aulast%3DIliescu%26aufirst%3DC.%26aulast%3DPatten%26aufirst%3DR.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DB.%26aulast%3DShevtsov%26aufirst%3DS.%26aulast%3DPesant%26aufirst%3DS.%26aulast%3DClubb%26aufirst%3DF.%2BJ.%26aulast%3DRosenzweig%26aufirst%3DA.%26aulast%3DSalomon%26aufirst%3DR.%2BN.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DAlroy%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DCardiotoxicity%2520of%2520the%2520cancer%2520therapeutic%2520agent%2520imatinib%2520mesylate%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D908%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodeheffer, R.</span><span> </span><span class="NLM_article-title">Clinical cardiac tolerability of trastuzumab</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2004.01.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14722042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=322-329&author=E.+A.+Perezauthor=R.+Rodeheffer&title=Clinical+cardiac+tolerability+of+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical cardiac tolerability of trastuzumab</span></div><div class="casAuthors">Perez, Edith A.; Rodeheffer, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This review provides an update on the current understanding of the clin. cardiac tolerability of trastuzumab, a humanized monoclonal antibody effective in the treatment of patients with advanced breast cancer overexpressing or amplifying HER2.  We produced a summary of currently available information regarding the incidence and natural history of trastuzumab-assocd. cardiac dysfunction.  Data from new, prospective clin. studies that incorporate close cardiac monitoring and standardized follow-up in patients with either advanced or earlier stages of breast cancer are also presented, and hypotheses regarding potential mechanisms of trastuzumab-related cardiotoxicity are discussed.  Patients treated with trastuzumab in the pivotal trials were found to have increased risk for cardiac dysfunction, mostly when used concurrent with anthracyclines.  Recent trials have required more stringent and consistent cardiac monitoring criteria and excluded patients with abnormal cardiac function, pre-existing heart disease, and/or high cumulative doses of anthracyclines.  Decreases of ejection fraction and a few cases of congestive heart failure (CHF) requiring medical therapy have been detected.  Improvements in ejection fraction and the symptoms of CHF have been subsequently noted in a significant no. of these patients.  Trastuzumab is assocd. with an increased risk of asymptomatic decreases in ejection fraction, and, in a small no. of patients, CHF that is almost always responsive to medical management.  This risk is greatest in patients receiving concurrent anthracyclines.  More data are needed to help elucidate the pathophysiol. of this syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4w4tmYBRz27Vg90H21EOLACvtfcHk0lgGHULT64W_YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKitLY%253D&md5=7666bf56fb54a5994af2e7a70a9146a6</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.01.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.01.120%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DRodeheffer%26aufirst%3DR.%26atitle%3DClinical%2520cardiac%2520tolerability%2520of%2520trastuzumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amirahmadi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinke-Braun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollica, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buerger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, G. L.</span><span> </span><span class="NLM_article-title">Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=612-617&author=J.+R.+McMullenauthor=F.+Amirahmadiauthor=E.+A.+Woodcockauthor=M.+Schinke-Braunauthor=R.+D.+Bouwmanauthor=K.+A.+Hewittauthor=J.+P.+Mollicaauthor=L.+Zhangauthor=Y.+Zhangauthor=T.+Shioiauthor=A.+Buergerauthor=S.+Izumoauthor=P.+Y.+Jayauthor=G.+L.+Jennings&title=Protective+effects+of+exercise+and+phosphoinositide+3-kinase%28p110alpha%29+signaling+in+dilated+and+hypertrophic+cardiomyopathy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DAmirahmadi%26aufirst%3DF.%26aulast%3DWoodcock%26aufirst%3DE.%2BA.%26aulast%3DSchinke-Braun%26aufirst%3DM.%26aulast%3DBouwman%26aufirst%3DR.%2BD.%26aulast%3DHewitt%26aufirst%3DK.%2BA.%26aulast%3DMollica%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShioi%26aufirst%3DT.%26aulast%3DBuerger%26aufirst%3DA.%26aulast%3DIzumo%26aufirst%3DS.%26aulast%3DJay%26aufirst%3DP.%2BY.%26aulast%3DJennings%26aufirst%3DG.%2BL.%26atitle%3DProtective%2520effects%2520of%2520exercise%2520and%2520phosphoinositide%25203-kinase%2528p110alpha%2529%2520signaling%2520in%2520dilated%2520and%2520hypertrophic%2520cardiomyopathy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2007%26volume%3D104%26spage%3D612%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P. Y.</span><span> </span><span class="NLM_article-title">PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=910-913&author=J.+R.+McMullenauthor=P.+Y.+Jay&title=PI3K%28p110alpha%29+inhibitors+as+anti-cancer+agents%3A+minding+the+heart"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DJay%26aufirst%3DP.%2BY.%26atitle%3DPI3K%2528p110alpha%2529%2520inhibitors%2520as%2520anti-cancer%2520agents%253A%2520minding%2520the%2520heart%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D910%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Butler, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=1685-1688&author=A.+A.+Butlerauthor=D.+LeRoith&title=Minireview%3A+tissue-specific+versus+generalized+gene+targeting+of+the+igf1+and+igf1r+genes+and+their+roles+in+insulin-like+growth+factor+physiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DA.%2BA.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DMinireview%253A%2520tissue-specific%2520versus%2520generalized%2520gene%2520targeting%2520of%2520the%2520igf1%2520and%2520igf1r%2520genes%2520and%2520their%2520roles%2520in%2520insulin-like%2520growth%2520factor%2520physiology%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26spage%3D1685%26epage%3D1688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Yakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stannard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluzik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouxsein, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1172%2FJCI200417763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14702113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=96-105&author=S.+Yakarauthor=J.+Setserauthor=H.+Zhaoauthor=B.+Stannardauthor=M.+Haluzikauthor=V.+Glattauthor=M.+L.+Bouxseinauthor=J.+J.+Kopchickauthor=D.+LeRoith&title=Inhibition+of+growth+hormone+action+improves+insulin+sensitivity+in+liver+IGF-1-deficient+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice</span></div><div class="casAuthors">Yakar, Shoshana; Setser, Jennifer; Zhao, Hong; Stannard, Bethel; Haluzik, Martin; Glatt, Vaida; Bouxsein, Mary L.; Kopchick, John J.; LeRoith, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Liver IGF-1-deficient (LID) mice have a 75% redn. in circulating IGF-1 levels and, as a result, a fourfold increase in growth hormone (GH) secretion.  To block GH action, LID mice were crossed with GH antagonist (GHa) transgenic mice.  Inactivation of GH action in the resulting LID + GHa mice led to decreased blood glucose and insulin levels and improved peripheral insulin sensitivity.  Hyperinsulinemic-euglycemic clamp studies showed that LID mice exhibit severe insulin resistance.  In contrast, expression of the GH antagonist transgene in LID + GHa mice led to enhanced insulin sensitivity and increased insulin-stimulated glucose uptake in muscle and white adipose tissue.  Interestingly, LID + GHa mice exhibit a twofold increase in white adipose tissue mass, as well as increased levels of serum-free fatty acids and triglycerides, but no increase in the triglyceride content of liver and muscle.  In conclusion, these results show that despite low levels of circulating IGF-1, insulin sensitivity in LID mice could be improved by inactivating GH action, suggesting that chronic elevation of GH levels plays a major role in insulin resistance.  These results suggest that IGF-1 plays a role in maintaining a fine balance between GH and insulin to promote normal carbohydrate and lipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSUCGSZalz7Vg90H21EOLACvtfcHk0ljzjgyWcBYyfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGlsQ%253D%253D&md5=dbd6b50304640304707ad2c6b36c0cfa</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1172%2FJCI200417763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200417763%26sid%3Dliteratum%253Aachs%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DStannard%26aufirst%3DB.%26aulast%3DHaluzik%26aufirst%3DM.%26aulast%3DGlatt%26aufirst%3DV.%26aulast%3DBouxsein%26aufirst%3DM.%2BL.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520growth%2520hormone%2520action%2520improves%2520insulin%2520sensitivity%2520in%2520liver%2520IGF-1-deficient%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D2004%26volume%3D113%26spage%3D96%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Kulkarni, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winnay, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruning, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flier, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span> </span><span class="NLM_article-title">Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">R69</span><span class="NLM_x">–</span> <span class="NLM_lpage">R75</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=R69-R75&author=R.+N.+Kulkarniauthor=J.+N.+Winnayauthor=M.+Danielsauthor=J.+C.+Bruningauthor=S.+N.+Flierauthor=D.+Hanahanauthor=C.+R.+Kahn&title=Altered+function+of+insulin+receptor+substrate-1-deficient+mouse+islets+and+cultured+beta-cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWinnay%26aufirst%3DJ.%2BN.%26aulast%3DDaniels%26aufirst%3DM.%26aulast%3DBruning%26aufirst%3DJ.%2BC.%26aulast%3DFlier%26aufirst%3DS.%2BN.%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26atitle%3DAltered%2520function%2520of%2520insulin%2520receptor%2520substrate-1-deficient%2520mouse%2520islets%2520and%2520cultured%2520beta-cell%2520lines%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3DR69%26epage%3DR75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Withers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towery, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamuro, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flint, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, M. F.</span><span> </span><span class="NLM_article-title">Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10471495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=32-40&author=D.+J.+Withersauthor=D.+J.+Burksauthor=H.+H.+Toweryauthor=S.+L.+Altamuroauthor=C.+L.+Flintauthor=M.+F.+White&title=Irs-2+coordinates+Igf-1+receptor-mediated+beta-cell+development+and+peripheral+insulin+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling</span></div><div class="casAuthors">Withers, Dominic J.; Burks, Deborah J.; Towery, Heather H.; Altamuro, Shari L.; Flint, Carrie L.; White, Morris F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-40</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Insulin receptor substrates (Irs proteins) mediate the pleiotropic effects of insulin and Igf-1 (insulin-like growth factor-1), including regulation of glucose homeostasis and cell growth and survival.  The authors intercrossed mice heterozygous for two null alleles (Irs1+/- and Irs2+/-) and investigated growth and glucose metab. in mice with viable genotypes.  The authors' expts. revealed that Irs-1 and Irs-2 are crit. for embryonic and post-natal growth, with Irs-1 having the predominant role.  By contrast, both Irs-1 and Irs-2 function in peripheral carbohydrate metab., but Irs-2 has the major role in β-cell development and compensation for peripheral insulin resistance.  To establish a role for the Igf-1 receptor in β-cells, the authors intercrossed mice heterozygous for null alleles of Igf1r and Irs2.  The authors' results reveal that Igf-1 receptors promote β-cell development and survival through the Irs-2 signaling pathway.  Thus, Irs-2 integrates the effects of insulin in peripheral target tissues with Igf-1 in pancreatic β-cells to maintain glucose homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc_S0y68m6qLVg90H21EOLACvtfcHk0ljzjgyWcBYyfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWhsL0%253D&md5=f0ef4c50a968001252813c325b9740eb</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWithers%26aufirst%3DD.%2BJ.%26aulast%3DBurks%26aufirst%3DD.%2BJ.%26aulast%3DTowery%26aufirst%3DH.%2BH.%26aulast%3DAltamuro%26aufirst%3DS.%2BL.%26aulast%3DFlint%26aufirst%3DC.%2BL.%26aulast%3DWhite%26aufirst%3DM.%2BF.%26atitle%3DIrs-2%2520coordinates%2520Igf-1%2520receptor-mediated%2520beta-cell%2520development%2520and%2520peripheral%2520insulin%2520signalling%26jtitle%3DNat.%2520Genet.%26date%3D1999%26volume%3D23%26spage%3D32%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berggren, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tally, M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1677%2Fjoe.0.1560573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9582514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXitVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1998&pages=573-581&author=Q.+Zhangauthor=P.+O.+Berggrenauthor=A.+Hanssonauthor=M.+Tally&title=Insulin-like+growth+factor-I-induced+DNA+synthesis+in+insulin-secreting+cell+line+RINm5F+is+associated+with+phosphorylation+of+the+insulin-like+growth+factor-I+receptor+and+the+insulin+receptor+substrate-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2</span></div><div class="casAuthors">Zhang, Q.; Berggren, P. -O.; Hansson, A.; Tally, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-581</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Journal of Endocrinology</span>)
        </div><div class="casAbstract">A proliferative effect of insulin-like growth factor-I (IGF-I) was previously shown in pancreatic islets.  However, the mechanism under which IGF-I actions are exerted in insulin-secreting cells is not clear.  The rat insulinoma cell line, RINm5F, was shown to have both IGF-I receptors and IGF-II/mannose-6-phosphate receptors.  IGF-I binding to cell surface receptors stimulated phosphorylation of 97 kDa and 93 kDa subunits of the IGF-I receptor and incorporation of [3H]thymidine into RINm5F cells.  Both the IGF-I-induced protein phosphorylation and [3H]thymidine incorporation were abolished in the presence of the tyrosine kinase inhibitor, genistein.  Under basal conditions, IGF-I did not induce insulin release or changes in cytosolic free Ca2+ concn.  Immunopptn. of proteins from RINm5F cells, using phosphotyrosine antibodies, followed by western blotting using antibody against IRS-1 revealed no distinct band of phosphorylated insulin receptor substrate (IRS)-1.  Instead, tyrosine-phosphorylated IRS-2 was detected and stimulated by IGF-I when western blotting was performed using antibody against IRS-2.  These results indicate that IRS-1 is not likely to be involved in IGF-I signaling in RINm5F cells.  Hence, IGF-I stimulated DNA synthesis in RINm5F cells was assocd. with phosphorylation of IGF-I receptors and IRS-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyrc6rzKGzhbVg90H21EOLACvtfcHk0lhmIrJ_4zhlaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVWjsrw%253D&md5=b342f79145ef08a8e22c70684981062a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1677%2Fjoe.0.1560573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.0.1560573%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBerggren%26aufirst%3DP.%2BO.%26aulast%3DHansson%26aufirst%3DA.%26aulast%3DTally%26aufirst%3DM.%26atitle%3DInsulin-like%2520growth%2520factor-I-induced%2520DNA%2520synthesis%2520in%2520insulin-secreting%2520cell%2520line%2520RINm5F%2520is%2520associated%2520with%2520phosphorylation%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520and%2520the%2520insulin%2520receptor%2520substrate-2%26jtitle%3DJ.%2520Endocrinol.%26date%3D1998%26volume%3D156%26spage%3D573%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">del Rincon, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaylinn, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbour, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draznin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorner, M. O.</span><span> </span><span class="NLM_article-title">Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1638</span><span class="NLM_x">–</span> <span class="NLM_lpage">1646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=1638-1646&author=J.+P.+del+Rinconauthor=K.+Iidaauthor=B.+D.+Gaylinnauthor=C.+E.+McCurdyauthor=J.+W.+Leitnerauthor=L.+A.+Barbourauthor=J.+J.+Kopchickauthor=J.+E.+Friedmanauthor=B.+Drazninauthor=M.+O.+Thorner&title=Growth+hormone+regulation+of+p85alpha+expression+and+phosphoinositide+3-kinase+activity+in+adipose+tissue%3A+mechanism+for+growth+hormone-mediated+insulin+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BRincon%26aufirst%3DJ.%2BP.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DGaylinn%26aufirst%3DB.%2BD.%26aulast%3DMcCurdy%26aufirst%3DC.%2BE.%26aulast%3DLeitner%26aufirst%3DJ.%2BW.%26aulast%3DBarbour%26aufirst%3DL.%2BA.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26aulast%3DFriedman%26aufirst%3DJ.%2BE.%26aulast%3DDraznin%26aufirst%3DB.%26aulast%3DThorner%26aufirst%3DM.%2BO.%26atitle%3DGrowth%2520hormone%2520regulation%2520of%2520p85alpha%2520expression%2520and%2520phosphoinositide%25203-kinase%2520activity%2520in%2520adipose%2520tissue%253A%2520mechanism%2520for%2520growth%2520hormone-mediated%2520insulin%2520resistance%26jtitle%3DDiabetes%26date%3D2007%26volume%3D56%26spage%3D1638%26epage%3D1646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Kahn, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flier, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span> </span><span class="NLM_article-title">The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=176581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaE287kvFylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=739-745&author=C.+R.+Kahnauthor=J.+S.+Flierauthor=R.+S.+Barauthor=J.+A.+Archerauthor=P.+Gordenauthor=M.+M.+Martinauthor=J.+Roth&title=The+syndromes+of+insulin+resistance+and+acanthosis+nigricans.+Insulin-receptor+disorders+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man</span></div><div class="casAuthors">Kahn C R; Flier J S; Bar R S; Archer J A; Gorden P; Martin M M; Roth J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">739-45</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">In six patients with acanthosis nigricans variable degrees of glucose intolerance, hyperinsulinemia and marked resistance to exogenous insulin were found.  Studies of insulin receptors on circulating monocytes suggest that the insulin resistance in these patients was due to a marked decrease in insulin binding to its membrane receptors.  When these patients were fasted, there was a fall in plasma insulin but no increase in insulin binding, suggesting that the receptor defect was not secondary to the hyperinsulinemia.  The clinical features shared by these cases and several similar ones previously reported may be divided into two unique clinical syndromes: Type A, a syndrome in younger females with signs of virilization or accelerated growth, in whom the receptor defect may be primary, and Type B, a syndrome in older females with signs of an immunologic disease, in whom circulating antibodies to the insulin receptor are found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK5kqY8sDhzDToTC3aBaesfW6udTcc2eagGOtgi7Dscbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287kvFylug%253D%253D&md5=6bf5e66c471a9e12cdc82066430add9e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DFlier%26aufirst%3DJ.%2BS.%26aulast%3DBar%26aufirst%3DR.%2BS.%26aulast%3DArcher%26aufirst%3DJ.%2BA.%26aulast%3DGorden%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DM.%2BM.%26aulast%3DRoth%26aufirst%3DJ.%26atitle%3DThe%2520syndromes%2520of%2520insulin%2520resistance%2520and%2520acanthosis%2520nigricans.%2520Insulin-receptor%2520disorders%2520in%2520man%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D739%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Railo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekonen, F.</span><span> </span><span class="NLM_article-title">The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">30A</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30A&publication_year=1994&pages=307-311&author=M.+J.+Railoauthor=S.+K.+vonauthor=F.+Pekonen&title=The+prognostic+value+of+insulin-like+growth+factor-I+in+breast+cancer+patients.+Results+of+a+follow-up+study+on+126+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRailo%26aufirst%3DM.%2BJ.%26aulast%3Dvon%26aufirst%3DS.%2BK.%26aulast%3DPekonen%26aufirst%3DF.%26atitle%3DThe%2520prognostic%2520value%2520of%2520insulin-like%2520growth%2520factor-I%2520in%2520breast%2520cancer%2520patients.%2520Results%2520of%2520a%2520follow-up%2520study%2520on%2520126%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1994%26volume%3D30A%26spage%3D307%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Ueda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigekawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraide, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, H.</span><span> </span><span class="NLM_article-title">Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1111%2Fj.1349-7006.2006.00228.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16827799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=597-604&author=S.+Uedaauthor=H.+Tsudaauthor=K.+Satoauthor=H.+Takeuchiauthor=T.+Shigekawaauthor=O.+Matsubaraauthor=H.+Hiraideauthor=H.+Mochizuki&title=Alternative+tyrosine+phosphorylation+of+signaling+kinases+according+to+hormone+receptor+status+in+breast+cancer+overexpressing+the+insulin-like+growth+factor+receptor+type+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1</span></div><div class="casAuthors">Ueda, Shigeto; Tsuda, Hitoshi; Sato, Kazuhiko; Takeuchi, Hideki; Shigekawa, Takashi; Matsubara, Osamu; Hiraide, Hoshio; Mochizuki, Hidetaka</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">597-604</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">The insulin-like growth factor receptor type 1 (IGF1R) is suggested to play important roles in cancer cell growth through cross-talk with hormone receptors and growth factor receptors.  However, its clin. significance in breast cancers in vivo is still unclear.  We examd. immunohistochem. the expression of IGF1R, phosphorylated-AKT (pAKT) and phosphorylated-ERK1/2 (pERK1/2) using tissue microarray slides contg. 150 cases of primary breast carcinoma.  Their mutual correlation and correlation with the status of hormone receptors epidermal growth factor receptor and human epidermal growth factor receptor type 2 were also investigated.  IGF1R overexpression was detected in 71 cases (47%), and was correlated with lower nuclear grade (P = 0.03), pos. estrogen receptor (ER) and/or progesterone receptor status (P = 0.002).  PERK1/2 expression, detected in 53 cases (35%), was correlated with pos. ER (P < 0.0001) and lower nuclear grade (P = 0.014).  PAKT expression, detected in 88 cases (59%), was not correlated with nuclear grade, hormone receptors status or other clin. parameters.  Of the 71 IGF1R-overexpressing tumors, pERK1/2 expression was detected in 27 (56%) of 48 ER-pos. cases but in only four (17%) of 23 ER-neg. cases (P = 0.022).  In contrast, pAKT expression was constantly (64% or higher) detected irresp. of hormone receptor status in IGF1R-overexpressing breast cancers.  Taken together, these findings suggest that IGF1R overexpression might activate pERK1/2 and pAKT in hormone receptor-pos. breast cancer, but activate only pAKT in hormone receptor-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaQKDT0pleprVg90H21EOLACvtfcHk0liuL2578yJq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOnt7c%253D&md5=035f51edd2bbecfe143a6c6b9d6c7663</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00228.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00228.x%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DShigekawa%26aufirst%3DT.%26aulast%3DMatsubara%26aufirst%3DO.%26aulast%3DHiraide%26aufirst%3DH.%26aulast%3DMochizuki%26aufirst%3DH.%26atitle%3DAlternative%2520tyrosine%2520phosphorylation%2520of%2520signaling%2520kinases%2520according%2520to%2520hormone%2520receptor%2520status%2520in%2520breast%2520cancer%2520overexpressing%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520type%25201%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D597%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Shimizu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsumata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span> </span><span class="NLM_article-title">Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1537</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.humpath.2004.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15619214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyku7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=1537-1542&author=C.+Shimizuauthor=T.+Hasegawaauthor=Y.+Taniauthor=F.+Takahashiauthor=M.+Takeuchiauthor=T.+Watanabeauthor=M.+Andoauthor=N.+Katsumataauthor=Y.+Fujiwara&title=Expression+of+insulin-like+growth+factor+1+receptor+in+primary+breast+cancer%3A+immunohistochemical+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis</span></div><div class="casAuthors">Shimizu, Chikako; Hasegawa, Tadashi; Tani, Yoichi; Takahashi, Fumiaki; Takeuchi, Masahiro; Watanabe, Toru; Ando, Masashi; Katsumata, Noriyuki; Fujiwara, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Human Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1537-1542</span>CODEN:
                <span class="NLM_cas:coden">HPCQA4</span>;
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-1 receptor (IGF-1R) has been implicated in regulation in tumor growth.  The results of previous studies performed by RIA are conflicting, and the prognostic significance of IGF-1R expression in primary breast cancer is still controversial.  IGF-1R expression was evaluated in formalin-fixed, paraffin-embedded tissue of 210 primary breast cancer patients by using anti-IGF-1R antibody.  The clinicopathol. variables and 5-yr disease-free survival were studied, and their correlations between IGF-1R expressions were investigated.  IGF-1R overexpression was obsd. in 43.8% of tumors.  IGF-1R overexpression had no correlation with prognosis or with other clinicopathol. parameters, such as age, tumor size, nodal status, histol. grade, hormone receptor status, and human epidermal growth factor 2 status.  Though its prognostic value in breast cancer is limited, immunohistochem. evaluation of IGF-1R by using this monoclonal antibody may be useful in translational research using archived material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7qcH_clPsYLVg90H21EOLACvtfcHk0liuL2578yJq8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyku7%252FE&md5=eb0bf648fd0edec48803632abb0ab1cd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.humpath.2004.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.humpath.2004.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DC.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DKatsumata%26aufirst%3DN.%26aulast%3DFujiwara%26aufirst%3DY.%26atitle%3DExpression%2520of%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520in%2520primary%2520breast%2520cancer%253A%2520immunohistochemical%2520analysis%26jtitle%3DHum.%2520Pathol.%26date%3D2004%26volume%3D35%26spage%3D1537%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Hellawell, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewster, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2942</span><span class="NLM_x">–</span> <span class="NLM_lpage">2950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=2942-2950&author=G.+O.+Hellawellauthor=G.+D.+Turnerauthor=D.+R.+Daviesauthor=R.+Poulsomauthor=S.+F.+Brewsterauthor=V.+M.+Macaulay&title=Expression+of+the+type+1+insulin-like+growth+factor+receptor+is+up-regulated+in+primary+prostate+cancer+and+commonly+persists+in+metastatic+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHellawell%26aufirst%3DG.%2BO.%26aulast%3DTurner%26aufirst%3DG.%2BD.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DPoulsom%26aufirst%3DR.%26aulast%3DBrewster%26aufirst%3DS.%2BF.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DExpression%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520is%2520up-regulated%2520in%2520primary%2520prostate%2520cancer%2520and%2520commonly%2520persists%2520in%2520metastatic%2520disease%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D2942%26epage%3D2950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Tennant, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrasher, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twomey, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drivdahl, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plymate, S. R.</span><span> </span><span class="NLM_article-title">Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">3774</span><span class="NLM_x">–</span> <span class="NLM_lpage">3782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fjc.81.10.3774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8855837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK28XmtlCmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1996&pages=3774-3782&author=M.+K.+Tennantauthor=J.+B.+Thrasherauthor=P.+A.+Twomeyauthor=R.+H.+Drivdahlauthor=R.+S.+Birnbaumauthor=S.+R.+Plymate&title=Protein+and+messenger+ribonucleic+acid+%28mRNA%29+for+the+type+1+insulin-like+growth+factor+%28IGF%29+receptor+is+decreased+and+IGF-II+mRNA+is+increased+in+human+prostate+carcinoma+compared+to+benign+prostate+epithelium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium</span></div><div class="casAuthors">Tennant, Marie K.; Thrasher, J. Brantley; Twomey, Patrick A.; Drivdahl, Rolf H.; Birnbaum, R. S.; Plymate, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3774-3782</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Insulin-like growth factors (IGFs) and the type 1 IGF receptor (IGF-R) are involved in normal growth and development of the human prostate.  Changes in levels of IGF-R and IGFs have been shown for several malignancies.  Immunohistochem. and in situ hybridization were performed to compare the expression of IGF-R and IGF-II in vivo in prostate tissue contg. benign epithelium, high grade prostate intraepithelial neoplasia (PIN), and adenocarcinoma.  The mRNA hybridization signals and immunoreactivity for IGF-R were localized primarily to epithelial cells, with less signal in stroma.  IGF-R mRNA was significantly decreased by 42% in PIN and 35% in cancer cells compared to that in benign epithelium.  IGF-R immunostaining was significantly decreased by 32% in PIN and by 42% in malignant epithelium compared to that in benign epithelium.  IGF-II mRNA was also localized primarily to epithelial cells.  IGF-II mRNA was significantly increased by 30% in adenocarcinoma compared to that in benign epithelium.  Immunoreactivity for IGF-II was localized to both stroma and epithelium.  Protein levels for IGF-II were not significantly increased in cancer cells compared to those in benign epithelium.  The decrease in the type 1 IGF receptor and increase in IGF-II mRNA may affect prostate cancer proliferation and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SAaiVAizUbVg90H21EOLACvtfcHk0lhJUyCjA8xHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlCmu7k%253D&md5=d0052fb7132b0136e4713734505baae6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1210%2Fjc.81.10.3774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.81.10.3774%26sid%3Dliteratum%253Aachs%26aulast%3DTennant%26aufirst%3DM.%2BK.%26aulast%3DThrasher%26aufirst%3DJ.%2BB.%26aulast%3DTwomey%26aufirst%3DP.%2BA.%26aulast%3DDrivdahl%26aufirst%3DR.%2BH.%26aulast%3DBirnbaum%26aufirst%3DR.%2BS.%26aulast%3DPlymate%26aufirst%3DS.%2BR.%26atitle%3DProtein%2520and%2520messenger%2520ribonucleic%2520acid%2520%2528mRNA%2529%2520for%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520receptor%2520is%2520decreased%2520and%2520IGF-II%2520mRNA%2520is%2520increased%2520in%2520human%2520prostate%2520carcinoma%2520compared%2520to%2520benign%2520prostate%2520epithelium%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab%26date%3D1996%26volume%3D81%26spage%3D3774%26epage%3D3782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Figueroa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speights, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinehart, J. J.</span><span> </span><span class="NLM_article-title">Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=28-34&author=J.+A.+Figueroaauthor=R.+S.+Deauthor=V.+O.+Speightsauthor=J.+J.+Rinehart&title=Gene+expression+of+insulin-like+growth+factors+and+receptors+in+neoplastic+prostate+tissues%3A+correlation+with+clinico-pathological+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFigueroa%26aufirst%3DJ.%2BA.%26aulast%3DDe%26aufirst%3DR.%2BS.%26aulast%3DSpeights%26aufirst%3DV.%2BO.%26aulast%3DRinehart%26aufirst%3DJ.%2BJ.%26atitle%3DGene%2520expression%2520of%2520insulin-like%2520growth%2520factors%2520and%2520receptors%2520in%2520neoplastic%2520prostate%2520tissues%253A%2520correlation%2520with%2520clinico-pathological%2520parameters%26jtitle%3DCancer%2520Invest.%26date%3D2001%26volume%3D19%26spage%3D28%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Miyata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanetake, H.</span><span> </span><span class="NLM_article-title">Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2003&pages=125-132&author=Y.+Miyataauthor=H.+Sakaiauthor=T.+Hayashiauthor=H.+Kanetake&title=Serum+insulin-like+growth+factor+binding+protein-3%2Fprostate-specific+antigen+ratio+is+a+useful+predictive+marker+in+patients+with+advanced+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DKanetake%26aufirst%3DH.%26atitle%3DSerum%2520insulin-like%2520growth%2520factor%2520binding%2520protein-3%252Fprostate-specific%2520antigen%2520ratio%2520is%2520a%2520useful%2520predictive%2520marker%2520in%2520patients%2520with%2520advanced%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2003%26volume%3D54%26spage%3D125%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Shariat, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slawin, K. M.</span><span> </span><span class="NLM_article-title">Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=359-364&author=S.+F.+Shariatauthor=J.+Kimauthor=C.+Nguyenauthor=T.+M.+Wheelerauthor=S.+P.+Lernerauthor=K.+M.+Slawin&title=Correlation+of+preoperative+levels+of+IGF-I+and+IGFBP-3+with+pathologic+parameters+and+clinical+outcome+in+patients+with+bladder+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShariat%26aufirst%3DS.%2BF.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DWheeler%26aufirst%3DT.%2BM.%26aulast%3DLerner%26aufirst%3DS.%2BP.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26atitle%3DCorrelation%2520of%2520preoperative%2520levels%2520of%2520IGF-I%2520and%2520IGFBP-3%2520with%2520pathologic%2520parameters%2520and%2520clinical%2520outcome%2520in%2520patients%2520with%2520bladder%2520cancer%26jtitle%3DUrology%26date%3D2003%26volume%3D61%26spage%3D359%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Giovannucci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platz, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majeed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speizer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankinson, S. E.</span><span> </span><span class="NLM_article-title">A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=345-349&author=E.+Giovannucciauthor=M.+N.+Pollakauthor=E.+A.+Platzauthor=W.+C.+Willettauthor=M.+J.+Stampferauthor=N.+Majeedauthor=G.+A.+Colditzauthor=F.+E.+Speizerauthor=S.+E.+Hankinson&title=A+prospective+study+of+plasma+insulin-like+growth+factor-1+and+binding+protein-3+and+risk+of+colorectal+neoplasia+in+women"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DPlatz%26aufirst%3DE.%2BA.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DMajeed%26aufirst%3DN.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DSpeizer%26aufirst%3DF.%2BE.%26aulast%3DHankinson%26aufirst%3DS.%2BE.%26atitle%3DA%2520prospective%2520study%2520of%2520plasma%2520insulin-like%2520growth%2520factor-1%2520and%2520binding%2520protein-3%2520and%2520risk%2520of%2520colorectal%2520neoplasia%2520in%2520women%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2000%26volume%3D9%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortolero-Luna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phatak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitz, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Follen, M.</span><span> </span><span class="NLM_article-title">Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">–</span> <span class="NLM_lpage">3361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12960122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=3356-3361&author=X.+Wuauthor=G.+Tortolero-Lunaauthor=H.+Zhaoauthor=D.+Phatakauthor=M.+R.+Spitzauthor=M.+Follen&title=Serum+levels+of+insulin-like+growth+factor+I+and+risk+of+squamous+intraepithelial+lesions+of+the+cervix"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix</span></div><div class="casAuthors">Wu, Xifeng; Tortolero-Luna, Guillermo; Zhao, Hua; Phatak, Deepali; Spitz, Margaret R.; Follen, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3356-3361</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Squamous intraepithelial lesions (SILs) are areas of precancerous growth in the cervix that can be indicative of future cervical cancer.  Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been implicated in cancer development.  Recent studies have demonstrated that elevated plasma IGF-I levels are assocd. with increased risk of prostate, lung, colon, and breast cancers.  In this case-control study, we analyzed the relationship between serum levels of IGF-I and IGFBP-3, and SILs of the cervix.  The case patients were comprised of 267 women treated at The University of Texas M. D. Anderson Cancer Center Colposcopy Clinic in Houston, Texas for abnormal Pap smears.  The clinic serves minority and economically disadvantaged women referred from the County Health Department clinics of Harris County, Texas.  The control subjects were 238 healthy women receiving family planning and screening services at two Harris County Health Department clinics.  Case patients with either high-grade or low-grade SILs had significantly higher serum levels of IGF-I, IGFBP-3, and molar ratios of IGF-I:IGFBP-3 than the control subjects did.  IGF-I levels in the highest quartile were assocd. with significantly higher risk of SILs compared with the lowest quartile, independent of IGFBP-3 levels.  The odds ratio for the fourth quartile of IGF-I level, relative to the first quartile, was 8.54 (95% confidence interval, 4.15-17.60; P < 0.0001) after adjustment for age, ethnicity, smoking status, and IGFBP-3 level.  There was a dose-response relationship between risk of SILs and the level of IGF-I: as the level of IGF-I increased, so did the risk of SILs.  In addn., the serum level of IGFBP-3 was significantly higher in case patients than in control subjects.  However, after adjustment for IGF-I, no relationship was evident between IGFBP-3 level and risk of SILs.  Serum levels of IGF-I may be a useful biomarker for assessing risk of SIL development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZcqscFE_2T7Vg90H21EOLACvtfcHk0lhJUyCjA8xHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCksb0%253D&md5=6e4e50dae429cdad259a2ef61464f903</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DTortolero-Luna%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPhatak%26aufirst%3DD.%26aulast%3DSpitz%26aufirst%3DM.%2BR.%26aulast%3DFollen%26aufirst%3DM.%26atitle%3DSerum%2520levels%2520of%2520insulin-like%2520growth%2520factor%2520I%2520and%2520risk%2520of%2520squamous%2520intraepithelial%2520lesions%2520of%2520the%2520cervix%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D3356%26epage%3D3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Chao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Amore, P. A.</span><span> </span><span class="NLM_article-title">IGF2: epigenetic regulation and role in development and disease</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.cytogfr.2008.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18308616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Wjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=111-120&author=W.+Chaoauthor=P.+A.+D%27Amore&title=IGF2%3A+epigenetic+regulation+and+role+in+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">IGF2: Epigenetic regulation and role in development and disease</span></div><div class="casAuthors">Chao, Wendy; D'Amore, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor II (IGF2) is perhaps the most intricately regulated of all growth factors characterized to date.  Its gene is imprinted - only one allele is active, depending on parental origin - and this pattern of expression is maintained epigenetically in almost all tissues.  IGF2 activity is further controlled through differential expression of receptors and IGF-binding proteins (IGFBPs) that det. protein availability.  This complex and multifaceted regulation emphasizes the importance of accurate IGF2 expression and activity.  This review will examine the regulation of the IGF2 gene and what it has revealed about the phenomenon of imprinting, which is frequently disrupted in cancer.  IGF2 protein function will be discussed, along with diseases that involve IGF2 overexpression.  Roles for IGF2 in sonic hedgehog (Shh) signaling and angiogenesis will also be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZuk6DOp4vrVg90H21EOLACvtfcHk0lgbYVfQlZYeLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Wjtrc%253D&md5=a54a762e44d514fba6e6f0c9795c7425</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2008.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2008.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DW.%26aulast%3DD%2527Amore%26aufirst%3DP.%2BA.%26atitle%3DIGF2%253A%2520epigenetic%2520regulation%2520and%2520role%2520in%2520development%2520and%2520disease%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2008%26volume%3D19%26spage%3D111%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Cui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Correa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardiello, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutcheon, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafonek, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandenburg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powe, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, A. P.</span><span> </span><span class="NLM_article-title">Loss of IGF2 imprinting: a potential marker of colorectal cancer risk</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1753-1755&author=H.+Cuiauthor=M.+Cruz-Correaauthor=F.+M.+Giardielloauthor=D.+F.+Hutcheonauthor=D.+R.+Kafonekauthor=S.+Brandenburgauthor=Y.+Wuauthor=X.+Heauthor=N.+R.+Poweauthor=A.+P.+Feinberg&title=Loss+of+IGF2+imprinting%3A+a+potential+marker+of+colorectal+cancer+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DCruz-Correa%26aufirst%3DM.%26aulast%3DGiardiello%26aufirst%3DF.%2BM.%26aulast%3DHutcheon%26aufirst%3DD.%2BF.%26aulast%3DKafonek%26aufirst%3DD.%2BR.%26aulast%3DBrandenburg%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPowe%26aufirst%3DN.%2BR.%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26atitle%3DLoss%2520of%2520IGF2%2520imprinting%253A%2520a%2520potential%2520marker%2520of%2520colorectal%2520cancer%2520risk%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1753%26epage%3D1755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Sakatani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobuzio-Donahue, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boom, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, A. P.</span><span> </span><span class="NLM_article-title">Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1976-1978&author=T.+Sakataniauthor=A.+Kanedaauthor=C.+A.+Iacobuzio-Donahueauthor=M.+G.+Carterauthor=W.+S.+de+Boomauthor=H.+Okanoauthor=M.+S.+Koauthor=R.+Ohlssonauthor=D.+L.+Longoauthor=A.+P.+Feinberg&title=Loss+of+imprinting+of+Igf2+alters+intestinal+maturation+and+tumorigenesis+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakatani%26aufirst%3DT.%26aulast%3DKaneda%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DCarter%26aufirst%3DM.%2BG.%26aulast%3Dde%2BBoom%26aufirst%3DW.%2BS.%26aulast%3DOkano%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DM.%2BS.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DLongo%26aufirst%3DD.%2BL.%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26atitle%3DLoss%2520of%2520imprinting%2520of%2520Igf2%2520alters%2520intestinal%2520maturation%2520and%2520tumorigenesis%2520in%2520mice%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1976%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span> </span><span class="NLM_article-title">Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program</span> <span class="citation_source-journal">Pediatr. Blood Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fpbc.21450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18260118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1c3jtFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=1190-1197&author=E.+A.+Kolbauthor=R.+Gorlickauthor=P.+J.+Houghtonauthor=C.+L.+Mortonauthor=R.+Lockauthor=H.+Carolauthor=C.+P.+Reynoldsauthor=J.+M.+Marisauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+a+monoclonal+antibody+%28SCH+717454%29+against+the+IGF-1+receptor+by+the+pediatric+preclinical+testing+program"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program</span></div><div class="casAuthors">Kolb E Anders; Gorlick Richard; Houghton Peter J; Morton Christopher L; Lock Richard; Carol Hernan; Reynolds C Patrick; Maris John M; Keir Stephen T; Billups Catherine A; Smith Malcolm A</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1190-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies.  The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP).  PROCEDURES:  SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection.  RESULTS:  SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel.  In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses).  Using the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels.  SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel.  CONCLUSIONS:  SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels.  Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlbcF-p4rZLBLDWw4HIq2sfW6udTcc2eaWv1n9cUHDKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3jtFaqtw%253D%253D&md5=32f7605ecdaba71e9fb978b05d0f10f1</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fpbc.21450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.21450%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DMorton%26aufirst%3DC.%2BL.%26aulast%3DLock%26aufirst%3DR.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520a%2520monoclonal%2520antibody%2520%2528SCH%2520717454%2529%2520against%2520the%2520IGF-1%2520receptor%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2008%26volume%3D50%26spage%3D1190%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Gil-Ad, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtaif, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture</span> <span class="citation_source-journal">Growth Horm. IGF Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fghir.1999.0130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10629167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFSrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=458-464&author=I.+Gil-Adauthor=B.+Shtaifauthor=D.+Luriaauthor=L.+Karpauthor=Y.+Fridmanauthor=A.+Weizman&title=Insulin-like-growth-factor-I+%28IGF-I%29+antagonizes+apoptosis+induced+by+serum+deficiency+and+doxorubicin+in+neuronal+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture</span></div><div class="casAuthors">Gil-Ad, I.; Shtaif, B.; Luria, D.; Karp, L.; Fridman, Y.; Weizman, A.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Hormone & IGF Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458-464</span>CODEN:
                <span class="NLM_cas:coden">GHIRF9</span>;
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">The authors evaluated the effect of insulin-like growth factor (IGF)-I on neuronal cell viability and apoptosis induced by exposure to serum-free (SF) medium and to doxorubicin.  In primary neuronal culture, IGF-I (0.5-2.0 μg/mL) slightly increased basal cell viability; SF medium tended to decrease viability (20-27%), and addn. of IGF-I significantly antagonized this decrease (P < 0.05).  In neuroblastoma (NB) SK-N-SH cell culture, IGF-I significantly increased viability (0.05-1.25 μg/mL) (P < 0.005); SF medium decreased it by 75%, and this decrease was prevented by IGF-I (0.5-1.0 μg/mL) (P < 0.005).  Flow cytometry studies showed an increased apoptosis on exposure to SF medium (88.8 vs 10.2%), which was suppressed to 38.3% by addn. of IGF-I.  Growth hormone (1-10 μU/mL) did not modify basal cell viability in either culture, and SF-induced cell death in NB cells.  Doxorubicin (1-100 μM) caused neurotoxicity in primary and NB cultures (66-39% and 39-10% of controls, resp.), and increased apoptosis in NB cells (73.8 vs 20.1%).  IGF-I antagonized these neurotoxic/apoptotic effects (P < 0.05).  This study suggests that IGF-I possesses a potent neuroprotective activity which may be involved in the resistance to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCVaXdSB62_bVg90H21EOLACvtfcHk0lgrL1n9p5290g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFSrtrk%253D&md5=57d8ac98d56a7027c134532313c13978</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1054%2Fghir.1999.0130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fghir.1999.0130%26sid%3Dliteratum%253Aachs%26aulast%3DGil-Ad%26aufirst%3DI.%26aulast%3DShtaif%26aufirst%3DB.%26aulast%3DLuria%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DL.%26aulast%3DFridman%26aufirst%3DY.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DInsulin-like-growth-factor-I%2520%2528IGF-I%2529%2520antagonizes%2520apoptosis%2520induced%2520by%2520serum%2520deficiency%2520and%2520doxorubicin%2520in%2520neuronal%2520cell%2520culture%26jtitle%3DGrowth%2520Horm.%2520IGF%2520Res.%26date%3D1999%26volume%3D9%26spage%3D458%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Gooch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Berg, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1023%2FA%3A1006208721167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10517338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=1-10&author=J.+L.+Goochauthor=C.+L.+Van+Den+Bergauthor=D.+Yee&title=Insulin-like+growth+factor+%28IGF%29-I+rescues+breast+cancer+cells+from+chemotherapy-induced+cell+death%E2%80%94proliferative+and+anti-apoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects</span></div><div class="casAuthors">Gooch, Jennifer L.; Van Den Berg, Carla L.; Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">IGF-I protects many cell types from apoptosis.  As a result, it is possible that IGF-I-responsive cancer cells may be resistant to apoptosis-inducing chemotherapies.  Therefore, the authors examd. the effects of IGF-I on paclitaxel- and doxorubicin-induced apoptosis in the IGF-I-responsive breast cancer cell line MCF-7.  Both drugs caused DNA laddering in a dose-dependent fashion, and IGF-I reduced the formation of ladders.  The authors next examd. the effects of IGF-I and estradiol on cell survival following drug treatment in monolayer culture.  IGF-I, but not estradiol, increased survival of MCF-7 cells in the presence of either drug.  Cell cycle progression and counting of trypan-blue stained cells showed that IGF-I was inducing proliferation in paclitaxel-treated but not doxorubicin-treated cells.  However, IGF-I decreased the fraction of apoptotic cells in doxorubicin- but not paclitaxel-treated cells.  Recent work has shown that mitogen-activated protein kinase (MAPK) and phosphotidylinositol-3 (PI-3) kinase are activated by IGF-I in these cells.  PI-3 kinase activation has been linked to anti-apoptotic functions while MAPK activation is assocd. with proliferation.  The authors found that IGF-I rescue of doxorubicin-induced apoptosis required PI-3 kinase but not MAPK function, suggesting that IGF-I inhibited apoptosis.  In contrast, IGF-I rescue of paclitaxel-induced apoptosis required both PI-3 kinase and MAPK, suggesting that IGF-I-mediated protection was due to enhancement of proliferation.  Therefore, IGF-I attenuated the response of breast cancer cells to doxorubicin and paclitaxel by at least two mechanisms: induction of proliferation and inhibition of apoptosis.  Thus, inhibition of IGF-I action could be a useful adjuvant to cytotoxic chemotherapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppJ62Chyw-grVg90H21EOLACvtfcHk0lgrL1n9p5290g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVyns7s%253D&md5=dd8d743e2d55006d4c702971eb66ec17</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006208721167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006208721167%26sid%3Dliteratum%253Aachs%26aulast%3DGooch%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BDen%2BBerg%26aufirst%3DC.%2BL.%26aulast%3DYee%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520%2528IGF%2529-I%2520rescues%2520breast%2520cancer%2520cells%2520from%2520chemotherapy-induced%2520cell%2520death%25E2%2580%2594proliferative%2520and%2520anti-apoptotic%2520effects%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1999%26volume%3D56%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span> </span><span class="NLM_article-title">Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=6071-6077&author=Y.+Jiangauthor=W.+N.+Romauthor=T.+A.+Yieauthor=C.+X.+Chiauthor=K.+M.+Tchou-Wong&title=Induction+of+tumor+suppression+and+glandular+differentiation+of+A549+lung+carcinoma+cells+by+dominant-negative+IGF-I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DChi%26aufirst%3DC.%2BX.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26atitle%3DInduction%2520of%2520tumor%2520suppression%2520and%2520glandular%2520differentiation%2520of%2520A549%2520lung%2520carcinoma%2520cells%2520by%2520dominant-negative%2520IGF-I%2520receptor%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D6071%26epage%3D6077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spandau, D. F.</span><span> </span><span class="NLM_article-title">Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F%28SICI%291097-0215%2819990129%2980%3A3%3C431%3A%3AAID-IJC16%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9935186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXovF2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1999&pages=431-438&author=C.+Kuhnauthor=S.+A.+Hurwitzauthor=M.+G.+Kumarauthor=J.+Cottonauthor=D.+F.+Spandau&title=Activation+of+the+insulin-like+growth+factor-1+receptor+promotes+the+survival+of+human+keratinocytes+following+ultraviolet+B+irradiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation</span></div><div class="casAuthors">Kuhn, Christine; Hurwitz, Steven A.; Kumar, Manish G.; Cotton, Jenny; Spandau, Dan F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The UVB component of sunlight causes non-melanoma skin cancers due to the damage it inflicts on genomic DNA.  The response of epidermal keratinocytes to sunlight depends on the dose of UVB received and the severity of the damage to the DNA.  Mild DNA damage typically induces DNA-repair pathways and cell survival, while severe DNA damage provokes apoptosis.  Primary human keratinocytes grown in serum-free media respond in a similar manner to UVB irradn.  However, we obsd. that keratinocytes are exquisitely more susceptible to UVB-induced apoptosis if the growth medium is depleted of exogenous growth factors.  Therefore, an exogenous growth factor could provide protection from UVB-induced apoptosis.  We found that the only growth factor that provided protection from UVB-induced apoptosis was insulin and that the protective effect elicited by insulin was not due to binding the insulin receptor but, rather, to activation of the insulin-like growth factor-1 (IGF-1) receptor.  Addnl., activation of the IGF-1 receptor in combination with UVB irradn. induced keratinocytes to become post-mitotic.  This survival function of the IGF-1 receptor in response to UVB irradn. was influenced by activation of phosphatidylinositol-3 kinase and MAP kinase.  Prior to UVB irradn., insulin or IGF-1 had little to no effect on cell growth or viability.  Therefore, activation of the IGF-1 receptor in conjunction with UVB irradn. promotes keratinocyte survival at the expense of cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3FXjbqmldcrVg90H21EOLACvtfcHk0lhHq6duL5bljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXovF2isw%253D%253D&md5=1026f3a33bcfc2fb0a6fff730a5ef47a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819990129%2980%3A3%3C431%3A%3AAID-IJC16%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819990129%252980%253A3%253C431%253A%253AAID-IJC16%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DHurwitz%26aufirst%3DS.%2BA.%26aulast%3DKumar%26aufirst%3DM.%2BG.%26aulast%3DCotton%26aufirst%3DJ.%26aulast%3DSpandau%26aufirst%3DD.%2BF.%26atitle%3DActivation%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520promotes%2520the%2520survival%2520of%2520human%2520keratinocytes%2520following%2520ultraviolet%2520B%2520irradiation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D80%26spage%3D431%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, R.</span><span> </span><span class="NLM_article-title">Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">570</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=570-576&author=Y.+Liuauthor=S.+Leharauthor=C.+Corviauthor=G.+Payneauthor=R.+O%27Connor&title=Expression+of+the+insulin-like+growth+factor+I+receptor+C+terminus+as+a+myristylated+protein+leads+to+induction+of+apoptosis+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLehar%26aufirst%3DS.%26aulast%3DCorvi%26aufirst%3DC.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DO%2527Connor%26aufirst%3DR.%26atitle%3DExpression%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520C%2520terminus%2520as%2520a%2520myristylated%2520protein%2520leads%2520to%2520induction%2520of%2520apoptosis%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D570%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Peters, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsark, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, L. M.</span><span> </span><span class="NLM_article-title">Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">722</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2307%2F3579363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8643832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK28XjsVWgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1996&pages=722-729&author=J.+M.+Petersauthor=E.+C.+Tsarkauthor=L.+M.+Wiley&title=Radiosensitive+target+in+the+mouse+embryo+chimera+assay%3A+implications+that+the+target+involves+autocrine+growth+factor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function</span></div><div class="casAuthors">Peters, Jeffrey M.; Tsark, Eleanor C.; Wiley, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-729</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    
            (<span class="NLM_cas:orgname">Kluge Carden Jennings Publishing</span>)
        </div><div class="casAbstract">Mouse preimplantation embryos express at least two functional cell surface growth factor receptors that are radiosensitive in other cell types, the epidermal growth factor I receptor (IGF-I receptor).  These embryos also express ligands that bind to and activate these receptors, including transforming growth factor alpha (TGF-α) and insulin-like growth factor II (IGF-II), which bind to the EGF receptor and IGF-I receptor, resp.  Embryo-expressed IGF-II and TGF-α increase embryo cell no. - a measure of proliferation rate - and stimulate blastocoele formation - a measure of cell differentiation - allowing the embryo to self-modulate cell proliferation and morphogenesis into a blastocyst (Paria and Dey, Proc. Natl. Acad. Sci. USA 87, 4756-4760, 1990; Dardik and Schultz, Development 113, 919-930, 1991; Rappolee et al., Genes Dev. 6, 939-952, 1992).  In this work, we tested the hypothesis that IGF-I receptor and/or EGF receptor function may be impaired to produce the radiation-induced competitive cell proliferation disadvantage that is expressed by irradiated embryos that are aggregated with nonirradiated embryos in chimeras.  Cleavage-stage embryos were irradiated with 137Cs γ rays (0.5 or 1.0 Gy) and paired with nonirradiated same-stage embryos to form groups of chimeras that were cultured in control medium or medium contg. IGF-II, insulin, EGF or TGF-α.  The cell proliferation disadvantage expressed by the irradiated embryos within chimeras was completely eliminated by IGF-II or insulin.  In contrast to the rescue action of IGF-II or insulin in chimeras, neither EGF nor TGF-α could prevent the cell proliferation disadvantage exhibited by irradiated embryos paired with nonirradiated embryos in chimeras.  For irradiated conventionally cultured zona-enclosed embryos, IGF-II and TGF-α did not increase mean embryo cell no. significantly, although both IGF-II and TGF-α did increase blastocoele formation significantly.  Collectively, these results support the following conclusions: (1) ligands for the IGF-I receptor can rescue irradiated embryos from competitive cell proliferation disadvantage in Chimeras, while ligands for the EGF receptor cannot; (2) IGF-I receptor function and EGF receptor function are affected differently by ionizing radiation with respect to competitive cell proliferation and are affected with respect to competitive cell proliferation and are affected similarly by ionizing radiation with respect to blastocoele formation; (3) EGF receptor-dependent stimulation of competitive cell proliferation and cell differentiation are affected differently by ionizing radiation in preimplantation embryos.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ30aDi2mMTrVg90H21EOLACvtfcHk0lhHq6duL5bljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVWgt7c%253D&md5=0df98ee022ed28c0bb6e353173619e39</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2307%2F3579363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3579363%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26aulast%3DTsark%26aufirst%3DE.%2BC.%26aulast%3DWiley%26aufirst%3DL.%2BM.%26atitle%3DRadiosensitive%2520target%2520in%2520the%2520mouse%2520embryo%2520chimera%2520assay%253A%2520implications%2520that%2520the%2520target%2520involves%2520autocrine%2520growth%2520factor%2520function%26jtitle%3DRadiat.%2520Res.%26date%3D1996%26volume%3D145%26spage%3D722%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span> </span><span class="NLM_article-title">Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">6702</span><span class="NLM_x">–</span> <span class="NLM_lpage">6709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=6702-6709&author=D.+Yuauthor=H.+Watanabeauthor=H.+Shibuyaauthor=M.+Miura&title=Redundancy+of+radioresistant+signaling+pathways+originating+from+insulin-like+growth+factor+I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DMiura%26aufirst%3DM.%26atitle%3DRedundancy%2520of%2520radioresistant%2520signaling%2520pathways%2520originating%2520from%2520insulin-like%2520growth%2520factor%2520I%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D6702%26epage%3D6709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Heron-Milhavet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">15600</span><span class="NLM_x">–</span> <span class="NLM_lpage">15606</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=15600-15606&author=L.+Heron-Milhavetauthor=D.+LeRoith&title=Insulin-like+growth+factor+I+induces+MDM2-dependent+degradation+of+p53+via+the+p38+MAPK+pathway+in+response+to+DNA+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeron-Milhavet%26aufirst%3DL.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520induces%2520MDM2-dependent%2520degradation%2520of%2520p53%2520via%2520the%2520p38%2520MAPK%2520pathway%2520in%2520response%2520to%2520DNA%2520damage%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D15600%26epage%3D15606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Guo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan-Sanders, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyn-Cook, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamae, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaletskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weydert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmate, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitz, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberley, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span> </span><span class="NLM_article-title">Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2362</span><span class="NLM_x">–</span> <span class="NLM_lpage">2378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.23.7.2362-2378.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12640121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFensbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=2362-2378&author=G.+Guoauthor=Y.+Yan-Sandersauthor=B.+D.+Lyn-Cookauthor=T.+Wangauthor=D.+Tamaeauthor=J.+Ogiauthor=A.+Khaletskiyauthor=Z.+Liauthor=C.+Weydertauthor=J.+A.+Longmateauthor=T.+T.+Huangauthor=D.+R.+Spitzauthor=L.+W.+Oberleyauthor=J.+J.+Li&title=Manganese+superoxide+dismutase-mediated+gene+expression+in+radiation-induced+adaptive+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses</span></div><div class="casAuthors">Guo, Guozheng; Yan-Sanders, Yan; Lyn-Cook, Beverly D.; Wang, Tieli; Tamae, Daniel; Ogi, Julie; Khaletskiy, Alexander; Li, Zhongkui; Weydert, Christine; Longmate, Jeffrey A.; Huang, Ting-Ting; Spitz, Douglas R.; Oberley, Larry W.; Li, Jian Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2362-2378</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Antioxidant enzymes are crit. in oxidative stress responses.  Radioresistant variants isolated from MCF-7 human carcinoma cells following fractionated ionizing radiation (MCF+FIR cells) or overexpression of manganese superoxide dismutase (MCF+SOD cells) demonstrated dose-modifying factors at 10% isosurvival of 1.8 and 2.3, resp.  MCF+FIR and MCF-7 cells (exposed to single-dose radiation) demonstrated 5- to 10-fold increases in MnSOD activity, mRNA, and immunoreactive protein.  Radioresistance in MCF+FIR and MCF+SOD cells was reduced following expression of antisense MnSOD.  DNA microarray anal. and immunoblotting identified p21, Myc, 14-3-3 zeta, cyclin A, cyclin B1, and GADD153 as genes constitutively overexpressed (2- to 10-fold) in both MCF+FIR and MCF+SOD cells.  Radiation-induced expression of these six genes was suppressed in fibroblasts from Sod2 knockout mice (-/-) as well as in MCF+FIR and MCF+SOD cells expressing antisense MnSOD.  Inhibiting NF-κB transcriptional activity in MCF+FIR cells, by using mutant IκBα, inhibited radioresistance as well as reducing steady-state levels of MnSOD, 14-3-3 zeta, GADD153, cyclin A, and cyclin B1 mRNA.  In contrast, mutant IκBα was unable to inhibit radioresistance or reduce 14-3-3 zeta, GADD153, cyclin A, and cyclin B1 mRNAs in MCF+SOD cells, where MnSOD overexpression was independent of NF-κB.  These results support the hypothesis that NF-κB is capable of regulating the expression of MnSOD, which in turn is capable of increasing the expression of genes that participate in radiation-induced adaptive responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpxTkCZEHfbVg90H21EOLACvtfcHk0lj5Tmscugl5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFensbg%253D&md5=bc288e5cd223e7e431a3db25629a893a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1128%2FMCB.23.7.2362-2378.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.23.7.2362-2378.2003%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DYan-Sanders%26aufirst%3DY.%26aulast%3DLyn-Cook%26aufirst%3DB.%2BD.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DTamae%26aufirst%3DD.%26aulast%3DOgi%26aufirst%3DJ.%26aulast%3DKhaletskiy%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWeydert%26aufirst%3DC.%26aulast%3DLongmate%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DSpitz%26aufirst%3DD.%2BR.%26aulast%3DOberley%26aufirst%3DL.%2BW.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26atitle%3DManganese%2520superoxide%2520dismutase-mediated%2520gene%2520expression%2520in%2520radiation-induced%2520adaptive%2520responses%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D2362%26epage%3D2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Guo, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, C. M.,  Jr.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F%28SICI%291097-4652%28199805%29175%3A2%3C141%3A%3AAID-JCP3%3E3.0.CO%3B2-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9525472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXit1Srt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1998&pages=141-148&author=Y.+S.+Guoauthor=G.+F.+Jinauthor=C.+W.+Houstonauthor=J.+C.+Thompsonauthor=C.+M.+Townsend&title=Insulin-like+growth+factor-I+promotes+multidrug+resistance+in+MCLM+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells</span></div><div class="casAuthors">Guo, Yan-Shi; Jin, Gui-Fang; Houston, Clifford W.; Thompson, James C.; Townsend, Courtney M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-148</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is known as a potent mitogen for a variety of cell types, including colon cancer cell lines.  The objective of this study was to det. the effect of IGF-I on cell death induced by cytotoxic agents actinomycin D (Act-D), lovastatin (LOV), and doxorubicin (DOX) in the MCLM mouse colon cancer cell line, and the mechanisms involved.  Subconfluent monolayer MCLM cells were treated with IGF-I (25 ng/mL) for 12 h in serum-free media.  Various concns. of cytotoxic agents then were added to the cells that were incubated continually at 370C for 24 h.  Cell survival was detd. with the MTT (3-[4-5-dimenthylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, which assesses mitochondrial function in living cells.  The mRNA expression for multidrug resistance gene-I (mdr-I), c-H-ras, and manganese superoxide dismutase (MnSOD) in cells treated with IGF-I was examd. by Northern blot or RNase protection assays.  The levels of p-glycoprotein, a drug efflux pump encoded by the mdr-I gene, were assessed by Western immunoblotting.  Results demonstrated that (1) IGF-I significantly inhibited the cell death and apoptosis of MCLM cells treated with Act-D, LOV, or DOX; (2) IGF-I increased mRNA expression for mdr-I, c-H-ras, and MnSOD; (3) the p-glycoproteins in cells treated with IGF-I or stably transfected with c-H-ras were elevated when compared with control.  These results suggest that IGF-I protects MCLM cells against death induced by cytotoxic agents; this acquired drug resistance may be mediated by multiple mechanisms, including promoting expression of mdr-I, c-H-ras, and MnSOD; whereas, the p-glycoprotein level stimulated by IGF-I may result partly from the increase of c-H-ras in the cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpefmohYIBQQbVg90H21EOLACvtfcHk0lj5Tmscugl5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1Srt7s%253D&md5=06f728d108d2c61b04f9687fade0482b</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4652%28199805%29175%3A2%3C141%3A%3AAID-JCP3%3E3.0.CO%3B2-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4652%2528199805%2529175%253A2%253C141%253A%253AAID-JCP3%253E3.0.CO%253B2-O%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BS.%26aulast%3DJin%26aufirst%3DG.%2BF.%26aulast%3DHouston%26aufirst%3DC.%2BW.%26aulast%3DThompson%26aufirst%3DJ.%2BC.%26aulast%3DTownsend%26aufirst%3DC.%2BM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520promotes%2520multidrug%2520resistance%2520in%2520MCLM%2520colon%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D1998%26volume%3D175%26spage%3D141%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Dunn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kari, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2687</span><span class="NLM_x">–</span> <span class="NLM_lpage">2693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=2687-2693&author=S.+E.+Dunnauthor=R.+A.+Hardmanauthor=F.+W.+Kariauthor=J.+C.+Barrett&title=Insulin-like+growth+factor+1+%28IGF-1%29+alters+drug+sensitivity+of+HBL100+human+breast+cancer+cells+by+inhibition+of+apoptosis+induced+by+diverse+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DS.%2BE.%26aulast%3DHardman%26aufirst%3DR.%2BA.%26aulast%3DKari%26aufirst%3DF.%2BW.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26atitle%3DInsulin-like%2520growth%2520factor%25201%2520%2528IGF-1%2529%2520alters%2520drug%2520sensitivity%2520of%2520HBL100%2520human%2520breast%2520cancer%2520cells%2520by%2520inhibition%2520of%2520apoptosis%2520induced%2520by%2520diverse%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D2687%26epage%3D2693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Dunn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrlich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span> </span><span class="NLM_article-title">A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=3353-3361&author=S.+E.+Dunnauthor=M.+Ehrlichauthor=N.+J.+Sharpauthor=K.+Reissauthor=G.+Solomonauthor=R.+Hawkinsauthor=R.+Basergaauthor=J.+C.+Barrett&title=A+dominant+negative+mutant+of+the+insulin-like+growth+factor-I+receptor+inhibits+the+adhesion%2C+invasion%2C+and+metastasis+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DS.%2BE.%26aulast%3DEhrlich%26aufirst%3DM.%26aulast%3DSharp%26aufirst%3DN.%2BJ.%26aulast%3DReiss%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DG.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26atitle%3DA%2520dominant%2520negative%2520mutant%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520inhibits%2520the%2520adhesion%252C%2520invasion%252C%2520and%2520metastasis%2520of%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D3353%26epage%3D3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Macaulay, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salisbury, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohula, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Playford, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smorodinsky, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiloh, Y.</span><span> </span><span class="NLM_article-title">Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4029</span><span class="NLM_x">–</span> <span class="NLM_lpage">4040</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=4029-4040&author=V.+M.+Macaulayauthor=A.+J.+Salisburyauthor=E.+A.+Bohulaauthor=M.+P.+Playfordauthor=N.+I.+Smorodinskyauthor=Y.+Shiloh&title=Downregulation+of+the+type+1+insulin-like+growth+factor+receptor+in+mouse+melanoma+cells+is+associated+with+enhanced+radiosensitivity+and+impaired+activation+of+Atm+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26aulast%3DSalisbury%26aufirst%3DA.%2BJ.%26aulast%3DBohula%26aufirst%3DE.%2BA.%26aulast%3DPlayford%26aufirst%3DM.%2BP.%26aulast%3DSmorodinsky%26aufirst%3DN.%2BI.%26aulast%3DShiloh%26aufirst%3DY.%26atitle%3DDownregulation%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520in%2520mouse%2520melanoma%2520cells%2520is%2520associated%2520with%2520enhanced%2520radiosensitivity%2520and%2520impaired%2520activation%2520of%2520Atm%2520kinase%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D4029%26epage%3D4040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Peretz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1676-1681&author=S.+Peretzauthor=R.+Jensenauthor=R.+Basergaauthor=P.+M.+Glazer&title=ATM-dependent+expression+of+the+insulin-like+growth+factor-I+receptor+in+a+pathway+regulating+radiation+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeretz%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DR.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DATM-dependent%2520expression%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520in%2520a%2520pathway%2520regulating%2520radiation%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D1676%26epage%3D1681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Shahrabani-Gargir, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, H.</span><span> </span><span class="NLM_article-title">Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">5679</span><span class="NLM_x">–</span> <span class="NLM_lpage">5687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2004&pages=5679-5687&author=L.+Shahrabani-Gargirauthor=T.+K.+Panditaauthor=H.+Werner&title=Ataxia-telangiectasia+mutated+gene+controls+insulin-like+growth+factor+I+receptor+gene+expression+in+a+deoxyribonucleic+acid+damage+response+pathway+via+mechanisms+involving+zinc-finger+transcription+factors+Sp1+and+WT1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShahrabani-Gargir%26aufirst%3DL.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26aulast%3DWerner%26aufirst%3DH.%26atitle%3DAtaxia-telangiectasia%2520mutated%2520gene%2520controls%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520gene%2520expression%2520in%2520a%2520deoxyribonucleic%2520acid%2520damage%2520response%2520pathway%2520via%2520mechanisms%2520involving%2520zinc-finger%2520transcription%2520factors%2520Sp1%2520and%2520WT1%26jtitle%3DEndocrinology%26date%3D2004%26volume%3D145%26spage%3D5679%26epage%3D5687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Cosaceanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carapancea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekedahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewensohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dricu, A.</span><span> </span><span class="NLM_article-title">Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">222</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.canlet.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15863266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2005&pages=173-181&author=D.+Cosaceanuauthor=M.+Carapanceaauthor=J.+Castroauthor=J.+Ekedahlauthor=L.+Kanterauthor=R.+Lewensohnauthor=A.+Dricu&title=Modulation+of+response+to+radiation+of+human+lung+cancer+cells+following+insulin-like+growth+factor+1+receptor+inactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation</span></div><div class="casAuthors">Cosaceanu, Daria; Carapancea, Mia; Castro, Juan; Ekedahl, Jessica; Kanter, Lena; Lewensohn, Rolf; Dricu, Anica</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeted disruption of the insulin-like growth factor 1 receptor (IGF-1R) restricts proliferation of tumor cells and enhances their in vitro radiosensitivity.  However, there is little information regarding the effect of IGF-1R expression and function on the lung cancer response to radiotherapy.  In this study, we evaluated the cell surface expression of IGF-1R and the antitumoral effect of IGF-1R blockade in combination with irradn. in 6 non-small cell lung cancer (NSCLC) cell lines.  All cell lines showed specific IGF-1 binding with an affinity ranging from 0.95×10-9 to 2.3×10-9 M, which was evaluated by competitive binding assay.  The amt. of binding sites ranged from 118 to 377 fmol/mg protein.  In one cell line (U1810), the combined treatment led to synergistic cell death and was assocd. with an accumulation of cells in the G2 phase.  IGF-1R activation was able to obstruct serum starvation/radiation-induced cell death in U1810 cell line.  Additive interactions were found for four cell lines (A549, H157, H23 and H125) whereas only subadditive effects were obsd. in U1752 cell line.  Our results indicate that the IGF-1R is present on NSCLC cells and thereby its involvement in the modulation of radiosensitivity in lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf3SUeT-rLxbVg90H21EOLACvtfcHk0linAe8dsWyC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs7g%253D&md5=eba00fbbc5900722c550c238d99de8e1</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCosaceanu%26aufirst%3DD.%26aulast%3DCarapancea%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEkedahl%26aufirst%3DJ.%26aulast%3DKanter%26aufirst%3DL.%26aulast%3DLewensohn%26aufirst%3DR.%26aulast%3DDricu%26aufirst%3DA.%26atitle%3DModulation%2520of%2520response%2520to%2520radiation%2520of%2520human%2520lung%2520cancer%2520cells%2520following%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520inactivation%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D222%26spage%3D173%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">Min, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imsumran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadaf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=591-600&author=Y.+Minauthor=Y.+Adachiauthor=H.+Yamamotoauthor=A.+Imsumranauthor=Y.+Arimuraauthor=T.+Endoauthor=Y.+Hinodaauthor=C.+T.+Leeauthor=S.+Nadafauthor=D.+P.+Carboneauthor=K.+Imai&title=Insulin-like+growth+factor+I+receptor+blockade+enhances+chemotherapy+and+radiation+responses+and+inhibits+tumour+growth+in+human+gastric+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DImsumran%26aufirst%3DA.%26aulast%3DArimura%26aufirst%3DY.%26aulast%3DEndo%26aufirst%3DT.%26aulast%3DHinoda%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DC.%2BT.%26aulast%3DNadaf%26aufirst%3DS.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DImai%26aufirst%3DK.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520blockade%2520enhances%2520chemotherapy%2520and%2520radiation%2520responses%2520and%2520inhibits%2520tumour%2520growth%2520in%2520human%2520gastric%2520cancer%2520xenografts%26jtitle%3DGut%26date%3D2005%26volume%3D54%26spage%3D591%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Perer, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shurin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakris, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romeguera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, D. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1006%2Fjsre.2000.5923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11038295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2000&pages=1-5&author=E.+S.+Pererauthor=A.+K.+Madanauthor=A.+Shurinauthor=E.+Zakrisauthor=K.+Romegueraauthor=Y.+Pangauthor=D.+J.+Beech&title=Insulin-like+growth+factor+I+receptor+antagonism+augments+response+to+chemoradiation+therapy+in+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells</span></div><div class="casAuthors">Perer, Elise S.; Madan, Atul K.; Shurin, Autumn; Zakris, Ellen; Romeguera, Keith; Pang, Ying; Beech, Derrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The frequent overexpression of insulin-like growth factor I receptor (IGF-I-R) in rectal adenocarcinoma suggests that inhibition of the signal transduction pathway may be a novel approach to enhance tumor response.  This work investigated the role of IGF-I-R antagonism, by monoclonal antibody α-IR3, in augmenting cytotoxicity to adjuvant chemoradiation therapy of adenocarcinoma of the rectum.  SW 480 colon cancer cells were cultured to semiconfluent conditions with dose titrns. performed for 5-fluorouracil (5-FU) to det. that the IC50 was 0.5 μg/mL.  The IC50 for 5-FU was reassessed in the presence of IGF-I. Exptl. groups included colon cancer cells treated with 5-FU; 6-MeV external beam radiation (100-500 cGy); and α-IR-3.  The addn. of 100 ng IGF-I/mL 1 h prior to 5-FU or radiation blunted the expected cytotoxicity, resulting in a 10-fold increase in the IC50 (from 0.5 to 5 μg/mL).  Receptor antagonism by the monoclonal antibody α-IR-3 (100-400 ng/mL) produced a concn.-dependent increase in cytotoxicity compared with that from 5-FU alone.  The use of radiation produced synergistic amplification of this response.  IGF-I-R activation blocks the expected cytotoxic effects of 5-FU and external beam radiation.  Receptor antagonism increased the cytotoxic response of chemoradiation therapy.  These data suggest the utility of inhibiting IGF-I-R signal transduction in the treatment of rectal adenocarcinoma.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqqRhgENJEFLVg90H21EOLACvtfcHk0linAe8dsWyC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKrt74%253D&md5=56096aaf5aa2a6ca23e763bb6b826db9</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5923%26sid%3Dliteratum%253Aachs%26aulast%3DPerer%26aufirst%3DE.%2BS.%26aulast%3DMadan%26aufirst%3DA.%2BK.%26aulast%3DShurin%26aufirst%3DA.%26aulast%3DZakris%26aufirst%3DE.%26aulast%3DRomeguera%26aufirst%3DK.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DBeech%26aufirst%3DD.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520antagonism%2520augments%2520response%2520to%2520chemoradiation%2520therapy%2520in%2520colon%2520cancer%2520cells%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D94%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Turner, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffty, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havre, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumbs, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgaud, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3079</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3079-3083&author=B.+C.+Turnerauthor=B.+G.+Hafftyauthor=L.+Narayananauthor=J.+Yuanauthor=P.+A.+Havreauthor=A.+A.+Gumbsauthor=L.+Kaplanauthor=J.+L.+Burgaudauthor=D.+Carterauthor=R.+Basergaauthor=P.+M.+Glazer&title=Insulin-like+growth+factor-I+receptor+overexpression+mediates+cellular+radioresistance+and+local+breast+cancer+recurrence+after+lumpectomy+and+radiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DB.%2BC.%26aulast%3DHaffty%26aufirst%3DB.%2BG.%26aulast%3DNarayanan%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DHavre%26aufirst%3DP.%2BA.%26aulast%3DGumbs%26aufirst%3DA.%2BA.%26aulast%3DKaplan%26aufirst%3DL.%26aulast%3DBurgaud%26aufirst%3DJ.%2BL.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520overexpression%2520mediates%2520cellular%2520radioresistance%2520and%2520local%2520breast%2520cancer%2520recurrence%2520after%2520lumpectomy%2520and%2520radiation%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3079%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Wen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marangoni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frascona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiorella, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdulkarim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavaudra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span> </span><span class="NLM_article-title">Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2017</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fbjoc.2001.2171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11747348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=2017-2021&author=B.+Wenauthor=E.+Deutschauthor=E.+Marangoniauthor=V.+Frasconaauthor=L.+Maggiorellaauthor=B.+Abdulkarimauthor=N.+Chavaudraauthor=J.+Bourhis&title=Tyrphostin+AG+1024+modulates+radiosensitivity+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells</span></div><div class="casAuthors">Wen, B.; Deutsch, E.; Marangoni, E.; Frascona, V.; Maggiorella, L.; Abdulkarim, B.; Chavaudra, N.; Bourhis, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2017-2021</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-1 (IGF-1) plays an important growth-promoting effect by activating the PI3K/Akt signalling pathway, inhibiting apoptotic pathways and mediating mitogenic actions.  Tyrphostin AG 1024, one selective inhibitor of IGF-1R, was used to evaluate effects on proliferation, radiosensitivity, and radiation-induced cell apoptosis in a human breast cancer cell line MCF-7.  Exposure to Tyrphostin AG 1024 inhibited proliferation and induced apoptosis in a time-dependent manner, and the degree of growth inhibition for IC20 plus irradn. (4 Gy) was up to 50% compared to the control.  Examn. of Tyrphostin AG 1024 effects on radiation response demonstrated a marked enhancement in radiosensitivity and amplification of radiation-induced apoptosis.  Western blot anal. indicated that Tyrphostin AG 1024-induced apoptosis was assocd. with a downregulation of expression of phospho-Akt1, increased expression of Bax, p53 and p21, and a decreased expression of bcl-2 expression, esp. when combined with irradn.  To our knowledge, this is the first report showing that an IGF-1 inhibitor was able to markedly increase the response of tumor cells to ionizing radiation.  These results suggest that Tyrphostin AG 1024 could be used as a potential therapeutic agent in combination with irradn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpARXRmECvMb7Vg90H21EOLACvtfcHk0lhfrSopc9Tg-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWmsr0%253D&md5=8d27001da364c6bcdbae0fb202179bbc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2171%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDeutsch%26aufirst%3DE.%26aulast%3DMarangoni%26aufirst%3DE.%26aulast%3DFrascona%26aufirst%3DV.%26aulast%3DMaggiorella%26aufirst%3DL.%26aulast%3DAbdulkarim%26aufirst%3DB.%26aulast%3DChavaudra%26aufirst%3DN.%26aulast%3DBourhis%26aufirst%3DJ.%26atitle%3DTyrphostin%2520AG%25201024%2520modulates%2520radiosensitivity%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D2017%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyson, N. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=200-207&author=A.+Chakravartiauthor=J.+S.+Loefflerauthor=N.+J.+Dyson&title=Insulin-like+growth+factor+receptor+I+mediates+resistance+to+anti-epidermal+growth+factor+receptor+therapy+in+primary+human+glioblastoma+cells+through+continued+activation+of+phosphoinositide+3-kinase+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%2520I%2520mediates%2520resistance%2520to%2520anti-epidermal%2520growth%2520factor%2520receptor%2520therapy%2520in%2520primary%2520human%2520glioblastoma%2520cells%2520through%2520continued%2520activation%2520of%2520phosphoinositide%25203-kinase%2520signaling%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D200%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=3788-3793&author=J.+A.+Engelmanauthor=P.+A.+Janneauthor=C.+Mermelauthor=J.+Pearlbergauthor=T.+Mukoharaauthor=C.+Fleetauthor=K.+Cichowskiauthor=B.+E.+Johnsonauthor=L.+C.+Cantley&title=ErbB-3+mediates+phosphoinositide+3-kinase+activity+in+gefitinib-sensitive+non-small+cell+lung+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DPearlberg%26aufirst%3DJ.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DFleet%26aufirst%3DC.%26aulast%3DCichowski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DErbB-3%2520mediates%2520phosphoinositide%25203-kinase%2520activity%2520in%2520gefitinib-sensitive%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D3788%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Jones, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiscox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowlden, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=793-814&author=H.+E.+Jonesauthor=L.+Goddardauthor=J.+M.+Geeauthor=S.+Hiscoxauthor=M.+Rubiniauthor=D.+Barrowauthor=J.+M.+Knowldenauthor=S.+Williamsauthor=A.+E.+Wakelingauthor=R.+I.+Nicholson&title=Insulin-like+growth+factor-I+receptor+signalling+and+acquired+resistance+to+gefitinib+%28ZD1839%3B+Iressa%29+in+human+breast+and+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BE.%26aulast%3DGoddard%26aufirst%3DL.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DHiscox%26aufirst%3DS.%26aulast%3DRubini%26aufirst%3DM.%26aulast%3DBarrow%26aufirst%3DD.%26aulast%3DKnowlden%26aufirst%3DJ.%2BM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520signalling%2520and%2520acquired%2520resistance%2520to%2520gefitinib%2520%2528ZD1839%253B%2520Iressa%2529%2520in%2520human%2520breast%2520and%2520prostate%2520cancer%2520cells%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2004%26volume%3D11%26spage%3D793%26epage%3D814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0ljtf35YmMdjOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas-Kogan, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dia, E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chute, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span> </span><span class="NLM_article-title">Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2012</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa051918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16282176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2012-2024&author=I.+K.+Mellinghoffauthor=M.+Y.+Wangauthor=I.+Vivancoauthor=D.+A.+Haas-Koganauthor=S.+Zhuauthor=E.+Q.+Diaauthor=K.+V.+Luauthor=K.+Yoshimotoauthor=J.+H.+Huangauthor=D.+J.+Chuteauthor=B.+L.+Riggsauthor=S.+Horvathauthor=L.+M.+Liauauthor=W.+K.+Caveneeauthor=P.+N.+Raoauthor=R.+Beroukhimauthor=T.+C.+Peckauthor=J.+C.+Leeauthor=W.+R.+Sellersauthor=D.+Stokoeauthor=M.+Pradosauthor=T.+F.+Cloughesyauthor=C.+L.+Sawyersauthor=P.+S.+Mischel&title=Molecular+determinants+of+the+response+of+glioblastomas+to+EGFR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</span></div><div class="casAuthors">Mellinghoff, Ingo K.; Wang, Maria Y.; Vivanco, Igor; Haas-Kogan, Daphne A.; Zhu, Shaojun; Dia, Ederlyn Q.; Lu, Kan V.; Yoshimoto, Koji; Huang, Julie H. Y.; Chute, Dennis J.; Riggs, Bridget L.; Horvath, Steve; Liau, Linda M.; Cavenee, Webster K.; Rao, P. Nagesh; Beroukhim, Rameen; Peck, Timothy C.; Lee, Jeffrey C.; Sellers, William R.; Stokoe, David; Prados, Michael; Cloughesy, Timothy F.; Sawyers, Charles L.; Mischel, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2012-2024</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but only 10 to 20 % of patients have a response to EGFR kinase inhibitors.  The mechanism of responsiveness of glioblastomas to these inhibitors is unknown.  We sequenced kinase domains in the EGFR and human EGFR type 2 (Her21neu) genes and analyzed the expression of EGFR, EGFR deletion mutantvariant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients who had received EGFR kinase inhibitors.  We detd. the mol. correlates of clin. response, validated them in an independent data set, and identified effects of the mol. abnormalities in vitro.  Of 49 patients with recurrent malignant glioma who were treated with EGFR kinase inhibitors, 9 had tumor shrinkage of at least 25 %.  Pretreatment tissue was available for mol. anal. from 26 patients, 7 of whom had a response and 19 of whom had rapid progression during therapy.  No mutations in EGFR or Her2/neu kinase domains were detected in the tumors.  Coexpression of EGFRvIII and PTEN was significantly assocd. with a clin. response (P <0.001; odds ratio, 51; 95 % confidence interval, 4 to 669).  These findings were validated in 33 patients who received similar treatment for glioblastoma at a different institution (P = 0.001; odds ratio, 40; 95 % confidence interval, 3 to 468).  In vitro, coexpression of EGFRvIII and PTEN sensitized glioblastoma cells to erlotinib.  Coexpression of EGFRvIII and PTEN by glioblastoma cells is assocd. with responsiveness to EGFR kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowUwTSK9-yL7Vg90H21EOLACvtfcHk0ljtf35YmMdjOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SrtrrE&md5=e19cb1d6924c5019a7ed5d5f1ccdb6d0</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051918%26sid%3Dliteratum%253Aachs%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DWang%26aufirst%3DM.%2BY.%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DDia%26aufirst%3DE.%2BQ.%26aulast%3DLu%26aufirst%3DK.%2BV.%26aulast%3DYoshimoto%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DChute%26aufirst%3DD.%2BJ.%26aulast%3DRiggs%26aufirst%3DB.%2BL.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPeck%26aufirst%3DT.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DPrados%26aufirst%3DM.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26atitle%3DMolecular%2520determinants%2520of%2520the%2520response%2520of%2520glioblastomas%2520to%2520EGFR%2520kinase%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2012%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljEEFt9VG_-RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4340</span><span class="NLM_x">–</span> <span class="NLM_lpage">4346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14555504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4340-4346&author=Q.+B.+Sheauthor=D.+Solitauthor=A.+Bassoauthor=M.+M.+Moasser&title=Resistance+to+gefitinib+in+PTEN-null+HER-overexpressing+tumor+cells+can+be+overcome+through+restoration+of+PTEN+function+or+pharmacologic+modulation+of+constitutive+phosphatidylinositol+3%E2%80%B2-kinase%2FAkt+pathway+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling</span></div><div class="casAuthors">She, Qing-Bai; Solit, David; Basso, Andrea; Moasser, Mark M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tyrosine kinase (TK) inhibitors are emerging as a promising new approach to the treatment of HER overexpressing tumors, however optimal use of these agents awaits further definition of the downstream signaling pathways that mediate their effects.  We reported previously that both EGFR- and Her2-overexpressing tumors are sensitive to the new EGFR-selective TK inhibitor gefitinib (ZD 1839, "Iressa"), and sensitivity to this agent correlated with its ability to down-regulate Akt.  However, EGFR-overexpressing MDA-468 cells, which lack PTEN function, are resistant to ZD 1839, and ZD 1839 is unable to down-regulate Akt activity in these cells.  To study the role of PTEN function, we generated MDA468 cells with tet-inducible PTEN expression.  We show here that the resistance of MDA-468 cells to ZD 1839 is attributable to EGFR-independent constitutive Akt activation caused by loss of PTEN function in these cells.  Reconstitution of PTEN function through tet-inducible expression restores ZD 1839 sensitivity to these cells and reestablishes EGFR-stimulated Akt signaling.  Although restoration of PTEN function to tumors is difficult to implement clin., much of the effects of PTEN loss are attributable to overactive phosphatidylinositol 3'-kinase (PI3K)/Akt pathway signaling, and this overactivity can be modulated by pharmacol. approaches.  We show here that pharmacol. down-regulation of constitutive PI3K/Akt pathway signaling using the PI3K inhibitor LY294002 similarly restores EGFR-stimulated Akt signaling and sensitizes MDA-468 cells to ZD 1839.  Sensitivity to ZD 1839 requires intact growth factor receptor-stimulated Akt signaling activity.  PTEN loss leads to uncoupling of this signaling pathway and results in ZD 1839 resistance, which can be reversed with reintroduction of PTEN or pharmacol. down-regulation of constitutive PI3K/Akt pathway activity.  These data have important predictive and therapeutic clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL23ncra0tHbVg90H21EOLACvtfcHk0ljEEFt9VG_-RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVShsLg%253D&md5=0fab02229bea07fa6c580ff8f2abbb08</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DResistance%2520to%2520gefitinib%2520in%2520PTEN-null%2520HER-overexpressing%2520tumor%2520cells%2520can%2520be%2520overcome%2520through%2520restoration%2520of%2520PTEN%2520function%2520or%2520pharmacologic%2520modulation%2520of%2520constitutive%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%252FAkt%2520pathway%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4340%26epage%3D4346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Tonra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhoul, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtrum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finnerty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrick, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Synergistic anti-tumor effects of anti-EGFR monoclonal antibody Erbitux combined with antibodies targeting IGF1R or VEGFR-2</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">5053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2009&pages=5053&author=J.+R.+Tonraauthor=E.+Corcoranauthor=G.+Makhoulauthor=D.+Burtrumauthor=B.+Finnertyauthor=J.+Huberauthor=F.+E.+Carrickauthor=D.+L.+Ludwigauthor=D.+J.+Hicklin&title=Synergistic+anti-tumor+effects+of+anti-EGFR+monoclonal+antibody+Erbitux+combined+with+antibodies+targeting+IGF1R+or+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonra%26aufirst%3DJ.%2BR.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DMakhoul%26aufirst%3DG.%26aulast%3DBurtrum%26aufirst%3DD.%26aulast%3DFinnerty%26aufirst%3DB.%26aulast%3DHuber%26aufirst%3DJ.%26aulast%3DCarrick%26aufirst%3DF.%2BE.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DSynergistic%2520anti-tumor%2520effects%2520of%2520anti-EGFR%2520monoclonal%2520antibody%2520Erbitux%2520combined%2520with%2520antibodies%2520targeting%2520IGF1R%2520or%2520VEGFR-2%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2009%26volume%3D2005%26spage%3D5053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liwOGMWadNh_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Camirand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakikhani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">R570</span><span class="NLM_x">–</span> <span class="NLM_lpage">R579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=R570-R579&author=A.+Camirandauthor=M.+Zakikhaniauthor=F.+Youngauthor=M.+Pollak&title=Inhibition+of+insulin-like+growth+factor-1+receptor+signaling+enhances+growth-inhibitory+and+proapoptotic+effects+of+gefitinib+%28Iressa%29+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamirand%26aufirst%3DA.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DF.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520signaling%2520enhances%2520growth-inhibitory%2520and%2520proapoptotic%2520effects%2520of%2520gefitinib%2520%2528Iressa%2529%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2005%26volume%3D7%26spage%3DR570%26epage%3DR579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtrum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">2856</span><span class="NLM_x">–</span> <span class="NLM_lpage">2865</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=2856-2865&author=D.+Luauthor=H.+Zhangauthor=D.+Ludwigauthor=A.+Persaudauthor=X.+Jimenezauthor=D.+Burtrumauthor=P.+Balderesauthor=M.+Liuauthor=P.+Bohlenauthor=L.+Witteauthor=Z.+Zhu&title=Simultaneous+blockade+of+both+the+epidermal+growth+factor+receptor+and+the+insulin-like+growth+factor+receptor+signaling+pathways+in+cancer+cells+with+a+fully+human+recombinant+bispecific+antibody"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DPersaud%26aufirst%3DA.%26aulast%3DJimenez%26aufirst%3DX.%26aulast%3DBurtrum%26aufirst%3DD.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSimultaneous%2520blockade%2520of%2520both%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520signaling%2520pathways%2520in%2520cancer%2520cells%2520with%2520a%2520fully%2520human%2520recombinant%2520bispecific%2520antibody%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D2856%26epage%3D2865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prewett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangalampalli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anselma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">19665</span><span class="NLM_x">–</span> <span class="NLM_lpage">19672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=19665-19672&author=D.+Luauthor=H.+Zhangauthor=H.+Kooauthor=J.+Tonraauthor=P.+Balderesauthor=M.+Prewettauthor=E.+Corcoranauthor=V.+Mangalampalliauthor=R.+Bassiauthor=D.+Anselmaauthor=D.+Patelauthor=X.+Kangauthor=D.+L.+Ludwigauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=L.+Witteauthor=Z.+Zhu&title=A+fully+human+recombinant+IgG-like+bispecific+antibody+to+both+the+epidermal+growth+factor+receptor+and+the+insulin-like+growth+factor+receptor+for+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DH.%26aulast%3DTonra%26aufirst%3DJ.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DPrewett%26aufirst%3DM.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DMangalampalli%26aufirst%3DV.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DAnselma%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DA%2520fully%2520human%2520recombinant%2520IgG-like%2520bispecific%2520antibody%2520to%2520both%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520for%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D19665%26epage%3D19672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1830</span><span class="NLM_x">–</span> <span class="NLM_lpage">1832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2F93.24.1830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11752000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FgtlKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1830-1832&author=J.+Albanellauthor=J.+Baselga&title=Unraveling+resistance+to+trastuzumab+%28Herceptin%29%3A+insulin-like+growth+factor-I+receptor%2C+a+new+suspect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect</span></div><div class="casAuthors">Albanell J; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1830-2</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRD5HLDjTaioFMGsG_HTXYFfW6udTcc2ebp0etDJEzISrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FgtlKrtA%253D%253D&md5=786ffccb7aa0661a54823768b051f64e</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.24.1830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.24.1830%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DUnraveling%2520resistance%2520to%2520trastuzumab%2520%2528Herceptin%2529%253A%2520insulin-like%2520growth%2520factor-I%2520receptor%252C%2520a%2520new%2520suspect%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1830%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Camirand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells</span> <span class="citation_source-journal">Med. Sci. Monit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">BR521</span><span class="NLM_x">–</span> <span class="NLM_lpage">BR526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=BR521-BR526&author=A.+Camirandauthor=Y.+Luauthor=M.+Pollak&title=Co-targeting+HER2%2FErbB2+and+insulin-like+growth+factor-1+receptors+causes+synergistic+inhibition+of+growth+in+HER2-overexpressing+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamirand%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DCo-targeting%2520HER2%252FErbB2%2520and%2520insulin-like%2520growth%2520factor-1%2520receptors%2520causes%2520synergistic%2520inhibition%2520of%2520growth%2520in%2520HER2-overexpressing%2520breast%2520cancer%2520cells%26jtitle%3DMed.%2520Sci.%2520Monit.%26date%3D2002%26volume%3D8%26spage%3DBR521%26epage%3DBR526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Chakraborty, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiGiovanna, M. P.</span><span> </span><span class="NLM_article-title">Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1538-1545&author=A.+K.+Chakrabortyauthor=K.+Liangauthor=M.+P.+DiGiovanna&title=Co-targeting+insulin-like+growth+factor+I+receptor+and+HER2%3A+dramatic+effects+of+HER2+inhibitors+on+nonoverexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DLiang%26aufirst%3DK.%26aulast%3DDiGiovanna%26aufirst%3DM.%2BP.%26atitle%3DCo-targeting%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520and%2520HER2%253A%2520dramatic%2520effects%2520of%2520HER2%2520inhibitors%2520on%2520nonoverexpressing%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1538%26epage%3D1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1852</span><span class="NLM_x">–</span> <span class="NLM_lpage">1857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2F93.24.1852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11752009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVWluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1852-1857&author=Y.+Luauthor=X.+Ziauthor=Y.+Zhaoauthor=D.+Mascarenhasauthor=M.+Pollak&title=Insulin-like+growth+factor-I+receptor+signaling+and+resistance+to+trastuzumab+%28Herceptin%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptor signaling and resistance to Trastuzumab (herceptin)</span></div><div class="casAuthors">Lu, Yuhong; Zi, Xiaolin; Zhao, Yunhua; Mascarenhas, Desmond; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1852-1857</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin), an anti-HER2/neu receptor monoclonal antibody that inhibits growth of ErbB2-overexpressing breast cancer, is used to treat such cancers.  Development of resistance to Trastuzumab, however, is common.  The authors investigated whether insulin-like growth factor-I (IGF-I), which activates cell survival signals, interferes with the growth-inhibitory action of Trastuzumab.  MCF-7/HER2-18 and SKBR3 human breast cancer models were used to assess cell proliferation, colony formation in soft agar, and cell cycle parameters.  Throughout, the authors used Trastuzumab at a dose of 10 μg/mL and IGF-I at a dose of 40 ng/mL.  All statistical tests were two-sided.  Trastuzumab inhibited the growth of MCF-7/HER2-18 cells, which overexpress HER2/neu receptors and express IGF-I receptors (IGF-IRs), only when IGF-IR signaling was minimized.  For example, in 1% fetal bovine serum (FBS), Trastuzumab reduced cell proliferation by 42%; however, in 10% FBS or IGF-I, Trastuzumab had no effect on proliferation.  In SKBR3 cells, which overexpress HER2/neu receptor but express few IGF-IRs, Trastuzumab reduced proliferation by 42% regardless of IGF-I concn.  When SKBR3 cells were genetically altered to overexpress IGF-IRs and cultured with IGF-I, Trastuzumab had no effect on proliferation.  However, the addn. of IGF-binding protein-3, which decreased IGF-IR signaling, restored Trastuzumab-induced growth inhibition.  In breast cancer cell models that overexpress HER2/neu, an increased level of IGF-IR signaling appears to interfere with the action of Trastuzumab.  Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to Trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQ9Lp7VRj9LVg90H21EOLACvtfcHk0liyjvxxsoR3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVWluw%253D%253D&md5=dab7e32075ddd55ee081a1eccb991a72</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.24.1852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.24.1852%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMascarenhas%26aufirst%3DD.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520signaling%2520and%2520resistance%2520to%2520trastuzumab%2520%2528Herceptin%2529%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1852%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fijc.11445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14648698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2004&pages=334-341&author=Y.+Luauthor=X.+Ziauthor=M.+Pollak&title=Molecular+mechanisms+underlying+IGF-I-induced+attenuation+of+the+growth-inhibitory+activity+of+trastuzumab+%28Herceptin%29+on+SKBR3+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (herceptin) on SKBR3 breast cancer cells</span></div><div class="casAuthors">Lu, Yuhong; Zi, Xiaolin; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The clin. usefulness of trastuzumab (Herceptin; Genentech, San Francisco, CA) in breast cancer treatment is limited by the rapid development of resistance.  We previously reported that IGF-I signaling confers resistance to the growth-inhibitory actions of trastuzumab in a model system, but the underlying mol. mechanism remains unknown.  We used SKBR3/neo cells (expressing few IGF-I receptors) and SKBR3/IGF-IR cells (overexpressing IGF-I receptor) as our exptl. model.  IGF-I antagonized the trastuzumab-induced increase in the level of the Cdk inhibitor p27Kip1.  This resulted in decreased assocn. of p27Kip1 with Cdk2, restoration of Cdk2 activity and attenuation of cell-cycle arrest in G1 phase, all of which had been induced by trastuzumab treatment in SKBR3/IGF-IR cells.  We also found that the decrease in p27Kip1 induced by IGF-I was accompanied by an increase in expression of Skp2, which is a ubiquitin ligase for p27Kip1, and by increased Skp2 assocn. with p27Kip1.  A specific proteasome inhibitor (LLnL) completely blocked the ability of IGF-I to reduce the p27Kip1 protein level, while IGF-I increased p27Kip1 ubiquitination.  This suggests that the action of IGF-I in conferring resistance to trastuzumab involves targeting of p27Kip1 to the ubiquitin/proteasome degrdn. machinery.  Finally, specific inhibitors of MAPK and PI3K suggest that the IGF-I-mediated redn. in p27Kip1 protein level by increased degrdn. predominantly involves the PI3K pathway.  Our results provide an example of resistance to an antineoplastic therapy that targets one tyrosine kinase receptor by increased signal transduction through an alternative pathway in a complex regulatory network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFa-Tpiak-QbVg90H21EOLACvtfcHk0liyjvxxsoR3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSmu7fI&md5=10074839f031c006c512b7b0e9be5373</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fijc.11445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11445%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZi%26aufirst%3DX.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520underlying%2520IGF-I-induced%2520attenuation%2520of%2520the%2520growth-inhibitory%2520activity%2520of%2520trastuzumab%2520%2528Herceptin%2529%2520on%2520SKBR3%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D108%26spage%3D334%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Martins, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackintosh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordonez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de, A. E.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-05-1778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16740780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=3532-3540&author=A.+S.+Martinsauthor=C.+Mackintoshauthor=D.+H.+Martinauthor=M.+Camposauthor=T.+Hernandezauthor=J.+L.+Ordonezauthor=A.+E.+de&title=Insulin-like+growth+factor+I+receptor+pathway+inhibition+by+ADW742%2C+alone+or+in+combination+with+imatinib%2C+doxorubicin%2C+or+vincristine%2C+is+a+novel+therapeutic+approach+in+Ewing+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor</span></div><div class="casAuthors">Martins, Ana S.; Mackintosh, Carlos; Martin, David Herrero; Campos, Maria; Hernandez, Teresa; Ordonez, Jose-Luis; de Alava, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11, Pt. 1</span>),
    <span class="NLM_cas:pages">3532-3540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ewing tumor cell survival and proliferation depends on several autocrine loops.  Targeting these loops is a promising therapeutic approach.  We recently showed the cytostatic role of imatinib, an inhibitor of the SCF-KIT loop, on Ewing tumor cells, and in this study, we intend to analyze the inhibition of the insulin-like growth factor I receptor (IGF1R) loop.  Exptl. Design: We analyzed IGF1R blockade by ADW742, a small mol. specific for this receptor, alone and in combination with imatinib, vincristine, and doxorubicin on Ewing tumor cell lines.  We studied the effect on proliferation, apoptosis, cell cycle, pathway phosphorylation, soft-agar growth, motility, and vascular endothelial growth factor expression levels.  Results: Treatment with ADW742 induced down-regulation of IGF1R/AKT/mammalian target of rapamycin (mTOR) phosphorylation, which was deeper in cell lines having higher IGF1R activation levels.  Treatment also induced dose-dependent inhibition of cell proliferation (IC50 = 0.55-1.4 μmol/L), inducing a G1 phase blockage and apoptosis.  Addn. of imatinib to ADW742 synergistically augmented these effects and was esp. effective in inhibiting AKT/mTOR phosphorylation and reducing vascular endothelial growth factor expression in cell lines having high IGF1R activation levels.  Combination with usual chemotherapeutic agents vincristine and doxorubicin showed synergistic interactions.  Conclusions: Inhibition of Ewing tumor cell proliferation by ADW742 is mediated through blockade of IGF1R signaling.  Combination of ADW742 with imatinib, vincristine, and doxorubicin induces a significant redn. of tumor cell growth, mainly by the increase in apoptosis with a pattern depending on IGF1R activation levels.  This study supports a potential role for ADW742 in the treatment of Ewing tumor and AKT/mTOR as a possible surrogate marker of response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI9m11e83OubVg90H21EOLACvtfcHk0lgofDKCn-EneQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyisb0%253D&md5=0023acfdf1cc972003ac3d1f9d2c4252</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1778%26sid%3Dliteratum%253Aachs%26aulast%3DMartins%26aufirst%3DA.%2BS.%26aulast%3DMackintosh%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DD.%2BH.%26aulast%3DCampos%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DT.%26aulast%3DOrdonez%26aufirst%3DJ.%2BL.%26aulast%3Dde%26aufirst%3DA.%2BE.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520pathway%2520inhibition%2520by%2520ADW742%252C%2520alone%2520or%2520in%2520combination%2520with%2520imatinib%252C%2520doxorubicin%252C%2520or%2520vincristine%252C%2520is%2520a%2520novel%2520therapeutic%2520approach%2520in%2520Ewing%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D3532%26epage%3D3540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenstein, A.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1533</span><span class="NLM_x">–</span> <span class="NLM_lpage">1540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-05-0068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16227402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWhtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1533-1540&author=Y.+Shiauthor=H.+Yanauthor=P.+Frostauthor=J.+Geraauthor=A.+Lichtenstein&title=Mammalian+target+of+rapamycin+inhibitors+activate+the+AKT+kinase+in+multiple+myeloma+cells+by+up-regulating+the+insulin-like+growth+factor+receptor%2Finsulin+receptor+substrate-1%2Fphosphatidylinositol+3-kinase+cascade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade</span></div><div class="casAuthors">Shi, Yijiang; Yan, Huajun; Frost, Patrick; Gera, Joseph; Lichtenstein, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1533-1540</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have shown preclin. potential as therapy for multiple myeloma.  By inhibiting expression of cell cycle proteins, these agents induce G1 arrest.  However, by also inhibiting an mTOR-dependent serine phosphorylation of insulin receptor substrate-1 (IRS-1), they may enhance insulin-like growth factor-I (IGF-I) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/AKT activation.  This may be a particular problem in multiple myeloma where IGF-I-induced activation of AKT is an important antiapoptotic cascade.  We, therefore, studied AKT activation in multiple myeloma cells treated with mTOR inhibitors.  Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.  CCI-779, used in a xenograft model, also resulted in multiple myeloma cell AKT activation in vivo.  Blockade of IGF-I receptor function prevented rapamycin's activation of AKT.  Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 assocn. with IGF-I receptors, and prevented IRS-1 degrdn.  Although similarly blocking IRS-1 degrdn., proteasome inhibitors did not activate AKT.  Thus, mTOR inhibitors activate PI3-K/AKT in multiple myeloma cells; activation depends on basal IGF-R signaling; and enhanced IRS-1/IGF-I receptor interactions secondary to inhibited IRS-1 serine phosphorylation may play a role in activation of the cascade.  In cotreatment expts., rapamycin inhibited myeloma cell apoptosis induced by PS-341.  These results provide a caveat for future use of mTOR inhibitors in myeloma patients if they are to be combined with apoptosis-inducing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB4Wab6SFXtbVg90H21EOLACvtfcHk0lgofDKCn-EneQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWhtLjE&md5=27833984d72f3bfa2da5d106604113aa</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0068%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DGera%26aufirst%3DJ.%26aulast%3DLichtenstein%26aufirst%3DA.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520inhibitors%2520activate%2520the%2520AKT%2520kinase%2520in%2520multiple%2520myeloma%2520cells%2520by%2520up-regulating%2520the%2520insulin-like%2520growth%2520factor%2520receptor%252Finsulin%2520receptor%2520substrate-1%252Fphosphatidylinositol%25203-kinase%2520cascade%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D1533%26epage%3D1540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Tamburini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sujobert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willems, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ifrah, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouscary, D.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=379-382&author=J.+Tamburiniauthor=N.+Chapuisauthor=V.+Bardetauthor=S.+Parkauthor=P.+Sujobertauthor=L.+Willemsauthor=N.+Ifrahauthor=F.+Dreyfusauthor=P.+Mayeuxauthor=C.+Lacombeauthor=D.+Bouscary&title=Mammalian+target+of+rapamycin+%28mTOR%29+inhibition+activates+phosphatidylinositol+3-kinase%2FAkt+by+up-regulating+insulin-like+growth+factor-1+receptor+signaling+in+acute+myeloid+leukemia%3A+rationale+for+therapeutic+inhibition+of+both+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DBardet%26aufirst%3DV.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DIfrah%26aufirst%3DN.%26aulast%3DDreyfus%26aufirst%3DF.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibition%2520activates%2520phosphatidylinositol%25203-kinase%252FAkt%2520by%2520up-regulating%2520insulin-like%2520growth%2520factor-1%2520receptor%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%253A%2520rationale%2520for%2520therapeutic%2520inhibition%2520of%2520both%2520pathways%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D379%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Wan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harkavy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span> </span><span class="NLM_article-title">Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1932</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1932-1940&author=X.+Wanauthor=B.+Harkavyauthor=N.+Shenauthor=P.+Groharauthor=L.+J.+Helman&title=Rapamycin+induces+feedback+activation+of+Akt+signaling+through+an+IGF-1R-dependent+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DX.%26aulast%3DHarkavy%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DGrohar%26aufirst%3DP.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DRapamycin%2520induces%2520feedback%2520activation%2520of%2520Akt%2520signaling%2520through%2520an%2520IGF-1R-dependent%2520mechanism%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1932%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe-Fukunaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span> </span><span class="NLM_article-title">Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">7405</span><span class="NLM_x">–</span> <span class="NLM_lpage">7413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.00760-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17724079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GltrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=7405-7413&author=X.+Wangauthor=P.+Yueauthor=C.+B.+Chanauthor=K.+Yeauthor=T.+Uedaauthor=R.+Watanabe-Fukunagaauthor=R.+Fukunagaauthor=H.+Fuauthor=F.+R.+Khuriauthor=S.+Y.+Sun&title=Inhibition+of+mammalian+target+of+rapamycin+induces+phosphatidylinositol+3-kinase-dependent+and+Mnk-mediated+eukaryotic+translation+initiation+factor+4E+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation</span></div><div class="casAuthors">Wang, Xuerong; Yue, Ping; Chan, Chi-Bun; Ye, Keqiang; Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukunaga, Rikiro; Fu, Haian; Khuri, Fadlo R.; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7405-7413</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The initiation factor eukaryotic translation initiation factor 4E (eIF4E) plays a crit. role in initiating translation of mRNAs, including those encoding oncogenic proteins.  Therefore, eIF4E is considered a survival protein involved in cell cycle progression, cell transformation, and apoptotic resistance.  Phosphorylation of eIF4E (usually at Ser209) increases its binding affinity for the cap of mRNA and may also favor its entry into initiation complexes.  Mammalian target of rapamycin (mTOR) inhibitors suppress cap-dependent translation through inhibition of the phosphorylation of eIF4E-binding protein 1.  Paradoxically, we have shown that inhibition of mTOR signaling increases eIF4E phosphorylation in human cancer cells.  In this study, we focused on revealing the mechanism by which mTOR inhibition increases eIF4E phosphorylation.  Silencing of either mTOR or raptor could mimic mTOR inhibitors' effects to increase eIF4E phosphorylation.  Moreover, knockdown of mTOR, but not rictor or p70S6K, abrogated rapamycin's ability to increase eIF4E phosphorylation.  These results indicate that mTOR inhibitor-induced eIF4E phosphorylation is secondary to mTOR/raptor inhibition and independent of p70S6K.  Importantly, mTOR inhibitors lost their ability to increase eIF4E phosphorylation only in cells where both Mnk1 and Mnk2 were knocked out, indicating that mTOR inhibitors increase eIF4E phosphorylation through a Mnk-dependent mechanism.  Given that mTOR inhibitors failed to increase Mnk and eIF4E phosphorylation in phosphatidylinositol 3-kinase (PI3K)-deficient cells, we conclude that mTOR inhibition increases eIF4E phosphorylation through a PI3K-dependent and Mnk-mediated mechanism.  In addn., we also suggest an effective therapeutic strategy for enhancing mTOR-targeted cancer therapy by cotargeting mTOR signaling and Mnk/eIF4E phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquXolS5uYp0LVg90H21EOLACvtfcHk0lhtLP7Mtay0EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GltrzE&md5=2dec230f38b5dc7cd95ddd8986f374e5</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1128%2FMCB.00760-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00760-07%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DC.%2BB.%26aulast%3DYe%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DWatanabe-Fukunaga%26aufirst%3DR.%26aulast%3DFukunaga%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DInhibition%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520induces%2520phosphatidylinositol%25203-kinase-dependent%2520and%2520Mnk-mediated%2520eukaryotic%2520translation%2520initiation%2520factor%25204E%2520phosphorylation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D7405%26epage%3D7413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncogenic kinase signalling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2F35077225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11357143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=355-365&author=P.+Blume-Jensenauthor=T.+Hunter&title=Oncogenic+kinase+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase signaling</span></div><div class="casAuthors">Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">6835</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 93 refs.  Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans.  Their activity is normally tightly controlled and regulated.  Perturbation of PTK signaling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation.  The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signaling.  This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signaling in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJiBzQk4vjZbVg90H21EOLACvtfcHk0lhtLP7Mtay0EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D&md5=cd1bce803c2daadb98cbdba8550be43b</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2F35077225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35077225%26sid%3Dliteratum%253Aachs%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncogenic%2520kinase%2520signalling%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Votta, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase as a therapeutic strategy</span> <span class="citation_source-journal">Immunopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0162-3109%2800%2900206-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10878289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=185-201&author=J.+C.+Leeauthor=S.+Kumarauthor=D.+E.+Griswoldauthor=D.+C.+Underwoodauthor=B.+J.+Vottaauthor=J.+L.+Adams&title=Inhibition+of+p38+MAP+kinase+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase as a therapeutic strategy</span></div><div class="casAuthors">Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">185-201</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with ∼200 refs.  Since the discovery of p38 MAP kinase in 1994, our understanding of its biol. has progressed dramatically.  The key advances include (1) identification of p38 MAP kinase homologs and protein kinases that act upstream and downstream from p38 MAP kinase, (2) identification of interesting and potentially important substrates, (3) elucidation of the role of p38 MAP kinase in cellular processes and (4) the establishment of the mechanism by which the pyridinylimidazole p38 MAP kinase inhibitors inhibit enzyme activity.  It is now known that there are four members of the p38 MAP kinase family.  They differ in their tissue distribution, regulation of kinase activation and subsequent phosphorylation of downstream substrates.  They also differ in terms of their sensitivities toward the p38 MAP kinase inhibitors.  The best-studied isoform is p38 alpha, whose activation has been obsd. in many hematopoietic and non-hematopoietic cell types upon treatment with appropriate stimuli.  The pyridinylimidazole compds., exemplified by SB 203580, were originally prepd. as inflammatory cytokine synthesis inhibitors that subsequently were selective inhibitors of p38 MAP kinase.  SB 203580 inhibits the catalytic activity of p38 MAP kinase by competitive binding in the ATP pocket.  X-ray crystallog. studies of the target enzyme complexed with inhibitor reinforce the observations made from site-directed mutagenesis studies, thereby providing a mol. basis for understanding the kinase selectivity of these inhibitors.  The p38 MAP kinase inhibitors are efficacious in several disease models, including inflammation, arthritis and other joint diseases, septic shock, and myocardial injury.  In all cases, p38 activation in key cell types correlated with disease initiation and progression.  Treatment with p38 MAP kinase inhibitors attenuated both p38 activation and disease severity.  Structurally diverse p38 MAP kinase inhibitors have been tested extensively in preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWDqUQeNxhwbVg90H21EOLACvtfcHk0lhtLP7Mtay0EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7Y%253D&md5=3d566c9a46952830fd4fca6692fb863b</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900206-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900206-X%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DUnderwood%26aufirst%3DD.%2BC.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D185%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Goepfert, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkley, B. R.</span><span> </span><span class="NLM_article-title">The centrosome-associated Aurora/Ipl-like kinase family</span> <span class="citation_source-journal">Curr. Top. Dev. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=331-342&author=T.+M.+Goepfertauthor=B.+R.+Brinkley&title=The+centrosome-associated+Aurora%2FIpl-like+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoepfert%26aufirst%3DT.%2BM.%26aulast%3DBrinkley%26aufirst%3DB.%2BR.%26atitle%3DThe%2520centrosome-associated%2520Aurora%252FIpl-like%2520kinase%2520family%26jtitle%3DCurr.%2520Top.%2520Dev.%2520Biol.%26date%3D2000%26volume%3D49%26spage%3D331%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Winder, W. W.</span><span> </span><span class="NLM_article-title">AMP-activated protein kinase: possible target for treatment of type 2 diabetes</span> <span class="citation_source-journal">Diabetes Technol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1089%2F15209150050194305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11467346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1SgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=441-448&author=W.+W.+Winder&title=AMP-activated+protein+kinase%3A+possible+target+for+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase: Possible target for treatment of type 2 diabetes</span></div><div class="casAuthors">Winder, W. W.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Technology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">DTTHFH</span>;
        ISSN:<span class="NLM_cas:issn">1520-9156</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review with 49 refs.  A considerable amt. of data have accumulated showing that contraction of muscle has an acute insulin-like effect, triggering the uptake of glucose.  Chronic muscle contraction, as seen in endurance training has effects on insulin sensitivity, enhancing the effect of insulin on glucose uptake.  Endurance training results in an increase in levels of GLUT4 in the muscle.  This increase in GLUT4 is thought to be responsible in part for the enhancement of insulin sensitivity.  Recent expts. have demonstrated that acute and chronic effects of muscle contraction on glucose uptake and the increase in GLUT4 may be due to activation of a protein kinase, AMP-activated protein kinase (AMPK).  This kinase is activated by the increase in 5'-AMP and the decline in creatine phosphate that occur during muscle contraction.  Phosphorylated AMPK then presumably phosphorylates undefined target proteins, which in turn increase glucose uptake and transcription of the GLUT4 gene.  Expts. have demonstrated that this kinase, normally activated during exercise, can be activated artificially in muscle by injecting non-exercising rats with 5-aminoimidazole-4-carboxamide-riboside (AICAR), an adenosine analog.  AICAR is taken up into muscle and phosphorylated to form an analog of 5'-AMP.  Acute (stimulation of glucose uptake into muscle) and chronic (increase in GLUT4) effects of exercise can be reproduced by injection of this drug.  These observations open the door to the possibility of treatment of patients with type 2 diabetes with AMPK activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4RkPNzHUbbVg90H21EOLACvtfcHk0lj8e7tM6Ya78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1SgsLs%253D&md5=64494f4ee3515880bc0b5dac35b4f002</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1089%2F15209150050194305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F15209150050194305%26sid%3Dliteratum%253Aachs%26aulast%3DWinder%26aufirst%3DW.%2BW.%26atitle%3DAMP-activated%2520protein%2520kinase%253A%2520possible%2520target%2520for%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Technol.%2520Ther.%26date%3D2000%26volume%3D2%26spage%3D441%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Wagman, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span> </span><span class="NLM_article-title">Current therapies and emerging targets for the treatment of diabetes</span> <span class="citation_source-journal">Curr. Pharm. Des</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F1381612013397915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11281851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=417-450&author=A.+S.+Wagmanauthor=J.+M.+Nuss&title=Current+therapies+and+emerging+targets+for+the+treatment+of+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Current therapies and emerging targets for the treatment of diabetes</span></div><div class="casAuthors">Wagman, Allan S.; Nuss, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-450</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 275 refs.  Concurrent with the spread of the western lifestyle, the prevalence of all types of diabetes is on the rise in the world's population.  The no. of diabetics is increasing by 4-5% per yr with an estd. 40-45% of individual's over the age of 65 yr having either type II diabetes or impaired glucose tolerance.  Since the signs of diabetes are not immediately obvious, diagnosis can be preceded by an extended period of impaired glucose tolerance resulting in the prevalence of beta-cell dysfunction and macrovascular complications.  In addn. to increased medical vigilance, diabetes is being combated through aggressive treatment directed at lowering circulating blood glucose and inhibiting postprandial hyperglycemic spikes.  Current strategies to treat diabetes include reducing insulin resistance using glitazones, supplementing insulin supplies with exogenous insulin, increasing endogenous insulin prodn. with sulfonylureas and meglitinides, reducing hepatic glucose prodn. through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors.  In all of these areas, new generations of small mols. are being investigated which exhibit improved efficacy and safety profiles.  Promising biol. targets are also emerging such as (1) insulin sensitizers including protein tyrosine phosphatase-1B (PTP-1B) and glycogen synthase kinase 3 (GSK3), (2) inhibitors of gluconeogenesis like pyruvate dehydrogenase kinase (PDH) inhibitors, (3) lipolysis inhibitors, (4) fat oxidn. including carnitine palmitoyltransferase (CPT) I and II inhibitors, and (5) energy expenditure by beta 3-adrenoceptor agonists.  Also important are alternative routes of glucose disposal such as Na+-glucose cotransporter (SGLT) inhibitors, combination therapies, and the treatment of diabetic complications (eg. retinopathy, nephropathy, and neuropathy).  With may new opportunities for drug discovery, the prospects are excellent for development of innovative therapies to effectively manage diabetes and prevent its long term complications.  This review highlights recent (1997-2000) advances in diabetes therapy and research with an emphasis on small mol. drug design (275 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEKavClISK_bVg90H21EOLACvtfcHk0lj8e7tM6Ya78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOjt74%253D&md5=c3b89d3fb630d6dbafdb9e42e014463f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.2174%2F1381612013397915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397915%26sid%3Dliteratum%253Aachs%26aulast%3DWagman%26aufirst%3DA.%2BS.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26atitle%3DCurrent%2520therapies%2520and%2520emerging%2520targets%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DCurr.%2520Pharm.%2520Des%26date%3D2001%26volume%3D7%26spage%3D417%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group">Kirschenbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, J. V.</span><span> </span><span class="NLM_article-title">Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">30701</span><span class="NLM_x">–</span> <span class="NLM_lpage">30707</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=30701-30707&author=F.+Kirschenbaumauthor=S.+C.+Hsuauthor=B.+Cordellauthor=J.+V.+McCarthy&title=Glycogen+synthase+kinase-3beta+regulates+presenilin+1+C-terminal+fragment+levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKirschenbaum%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DS.%2BC.%26aulast%3DCordell%26aufirst%3DB.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BV.%26atitle%3DGlycogen%2520synthase%2520kinase-3beta%2520regulates%2520presenilin%25201%2520C-terminal%2520fragment%2520levels%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D30701%26epage%3D30707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sali, A.</span><span> </span><span class="NLM_article-title">Comparative protein structure modeling. Introduction and practical examples with modeller</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11084904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVehtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2000&pages=97-129&author=R.+Sanchezauthor=A.+Sali&title=Comparative+protein+structure+modeling.+Introduction+and+practical+examples+with+modeller"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative protein structure modeling - introduction and practical examples with MODELLER</span></div><div class="casAuthors">Sanchez, Roberto; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, New Jersey)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">Protein Structure Prediction</span>),
    <span class="NLM_cas:pages">97-129</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review with 75 refs.  Topics discussed include the usefulness of comparative modeling, steps in comparative modeling, and examples of typical comparative modeling cases using the program MODELLER and other freely available software.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1LXDmFwRarVg90H21EOLACvtfcHk0lj8e7tM6Ya78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVehtbc%253D&md5=57872474e6a98bb003a27e8100619e89</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparative%2520protein%2520structure%2520modeling.%2520Introduction%2520and%2520practical%2520examples%2520with%2520modeller%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2000%26volume%3D143%26spage%3D97%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Zheng, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirion, R.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway</span> <span class="citation_source-journal">J. Neural Transm., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11205145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gt1OitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=261-272&author=W.+H.+Zhengauthor=S.+Karauthor=S.+Doreauthor=R.+Quirion&title=Insulin-like+growth+factor-1+%28IGF-1%29%3A+a+neuroprotective+trophic+factor+acting+via+the+Akt+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway</span></div><div class="casAuthors">Zheng W H; Kar S; Dore S; Quirion R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission. Supplementum</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">60</span>),
    <span class="NLM_cas:pages">261-72</span>
        ISSN:<span class="NLM_cas:issn">0303-6995</span>.
    </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a pleiotropic polypeptide with a wide range of actions in both central and peripheral nervous sytems.  Over the past few years, we studied the trophic as well as neuromodulatory roles of IGF-I in the brain.  Accumulated evidence indicates that IGF-I, apart from regulating growth and development, protects neurons against cell death induced by amyloidogenic derivatives, glucose or serum deprivation via the activation of intracellular pathways implicating phosphatidylinositide 3/Akt kinase, winged-helix family of transcription factor FKHRL1 phosphorylation or production of free radicals.  The effects of IGF-I on neuroprotection, glucose metabolism and activity-dependent plasticity suggest the potential usefulness of this growth factor or related mimetics in the treatment of Alzheimer's disease and other neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj2Aw68nvLXcULxIEhxUjPfW6udTcc2ebTFYud1iE05rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gt1OitA%253D%253D&md5=d5004c17799f1d3b14ab846dd0d57532</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DW.%2BH.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DDore%26aufirst%3DS.%26aulast%3DQuirion%26aufirst%3DR.%26atitle%3DInsulin-like%2520growth%2520factor-1%2520%2528IGF-1%2529%253A%2520a%2520neuroprotective%2520trophic%2520factor%2520acting%2520via%2520the%2520Akt%2520kinase%2520pathway%26jtitle%3DJ.%2520Neural%2520Transm.%252C%2520Suppl.%26date%3D2000%26spage%3D261%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2001</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">37</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">267</span>− <span class="NLM_lpage">268</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=267-268&author=A.+M.+Dohertyauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942001%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2002%26spage%3D267%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2002</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">38</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">358</span>− <span class="NLM_lpage">359</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=358-359&author=A.+M.+Dohertyauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942002%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2003%26spage%3D358%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2004</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">40</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">454</span>− <span class="NLM_lpage">455</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=454-455&author=S.+Hegde&author=M.+Schmidtauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942004%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2005%26spage%3D454%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2005</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">41</span>st ed.; <span class="NLM_contrib-group">Wood, A.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">466</span>− <span class="NLM_lpage">467</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=466-467&author=S.+Hegde&author=M.+Schmidtauthor=A.+Wood&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942005%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DWood%26aufirst%3DA.%26pub%3DAcademic%2520Press%26date%3D2006%26spage%3D466%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group">Liao, J. J.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&author=J.+J.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0liszz0q2PMzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span>FDA News. FDA Approves Tykerb for Advanced Breast Cancer Patients. <a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html" class="extLink">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html</a>. Mar 13,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News.+FDA+Approves+Tykerb+for+Advanced+Breast+Cancer+Patients.+http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FNEWS%2F2007%2FNEW01586.html.+Mar+13%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span>FDA News. FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia. <a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html" class="extLink">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html</a>. Oct 13,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News.+FDA+Approves+Tasigna+for+Treatment+of+Philadelphia+Chromosome+Positive+Chronic+Myeloid+Leukemia.+http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FNEWS%2F2007%2FNEW01734.html.+Oct+13%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span><span> </span><span class="NLM_article-title">Kinase Inhibitor Drugs</span>. In  <span class="citation_source-book">Drug Discovery and Development</span>; <span class="NLM_contrib-group">Wang, B.</span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>; in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Li%2C+R.%3B+Stafford%2C+J.+A.+Kinase+Inhibitor+Drugs.+In+Drug+Discovery+and+Development%3B+Wang%2C+B.%2C+Ed.%3B+John+Wiley+%26+Sons%2C+Inc.%3A+Hoboken%2C+NJ%3B+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26atitle%3DKinase%2520Inhibitor%2520Drugs%26btitle%3DDrug%2520Discovery%2520and%2520Development%26aulast%3DWang%26aufirst%3DB.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liszz0q2PMzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span> </span><span class="NLM_article-title">Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR)</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=41-46&author=R.+D.+Hubbardauthor=J.+L.+Wilsbacher&title=Advances+towards+the+development+of+ATP-competitive+small-molecule+inhibitors+of+the+insulin-like+growth+factor+receptor+%28IGF-IR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26atitle%3DAdvances%2520towards%2520the%2520development%2520of%2520ATP-competitive%2520small-molecule%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-IR%2529%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D41%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1041-1047&author=F.+Hofmannauthor=C.+Garcia-Echeverria&title=Blocking+the+insulin-like+growth+factor-I+receptor+as+a+strategy+for+targeting+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DBlocking%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520as%2520a%2520strategy%2520for%2520targeting%2520cancer%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1041%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span> </span><span class="NLM_article-title">Role of insulin-like growth factor 1 receptor signalling in cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.bjc.6602627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15956962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVygtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=2097-2101&author=O.+Larssonauthor=A.+Girnitaauthor=L.+Girnita&title=Role+of+insulin-like+growth+factor+1+receptor+signalling+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Role of insulin-like growth factor 1 receptor signalling in cancer</span></div><div class="casAuthors">Larsson, O.; Girnita, A.; Girnita, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2097-2101</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor (IGF-1) signalling is highly implicated in cancer.  In this signalling the IGF-1 receptor (IGF-1R) is unquestionable, the predominating single factor.  IGF-1R is crucial for tumor transformation and survival of malignant cell, but is only partially involved in normal cell growth.  This is in part due to the interactions with oncogenes.  Recent findings suggest a close interplay with the p53/MDM2 pathway.  Disturbances in components in the p53/MDM2/IGF-1R network may cause IGF-1R upregulation and growth advantage for the cancer cell.  Targeting of IGF-1R is more and more seen as a promising option for future cancer therapy.  Single chain antibodies and small mols. with selective effects on IGF-1R dependent malignant growth are of particular interest.  Forthcoming clin. trials are welcome and will indeed be the only way to evaluate the impact of IGF-1R targeting in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqurCbuWDX67Vg90H21EOLACvtfcHk0liszz0q2PMzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVygtL0%253D&md5=c767b37b998115faed09101c57096238</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602627%26sid%3Dliteratum%253Aachs%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DGirnita%26aufirst%3DL.%26atitle%3DRole%2520of%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signalling%2520in%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D2097%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group">Saxena, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari Narayana Moorthy, N. S.</span><span> </span><span class="NLM_article-title">Insulin like growth factor-1 receptor: an anticancer target waiting for hit</span> <span class="citation_source-journal">Int. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.3923%2Fijcr.2007.54.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotl2mtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=54-73&author=V.+Saxenaauthor=N.+S.+Hari+Narayana+Moorthy&title=Insulin+like+growth+factor-1+receptor%3A+an+anticancer+target+waiting+for+hit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin like growth factor-1 receptor: an anticancer target waiting for hit</span></div><div class="casAuthors">Saxena, Vipin; Moorthy, N. S. Hari Narayana</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-73</span>CODEN:
                <span class="NLM_cas:coden">IJCRCC</span>;
        ISSN:<span class="NLM_cas:issn">1811-9727</span>.
    
            (<span class="NLM_cas:orgname">Academic Journals</span>)
        </div><div class="casAbstract">A review.  The Insulin like Growth Factor-1 (IGF-1) receptors are members of the super family of Receptor Tyrosine Kinase (RTKs) implicated in human cancers due to amplification, overexpression or somatic mutation of the gene.  The type-1 insulin like growth receptors (IGF-1R) is overexpressed by many tumors and mediates proliferation, motility and apoptosis protection.  Tumor growth and metastasis can be blocked by agents that inhibit IGF-1R expression or function, suggesting that the IGF-1R is a promising treatment target.  The strategies to block IGF-1R function employed anti-IGF-1R antibodies, small-mol. inhibitors of the IGF-1R tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant neg. mutant and various compds. reducing ligand availability.  Studies show that antisense IGF-1R expression in melanoma cells leads to enhanced radio sensitivity and impaired activation of ATM, required for DNA double strand break repair.  Antisense and dominant neg. strategies also enhance tumor cell chemosensitivity induced by tumor cells and killed in vivo by IGF-1R antisense.  However, antisense agents cause only modest IGF-1R down regulation and can affect the insulin receptor.  Specificity is an important issue for the development of both kinase inhibitors and mol. reagents.  Using an array-based screen to identify accessible region of IGF-1R mRNA, are designed small interfering RNAs (siRNAs) that induce potent IGF-1R gene silencing without affecting the insulin receptor.  These siRNAs block IGF-signaling, enhancing radio and chemosensitivity and show a genuine therapeutic potential.  The clin. efficacy of IGF-1R targeting will be detd. by key factors including the role of receptors in established tumors.  The potency of inhibition achieved in vivo and the extent to which other signaling pathways compensate for IGF-1R loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVvZOf269Y0rVg90H21EOLACvtfcHk0ljbTJdWcHUOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotl2mtb4%253D&md5=d8acac03ab8ca18442f9b15fe8adf971</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.3923%2Fijcr.2007.54.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3923%252Fijcr.2007.54.73%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DV.%26aulast%3DHari%2BNarayana%2BMoorthy%26aufirst%3DN.%2BS.%26atitle%3DInsulin%2520like%2520growth%2520factor-1%2520receptor%253A%2520an%2520anticancer%2520target%2520waiting%2520for%2520hit%26jtitle%3DInt.%2520J.%2520Cancer%2520Res.%26date%3D2007%26volume%3D3%26spage%3D54%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2F978-3-540-31209-3_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17607936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsleitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2007&pages=59-76&author=Y.+Wangauthor=Q.+S.+Jiauthor=M.+Mulvihillauthor=J.+A.+Pachter&title=Inhibition+of+the+IGF-I+receptor+for+treatment+of+cancer.+Kinase+inhibitors+and+monoclonal+antibodies+as+alternative+approaches"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches</span></div><div class="casAuthors">Wang, Yan; Ji, Qun-sheng; Mulvihill, Mark; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">Targeted Interference with Signal Transduction Events</span>),
    <span class="NLM_cas:pages">59-76</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review on the role of insulin-like growth factor receptor in cancer and therapeutic approaches targeting the IGF-IR that have been developed for the treatment of cancer.  The normal physiol. of IGF action is discussed, along with IGF signaling in cancer, targeting of IGF-IR for treatment of human cancer, and small-mol. IGF-IR kinase inhibitors with selectivity vs. IR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLNmWdg_q-CLVg90H21EOLACvtfcHk0ljbTJdWcHUOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsleitr8%253D&md5=32a15d51321a529347577669efe42283</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-31209-3_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-31209-3_5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMulvihill%26aufirst%3DM.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520the%2520IGF-I%2520receptor%2520for%2520treatment%2520of%2520cancer.%2520Kinase%2520inhibitors%2520and%2520monoclonal%2520antibodies%2520as%2520alternative%2520approaches%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2007%26volume%3D172%26spage%3D59%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group">Sarma, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tandon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dastidar, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span> </span><span class="NLM_article-title">Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F13543776.17.1.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=25-35&author=P.+K.+S.+Sarmaauthor=R.+Tandonauthor=P.+Guptaauthor=S.+G.+Dastidarauthor=A.+Rayauthor=B.+Dasauthor=I.+A.+Cliffe&title=Progress+in+the+development+of+small+molecule+inhibitors+of+insulin-like+growth+factor-1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase</span></div><div class="casAuthors">Sarma, P. K. S.; Tandon, Ruchi; Gupta, Praful; Dastidar, Sunanda G.; Ray, Abhijit; Das, Biswajit; Cliffe, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase that plays a key role in tumor cell proliferation and in the inhibition of apoptosis, and therefore is a potential target for the treatment of cancer.  The blockade of IGF-1R kinase activity by small mol. binding to the catalytic domain of the receptor offers promise for the future and this review summarizes the patent literature from 2000 to early 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPOksMdgUQ7Vg90H21EOLACvtfcHk0ljbTJdWcHUOYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitFSktQ%253D%253D&md5=3cb01d7455aaf0707e8e94666fe95961</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1517%2F13543776.17.1.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.17.1.25%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DP.%2BK.%2BS.%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2007%26volume%3D17%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group">Yaish, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">242</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1988&pages=933-935&author=P.+Yaishauthor=A.+Gazitauthor=C.+Gilonauthor=A.+Levitzki&title=Blocking+of+EGF-dependent+cell+proliferation+by+EGF+receptor+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYaish%26aufirst%3DP.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DBlocking%2520of%2520EGF-dependent%2520cell%2520proliferation%2520by%2520EGF%2520receptor%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D1988%26volume%3D242%26spage%3D933%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaish, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2352</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00130a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2344-2352&author=A.+Gazitauthor=P.+Yaishauthor=C.+Gilonauthor=A.+Levitzki&title=Tyrphostins+I%3A+synthesis+and+biological+activity+of+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fjm00130a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00130a020%26sid%3Dliteratum%253Aachs%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DYaish%26aufirst%3DP.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DTyrphostins%2520I%253A%2520synthesis%2520and%2520biological%2520activity%2520of%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2344%26epage%3D2352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Tyrphostins—potential antiproliferative agents and novel molecular tools</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=913-918&author=A.+Levitzki&title=Tyrphostins%E2%80%94potential+antiproliferative+agents+and+novel+molecular+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DTyrphostins%25E2%2580%2594potential%2520antiproliferative%2520agents%2520and%2520novel%2520molecular%2520tools%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D40%26spage%3D913%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span> </span><span class="NLM_article-title">Tyrphostins as molecular tools and potential antiproliferative drugs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">174</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1991&pages=171-174&author=A.+Levitzkiauthor=C.+Gilon&title=Tyrphostins+as+molecular+tools+and+potential+antiproliferative+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DGilon%26aufirst%3DC.%26atitle%3DTyrphostins%2520as%2520molecular%2520tools%2520and%2520potential%2520antiproliferative%2520drugs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1991%26volume%3D12%26spage%3D171%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibition: an approach to drug development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1782</span><span class="NLM_x">–</span> <span class="NLM_lpage">1788</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=1782-1788&author=A.+Levitzkiauthor=A.+Gazit&title=Tyrosine+kinase+inhibition%3A+an+approach+to+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibition%253A%2520an%2520approach%2520to%2520drug%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D1782%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group">Parrizas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheimer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1997&pages=1427-1433&author=M.+Parrizasauthor=A.+Gazitauthor=A.+Levitzkiauthor=E.+Wertheimerauthor=D.+LeRoith&title=Specific+inhibition+of+insulin-like+growth+factor-1+and+insulin+receptor+tyrosine+kinase+activity+and+biological+function+by+tyrphostins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParrizas%26aufirst%3DM.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DWertheimer%26aufirst%3DE.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DSpecific%2520inhibition%2520of%2520insulin-like%2520growth%2520factor-1%2520and%2520insulin%2520receptor%2520tyrosine%2520kinase%2520activity%2520and%2520biological%2520function%2520by%2520tyrphostins%26jtitle%3DEndocrinology%26date%3D1997%26volume%3D138%26spage%3D1427%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group">Jaleel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visweswariah, S. S.</span><span> </span><span class="NLM_article-title">Tyrphostins are inhibitors of guanylyl and adenylyl cyclases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">8247</span><span class="NLM_x">–</span> <span class="NLM_lpage">8255</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi036234n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=8247-8255&author=M.+Jaleelauthor=A.+R.+Shenoyauthor=S.+S.+Visweswariah&title=Tyrphostins+are+inhibitors+of+guanylyl+and+adenylyl+cyclases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fbi036234n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036234n%26sid%3Dliteratum%253Aachs%26aulast%3DJaleel%26aufirst%3DM.%26aulast%3DShenoy%26aufirst%3DA.%2BR.%26aulast%3DVisweswariah%26aufirst%3DS.%2BS.%26atitle%3DTyrphostins%2520are%2520inhibitors%2520of%2520guanylyl%2520and%2520adenylyl%2520cyclases%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D8247%26epage%3D8255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group">Kamath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buolamwini, J. K.</span><span> </span><span class="NLM_article-title">Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4657</span><span class="NLM_x">–</span> <span class="NLM_lpage">4668</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030065n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4657-4668&author=S.+Kamathauthor=J.+K.+Buolamwini&title=Receptor-guided+alignment-based+comparative+3D-QSAR+studies+of+benzylidene+malonitrile+tyrphostins+as+EGFR+and+HER-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Fjm030065n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030065n%26sid%3Dliteratum%253Aachs%26aulast%3DKamath%26aufirst%3DS.%26aulast%3DBuolamwini%26aufirst%3DJ.%2BK.%26atitle%3DReceptor-guided%2520alignment-based%2520comparative%25203D-QSAR%2520studies%2520of%2520benzylidene%2520malonitrile%2520tyrphostins%2520as%2520EGFR%2520and%2520HER-2%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4657%26epage%3D4668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group">Meydan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidot, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeder, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roifman, C. M.</span><span> </span><span class="NLM_article-title">Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=1996&pages=645-648&author=N.+Meydanauthor=T.+Grunbergerauthor=H.+Dadiauthor=M.+Shaharauthor=E.+Arpaiaauthor=Z.+Lapidotauthor=J.+S.+Leederauthor=M.+Freedmanauthor=A.+Cohenauthor=A.+Gazitauthor=A.+Levitzkiauthor=C.+M.+Roifman&title=Inhibition+of+acute+lymphoblastic+leukaemia+by+a+Jak-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeydan%26aufirst%3DN.%26aulast%3DGrunberger%26aufirst%3DT.%26aulast%3DDadi%26aufirst%3DH.%26aulast%3DShahar%26aufirst%3DM.%26aulast%3DArpaia%26aufirst%3DE.%26aulast%3DLapidot%26aufirst%3DZ.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3DFreedman%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DRoifman%26aufirst%3DC.%2BM.%26atitle%3DInhibition%2520of%2520acute%2520lymphoblastic%2520leukaemia%2520by%2520a%2520Jak-2%2520inhibitor%26jtitle%3DNature%26date%3D1996%26volume%3D379%26spage%3D645%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors as a therapeutic modality</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar0201207" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=462-469&author=A.+Levitzki&title=Protein+kinase+inhibitors+as+a+therapeutic+modality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Far0201207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far0201207%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DProtein%2520kinase%2520inhibitors%2520as%2520a%2520therapeutic%2520modality%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D462%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group">Warshamana-Greene, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, G. W.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15141010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=527-535&author=G.+S.+Warshamana-Greeneauthor=J.+Litzauthor=E.+Buchdungerauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=G.+W.+Krystal&title=The+insulin-like+growth+factor-I+%28IGF-I%29+receptor+kinase+inhibitor+NVP-ADW742%2C+in+combination+with+STI571%2C+delineates+a+spectrum+of+dependence+of+small+cell+lung+cancer+on+IGF-I+and+stem+cell+factor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling</span></div><div class="casAuthors">Warshamana-Greene, G. Sakuntala; Litz, Julie; Buchdunger, Elisabeth; Hofmann, Francesco; Garcia-Echeverria, Carlos; Krystal, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stem cell factor (SCF)/Kit and insulin-like growth factor-I (IGF-I)/IGF-I receptor (IGF-IR) autocrine loops play a prominent role in the growth of small cell lung cancer (SCLC).  Previous data suggested that IGF-I protects cells from apoptosis induced by STI571, an efficient inhibitor of Kit signal transduction, by activating the crit. phosphatidylinositol 3-kinase-Akt pathway.  To det. if inhibition of IGF-IR signaling would be therapeutically relevant in SCLC, the activity of a novel kinase inhibitor of IGF-IR, NVP-ADW742 (Novartis Pharma AG, Basel, Switzerland), was characterized.  Pretreatment of the H526 cell line with NVP-ADW742 inhibited IGF-IR signaling and growth with IC50 values between 0.1 and 0.4 μM.  SCF-mediated Kit phosphorylation and Akt activation were inhibited with IC50 values in the 1-5 μM range.  However, NVP-ADW742 affected neither hepatocyte growth factor-mediated Akt activation nor activity of constitutively active Akt.  The therapeutic potential of NVP-ADW742 was assessed by detg. its effect on growth of several SCLC cell lines in serum.  These studies clearly delineated two populations of cell lines as detd. by differential sensitivity to NVP-ADW742.  One population, which lacks active SCF/Kit autocrine loops, was inhibited with IC50 values between 0.1 and 0.5 μM.  A second population, which has active SCF/Kit autocrine loops, was inhibited with IC50 values in the 4-7 μM range.  When these cell lines were treated with a combination of STI571 and NVP-ADW742, no advantage was seen in the former group, whereas, in the latter group, a clearly synergistic response to the combination was seen when growth, apoptosis, or Akt activation was assessed.  These data demonstrate that NVP-ADW742 is a potent and selective IGF-IR kinase inhibitor that can efficiently inhibit the growth of cells that are highly dependent on IGF-I signaling.  However, for optimal growth inhibition of SCLC cells with an active SCF/Kit autocrine loop, a combination of a Kit inhibitor (STI571) and an IGF-IR inhibitor (NVP-ADW742) appears to be necessary.  These observations suggest that, in tumors in which crit. signal transduction pathways can be activated by alternative receptors, optimal therapy may require inhibition of multiple receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7Sxl-483BrVg90H21EOLACvtfcHk0liv7T9ls78SEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVKntLY%253D&md5=7751c83d0080df2177e096c0874cc5a0</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWarshamana-Greene%26aufirst%3DG.%2BS.%26aulast%3DLitz%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DKrystal%26aufirst%3DG.%2BW.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520kinase%2520inhibitor%2520NVP-ADW742%252C%2520in%2520combination%2520with%2520STI571%252C%2520delineates%2520a%2520spectrum%2520of%2520dependence%2520of%2520small%2520cell%2520lung%2520cancer%2520on%2520IGF-I%2520and%2520stem%2520cell%2520factor%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D527%26epage%3D535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group">Favelyukis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span> </span><span class="NLM_article-title">Structure and autoregulation of the insulin-like growth factor 1 receptor kinase</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=1058-1063&author=S.+Favelyukisauthor=J.+H.+Tillauthor=S.+R.+Hubbardauthor=W.+T.+Miller&title=Structure+and+autoregulation+of+the+insulin-like+growth+factor+1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFavelyukis%26aufirst%3DS.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DStructure%2520and%2520autoregulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520kinase%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D1058%26epage%3D1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group">Capraro, H. G.; Furet, P.; Garcia-Echeverria, C.; Manley, P. W.</span><span> </span><span class="NLM_article-title">4-Amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-<i>d</i>]pyrimidine Derivatives</span>. PCT Int. Pat. Appl. WO02/92599,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=H.+G.+Capraro&author=P.+Furet&author=C.+Garcia-Echeverria&author=P.+W.+Manley&title=4-Amino-5-phenyl-7-cyclobutyl-pyrrolo%5B2%2C3-d%5Dpyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCapraro%26aufirst%3DH.%2BG.%26atitle%3D4-Amino-5-phenyl-7-cyclobutyl-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Derivatives%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group">Tanno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancuso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominici, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschella, G.</span><span> </span><span class="NLM_article-title">Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6772</span><span class="NLM_x">–</span> <span class="NLM_lpage">6780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-06-1479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17121898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1elsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6772-6780&author=B.+Tannoauthor=C.+Manciniauthor=R.+Vitaliauthor=M.+Mancusoauthor=H.+P.+McDowellauthor=C.+Dominiciauthor=G.+Raschella&title=Down-regulation+of+insulin-like+growth+factor+I+receptor+activity+by+NVP-AEW541+has+an+antitumor+effect+on+neuroblastoma+cells+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of insulin-like growth gactor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo</span></div><div class="casAuthors">Tanno, Barbara; Mancini, Camillo; Vitali, Roberta; Mancuso, Mariateresa; McDowell, Heather P.; Dominici, Carlo; Raschella, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6772-6780</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through insulin-like growth factor I receptor (IGF-IR) is important for growth and survival of many tumor types.  Neuroblastoma is sensitive to IGF.  We assessed the ability of NVP-AEW541, a recently developed small mol. that selectively inhibits IGF-IR activity, for neuroblastoma growth effects in vitro and in vivo.  The data showed that, in a panel of 10 neuroblastoma cell lines pos. for IGF-IR expression, NVP-AEW541 inhibited in vitro proliferation in a submicromolar/micromolar (0.4-6.8) range of concns.  As expected, NVP-AEW541 inhibited IGF-II-mediated stimulation of IGF-IR and Akt.  In addn. to growth inhibition, the drug also induced apoptosis in vitro.  Oral administration of NVP-AEW541 (50 mg/kg twice daily) inhibited tumor growth of neuroblastoma xenografts in nude mice.  Anal. of tumors from the drug-treated animals revealed a marked apoptotic pattern and a decrease in microvascularization compared with controls.  Interestingly, quant. real-time PCR detected both in vitro and in vivo a significant down-regulation of mRNA for vascular endothelial growth factor (VEGF) caused by NVP-AEW541.  In addn., in Matrigel-coated chambers and in severe combined immunodeficient mice tail vein injected with neuroblastoma cells, tumor invasiveness was significantly reduced by this agent.  Anal. of IGF-IR expression in a series of 43 neuroblastoma primary tumors revealed IGF-IR positivity in 86% of cases.  Taken together, these data indicate that NVP-AEW541 can be considered as a novel promising candidate for treatment of neuroblastoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_GfBCaanIDrVg90H21EOLACvtfcHk0liz6bnbdnK1Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1elsLzI&md5=b84ea9d198ce7f8ac18d2fb947eb46dd</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1479%26sid%3Dliteratum%253Aachs%26aulast%3DTanno%26aufirst%3DB.%26aulast%3DMancini%26aufirst%3DC.%26aulast%3DVitali%26aufirst%3DR.%26aulast%3DMancuso%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DH.%2BP.%26aulast%3DDominici%26aufirst%3DC.%26aulast%3DRaschella%26aufirst%3DG.%26atitle%3DDown-regulation%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520activity%2520by%2520NVP-AEW541%2520has%2520an%2520antitumor%2520effect%2520on%2520neuroblastoma%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6772%26epage%3D6780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group">Manara, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landuzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lollini, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotlandi, K.</span><span> </span><span class="NLM_article-title">Preclinical in vivo study of new insulin-like growth factor-I receptor—specific inhibitor in Ewing's sarcoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1322</span><span class="NLM_x">–</span> <span class="NLM_lpage">1330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-06-1518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17317844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1322-1330&author=M.+C.+Manaraauthor=L.+Landuzziauthor=P.+Nanniauthor=G.+Nicolettiauthor=D.+Zambelliauthor=P.+L.+Lolliniauthor=C.+Nanniauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=P.+Picciauthor=K.+Scotlandi&title=Preclinical+in+vivo+study+of+new+insulin-like+growth+factor-I+receptor%E2%80%94specific+inhibitor+in+Ewing%27s+sarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma</span></div><div class="casAuthors">Manara, Maria C.; Landuzzi, Lorena; Nanni, Patrizia; Nicoletti, Giordano; Zambelli, Diana; Lollini, Pier Luigi; Nanni, Cristina; Hofmann, Francesco; Garcia-Echeverria, Carlos; Picci, Piero; Scotlandi, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1322-1330</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Small-mol. insulin-like growth factor-I receptor (IGF-IR)-specific tyrosine kinase inhibitors have been recently proposed as clin. viable approaches to impair IGF-IR functions.  NVP-AEW541 seems one of the most promising agents.  In this article, we point out its effects against migration, metastasis, vasculogenicity, and angiogenesis of Ewing's sarcoma cells.  Exptl. Design: In vivo NVP-AEW541 effectiveness was analyzed against TC-71 Ewing's sarcoma growth and bone metastasis after cell inoculation in athymic mice.  Activity of the compd. against angiogenesis as well as vasculogenesis properties was also considered both in vitro and in xenografts.  Serum glucose, urea, transaminase levels, as well as other signs of distress were checked in mice treated with the IGF-IR inhibitor.  Results: Significant inhibition of migration, metastasis, vasculogenicity, and angiogenesis was recorded after treatment of Ewing's sarcoma cells with NVP-AEW541.  In view of its application and the similarity of insulin receptor and IGF-IR, diabetogenic side effects were considered.  We obsd. a significant decrease of glucose blood serum due to increased glucose uptake at cellular level and an increase in urea concn.  Moreover, an initial wt. loss was obsd. in mice bearing tumors.  All these side effects were similarly detected in mice treated with vincristine.  After the first days of treatment, all the animals started to grow again.  Conclusions: Our results globally reinforce the idea that IGF-IR inhibitor NVP-AEW541 could have a role in future combined therapies and suggest to pursue a thorough mol. anal. of the metabolic activity of IGF-IR to avoid possible side effects of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3OEZmWhDvprVg90H21EOLACvtfcHk0liz6bnbdnK1Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrc%253D&md5=8c6941407541059ab78d0ac91685c467</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1518%26sid%3Dliteratum%253Aachs%26aulast%3DManara%26aufirst%3DM.%2BC.%26aulast%3DLanduzzi%26aufirst%3DL.%26aulast%3DNanni%26aufirst%3DP.%26aulast%3DNicoletti%26aufirst%3DG.%26aulast%3DZambelli%26aufirst%3DD.%26aulast%3DLollini%26aufirst%3DP.%2BL.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DScotlandi%26aufirst%3DK.%26atitle%3DPreclinical%2520in%2520vivo%2520study%2520of%2520new%2520insulin-like%2520growth%2520factor-I%2520receptor%25E2%2580%2594specific%2520inhibitor%2520in%2520Ewing%2527s%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1322%26epage%3D1330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group">Tazzari, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabellini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelisti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grafone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, A. M.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">886</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=886-896&author=P.+L.+Tazzariauthor=G.+Tabelliniauthor=R.+Bortulauthor=V.+Papaauthor=C.+Evangelistiauthor=T.+Grafoneauthor=G.+Martinelliauthor=J.+A.+McCubreyauthor=A.+M.+Martelli&title=The+insulin-like+growth+factor-I+receptor+kinase+inhibitor+NVP-AEW541+induces+apoptosis+in+acute+myeloid+leukemia+cells+exhibiting+autocrine+insulin-like+growth+factor-I+secretion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTazzari%26aufirst%3DP.%2BL.%26aulast%3DTabellini%26aufirst%3DG.%26aulast%3DBortul%26aufirst%3DR.%26aulast%3DPapa%26aufirst%3DV.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DGrafone%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520NVP-AEW541%2520induces%2520apoptosis%2520in%2520acute%2520myeloid%2520leukemia%2520cells%2520exhibiting%2520autocrine%2520insulin-like%2520growth%2520factor-I%2520secretion%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D886%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garayoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandiella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, J. F.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1111%2Fj.1365-2141.2008.07049.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18341634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1eis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=470-482&author=P.+Maisoauthor=E.+M.+Ocioauthor=M.+Garayoaauthor=J.+C.+Monteroauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=J.+Zimmermannauthor=A.+Pandiellaauthor=J.+F.+San+Miguel&title=The+insulin-like+growth+factor-I+receptor+inhibitor+NVP-AEW541+provokes+cell+cycle+arrest+and+apoptosis+in+multiple+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</span></div><div class="casAuthors">Maiso, Patricia; Ocio, Enrique M.; Garayoa, Mercedes; Montero, Juan C.; Hofmann, Francesco; Garcia-Echeverria, Carlos; Zimmermann, Johann; Pandiella, Atanasio; San Miguel, Jesus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a B-cell malignancy characterized by accumulation of monoclonal plasma cells in the bone marrow (BM).  Despite recent advances in the treatment, MM represents an incurable disease for which development of new therapies is required.  We report the antimyeloma effect of NVP-AEW541, a small mol. that belongs to the pyrrolo[2,3-d]pyrimidine class, identified as a selective inhibitor of the insulin-like growth factor-I receptor (IGF-IR) in vitro kinase activity.  NVP-AEW541 had a potent cytotoxic effect on fresh cells and in a murine MM model.  NVP-AEW541 partially abrogated the proliferative advantage conferred by the coculture with BM stromal cells and the presence of growth factors produced by the BM microenvironment.  In addn., NVP-AEW541 potentiated the action of drugs, such as bortezomib, lenalidomide, dexamethasone or melphalan.  Moreover the triple combination of NVP-AEW541, dexamethasone and bortezomib resulted in a significant increase in growth inhibition.  Mechanistic studies indicated that NVP-AEW541 provoked a marked cell cycle blockade accompanied by pRb downregulation.  Interestingly, NVP-AEW541 increased the levels of p27 assocd. with a redn. in the CDK2 activity.  Finally, NVP-AEW541 induced cell death through caspase-dependent and -independent mechanisms.  All these data, suggest the potential effect of IGF-IR kinase inhibitors as therapeutic agents for MM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpl109zeOZrVg90H21EOLACvtfcHk0liiybHxINq7Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1eis7c%253D&md5=970e997f2c02e4f206a6738223366133</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07049.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07049.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DJ.%2BC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520inhibitor%2520NVP-AEW541%2520provokes%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D470%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group">Moser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schachtschneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlitt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeltzing, O.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1577</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=1577-1586&author=C.+Moserauthor=P.+Schachtschneiderauthor=S.+A.+Langauthor=A.+Gaumannauthor=A.+Moriauthor=J.+Zimmermannauthor=H.+J.+Schlittauthor=E.+K.+Geisslerauthor=O.+Stoeltzing&title=Inhibition+of+insulin-like+growth+factor-I+receptor+%28IGF-IR%29+using+NVP-AEW541%2C+a+small+molecule+kinase+inhibitor%2C+reduces+orthotopic+pancreatic+cancer+growth+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DC.%26aulast%3DSchachtschneider%26aufirst%3DP.%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DGaumann%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStoeltzing%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor-I%2520receptor%2520%2528IGF-IR%2529%2520using%2520NVP-AEW541%252C%2520a%2520small%2520molecule%2520kinase%2520inhibitor%252C%2520reduces%2520orthotopic%2520pancreatic%2520cancer%2520growth%2520and%2520angiogenesis%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D1577%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group">Piao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imsumran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-07-2395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18566219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1483-1493&author=W.+Piaoauthor=Y.+Wangauthor=Y.+Adachiauthor=H.+Yamamotoauthor=R.+Liauthor=A.+Imsumranauthor=H.+Liauthor=T.+Maehataauthor=M.+Iiauthor=Y.+Arimuraauthor=C.+T.+Leeauthor=Y.+Shinomuraauthor=D.+P.+Carboneauthor=K.+Imai&title=Insulin-like+growth+factor-I+receptor+blockade+by+a+specific+tyrosine+kinase+inhibitor+for+human+gastrointestinal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas</span></div><div class="casAuthors">Piao, Wenhua; Wang, Yu; Adachi, Yasushi; Yamamoto, Hiroyuki; Li, Rong; Imsumran, Arisa; Li, Hua; Maehata, Tadateru; Ii, Masanori; Arimura, Yoshiaki; Lee, Choon-Taek; Shinomura, Yasuhisa; Carbone, David P.; Imai, Kohzoh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1483-1493</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers.  In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas.  We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5.  The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts.  We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor.  NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin.  NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines.  The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility.  NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis.  Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice.  This compd. did not influence hybrid receptor formation.  Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PW2tBfNRSrVg90H21EOLACvtfcHk0liiybHxINq7Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSktL8%253D&md5=61b8dc8245368720b70fcd486e170bfb</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2395%26sid%3Dliteratum%253Aachs%26aulast%3DPiao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DImsumran%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMaehata%26aufirst%3DT.%26aulast%3DIi%26aufirst%3DM.%26aulast%3DArimura%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DC.%2BT.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DImai%26aufirst%3DK.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520blockade%2520by%2520a%2520specific%2520tyrosine%2520kinase%2520inhibitor%2520for%2520human%2520gastrointestinal%2520carcinomas%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1483%26epage%3D1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favelyukis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6−5 ring-fused compounds</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=145-154&author=W.+Liauthor=S.+Favelyukisauthor=J.+Yangauthor=Y.+Zengauthor=J.+Yuauthor=A.+Gangjeeauthor=W.+T.+Miller&title=Inhibition+of+insulin-like+growth+factor+I+receptor+autophosphorylation+by+novel+6%E2%88%925+ring-fused+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFavelyukis%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520autophosphorylation%2520by%2520novel%25206%25E2%2588%25925%2520ring-fused%2520compounds%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D145%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, S.</span><span> </span><span class="NLM_article-title">Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-<i>d</i>]pyrimidines as inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5155</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5155-5170&author=A.+Gangjeeauthor=J.+Yangauthor=M.+A.+Ihnatauthor=S.+Kamat&title=Antiangiogenic+and+antitumor+agents.+Design%2C+synthesis%2C+and+evaluation+of+novel+2-amino-4-%283-bromoanilino%29-6-benzylsubstituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKamat%26aufirst%3DS.%26atitle%3DAntiangiogenic%2520and%2520antitumor%2520agents.%2520Design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202-amino-4-%25283-bromoanilino%2529-6-benzylsubstituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5155%26epage%3D5170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesnitzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowand, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span> </span><span class="NLM_article-title">Optimization of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=360-364&author=S.+D.+Chamberlainauthor=A.+M.+Redmanauthor=J.+W.+Wilsonauthor=F.+Deandaauthor=J.+B.+Shotwellauthor=R.+Gerdingauthor=H.+Leiauthor=B.+Yangauthor=K.+L.+Stevensauthor=A.+M.+Hassellauthor=L.+M.+Shewchukauthor=M.+A.+Leesnitzerauthor=J.+L.+Smithauthor=P.+Sabbatiniauthor=C.+Atkinsauthor=A.+Groyauthor=J.+L.+Rowandauthor=R.+Kumarauthor=R.+A.+Mookauthor=G.+Moorthyauthor=S.+Patnaik&title=Optimization+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidine+IGF-1R+tyrosine+kinase+inhibitors+towards+JNK+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DLeesnitzer%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DPatnaik%26aufirst%3DS.%26atitle%3DOptimization%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520IGF-1R%2520tyrosine%2520kinase%2520inhibitors%2520towards%2520JNK%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D360%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickhouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brad, S. J.</span><span> </span><span class="NLM_article-title">Optimization of a series of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=373-377&author=S.+D.+Chamberlainauthor=A.+M.+Redmanauthor=S.+Patnaikauthor=K.+Brickhouseauthor=Y.+C.+Chewauthor=F.+Deandaauthor=R.+Gerdingauthor=H.+Leiauthor=G.+Moorthyauthor=M.+Patrickauthor=K.+L.+Stevensauthor=J.+W.+Wilsonauthor=S.+J.+Brad&title=Optimization+of+a+series+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidine+inhibitors+of+IGF-1R%3A+elimination+of+an+acid-mediated+decomposition+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DPatnaik%26aufirst%3DS.%26aulast%3DBrickhouse%26aufirst%3DK.%26aulast%3DChew%26aufirst%3DY.%2BC.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DPatrick%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DBrad%26aufirst%3DS.%2BJ.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520inhibitors%2520of%2520IGF-1R%253A%2520elimination%2520of%2520an%2520acid-mediated%2520decomposition%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D373%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesnitzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowand, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=469-473&author=S.+D.+Chamberlainauthor=J.+W.+Wilsonauthor=F.+Deandaauthor=S.+Patnaikauthor=A.+M.+Redmanauthor=B.+Yangauthor=L.+Shewchukauthor=P.+Sabbatiniauthor=M.+A.+Leesnitzerauthor=A.+Groyauthor=C.+Atkinsauthor=R.+Gerdingauthor=A.+M.+Hassellauthor=H.+Leiauthor=R.+A.+Mookauthor=G.+Moorthyauthor=J.+L.+Rowandauthor=K.+L.+Stevensauthor=R.+Kumarauthor=J.+B.+Shotwell&title=Discovery+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidines%3A+potent+inhibitors+of+the+IGF-1R+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DPatnaik%26aufirst%3DS.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DLeesnitzer%26aufirst%3DM.%2BA.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidines%253A%2520potent%2520inhibitors%2520of%2520the%2520IGF-1R%2520receptor%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D469%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eummer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frennesson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnananthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery of a (1<i>H</i>-benzoimidazol-2-yl)-1<i>H</i>-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5639</span><span class="NLM_x">–</span> <span class="NLM_lpage">5643</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050392q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5639-5643&author=M.+Wittmanauthor=J.+Carboniauthor=R.+Attarauthor=B.+Balasubramanianauthor=P.+Balimaneauthor=P.+Brassilauthor=F.+Beaulieuauthor=C.+Changauthor=W.+Clarkeauthor=J.+Dellauthor=J.+Eummerauthor=D.+Frennessonauthor=M.+Gottardisauthor=A.+Greerauthor=S.+Hanselauthor=W.+Hurlburtauthor=B.+Jacobsonauthor=S.+Krishnananthanauthor=F.+Y.+Leeauthor=A.+Liauthor=T.+A.+Linauthor=P.+Liuauthor=C.+Ouelletauthor=X.+Sangauthor=M.+G.+Saulnierauthor=K.+Stoffanauthor=Y.+Sunauthor=U.+Velaparthiauthor=H.+Wongauthor=Z.+Yangauthor=K.+Zimmermannauthor=M.+Zoecklerauthor=D.+Vyas&title=Discovery+of+a+%281H-benzoimidazol-2-yl%29-1H-pyridin-2-one+%28BMS-536924%29+inhibitor+of+insulin-like+growth+factor+I+receptor+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1021%2Fjm050392q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050392q%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBeaulieu%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DDell%26aufirst%3DJ.%26aulast%3DEummer%26aufirst%3DJ.%26aulast%3DFrennesson%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHansel%26aufirst%3DS.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DT.%2BA.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520%25281H-benzoimidazol-2-yl%2529-1H-pyridin-2-one%2520%2528BMS-536924%2529%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5639%26epage%3D5643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group">Wittman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnanathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span> </span><span class="NLM_article-title">Novel 1<i>H</i>-(benzimidazol-2-yl)-1<i>H</i>-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=974-977&author=M.+D.+Wittmanauthor=B.+Balasubramanianauthor=K.+Stoffanauthor=U.+Velaparthiauthor=P.+Liuauthor=S.+Krishnanathanauthor=J.+Carboniauthor=A.+Liauthor=A.+Greerauthor=R.+Attarauthor=M.+Gottardisauthor=C.+Changauthor=B.+Jacobsonauthor=Y.+Sunauthor=S.+Hanselauthor=M.+Zoecklerauthor=D.+M.+Vyas&title=Novel+1H-%28benzimidazol-2-yl%29-1H-pyridin-2-one+inhibitors+of+insulin-like+growth+factor+I+%28IGF-1R%29+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DKrishnanathan%26aufirst%3DS.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHansel%26aufirst%3DS.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26atitle%3DNovel%25201H-%2528benzimidazol-2-yl%2529-1H-pyridin-2-one%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520I%2520%2528IGF-1R%2529%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D974%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of 3-(1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2317</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2317-2321&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=K.+Stoffanauthor=K.+Zimmermannauthor=X.+Sangauthor=J.+Carboniauthor=A.+Liauthor=R.+Attarauthor=M.+Gottardisauthor=A.+Greerauthor=C.+Y.+Changauthor=B.+L.+Jacobsenauthor=J.+S.+Sackauthor=Y.+Sunauthor=D.+R.+Langleyauthor=B.+Balasubramanianauthor=D.+Vyas&title=Discovery+and+initial+SAR+of+3-%281H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-ones+as+inhibitors+of+insulin-like+growth+factor+1-receptor+%28IGF-1R%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DJacobsen%26aufirst%3DB.%2BL.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%25203-%25281H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-ones%2520as%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%25201-receptor%2520%2528IGF-1R%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2317%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Imidazole moiety replacements in the 3-(1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3072</span><span class="NLM_x">–</span> <span class="NLM_lpage">3076</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3072-3076&author=U.+Velaparthiauthor=P.+Liuauthor=B.+Balasubramanianauthor=J.+Carboniauthor=R.+Attarauthor=M.+Gottardisauthor=A.+Liauthor=A.+Greerauthor=M.+Zoecklerauthor=M.+D.+Wittmanauthor=D.+Vyas&title=Imidazole+moiety+replacements+in+the+3-%281H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+inhibitors+of+insulin-like+growth+factor+receptor-1+%28IGF-1R%29+to+improve+cytochrome+P450+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DImidazole%2520moiety%2520replacements%2520in%2520the%25203-%25281H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor-1%2520%2528IGF-1R%2529%2520to%2520improve%2520cytochrome%2520P450%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3072%26epage%3D3076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperid in-4-yl)-4-methyl-1<i>H</i>-benzo[d]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5897</span><span class="NLM_x">–</span> <span class="NLM_lpage">5900</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperid+in-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperid%2520in-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5897%26epage%3D5900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesario, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saroglou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sujka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkes, R.</span><span> </span><span class="NLM_article-title">1,3-Disubstituted-imidazo[1,5-<i>a</i>]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1091-1097&author=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=D.+Wernerauthor=P.+Beckauthor=C.+Cesarioauthor=A.+Cookeauthor=M.+Coxauthor=A.+Crewauthor=H.+Dongauthor=L.+Fengauthor=K.+W.+Foremanauthor=G.+Makauthor=A.+Nigroauthor=M.+O%27Connorauthor=L.+Saroglouauthor=K.+M.+Stolzauthor=I.+Sujkaauthor=B.+Volkauthor=Q.+Wengauthor=R.+Wilkes&title=1%2C3-Disubstituted-imidazo%5B1%2C5-a%5Dpyrazines+as+insulin-like+growth-factor-I+receptor+%28IGF-IR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DWerner%26aufirst%3DD.%26aulast%3DBeck%26aufirst%3DP.%26aulast%3DCesario%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DCox%26aufirst%3DM.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DForeman%26aufirst%3DK.%2BW.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DNigro%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DSaroglou%26aufirst%3DL.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DSujka%26aufirst%3DI.%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DWeng%26aufirst%3DQ.%26aulast%3DWilkes%26aufirst%3DR.%26atitle%3D1%252C3-Disubstituted-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520insulin-like%2520growth-factor-I%2520receptor%2520%2528IGF-IR%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1091%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group">Volk, B.; Mulvihill, M. J.; Buck, E.; Cooke, A.; Crew, A.; Dong, H.; Eyzaguirre, A.; Franklin, M.; Feng, L.; Foreman, K. W.; Ji, Q.-S.; Landfair, D.; Mao, Y.; O'Connor, M.; Pirritt, C.; Silva, S.; Siu, K.; Steinig, A.; Stolz, K.; Tavares, P.; Werner, D.</span><span> </span><span class="NLM_article-title">Identification of Clinical Candidate OSI-906 as a Potent, Selective and Orally Bioavailable IGF-1R Inhibitor</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 40th Middle Atlantic Regional Meeting of the American Chemical Society,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>MRM-313, p  <span class="NLM_fpage">313</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=313&author=B.+Volk&author=M.+J.+Mulvihill&author=E.+Buck&author=A.+Cooke&author=A.+Crew&author=H.+Dong&author=A.+Eyzaguirre&author=M.+Franklin&author=L.+Feng&author=K.+W.+Foreman&author=Q.-S.+Ji&author=D.+Landfair&author=Y.+Mao&author=M.+O%27Connor&author=C.+Pirritt&author=S.+Silva&author=K.+Siu&author=A.+Steinig&author=K.+Stolz&author=P.+Tavares&author=D.+Werner&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520Clinical%2520Candidate%2520OSI-906%2520as%2520a%2520Potent%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520IGF-1R%2520Inhibitor%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2008%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2008%26spage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1985</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1985-1994&author=J.+Wuauthor=W.+Liauthor=B.+P.+Craddockauthor=K.+W.+Foremanauthor=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=W.+T.+Millerauthor=S.+R.+Hubbard&title=Small-molecule+inhibition+and+activation-loop+trans-phosphorylation+of+the+IGF1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DCraddock%26aufirst%3DB.%2BP.%26aulast%3DForeman%26aufirst%3DK.%2BW.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DSmall-molecule%2520inhibition%2520and%2520activation-loop%2520trans-phosphorylation%2520of%2520the%2520IGF1%2520receptor%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1985%26epage%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld-Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigro, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirrit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinig, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-<i>a</i>]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1359-1375&author=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=H.+R.+Coateauthor=A.+Cookeauthor=H.+Dongauthor=L.+Fengauthor=K.+Foremanauthor=M.+Rosenfeld-Franklinauthor=A.+Hondaauthor=G.+Makauthor=K.+M.+Mulvihillauthor=A.+I.+Nigroauthor=M.+O%27Connorauthor=C.+Pirritauthor=A.+G.+Steinigauthor=K.+Siuauthor=K.+M.+Stolzauthor=Y.+Sunauthor=P.+A.+Tavaresauthor=Y.+Yaoauthor=N.+W.+Gibson&title=Novel+2-phenylquinolin-7-yl-derived+imidazo%5B1%2C5-a%5Dpyrazines+as+potent+insulin-like+growth+factor-I+receptor+%28IGF-IR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DCoate%26aufirst%3DH.%2BR.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DHonda%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DMulvihill%26aufirst%3DK.%2BM.%26aulast%3DNigro%26aufirst%3DA.%2BI.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DPirrit%26aufirst%3DC.%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTavares%26aufirst%3DP.%2BA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DNovel%25202-phenylquinolin-7-yl-derived%2520imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520potent%2520insulin-like%2520growth%2520factor-I%2520receptor%2520%2528IGF-IR%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D1359%26epage%3D1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group">Bandiera, T.; Perrone, E.; Lombardi Borgia, A.; Varasi, M.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo[4,3-<i>c</i>]pyridine Derivatives as IGF-1R Inhibitors</span>. PCT Int. Appl. WO 2007099166,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=E.+Perrone&author=A.+Lombardi+Borgia&author=M.+Varasi&title=Preparation+of+Pyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+IGF-1R+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Pyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520IGF-1R%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group">Bandiera, T.; Lombardi Borgia, A.; Polucci, P.; Villa, M.; Nesi, M.; Angiolini, M.; Varasi, M.</span><span> </span><span class="NLM_article-title">Substituted Pyrazolo[4,3-<i>c</i>]pyridine Derivatives as Tyrosine Kinase Inhibitors, Particularly IGF-1R Inhibitors, Their Preparation, Pharmaceutical Compositions, and Use in Therapy</span>. PCT Int. Appl. WO 2007068619,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=A.+Lombardi+Borgia&author=P.+Polucci&author=M.+Villa&author=M.+Nesi&author=M.+Angiolini&author=M.+Varasi&title=Substituted+Pyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+Tyrosine+Kinase+Inhibitors%2C+Particularly+IGF-1R+Inhibitors%2C+Their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Use+in+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DSubstituted%2520Pyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520Tyrosine%2520Kinase%2520Inhibitors%252C%2520Particularly%2520IGF-1R%2520Inhibitors%252C%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Use%2520in%2520Therapy%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group">Bandiera, T.; Bertrand, J. A.; Pevarello, P.; Perrone, E.; Lombardi Borgia, A.; Orrenius, S. C.; Angiolini, M.; Fancelli, D.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolo[3,4-<i>c</i>]pyrazole Derivatives as IGF-1R Inhibitors</span>. PCT Int. Appl. WO 2007099171,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=J.+A.+Bertrand&author=P.+Pevarello&author=E.+Perrone&author=A.+Lombardi+Borgia&author=S.+C.+Orrenius&author=M.+Angiolini&author=D.+Fancelli&title=Preparation+of+Pyrrolo%5B3%2C4-c%5Dpyrazole+Derivatives+as+IGF-1R+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Pyrrolo%255B3%252C4-c%255Dpyrazole%2520Derivatives%2520as%2520IGF-1R%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermakova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogozin, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">598</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=598-605&author=M.+Liauthor=Z.+Heauthor=S.+Ermakovaauthor=D.+Zhengauthor=F.+Tangauthor=Y.+Y.+Choauthor=F.+Zhuauthor=W.+Y.+Maauthor=Y.+Shamauthor=E.+A.+Rogozinauthor=A.+M.+Bodeauthor=Y.+Caoauthor=Z.+Dong&title=Direct+inhibition+of+insulin-like+growth+factor-I+receptor+kinase+activity+by+%28%E2%88%92%29-epigallocatechin-3-gallate+regulates+cell+transformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DErmakova%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DY.%2BY.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DW.%2BY.%26aulast%3DSham%26aufirst%3DY.%26aulast%3DRogozin%26aufirst%3DE.%2BA.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DDirect%2520inhibition%2520of%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520activity%2520by%2520%2528%25E2%2588%2592%2529-epigallocatechin-3-gallate%2520regulates%2520cell%2520transformation%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2007%26volume%3D16%26spage%3D598%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kett, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quigley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxman, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zartman, C. B.</span><span> </span><span class="NLM_article-title">Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">9430</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0500628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=9430-9440&author=I.+M.+Bellauthor=S.+M.+Stirdivantauthor=J.+Ahernauthor=J.+C.+Culbersonauthor=P.+L.+Darkeauthor=C.+J.+Dinsmoreauthor=R.+A.+Drakasauthor=S.+N.+Gallicchioauthor=S.+L.+Grahamauthor=D.+C.+Heimbrookauthor=D.+L.+Hallauthor=J.+Huaauthor=N.+R.+Kettauthor=A.+S.+Kimauthor=M.+Kornienkoauthor=L.+C.+Kuoauthor=S.+K.+Munshiauthor=A.+G.+Quigleyauthor=J.+C.+Reidauthor=B.+W.+Trotterauthor=L.+H.+Waxmanauthor=T.+M.+Williamsauthor=C.+B.+Zartman&title=Biochemical+and+structural+characterization+of+a+novel+class+of+inhibitors+of+the+type+1+insulin-like+growth+factor+and+insulin+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fbi0500628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0500628%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DAhern%26aufirst%3DJ.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DWaxman%26aufirst%3DL.%2BH.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26atitle%3DBiochemical%2520and%2520structural%2520characterization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520and%2520insulin%2520receptor%2520kinases%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D9430%26epage%3D9440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group">Miller, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.bmcl.2008.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19041240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvF2h" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=62-66&author=L.+M.+Millerauthor=S.+C.+Mayerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=F.+Boschelliauthor=L.+Diauthor=X.+Duauthor=M.+Dutiaauthor=M.+B.+Floydauthor=M.+Johnsonauthor=C.+H.+Kennyauthor=G.+Krishnamurthyauthor=F.+Moyauthor=S.+Petuskyauthor=D.+Tkachauthor=N.+Torresauthor=B.+Wuauthor=W.+Xu&title=Lead+identification+to+generate+3-cyanoquinoline+inhibitors+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+for+potential+use+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span></div><div class="casAuthors">Miller, Lori M.; Mayer, Scott C.; Berger, Dan M.; Boschelli, Diane H.; Boschelli, Frank; Di, Li; Du, Xuemei; Dutia, Minu; Floyd, Middleton B.; Johnson, Mark; Kenny, Cynthia Hess; Krishnamurthy, Girija; Moy, Franklin; Petusky, Susan; Tkach, Diane; Torres, Nancy; Wu, Biqi; Xu, Weixin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-66</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a crit. mediator of cell proliferation and survival.  Inhibitors of this receptor are believed to provide a new target in cancer therapy.  We previously reported an isoquinolinedione series of IGF-1R inhibitors.  Now we have identified a series of 3-cyanoquinoline compds. that are low nanomolar inhibitors of IGF-1R.  The strategies, synthesis, and SAR behind the cyanoquinoline scaffold will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoDq9AfF4LrVg90H21EOLACvtfcHk0liraFazwdO8fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvF2h&md5=71e5721385a22c44586f9e86841c7d2a</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BM.%26aulast%3DMayer%26aufirst%3DS.%2BC.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKenny%26aufirst%3DC.%2BH.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DMoy%26aufirst%3DF.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DLead%2520identification%2520to%2520generate%25203-cyanoquinoline%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520for%2520potential%2520use%2520in%2520cancer%2520treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D62%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group">Mayer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutterer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3641</span><span class="NLM_x">–</span> <span class="NLM_lpage">3645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.bmcl.2008.04.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18501599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3641-3645&author=S.+C.+Mayerauthor=A.+L.+Bankerauthor=F.+Boschelliauthor=L.+Diauthor=M.+Johnsonauthor=C.+H.+Kennyauthor=G.+Krishnamurthyauthor=K.+Kuttererauthor=F.+Moyauthor=S.+Petuskyauthor=M.+Raviauthor=D.+Tkachauthor=H.+R.+Tsouauthor=W.+Xu&title=Lead+identification+to+generate+isoquinolinedione+inhibitors+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+for+potential+use+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span></div><div class="casAuthors">Mayer, Scott C.; Banker, Annette L.; Boschelli, Frank; Di, Li; Johnson, Mark; Kenny, Cynthia Hess; Krishnamurthy, Girija; Kutterer, Kristina; Moy, Franklin; Petusky, Susan; Ravi, Malini; Tkach, Diane; Tsou, Hwei-Ru; Xu, Weixin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3641-3645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a crit. mediator of cell proliferation and survival.  This receptor is over-expressed or activated in tumor cells and is emerging as a novel target in cancer therapy.  Efforts in our "Hit to Lead" group have generated a novel series of submicromolar IGF-1R inhibitors based on a isoquinolinedione template originating from a Lance enzyme HTS screen.  Chem. triage and parallel synthesis incorporating focused library arrays were instrumental in moving these investigations through the Wyeth exploratory medicinal chem. process.  The strategies, synthesis, and SAR behind this interesting kinase scaffold will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRW-BDE6Ykw7Vg90H21EOLACvtfcHk0liraFazwdO8fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFSntbw%253D&md5=0784e3b99a08161dec437f7ef0ee456f</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.044%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DS.%2BC.%26aulast%3DBanker%26aufirst%3DA.%2BL.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKenny%26aufirst%3DC.%2BH.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DKutterer%26aufirst%3DK.%26aulast%3DMoy%26aufirst%3DF.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DRavi%26aufirst%3DM.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DLead%2520identification%2520to%2520generate%2520isoquinolinedione%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520for%2520potential%2520use%2520in%2520cancer%2520treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3641%26epage%3D3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolazzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span> </span><span class="NLM_article-title">Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-03-2522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14729630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslyltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=236-242&author=A.+Girnitaauthor=L.+Girnitaauthor=P.+F.+delauthor=A.+Bartolazziauthor=O.+Larssonauthor=M.+Axelson&title=Cyclolignans+as+inhibitors+of+the+insulin-like+growth+factor-1+receptor+and+malignant+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth</span></div><div class="casAuthors">Girnita, Ada; Girnita, Leonard; Del Prete, Fabrizio; Bartolazzi, Armando; Larsson, Olle; Axelson, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-1 receptor (IGF-1R) plays a pivotal role in transformation, growth, and survival of malignant cells, and has emerged as a general and promising target for cancer treatment.  However, no fully selective IGF-1R inhibitors have thus far been found.  This is explained by the fact that IGF-1R is highly homologous to the insulin receptor, coinhibition of which may cause diabetic response.  The receptors are both tyrosine kinases, and their ATP binding sites are identical, implying that ATP inhibitors cannot discriminate between them.  Therefore, the current strategy has been to identify compds. interfering with receptor autophosphorylation at the substrate level.  In this study we investigated the effects of cyclolignans and related mols. on IGF-1R activity.  We report that certain cyclolignans are potent and selective inhibitors of tyrosine phosphorylation of the IGF-1R.  Of particular interest was picropodophyllin (PPP), which is almost nontoxic (LD50 >500 mg/kg in rodents).  PPP efficiently blocked IGF-1R activity, reduced pAkt and phosphorylated extracellular signal regulated kinase 1 and 2 (pErk1/2), induced apoptosis in cultured IGF-1R-pos. tumor cells, and caused complete tumor regression in xenografted and allografted mice.  PPP did not affect the insulin receptor or compete with ATP in an in vitro kinase assay, suggesting that it may inhibit IGF-1R autophosphorylation at the substrate level.  This is also in agreement with our mol. model of how the cyclolignans may act on the IGF-1R kinase.  Our results open the possibility to use PPP or related compds. with inhibitory effects on IGF-1R as lead compds. in development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvDfY_KrOXw7Vg90H21EOLACvtfcHk0liraFazwdO8fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslyltA%253D%253D&md5=4008ab5c134757fea02a17b0ccc761d2</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2522%26sid%3Dliteratum%253Aachs%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DGirnita%26aufirst%3DL.%26aulast%3Ddel%26aufirst%3DP.%2BF.%26aulast%3DBartolazzi%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DAxelson%26aufirst%3DM.%26atitle%3DCyclolignans%2520as%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520and%2520malignant%2520cell%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D236%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group">Vasilcanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lui, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilcanu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3186</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=3186-3195&author=D.+Vasilcanuauthor=W.+H.+Wengauthor=A.+Girnitaauthor=W.+O.+Luiauthor=R.+Vasilcanuauthor=M.+Axelsonauthor=O.+Larssonauthor=C.+Larssonauthor=L.+Girnita&title=The+insulin-like+growth+factor-1+receptor+inhibitor+PPP+produces+only+very+limited+resistance+in+tumor+cells+exposed+to+long-term+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVasilcanu%26aufirst%3DD.%26aulast%3DWeng%26aufirst%3DW.%2BH.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DLui%26aufirst%3DW.%2BO.%26aulast%3DVasilcanu%26aufirst%3DR.%26aulast%3DAxelson%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DLarsson%26aufirst%3DC.%26aulast%3DGirnita%26aufirst%3DL.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-1%2520receptor%2520inhibitor%2520PPP%2520produces%2520only%2520very%2520limited%2520resistance%2520in%2520tumor%2520cells%2520exposed%2520to%2520long-term%2520selection%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D3186%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group">Vasilcanu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilcanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalishvili, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1629</span><span class="NLM_x">–</span> <span class="NLM_lpage">1638</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1629-1638&author=R.+Vasilcanuauthor=D.+Vasilcanuauthor=L.+Rosengrenauthor=N.+Natalishviliauthor=B.+Sehatauthor=S.+Yinauthor=A.+Girnitaauthor=M.+Axelsonauthor=L.+Girnitaauthor=O.+Larsson&title=Picropodophyllin+induces+downregulation+of+the+insulin-like+growth+factor+1+receptor%3A+potential+mechanistic+involvement+of+Mdm2+and+beta-arrestin1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVasilcanu%26aufirst%3DR.%26aulast%3DVasilcanu%26aufirst%3DD.%26aulast%3DRosengren%26aufirst%3DL.%26aulast%3DNatalishvili%26aufirst%3DN.%26aulast%3DSehat%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DAxelson%26aufirst%3DM.%26aulast%3DGirnita%26aufirst%3DL.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DPicropodophyllin%2520induces%2520downregulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%253A%2520potential%2520mechanistic%2520involvement%2520of%2520Mdm2%2520and%2520beta-arrestin1%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D1629%26epage%3D1638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor as a target for cancer therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F14728222.9.4.753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16083341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFels7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=753-768&author=R.+Baserga&title=The+insulin-like+growth+factor-I+receptor+as+a+target+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I receptor as a target for cancer therapy</span></div><div class="casAuthors">Baserga, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">This review examines the rationale for targeting the insulin-like growth factor (IGF)-I receptor in the therapy of human tumors and their metastases.  The rationale is based on two crucial findings: (1) in exptl. animals, normal cells are only partially affected by the deletion of the IGF-I receptor, whereas tumor cells undergo apoptosis when the IGF-I receptor is downregulated; and (2) cells with a deleted IGF-I receptor are refractory to transformation by viral and cellular oncogenes.  This review focuses on the mechanisms underlying the exptl. findings, and discusses the possibility of extrapolating the results obtained in animals to the cure of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpjOKN3IsjbVg90H21EOLACvtfcHk0lh6AFXlJ5DdCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFels7w%253D&md5=f07d91258f90130e9cb023e9d7a79e03</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.4.753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.4.753%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26spage%3D753%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Substrate competitive inhibitors of IGF-1 receptor kinase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">15705</span><span class="NLM_x">–</span> <span class="NLM_lpage">15712</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi001516y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=15705-15712&author=G.+Blumauthor=A.+Gazitauthor=A.+Levitzki&title=Substrate+competitive+inhibitors+of+IGF-1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1021%2Fbi001516y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi001516y%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DSubstrate%2520competitive%2520inhibitors%2520of%2520IGF-1%2520receptor%2520kinase%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D15705%26epage%3D15712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">40442</span><span class="NLM_x">–</span> <span class="NLM_lpage">40454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=40442-40454&author=G.+Blumauthor=A.+Gazitauthor=A.+Levitzki&title=Development+of+new+insulin-like+growth+factor-1+receptor+kinase+inhibitors+using+catechol+mimics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520new%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520inhibitors%2520using%2520catechol%2520mimics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D40442%26epage%3D40454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group">Steiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedmann, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">562</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ejphar.2007.01.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17376430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjslSksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=562&publication_year=2007&pages=1-11&author=L.+Steinerauthor=G.+Blumauthor=Y.+Friedmannauthor=A.+Levitzki&title=ATP+non-competitive+IGF-1+receptor+kinase+inhibitors+as+lead+anti-neoplastic+and+anti-papilloma+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents</span></div><div class="casAuthors">Steiner, Lilach; Blum, Galia; Friedmann, Yael; Levitzki, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">562</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The insulin-like growth factor-1 receptor (IGF-1 receptor) is a receptor tyrosine kinase, highly homologous to the insulin receptor.  In contrast to the insulin receptor, which is mostly involved in metabolic pathways, the IGF-1 system plays a pivotal role in normal and neoplastic cell growth through anti-apoptotic, proliferative and metastatic pathways.  Furthermore, IGF-1 receptor over-activation is found to correlate with a variety of tumors, such as breast cancer, prostate cancer, hematol. malignancies, colorectal cancer and other proliferative diseases, such as psoriasis and papilloma.  In addn., accumulating evidence implies that blockade of IGF-1 receptor activity causes reversal of tumor progression in cell lines as well as in animal tumor models.  Because of the central role the IGF-1 receptor plays in oncogenic maintenance and metastatic processes, it is a highly appropriate target for anti-cancer agents.  Here we report on a novel substrate-mimic family of IGF-1 receptor inhibitors.  These compds. are tertiary arom. amines, non-competitive with ATP and possess high affinity towards the IGF-1 receptor.  The most potent compd., SBL02 inhibited the IGF-1 receptor with an IC50 of 170 nM in a cell-free kinase assay and was found to inhibit IGF-1 receptor auto-phosphorylation and substrate phosphorylation at the low micromolar range in cellular assays.  SBL02 also blocks the formation of colonies in soft agar by cancer cells and inhibits the growth of keratinocytes and of HPV16 immortalized keratinocytes.  This new family of non-ATP competitive, IGF-1 receptor inhibitors can serve as a lead for the development of anti-cancer, anti-psoriatic and anti-papilloma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE62emXLYfP7Vg90H21EOLACvtfcHk0lh6AFXlJ5DdCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjslSksLc%253D&md5=ef00cdacf5de58a183641e5d32dd6cc2</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DFriedmann%26aufirst%3DY.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DATP%2520non-competitive%2520IGF-1%2520receptor%2520kinase%2520inhibitors%2520as%2520lead%2520anti-neoplastic%2520and%2520anti-papilloma%2520agents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D562%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group">Gable, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schow, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span> </span><span class="NLM_article-title">Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-05-0397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16648580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1079-1086&author=K.+L.+Gableauthor=B.+A.+Madduxauthor=C.+Penarandaauthor=M.+Zavodovskayaauthor=M.+J.+Campbellauthor=M.+Loboauthor=L.+Robinsonauthor=S.+Schowauthor=J.+A.+Kernerauthor=I.+D.+Goldfineauthor=J.+F.+Youngren&title=Diarylureas+are+small-molecule+inhibitors+of+insulin-like+growth+factor+I+receptor+signaling+and+breast+cancer+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth</span></div><div class="casAuthors">Gable, Karissa L.; Maddux, Betty A.; Penaranda, Cristina; Zavodovskaya, Marianna; Campbell, Michael J.; Lobo, Margaret; Robinson, Louise; Schow, Steven; Kerner, John A.; Goldfine, Ira D.; Youngren, Jack F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1079-1086</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In breast and certain other cancers, receptor tyrosine kinases, including the insulin-like growth factor I receptor (IGF-IR), play an important role in promoting the oncogenic process.  The IGF-IR is therefore an important target for developing new anti-breast cancer therapies.  An initial screening of a chem. library against the IGF-IR in breast cancer cells identified a diaryl urea compd. as a potent inhibitor of IGF-IR signaling.  This class of compds. has not been studied as inhibitors of the IGF-IR.  We studied the effectiveness of one diaryl urea compd., PQ401, at antagonizing IGF-IR signaling and inhibiting breast cancer cell growth in culture and in vivo.  PQ401 inhibited autophosphorylation of the IGF-IR in cultured human MCF-7 cells with an IC50 of 12 μmol/L and autophosphorylation of the isolated kinase domain of the IGF-IR with an IC50 <1 μmol/L.  In addn., PQ401 inhibited the growth of cultured breast cancer cells in serum at 10 μmol/L.  PQ401 was even more effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μmol/L).  Treatment of MCF-7 cells with PQ401 was assocd. with a decrease in IGF-I-mediated signaling through the Akt antiapoptotic pathway.  Twenty-four hours of treatment with 15 μmol/L PQ401 induced caspase-mediated apoptosis.  In vivo, treatment with PQ401 (i.p. injection thrice a week) reduced the growth rate of MCNeuA cells implanted into mice.  These studies indicate that diaryl urea compds. are potential new agents to test in the treatment of breast and other IGF-I-sensitive cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXFuJfg99m7Vg90H21EOLACvtfcHk0liZrKYHjm-5Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksb4%253D&md5=93934fa4704b46bb1a7734fae8be5b46</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0397%26sid%3Dliteratum%253Aachs%26aulast%3DGable%26aufirst%3DK.%2BL.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26aulast%3DLobo%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DSchow%26aufirst%3DS.%26aulast%3DKerner%26aufirst%3DJ.%2BA.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26atitle%3DDiarylureas%2520are%2520small-molecule%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520signaling%2520and%2520breast%2520cancer%2520cell%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1079%26epage%3D1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0liZrKYHjm-5Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitfelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span> </span><span class="NLM_article-title">Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2994</span><span class="NLM_x">–</span> <span class="NLM_lpage">3008</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020057r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFagt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2994-3008&author=J.+Reganauthor=S.+Breitfelderauthor=P.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=B.+Klausauthor=J.+Madwedauthor=M.+Moriakauthor=N.+Mossauthor=C.+Pargellisauthor=S.+Pavauthor=A.+Protoauthor=A.+Swinamerauthor=L.+Tongauthor=C.+Torcellini&title=Pyrazole+urea-based+inhibitors+of+p38+MAP+kinase%3A+from+lead+compound+to+clinical+candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate</span></div><div class="casAuthors">Regan, John; Breitfelder, Steffen; Cirillo, Pier; Gilmore, Thomas; Graham, Anne G.; Hickey, Eugene; Klaus, Bernhard; Madwed, Jeffrey; Moriak, Monica; Moss, Neil; Pargellis, Chris; Pav, Sue; Proto, Alfred; Swinamer, Alan; Tong, Liang; Torcellini, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2994-3008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase.  Importantly, a key binding domain that is distinct from the ATP (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein.  We describe the correlation of the structure-activity relationships and crystallog. structures of these inhibitors with p38.  In addn., we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site.  This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of Compd. 45 (BIRB 796) as a clin. candidate for the treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotOOfLV3xRbVg90H21EOLACvtfcHk0lhNWPjNaUm7YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFagt7k%253D&md5=e473f514179c8fe24ab3efccc292b6c6</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1021%2Fjm020057r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020057r%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DBreitfelder%26aufirst%3DS.%26aulast%3DCirillo%26aufirst%3DP.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKlaus%26aufirst%3DB.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTorcellini%26aufirst%3DC.%26atitle%3DPyrazole%2520urea-based%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%253A%2520from%2520lead%2520compound%2520to%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2994%26epage%3D3008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17308062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=667-674&author=R.+Nahtaauthor=L.+X.+Yuanauthor=Y.+Duauthor=F.+J.+Esteva&title=Lapatinib+induces+apoptosis+in+trastuzumab-resistant+breast+cancer+cells%3A+effects+on+insulin-like+growth+factor+I+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling</span></div><div class="casAuthors">Nahta, Rita; Yuan, Linda X. H.; Du, Yi; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">667-674</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of breast cancer patients who achieve an initial therapeutic response to the HER2-targeted antibody trastuzumab will show disease progression within 1 yr.  Thus, the identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab is crit.  In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.  Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase, and S6 kinases and inducing expression of p27kip1.  Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody αIR3.  As increased IGF-I receptor signaling has been implicated in trastuzumab resistance, our data strongly support further study of lapatinib as a potential therapeutic in breast cancers that have progressed on trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgA2XSBOQGErVg90H21EOLACvtfcHk0lhNWPjNaUm7YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWrsbc%253D&md5=4bee464a1d992a25a4c5f832cb4b0086</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0423%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DL.%2BX.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DLapatinib%2520induces%2520apoptosis%2520in%2520trastuzumab-resistant%2520breast%2520cancer%2520cells%253A%2520effects%2520on%2520insulin-like%2520growth%2520factor%2520I%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D667%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhNWPjNaUm7YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer</span> <span class="citation_source-journal">J. Mammary Gland Biol. Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2Fs10911-008-9107-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19034632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1cjns1Grtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=485-498&author=Q.+Jinauthor=F.+J.+Esteva&title=Cross-talk+between+the+ErbB%2FHER+family+and+the+type+I+insulin-like+growth+factor+receptor+signaling+pathway+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer</span></div><div class="casAuthors">Jin Quanri; Esteva Francisco J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of mammary gland biology and neoplasia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Understanding the molecular mechanisms involved in tumorigenesis and their influence on clinical outcome is providing specific molecular markers for targeted therapy.  Activation of tyrosine kinase receptors from the human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) and the insulin-like growth factor receptor I (IGF-IR) plays a key role in the initiation and progression of breast cancer.  HER2 overexpression is a validated therapeutic target, as shown by the clinical efficacy of trastuzumab and lapatinib.  However, only 25-30% of patients with HER2-overexpressing tumors respond to single-agent trastuzumab or lapatinib, and resistance develops even in responding patients.  Therefore, to optimize therapeutic efficacy, it is urgent to elucidate the complex network of signaling pathways that develop in breast cancer cells.  Signaling interactions have been reported between ErbB/HER family members and IGF-IR.  As increased IGF-IR signaling has been implicated in trastuzumab resistance, agents targeting HER2, and IGF-IR could be potential therapeutic tools in breast cancers that develop resistance to HER2-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTY4qBC_Z7VX5agfuraLLzSfW6udTcc2eajZRURbaIYsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjns1Grtw%253D%253D&md5=3d72938ec12e8b4cbb1d7695f7b528df</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1007%2Fs10911-008-9107-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10911-008-9107-3%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DCross-talk%2520between%2520the%2520ErbB%252FHER%2520family%2520and%2520the%2520type%2520I%2520insulin-like%2520growth%2520factor%2520receptor%2520signaling%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Mammary%2520Gland%2520Biol.%2520Neoplasia%26date%3D2008%26volume%3D13%26spage%3D485%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group">Saxena, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliaferro-Smith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anania, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Regan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, D.</span><span> </span><span class="NLM_article-title">Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9712</span><span class="NLM_x">–</span> <span class="NLM_lpage">9722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9712-9722&author=N.+K.+Saxenaauthor=L.+Taliaferro-Smithauthor=B.+B.+Knightauthor=D.+Merlinauthor=F.+A.+Ananiaauthor=R.+M.+O%27Reganauthor=D.+Sharma&title=Bidirectional+crosstalk+between+leptin+and+insulin-like+growth+factor-I+signaling+promotes+invasion+and+migration+of+breast+cancer+cells+via+transactivation+of+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DN.%2BK.%26aulast%3DTaliaferro-Smith%26aufirst%3DL.%26aulast%3DKnight%26aufirst%3DB.%2BB.%26aulast%3DMerlin%26aufirst%3DD.%26aulast%3DAnania%26aufirst%3DF.%2BA.%26aulast%3DO%2527Regan%26aufirst%3DR.%2BM.%26aulast%3DSharma%26aufirst%3DD.%26atitle%3DBidirectional%2520crosstalk%2520between%2520leptin%2520and%2520insulin-like%2520growth%2520factor-I%2520signaling%2520promotes%2520invasion%2520and%2520migration%2520of%2520breast%2520cancer%2520cells%2520via%2520transactivation%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9712%26epage%3D9722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gable, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2Fs10549-005-6939-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16142439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=37-46&author=J.+F.+Youngrenauthor=K.+Gableauthor=C.+Penarandaauthor=B.+A.+Madduxauthor=M.+Zavodovskayaauthor=M.+Loboauthor=M.+Campbellauthor=J.+Kernerauthor=I.+D.+Goldfine&title=Nordihydroguaiaretic+acid+%28NDGA%29+inhibits+the+IGF-1+and+c-erbB2%2FHER2%2Fneu+receptors+and+suppresses+growth+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells</span></div><div class="casAuthors">Youngren, Jack F.; Gable, Karissa; Penaranda, Cristina; Maddux, Betty A.; Zavodovskaya, Marianna; Lobo, Margaret; Campbell, Michael; Kerner, John; Goldfine, Ira D.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-46</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nordihydroguaiaretic acid (NDGA) is a phenolic compd. isolated from the creosote bush Larrea divaricata that has anti-cancer activities both in vitro and in vivo.  We can now attribute certain of these anti-cancer properties in breast cancer cells to the ability of NDGA to directly inhibit the function of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu (HER2/neu) receptor.  In MCF-7 human breast cancer cells, low micromolar concns. of NDGA inhibited activation of the IGF-1R, and downstream phosphorylation of both the Akt/PKB serine kinase and the pro-apoptotic protein BAD.  In mouse MCNeuA cells, NDGA also inhibited ligand independent phosphorylation of HER2/neu.  To study whether this inhibitory effect in cells was due to a direct action on these receptors, we studied the IGF-1-stimulated tyrosine kinase activity of isolated IGF-1R, which was inhibited by NDGA at 10 μM or less.  NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concns.  In addn., NDGA inhibited IGF-1 specific growth of cultured breast cancer cells with an IC50 of approx. 30 μM.  NDGA treatment (i.p. injection 3 times per wk) also decreased the activity of the IGF-1R and the HER2/neu receptor in MCNeuA cells implanted into mice.  This inhibition of RTK activity was assocd. with decreased growth rates of MCNeuA cells in vivo.  These studies indicate that the anti-breast cancer properties of NDGA are related to the inhibition of two important RTKs.  Agents of this class may therefore provide new insights into potential therapies for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreUxoBHJItcrVg90H21EOLACvtfcHk0lg4omCNn2fozQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjN&md5=2c2d27fd3d500655dd32a568b62e2938</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6939-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6939-z%26sid%3Dliteratum%253Aachs%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DGable%26aufirst%3DK.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DLobo%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DKerner%26aufirst%3DJ.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26atitle%3DNordihydroguaiaretic%2520acid%2520%2528NDGA%2529%2520inhibits%2520the%2520IGF-1%2520and%2520c-erbB2%252FHER2%252Fneu%2520receptors%2520and%2520suppresses%2520growth%2520in%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D37%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group">Blecha, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guevarra, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pender, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkman, C. E.</span><span> </span><span class="NLM_article-title">Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4026</span><span class="NLM_x">–</span> <span class="NLM_lpage">4029</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4026-4029&author=J.+E.+Blechaauthor=M.+O.+Andersonauthor=J.+M.+Chowauthor=C.+C.+Guevarraauthor=C.+Penderauthor=C.+Penarandaauthor=M.+Zavodovskayaauthor=J.+F.+Youngrenauthor=C.+E.+Berkman&title=Inhibition+of+IGF-1R+and+lipoxygenase+by+nordihydroguaiaretic+acid+%28NDGA%29+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlecha%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DChow%26aufirst%3DJ.%2BM.%26aulast%3DGuevarra%26aufirst%3DC.%2BC.%26aulast%3DPender%26aufirst%3DC.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DBerkman%26aufirst%3DC.%2BE.%26atitle%3DInhibition%2520of%2520IGF-1R%2520and%2520lipoxygenase%2520by%2520nordihydroguaiaretic%2520acid%2520%2528NDGA%2529%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4026%26epage%3D4029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=624-635&author=M.+Zavodovskayaauthor=M.+J.+Campbellauthor=B.+A.+Madduxauthor=L.+Shiryauthor=G.+Allanauthor=L.+Hodgesauthor=P.+Kushnerauthor=J.+A.+Kernerauthor=J.+F.+Youngrenauthor=I.+D.+Goldfine&title=Nordihydroguaiaretic+acid+%28NDGA%29%2C+an+inhibitor+of+the+HER2+and+IGF-1+receptor+tyrosine+kinases%2C+blocks+the+growth+of+HER2-overexpressing+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DShiry%26aufirst%3DL.%26aulast%3DAllan%26aufirst%3DG.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%26aulast%3DKerner%26aufirst%3DJ.%2BA.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26atitle%3DNordihydroguaiaretic%2520acid%2520%2528NDGA%2529%252C%2520an%2520inhibitor%2520of%2520the%2520HER2%2520and%2520IGF-1%2520receptor%2520tyrosine%2520kinases%252C%2520blocks%2520the%2520growth%2520of%2520HER2-overexpressing%2520human%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D103%26spage%3D624%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group">Rowe, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozbay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahta, R.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1900</span><span class="NLM_x">–</span> <span class="NLM_lpage">1908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-08-0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18645000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1900-1908&author=D.+L.+Roweauthor=T.+Ozbayauthor=L.+M.+Benderauthor=R.+Nahta&title=Nordihydroguaiaretic+acid%2C+a+cytotoxic+insulin-like+growth+factor-I+receptor%2FHER2+inhibitor+in+trastuzumab-resistant+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer</span></div><div class="casAuthors">Rowe, Danica L.; Ozbay, Tuba; Bender, Laura M.; Nahta, Rita</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1900-1908</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of patients with HER2-overexpressing metastatic breast cancer who initially respond to the HER2-targeted antibody trastuzumab show disease progression within 1 yr.  The identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab is crit. for improving outcome for this patient population.  In the current study, we show that the phenolic compd. nordihydroguaiaretic acid (NDGA) promoted cell death of trastuzumab-naive and trastuzumab-refractory HER2-overexpressing breast cancer cells.  NDGA induced DNA fragmentation, cleavage of poly(ADP-ribose) polymerase and caspase-3, and inhibition of colony formation.  In addn., NDGA inhibited insulin-like growth factor-I and HER2 signaling in trastuzumab-refractory cells, with reduced downstream phosphatidylinositol-3 kinase/Akt signaling.  Importantly, combination treatment with NDGA and trastuzumab suppressed proliferation and survival of trastuzumab-refractory cells to a greater degree than either agent alone, suggesting that NDGA increases the sensitivity of refractory cells to trastuzumab.  Derivs. of NDGA are currently in clin. trial for other solid tumors.  Our data strongly support further study of NDGA as a potential therapeutic against breast cancers that have progressed on trastuzumab. [Mol Cancer Ther 2008;7(7):1900-8].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5znLMBtcqLrVg90H21EOLACvtfcHk0lh2oLSh6qRn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtbs%253D&md5=5521436204e960f408f4f29700a1a780</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0012%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DD.%2BL.%26aulast%3DOzbay%26aufirst%3DT.%26aulast%3DBender%26aufirst%3DL.%2BM.%26aulast%3DNahta%26aufirst%3DR.%26atitle%3DNordihydroguaiaretic%2520acid%252C%2520a%2520cytotoxic%2520insulin-like%2520growth%2520factor-I%2520receptor%252FHER2%2520inhibitor%2520in%2520trastuzumab-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1900%26epage%3D1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group">Carlberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dricu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blegen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjertman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zickert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoog, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">17453</span><span class="NLM_x">–</span> <span class="NLM_lpage">17462</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=17453-17462&author=M.+Carlbergauthor=A.+Dricuauthor=H.+Blegenauthor=M.+Wangauthor=M.+Hjertmanauthor=P.+Zickertauthor=A.+Hoogauthor=O.+Larsson&title=Mevalonic+acid+is+limiting+for+N-linked+glycosylation+and+translocation+of+the+insulin-like+growth+factor-1+receptor+to+the+cell+surface.+Evidence+for+a+new+link+between+3-hydroxy-3-methylglutaryl-coenzyme+a+reductase+and+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlberg%26aufirst%3DM.%26aulast%3DDricu%26aufirst%3DA.%26aulast%3DBlegen%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHjertman%26aufirst%3DM.%26aulast%3DZickert%26aufirst%3DP.%26aulast%3DHoog%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DMevalonic%2520acid%2520is%2520limiting%2520for%2520N-linked%2520glycosylation%2520and%2520translocation%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520to%2520the%2520cell%2520surface.%2520Evidence%2520for%2520a%2520new%2520link%2520between%25203-hydroxy-3-methylglutaryl-coenzyme%2520a%2520reductase%2520and%2520cell%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D17453%26epage%3D17462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group">Schenk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waechter, C. J.</span><span> </span><span class="NLM_article-title">The ins(ide) and out(side) of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum</span> <span class="citation_source-journal">Glycobiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">61R</span><span class="NLM_x">–</span> <span class="NLM_lpage">70R</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=61R-70R&author=B.+Schenkauthor=F.+Fernandezauthor=C.+J.+Waechter&title=The+ins%28ide%29+and+out%28side%29+of+dolichyl+phosphate+biosynthesis+and+recycling+in+the+endoplasmic+reticulum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenk%26aufirst%3DB.%26aulast%3DFernandez%26aufirst%3DF.%26aulast%3DWaechter%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520ins%2528ide%2529%2520and%2520out%2528side%2529%2520of%2520dolichyl%2520phosphate%2520biosynthesis%2520and%2520recycling%2520in%2520the%2520endoplasmic%2520reticulum%26jtitle%3DGlycobiology%26date%3D2001%26volume%3D11%26spage%3D61R%26epage%3D70R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group">Dricu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjertman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blegen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wejde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc</span> <span class="citation_source-journal">Glycobiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=625-633&author=A.+Dricuauthor=M.+Wangauthor=M.+Hjertmanauthor=M.+Malecauthor=H.+Blegenauthor=J.+Wejdeauthor=M.+Carlbergauthor=O.+Larsson&title=Mevalonate-regulated+mechanisms+in+cell+growth+control%3A+role+of+dolichyl+phosphate+in+expression+of+the+insulin-like+growth+factor-1+receptor+%28IGF-1R%29+in+comparison+to+Ras+prenylation+and+expression+of+c-myc"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDricu%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHjertman%26aufirst%3DM.%26aulast%3DMalec%26aufirst%3DM.%26aulast%3DBlegen%26aufirst%3DH.%26aulast%3DWejde%26aufirst%3DJ.%26aulast%3DCarlberg%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DMevalonate-regulated%2520mechanisms%2520in%2520cell%2520growth%2520control%253A%2520role%2520of%2520dolichyl%2520phosphate%2520in%2520expression%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520%2528IGF-1R%2529%2520in%2520comparison%2520to%2520Ras%2520prenylation%2520and%2520expression%2520of%2520c-myc%26jtitle%3DGlycobiology%26date%3D1997%26volume%3D7%26spage%3D625%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsubo, Y.</span><span> </span><span class="NLM_article-title">Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner</span> <span class="citation_source-journal">J. Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2131%2Fjts.32.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17327694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=57-67&author=T.+Oguraauthor=Y.+Tanakaauthor=T.+Nakataauthor=T.+Namikawaauthor=H.+Kataokaauthor=Y.+Ohtsubo&title=Simvastatin+reduces+insulin-like+growth+factor-1+signaling+in+differentiating+C2C12+mouse+myoblast+cells+in+an+HMG-CoA+reductase+inhibition-independent+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Simvastatin reduced insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner</span></div><div class="casAuthors">Ogura, Takeharu; Tanaka, Yoshiyuki; Nakata, Tetsushi; Namikawa, Tomoko; Kataoka, Hirofumi; Ohtsubo, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">JTSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0388-1350</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicology</span>)
        </div><div class="casAbstract">Inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase occasionally cause myopathy characterized by weakness, pain, and elevated serum creatine phosphokinase (CK).  In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells.  Simvastatin decreased cell viability and CK activity, a marker of myogenesis, in differentiating cells in a dose-dependent manner.  Although the simvastatin-induced decrease in viability in proliferating and differentiated cells was completely abolished by mevalonate or geranylgeranyl-pyrophosphate, the inhibitory effects of simvastatin in differentiating cells were not abolished by mevalonate or isoprenoid derivs. of mevalonate.  Moreover, the sensitivity of differentiating cells to simvastatin regarding cell viability was about 7 times higher than that of proliferating cells.  After induction of differentiation in the presence of 1 μM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased.  Although mRNA expression of the IGF-1 receptor β-chain (IGF-1Rβ) did not change, protein level of the 200 kDa IGF-1Rβ precursor was significantly increased by simvastatin in a dose-dependent manner.  Mevalonate did not abolish the effect of simvastatin on IGF-1Rβ expression.  These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rβ in an HMG-CoA reductase inhibition-independent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBqO3pZyucrVg90H21EOLACvtfcHk0lh2oLSh6qRn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFWltLo%253D&md5=a999a54d44ce7f88ea1102a2ca7eac57</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.2131%2Fjts.32.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2131%252Fjts.32.57%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DNamikawa%26aufirst%3DT.%26aulast%3DKataoka%26aufirst%3DH.%26aulast%3DOhtsubo%26aufirst%3DY.%26atitle%3DSimvastatin%2520reduces%2520insulin-like%2520growth%2520factor-1%2520signaling%2520in%2520differentiating%2520C2C12%2520mouse%2520myoblast%2520cells%2520in%2520an%2520HMG-CoA%2520reductase%2520inhibition-independent%2520manner%26jtitle%3DJ.%2520Toxicol.%2520Sci.%26date%3D2007%26volume%3D32%26spage%3D57%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, K.</span><span> </span><span class="NLM_article-title">Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=356-361&author=Y.+Sekineauthor=Y.+Furuyaauthor=M.+Nishiiauthor=H.+Koikeauthor=H.+Matsuiauthor=K.+Suzuki&title=Simvastatin+inhibits+the+proliferation+of+human+prostate+cancer+PC-3+cells+via+down-regulation+of+the+insulin-like+growth+factor+1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DFuruya%26aufirst%3DY.%26aulast%3DNishii%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DSimvastatin%2520inhibits%2520the%2520proliferation%2520of%2520human%2520prostate%2520cancer%2520PC-3%2520cells%2520via%2520down-regulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D372%26spage%3D356%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref289"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref289'); return false;" data-citation="" class="refNumLink">289</a></strong><div class="NLM_citation" id="cit289"><span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multhoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, C.</span><span> </span><span class="NLM_article-title">Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1189%2Fjlb.0306167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16931602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=15-27&author=E.+Schmittauthor=M.+Gehrmannauthor=M.+Brunetauthor=G.+Multhoffauthor=C.+Garrido&title=Intracellular+and+extracellular+functions+of+heat+shock+proteins%3A+repercussions+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy</span></div><div class="casAuthors">Schmitt, E.; Gehrmann, M.; Brunet, M.; Multhoff, G.; Garrido, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Stress or heat shock proteins (HSPs) are the most conserved proteins present in both prokaryotes and eukaryotes.  Their expression is induced in response to a wide variety of physiol. and environmental insults.  These proteins play an essential role as mol. chaperones by assisting the correct folding of nascent and stress-accumulated misfolded proteins, and preventing their aggregation.  HSPs have a dual function depending on their intracellular or extracellular location.  Intracellular HSPs have a protective function.  They allow the cells to survive lethal conditions.  Various mechanisms have been proposed to account for the cytoprotective functions of HSPs.  Several HSPs have also been demonstrated to directly interact with various components of the tightly regulated programmed cell death machinery, upstream and downstream of the mitochondrial events.  On the other hand, extracellular located or membrane-bound HSPs mediate immunol. functions.  They can elicit an immune response modulated either by the adaptive or innate immune system.  This review will focus on HSP27, HSP70, and HSP90.  We will discuss the dual role of these HSPs, protective vs. immunogenic properties, making a special emphasis in their utility as targets in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5_zxS3nMjgLVg90H21EOLACvtfcHk0lirD34ZVaeyVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVaisA%253D%253D&md5=df40eb312cf127833e028c7cc26c00b5</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0306167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0306167%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DGehrmann%26aufirst%3DM.%26aulast%3DBrunet%26aufirst%3DM.%26aulast%3DMulthoff%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DC.%26atitle%3DIntracellular%2520and%2520extracellular%2520functions%2520of%2520heat%2520shock%2520proteins%253A%2520repercussions%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2007%26volume%3D81%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref290"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref290'); return false;" data-citation="" class="refNumLink">290</a></strong><div class="NLM_citation" id="cit290"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S. L.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lirD34ZVaeyVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref291"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref291'); return false;" data-citation="" class="refNumLink">291</a></strong><div class="NLM_citation" id="cit291"><span><span class="NLM_contrib-group">Saetrum, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P. H.</span><span> </span><span class="NLM_article-title">IGF-I is a matter of heart</span> <span class="citation_source-journal">Growth Horm. IGF Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ghir.2005.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15809013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ns1WjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=89-94&author=O.+O.+Saetrumauthor=P.+H.+Wang&title=IGF-I+is+a+matter+of+heart"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-I is a matter of heart</span></div><div class="casAuthors">Saetrum Opgaard Ole; Wang Ping H</div><div class="citationInfo"><span class="NLM_cas:title">Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-94</span>
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    </div><div class="casAbstract">An intriguing relationship between IGF-I action and cardiac function has been noted for some time, but exactly how IGF-I modulates myocardial function remained obscure.  Recent research shed novel insight into potential mechanisms of IGF-I actions in cardiac muscle.  New discoveries help elucidate the role of IGF-I signaling in protecting cardiac muscle against injuries, and support potential therapeutic roles for IGF-I in cardiomyopathy.  Multiple actions of IGF-I has been described in cardiac muscle cells, including the well-documented anti-apoptosis effect and the newly emerged action on cardiac muscle regeneration.  Furthermore, interplay between heat shock protein and IGF-I receptor signaling has been identified and this new paradigm might be involved in the development of diabetic cardiomyopathy.  This article reviews recent research findings and outlines potential therapeutic implications of IGF-I in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0dmtylvE3VkwlCcfExbvbfW6udTcc2eYrnb7JJoLDmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ns1WjsA%253D%253D&md5=dd48a632ec0d2d6fbd76c36c1869ceb5</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1016%2Fj.ghir.2005.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ghir.2005.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DSaetrum%26aufirst%3DO.%2BO.%26aulast%3DWang%26aufirst%3DP.%2BH.%26atitle%3DIGF-I%2520is%2520a%2520matter%2520of%2520heart%26jtitle%3DGrowth%2520Horm.%2520IGF%2520Res.%26date%3D2005%26volume%3D15%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref292"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref292'); return false;" data-citation="" class="refNumLink">292</a></strong><div class="NLM_citation" id="cit292"><span><span class="NLM_contrib-group">Lang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glockzin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlke, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlitt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeltzing, O.</span><span> </span><span class="NLM_article-title">Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">6459</span><span class="NLM_x">–</span> <span class="NLM_lpage">6468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17975158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CgtbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=6459-6468&author=S.+A.+Langauthor=C.+Moserauthor=A.+Gaumannauthor=D.+Kleinauthor=G.+Glockzinauthor=F.+C.+Poppauthor=M.+H.+Dahlkeauthor=P.+Pisoauthor=H.+J.+Schlittauthor=E.+K.+Geisslerauthor=O.+Stoeltzing&title=Targeting+heat+shock+protein+90+in+pancreatic+cancer+impairs+insulin-like+growth+factor-I+receptor+signaling%2C+disrupts+an+interleukin-6%2Fsignal-transducer+and+activator+of+transcription+3%2Fhypoxia-inducible+factor-1alpha+autocrine+loop%2C+and+reduces+orthotopic+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1α Autocrine Loop, and Reduces Orthotopic Tumor Growth</span></div><div class="casAuthors">Lang, Sven A.; Moser, Christian; Gaumann, Andreas; Klein, Dagmar; Glockzin, Gabriel; Popp, Felix C.; Dahlke, Marc H.; Piso, Pompiliu; Schlitt, Hans J.; Geissler, Edward K.; Stoeltzing, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6459-6468</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inhibitors of heat-shock protein 90 (Hsp90) may interfere with oncogenic signaling pathways, including Erk, Akt, and hypoxia-inducible factor-1α (HIF-1α).  Because insulin-like growth factor-I receptor (IGF-IR) and signal transducer and activator of transcription 3 (STAT3) signaling pathways are implicated in the progression of pancreatic cancer, we hypothesized that blocking Hsp90 with geldanamycin derivates [17-allylamino-geldanamycin (17-AAG), 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG)] would impair IGF-I- and interleukin-6-mediated signaling and thus reduce pancreatic tumor growth and angiogenesis in vivo.  Exptl. Design: Human pancreatic cancer cells (HPAF-II, L3.6pl) were used for expts.  Changes in signaling pathway activation upon Hsp90 blockade were investigated by Western blotting.  Effects of Hsp90 inhibition (17-AAG) on vascular endothelial growth factor were detd. by ELISA and real-time PCR.  Effects of 17-DMAG (25 mg/kg; thrice a week; i.p.) on tumor growth and vascularization were investigated in a s.c. xenograft model and in an orthotopic model of pancreatic cancer.  Results: 17-AAG inhibited IGF-IR signaling by down-regulating IGF-IRβ and directly impairing IGF-IR phosphorylation.  Hypoxia- and IL-6-mediated activation of HIF-1α or STAT3/STAT5 were substantially inhibited by 17-AAG.  Moreover, a novel IL-6/STAT3/HIF-1α autocrine loop was effectively disrupted by Hsp90 blockade.  In vivo, 17-DMAG significantly reduced s.c. tumor growth and diminished STAT3 phosphorylation and IGF-IRβ expression in tumor tissues.  In an orthotopic model, pancreatic tumor growth and vascularization were both significantly reduced upon Hsp90 inhibition, as reflected by final tumor wts. and CD31 staining, resp.  Conclusions: Blocking Hsp90 disrupts IGF-I and IL-6-induced proangiogenic signaling cascades by targeting IGF-IR and STAT3 in pancreatic cancer, leading to significant growth-inhibitory effects.  Therefore, we suggest that Hsp90 inhibitors could prove to be valuable in the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJOAQLw4Ir7Vg90H21EOLACvtfcHk0liC5eN4x7Le7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CgtbzE&md5=0504e4a34116c70b17dd9e0dd03c8d2b</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1104%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DMoser%26aufirst%3DC.%26aulast%3DGaumann%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DD.%26aulast%3DGlockzin%26aufirst%3DG.%26aulast%3DPopp%26aufirst%3DF.%2BC.%26aulast%3DDahlke%26aufirst%3DM.%2BH.%26aulast%3DPiso%26aufirst%3DP.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStoeltzing%26aufirst%3DO.%26atitle%3DTargeting%2520heat%2520shock%2520protein%252090%2520in%2520pancreatic%2520cancer%2520impairs%2520insulin-like%2520growth%2520factor-I%2520receptor%2520signaling%252C%2520disrupts%2520an%2520interleukin-6%252Fsignal-transducer%2520and%2520activator%2520of%2520transcription%25203%252Fhypoxia-inducible%2520factor-1alpha%2520autocrine%2520loop%252C%2520and%2520reduces%2520orthotopic%2520tumor%2520growth%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D6459%26epage%3D6468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref293"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref293'); return false;" data-citation="" class="refNumLink">293</a></strong><div class="NLM_citation" id="cit293"><span><span class="NLM_contrib-group">Boehm, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortier, L. A.</span><span> </span><span class="NLM_article-title">Hsp90 mediates insulin-like growth factor 1 and interleukin-1beta signaling in an age-dependent manner in equine articular chondrocytes</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fart.22664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17599753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFSgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=2335-2343&author=A.+K.+Boehmauthor=M.+Sethauthor=K.+G.+Mayrauthor=L.+A.+Fortier&title=Hsp90+mediates+insulin-like+growth+factor+1+and+interleukin-1beta+signaling+in+an+age-dependent+manner+in+equine+articular+chondrocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 mediates insulin-like growth factor 1 and interleukin-1β signaling in an age-dependent manner in equine articular chondrocytes</span></div><div class="casAuthors">Boehm, Amber K.; Seth, Mayank; Mayr, Karen G.; Fortier, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2335-2343</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Many metabolic processes in chondrocytes thought to contribute to age-related changes in the extracellular matrix are influenced by known roles of Hsp90.  Age-related decreases in the level of Hsp90 have been documented in numerous cell types and could contribute to cartilage degeneration.  The aim of this study was to investigate the roles of age and Hsp90 in insulin-like growth factor 1 (IGF-1) and interleukin-1β (IL-1β) signaling in chondrocytes.  Methods: Levels of Hsp90 mRNA (mRNA) and protein, with respect to age, were detd. by quant. real-time polymerase chain reaction (PCR) and Western blot anal., resp.  The Hsp90 inhibitor geldanamycin (50 nM, 100 nM, or 500 nM) was used to assess age-related responses to Hsp90 with concurrent IGF-1 or IL-1β stimulation of chondrocytes.  Quant. real-time PCR was used to measure COL2A1 and matrix metalloproteinase 13 (MMP13) gene expression; Western blot anal. was performed to det. the phosphorylation status of p42/44 and Akt/protein kinase B.  Results: The effects of Hsp90 inhibition with geldanamycin were concn. dependent.  Inhibition of Hsp90 with 100 nM or 500 nM geldanamycin blocked IGF-1-induced cell proliferation, Akt and p42/44 activation, and COL2A1 expression.  Basal and IL-1β-induced up-regulation of MMP13 mRNA was blocked by all concns. of geldanamycin tested.  Gain-of-function assays with Hsp90 resulted in increased expression of MMP13 mRNA.  Conclusion: These results suggest that Hsp90 is involved in opposing signaling pathways of cartilage homeostasis, and that catabolic responses are more sensitive to Hsp90 inhibition than are anabolic responses.  Further studies are needed to det. the role of Hsp90 inhibition in osteoarthritis in order to assess its potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozztUun13iBLVg90H21EOLACvtfcHk0liC5eN4x7Le7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFSgtbk%253D&md5=776b22b27ef0cfa0215aa5c878087b47</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1002%2Fart.22664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.22664%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DA.%2BK.%26aulast%3DSeth%26aufirst%3DM.%26aulast%3DMayr%26aufirst%3DK.%2BG.%26aulast%3DFortier%26aufirst%3DL.%2BA.%26atitle%3DHsp90%2520mediates%2520insulin-like%2520growth%2520factor%25201%2520and%2520interleukin-1beta%2520signaling%2520in%2520an%2520age-dependent%2520manner%2520in%2520equine%2520articular%2520chondrocytes%26jtitle%3DArthritis%2520Rheum.%26date%3D2007%26volume%3D56%26spage%3D2335%26epage%3D2343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref294"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref294'); return false;" data-citation="" class="refNumLink">294</a></strong><div class="NLM_citation" id="cit294"><span><span class="NLM_contrib-group">Fattori, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squarcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartoli, S.</span><span> </span><span class="NLM_article-title">Fragment-based approach to drug lead discovery: overview and advances in various techniques</span> <span class="citation_source-journal">Drugs R&D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2165%2F00126839-200809040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18588353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=217-227&author=D.+Fattoriauthor=A.+Squarciaauthor=S.+Bartoli&title=Fragment-based+approach+to+drug+lead+discovery%3A+overview+and+advances+in+various+techniques"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based approach to drug lead discovery: overview and advances in various techniques</span></div><div class="casAuthors">Fattori, Daniela; Squarcia, Antonella; Bartoli, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chem., has produced new tools for the discovery of biol. active mols.  In the past decade, fragment-based drug discovery has emerged as a more rational and focused approach that concs. on the quality, rather than the quantity, of hits and leads.  The principles behind this strategy are different from those that represented the basis of conventional HTS.  The starting point of this approach is always a small chem. entity (typically MW 150-200), a fragment, with low affinity for the selected target.  Fragments should satisfy key features such as diversity, reduced structural complexity, aq. soly. and availability.  Because of their small size, they occupy a smaller region of chem. space if compared with classical HTS compds.; hence, fragment libraries provide a good diversity with a relatively low no. of compds.  Classical biochem. assays are often not suitable to detect the low binding affinities involved, so some well known biophys. techniques, such as NMR and x-ray, have been opportunely modified in order to render them able to perform the task.  When selecting fragments suitable for subsequent optimization, a useful parameter has been introduced, the ligand efficiency, which is defined as the free energy of binding divided by the non-hydrogen atom count.  Once selected, a fragment must undergo a heavy elaboration to improve binding affinity, at the same time acquiring drug-like properties.  There are two main ways to go on at this point.  The most common one is the so-called 'fragment evolution', consisting of a stepwise and systematic addn. of chem. functionalities to the starting fragment core, together with a continuous feedback for pharmacol. and physicochem. properties.  The second one, less common but with great potential, is 'fragment linking': when two or more fragment hits are found to bind in adjacent regions of the target protein, they can be linked through appropriate spacers to rapidly produce a single mol. with much higher binding affinity.  Two representative case histories are described: Abbott's ABT 518, an MMP (matrix metalloproteinase) inhibitor, and Eli-Lilly's LY-517717, an inhibitor of factor Xa serine protease.  In addn., a list of mols. claimed to be derived from fragment approach and currently undergoing clin. trials is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobrVRjDoPS8LVg90H21EOLACvtfcHk0liC5eN4x7Le7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt7w%253D&md5=db1cfcf0f9320e95c5dcf4a713c2c2e1</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.2165%2F00126839-200809040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200809040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DFattori%26aufirst%3DD.%26aulast%3DSquarcia%26aufirst%3DA.%26aulast%3DBartoli%26aufirst%3DS.%26atitle%3DFragment-based%2520approach%2520to%2520drug%2520lead%2520discovery%253A%2520overview%2520and%2520advances%2520in%2520various%2520techniques%26jtitle%3DDrugs%2520R%2526D%26date%3D2008%26volume%3D9%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref295"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref295'); return false;" data-citation="" class="refNumLink">295</a></strong><div class="NLM_citation" id="cit295"><span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Structure-based design of molecular cancer therapeutics</span> <span class="citation_source-journal">Trends Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=315-328&issue=5&author=R.+L.+van+Montfortauthor=P.+Workman&title=Structure-based+design+of+molecular+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520molecular%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Biotechnol.%26date%3D2009%26volume%3D27%26issue%3D5%26spage%3D315%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref296"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref296'); return false;" data-citation="" class="refNumLink">296</a></strong><div class="NLM_citation" id="cit296"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">Recent developments in fragment-based drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3661</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8000373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3661-3680&author=M.+Congreveauthor=G.+Chessariauthor=D.+Tisiauthor=A.+J.+Woodhead&title=Recent+developments+in+fragment-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=10.1021%2Fjm8000373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000373%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520developments%2520in%2520fragment-based%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3661%26epage%3D3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref297"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref297'); return false;" data-citation="" class="refNumLink">297</a></strong><div class="NLM_citation" id="cit297"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: To be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%27Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+To+be+or+not+to+be%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit297R"><div class="casContent"><span class="casTitleNuber">297</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0lgpOQNugkQ3EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520To%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref298"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref298'); return false;" data-citation="" class="refNumLink">298</a></strong><div class="NLM_citation" id="cit298"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleickardt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicaise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=485-493&author=N.+P.+Shahauthor=C.+Kasapauthor=C.+Weierauthor=M.+Balbasauthor=J.+M.+Nicollauthor=E.+Bleickardtauthor=C.+Nicaiseauthor=C.+L.+Sawyers&title=Transient+potent+BCR-ABL+inhibition+is+sufficient+to+commit+chronic+myeloid+leukemia+cells+irreversibly+to+apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DWeier%26aufirst%3DC.%26aulast%3DBalbas%26aufirst%3DM.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DBleickardt%26aufirst%3DE.%26aulast%3DNicaise%26aufirst%3DC.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DTransient%2520potent%2520BCR-ABL%2520inhibition%2520is%2520sufficient%2520to%2520commit%2520chronic%2520myeloid%2520leukemia%2520cells%2520irreversibly%2520to%2520apoptosis%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref299"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref299'); return false;" data-citation="" class="refNumLink">299</a></strong><div class="NLM_citation" id="cit299"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Customizing the targeting of IGF-1 receptor</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2217%2F14796694.5.1.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19243297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=43-50&author=R.+Baserga&title=Customizing+the+targeting+of+IGF-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit299R"><div class="casContent"><span class="casTitleNuber">299</span><div class="casTitle"><span class="NLM_cas:atitle">Customizing the targeting of IGF-1 receptor</span></div><div class="casAuthors">Baserga, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiol. concns.  It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clin. trials.  Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors.  This review focuses on the optimization of IGF-IR targeting in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2U7de1wk-FrVg90H21EOLACvtfcHk0lgpOQNugkQ3EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyltLw%253D&md5=a976e08ec9ba87222cd55d8c5f8c4ada</span></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=10.2217%2F14796694.5.1.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796694.5.1.43%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DCustomizing%2520the%2520targeting%2520of%2520IGF-1%2520receptor%26jtitle%3DFuture%2520Oncol.%26date%3D2009%26volume%3D5%26spage%3D43%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref300"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref300'); return false;" data-citation="" class="refNumLink">300</a></strong><div class="NLM_citation" id="cit300"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">The insulin receptor substrate-1: a biomarker for cancer?</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.yexcr.2008.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18851963" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2008&pages=727-732&author=R.+Baserga&title=The+insulin+receptor+substrate-1%3A+a+biomarker+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2008.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2008.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DThe%2520insulin%2520receptor%2520substrate-1%253A%2520a%2520biomarker%2520for%2520cancer%253F%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2008%26volume%3D315%26spage%3D727%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref301"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref301'); return false;" data-citation="" class="refNumLink">301</a></strong><div class="NLM_citation" id="cit301"><span><span class="NLM_contrib-group">Hewish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=54-72&author=M.+Hewishauthor=I.+Chauauthor=D.+Cunningham&title=Insulin-like+growth+factor+1+receptor+targeted+therapeutics%3A+novel+compounds+and+novel+treatment+strategies+for+cancer+medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHewish%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DI.%26aulast%3DCunningham%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%25201%2520receptor%2520targeted%2520therapeutics%253A%2520novel%2520compounds%2520and%2520novel%2520treatment%2520strategies%2520for%2520cancer%2520medicine%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2009%26volume%3D4%26spage%3D54%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref302"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref302'); return false;" data-citation="" class="refNumLink">302</a></strong><div class="NLM_citation" id="cit302"><span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toretsky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span> </span><span class="NLM_article-title">The role of IGF-1R in pediatric malignancies</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=83-91&author=S.+Y.+Kimauthor=J.+A.+Toretskyauthor=D.+Scherauthor=L.+J.+Helman&title=The+role+of+IGF-1R+in+pediatric+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DToretsky%26aufirst%3DJ.%2BA.%26aulast%3DScher%26aufirst%3DD.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520role%2520of%2520IGF-1R%2520in%2520pediatric%2520malignancies%26jtitle%3DOncologist%26date%3D2009%26volume%3D14%26spage%3D83%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref303"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref303'); return false;" data-citation="" class="refNumLink">303</a></strong><div class="NLM_citation" id="cit303"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinilla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clary, D. O.</span><span> </span><span class="NLM_article-title">Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=474&author=N.+P.+Shahauthor=C.+Kasapauthor=R.+Paquetteauthor=J.+Cortesauthor=J.+Pinillaauthor=M.+Talpazauthor=L.+A.+Buiauthor=D.+O.+Clary&title=Targeting+drug-resistant+CML+and+Ph%2B-ALL+with+the+spectrum+selective+protein+kinase+inhibitor+XL228"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DPinilla%26aufirst%3DJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DBui%26aufirst%3DL.%2BA.%26aulast%3DClary%26aufirst%3DD.%2BO.%26atitle%3DTargeting%2520drug-resistant%2520CML%2520and%2520Ph%252B-ALL%2520with%2520the%2520spectrum%2520selective%2520protein%2520kinase%2520inhibitor%2520XL228%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref304"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref304'); return false;" data-citation="" class="refNumLink">304</a></strong><div class="NLM_citation" id="cit304"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lhEFPf3EjEL3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref305"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref305'); return false;" data-citation="" class="refNumLink">305</a></strong><div class="NLM_citation" id="cit305"><span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, R. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2575</span><span class="NLM_x">–</span> <span class="NLM_lpage">2588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-08-0265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18790742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2575-2588&author=J.+Rodonauthor=V.+DeSantosauthor=R.+J.+Ferryauthor=R.+Kurzrock&title=Early+drug+development+of+inhibitors+of+the+insulin-like+growth+factor-I+receptor+pathway%3A+lessons+from+the+first+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit305R"><div class="casContent"><span class="casTitleNuber">305</span><div class="casTitle"><span class="NLM_cas:atitle">Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials</span></div><div class="casAuthors">Rodon, Jordi; De Santos, Victoria; Ferry, Robert Jean, Jr.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2575-2588</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986.  Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate.  The understanding of the roles of hormones in cancer and the growth hormone-IGF-IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling assocd. with this axis.  The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis.  Nowadays, >25 mols. with the same goal are at different stages of development.  Here, we review the clin. and preclin. experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations.  We also review the biomarkers explored in the first clin. trials, the strategies that have been explored thus far, and the clin. trials that are going to explore their role in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDZwaTmwi46rVg90H21EOLACvtfcHk0lhEFPf3EjEL3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7jJ&md5=d37e37d3752231ef2c152110c1e85a66</span></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0265%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDeSantos%26aufirst%3DV.%26aulast%3DFerry%26aufirst%3DR.%2BJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DEarly%2520drug%2520development%2520of%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520pathway%253A%2520lessons%2520from%2520the%2520first%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2575%26epage%3D2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288'],'ref289':['cit289'],'ref290':['cit290'],'ref291':['cit291'],'ref292':['cit292'],'ref293':['cit293'],'ref294':['cit294'],'ref295':['cit295'],'ref296':['cit296'],'ref297':['cit297'],'ref298':['cit298'],'ref299':['cit299'],'ref300':['cit300'],'ref301':['cit301'],'ref302':['cit302'],'ref303':['cit303'],'ref304':['cit304'],'ref305':['cit305']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 79 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yaozong Li, <span class="NLM_string-name hlFld-ContribAuthor">Kwangho Nam</span>. </span><span class="cited-content_cbyCitation_article-title">Repulsive Soft-Core Potentials for Efficient Alchemical Free Energy Calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2020,</strong> <em>16 </em>
                                    (8)
                                     , 4776-4789. <a href="https://doi.org/10.1021/acs.jctc.0c00163" title="DOI URL">https://doi.org/10.1021/acs.jctc.0c00163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.0c00163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.0c00163%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DRepulsive%252BSoft-Core%252BPotentials%252Bfor%252BEfficient%252BAlchemical%252BFree%252BEnergy%252BCalculations%26aulast%3DLi%26aufirst%3DYaozong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17022020%26date%3D06072020%26date%3D19062020%26volume%3D16%26issue%3D8%26spage%3D4776%26epage%3D4789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Debasmita Saha, Anupreet Kharbanda, Wei Yan, Naga Rajiv Lakkaniga, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 441-469. <a href="https://doi.org/10.1021/acs.jmedchem.9b00640" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BExploration%252Bof%252BChirality%252Bfor%252BImproved%252BDruggability%252Bwithin%252Bthe%252BHuman%252BKinome%26aulast%3DSaha%26aufirst%3DDebasmita%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D15042019%26date%3D09102019%26date%3D24092019%26volume%3D63%26issue%3D2%26spage%3D441%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Dong  Shao</span>, <span class="hlFld-ContribAuthor ">Jia  Su</span>, <span class="hlFld-ContribAuthor ">Baixin  Ye</span>, <span class="hlFld-ContribAuthor ">Jiang-Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Li  Zuo</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Yue-Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Chengfeng  Xia</span>, and <span class="hlFld-ContribAuthor ">Qin-Shi  Zhao</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 9053-9066. <a href="https://doi.org/10.1021/acs.jmedchem.7b01395" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01395%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BActivities%252Bof%252BVibsanin%252BB%252BDerivatives%25253A%252BA%252BNew%252BClass%252Bof%252BHSP90%252BC-Terminal%252BInhibitors%26aulast%3DShao%26aufirst%3DLi-Dong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20092017%26date%3D24102017%26date%3D09112017%26date%3D11102017%26volume%3D60%26issue%3D21%26spage%3D9053%26epage%3D9066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meizhong  Jin</span>, <span class="hlFld-ContribAuthor ">Brenda A.  Petronella</span>, <span class="hlFld-ContribAuthor ">Andy  Cooke</span>, <span class="hlFld-ContribAuthor ">Mridula  Kadalbajoo</span>, <span class="hlFld-ContribAuthor ">Kam W.  Siu</span>, <span class="hlFld-ContribAuthor ">Andrew  Kleinberg</span>, <span class="hlFld-ContribAuthor ">Earl W.  May</span>, <span class="hlFld-ContribAuthor ">Prafulla C.  Gokhale</span>, <span class="hlFld-ContribAuthor ">Ryan  Schulz</span>, <span class="hlFld-ContribAuthor ">Jennifer  Kahler</span>, <span class="hlFld-ContribAuthor ">Mark A.  Bittner</span>, <span class="hlFld-ContribAuthor ">Kenneth  Foreman</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Pachter</span>, <span class="hlFld-ContribAuthor ">Robert  Wild</span>, <span class="hlFld-ContribAuthor ">David  Epstein</span>, and <span class="hlFld-ContribAuthor ">Mark J.  Mulvihill</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (7)
                                     , 627-631. <a href="https://doi.org/10.1021/ml400160a" title="DOI URL">https://doi.org/10.1021/ml400160a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400160a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400160a%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BInsulin-Like%252BGrowth%252BFactor-1%252BReceptor%252BInhibitors%252Bwith%252BUnique%252BTime-Dependent%252BBinding%252BKinetics%26aulast%3DJin%26aufirst%3DMeizhong%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D03052013%26date%3D23052013%26date%3D28052013%26date%3D11072013%26date%3D23052013%26volume%3D4%26issue%3D7%26spage%3D627%26epage%3D631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meizhong  Jin</span>, <span class="hlFld-ContribAuthor ">Prafulla C.  Gokhale</span>, <span class="hlFld-ContribAuthor ">Andy  Cooke</span>, <span class="hlFld-ContribAuthor ">Kenneth  Foreman</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Buck</span>, <span class="hlFld-ContribAuthor ">Earl W.  May</span>, <span class="hlFld-ContribAuthor ">Lixin  Feng</span>, <span class="hlFld-ContribAuthor ">Mark A.  Bittner</span>, <span class="hlFld-ContribAuthor ">Mridula  Kadalbajoo</span>, <span class="hlFld-ContribAuthor ">Darla  Landfair</span>, <span class="hlFld-ContribAuthor ">Kam W.  Siu</span>, <span class="hlFld-ContribAuthor ">Kathryn M.  Stolz</span>, <span class="hlFld-ContribAuthor ">Douglas S.  Werner</span>, <span class="hlFld-ContribAuthor ">Radoslaw S.  Laufer</span>, <span class="hlFld-ContribAuthor ">An-Hu  Li</span>, <span class="hlFld-ContribAuthor ">Hanqing  Dong</span>, <span class="hlFld-ContribAuthor ">Arno G.  Steinig</span>, <span class="hlFld-ContribAuthor ">Andrew  Kleinberg</span>, <span class="hlFld-ContribAuthor ">Yan  Yao</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Pachter</span>, <span class="hlFld-ContribAuthor ">Robert  Wild</span>, and <span class="hlFld-ContribAuthor ">Mark J.  Mulvihill</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>1 </em>
                                    (9)
                                     , 510-515. <a href="https://doi.org/10.1021/ml100178g" title="DOI URL">https://doi.org/10.1021/ml100178g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml100178g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml100178g%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ban%252BOrally%252BEfficacious%252BImidazo%25255B5%25252C1-f%25255D%25255B1%25252C2%25252C4%25255Dtriazine%252BDual%252BInhibitor%252Bof%252BIGF-1R%252Band%252BIR%26aulast%3DJin%26aufirst%3DMeizhong%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D23072010%26date%3D14082010%26date%3D30082010%26date%3D09122010%26volume%3D1%26issue%3D9%26spage%3D510%26epage%3D515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daria  Grechishnikova</span>. </span><span class="cited-content_cbyCitation_article-title">Transformer neural network for protein-specific de novo drug generation as a machine translation problem. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-79682-4" title="DOI URL">https://doi.org/10.1038/s41598-020-79682-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-79682-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-79682-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DTransformer%252Bneural%252Bnetwork%252Bfor%252Bprotein-specific%252Bde%252Bnovo%252Bdrug%252Bgeneration%252Bas%252Ba%252Bmachine%252Btranslation%252Bproblem%26aulast%3DGrechishnikova%26aufirst%3DDaria%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie  Bolcaen</span>, <span class="hlFld-ContribAuthor ">Shankari  Nair</span>, <span class="hlFld-ContribAuthor ">Cathryn  Driver</span>, <span class="hlFld-ContribAuthor ">Tebatso  Boshomane</span>, <span class="hlFld-ContribAuthor ">Thomas  Ebenhan</span>, <span class="hlFld-ContribAuthor ">Charlot  Vandevoorde</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (7)
                                     , 626. <a href="https://doi.org/10.3390/ph14070626" title="DOI URL">https://doi.org/10.3390/ph14070626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14070626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14070626%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DNovel%252BReceptor%252BTyrosine%252BKinase%252BPathway%252BInhibitors%252Bfor%252BTargeted%252BRadionuclide%252BTherapy%252Bof%252BGlioblastoma%26aulast%3DBolcaen%26aufirst%3DJulie%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D7%26spage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nasima  Bano</span>, <span class="hlFld-ContribAuthor ">Md Mehedi  Hossain</span>, <span class="hlFld-ContribAuthor ">Aadil Qadir  Bhat</span>, <span class="hlFld-ContribAuthor ">Mir Owais  Ayaz</span>, <span class="hlFld-ContribAuthor ">Monika  Kumari</span>, <span class="hlFld-ContribAuthor ">Padmani  Sandhu</span>, <span class="hlFld-ContribAuthor ">Yusuf  Akhter</span>, <span class="hlFld-ContribAuthor ">Mohd Jamal  Dar</span>. </span><span class="cited-content_cbyCitation_article-title">Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Growth Hormone & IGF Research</span><span> <strong>2020,</strong> <em>55 </em>, 101343. <a href="https://doi.org/10.1016/j.ghir.2020.101343" title="DOI URL">https://doi.org/10.1016/j.ghir.2020.101343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ghir.2020.101343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ghir.2020.101343%26sid%3Dliteratum%253Aachs%26jtitle%3DGrowth%2520Hormone%2520%2526%2520IGF%2520Research%26atitle%3DAnalyzing%252Bstructural%252Bdifferences%252Bbetween%252Binsulin%252Breceptor%252B%252528IR%252529%252Band%252BIGF1R%252Bfor%252Bdesigning%252Bsmall%252Bmolecule%252Ballosteric%252Binhibitors%252Bof%252BIGF1R%252Bas%252Bnovel%252Banti-cancer%252Bagents%26aulast%3DBano%26aufirst%3DNasima%26date%3D2020%26volume%3D55%26spage%3D101343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María  Fuentes-Baile</span>, <span class="hlFld-ContribAuthor ">María P.  Ventero</span>, <span class="hlFld-ContribAuthor ">José A.  Encinar</span>, <span class="hlFld-ContribAuthor ">Pilar  García-Morales</span>, <span class="hlFld-ContribAuthor ">María  Poveda-Deltell</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Pérez-Valenciano</span>, <span class="hlFld-ContribAuthor ">Víctor M.  Barberá</span>, <span class="hlFld-ContribAuthor ">Javier  Gallego-Plazas</span>, <span class="hlFld-ContribAuthor ">Álvaro  Rodríguez-Lescure</span>, <span class="hlFld-ContribAuthor ">José  Martín-Nieto</span>, <span class="hlFld-ContribAuthor ">Miguel  Saceda</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (12)
                                     , 3717. <a href="https://doi.org/10.3390/cancers12123717" title="DOI URL">https://doi.org/10.3390/cancers12123717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12123717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12123717%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDifferential%252BEffects%252Bof%252BIGF-1R%252BSmall%252BMolecule%252BTyrosine%252BKinase%252BInhibitors%252BBMS-754807%252Band%252BOSI-906%252Bon%252BHuman%252BCancer%252BCell%252BLines%26aulast%3DFuentes-Baile%26aufirst%3DMar%25C3%25ADa%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D12%26spage%3D3717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  García-Huerta</span>, <span class="hlFld-ContribAuthor ">Paulina  Troncoso-Escudero</span>, <span class="hlFld-ContribAuthor ">Di  Wu</span>, <span class="hlFld-ContribAuthor ">Arun  Thiruvalluvan</span>, <span class="hlFld-ContribAuthor ">Marisol  Cisternas-Olmedo</span>, <span class="hlFld-ContribAuthor ">Daniel R.  Henríquez</span>, <span class="hlFld-ContribAuthor ">Lars  Plate</span>, <span class="hlFld-ContribAuthor ">Pedro  Chana-Cuevas</span>, <span class="hlFld-ContribAuthor ">Cristian  Saquel</span>, <span class="hlFld-ContribAuthor ">Peter  Thielen</span>, <span class="hlFld-ContribAuthor ">Kenneth A.  Longo</span>, <span class="hlFld-ContribAuthor ">Brad J.  Geddes</span>, <span class="hlFld-ContribAuthor ">Gerardo Z.  Lederkremer</span>, <span class="hlFld-ContribAuthor ">Neeraj  Sharma</span>, <span class="hlFld-ContribAuthor ">Marina  Shenkman</span>, <span class="hlFld-ContribAuthor ">Swati  Naphade</span>, <span class="hlFld-ContribAuthor ">S. Pablo  Sardi</span>, <span class="hlFld-ContribAuthor ">Carlos  Spichiger</span>, <span class="hlFld-ContribAuthor ">Hans G.  Richter</span>, <span class="hlFld-ContribAuthor ">Felipe A.  Court</span>, <span class="hlFld-ContribAuthor ">Kizito Tshitoko  Tshilenge</span>, <span class="hlFld-ContribAuthor ">Lisa M.  Ellerby</span>, <span class="hlFld-ContribAuthor ">R. Luke  Wiseman</span>, <span class="hlFld-ContribAuthor ">Christian  Gonzalez-Billault</span>, <span class="hlFld-ContribAuthor ">Steven  Bergink</span>, <span class="hlFld-ContribAuthor ">Rene L.  Vidal</span>, <span class="hlFld-ContribAuthor ">Claudio  Hetz</span>. </span><span class="cited-content_cbyCitation_article-title">Insulin-like growth factor 2 (IGF2) protects against Huntington’s disease through the extracellular disposal of protein aggregates. </span><span class="cited-content_cbyCitation_journal-name">Acta Neuropathologica</span><span> <strong>2020,</strong> <em>140 </em>
                                    (5)
                                     , 737-764. <a href="https://doi.org/10.1007/s00401-020-02183-1" title="DOI URL">https://doi.org/10.1007/s00401-020-02183-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00401-020-02183-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00401-020-02183-1%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Neuropathologica%26atitle%3DInsulin-like%252Bgrowth%252Bfactor%252B2%252B%252528IGF2%252529%252Bprotects%252Bagainst%252BHuntington%2525E2%252580%252599s%252Bdisease%252Bthrough%252Bthe%252Bextracellular%252Bdisposal%252Bof%252Bprotein%252Baggregates%26aulast%3DGarc%25C3%25ADa-Huerta%26aufirst%3DPaula%26date%3D2020%26date%3D2020%26volume%3D140%26issue%3D5%26spage%3D737%26epage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Holly L.  Racine</span>, <span class="hlFld-ContribAuthor ">Maria A.  Serrat</span>. </span><span class="cited-content_cbyCitation_article-title">The Actions of IGF-1 in the Growth Plate and Its Role in Postnatal Bone Elongation. </span><span class="cited-content_cbyCitation_journal-name">Current Osteoporosis Reports</span><span> <strong>2020,</strong> <em>18 </em>
                                    (3)
                                     , 210-227. <a href="https://doi.org/10.1007/s11914-020-00570-x" title="DOI URL">https://doi.org/10.1007/s11914-020-00570-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11914-020-00570-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11914-020-00570-x%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Osteoporosis%2520Reports%26atitle%3DThe%252BActions%252Bof%252BIGF-1%252Bin%252Bthe%252BGrowth%252BPlate%252Band%252BIts%252BRole%252Bin%252BPostnatal%252BBone%252BElongation%26aulast%3DRacine%26aufirst%3DHolly%2BL.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D3%26spage%3D210%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudhakar  Manda</span>, <span class="hlFld-ContribAuthor ">Na Keum  Lee</span>, <span class="hlFld-ContribAuthor ">Dong-Chan  Oh</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (8)
                                     , 1948. <a href="https://doi.org/10.3390/molecules25081948" title="DOI URL">https://doi.org/10.3390/molecules25081948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25081948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25081948%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BProteolysis%252BTargeting%252BChimeras%252B%252528PROTACs%252529%252Bfor%252Bthe%252BDual%252BDegradation%252Bof%252BIGF-1R%252Band%252BSrc%26aulast%3DManda%26aufirst%3DSudhakar%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D1948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huiru  Li</span>, <span class="hlFld-ContribAuthor ">Xinyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Xilin  Lin</span>, <span class="hlFld-ContribAuthor ">Shuqiang  Zhuang</span>, <span class="hlFld-ContribAuthor ">Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Zhong  Liu</span>, <span class="hlFld-ContribAuthor ">Jianhua  Rong</span>, <span class="hlFld-ContribAuthor ">Jianhao  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">CaCO
              3
              nanoparticles pH-sensitively induce blood coagulation as a potential strategy for starving tumor therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2020,</strong> <em>8 </em>
                                    (6)
                                     , 1223-1234. <a href="https://doi.org/10.1039/C9TB02684C" title="DOI URL">https://doi.org/10.1039/C9TB02684C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9TB02684C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9TB02684C%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DCaCO%252B3%252Bnanoparticles%252BpH-sensitively%252Binduce%252Bblood%252Bcoagulation%252Bas%252Ba%252Bpotential%252Bstrategy%252Bfor%252Bstarving%252Btumor%252Btherapy%26aulast%3DLi%26aufirst%3DHuiru%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D6%26spage%3D1223%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bumhee  Lim</span>, <span class="hlFld-ContribAuthor ">Jinah  Lee</span>, <span class="hlFld-ContribAuthor ">Byungjin  Kim</span>, <span class="hlFld-ContribAuthor ">Rang  Lee</span>, <span class="hlFld-ContribAuthor ">Jaehyun  Park</span>, <span class="hlFld-ContribAuthor ">Dong‐Chan  Oh</span>, <span class="hlFld-ContribAuthor ">Jongsik  Gam</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Target Identification of a 1,3,4‐Oxadiazin‐5(6
              H
              )‐One Anticancer Agent via Photoaffinity Labelling. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 1626-1630. <a href="https://doi.org/10.1002/ajoc.201900258" title="DOI URL">https://doi.org/10.1002/ajoc.201900258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900258%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTarget%252BIdentification%252Bof%252Ba%252B1%25252C3%25252C4%2525E2%252580%252590Oxadiazin%2525E2%252580%2525905%2525286%252BH%252B%252529%2525E2%252580%252590One%252BAnticancer%252BAgent%252Bvia%252BPhotoaffinity%252BLabelling%26aulast%3DLim%26aufirst%3DBumhee%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D1626%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saher  Zaidi</span>, <span class="hlFld-ContribAuthor ">Jason  Gandhi</span>, <span class="hlFld-ContribAuthor ">Gunjan  Joshi</span>, <span class="hlFld-ContribAuthor ">Noel L.  Smith</span>, <span class="hlFld-ContribAuthor ">Sardar Ali  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">The anticancer potential of metformin on prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Prostate Cancer and Prostatic Diseases</span><span> <strong>2019,</strong> <em>22 </em>
                                    (3)
                                     , 351-361. <a href="https://doi.org/10.1038/s41391-018-0085-2" title="DOI URL">https://doi.org/10.1038/s41391-018-0085-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41391-018-0085-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41391-018-0085-2%26sid%3Dliteratum%253Aachs%26jtitle%3DProstate%2520Cancer%2520and%2520Prostatic%2520Diseases%26atitle%3DThe%252Banticancer%252Bpotential%252Bof%252Bmetformin%252Bon%252Bprostate%252Bcancer%26aulast%3DZaidi%26aufirst%3DSaher%26date%3D2019%26date%3D2019%26volume%3D22%26issue%3D3%26spage%3D351%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian‐Jun  Xi</span>, <span class="hlFld-ContribAuthor ">Ruo‐Yu  He</span>, <span class="hlFld-ContribAuthor ">Jian‐Kang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhao‐Bin  Cai</span>, <span class="hlFld-ContribAuthor ">Rang‐Xiao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Yan‐Mei  Zhao</span>, <span class="hlFld-ContribAuthor ">Yi‐Dan  Shao</span>, <span class="hlFld-ContribAuthor ">Xu‐Wang  Pan</span>, <span class="hlFld-ContribAuthor ">Ting‐Ting  Shi</span>, <span class="hlFld-ContribAuthor ">Zuo‐Jun  Dong</span>, <span class="hlFld-ContribAuthor ">Shou‐Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Li‐Min  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel 3‐(thiophen‐2‐ylthio)pyridine derivatives as potential multitarget anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2019,</strong> <em>352 </em>
                                    (8)
                                     , 1900024. <a href="https://doi.org/10.1002/ardp.201900024" title="DOI URL">https://doi.org/10.1002/ardp.201900024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900024%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B3%2525E2%252580%252590%252528thiophen%2525E2%252580%2525902%2525E2%252580%252590ylthio%252529pyridine%252Bderivatives%252Bas%252Bpotential%252Bmultitarget%252Banticancer%252Bagents%26aulast%3DXi%26aufirst%3DJian%25E2%2580%2590Jun%26date%3D2019%26date%3D2019%26volume%3D352%26issue%3D8%26spage%3D1900024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eliot  Osher</span>, <span class="hlFld-ContribAuthor ">Valentine M.  Macaulay</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of the IGF Axis. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (8)
                                     , 895. <a href="https://doi.org/10.3390/cells8080895" title="DOI URL">https://doi.org/10.3390/cells8080895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8080895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8080895%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTherapeutic%252BTargeting%252Bof%252Bthe%252BIGF%252BAxis%26aulast%3DOsher%26aufirst%3DEliot%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Livia  Manzella</span>, <span class="hlFld-ContribAuthor ">Michele  Massimino</span>, <span class="hlFld-ContribAuthor ">Stefania  Stella</span>, <span class="hlFld-ContribAuthor ">Elena  Tirrò</span>, <span class="hlFld-ContribAuthor ">Maria Stella  Pennisi</span>, <span class="hlFld-ContribAuthor ">Federica  Martorana</span>, <span class="hlFld-ContribAuthor ">Gianmarco  Motta</span>, <span class="hlFld-ContribAuthor ">Silvia Rita  Vitale</span>, <span class="hlFld-ContribAuthor ">Adriana  Puma</span>, <span class="hlFld-ContribAuthor ">Chiara  Romano</span>, <span class="hlFld-ContribAuthor ">Sandra  Di Gregorio</span>, <span class="hlFld-ContribAuthor ">Marco  Russo</span>, <span class="hlFld-ContribAuthor ">Pasqualino  Malandrino</span>, <span class="hlFld-ContribAuthor ">Paolo  Vigneri</span>. </span><span class="cited-content_cbyCitation_article-title">Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (13)
                                     , 3258. <a href="https://doi.org/10.3390/ijms20133258" title="DOI URL">https://doi.org/10.3390/ijms20133258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20133258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20133258%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DActivation%252Bof%252Bthe%252BIGF%252BAxis%252Bin%252BThyroid%252BCancer%25253A%252BImplications%252Bfor%252BTumorigenesis%252Band%252BTreatment%26aulast%3DManzella%26aufirst%3DLivia%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D13%26spage%3D3258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. Yu.  Vladimirova</span>, <span class="hlFld-ContribAuthor ">A. A.  Lyanova</span>, <span class="hlFld-ContribAuthor ">E. M.  Frantsiyants</span>, <span class="hlFld-ContribAuthor ">D. S.  Kutilin</span>, <span class="hlFld-ContribAuthor ">M. A.  Engibaryan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of resistance to monoclonal antibodies therapy patients with squamous cell carcinoma of the tongue and mucosa of the oral cavity. </span><span class="cited-content_cbyCitation_journal-name">Malignant tumours</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , 13-25. <a href="https://doi.org/10.18027/2224-5057-2018-8-4-13-25" title="DOI URL">https://doi.org/10.18027/2224-5057-2018-8-4-13-25</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18027/2224-5057-2018-8-4-13-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18027%2F2224-5057-2018-8-4-13-25%26sid%3Dliteratum%253Aachs%26jtitle%3DMalignant%2520tumours%26atitle%3DMolecular%252Bmechanisms%252Bof%252Bresistance%252Bto%252Bmonoclonal%252Bantibodies%252Btherapy%252Bpatients%252Bwith%252Bsquamous%252Bcell%252Bcarcinoma%252Bof%252Bthe%252Btongue%252Band%252Bmucosa%252Bof%252Bthe%252Boral%252Bcavity%26aulast%3DVladimirova%26aufirst%3DL.%2BYu.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3D13%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anuradha A.  Shastri</span>, <span class="hlFld-ContribAuthor ">Vijay  Hegde</span>, <span class="hlFld-ContribAuthor ">Swetha  Peddibhotla</span>, <span class="hlFld-ContribAuthor ">Zahra  Feizy</span>, <span class="hlFld-ContribAuthor ">Nikhil V.  Dhurandhar</span>, . </span><span class="cited-content_cbyCitation_article-title">E4orf1: A protein for enhancing glucose uptake despite impaired proximal insulin signaling. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2018,</strong> <em>13 </em>
                                    (12)
                                     , e0208427. <a href="https://doi.org/10.1371/journal.pone.0208427" title="DOI URL">https://doi.org/10.1371/journal.pone.0208427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0208427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0208427%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DE4orf1%25253A%252BA%252Bprotein%252Bfor%252Benhancing%252Bglucose%252Buptake%252Bdespite%252Bimpaired%252Bproximal%252Binsulin%252Bsignaling%26aulast%3DShastri%26aufirst%3DAnuradha%2BA.%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D12%26spage%3De0208427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ho Jin  Lee</span>, <span class="hlFld-ContribAuthor ">Phuong Chi  Pham</span>, <span class="hlFld-ContribAuthor ">Seung Yeob  Hyun</span>, <span class="hlFld-ContribAuthor ">Byungyeob  Baek</span>, <span class="hlFld-ContribAuthor ">Byungjin  Kim</span>, <span class="hlFld-ContribAuthor ">Yunha  Kim</span>, <span class="hlFld-ContribAuthor ">Hye-Young  Min</span>, <span class="hlFld-ContribAuthor ">Jeeyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0802-4" title="DOI URL">https://doi.org/10.1186/s12943-018-0802-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0802-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0802-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DDevelopment%252Bof%252Ba%252B4-aminopyrazolo%25255B3%25252C4-d%25255Dpyrimidine-based%252Bdual%252BIGF1R%25252FSrc%252Binhibitor%252Bas%252Ba%252Bnovel%252Banticancer%252Bagent%252Bwith%252Bminimal%252Btoxicity%26aulast%3DLee%26aufirst%3DHo%2BJin%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Una  Glamočlija</span>, <span class="hlFld-ContribAuthor ">Subhash  Padhye</span>, <span class="hlFld-ContribAuthor ">Selma  Špirtović-Halilović</span>, <span class="hlFld-ContribAuthor ">Amar  Osmanović</span>, <span class="hlFld-ContribAuthor ">Elma  Veljović</span>, <span class="hlFld-ContribAuthor ">Sunčica  Roca</span>, <span class="hlFld-ContribAuthor ">Irena  Novaković</span>, <span class="hlFld-ContribAuthor ">Boris  Mandić</span>, <span class="hlFld-ContribAuthor ">Iztok  Turel</span>, <span class="hlFld-ContribAuthor ">Jakob  Kljun</span>, <span class="hlFld-ContribAuthor ">Snežana  Trifunović</span>, <span class="hlFld-ContribAuthor ">Emira  Kahrović</span>, <span class="hlFld-ContribAuthor ">Sandra  Kraljević Pavelić</span>, <span class="hlFld-ContribAuthor ">Anja  Harej</span>, <span class="hlFld-ContribAuthor ">Marko  Klobučar</span>, <span class="hlFld-ContribAuthor ">Davorka  Završnik</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Biological Evaluation and Docking Studies of Benzoxazoles Derived from Thymoquinone. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (12)
                                     , 3297. <a href="https://doi.org/10.3390/molecules23123297" title="DOI URL">https://doi.org/10.3390/molecules23123297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23123297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23123297%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BBiological%252BEvaluation%252Band%252BDocking%252BStudies%252Bof%252BBenzoxazoles%252BDerived%252Bfrom%252BThymoquinone%26aulast%3DGlamo%25C4%258Dlija%26aufirst%3DUna%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D12%26spage%3D3297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jenna  Penney</span>, <span class="hlFld-ContribAuthor ">Julang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Protegrin 1 Enhances Innate Cellular Defense via the Insulin-Like Growth Factor 1 Receptor Pathway. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular and Infection Microbiology</span><span> <strong>2018,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcimb.2018.00331" title="DOI URL">https://doi.org/10.3389/fcimb.2018.00331</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcimb.2018.00331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcimb.2018.00331%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520and%2520Infection%2520Microbiology%26atitle%3DProtegrin%252B1%252BEnhances%252BInnate%252BCellular%252BDefense%252Bvia%252Bthe%252BInsulin-Like%252BGrowth%252BFactor%252B1%252BReceptor%252BPathway%26aulast%3DPenney%26aufirst%3DJenna%26date%3D2018%26date%3D2018%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam J.  Camblin</span>, <span class="hlFld-ContribAuthor ">Emily A.  Pace</span>, <span class="hlFld-ContribAuthor ">Sharlene  Adams</span>, <span class="hlFld-ContribAuthor ">Michael D.  Curley</span>, <span class="hlFld-ContribAuthor ">Victoria  Rimkunas</span>, <span class="hlFld-ContribAuthor ">Lin  Nie</span>, <span class="hlFld-ContribAuthor ">Gege  Tan</span>, <span class="hlFld-ContribAuthor ">Troy  Bloom</span>, <span class="hlFld-ContribAuthor ">Sergio  Iadevaia</span>, <span class="hlFld-ContribAuthor ">Jason  Baum</span>, <span class="hlFld-ContribAuthor ">Charlene  Minx</span>, <span class="hlFld-ContribAuthor ">Akos  Czibere</span>, <span class="hlFld-ContribAuthor ">Chrystal U.  Louis</span>, <span class="hlFld-ContribAuthor ">Daryl C.  Drummond</span>, <span class="hlFld-ContribAuthor ">Ulrik B.  Nielsen</span>, <span class="hlFld-ContribAuthor ">Birgit  Schoeberl</span>, <span class="hlFld-ContribAuthor ">J. Marc  Pipas</span>, <span class="hlFld-ContribAuthor ">Robert M.  Straubinger</span>, <span class="hlFld-ContribAuthor ">Vasileios  Askoxylakis</span>, <span class="hlFld-ContribAuthor ">Alexey A.  Lugovskoy</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (12)
                                     , 2873-2885. <a href="https://doi.org/10.1158/1078-0432.CCR-17-2262" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-2262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-2262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-2262%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DDual%252BInhibition%252Bof%252BIGF-1R%252Band%252BErbB3%252BEnhances%252Bthe%252BActivity%252Bof%252BGemcitabine%252Band%252BNab-Paclitaxel%252Bin%252BPreclinical%252BModels%252Bof%252BPancreatic%252BCancer%26aulast%3DCamblin%26aufirst%3DAdam%2BJ.%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D12%26spage%3D2873%26epage%3D2885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irem  Dogan Turacli</span>, <span class="hlFld-ContribAuthor ">Haldun  Umudum</span>, <span class="hlFld-ContribAuthor ">Arzu  Pampal</span>, <span class="hlFld-ContribAuthor ">Tuba  Candar</span>, <span class="hlFld-ContribAuthor ">Lara  Kavasoglu</span>, <span class="hlFld-ContribAuthor ">Yaren  Sari</span>. </span><span class="cited-content_cbyCitation_article-title">Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2018,</strong> <em>45 </em>
                                    (3)
                                     , 195-201. <a href="https://doi.org/10.1007/s11033-018-4152-5" title="DOI URL">https://doi.org/10.1007/s11033-018-4152-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-018-4152-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-018-4152-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DDo%252BMCF7%252Bcells%252Bcope%252Bwith%252Bmetformin%252Btreatment%252Bunder%252Benergetic%252Bstress%252Bin%252Blow%252Bglucose%252Bconditions%25253F%26aulast%3DDogan%2BTuracli%26aufirst%3DIrem%26date%3D2018%26date%3D2018%26volume%3D45%26issue%3D3%26spage%3D195%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gayatri  Jamwal</span>, <span class="hlFld-ContribAuthor ">Gurjinder  Singh</span>, <span class="hlFld-ContribAuthor ">Mohd Saleem  Dar</span>, <span class="hlFld-ContribAuthor ">Paramjeet  Singh</span>, <span class="hlFld-ContribAuthor ">Nasima  Bano</span>, <span class="hlFld-ContribAuthor ">Sajad Hussain  Syed</span>, <span class="hlFld-ContribAuthor ">Padmani  Sandhu</span>, <span class="hlFld-ContribAuthor ">Yusuf  Akhter</span>, <span class="hlFld-ContribAuthor ">Satdarshan P.  Monga</span>, <span class="hlFld-ContribAuthor ">Mohd Jamal  Dar</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/β-catenin signaling pathways. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</span><span> <strong>2018,</strong> <em>1865 </em>
                                    (6)
                                     , 920-931. <a href="https://doi.org/10.1016/j.bbamcr.2018.03.013" title="DOI URL">https://doi.org/10.1016/j.bbamcr.2018.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbamcr.2018.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbamcr.2018.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Molecular%2520Cell%2520Research%26atitle%3DIdentification%252Bof%252Ba%252Bunique%252Bloss-of-function%252Bmutation%252Bin%252BIGF1R%252Band%252Ba%252Bcrosstalk%252Bbetween%252BIGF1R%252Band%252BWnt%25252F%2525CE%2525B2-catenin%252Bsignaling%252Bpathways%26aulast%3DJamwal%26aufirst%3DGayatri%26date%3D2018%26volume%3D1865%26issue%3D6%26spage%3D920%26epage%3D931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Hou</span>, <span class="hlFld-ContribAuthor ">Hajime  Ishinaga</span>, <span class="hlFld-ContribAuthor ">Kaoru  Midorikawa</span>, <span class="hlFld-ContribAuthor ">Satoshi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Yusuke  Hiraku</span>, <span class="hlFld-ContribAuthor ">Shinji  Oikawa</span>, <span class="hlFld-ContribAuthor ">Ning  Ma</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Mariko  Murata</span>. </span><span class="cited-content_cbyCitation_article-title">Let-7c inhibits migration and epithelial-mesenchymal transition in head and neck squamous cell carcinoma by targeting
              IGF1R
              and
              HMGA2. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (10)
                                     , 8927-8940. <a href="https://doi.org/10.18632/oncotarget.23826" title="DOI URL">https://doi.org/10.18632/oncotarget.23826</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.23826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.23826%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DLet-7c%252Binhibits%252Bmigration%252Band%252Bepithelial-mesenchymal%252Btransition%252Bin%252Bhead%252Band%252Bneck%252Bsquamous%252Bcell%252Bcarcinoma%252Bby%252Btargeting%252BIGF1R%252Band%252BHMGA2%26aulast%3DHou%26aufirst%3DBo%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D10%26spage%3D8927%26epage%3D8940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Küffer</span>, <span class="hlFld-ContribAuthor ">Tobias  Gutting</span>, <span class="hlFld-ContribAuthor ">Djeda  Belharazem</span>, <span class="hlFld-ContribAuthor ">Christian  Sauer</span>, <span class="hlFld-ContribAuthor ">Maurice S.  Michel</span>, <span class="hlFld-ContribAuthor ">Alexander  Marx</span>, <span class="hlFld-ContribAuthor ">Lutz  Trojan</span>, <span class="hlFld-ContribAuthor ">Philipp  Ströbel</span>. </span><span class="cited-content_cbyCitation_article-title">Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2018,</strong> <em>12 </em>
                                    (2)
                                     , 256-266. <a href="https://doi.org/10.1002/1878-0261.12164" title="DOI URL">https://doi.org/10.1002/1878-0261.12164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1878-0261.12164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1878-0261.12164%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DInsulin-like%252Bgrowth%252Bfactor%252B2%252Bexpression%252Bin%252Bprostate%252Bcancer%252Bis%252Bregulated%252Bby%252Bpromoter-specific%252Bmethylation%26aulast%3DK%25C3%25BCffer%26aufirst%3DStefan%26date%3D2018%26date%3D2018%26volume%3D12%26issue%3D2%26spage%3D256%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron  Simpson</span>, <span class="hlFld-ContribAuthor ">Wilfride  Petnga</span>, <span class="hlFld-ContribAuthor ">Valentine M.  Macaulay</span>, <span class="hlFld-ContribAuthor ">Ulrike  Weyer-Czernilofsky</span>, <span class="hlFld-ContribAuthor ">Thomas  Bogenrieder</span>. </span><span class="cited-content_cbyCitation_article-title">Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (5)
                                     , 571-597. <a href="https://doi.org/10.1007/s11523-017-0514-5" title="DOI URL">https://doi.org/10.1007/s11523-017-0514-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-017-0514-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-017-0514-5%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DInsulin-Like%252BGrowth%252BFactor%252B%252528IGF%252529%252BPathway%252BTargeting%252Bin%252BCancer%25253A%252BRole%252Bof%252Bthe%252BIGF%252BAxis%252Band%252BOpportunities%252Bfor%252BFuture%252BCombination%252BStudies%26aulast%3DSimpson%26aufirst%3DAaron%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3D571%26epage%3D597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Fang  Guo</span>, <span class="hlFld-ContribAuthor ">Xiao-Fei  Zhu</span>, <span class="hlFld-ContribAuthor ">Hai-Ying  Cao</span>, <span class="hlFld-ContribAuthor ">Gen-Shen  Zhong</span>, <span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Bao-Guo  Deng</span>, <span class="hlFld-ContribAuthor ">Ping  Chen</span>, <span class="hlFld-ContribAuthor ">Pei-Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Qing-Fang  Miao</span>, <span class="hlFld-ContribAuthor ">Yong-Su  Zhen</span>. </span><span class="cited-content_cbyCitation_article-title">A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (16)
                                     , 27286-27299. <a href="https://doi.org/10.18632/oncotarget.15933" title="DOI URL">https://doi.org/10.18632/oncotarget.15933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.15933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.15933%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DA%252Bbispecific%252Benediyne-energized%252Bfusion%252Bprotein%252Btargeting%252Bboth%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Band%252Binsulin-like%252Bgrowth%252Bfactor%252B1%252Breceptor%252Bshowing%252Benhanced%252Bantitumor%252Befficacy%252Bagainst%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DGuo%26aufirst%3DXiao-Fang%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D16%26spage%3D27286%26epage%3D27299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wataru  Ichikawa</span>, <span class="hlFld-ContribAuthor ">Masanori  Terashima</span>, <span class="hlFld-ContribAuthor ">Atsushi  Ochiai</span>, <span class="hlFld-ContribAuthor ">Koji  Kitada</span>, <span class="hlFld-ContribAuthor ">Issei  Kurahashi</span>, <span class="hlFld-ContribAuthor ">Shinichi  Sakuramoto</span>, <span class="hlFld-ContribAuthor ">Hitoshi  Katai</span>, <span class="hlFld-ContribAuthor ">Takeshi  Sano</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Imamura</span>, <span class="hlFld-ContribAuthor ">Mitsuru  Sasako</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer. </span><span class="cited-content_cbyCitation_journal-name">Gastric Cancer</span><span> <strong>2017,</strong> <em>20 </em>
                                    (2)
                                     , 263-273. <a href="https://doi.org/10.1007/s10120-016-0600-x" title="DOI URL">https://doi.org/10.1007/s10120-016-0600-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10120-016-0600-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10120-016-0600-x%26sid%3Dliteratum%253Aachs%26jtitle%3DGastric%2520Cancer%26atitle%3DImpact%252Bof%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252Band%252Bamphiregulin%252Bexpression%252Bon%252Bsurvival%252Bin%252Bpatients%252Bwith%252Bstage%252BII%25252FIII%252Bgastric%252Bcancer%252Benrolled%252Bin%252Bthe%252BAdjuvant%252BChemotherapy%252BTrial%252Bof%252BS-1%252Bfor%252BGastric%252BCancer%26aulast%3DIchikawa%26aufirst%3DWataru%26date%3D2017%26date%3D2016%26volume%3D20%26issue%3D2%26spage%3D263%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weibin  Wu</span>, <span class="hlFld-ContribAuthor ">Jieyi  Ma</span>, <span class="hlFld-ContribAuthor ">Nan  Shao</span>, <span class="hlFld-ContribAuthor ">Yawei  Shi</span>, <span class="hlFld-ContribAuthor ">Ruiming  Liu</span>, <span class="hlFld-ContribAuthor ">Wen  Li</span>, <span class="hlFld-ContribAuthor ">Yin  Lin</span>, <span class="hlFld-ContribAuthor ">Shenming  Wang</span>, . </span><span class="cited-content_cbyCitation_article-title">Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2017,</strong> <em>12 </em>
                                    (1)
                                     , e0169229. <a href="https://doi.org/10.1371/journal.pone.0169229" title="DOI URL">https://doi.org/10.1371/journal.pone.0169229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0169229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0169229%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DCo-Targeting%252BIGF-1R%252Band%252BAutophagy%252BEnhances%252Bthe%252BEffects%252Bof%252BCell%252BGrowth%252BSuppression%252Band%252BApoptosis%252BInduced%252Bby%252Bthe%252BIGF-1R%252BInhibitor%252BNVP-AEW541%252Bin%252BTriple-Negative%252BBreast%252BCancer%252BCells%26aulast%3DWu%26aufirst%3DWeibin%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D1%26spage%3De0169229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Lapatinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 243-264. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00011-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00011-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00011-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00011-1%26sid%3Dliteratum%253Aachs%26atitle%3DLapatinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D243%26epage%3D264%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yahu A.  Liu</span>, <span class="hlFld-ContribAuthor ">Vlad E.  Gregor</span>. </span><span class="cited-content_cbyCitation_article-title">A Practical and Scalable Synthesis of GTx-134, an IGF-1R Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2016,</strong> <em>53 </em>
                                    (5)
                                     , 1430-1438. <a href="https://doi.org/10.1002/jhet.2443" title="DOI URL">https://doi.org/10.1002/jhet.2443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2443%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DA%252BPractical%252Band%252BScalable%252BSynthesis%252Bof%252BGTx-134%25252C%252Ban%252BIGF-1R%252BInhibitor%26aulast%3DLiu%26aufirst%3DYahu%2BA.%26date%3D2016%26date%3D2015%26volume%3D53%26issue%3D5%26spage%3D1430%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuaipeng  Hu</span>, <span class="hlFld-ContribAuthor ">Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Shanshan  Yang</span>, <span class="hlFld-ContribAuthor ">Kaiyuan  Ji</span>, <span class="hlFld-ContribAuthor ">Xuexian  Liu</span>, <span class="hlFld-ContribAuthor ">Junzhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruiwen  Fan</span>, <span class="hlFld-ContribAuthor ">Changsheng  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">The effects of IGF1 on the melanogenesis in alpaca melanocytes in vitro. </span><span class="cited-content_cbyCitation_journal-name">In Vitro Cellular & Developmental Biology - Animal</span><span> <strong>2016,</strong> <em>52 </em>
                                    (8)
                                     , 806-811. <a href="https://doi.org/10.1007/s11626-016-0052-y" title="DOI URL">https://doi.org/10.1007/s11626-016-0052-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11626-016-0052-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11626-016-0052-y%26sid%3Dliteratum%253Aachs%26jtitle%3DIn%2520Vitro%2520Cellular%2520%2526%2520Developmental%2520Biology%2520-%2520Animal%26atitle%3DThe%252Beffects%252Bof%252BIGF1%252Bon%252Bthe%252Bmelanogenesis%252Bin%252Balpaca%252Bmelanocytes%252Bin%252Bvitro%26aulast%3DHu%26aufirst%3DShuaipeng%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D8%26spage%3D806%26epage%3D811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuliana  Cassinelli</span>, <span class="hlFld-ContribAuthor ">Enrica  Favini</span>, <span class="hlFld-ContribAuthor ">Laura  Dal Bo</span>, <span class="hlFld-ContribAuthor ">Monica  Tortoreto</span>, <span class="hlFld-ContribAuthor ">Marcella  De Maglie</span>, <span class="hlFld-ContribAuthor ">Gianpaolo  Dagrada</span>, <span class="hlFld-ContribAuthor ">Silvana  Pilotti</span>, <span class="hlFld-ContribAuthor ">Franco  Zunino</span>, <span class="hlFld-ContribAuthor ">Nadia  Zaffaroni</span>, <span class="hlFld-ContribAuthor ">Cinzia  Lanzi</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (30)
                                     , 47848-47863. <a href="https://doi.org/10.18632/oncotarget.10292" title="DOI URL">https://doi.org/10.18632/oncotarget.10292</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.10292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.10292%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DAntitumor%252Befficacy%252Bof%252Bthe%252Bheparan%252Bsulfate%252Bmimic%252Broneparstat%252B%252528SST0001%252529%252Bagainst%252Bsarcoma%252Bmodels%252Binvolves%252Bmulti-target%252Binhibition%252Bof%252Breceptor%252Btyrosine%252Bkinases%26aulast%3DCassinelli%26aufirst%3DGiuliana%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D30%26spage%3D47848%26epage%3D47863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel  Del Pino Curbelo</span>, <span class="hlFld-ContribAuthor ">Amelia  Rodríguez Rodríguez</span>, <span class="hlFld-ContribAuthor ">Jaume  Buxeda i Garrigós</span>, <span class="hlFld-ContribAuthor ">José  Mangas Viñuela</span>, <span class="hlFld-ContribAuthor ">Peter M.  Day</span>, <span class="hlFld-ContribAuthor ">Pedro  González Quintero</span>, <span class="hlFld-ContribAuthor ">Marco A.  Moreno Benítez</span>. </span><span class="cited-content_cbyCitation_article-title">Las cerámicas aborígenes de Gran Canaria (Islas Canarias) a través del yacimiento de La Cerera: materias primas, tecnología y función. </span><span class="cited-content_cbyCitation_journal-name">Trabajos de Prehistoria</span><span> <strong>2016,</strong> <em>73 </em>
                                    (1)
                                     , 90-114. <a href="https://doi.org/10.3989/tp.2016.12165" title="DOI URL">https://doi.org/10.3989/tp.2016.12165</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3989/tp.2016.12165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3989%2Ftp.2016.12165%26sid%3Dliteratum%253Aachs%26jtitle%3DTrabajos%2520de%2520Prehistoria%26atitle%3DLas%252Bcer%2525C3%2525A1micas%252Babor%2525C3%2525ADgenes%252Bde%252BGran%252BCanaria%252B%252528Islas%252BCanarias%252529%252Ba%252Btrav%2525C3%2525A9s%252Bdel%252Byacimiento%252Bde%252BLa%252BCerera%25253A%252Bmaterias%252Bprimas%25252C%252Btecnolog%2525C3%2525ADa%252By%252Bfunci%2525C3%2525B3n%26aulast%3DDel%2BPino%2BCurbelo%26aufirst%3DMiguel%26date%3D2016%26date%3D2016%26volume%3D73%26issue%3D1%26spage%3D90%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunan  Ye</span>, <span class="hlFld-ContribAuthor ">Jacson  Shen</span>, <span class="hlFld-ContribAuthor ">Edwin  Choy</span>, <span class="hlFld-ContribAuthor ">Cao  Yang</span>, <span class="hlFld-ContribAuthor ">Henry  Mankin</span>, <span class="hlFld-ContribAuthor ">Francis  Hornicek</span>, <span class="hlFld-ContribAuthor ">Zhenfeng  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2016,</strong> <em>77 </em>
                                    (2)
                                     , 349-356. <a href="https://doi.org/10.1007/s00280-015-2944-z" title="DOI URL">https://doi.org/10.1007/s00280-015-2944-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-015-2944-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-015-2944-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3Dp53%252Boverexpression%252Bincreases%252Bchemosensitivity%252Bin%252Bmultidrug-resistant%252Bosteosarcoma%252Bcell%252Blines%26aulast%3DYe%26aufirst%3DShunan%26date%3D2016%26date%3D2015%26volume%3D77%26issue%3D2%26spage%3D349%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ali  Vaziri-Gohar</span>, <span class="hlFld-ContribAuthor ">Kevin D.  Houston</span>. </span><span class="cited-content_cbyCitation_article-title">GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2016,</strong> <em>422 </em>, 160-171. <a href="https://doi.org/10.1016/j.mce.2015.11.033" title="DOI URL">https://doi.org/10.1016/j.mce.2015.11.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2015.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2015.11.033%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DGPER1-mediated%252BIGFBP-1%252Binduction%252Bmodulates%252BIGF-1-dependent%252Bsignaling%252Bin%252Btamoxifen-treated%252Bbreast%252Bcancer%252Bcells%26aulast%3DVaziri-Gohar%26aufirst%3DAli%26date%3D2016%26volume%3D422%26spage%3D160%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isabel  Heidegger</span>, <span class="hlFld-ContribAuthor ">Petra  Massoner</span>, <span class="hlFld-ContribAuthor ">Natalie  Sampson</span>, <span class="hlFld-ContribAuthor ">Helmut  Klocker</span>. </span><span class="cited-content_cbyCitation_article-title">The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2015,</strong> <em>367 </em>
                                    (2)
                                     , 113-121. <a href="https://doi.org/10.1016/j.canlet.2015.07.026" title="DOI URL">https://doi.org/10.1016/j.canlet.2015.07.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2015.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2015.07.026%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DThe%252Binsulin-like%252Bgrowth%252Bfactor%252B%252528IGF%252529%252Baxis%252Bas%252Ban%252Banticancer%252Btarget%252Bin%252Bprostate%252Bcancer%26aulast%3DHeidegger%26aufirst%3DIsabel%26date%3D2015%26volume%3D367%26issue%3D2%26spage%3D113%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">KATHY  GATELY</span>, <span class="hlFld-ContribAuthor ">LYDIA  FORDE</span>, <span class="hlFld-ContribAuthor ">STEPHEN  GRAY</span>, <span class="hlFld-ContribAuthor ">DEREK  MORRIS</span>, <span class="hlFld-ContribAuthor ">AIDAN  CORVIN</span>, <span class="hlFld-ContribAuthor ">PRERNA  TEWARI</span>, <span class="hlFld-ContribAuthor ">KENNETH  O'BYRNE</span>. </span><span class="cited-content_cbyCitation_article-title">Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Clinical Oncology</span><span> <strong>2015,</strong> <em>3 </em>
                                    (5)
                                     , 1073-1079. <a href="https://doi.org/10.3892/mco.2015.580" title="DOI URL">https://doi.org/10.3892/mco.2015.580</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/mco.2015.580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fmco.2015.580%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Clinical%2520Oncology%26atitle%3DMutational%252Banalysis%252Bof%252Bthe%252Binsulin-like%252Bgrowth%252Bfactor%252B1%252Breceptor%252Btyrosine%252Bkinase%252Bdomain%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bpatients%26aulast%3DGATELY%26aufirst%3DKATHY%26date%3D2015%26date%3D2015%26volume%3D3%26issue%3D5%26spage%3D1073%26epage%3D1079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kathryn  Tworkoski</span>, <span class="hlFld-ContribAuthor ">Nancy  Raab-Traub</span>, . </span><span class="cited-content_cbyCitation_article-title">LMP1 Promotes Expression of Insulin-Like Growth Factor 1 (IGF1) To Selectively Activate IGF1 Receptor and Drive Cell Proliferation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2015,</strong> <em>89 </em>
                                    (5)
                                     , 2590-2602. <a href="https://doi.org/10.1128/JVI.02921-14" title="DOI URL">https://doi.org/10.1128/JVI.02921-14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.02921-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.02921-14%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DLMP1%252BPromotes%252BExpression%252Bof%252BInsulin-Like%252BGrowth%252BFactor%252B1%252B%252528IGF1%252529%252BTo%252BSelectively%252BActivate%252BIGF1%252BReceptor%252Band%252BDrive%252BCell%252BProliferation%26aulast%3DTworkoski%26aufirst%3DKathryn%26date%3D2015%26date%3D2014%26volume%3D89%26issue%3D5%26spage%3D2590%26epage%3D2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aubie K.  Shaw</span>, <span class="hlFld-ContribAuthor ">Michael W.  Pickup</span>, <span class="hlFld-ContribAuthor ">Anna  Chytil</span>, <span class="hlFld-ContribAuthor ">Mary  Aakre</span>, <span class="hlFld-ContribAuthor ">Philip  Owens</span>, <span class="hlFld-ContribAuthor ">Harold L.  Moses</span>, <span class="hlFld-ContribAuthor ">Sergey V.  Novitskiy</span>, . </span><span class="cited-content_cbyCitation_article-title">TGFβ Signaling in Myeloid Cells Regulates Mammary Carcinoma Cell Invasion through Fibroblast Interactions. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (1)
                                     , e0117908. <a href="https://doi.org/10.1371/journal.pone.0117908" title="DOI URL">https://doi.org/10.1371/journal.pone.0117908</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0117908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0117908%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DTGF%2525CE%2525B2%252BSignaling%252Bin%252BMyeloid%252BCells%252BRegulates%252BMammary%252BCarcinoma%252BCell%252BInvasion%252Bthrough%252BFibroblast%252BInteractions%26aulast%3DShaw%26aufirst%3DAubie%2BK.%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3De0117908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandy T.  Liu</span>, <span class="hlFld-ContribAuthor ">Andrew E.  Hendifar</span>, <span class="hlFld-ContribAuthor ">Edward M.  Wolin</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Targets for Future Medical Treatments. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 145-162. <a href="https://doi.org/10.1007/978-1-4939-1798-3_12" title="DOI URL">https://doi.org/10.1007/978-1-4939-1798-3_12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-1798-3_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-1798-3_12%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%252BTargets%252Bfor%252BFuture%252BMedical%252BTreatments%26aulast%3DLiu%26aufirst%3DSandy%2BT.%26date%3D2015%26date%3D2014%26spage%3D145%26epage%3D162%26pub%3DSpringer%2520New%2520York%26atitle%3DManagement%252Bof%252BPancreatic%252BNeuroendocrine%252BTumors%26aulast%3DPisegna%26aufirst%3DJoseph%2BR.%26date%3D2015%26volume%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Noyko S.  Stanilov</span>, <span class="hlFld-ContribAuthor ">Iliya A.  Karakolev</span>, <span class="hlFld-ContribAuthor ">Tashko S.  Deliysky</span>, <span class="hlFld-ContribAuthor ">Jovcho P.  Jovchev</span>, <span class="hlFld-ContribAuthor ">Spaska A.  Stanilova</span>. </span><span class="cited-content_cbyCitation_article-title">Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2014,</strong> <em>41 </em>
                                    (12)
                                     , 8099-8106. <a href="https://doi.org/10.1007/s11033-014-3708-2" title="DOI URL">https://doi.org/10.1007/s11033-014-3708-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-014-3708-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-014-3708-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DAssociation%252Bof%252Binsulin-like%252Bgrowth%252Bfactor-I%252Breceptor%252Bpolymorphism%252Bwith%252Bcolorectal%252Bcancer%252Bdevelopment%26aulast%3DStanilov%26aufirst%3DNoyko%2BS.%26date%3D2014%26date%3D2014%26volume%3D41%26issue%3D12%26spage%3D8099%26epage%3D8106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Pivonello</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  De Martino</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Negri</span>, <span class="hlFld-ContribAuthor ">Gaia  Cuomo</span>, <span class="hlFld-ContribAuthor ">Federica  Cariati</span>, <span class="hlFld-ContribAuthor ">Francesco  Izzo</span>, <span class="hlFld-ContribAuthor ">Annamaria  Colao</span>, <span class="hlFld-ContribAuthor ">Rosario  Pivonello</span>. </span><span class="cited-content_cbyCitation_article-title">The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">Infectious Agents and Cancer</span><span> <strong>2014,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/1750-9378-9-27" title="DOI URL">https://doi.org/10.1186/1750-9378-9-27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1750-9378-9-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1750-9378-9-27%26sid%3Dliteratum%253Aachs%26jtitle%3DInfectious%2520Agents%2520and%2520Cancer%26atitle%3DThe%252BGH-IGF-SST%252Bsystem%252Bin%252Bhepatocellular%252Bcarcinoma%25253A%252Bbiological%252Band%252Bmolecular%252Bpathogenetic%252Bmechanisms%252Band%252Btherapeutic%252Btargets%26aulast%3DPivonello%26aufirst%3DClaudia%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yinxian  Wen</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Tan</span>, <span class="hlFld-ContribAuthor ">Jun  Qin</span>, <span class="hlFld-ContribAuthor ">Xianfei  Xie</span>, <span class="hlFld-ContribAuthor ">Linlong  Wang</span>, <span class="hlFld-ContribAuthor ">Qibing  Mei</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Jacques  Magdalou</span>, <span class="hlFld-ContribAuthor ">Liaobin  Chen</span>, . </span><span class="cited-content_cbyCitation_article-title">Angelica Sinensis Polysaccharides Stimulated UDP-Sugar Synthase Genes through Promoting Gene Expression of IGF-1 and IGF1R in Chondrocytes: Promoting Anti-Osteoarthritic Activity. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (9)
                                     , e107024. <a href="https://doi.org/10.1371/journal.pone.0107024" title="DOI URL">https://doi.org/10.1371/journal.pone.0107024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0107024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0107024%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DAngelica%252BSinensis%252BPolysaccharides%252BStimulated%252BUDP-Sugar%252BSynthase%252BGenes%252Bthrough%252BPromoting%252BGene%252BExpression%252Bof%252BIGF-1%252Band%252BIGF1R%252Bin%252BChondrocytes%25253A%252BPromoting%252BAnti-Osteoarthritic%252BActivity%26aulast%3DWen%26aufirst%3DYinxian%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D9%26spage%3De107024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth J.  Perlman</span>, <span class="hlFld-ContribAuthor ">Peter  Hohenstein</span>. </span><span class="cited-content_cbyCitation_article-title">Wilms Tumors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 397-413. <a href="https://doi.org/10.1016/B978-0-12-396967-5.00023-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-396967-5.00023-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-396967-5.00023-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-396967-5.00023-2%26sid%3Dliteratum%253Aachs%26atitle%3DWilms%252BTumors%26aulast%3DPerlman%26aufirst%3DElizabeth%2BJ.%26date%3D2014%26spage%3D397%26epage%3D413%26pub%3DElsevier%26atitle%3DCancer%252BGenomics%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne  Aucher</span>, <span class="hlFld-ContribAuthor ">Dominika  Rudnicka</span>, <span class="hlFld-ContribAuthor ">Daniel M.  Davis</span>. </span><span class="cited-content_cbyCitation_article-title">MicroRNAs Transfer from Human Macrophages to Hepato-Carcinoma Cells and Inhibit Proliferation. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2013,</strong> <em>191 </em>
                                    (12)
                                     , 6250-6260. <a href="https://doi.org/10.4049/jimmunol.1301728" title="DOI URL">https://doi.org/10.4049/jimmunol.1301728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1301728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1301728%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DMicroRNAs%252BTransfer%252Bfrom%252BHuman%252BMacrophages%252Bto%252BHepato-Carcinoma%252BCells%252Band%252BInhibit%252BProliferation%26aulast%3DAucher%26aufirst%3DAnne%26date%3D2013%26date%3D2013%26volume%3D191%26issue%3D12%26spage%3D6250%26epage%3D6260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niuscha  Yaktapour</span>, <span class="hlFld-ContribAuthor ">Rudolf  Übelhart</span>, <span class="hlFld-ContribAuthor ">Julia  Schüler</span>, <span class="hlFld-ContribAuthor ">Konrad  Aumann</span>, <span class="hlFld-ContribAuthor ">Christine  Dierks</span>, <span class="hlFld-ContribAuthor ">Meike  Burger</span>, <span class="hlFld-ContribAuthor ">Dietmar  Pfeifer</span>, <span class="hlFld-ContribAuthor ">Hassan  Jumaa</span>, <span class="hlFld-ContribAuthor ">Hendrik  Veelken</span>, <span class="hlFld-ContribAuthor ">Tilman  Brummer</span>, <span class="hlFld-ContribAuthor ">Katja  Zirlik</span>. </span><span class="cited-content_cbyCitation_article-title">Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2013,</strong> <em>122 </em>
                                    (9)
                                     , 1621-1633. <a href="https://doi.org/10.1182/blood-2013-02-484386" title="DOI URL">https://doi.org/10.1182/blood-2013-02-484386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2013-02-484386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2013-02-484386%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DInsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252B%252528IGF1R%252529%252Bas%252Ba%252Bnovel%252Btarget%252Bin%252Bchronic%252Blymphocytic%252Bleukemia%26aulast%3DYaktapour%26aufirst%3DNiuscha%26date%3D2013%26volume%3D122%26issue%3D9%26spage%3D1621%26epage%3D1633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hadas  Reuveni</span>, <span class="hlFld-ContribAuthor ">Efrat  Flashner-Abramson</span>, <span class="hlFld-ContribAuthor ">Lilach  Steiner</span>, <span class="hlFld-ContribAuthor ">Kirill  Makedonski</span>, <span class="hlFld-ContribAuthor ">Renduo  Song</span>, <span class="hlFld-ContribAuthor ">Alexei  Shir</span>, <span class="hlFld-ContribAuthor ">Meenhard  Herlyn</span>, <span class="hlFld-ContribAuthor ">Menashe  Bar-Eli</span>, <span class="hlFld-ContribAuthor ">Alexander  Levitzki</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2013,</strong> <em>73 </em>
                                    (14)
                                     , 4383-4394. <a href="https://doi.org/10.1158/0008-5472.CAN-12-3385" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-12-3385</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-12-3385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-12-3385%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DTherapeutic%252BDestruction%252Bof%252BInsulin%252BReceptor%252BSubstrates%252Bfor%252BCancer%252BTreatment%26aulast%3DReuveni%26aufirst%3DHadas%26date%3D2013%26date%3D2013%26volume%3D73%26issue%3D14%26spage%3D4383%26epage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">ASHOK V  BORHADE</span>, <span class="hlFld-ContribAuthor ">BHAGWAT K  UPHADE</span>, <span class="hlFld-ContribAuthor ">DIPAK R  TOPE</span>. </span><span class="cited-content_cbyCitation_article-title">PbO as an efficient and reusable catalyst for one-pot synthesis of tetrahydro benzo pyrans and benzylidene malonitriles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Sciences</span><span> <strong>2013,</strong> <em>125 </em>
                                    (3)
                                     , 583-589. <a href="https://doi.org/10.1007/s12039-013-0396-8" title="DOI URL">https://doi.org/10.1007/s12039-013-0396-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12039-013-0396-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12039-013-0396-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Sciences%26atitle%3DPbO%252Bas%252Ban%252Befficient%252Band%252Breusable%252Bcatalyst%252Bfor%252Bone-pot%252Bsynthesis%252Bof%252Btetrahydro%252Bbenzo%252Bpyrans%252Band%252Bbenzylidene%252Bmalonitriles%26aulast%3DBORHADE%26aufirst%3DASHOK%2BV%26date%3D2013%26date%3D2013%26volume%3D125%26issue%3D3%26spage%3D583%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">X  Zhao</span>, <span class="hlFld-ContribAuthor ">W  Dou</span>, <span class="hlFld-ContribAuthor ">L  He</span>, <span class="hlFld-ContribAuthor ">S  Liang</span>, <span class="hlFld-ContribAuthor ">J  Tie</span>, <span class="hlFld-ContribAuthor ">C  Liu</span>, <span class="hlFld-ContribAuthor ">T  Li</span>, <span class="hlFld-ContribAuthor ">Y  Lu</span>, <span class="hlFld-ContribAuthor ">P  Mo</span>, <span class="hlFld-ContribAuthor ">Y  Shi</span>, <span class="hlFld-ContribAuthor ">K  Wu</span>, <span class="hlFld-ContribAuthor ">Y  Nie</span>, <span class="hlFld-ContribAuthor ">D  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2013,</strong> <em>32 </em>
                                    (11)
                                     , 1363-1372. <a href="https://doi.org/10.1038/onc.2012.156" title="DOI URL">https://doi.org/10.1038/onc.2012.156</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2012.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2012.156%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DMicroRNA-7%252Bfunctions%252Bas%252Ban%252Banti-metastatic%252BmicroRNA%252Bin%252Bgastric%252Bcancer%252Bby%252Btargeting%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%26aulast%3DZhao%26aufirst%3DX%26date%3D2013%26date%3D2012%26volume%3D32%26issue%3D11%26spage%3D1363%26epage%3D1372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dana  Faingold</span>, <span class="hlFld-ContribAuthor ">Dawn  Russell-Hermanns</span>, <span class="hlFld-ContribAuthor ">Silvin  Bakalian</span>. </span><span class="cited-content_cbyCitation_article-title">Prerequisite Genetic Traits for Metastasis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 403-444. <a href="https://doi.org/10.1007/978-1-4614-3685-0_27" title="DOI URL">https://doi.org/10.1007/978-1-4614-3685-0_27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4614-3685-0_27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4614-3685-0_27%26sid%3Dliteratum%253Aachs%26atitle%3DPrerequisite%252BGenetic%252BTraits%252Bfor%252BMetastasis%26aulast%3DFaingold%26aufirst%3DDana%26date%3D2013%26date%3D2013%26spage%3D403%26epage%3D444%26pub%3DSpringer%2520New%2520York%26atitle%3DExperimental%252Band%252BClinical%252BMetastasis%26aulast%3DBurnier%26aufirst%3DJulia%2BV.%26date%3D2013%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L.I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yu. B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XI, 2008–2009. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 195-290. <a href="https://doi.org/10.1016/B978-0-12-404598-9.00003-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-404598-9.00003-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-404598-9.00003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-404598-9.00003-1%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXI%25252C%252B2008%2525E2%252580%2525932009%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DL.I.%26date%3D2013%26spage%3D195%26epage%3D290%26pub%3DElsevier%26date%3D2013%26volume%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong  Fan</span>, <span class="hlFld-ContribAuthor ">Yan-Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Yong-Li  Bao</span>, <span class="hlFld-ContribAuthor ">Lu-Guo  Sun</span>, <span class="hlFld-ContribAuthor ">Yin  Wu</span>, <span class="hlFld-ContribAuthor ">Chun-Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhen-Bo  Song</span>, <span class="hlFld-ContribAuthor ">Li-Hua  Zheng</span>, <span class="hlFld-ContribAuthor ">Ying  Sun</span>, <span class="hlFld-ContribAuthor ">Guan-Nan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Xin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Virtual Screening of Specific Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors from the National Cancer Institute (NCI) Molecular Database. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2012,</strong> <em>13 </em>
                                    (12)
                                     , 17185-17209. <a href="https://doi.org/10.3390/ijms131217185" title="DOI URL">https://doi.org/10.3390/ijms131217185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms131217185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms131217185%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DVirtual%252BScreening%252Bof%252BSpecific%252BInsulin-Like%252BGrowth%252BFactor%252B1%252BReceptor%252B%252528IGF1R%252529%252BInhibitors%252Bfrom%252Bthe%252BNational%252BCancer%252BInstitute%252B%252528NCI%252529%252BMolecular%252BDatabase%26aulast%3DFan%26aufirst%3DCong%26date%3D2012%26date%3D2012%26volume%3D13%26issue%3D12%26spage%3D17185%26epage%3D17209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Sheng  Li</span>, <span class="hlFld-ContribAuthor ">Lu  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiang  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular docking and 3D QSAR studies of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as insulin-like growth factor-1 receptor (IGF1R) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2012,</strong> <em>21 </em>
                                    (10)
                                     , 3301-3311. <a href="https://doi.org/10.1007/s00044-011-9877-9" title="DOI URL">https://doi.org/10.1007/s00044-011-9877-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-011-9877-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-011-9877-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DMolecular%252Bdocking%252Band%252B3D%252BQSAR%252Bstudies%252Bof%252Bsubstituted%252B4-amino-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidines%252Bas%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252B%252528IGF1R%252529%252Binhibitors%26aulast%3DLi%26aufirst%3DYu-Sheng%26date%3D2012%26date%3D2011%26volume%3D21%26issue%3D10%26spage%3D3301%26epage%3D3311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thommey P.  Thomas</span>, <span class="hlFld-ContribAuthor ">Yu-Chung  Chang</span>, <span class="hlFld-ContribAuthor ">Jing Yong  Ye</span>, <span class="hlFld-ContribAuthor ">Alina  Kotlyar</span>, <span class="hlFld-ContribAuthor ">Zhengyi  Cao</span>, <span class="hlFld-ContribAuthor ">Rameshwer  Shukla</span>, <span class="hlFld-ContribAuthor ">Suyang  Qin</span>, <span class="hlFld-ContribAuthor ">Theodore B.  Norris</span>, <span class="hlFld-ContribAuthor ">James R.  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Optical fiber-based in vivo quantification of growth factor receptors. </span><span class="cited-content_cbyCitation_journal-name">Cancer</span><span> <strong>2012,</strong> <em>118 </em>
                                    (8)
                                     , 2148-2156. <a href="https://doi.org/10.1002/cncr.26487" title="DOI URL">https://doi.org/10.1002/cncr.26487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cncr.26487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcncr.26487%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%26atitle%3DOptical%252Bfiber-based%252Bin%252Bvivo%252Bquantification%252Bof%252Bgrowth%252Bfactor%252Breceptors%26aulast%3DThomas%26aufirst%3DThommey%2BP.%26date%3D2012%26date%3D2011%26volume%3D118%26issue%3D8%26spage%3D2148%26epage%3D2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marielle  Brockhoff</span>, <span class="hlFld-ContribAuthor ">Jean-Christophe  Hau</span>, <span class="hlFld-ContribAuthor ">Patrizia  Fontana</span>, <span class="hlFld-ContribAuthor ">Catherine  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Alain  De Pover</span>, <span class="hlFld-ContribAuthor ">Dirk  Erdmann</span>, <span class="hlFld-ContribAuthor ">Patrick  Chène</span>. </span><span class="cited-content_cbyCitation_article-title">Factors influencing the inhibition of protein kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2012,</strong> <em>27 </em>
                                    (2)
                                     , 194-200. <a href="https://doi.org/10.3109/14756366.2011.583922" title="DOI URL">https://doi.org/10.3109/14756366.2011.583922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/14756366.2011.583922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F14756366.2011.583922%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DFactors%252Binfluencing%252Bthe%252Binhibition%252Bof%252Bprotein%252Bkinases%26aulast%3DBrockhoff%26aufirst%3DMarielle%26date%3D2012%26date%3D2011%26volume%3D27%26issue%3D2%26spage%3D194%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">O. L.  Polanovski</span>, <span class="hlFld-ContribAuthor ">E. N.  Lebedenko</span>, <span class="hlFld-ContribAuthor ">S. M.  Deyev</span>. </span><span class="cited-content_cbyCitation_article-title">ERBB oncogene proteins as targets for monoclonal antibodies. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry (Moscow)</span><span> <strong>2012,</strong> <em>77 </em>
                                    (3)
                                     , 227-245. <a href="https://doi.org/10.1134/S0006297912030029" title="DOI URL">https://doi.org/10.1134/S0006297912030029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S0006297912030029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS0006297912030029%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26atitle%3DERBB%252Boncogene%252Bproteins%252Bas%252Btargets%252Bfor%252Bmonoclonal%252Bantibodies%26aulast%3DPolanovski%26aufirst%3DO.%2BL.%26date%3D2012%26date%3D2012%26volume%3D77%26issue%3D3%26spage%3D227%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meizhong  Jin</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Buck</span>, <span class="hlFld-ContribAuthor ">Mark J  Mulvihill</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (3)
                                     , 315-328. <a href="https://doi.org/10.4155/fmc.11.180" title="DOI URL">https://doi.org/10.4155/fmc.11.180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.11.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.11.180%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DSmall-molecule%252BATP-competitive%252Bdual%252BIGF-1R%252Band%252Binsulin%252Breceptor%252Binhibitors%25253A%252Bstructural%252Binsights%25252C%252Bchemical%252Bdiversity%252Band%252Bmolecular%252Bevolution%26aulast%3DJin%26aufirst%3DMeizhong%26date%3D2012%26volume%3D4%26issue%3D3%26spage%3D315%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joan M.  Carboni</span>, <span class="hlFld-ContribAuthor ">Mark  Wittman</span>, <span class="hlFld-ContribAuthor ">Fei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Insulin Receptor Signaling by Tyrosine Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 215-229. <a href="https://doi.org/10.1007/978-1-4614-0598-6_11" title="DOI URL">https://doi.org/10.1007/978-1-4614-0598-6_11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4614-0598-6_11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4614-0598-6_11%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BInsulin-Like%252BGrowth%252BFactor%252BReceptor%252B1%252B%252528IGF-1R%252529%252Band%252BInsulin%252BReceptor%252BSignaling%252Bby%252BTyrosine%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DCarboni%26aufirst%3DJoan%2BM.%26date%3D2012%26date%3D2011%26spage%3D215%26epage%3D229%26pub%3DSpringer%2520US%26atitle%3DInsulin-like%252BGrowth%252BFactors%252Band%252BCancer%26aulast%3DLeRoith%26aufirst%3DDerek%26date%3D2012%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jilong  Yang</span>, <span class="hlFld-ContribAuthor ">Antti  Ylipää</span>, <span class="hlFld-ContribAuthor ">Yan  Sun</span>, <span class="hlFld-ContribAuthor ">Hong  Zheng</span>, <span class="hlFld-ContribAuthor ">Kexin  Chen</span>, <span class="hlFld-ContribAuthor ">Matti  Nykter</span>, <span class="hlFld-ContribAuthor ">Jonathan  Trent</span>, <span class="hlFld-ContribAuthor ">Nancy  Ratner</span>, <span class="hlFld-ContribAuthor ">Dina C.  Lev</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2011,</strong> <em>17 </em>
                                    (24)
                                     , 7563-7573. <a href="https://doi.org/10.1158/1078-0432.CCR-11-1707" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-11-1707</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-11-1707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-11-1707%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DGenomic%252Band%252BMolecular%252BCharacterization%252Bof%252BMalignant%252BPeripheral%252BNerve%252BSheath%252BTumor%252BIdentifies%252Bthe%252BIGF1R%252BPathway%252Bas%252Ba%252BPrimary%252BTarget%252Bfor%252BTreatment%26aulast%3DYang%26aufirst%3DJilong%26date%3D2011%26date%3D2011%26volume%3D17%26issue%3D24%26spage%3D7563%26epage%3D7573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng You  Jia</span>, <span class="hlFld-ContribAuthor ">Hui Hui  Li</span>, <span class="hlFld-ContribAuthor ">Xu Chao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yi Wei  Dong</span>, <span class="hlFld-ContribAuthor ">Da  Fu</span>, <span class="hlFld-ContribAuthor ">Qian Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Wu</span>, <span class="hlFld-ContribAuthor ">Xing Zhong  Wu</span>, . </span><span class="cited-content_cbyCitation_article-title">MiR-223 Suppresses Cell Proliferation by Targeting IGF-1R. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2011,</strong> <em>6 </em>
                                    (11)
                                     , e27008. <a href="https://doi.org/10.1371/journal.pone.0027008" title="DOI URL">https://doi.org/10.1371/journal.pone.0027008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0027008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0027008%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DMiR-223%252BSuppresses%252BCell%252BProliferation%252Bby%252BTargeting%252BIGF-1R%26aulast%3DJia%26aufirst%3DCheng%2BYou%26date%3D2011%26date%3D2011%26volume%3D6%26issue%3D11%26spage%3De27008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daowan  Lai</span>, <span class="hlFld-ContribAuthor ">Shanjiang  Yu</span>, <span class="hlFld-ContribAuthor ">Leen  van Ofwegen</span>, <span class="hlFld-ContribAuthor ">Frank  Totzke</span>, <span class="hlFld-ContribAuthor ">Peter  Proksch</span>, <span class="hlFld-ContribAuthor ">Wenhan  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">9,10-Secosteroids, protein kinase inhibitors from the Chinese gorgonian Astrogorgia sp.. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (22)
                                     , 6873-6880. <a href="https://doi.org/10.1016/j.bmc.2011.09.028" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.09.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.09.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D9%25252C10-Secosteroids%25252C%252Bprotein%252Bkinase%252Binhibitors%252Bfrom%252Bthe%252BChinese%252Bgorgonian%252BAstrogorgia%252Bsp.%26aulast%3DLai%26aufirst%3DDaowan%26date%3D2011%26volume%3D19%26issue%3D22%26spage%3D6873%26epage%3D6880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Kuchenbauer</span>, <span class="hlFld-ContribAuthor ">Sarah M.  Mah</span>, <span class="hlFld-ContribAuthor ">Michael  Heuser</span>, <span class="hlFld-ContribAuthor ">Andrew  McPherson</span>, <span class="hlFld-ContribAuthor ">Jens  Rüschmann</span>, <span class="hlFld-ContribAuthor ">Arefeh  Rouhi</span>, <span class="hlFld-ContribAuthor ">Tobias  Berg</span>, <span class="hlFld-ContribAuthor ">Lars  Bullinger</span>, <span class="hlFld-ContribAuthor ">Bob  Argiropoulos</span>, <span class="hlFld-ContribAuthor ">Ryan D.  Morin</span>, <span class="hlFld-ContribAuthor ">David  Lai</span>, <span class="hlFld-ContribAuthor ">Daniel T.  Starczynowski</span>, <span class="hlFld-ContribAuthor ">Aly  Karsan</span>, <span class="hlFld-ContribAuthor ">Connie J.  Eaves</span>, <span class="hlFld-ContribAuthor ">Akira  Watahiki</span>, <span class="hlFld-ContribAuthor ">Yuzhuo  Wang</span>, <span class="hlFld-ContribAuthor ">Samuel A.  Aparicio</span>, <span class="hlFld-ContribAuthor ">Arnold  Ganser</span>, <span class="hlFld-ContribAuthor ">Jürgen  Krauter</span>, <span class="hlFld-ContribAuthor ">Hartmut  Döhner</span>, <span class="hlFld-ContribAuthor ">Konstanze  Döhner</span>, <span class="hlFld-ContribAuthor ">Marco A.  Marra</span>, <span class="hlFld-ContribAuthor ">Fernando D.  Camargo</span>, <span class="hlFld-ContribAuthor ">Lars  Palmqvist</span>, <span class="hlFld-ContribAuthor ">Christian  Buske</span>, <span class="hlFld-ContribAuthor ">R. Keith  Humphries</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2011,</strong> <em>118 </em>
                                    (12)
                                     , 3350-3358. <a href="https://doi.org/10.1182/blood-2010-10-312454" title="DOI URL">https://doi.org/10.1182/blood-2010-10-312454</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2010-10-312454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2010-10-312454%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DComprehensive%252Banalysis%252Bof%252Bmammalian%252BmiRNA%252A%252Bspecies%252Band%252Btheir%252Brole%252Bin%252Bmyeloid%252Bcells%26aulast%3DKuchenbauer%26aufirst%3DFlorian%26date%3D2011%26volume%3D118%26issue%3D12%26spage%3D3350%26epage%3D3358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph A.  Ludwig</span>, <span class="hlFld-ContribAuthor ">Salah-Eddine  Lamhamedi-Cherradi</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>, <span class="hlFld-ContribAuthor ">Aung  Naing</span>, <span class="hlFld-ContribAuthor ">Robert  Benjamin</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2011,</strong> <em>3 </em>
                                    (3)
                                     , 3029-3054. <a href="https://doi.org/10.3390/cancers3033029" title="DOI URL">https://doi.org/10.3390/cancers3033029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers3033029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers3033029%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BTargeting%252Bof%252Bthe%252BInsulin-Like%252BGrowth%252BFactor%252Band%252BCollateral%252BPathways%252Bin%252BCancer%25253A%252BCombating%252BDrug%252BResistance%26aulast%3DLudwig%26aufirst%3DJoseph%2BA.%26date%3D2011%26date%3D2011%26volume%3D3%26issue%3D3%26spage%3D3029%26epage%3D3054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuo-Chang  Yin</span>, <span class="hlFld-ContribAuthor ">Dave  Chen</span>, <span class="hlFld-ContribAuthor ">Ray  Bakhtiar</span>, <span class="hlFld-ContribAuthor ">Thorsten  Verch</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2011,</strong> <em>3 </em>
                                    (18)
                                     , 2107-2117. <a href="https://doi.org/10.4155/bio.11.208" title="DOI URL">https://doi.org/10.4155/bio.11.208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio.11.208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio.11.208%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DEvaluation%252Bof%252Btwo%252BELISA%252Bmethods%252Bto%252Bdetect%252Btherapeutic%252Banti-IGF1R%252Bantibodies%252Bin%252Bclinical%252Bstudy%252Bsamples%252Bof%252Bdalotuzumab%26aulast%3DYin%26aufirst%3DKuo-Chang%26date%3D2011%26volume%3D3%26issue%3D18%26spage%3D2107%26epage%3D2117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Ducray</span>, <span class="hlFld-ContribAuthor ">Iain  Simpson</span>, <span class="hlFld-ContribAuthor ">Frederic H.  Jung</span>, <span class="hlFld-ContribAuthor ">J. Willem M.  Nissink</span>, <span class="hlFld-ContribAuthor ">Peter W.  Kenny</span>, <span class="hlFld-ContribAuthor ">Martina  Fitzek</span>, <span class="hlFld-ContribAuthor ">Graeme E.  Walker</span>, <span class="hlFld-ContribAuthor ">Lara T.  Ward</span>, <span class="hlFld-ContribAuthor ">Kevin  Hudson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (16)
                                     , 4698-4701. <a href="https://doi.org/10.1016/j.bmcl.2011.06.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.06.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.06.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.06.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bimidazo%25255B1%25252C2-a%25255Dpyridines%252Bas%252Binhibitors%252Bof%252Bthe%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252Btyrosine%252Bkinase%26aulast%3DDucray%26aufirst%3DRichard%26date%3D2011%26volume%3D21%26issue%3D16%26spage%3D4698%26epage%3D4701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Christophe  Hau</span>, <span class="hlFld-ContribAuthor ">Patrizia  Fontana</span>, <span class="hlFld-ContribAuthor ">Catherine  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Alain  De Pover</span>, <span class="hlFld-ContribAuthor ">Dirk  Erdmann</span>, <span class="hlFld-ContribAuthor ">Patrick  Chène</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging the Contribution of Thermodynamics in Drug Discovery with the Help of Fluorescence-Based Thermal Shift Assays. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Screening</span><span> <strong>2011,</strong> <em>16 </em>
                                    (5)
                                     , 552-556. <a href="https://doi.org/10.1177/1087057111399573" title="DOI URL">https://doi.org/10.1177/1087057111399573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057111399573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057111399573%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Screening%26atitle%3DLeveraging%252Bthe%252BContribution%252Bof%252BThermodynamics%252Bin%252BDrug%252BDiscovery%252Bwith%252Bthe%252BHelp%252Bof%252BFluorescence-Based%252BThermal%252BShift%252BAssays%26aulast%3DHau%26aufirst%3DJean%2BChristophe%26date%3D2011%26date%3D2011%26volume%3D16%26issue%3D5%26spage%3D552%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John L.  Buchanan</span>, <span class="hlFld-ContribAuthor ">John R.  Newcomb</span>, <span class="hlFld-ContribAuthor ">David P.  Carney</span>, <span class="hlFld-ContribAuthor ">Stuart C.  Chaffee</span>, <span class="hlFld-ContribAuthor ">Lilly  Chai</span>, <span class="hlFld-ContribAuthor ">Rod  Cupples</span>, <span class="hlFld-ContribAuthor ">Linda F.  Epstein</span>, <span class="hlFld-ContribAuthor ">Paul  Gallant</span>, <span class="hlFld-ContribAuthor ">Yan  Gu</span>, <span class="hlFld-ContribAuthor ">Jean-Christophe  Harmange</span>, <span class="hlFld-ContribAuthor ">Kathy  Hodge</span>, <span class="hlFld-ContribAuthor ">Brett E.  Houk</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Janan  Jona</span>, <span class="hlFld-ContribAuthor ">Smriti  Joseph</span>, <span class="hlFld-ContribAuthor ">H. Toni  Jun</span>, <span class="hlFld-ContribAuthor ">Rakesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Chun  Li</span>, <span class="hlFld-ContribAuthor ">John  Lu</span>, <span class="hlFld-ContribAuthor ">Tom  Menges</span>, <span class="hlFld-ContribAuthor ">Michael J.  Morrison</span>, <span class="hlFld-ContribAuthor ">Perry M.  Novak</span>, <span class="hlFld-ContribAuthor ">Simon  van der Plas</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Paul E.  Rose</span>, <span class="hlFld-ContribAuthor ">Satin  Sawant</span>, <span class="hlFld-ContribAuthor ">Ji-Rong  Sun</span>, <span class="hlFld-ContribAuthor ">Sekhar  Surapaneni</span>, <span class="hlFld-ContribAuthor ">Susan M.  Turci</span>, <span class="hlFld-ContribAuthor ">Keyang  Xu</span>, <span class="hlFld-ContribAuthor ">Evelyn  Yanez</span>, <span class="hlFld-ContribAuthor ">Huilin  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (8)
                                     , 2394-2399. <a href="https://doi.org/10.1016/j.bmcl.2011.02.075" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.02.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.02.075%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B2%25252C4-bis-arylamino-1%25252C3-pyrimidines%252Bas%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252B%252528IGF-1R%252529%252Binhibitors%26aulast%3DBuchanan%26aufirst%3DJohn%2BL.%26date%3D2011%26volume%3D21%26issue%3D8%26spage%3D2394%26epage%3D2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominique  Lesuisse</span>, <span class="hlFld-ContribAuthor ">Jacques  Mauger</span>, <span class="hlFld-ContribAuthor ">Conception  Nemecek</span>, <span class="hlFld-ContribAuthor ">Sébastien  Maignan</span>, <span class="hlFld-ContribAuthor ">Janine  Boiziau</span>, <span class="hlFld-ContribAuthor ">Greg  Harlow</span>, <span class="hlFld-ContribAuthor ">Augustin  Hittinger</span>, <span class="hlFld-ContribAuthor ">Swen  Ruf</span>, <span class="hlFld-ContribAuthor ">Hartmut  Strobel</span>, <span class="hlFld-ContribAuthor ">Anil  Nair</span>, <span class="hlFld-ContribAuthor ">Kurt  Ritter</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Malleron</span>, <span class="hlFld-ContribAuthor ">Anne  Dagallier</span>, <span class="hlFld-ContribAuthor ">Youssef  El-Ahmad</span>, <span class="hlFld-ContribAuthor ">Jean-Pierre  Guilloteau</span>, <span class="hlFld-ContribAuthor ">Houlfa  Guizani</span>, <span class="hlFld-ContribAuthor ">Hervé  Bouchard</span>, <span class="hlFld-ContribAuthor ">Corinne  Venot</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (8)
                                     , 2224-2228. <a href="https://doi.org/10.1016/j.bmcl.2011.03.003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.03.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.03.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bthe%252Bfirst%252Bnon-ATP%252Bcompetitive%252BIGF-1R%252Bkinase%252Binhibitors%25253A%252BAdvantages%252Bin%252Bcomparison%252Bwith%252Bcompetitive%252Binhibitors%26aulast%3DLesuisse%26aufirst%3DDominique%26date%3D2011%26volume%3D21%26issue%3D8%26spage%3D2224%26epage%3D2228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meizhong  Jin</span>, <span class="hlFld-ContribAuthor ">Andrew  Kleinberg</span>, <span class="hlFld-ContribAuthor ">Andy  Cooke</span>, <span class="hlFld-ContribAuthor ">Prafulla C.  Gokhale</span>, <span class="hlFld-ContribAuthor ">Kenneth  Foreman</span>, <span class="hlFld-ContribAuthor ">Hanqing  Dong</span>, <span class="hlFld-ContribAuthor ">Kam W.  Siu</span>, <span class="hlFld-ContribAuthor ">Mark A.  Bittner</span>, <span class="hlFld-ContribAuthor ">Kristen M.  Mulvihill</span>, <span class="hlFld-ContribAuthor ">Yan  Yao</span>, <span class="hlFld-ContribAuthor ">Darla  Landfair</span>, <span class="hlFld-ContribAuthor ">Matthew  O’Connor</span>, <span class="hlFld-ContribAuthor ">Gilda  Mak</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Pachter</span>, <span class="hlFld-ContribAuthor ">Robert  Wild</span>, <span class="hlFld-ContribAuthor ">Maryland  Rosenfeld-Franklin</span>, <span class="hlFld-ContribAuthor ">Qunsheng  Ji</span>, <span class="hlFld-ContribAuthor ">Mark J.  Mulvihill</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (4)
                                     , 1176-1180. <a href="https://doi.org/10.1016/j.bmcl.2010.12.094" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.12.094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.12.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.12.094%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%252Band%252Bselective%252Bcyclohexyl-derived%252Bimidazopyrazine%252Binsulin-like%252Bgrowth%252Bfactor%252B1%252Breceptor%252Binhibitors%252Bwith%252Bin%252Bvivo%252Befficacy%26aulast%3DJin%26aufirst%3DMeizhong%26date%3D2011%26volume%3D21%26issue%3D4%26spage%3D1176%26epage%3D1180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jose  Diaz-Romero</span>, <span class="hlFld-ContribAuthor ">Salvatore  Romeo</span>, <span class="hlFld-ContribAuthor ">Judith V.M.G.  Bovée</span>, <span class="hlFld-ContribAuthor ">Pancras C.W.  Hogendoorn</span>, <span class="hlFld-ContribAuthor ">Paul F.  Heini</span>, <span class="hlFld-ContribAuthor ">Pierre  Mainil-Varlet</span>. </span><span class="cited-content_cbyCitation_article-title">Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2010,</strong> <em>225 </em>
                                    (2)
                                     , 601-611. <a href="https://doi.org/10.1002/jcp.22245" title="DOI URL">https://doi.org/10.1002/jcp.22245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.22245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.22245%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DHierarchical%252Bclustering%252Bof%252Bflow%252Bcytometry%252Bdata%252Bfor%252Bthe%252Bstudy%252Bof%252Bconventional%252Bcentral%252Bchondrosarcoma%26aulast%3DDiaz-Romero%26aufirst%3DJose%26date%3D2010%26date%3D2010%26volume%3D225%26issue%3D2%26spage%3D601%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary T.  Wang</span>, <span class="hlFld-ContribAuthor ">Robert A.  Mantei</span>, <span class="hlFld-ContribAuthor ">Robert D.  Hubbard</span>, <span class="hlFld-ContribAuthor ">Julie L.  Wilsbacher</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Lora  Tucker</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Hu</span>, <span class="hlFld-ContribAuthor ">Peter  Kovar</span>, <span class="hlFld-ContribAuthor ">Eric F.  Johnson</span>, <span class="hlFld-ContribAuthor ">Donald J.  Osterling</span>, <span class="hlFld-ContribAuthor ">Jennifer  Bouska</span>, <span class="hlFld-ContribAuthor ">Jieyi  Wang</span>, <span class="hlFld-ContribAuthor ">Steven K.  Davidsen</span>, <span class="hlFld-ContribAuthor ">Randy L.  Bell</span>, <span class="hlFld-ContribAuthor ">George S.  Sheppard</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (20)
                                     , 6067-6071. <a href="https://doi.org/10.1016/j.bmcl.2010.08.052" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.08.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.08.052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSubstituted%252B4-amino-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidines%252Bas%252Bmulti-targeted%252Binhibitors%252Bof%252Binsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252B%252528IGF1R%252529%252Band%252Bmembers%252Bof%252BErbB-family%252Breceptor%252Bkinases%26aulast%3DWang%26aufirst%3DGary%2BT.%26date%3D2010%26volume%3D20%26issue%3D20%26spage%3D6067%26epage%3D6071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie Jack  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Pazopanib (Votrient): A VEGFR Tyrosine Kinase Inhibitor for Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2010,</strong>,, 111-122. <a href="https://doi.org/10.1002/9780470768594.ch9" title="DOI URL">https://doi.org/10.1002/9780470768594.ch9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470768594.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470768594.ch9%26sid%3Dliteratum%253Aachs%26atitle%3DPazopanib%252B%252528Votrient%252529%25253A%252BA%252BVEGFR%252BTyrosine%252BKinase%252BInhibitor%252Bfor%252BCancer%26aulast%3DZhang%26aufirst%3DJi%26date%3D2010%26date%3D2010%26spage%3D111%26epage%3D122%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DModern%252BDrug%252BSynthesis%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2010%26date%3D2010%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Upender  Velaparthi</span>, <span class="hlFld-ContribAuthor ">Mark G.  Saulnier</span>, <span class="hlFld-ContribAuthor ">Mark D.  Wittman</span>, <span class="hlFld-ContribAuthor ">Peiying  Liu</span>, <span class="hlFld-ContribAuthor ">David B.  Frennesson</span>, <span class="hlFld-ContribAuthor ">Kurt  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Joan M.  Carboni</span>, <span class="hlFld-ContribAuthor ">Marco  Gottardis</span>, <span class="hlFld-ContribAuthor ">Aixin  Li</span>, <span class="hlFld-ContribAuthor ">Ann  Greer</span>, <span class="hlFld-ContribAuthor ">Wendy  Clarke</span>, <span class="hlFld-ContribAuthor ">Zheng  Yang</span>, <span class="hlFld-ContribAuthor ">Krista  Menard</span>, <span class="hlFld-ContribAuthor ">Francis Y.  Lee</span>, <span class="hlFld-ContribAuthor ">George  Trainor</span>, <span class="hlFld-ContribAuthor ">Dolatrai  Vyas</span>. </span><span class="cited-content_cbyCitation_article-title">Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (10)
                                     , 3182-3185. <a href="https://doi.org/10.1016/j.bmcl.2010.03.057" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.03.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.03.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.03.057%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInsulin-like%252Bgrowth%252Bfactor-1%252Breceptor%252B%252528IGF-1R%252529%252Bkinase%252Binhibitors%25253A%252BSAR%252Bof%252Ba%252Bseries%252Bof%252B3-%25255B6-%2525284-substituted-piperazin-1-yl%252529-4-methyl-1H-benzimidazol-2-yl%25255D-1H-pyridine-2-one%26aulast%3DVelaparthi%26aufirst%3DUpender%26date%3D2010%26volume%3D20%26issue%3D10%26spage%3D3182%26epage%3D3185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kurt  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Mark D.  Wittman</span>, <span class="hlFld-ContribAuthor ">Mark G.  Saulnier</span>, <span class="hlFld-ContribAuthor ">Upender  Velaparthi</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Sang</span>, <span class="hlFld-ContribAuthor ">David B.  Frennesson</span>, <span class="hlFld-ContribAuthor ">Charles  Struzynski</span>, <span class="hlFld-ContribAuthor ">Steven P.  Seitz</span>, <span class="hlFld-ContribAuthor ">Liqi  He</span>, <span class="hlFld-ContribAuthor ">Joan M.  Carboni</span>, <span class="hlFld-ContribAuthor ">Aixin  Li</span>, <span class="hlFld-ContribAuthor ">Ann F.  Greer</span>, <span class="hlFld-ContribAuthor ">Marco  Gottardis</span>, <span class="hlFld-ContribAuthor ">Ricardo M.  Attar</span>, <span class="hlFld-ContribAuthor ">Zheng  Yang</span>, <span class="hlFld-ContribAuthor ">Praveen  Balimane</span>, <span class="hlFld-ContribAuthor ">Lorell N.  Discenza</span>, <span class="hlFld-ContribAuthor ">Francis Y.  Lee</span>, <span class="hlFld-ContribAuthor ">Michael  Sinz</span>, <span class="hlFld-ContribAuthor ">Sean  Kim</span>, <span class="hlFld-ContribAuthor ">Dolatrai  Vyas</span>. </span><span class="cited-content_cbyCitation_article-title">SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (5)
                                     , 1744-1748. <a href="https://doi.org/10.1016/j.bmcl.2010.01.087" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.01.087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.01.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.01.087%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSAR%252Bof%252BPXR%252Btransactivation%252Bin%252Bbenzimidazole-based%252BIGF-1R%252Bkinase%252Binhibitors%26aulast%3DZimmermann%26aufirst%3DKurt%26date%3D2010%26volume%3D20%26issue%3D5%26spage%3D1744%26epage%3D1748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rongshi  Li</span>, <span class="hlFld-ContribAuthor ">Alan  Pourpak</span>, <span class="hlFld-ContribAuthor ">Stephan W.  Morris</span>. </span><span class="cited-content_cbyCitation_article-title">ChemInform Abstract: Inhibition of the Insulin-Like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach. </span><span class="cited-content_cbyCitation_journal-name">ChemInform</span><span> <strong>2009,</strong> <em>40 </em>
                                    (48)
                                     <a href="https://doi.org/10.1002/chin.200948238" title="DOI URL">https://doi.org/10.1002/chin.200948238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chin.200948238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchin.200948238%26sid%3Dliteratum%253Aachs%26jtitle%3DChemInform%26atitle%3DChemInform%252BAbstract%25253A%252BInhibition%252Bof%252Bthe%252BInsulin-Like%252BGrowth%252BFactor-1%252BReceptor%252B%252528IGF1R%252529%252BTyrosine%252BKinase%252Bas%252Ba%252BNovel%252BCancer%252BTherapy%252BApproach%26aulast%3DLi%26aufirst%3DRongshi%26date%3D2009%26volume%3D40%26issue%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Major signaling pathways activated by the IGF1R. The RAS/RAF/MEK/ERK and PI3K/AKT pathways are depicted above. The IGF1R is activated by binding of either IGF1 or IGF2. Binding of ligand induces a conformational change and autophosphorylation of key residues in the β subunits of the receptor, and docking proteins then interact with the phosphorylated residues of the activated receptor. Activation of the receptor and transduction of the intracellular signaling kinase cascades culminates in cell proliferation and antiapoptotic effects. Detailed descriptions of the regulation of IGF1R activation and of these signaling pathways can be found in sections <a class="ref internalNav" href="#sec2_1" aria-label=""></a> and <a class="ref internalNav" href="#sec2_2" aria-label=""></a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of kinase inhibitors approved for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of ATP-competitive inhibitors (I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of ATP-competitive inhibitors (II).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of ATP-competitive inhibitors (III).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/medium/jm-2009-002395_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of ATP-noncompetitive or “mechanism unknown” inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-16/jm9002395/production/images/large/jm-2009-002395_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9002395&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 305 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Salmon, W. D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daughaday, W. H.</span><span> </span><span class="NLM_article-title">A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro</span> <span class="citation_source-journal">J. Lab. Clin. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1957</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1957&pages=825-836&author=W.+D.+Salmonauthor=W.+H.+Daughaday&title=A+hormonally+controlled+serum+factor+which+stimulates+sulfate+incorporation+by+cartilage+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalmon%26aufirst%3DW.%2BD.%26aulast%3DDaughaday%26aufirst%3DW.%2BH.%26atitle%3DA%2520hormonally%2520controlled%2520serum%2520factor%2520which%2520stimulates%2520sulfate%2520incorporation%2520by%2520cartilage%2520in%2520vitro%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1957%26volume%3D49%26spage%3D825%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bell, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pictet, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutter, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, H. M.</span><span> </span><span class="NLM_article-title">Sequence of the human insulin gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=1980&pages=26-32&author=G.+I.+Bellauthor=R.+L.+Pictetauthor=W.+J.+Rutterauthor=B.+Cordellauthor=E.+Tischerauthor=H.+M.+Goodman&title=Sequence+of+the+human+insulin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DG.%2BI.%26aulast%3DPictet%26aufirst%3DR.%2BL.%26aulast%3DRutter%26aufirst%3DW.%2BJ.%26aulast%3DCordell%26aufirst%3DB.%26aulast%3DTischer%26aufirst%3DE.%26aulast%3DGoodman%26aufirst%3DH.%2BM.%26atitle%3DSequence%2520of%2520the%2520human%2520insulin%2520gene%26jtitle%3DNature%26date%3D1980%26volume%3D284%26spage%3D26%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayflick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor II precursor gene organization in relation to insulin gene family</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">310</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=1984&pages=777-781&author=T.+J.+Dullauthor=A.+Grayauthor=J.+S.+Hayflickauthor=A.+Ullrich&title=Insulin-like+growth+factor+II+precursor+gene+organization+in+relation+to+insulin+gene+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DHayflick%26aufirst%3DJ.%2BS.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DInsulin-like%2520growth%2520factor%2520II%2520precursor%2520gene%2520organization%2520in%2520relation%2520to%2520insulin%2520gene%2520family%26jtitle%3DNature%26date%3D1984%26volume%3D310%26spage%3D777%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Jansen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schaik, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricker, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabbay, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussbaum, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussenbach, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Brande, J. L.</span><span> </span><span class="NLM_article-title">Sequence of cDNA encoding human insulin-like growth factor I precursor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1983&pages=609-611&author=M.+Jansenauthor=F.+M.+van+Schaikauthor=A.+T.+Rickerauthor=B.+Bullockauthor=D.+E.+Woodsauthor=K.+H.+Gabbayauthor=A.+L.+Nussbaumauthor=J.+S.+Sussenbachauthor=J.+L.+Van+den+Brande&title=Sequence+of+cDNA+encoding+human+insulin-like+growth+factor+I+precursor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJansen%26aufirst%3DM.%26aulast%3Dvan%2BSchaik%26aufirst%3DF.%2BM.%26aulast%3DRicker%26aufirst%3DA.%2BT.%26aulast%3DBullock%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DD.%2BE.%26aulast%3DGabbay%26aufirst%3DK.%2BH.%26aulast%3DNussbaum%26aufirst%3DA.%2BL.%26aulast%3DSussenbach%26aufirst%3DJ.%2BS.%26aulast%3DVan%2Bden%2BBrande%26aufirst%3DJ.%2BL.%26atitle%3DSequence%2520of%2520cDNA%2520encoding%2520human%2520insulin-like%2520growth%2520factor%2520I%2520precursor%26jtitle%3DNature%26date%3D1983%26volume%3D306%26spage%3D609%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brosius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sures, I.</span><span> </span><span class="NLM_article-title">Genetic variation in the human insulin gene</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">209</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=1980&pages=612-615&author=A.+Ullrichauthor=T.+J.+Dullauthor=A.+Grayauthor=J.+Brosiusauthor=I.+Sures&title=Genetic+variation+in+the+human+insulin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DBrosius%26aufirst%3DJ.%26aulast%3DSures%26aufirst%3DI.%26atitle%3DGenetic%2520variation%2520in%2520the%2520human%2520insulin%2520gene%26jtitle%3DScience%26date%3D1980%26volume%3D209%26spage%3D612%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petruzzelli, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dull, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coussens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubokawa, M.</span><span> </span><span class="NLM_article-title">Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">761</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=756-761&author=A.+Ullrichauthor=J.+R.+Bellauthor=E.+Y.+Chenauthor=R.+Herreraauthor=L.+M.+Petruzzelliauthor=T.+J.+Dullauthor=A.+Grayauthor=L.+Coussensauthor=Y.+C.+Liaoauthor=M.+Tsubokawa&title=Human+insulin+receptor+and+its+relationship+to+the+tyrosine+kinase+family+of+oncogenes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DBell%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DE.%2BY.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DPetruzzelli%26aufirst%3DL.%2BM.%26aulast%3DDull%26aufirst%3DT.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DCoussens%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DY.%2BC.%26aulast%3DTsubokawa%26aufirst%3DM.%26atitle%3DHuman%2520insulin%2520receptor%2520and%2520its%2520relationship%2520to%2520the%2520tyrosine%2520kinase%2520family%2520of%2520oncogenes%26jtitle%3DNature%26date%3D1985%26volume%3D313%26spage%3D756%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang-Feng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henzel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kathuria, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2503</span><span class="NLM_x">–</span> <span class="NLM_lpage">2512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1986&pages=2503-2512&author=A.+Ullrichauthor=A.+Grayauthor=A.+W.+Tamauthor=T.+Yang-Fengauthor=M.+Tsubokawaauthor=C.+Collinsauthor=W.+Henzelauthor=B.+T.+Leauthor=S.+Kathuriaauthor=E.+Chen&title=Insulin-like+growth+factor+I+receptor+primary+structure%3A+comparison+with+insulin+receptor+suggests+structural+determinants+that+define+functional+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DA.%2BW.%26aulast%3DYang-Feng%26aufirst%3DT.%26aulast%3DTsubokawa%26aufirst%3DM.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DHenzel%26aufirst%3DW.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DKathuria%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DE.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520primary%2520structure%253A%2520comparison%2520with%2520insulin%2520receptor%2520suggests%2520structural%2520determinants%2520that%2520define%2520functional%2520specificity%26jtitle%3DEMBO%2520J.%26date%3D1986%26volume%3D5%26spage%3D2503%26epage%3D2512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Myal, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiu, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhaumick, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bala, M.</span><span> </span><span class="NLM_article-title">Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">5486</span><span class="NLM_x">–</span> <span class="NLM_lpage">5490</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1984&pages=5486-5490&author=Y.+Myalauthor=R.+P.+Shiuauthor=B.+Bhaumickauthor=M.+Bala&title=Receptor+binding+and+growth-promoting+activity+of+insulin-like+growth+factors+in+human+breast+cancer+cells+%28T-47D%29+in+culture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMyal%26aufirst%3DY.%26aulast%3DShiu%26aufirst%3DR.%2BP.%26aulast%3DBhaumick%26aufirst%3DB.%26aulast%3DBala%26aufirst%3DM.%26atitle%3DReceptor%2520binding%2520and%2520growth-promoting%2520activity%2520of%2520insulin-like%2520growth%2520factors%2520in%2520human%2520breast%2520cancer%2520cells%2520%2528T-47D%2529%2520in%2520culture%26jtitle%3DCancer%2520Res.%26date%3D1984%26volume%3D44%26spage%3D5486%26epage%3D5490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdue, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolese, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, M.</span><span> </span><span class="NLM_article-title">Presence of somatomedin receptors on primary human breast and colon carcinomas</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0304-3835%2887%2990218-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=2961436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaL1cXpt1Citg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1987&pages=223-230&author=M.+N.+Pollakauthor=J.+F.+Perdueauthor=R.+G.+Margoleseauthor=K.+Baerauthor=M.+Richard&title=Presence+of+somatomedin+receptors+on+primary+human+breast+and+colon+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Presence of somatomedin receptors on primary human breast and colon carcinomas</span></div><div class="casAuthors">Pollak, Michael N.; Perdue, James F.; Margolese, Richard G.; Baer, Kathy; Richard, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">223-30</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">Competitive binding techniques were used to study the interaction of insulin-like growth factor I (IGF-I) with a plasma membrane-enriched subcellular fraction purified from primary breast and colon carcinoma specimens obtained at surgery.  The presence of specific binding sites for IGF-I was detected in all tumor specimens studied.  Scatchard anal. and competition studies with insulin and insulin-like growth factor-II (IGF-II) revealed the presence of specific IGF-I receptors, with a Kd of ∼2 nM.  These results are consistent with the hypothesis that somatomedins play a role in detg. the proliferative behavior of human breast and colon tumors, and suggest that recent lab. studies showing dependence of neoplastic cells on somatomedins (insulin-like growth factors) for optimum proliferation may have clin. relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodS2tABEEBO7Vg90H21EOLACvtfcHk0lgAfcRPIN-c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXpt1Citg%253D%253D&md5=db53dd74a8ea856c46bd508836d7694d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2887%2990218-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252887%252990218-7%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DPerdue%26aufirst%3DJ.%2BF.%26aulast%3DMargolese%26aufirst%3DR.%2BG.%26aulast%3DBaer%26aufirst%3DK.%26aulast%3DRichard%26aufirst%3DM.%26atitle%3DPresence%2520of%2520somatomedin%2520receptors%2520on%2520primary%2520human%2520breast%2520and%2520colon%2520carcinomas%26jtitle%3DCancer%2520Lett.%26date%3D1987%26volume%3D38%26spage%3D223%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Arteaga, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitten, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coronado, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, F. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, C. K.</span><span> </span><span class="NLM_article-title">Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1418</span><span class="NLM_x">–</span> <span class="NLM_lpage">1423</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1989&pages=1418-1423&author=C.+L.+Arteagaauthor=L.+J.+Kittenauthor=E.+B.+Coronadoauthor=S.+Jacobsauthor=F.+C.+Kullauthor=D.+C.+Allredauthor=C.+K.+Osborne&title=Blockade+of+the+type+I+somatomedin+receptor+inhibits+growth+of+human+breast+cancer+cells+in+athymic+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArteaga%26aufirst%3DC.%2BL.%26aulast%3DKitten%26aufirst%3DL.%2BJ.%26aulast%3DCoronado%26aufirst%3DE.%2BB.%26aulast%3DJacobs%26aufirst%3DS.%26aulast%3DKull%26aufirst%3DF.%2BC.%26aulast%3DAllred%26aufirst%3DD.%2BC.%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26atitle%3DBlockade%2520of%2520the%2520type%2520I%2520somatomedin%2520receptor%2520inhibits%2520growth%2520of%2520human%2520breast%2520cancer%2520cells%2520in%2520athymic%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D1989%26volume%3D84%26spage%3D1418%26epage%3D1423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Chan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giovannucci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">563</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.279.5350.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9438850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=563-566&author=J.+M.+Chanauthor=M.+J.+Stampferauthor=E.+Giovannucciauthor=P.+H.+Gannauthor=J.+Maauthor=P.+Wilkinsonauthor=C.+H.+Hennekensauthor=M.+Pollak&title=Plasma+insulin-like+growth+factor-I+and+prostate+cancer+risk%3A+a+prospective+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</span></div><div class="casAuthors">Chan, June M.; Stempfer, Meir J.; Giovannucci, Edward; Gann, Peter H.; Ma, Jing; Wilkinson, Peter; Hennekens, Charles H.; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">563-566</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells.  To investigate assocns. between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' health Study was conducted on prospectively collected plasma from 152 cases and 152 controls.  A strong pos. assocn. was obsd. between IGF-I levels and prostate cancer risk.  Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 % confidence interval 1.8 to 10.6) compared with men in the lowest quartile.  This assocn. was independent of baseline prostate-specific antigen levels.  Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk redn. and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN8T4rIgzxMLVg90H21EOLACvtfcHk0lgAfcRPIN-c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOqsg%253D%253D&md5=43c076479c5fb946f61a42758043bd92</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.563%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BM.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DGann%26aufirst%3DP.%2BH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWilkinson%26aufirst%3DP.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DPlasma%2520insulin-like%2520growth%2520factor-I%2520and%2520prostate%2520cancer%2520risk%253A%2520a%2520prospective%2520study%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D563%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Majeed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry-Shaw, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bismar, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4736</span><span class="NLM_x">–</span> <span class="NLM_lpage">4740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=4736-4740&author=N.+Majeedauthor=M.+J.+Blouinauthor=P.+J.+Kaplan-Lefkoauthor=J.+Barry-Shawauthor=N.+M.+Greenbergauthor=P.+Gaudreauauthor=T.+A.+Bismarauthor=M.+Pollak&title=A+germ+line+mutation+that+delays+prostate+cancer+progression+and+prolongs+survival+in+a+murine+prostate+cancer+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMajeed%26aufirst%3DN.%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%2BJ.%26aulast%3DBarry-Shaw%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DN.%2BM.%26aulast%3DGaudreau%26aufirst%3DP.%26aulast%3DBismar%26aufirst%3DT.%2BA.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DA%2520germ%2520line%2520mutation%2520that%2520delays%2520prostate%2520cancer%2520progression%2520and%2520prolongs%2520survival%2520in%2520a%2520murine%2520prostate%2520cancer%2520model%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D4736%26epage%3D4740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blouin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span> </span><span class="NLM_article-title">Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fbjoc.2001.1895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11487276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=428-430&author=M.+Pollakauthor=M.+J.+Blouinauthor=J.+C.+Zhangauthor=J.+J.+Kopchick&title=Reduced+mammary+gland+carcinogenesis+in+transgenic+mice+expressing+a+growth+hormone+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist</span></div><div class="casAuthors">Pollak, M.; Blouin, M.-J.; Zhang, J.-C.; Kopchick, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">428-430</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Several reports have provided evidence that body size early in life is pos. correlated with risk of subsequent breast cancer, but the biol. basis for this relationship is unclear.  We examd. tumor incidence in transgenic mice expressing a growth hormone (GH) antagonist and in non-transgenic littermates following exposure to dimethylbenz[a]anthracene (DMBA), a well characterized murine mammary gland carcinogen.  The transgenic animals had lower IGF-I levels, were smaller in terms of body size and wt., and exhibited decreased tumor incidence relative to controls.  The demonstration that both body size early in life and breast cancer incidence are influenced by exptl. perturbation of the GH-IGF-I axis in a transgenic model provides evidence that variability between individuals with respect to these hormones underlies the relationship between body size early in life and breast cancer risk obsd. in epidemiol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoem3KP3bi6qbVg90H21EOLACvtfcHk0lgDfV8c1IwysQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslSgt7o%253D&md5=2c353440324684e27bfeed56cc8090f1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.1895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.1895%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DBlouin%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%2BC.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26atitle%3DReduced%2520mammary%2520gland%2520carcinogenesis%2520in%2520transgenic%2520mice%2520expressing%2520a%2520growth%2520hormone%2520antagonist%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D428%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efstratiadis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">11217</span><span class="NLM_x">–</span> <span class="NLM_lpage">11221</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=11217-11221&author=C.+Sellauthor=M.+Rubiniauthor=R.+Rubinauthor=J.+P.+Liuauthor=A.+Efstratiadisauthor=R.+Baserga&title=Simian+virus+40+large+tumor+antigen+is+unable+to+transform+mouse+embryonic+fibroblasts+lacking+type+1+insulin-like+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSell%26aufirst%3DC.%26aulast%3DRubini%26aufirst%3DM.%26aulast%3DRubin%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DEfstratiadis%26aufirst%3DA.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DSimian%2520virus%252040%2520large%2520tumor%2520antigen%2520is%2520unable%2520to%2520transform%2520mouse%2520embryonic%2520fibroblasts%2520lacking%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D11217%26epage%3D11221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennighausen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakar, S.</span><span> </span><span class="NLM_article-title">Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">4384</span><span class="NLM_x">–</span> <span class="NLM_lpage">4388</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=4384-4388&author=Y.+Wuauthor=K.+Cuiauthor=K.+Miyoshiauthor=L.+Hennighausenauthor=J.+E.+Greenauthor=J.+Setserauthor=D.+LeRoithauthor=S.+Yakar&title=Reduced+circulating+insulin-like+growth+factor+I+levels+delay+the+onset+of+chemically+and+genetically+induced+mammary+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DK.%26aulast%3DHennighausen%26aufirst%3DL.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DYakar%26aufirst%3DS.%26atitle%3DReduced%2520circulating%2520insulin-like%2520growth%2520factor%2520I%2520levels%2520delay%2520the%2520onset%2520of%2520chemically%2520and%2520genetically%2520induced%2520mammary%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D4384%26epage%3D4388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Yang, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beamer, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1509</span><span class="NLM_x">–</span> <span class="NLM_lpage">1511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=1509-1511&author=X.+F.+Yangauthor=W.+G.+Beamerauthor=H.+Huynhauthor=M.+Pollak&title=Reduced+growth+of+human+breast+cancer+xenografts+in+hosts+homozygous+for+the+lit+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BF.%26aulast%3DBeamer%26aufirst%3DW.%2BG.%26aulast%3DHuynh%26aufirst%3DH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DReduced%2520growth%2520of%2520human%2520breast%2520cancer%2520xenografts%2520in%2520hosts%2520homozygous%2520for%2520the%2520lit%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D1996%26volume%3D56%26spage%3D1509%26epage%3D1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capraro, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porta, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebetanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruetz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span> </span><span class="NLM_article-title">In vivo antitumor activity of NVP-AEW541, a novel, potent, and selective inhibitor of the IGF-IR kinase</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=231-239&author=C.+Garcia-Echeverriaauthor=M.+A.+Pearsonauthor=A.+Martiauthor=T.+Meyerauthor=J.+Mestanauthor=J.+Zimmermannauthor=J.+Gaoauthor=J.+Brueggenauthor=H.+G.+Capraroauthor=R.+Cozensauthor=D.+B.+Evansauthor=D.+Fabbroauthor=P.+Furetauthor=D.+G.+Portaauthor=J.+Liebetanzauthor=G.+Martiny-Baronauthor=S.+Ruetzauthor=F.+Hofmann&title=In+vivo+antitumor+activity+of+NVP-AEW541%2C+a+novel%2C+potent%2C+and+selective+inhibitor+of+the+IGF-IR+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPearson%26aufirst%3DM.%2BA.%26aulast%3DMarti%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DCapraro%26aufirst%3DH.%2BG.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DPorta%26aufirst%3DD.%2BG.%26aulast%3DLiebetanz%26aufirst%3DJ.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DRuetz%26aufirst%3DS.%26aulast%3DHofmann%26aufirst%3DF.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%2520NVP-AEW541%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520the%2520IGF-IR%2520kinase%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D231%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Goya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shitara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasebe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochiai, A.</span><span> </span><span class="NLM_article-title">Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">6252</span><span class="NLM_x">–</span> <span class="NLM_lpage">6258</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6252-6258&author=M.+Goyaauthor=S.+Miyamotoauthor=K.+Nagaiauthor=Y.+Ohkiauthor=K.+Nakamuraauthor=K.+Shitaraauthor=H.+Maedaauthor=T.+Sangaiauthor=K.+Kodamaauthor=Y.+Endohauthor=G.+Ishiiauthor=T.+Hasebeauthor=H.+Yonouauthor=T.+Hatanoauthor=Y.+Ogawaauthor=A.+Ochiai&title=Growth+inhibition+of+human+prostate+cancer+cells+in+human+adult+bone+implanted+into+nonobese+diabetic%2Fsevere+combined+immunodeficient+mice+by+a+ligand-specific+antibody+to+human+insulin-like+growth+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoya%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DNagai%26aufirst%3DK.%26aulast%3DOhki%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DK.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DSangai%26aufirst%3DT.%26aulast%3DKodama%26aufirst%3DK.%26aulast%3DEndoh%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DHasebe%26aufirst%3DT.%26aulast%3DYonou%26aufirst%3DH.%26aulast%3DHatano%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DGrowth%2520inhibition%2520of%2520human%2520prostate%2520cancer%2520cells%2520in%2520human%2520adult%2520bone%2520implanted%2520into%2520nonobese%2520diabetic%252Fsevere%2520combined%2520immunodeficient%2520mice%2520by%2520a%2520ligand-specific%2520antibody%2520to%2520human%2520insulin-like%2520growth%2520factors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6252%26epage%3D6258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frennesson, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalli, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conover, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=362-371&author=P.+Haluskaauthor=J.+M.+Carboniauthor=D.+A.+Loegeringauthor=F.+Y.+Leeauthor=M.+Wittmanauthor=M.+G.+Saulnierauthor=D.+B.+Frennessonauthor=K.+R.+Kalliauthor=C.+A.+Conoverauthor=R.+M.+Attarauthor=S.+H.+Kaufmannauthor=M.+Gottardisauthor=C.+Erlichman&title=In+vitro+and+in+vivo+antitumor+effects+of+the+dual+insulin-like+growth+factor-I%2Finsulin+receptor+inhibitor%2C+BMS-554417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DFrennesson%26aufirst%3DD.%2BB.%26aulast%3DKalli%26aufirst%3DK.%2BR.%26aulast%3DConover%26aufirst%3DC.%2BA.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520effects%2520of%2520the%2520dual%2520insulin-like%2520growth%2520factor-I%252Finsulin%2520receptor%2520inhibitor%252C%2520BMS-554417%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D362%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld-Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirritt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyzaguirre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2158</span><span class="NLM_x">–</span> <span class="NLM_lpage">2167</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-07-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17671083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2158-2167&author=Q.+S.+Jiauthor=M.+J.+Mulvihillauthor=M.+Rosenfeld-Franklinauthor=A.+Cookeauthor=L.+Fengauthor=G.+Makauthor=M.+O%27Connorauthor=Y.+Yaoauthor=C.+Pirrittauthor=E.+Buckauthor=A.+Eyzaguirreauthor=L.+D.+Arnoldauthor=N.+W.+Gibsonauthor=J.+A.+Pachter&title=A+novel%2C+potent%2C+and+selective+insulin-like+growth+factor-I+receptor+kinase+inhibitor+blocks+insulin-like+growth+factor-I+receptor+signaling+in+vitro+and+inhibits+insulin-like+growth+factor-I+receptor+dependent+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo</span></div><div class="casAuthors">Ji, Qun-sheng; Mulvihill, Mark J.; Rosenfeld-Franklin, Maryland; Cooke, Andrew; Feng, Lixin; Mak, Gilda; O'Connor, Matthew; Yao, Yan; Pirritt, Caroline; Buck, Elizabeth; Eyzaguirre, Alexandra; Arnold, Lee D.; Gibson, Neil W.; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2158-2167</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and IGF-II, are up-regulated in a variety of human cancers.  In tumors, such as colorectal, non-small cell lung, ovarian, and pediatric cancers, which may drive their own growth and survival through autocrine IGF-II expression, the role of IGF-IR is esp. crit.  Here, we present a novel small-mol. IGF-IR kinase inhibitor, cis-3-[3-(4-methyl-piperazin-l-yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine (PQIP), which displayed a cellular IC50 of 19 nmol/L for inhibition of ligand-dependent autophosphorylation of human IGF-IR with 14-fold cellular selectivity relative to the human insulin receptor.  PQIP showed minimal activity against a panel of 32 other protein kinases.  It also abolished the ligand-induced activation of downstream phosphorylated AKT and phosphorylated extracellular signal-regulated kinase 1/2 in both IGF-IR transfectant cells and a GEO human colorectal cancer cell line.  Anal. of GEO cells revealed a significant level of both phosphorylated IGF-IR and IGF-II expression.  Furthermore, inactivation of IGF-II in conditioned GEO culture medium by a neutralizing antibody diminished IGF-IR activation, indicating the presence of a functional IGF-II/IGF-IR autocrine loop in GEO cells.  Once daily oral dosing of PQIP induced robust antitumor efficacy in GEO xenografts.  The antitumor efficacy correlated with the degree and duration of inhibition of tumor IGF-IR phosphorylation in vivo by this compd.  Moreover, when mice were treated for 3 days with a dose of PQIP that maximally inhibited tumor growth, only minor changes in blood glucose were obsd.  Thus, PQIP represents a potent and selective IGF-IR kinase inhibitor that is esp. efficacious in an IGF-II-driven human tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUljsbsd3CzbVg90H21EOLACvtfcHk0lh5kmwtfdD84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltLg%253D&md5=d0d7c5cb6b4ec09893b3ff178f4613d7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0070%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPirritt%26aufirst%3DC.%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DEyzaguirre%26aufirst%3DA.%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DA%2520novel%252C%2520potent%252C%2520and%2520selective%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520blocks%2520insulin-like%2520growth%2520factor-I%2520receptor%2520signaling%2520in%2520vitro%2520and%2520inhibits%2520insulin-like%2520growth%2520factor-I%2520receptor%2520dependent%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2158%26epage%3D2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L.</span><span> </span><span class="NLM_article-title">The new kid on the block(ade) of the IGF-1 receptor</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=201-202&author=D.+LeRoithauthor=L.+Helman&title=The+new+kid+on+the+block%28ade%29+of+the+IGF-1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DHelman%26aufirst%3DL.%26atitle%3DThe%2520new%2520kid%2520on%2520the%2520block%2528ade%2529%2520of%2520the%2520IGF-1%2520receptor%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D201%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMullan, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulaki, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shringarpure, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chauhan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libermann, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span> </span><span class="NLM_article-title">Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">230</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=221-230&author=C.+S.+Mitsiadesauthor=N.+S.+Mitsiadesauthor=C.+J.+McMullanauthor=V.+Poulakiauthor=R.+Shringarpureauthor=M.+Akiyamaauthor=T.+Hideshimaauthor=D.+Chauhanauthor=M.+Josephauthor=T.+A.+Libermannauthor=C.+Garcia-Echeverriaauthor=M.+A.+Pearsonauthor=F.+Hofmannauthor=K.+C.+Andersonauthor=A.+L.+Kung&title=Inhibition+of+the+insulin-like+growth+factor+receptor-1+tyrosine+kinase+activity+as+a+therapeutic+strategy+for+multiple+myeloma%2C+other+hematologic+malignancies%2C+and+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%2BS.%26aulast%3DMcMullan%26aufirst%3DC.%2BJ.%26aulast%3DPoulaki%26aufirst%3DV.%26aulast%3DShringarpure%26aufirst%3DR.%26aulast%3DAkiyama%26aufirst%3DM.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DLibermann%26aufirst%3DT.%2BA.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPearson%26aufirst%3DM.%2BA.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DKung%26aufirst%3DA.%2BL.%26atitle%3DInhibition%2520of%2520the%2520insulin-like%2520growth%2520factor%2520receptor-1%2520tyrosine%2520kinase%2520activity%2520as%2520a%2520therapeutic%2520strategy%2520for%2520multiple%2520myeloma%252C%2520other%2520hematologic%2520malignancies%252C%2520and%2520solid%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D5%26spage%3D221%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvaia, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetsch, L.</span><span> </span><span class="NLM_article-title">Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=1318-1327&author=G.+Pandiniauthor=T.+Wurchauthor=B.+Aklaauthor=N.+Corvaiaauthor=A.+Belfioreauthor=L.+Goetsch&title=Functional+responses+and+in+vivo+anti-tumour+activity+of+h7C10%3A+a+humanised+monoclonal+antibody+with+neutralising+activity+against+the+insulin-like+growth+factor-1+%28IGF-1%29+receptor+and+insulin%2FIGF-1+hybrid+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DWurch%26aufirst%3DT.%26aulast%3DAkla%26aufirst%3DB.%26aulast%3DCorvaia%26aufirst%3DN.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26atitle%3DFunctional%2520responses%2520and%2520in%2520vivo%2520anti-tumour%2520activity%2520of%2520h7C10%253A%2520a%2520humanised%2520monoclonal%2520antibody%2520with%2520neutralising%2520activity%2520against%2520the%2520insulin-like%2520growth%2520factor-1%2520%2528IGF-1%2529%2520receptor%2520and%2520insulin%252FIGF-1%2520hybrid%2520receptors%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D1318%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Osborne, R.</span><span> </span><span class="NLM_article-title">Commercial interest waxes for IGF-1 blockers</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=719-720&author=R.+Osborne&title=Commercial+interest+waxes+for+IGF-1+blockers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DR.%26atitle%3DCommercial%2520interest%2520waxes%2520for%2520IGF-1%2520blockers%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D719%26epage%3D720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batzel, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molife, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gualberto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5834</span><span class="NLM_x">–</span> <span class="NLM_lpage">5840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-1118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17908976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSntLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=5834-5840&author=P.+Haluskaauthor=H.+M.+Shawauthor=G.+N.+Batzelauthor=D.+Yinauthor=J.+R.+Molinaauthor=L.+R.+Molifeauthor=T.+A.+Yapauthor=M.+L.+Robertsauthor=A.+Sharmaauthor=A.+Gualbertoauthor=A.+A.+Adjeiauthor=J.+S.+de+Bono&title=Phase+I+dose+escalation+study+of+the+anti-insulin-like+growth+factor-I+receptor+monoclonal+antibody+CP-751%2C871+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Dose Escalation Study of the Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors</span></div><div class="casAuthors">Haluska, Paul; Shaw, Heather M.; Batzel, Gretchen N.; Yin, Donghua; Molina, Julian R.; Molife, L. Rhoda; Yap, Timothy A.; Roberts, M. Luisa; Sharma, Amarnath; Gualberto, Antonio; Adjei, Alex A.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5834-5840</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: This phase I study was undertaken to define the max. tolerated dose, safety, and pharmacokinetic profile of CP-751,871.  Exptl. Design: Using a rapid dose escalation design, patients with advanced nonhematol. malignancies were treated with CP-751,871 in four dose escalation cohorts.  CP-751,871 was administered i.v. on day 1 of each 21-day cycle.  Pharmacokinetic evaluation was done in all treatment cohorts during cycles 1 and 4.  RESULTS: Twenty-four patients received 110 cycles at four dose levels.  The max. tolerated dose exceeded the maximal feasible dose of 20 mg/kg and, thus, was not identified.  Treatment-related toxicities were generally mild.  The most common adverse events were hyperglycemia, anorexia, nausea, elevated aspartate aminotransferase, elevated γ-glutamyltransferase, diarrhea, hyperuracemia, and fatigue.  At 20 mg/kg, 10 of 15 patients experienced stability of disease.  Two of these patients experienced long-term stability.  There were no objective responses.  Pharmacokinetic anal. revealed a dose-dependent increase in CP-751,871 exposure and ∼2-fold accumulation on repeated dosing in 21-day cycles.  Plasma concns. of CP-751,871 attained were several log-fold greater than the biol. active concn.  Treatment with CP-751,871 increased serum insulin and human growth hormone levels, with modest increases in serum glucose levels.  CONCLUSIONS: CP-751,871 has a favorable safety profile and was well tolerated when given in continuous cycles.  At the maximal feasible dose of 20 mg/kg, there was a moderate accumulation in plasma exposure, and most of the treated patients experienced stability of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2fKATmHTVIbVg90H21EOLACvtfcHk0lje6ed2ZIZZRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSntLrE&md5=e86e9de9cf2f9d8cea5e32376c8c5f18</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1118%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DShaw%26aufirst%3DH.%2BM.%26aulast%3DBatzel%26aufirst%3DG.%2BN.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DRoberts%26aufirst%3DM.%2BL.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DGualberto%26aufirst%3DA.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520study%2520of%2520the%2520anti-insulin-like%2520growth%2520factor-I%2520receptor%2520monoclonal%2520antibody%2520CP-751%252C871%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D5834%26epage%3D5840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vuky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayburn, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picozzi, V. J.</span><span> </span><span class="NLM_article-title">A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3520</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3520&author=M.+Hidalgoauthor=M.+Tirado+Gomezauthor=N.+Lewisauthor=J.+L.+Vukyauthor=G.+Taylorauthor=J.+L.+Hayburnauthor=K.+Hsuauthor=M.+Koshauthor=V.+J.+Picozzi&title=A+phase+I+study+of+MK-0646%2C+a+humanized+monoclonal+antibody+against+the+insulin-like+growth+factor+receptor+type+1+%28IGF1R%29+in+advanced+solid+tumor+patients+in+a+q2+wk+schedule"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DTirado%2BGomez%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DN.%26aulast%3DVuky%26aufirst%3DJ.%2BL.%26aulast%3DTaylor%26aufirst%3DG.%26aulast%3DHayburn%26aufirst%3DJ.%2BL.%26aulast%3DHsu%26aufirst%3DK.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DPicozzi%26aufirst%3DV.%2BJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520MK-0646%252C%2520a%2520humanized%2520monoclonal%2520antibody%2520against%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520type%25201%2520%2528IGF1R%2529%2520in%2520advanced%2520solid%2520tumor%2520patients%2520in%2520a%2520q2%2520wk%2520schedule%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Higano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssoufian, H.</span><span> </span><span class="NLM_article-title">A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-1 receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer</span> <span class="citation_source-journal">Eur. J. Cancer, Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1359-6349%2806%2970653-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=195&author=C.+Higanoauthor=M.+Gordonauthor=R.+LoRussoauthor=F.+Foxauthor=T.+Katzauthor=J.+Roeckerauthor=E.+Rowinskyauthor=H.+Youssoufian&title=A+phase+I+dose-escalation+study+of+weekly+IMC-A12%2C+a+fully+human+insulin+like+growth+factor-1+receptor+%28IGF-IR%29+IgG1+monoclonal+antibody+%28Mab%29%2C+in+patients+%28pts%29+with+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2806%2970653-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252806%252970653-X%26sid%3Dliteratum%253Aachs%26aulast%3DHigano%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DLoRusso%26aufirst%3DR.%26aulast%3DFox%26aufirst%3DF.%26aulast%3DKatz%26aufirst%3DT.%26aulast%3DRoecker%26aufirst%3DJ.%26aulast%3DRowinsky%26aufirst%3DE.%26aulast%3DYoussoufian%26aufirst%3DH.%26atitle%3DA%2520phase%2520I%2520dose-escalation%2520study%2520of%2520weekly%2520IMC-A12%252C%2520a%2520fully%2520human%2520insulin%2520like%2520growth%2520factor-1%2520receptor%2520%2528IGF-IR%2529%2520IgG1%2520monoclonal%2520antibody%2520%2528Mab%2529%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520advanced%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%252C%2520Suppl.%26date%3D2006%26volume%3D4%26spage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boccadoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mery-Mignard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deslandes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harousseau, J. L.</span><span> </span><span class="NLM_article-title">Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1166&author=P.+Moreauauthor=C.+Hulinauthor=T.+Faconauthor=M.+Boccadoroauthor=D.+Mery-Mignardauthor=A.+Deslandesauthor=J.+L.+Harousseau&title=Phase+I+Study+of+AVE1642+Anti+IGF-1R+Monoclonal+Antibody+in+Patients+with+Advanced+Multiple+Myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DHulin%26aufirst%3DC.%26aulast%3DFacon%26aufirst%3DT.%26aulast%3DBoccadoro%26aufirst%3DM.%26aulast%3DMery-Mignard%26aufirst%3DD.%26aulast%3DDeslandes%26aufirst%3DA.%26aulast%3DHarousseau%26aufirst%3DJ.%2BL.%26atitle%3DPhase%2520I%2520Study%2520of%2520AVE1642%2520Anti%2520IGF-1R%2520Monoclonal%2520Antibody%2520in%2520Patients%2520with%2520Advanced%2520Multiple%2520Myeloma%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Rothenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poplin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermeulen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youssoufian, H.</span><span> </span><span class="NLM_article-title">Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span><span class="NLM_elocation-id">C84</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Rothenbergauthor=E.+Poplinauthor=A.+Sandlerauthor=E.+Rubinauthor=F.+Foxauthor=J.+Schwartzauthor=W.+Vermeulenauthor=H.+Youssoufian&title=Phase+I+dose-escalation+study+of+the+anti-IGF-IR+recombinant+human+IgG1+monoclonal+antibody+%28Mab%29+IMC-A12%2C+administered+every+other+week+to+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRothenberg%26aufirst%3DM.%26aulast%3DPoplin%26aufirst%3DE.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DRubin%26aufirst%3DE.%26aulast%3DFox%26aufirst%3DF.%26aulast%3DSchwartz%26aufirst%3DJ.%26aulast%3DVermeulen%26aufirst%3DW.%26aulast%3DYoussoufian%26aufirst%3DH.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520anti-IGF-IR%2520recombinant%2520human%2520IgG1%2520monoclonal%2520antibody%2520%2528Mab%2529%2520IMC-A12%252C%2520administered%2520every%2520other%2520week%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbeke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haqq, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span> </span><span class="NLM_article-title">A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2006.08.8898" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3002&author=A.+W.+Tolcherauthor=M.+L.+Rothenbergauthor=J.+Rodonauthor=D.+Delbekeauthor=A.+Patnaikauthor=L.+Nguyenauthor=F.+Youngauthor=Y.+Hwangauthor=C.+Haqqauthor=I.+Puzanov&title=A+phase+I+pharmacokinetic+and+pharmacodynamic+study+of+AMG+479%2C+a+fully+human+monoclonal+antibody+against+insulin-like+growth+factor+type+1+receptor+%28IGF-1R%29%2C+in+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.08.8898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.08.8898%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDelbeke%26aufirst%3DD.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DF.%26aulast%3DHwang%26aufirst%3DY.%26aulast%3DHaqq%26aufirst%3DC.%26aulast%3DPuzanov%26aufirst%3DI.%26atitle%3DA%2520phase%2520I%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520AMG%2520479%252C%2520a%2520fully%2520human%2520monoclonal%2520antibody%2520against%2520insulin-like%2520growth%2520factor%2520type%25201%2520receptor%2520%2528IGF-1R%2529%252C%2520in%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Chitnis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protheroe, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">The type 1 insulin-like growth factor receptor pathway</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6364</span><span class="NLM_x">–</span> <span class="NLM_lpage">6370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-4879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18927274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=6364-6370&author=M.+M.+Chitnisauthor=J.+S.+Yuenauthor=A.+S.+Protheroeauthor=M.+Pollakauthor=V.+M.+Macaulay&title=The+type+1+insulin-like+growth+factor+receptor+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Type 1 Insulin-Like Growth Factor Receptor Pathway</span></div><div class="casAuthors">Chitnis, Meenali M.; Yuen, John S. P.; Protheroe, Andrew S.; Pollak, Michael; Macaulay, Valentine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6364-6370</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Research conducted over the past two decades has shown the importance of the type 1 insulin-like growth factor receptor (IGF1R) in tumorigenesis, metastasis, and resistance to existing forms of cancer therapy.  The IGF1R itself has only recently been accepted as a credible treatment target, however, perhaps reflecting the potential problems for drug design posed by normal tissue IGF1R expression, and close homol. with the insulin receptor.  Currently ∼12 anti-IGF1R therapeutics are undergoing clin. evaluation, including blocking antibodies and tyrosine kinase inhibitors.  This review will summarize the principal signaling pathways activated by IGF1R and the preclin. data that validated this receptor as a treatment target.  We will review clin. progress in the testing of IGF1R inhibitory drug candidates, the relative benefits and potential toxicities of coinhibition of the insulin receptor, and the rationale for combining IGF1R blockade with other cancer treatments.  An understanding of IGF1R signaling is important because it will guide the incorporation of appropriate mol. markers into clin. trial design.  This will be key to the identification of patients most likely to benefit, and so will influence the ability of IGF1R inhibition to make the transition from exptl. intervention to clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gRwsJwfjNbVg90H21EOLACvtfcHk0lgWWLZIEn7Cyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KgtbrP&md5=2596cc57323f1aa5eee0b87e4554a0fe</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4879%26sid%3Dliteratum%253Aachs%26aulast%3DChitnis%26aufirst%3DM.%2BM.%26aulast%3DYuen%26aufirst%3DJ.%2BS.%26aulast%3DProtheroe%26aufirst%3DA.%2BS.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DThe%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520pathway%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D6364%26epage%3D6370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kurmasheva, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">IGF-I mediated survival pathways in normal and malignant cells</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1766</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1766&publication_year=2006&pages=1-22&author=R.+T.+Kurmashevaauthor=P.+J.+Houghton&title=IGF-I+mediated+survival+pathways+in+normal+and+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DIGF-I%2520mediated%2520survival%2520pathways%2520in%2520normal%2520and%2520malignant%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2006%26volume%3D1766%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mateos, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandiella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San-Miguel, J. F.</span><span> </span><span class="NLM_article-title">New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1157</span><span class="NLM_x">–</span> <span class="NLM_lpage">1165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1470-2045%2808%2970304-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19038762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=1157-1165&author=E.+M.+Ocioauthor=M.+V.+Mateosauthor=P.+Maisoauthor=A.+Pandiellaauthor=J.+F.+San-Miguel&title=New+drugs+in+multiple+myeloma%3A+mechanisms+of+action+and+phase+I%2FII+clinical+findings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings</span></div><div class="casAuthors">Ocio, Enrique M.; Mateos, Maria-Victoria; Maiso, Patricia; Pandiella, Atanasio; San-Miguel, Jesus F.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib.  Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance.  In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclin. and clin. studies in multiple myeloma.  Unfortunately, the single-agent clin. activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1keNCrAvODbVg90H21EOLACvtfcHk0lgK_5cbeNl07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWrsL7K&md5=6f48bee7ba0f1278bc174352a6be08e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2808%2970304-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252808%252970304-8%26sid%3Dliteratum%253Aachs%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DMateos%26aufirst%3DM.%2BV.%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26atitle%3DNew%2520drugs%2520in%2520multiple%2520myeloma%253A%2520mechanisms%2520of%2520action%2520and%2520phase%2520I%252FII%2520clinical%2520findings%26jtitle%3DLancet%2520Oncol.%26date%3D2008%26volume%3D9%26spage%3D1157%26epage%3D1165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor signalling in neoplasia</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrc2536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19029956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=915-928&author=M.+Pollak&title=Insulin+and+insulin-like+growth+factor+signalling+in+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor signalling in neoplasia</span></div><div class="casAuthors">Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">915-928</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metab. and growth.  There is now considerable evidence that these hormones and the signal transduction networks they regulate have important roles in neoplasia.  Epidermiol., clin. and lab. research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signaling.  Pharmacol. strategies under study include the use of novel receptor-specific antibodies, receptor kinase inhibitors and AMP-activated protein kinase activators such as metformin.  There is evidence that insulin and IGF signaling may also be relevant to dietary and lifestyle factors that influence cancer risk and cancer prognosis.  Recent results are encouraging and have justified the expansion of many translational research programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Q6Nlh1d68rVg90H21EOLACvtfcHk0lgK_5cbeNl07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rL&md5=9a7b5e7c67599c7396033f83276f2cb0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrc2536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2536%26sid%3Dliteratum%253Aachs%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor%2520signalling%2520in%2520neoplasia%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D915%26epage%3D928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Riedemann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">IGF1R signalling and its inhibition</span> <span class="citation_source-journal">Endocr.-Relat Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S33</span><span class="NLM_x">–</span> <span class="NLM_lpage">S43</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=S33-S43&issue=Suppl.+1&author=J.+Riedemannauthor=V.+M.+Macaulay&title=IGF1R+signalling+and+its+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiedemann%26aufirst%3DJ.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DIGF1R%2520signalling%2520and%2520its%2520inhibition%26jtitle%3DEndocr.-Relat%2520Cancer%26date%3D2006%26volume%3D13%26issue%3DSuppl.%25201%26spage%3DS33%26epage%3DS43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Ryan, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, P. E.</span><span> </span><span class="NLM_article-title">The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=16-24&author=P.+D.+Ryanauthor=P.+E.+Goss&title=The+emerging+role+of+the+insulin-like+growth+factor+pathway+as+a+therapeutic+target+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DP.%2BD.%26aulast%3DGoss%26aufirst%3DP.%2BE.%26atitle%3DThe%2520emerging%2520role%2520of%2520the%2520insulin-like%2520growth%2520factor%2520pathway%2520as%2520a%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DOncologist%26date%3D2008%26volume%3D13%26spage%3D16%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Sachdev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Disrupting insulin-like growth factor signaling as a potential cancer therapy</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17237261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsVantg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1-12&author=D.+Sachdevauthor=D.+Yee&title=Disrupting+insulin-like+growth+factor+signaling+as+a+potential+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupting insulin-like growth factor signaling as a potential cancer therapy</span></div><div class="casAuthors">Sachdev, Deepali; Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of insulin-like growth factor-I (IGF-I) are assocd. with increased risk of breast, colon, and prostate cancers.  Because IGF-II and insulin signal via the insulin receptor (IR) to stimulate the growth of cancer cells, inhibition of IR might be necessary to totally disrupt the action of IGFs and their receptors.  This review describes the well-recognized roles of IGF-IR in driving the malignant phenotype, examines the evidence that perhaps IR should also be targeted to inhibit the effects of the IGF ligands and insulin in cancer, describes the strategies to disrupt IGF signaling in cancer, and highlights some key issues that need to be considered as clin. trials targeting IGF-IR proceed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDCcpW1cNYXbVg90H21EOLACvtfcHk0lgK_5cbeNl07Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsVantg%253D%253D&md5=90c2e9e9ea4eeac9a1b458b097442284</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0080%26sid%3Dliteratum%253Aachs%26aulast%3DSachdev%26aufirst%3DD.%26aulast%3DYee%26aufirst%3DD.%26atitle%3DDisrupting%2520insulin-like%2520growth%2520factor%2520signaling%2520as%2520a%2520potential%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Samani, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodt, P.</span><span> </span><span class="NLM_article-title">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2006-0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16931767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=20-47&author=A.+A.+Samaniauthor=S.+Yakarauthor=D.+LeRoithauthor=P.+Brodt&title=The+role+of+the+IGF+system+in+cancer+growth+and+metastasis%3A+overview+and+recent+insights"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the IGF system in cancer growth and metastasis: overview and recent insights</span></div><div class="casAuthors">Samani, Amir Abbas; Yakar, Shoshana; LeRoith, Derek; Brodt, Pnina</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-47</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  IGF-I receptor (IGF-IR) signaling and functions are mediated through the activities of a complex mol. network of pos. (e.g., type I IGF) and neg. (e.g., the type II IGF receptor, IGF-IIR) effectors.  Under normal physiol. conditions, the balance between the expression and activities of these mols. is tightly controlled.  Changes in this delicate balance (e.g., overexpression of one effector) may trigger a cascade of mol. events that can ultimately lead to malignancy.  In recent years, evidence has been mounting that the IGF axis may be involved in human cancer progression and can be targeted for therapeutic intervention.  Here we review old and more recent evidence on the role the IGF system in malignancy and highlight exptl. and clin. studies that provide novel insights into the complex mechanisms that contribute to its oncogenic potential.  Controversies arising from conflicting evidence on the relevance of IGF-IR and its ligands to human cancer are discussed.  Our review highlights the importance of viewing the IGF axis as a complex multifactorial system and shows that changes in the expression levels of any one component of the axis, in a given malignancy, should be interpreted with caution and viewed in a wider context that takes into account the expression levels, state of activation, accessibility, and functionality of other interacting components.  Because IGF targeting for anticancer therapy is rapidly becoming a clin. reality, an understanding of this complexity is timely because it is likely to have an impact on the design, mode of action, and clin. outcomes of newly developed drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaVO8jlyh3LVg90H21EOLACvtfcHk0lhiqZQAyKyTyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFCgsrg%253D&md5=f900044e75292ad8c7797407fe500025</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1210%2Fer.2006-0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2006-0001%26sid%3Dliteratum%253Aachs%26aulast%3DSamani%26aufirst%3DA.%2BA.%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DBrodt%26aufirst%3DP.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%2520growth%2520and%2520metastasis%253A%2520overview%2520and%2520recent%2520insights%26jtitle%3DEndocr.%2520Rev.%26date%3D2007%26volume%3D28%26spage%3D20%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Tao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span> </span><span class="NLM_article-title">Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncponc0934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17898809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtV2isLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=591-602&author=Y.+Taoauthor=V.+Pinziauthor=J.+Bourhisauthor=E.+Deutsch&title=Mechanisms+of+disease%3A+signaling+of+the+insulin-like+growth+factor+1+receptor+pathway%E2%80%94therapeutic+perspectives+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer</span></div><div class="casAuthors">Tao, Yungan; Pinzi, Valentina; Bourhis, Jean; Deutsch, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">591-602</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer.  IGF1R signaling has been found to correlate with resistance to anti-EGFR and HER2-based therapies in exptl. systems.  This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of the IGF1R in the resistance of other receptor-targeted therapies.  The insulin-like growth factor 1 (IGF1) signaling pathway is implicated in the development of cancer.  High levels of circulating IGF1 and certain genetic polymorphisms of IGF1 and IGFBP3 are assocd. with an increased risk of several common cancers.  The IGF1 receptor (IGF1R) has been shown to be expressed in a wide range of tumors, and IGF1R signaling is crucial for tumor transformation and the survival of malignant cells.  Several monoclonal antibodies and small-mol. inhibitors have been tested in preclin. studies and early-phase clin. studies.  IGF1R signaling interferes with numerous growth factors and receptors such as VEGF and EGFR.  In the exptl. system, IGF1R signaling has been found to correlate with resistance to therapies based on the inhibition of EGFR and HER2.  This Review highlights the most relevant studies in this exciting area of research, focusing in particular on the role of IGF1R in resistance to other receptor-targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxL4VL6f6eMrVg90H21EOLACvtfcHk0lhiqZQAyKyTyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtV2isLfE&md5=89dcfab09c26f07e2f0da1bd23c06d5f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fncponc0934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0934%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%26aulast%3DPinzi%26aufirst%3DV.%26aulast%3DBourhis%26aufirst%3DJ.%26aulast%3DDeutsch%26aufirst%3DE.%26atitle%3DMechanisms%2520of%2520disease%253A%2520signaling%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520pathway%25E2%2580%2594therapeutic%2520perspectives%2520in%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2007%26volume%3D4%26spage%3D591%26epage%3D602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Jansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berghard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kordel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, B.</span><span> </span><span class="NLM_article-title">Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">8189</span><span class="NLM_x">–</span> <span class="NLM_lpage">8197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1074%2Fjbc.272.13.8189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9079636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK2sXitF2nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=8189-8197&author=M.+Janssonauthor=D.+Hallenauthor=H.+Kohoauthor=G.+Anderssonauthor=L.+Berghardauthor=J.+Heidrichauthor=E.+Nybergauthor=M.+Uhlenauthor=J.+Kordelauthor=B.+Nilsson&title=Characterization+of+ligand+binding+of+a+soluble+human+insulin-like+growth+factor+I+receptor+variant+suggests+a+ligand-induced+conformational+change"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change</span></div><div class="casAuthors">Jansson, Magnus; Hallen, Dan; Koho, Hannu; Andersson, Gunilla; Berghard, Lotta; Heidrich, Jessica; Nyberg, Elisabeth; Uhlen, Mathias; Koerdel, Johan; Nilsson, Bjoern</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8189-8197</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Details of the signal transduction mechanisms of the tyrosine kinase family of growth factor receptors remain elusive.  The authors describe an extensive study of kinetic and thermodn. aspects of growth factor binding to a sol. extracellular human insulin-like growth factor-I receptor (sIGF-IR) variant.  The extracellular receptor domains were produced fused to an IgG-binding protein domain (Z) in transfected human 293 cells as a correctly processed secreted α-β'-Z dimer.  The receptor was purified using IgG affinity chromatog., rendering a pure and homogeneous protein in yields from 1 to 5 mg/L of conditioned cell media.  Biosensor technol. (BIAcore) was applied to measure the insulin-like growth factor-I (IGF-I), des(1-3)IGF-I, insulin-like growth factor-II, and insulin ligand binding rate consts. to the immobilized IGF-IR-Z.  The assocn. equil. const., Ka, for the IGF-I interaction is detd. to 2.8 × 108 M-1 (25°).  Microcalorimetric titrns. on IGF-I/IGF-IR-Z were performed at three different temps. (15, 25, and 37°) and in two different buffer systems at 25°.  From these measurements, equil. consts. for the 1:1 (IGF-I:(α-β'-Z)2) receptor complex in soln. are deduced to 0.96 × 108 M-1 (25°).  The detd. heat capacity change for the process is large and neg., -51 kcal (K mol.)-1.  Further, the entropy change (ΔS) at 25° is large and neg.  Far- and near-UV CD measurements display significant changes over the entire wavelength range upon binding of IGF-I to IGF-IR-Z.  These data are all consistent with a significant change in structure of the system upon IGF-I binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcVNzbHrKkCbVg90H21EOLACvtfcHk0lhiqZQAyKyTyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitF2nsr4%253D&md5=ba0e5756450d1d62d7826cd1e2b83ab3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.13.8189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.13.8189%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DHallen%26aufirst%3DD.%26aulast%3DKoho%26aufirst%3DH.%26aulast%3DAndersson%26aufirst%3DG.%26aulast%3DBerghard%26aufirst%3DL.%26aulast%3DHeidrich%26aufirst%3DJ.%26aulast%3DNyberg%26aufirst%3DE.%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DKordel%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DB.%26atitle%3DCharacterization%2520of%2520ligand%2520binding%2520of%2520a%2520soluble%2520human%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520variant%2520suggests%2520a%2520ligand-induced%2520conformational%2520change%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D8189%26epage%3D8197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Massague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czech, M. P.</span><span> </span><span class="NLM_article-title">The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">5038</span><span class="NLM_x">–</span> <span class="NLM_lpage">5045</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=5038-5045&author=J.+Massagueauthor=M.+P.+Czech&title=The+subunit+structures+of+two+distinct+receptors+for+insulin-like+growth+factors+I+and+II+and+their+relationship+to+the+insulin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMassague%26aufirst%3DJ.%26aulast%3DCzech%26aufirst%3DM.%2BP.%26atitle%3DThe%2520subunit%2520structures%2520of%2520two%2520distinct%2520receptors%2520for%2520insulin-like%2520growth%2520factors%2520I%2520and%2520II%2520and%2520their%2520relationship%2520to%2520the%2520insulin%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D5038%26epage%3D5045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Garrett, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKern, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenkel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovrecz, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elleman, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, C. W.</span><span> </span><span class="NLM_article-title">Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">394</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=1998&pages=395-399&author=T.+P.+Garrettauthor=N.+M.+McKernauthor=M.+Louauthor=M.+J.+Frenkelauthor=J.+D.+Bentleyauthor=G.+O.+Lovreczauthor=T.+C.+Ellemanauthor=L.+J.+Cosgroveauthor=C.+W.+Ward&title=Crystal+structure+of+the+first+three+domains+of+the+type-1+insulin-like+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DT.%2BP.%26aulast%3DMcKern%26aufirst%3DN.%2BM.%26aulast%3DLou%26aufirst%3DM.%26aulast%3DFrenkel%26aufirst%3DM.%2BJ.%26aulast%3DBentley%26aufirst%3DJ.%2BD.%26aulast%3DLovrecz%26aufirst%3DG.%2BO.%26aulast%3DElleman%26aufirst%3DT.%2BC.%26aulast%3DCosgrove%26aufirst%3DL.%2BJ.%26aulast%3DWard%26aufirst%3DC.%2BW.%26atitle%3DCrystal%2520structure%2520of%2520the%2520first%2520three%2520domains%2520of%2520the%2520type-1%2520insulin-like%2520growth%2520factor%2520receptor%26jtitle%3DNature%26date%3D1998%26volume%3D394%26spage%3D395%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Furstenberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senn, H. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factors and cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1470-2045%2802%2900731-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12067807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlWhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=298-302&author=G.+Furstenbergerauthor=H.+J.+Senn&title=Insulin-like+growth+factors+and+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factors and cancer</span></div><div class="casAuthors">Furstenberger, Gregor; Senn, Hans-Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">298-302</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Interest in insulin-like growth factors (IGFs) and their effect on carcinogenesis has increased recently because high serum concns. of IGF1 are assocd. with an increased risk of breast, prostate, colorectal, and lung cancers.  Physiol., IGF1 is the major mediator of the effects of the growth hormone; it thus has a strong influence on cell proliferation and differentiation and is a potent inhibitor of apoptosis.  The action of IGF1 is predominantly mediated through the IGF1 receptor (IGF1R).  IGF1R is involved in several oncogenic transformation processes.  The availability of unbound IGF1 for interaction with IGF1R is modulated by IGF-binding proteins (IGFBP1-6).  IGFBPs, esp. IGFBP3, have independent effects on cell growth, for example, IGFBP3 has proapoptotic activities both dependent on and independent of p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zKKsA1j2FrVg90H21EOLACvtfcHk0lifgtNLAm1jCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlWhsb0%253D&md5=1000da87e64e46d338826835e84861e7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900731-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900731-3%26sid%3Dliteratum%253Aachs%26aulast%3DFurstenberger%26aufirst%3DG.%26aulast%3DSenn%26aufirst%3DH.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factors%2520and%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D298%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Bennett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagashima, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintz, R. L.</span><span> </span><span class="NLM_article-title">Levels of insulin-like growth factors I and II in human cord blood</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">609</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fjcem-57-3-609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=6348065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaL3sXltFKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1983&pages=609-612&author=A.+Bennettauthor=D.+M.+Wilsonauthor=F.+Liuauthor=R.+Nagashimaauthor=R.+G.+Rosenfeldauthor=R.+L.+Hintz&title=Levels+of+insulin-like+growth+factors+I+and+II+in+human+cord+blood"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Levels of insulin-like growth factors I and II in human cord blood</span></div><div class="casAuthors">Bennett, Ann; Wilson, Darrell M.; Liu, Frances; Nagashima, Raymond; Rosenfeld, Ron G.; Hintz, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">609-12</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">Levels of insulin-like growth factor I (IGF-I)  [67763-96-6], IGF-II  [67763-97-7], and somatomedin  [9038-70-4] peptide content (SMPC) were measured in 32 normal term and 11 preterm infants.  After acid chromatog. to remove somatomedin-binding protein, SMPC was measured by placental membrane radioreceptor assay, whereas plasma IGF-I and IGF-II concns. were measured by specific RIAs.  SMPC levels in term infants were significantly below normal adult levels [0.49 units/mL for infants compared to 1.30 units/mL for adult males].  IGF-I levels in term infants were also low, averaging 11.3 ng/mL for infants, the normal adult levels is 184 ng/mL.  The IGF-II level was 282 ng/mL for infants and 687 ng/mL for adults.  Both IGF-I and IGF-II levels in preterm infants were lower than those in term infants.  IGF-I, IGF-II, and SMPC levels showed a pos. correlation with birth wt. in term infants.  Both IGF-I and IGF-II levels showed a strong pos. correlation with gestational age in all infants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKyXo_o9YuLVg90H21EOLACvtfcHk0lifgtNLAm1jCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltFKrtrw%253D&md5=301207f49082188b174c770d577c6922</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1210%2Fjcem-57-3-609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem-57-3-609%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DNagashima%26aufirst%3DR.%26aulast%3DRosenfeld%26aufirst%3DR.%2BG.%26aulast%3DHintz%26aufirst%3DR.%2BL.%26atitle%3DLevels%2520of%2520insulin-like%2520growth%2520factors%2520I%2520and%2520II%2520in%2520human%2520cord%2520blood%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab%26date%3D1983%26volume%3D57%26spage%3D609%26epage%3D612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Germain-Lee, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casella, S. J.</span><span> </span><span class="NLM_article-title">Expression of a type I insulin-like growth factor receptor with low affinity for insulin-like growth factor II</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x"> (</span><span class="NLM_issue">Part 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1992&pages=413-417&issue=Part+2&author=E.+L.+Germain-Leeauthor=M.+Janicotauthor=R.+Lammersauthor=A.+Ullrichauthor=S.+J.+Casella&title=Expression+of+a+type+I+insulin-like+growth+factor+receptor+with+low+affinity+for+insulin-like+growth+factor+II"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGermain-Lee%26aufirst%3DE.%2BL.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DLammers%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DCasella%26aufirst%3DS.%2BJ.%26atitle%3DExpression%2520of%2520a%2520type%2520I%2520insulin-like%2520growth%2520factor%2520receptor%2520with%2520low%2520affinity%2520for%2520insulin-like%2520growth%2520factor%2520II%26jtitle%3DBiochem.%2520J.%26date%3D1992%26volume%3D281%26issue%3DPart%25202%26spage%3D413%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Steele-Perkins, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, R. A.</span><span> </span><span class="NLM_article-title">Monoclonal antibody alpha IR-3 inhibits the ability of insulin-like growth factor II to stimulate a signal from the type I receptor without inhibiting its binding</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">1244</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=1990&pages=1244-1251&author=G.+Steele-Perkinsauthor=R.+A.+Roth&title=Monoclonal+antibody+alpha+IR-3+inhibits+the+ability+of+insulin-like+growth+factor+II+to+stimulate+a+signal+from+the+type+I+receptor+without+inhibiting+its+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSteele-Perkins%26aufirst%3DG.%26aulast%3DRoth%26aufirst%3DR.%2BA.%26atitle%3DMonoclonal%2520antibody%2520alpha%2520IR-3%2520inhibits%2520the%2520ability%2520of%2520insulin-like%2520growth%2520factor%2520II%2520to%2520stimulate%2520a%2520signal%2520from%2520the%2520type%2520I%2520receptor%2520without%2520inhibiting%2520its%2520binding%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D171%26spage%3D1244%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Danielsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gammeltoft, S.</span><span> </span><span class="NLM_article-title">Chromaffin cells express two types of insulin-like growth factor receptors</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">518</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0006-8993%2890%2990958-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=2167752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK3cXltV2qsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=518&publication_year=1990&pages=95-100&author=A.+Danielsenauthor=E.+Larsenauthor=S.+Gammeltoft&title=Chromaffin+cells+express+two+types+of+insulin-like+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Chromaffin cells express two types of insulin-like growth factor receptors</span></div><div class="casAuthors">Danielsen, Anne; Larsen, Elisabeth; Gammeltoft, Steen</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">518</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The receptor binding, internalization, and tyrosine kinase activation of insulin-like growth factors (IGF) I and II have been investigated in cultured adult bovine chromaffin cells.  IGF-I receptor α-subunits (Mr ∼130,000) bound IGF-I and IGF-II with identical affinity (Kd ∼1 nM) and insulin with about 1000-times lower affinity, IGF-II receptors (Mr ∼250,000) bound IGF-II with a Kd of 0.5 nM, IGF-I with about 10-times lower affinity and insulin with >10,000-times lower affinity.  The amts. of IGF-I and IGF-II receptors on the cell surface were 8 × 104 and 4 × 104 sites per cell, resp.  Insulin bound to a specific receptor with Kd ∼2 nM and the amt. of receptors was 1.5 × 104 sites per cell.  IGF-I and IGF-II stimulated tyrosine kinase activity and autophosphorylation of the IGF-I receptor β-subunit (Mr ∼94,000) with equal potency (ED50 ∼1 nM), whereas insulin was ∼5-times less potent.  Both IGF-I and IGF-II were internalized after their binding to cell surface receptors.  Mannose-6-phosphate, which binds to the IGF-II receptor, did not alter the binding or internalization of IGF-II.  IGF-I and IGF-II can exert their biol. effects in chromaffin cells by activation of the IGF-I receptor tyrosine kinase or by interaction with the IGF-II receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyB6HpbzrblbVg90H21EOLACvtfcHk0lhOxj9BoLt7yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltV2qsb4%253D&md5=d51ef6ae5177b1e01b6e7d796c127c51</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2890%2990958-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252890%252990958-E%26sid%3Dliteratum%253Aachs%26aulast%3DDanielsen%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DE.%26aulast%3DGammeltoft%26aufirst%3DS.%26atitle%3DChromaffin%2520cells%2520express%2520two%2520types%2520of%2520insulin-like%2520growth%2520factor%2520receptors%26jtitle%3DBrain%2520Res.%26date%3D1990%26volume%3D518%26spage%3D95%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Forbes, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeil, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surinya, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, J. C.</span><span> </span><span class="NLM_article-title">Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">961</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1046%2Fj.0014-2956.2001.02735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11846798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtlKnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2002&pages=961-968&author=B.+E.+Forbesauthor=P.+J.+Hartfieldauthor=K.+A.+McNeilauthor=K.+H.+Surinyaauthor=S.+J.+Milnerauthor=L.+J.+Cosgroveauthor=J.+C.+Wallace&title=Characteristics+of+binding+of+insulin-like+growth+factor+%28IGF%29-I+and+IGF-II+analogues+to+the+type+1+IGF+receptor+determined+by+BIAcore+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis: correlation of binding affinity with ability to prevent apoptosis</span></div><div class="casAuthors">Forbes, Briony E.; Hartfield, Perry J.; McNeil, Kerrie A.; Surinya, Kathy H.; Milner, Steven J.; Cosgrove, Leah J.; Wallace, John C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">961-968</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor (IGF) binding to the type 1 IGF receptor (IGF1R) elicits mitogenic effects, promotion of differentiation and protection from apoptosis.  This study has systematically measured IGF1R binding affinities of IGF-I, IGF-II and 14 IGF analogs to a recombinant high-affinity form of the IGF1R using BIAcore technol.  The analogs assessed could be divided into two groups: (a) those designed to investigate binding of IGF-binding protein, which exhibited IGF1R-binding affinities similar to those of IGF-I or IGF-II; (b) those generated to probe IGF1R interactions with greatly reduced IGF1R-binding affinities.  The relative binding affinities of IGF-I analogs and IGF-I for the IGF1R detd. by BIAcore anal. agreed closely with existing data from receptor-binding assays using cells or tissue membranes, demonstrating that BIAcore technol. is a powerful tool for measuring affinities of IGFs for IGF1R.  In parallel studies, IGF1R-binding affinities were related to ability to protect against serum withdrawal-induced apoptosis in three different assays including Hoechst 33258 staining, cell survival, and DNA fragmentation assays using the rat pheochromocytoma cell line, PC12.  In this model system, IGF-I and IGF-II at low nanomolar concns. are able to prevent apoptosis completely.  The authors conclude that ability to protect against apoptosis is directly related to ability to bind the IGF1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFjO9roFmz8bVg90H21EOLACvtfcHk0lhOxj9BoLt7yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtlKnu7g%253D&md5=695e4e4e7354723281ca666b0343daf9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1046%2Fj.0014-2956.2001.02735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0014-2956.2001.02735.x%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DB.%2BE.%26aulast%3DHartfield%26aufirst%3DP.%2BJ.%26aulast%3DMcNeil%26aufirst%3DK.%2BA.%26aulast%3DSurinya%26aufirst%3DK.%2BH.%26aulast%3DMilner%26aufirst%3DS.%2BJ.%26aulast%3DCosgrove%26aufirst%3DL.%2BJ.%26aulast%3DWallace%26aufirst%3DJ.%2BC.%26atitle%3DCharacteristics%2520of%2520binding%2520of%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529-I%2520and%2520IGF-II%2520analogues%2520to%2520the%2520type%25201%2520IGF%2520receptor%2520determined%2520by%2520BIAcore%2520analysis%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2002%26volume%3D269%26spage%3D961%26epage%3D968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantzoros, C. S.</span><span> </span><span class="NLM_article-title">The role of the IGF system in cancer: from basic to clinical studies and clinical applications</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2002&pages=317-332&author=S.+J.+Moschosauthor=C.+S.+Mantzoros&title=The+role+of+the+IGF+system+in+cancer%3A+from+basic+to+clinical+studies+and+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DMantzoros%26aufirst%3DC.%2BS.%26atitle%3DThe%2520role%2520of%2520the%2520IGF%2520system%2520in%2520cancer%253A%2520from%2520basic%2520to%2520clinical%2520studies%2520and%2520clinical%2520applications%26jtitle%3DOncology%26date%3D2002%26volume%3D63%26spage%3D317%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3278</span><span class="NLM_x">–</span> <span class="NLM_lpage">3288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10207053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXislSltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=3278-3288&author=F.+Frascaauthor=G.+Pandiniauthor=P.+Scaliaauthor=L.+Sciaccaauthor=R.+Mineoauthor=A.+Costantinoauthor=I.+D.+Goldfineauthor=A.+Belfioreauthor=R.+Vigneri&title=Insulin+receptor+isoform+A%2C+a+newly+recognized%2C+high-affinity+insulin-like+growth+factor+II+receptor+in+fetal+and+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells</span></div><div class="casAuthors">Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I. D.; Belfiore, A.; Vigneri, R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3278-3288</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Insulin-like growth factor II (IGF-II) is a peptide growth factor that is homologous to both insulin-like growth factor I (IGF-I) and insulin and plays an important role in embryonic development and carcinogenesis.  IGF-II is believed to mediate its cellular signaling via the transmembrane tyrosine kinase type 1 insulin-like growth factor receptor (IGF-I-R), which is also the receptor for IGF-I.  Earlier studies with both cultured cells and transgenic mice, however, have suggested that in the embryo the insulin receptor (IR) may also be a receptor for IGF-II.  In most cells and tissues, IR binds IGF-II with relatively low affinity.  The IR is expressed in two isoforms (IR-A and IR-B) differing by 12 amino acids due to the alternative splicing of exon 11.  In the present study the authors found that IR-A but not IR-B bound IGF-II with an affinity close to that of insulin.  Moreover, IGF-II bound to IR-A with an affinity equal to that of IGF-II binding to the IGF-I-R.  Activation of IR-A by insulin led primarily to metabolic effects, whereas activation of IR-A by IGF-II led primarily to mitogenic effects.  These differences in the biol. effects of IR-A when activated by either IGF-II or insulin were assocd. with differential recruitment and activation of intracellular substrates.  IR-A was preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney and had a relatively increased proportion of isoform A.  IR-A expression was also increased in several tumors including those of the breast and colon.  These data indicate, therefore, that there are two receptors for IGF-II, both IGF-I-R and IR-A.  Further, they suggest that interaction of IGF-II with IR-A may play a role both in fetal growth and cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNrk0Logv4N7Vg90H21EOLACvtfcHk0lij8Wd98UDJaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXislSltLk%253D&md5=689c94d9ae9c1e5466517e3b25453aa9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DScalia%26aufirst%3DP.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DInsulin%2520receptor%2520isoform%2520A%252C%2520a%2520newly%2520recognized%252C%2520high-affinity%2520insulin-like%2520growth%2520factor%2520II%2520receptor%2520in%2520fetal%2520and%2520cancer%2520cells%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1999%26volume%3D19%26spage%3D3278%26epage%3D3288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzino, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squatrito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">The role of insulin receptors and IGF-I receptors in cancer and other diseases</span> <span class="citation_source-journal">Arch. Physiol. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1080%2F13813450801969715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18465356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlKls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2008&pages=23-37&author=F.+Frascaauthor=G.+Pandiniauthor=L.+Sciaccaauthor=V.+Pezzinoauthor=S.+Squatritoauthor=A.+Belfioreauthor=R.+Vigneri&title=The+role+of+insulin+receptors+and+IGF-I+receptors+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The role of insulin receptors and IGF-I receptors in cancer and other diseases</span></div><div class="casAuthors">Frasca, Francesco; Pandini, Giuseppe; Sciacca, Laura; Pezzino, Vincenzo; Squatrito, Sebastiano; Belfiore, Antonio; Vigneri, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-37</span>CODEN:
                <span class="NLM_cas:coden">APBIF5</span>;
        ISSN:<span class="NLM_cas:issn">1381-3455</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  There is evidence, both in vitro and in vivo, that receptor tyrosine kinases play a key role in the formation and progression of human cancer.  In particular, the insulin-like growth factor receptor (IGF-IR), a tyrosine kinase receptor for IGF-I and IGF-II, was well documented in cell culture, animal studies, and humans to play a role in malignant transformation, progression, protection from apoptosis, and metastasis.  In addn., the hormone insulin (which is very closely related to the IGFs) and its tyrosine kinase receptor (the IR, which is very closely related to the IGR-IR) were documented both in vitro and in vivo to play a key role in cancer biol.  Indeed, several epidemiol. studies have shown that insulin resistance status, characterized by hyperinsulinemia, is assocd. with an increased risk for a no. of malignancies, including carcinomas of the breast, prostate, colon and kidney.  Recent data have elucidated some mol. mechanisms by which IR is involved in cancer.  IR is over-expressed in several human malignancies.  Interestingly, one of the 2 IR isoform (IR-A) is esp. over-expressed in cancer.  IR-A is the IR fetal isoform and has the peculiar characteristic to bind not only insulin but also IGF-II.  In addn., the IR contributes to formation of hybrid receptors with the IGF-IR (HR).  By binding to hybrid receptors, insulin may stimulate specific IGF-IR signaling pathways.  Over-expression of IR-A is, therefore, a major mechanism of IGF system over-activation in cancer.  In this respect, IR-A isoform and hybrid receptors should be regarded as potential mol. targets, in addn. to IGF-IR, for novel anti-cancer therapy.  These findings may have important implications for both the prevention and treatment of common human malignancies.  They underline the concept that hyperinsulinemia, assocd. with insulin resistance and obesity, should be treated by changes in life style and/or pharmacol. approaches to avoid an increased risk for cancer.  Moreover, native insulin and insulin analog administration should be carefully evaluated in terms of the possible increase in cancer risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGXs0W7l05vLVg90H21EOLACvtfcHk0lij8Wd98UDJaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlKls7s%253D&md5=134ab24a4e7cc0b88d8d4d50c92753c6</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1080%2F13813450801969715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13813450801969715%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DPezzino%26aufirst%3DV.%26aulast%3DSquatrito%26aufirst%3DS.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DThe%2520role%2520of%2520insulin%2520receptors%2520and%2520IGF-I%2520receptors%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DArch.%2520Physiol.%2520Biochem.%26date%3D2008%26volume%3D114%26spage%3D23%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">39684</span><span class="NLM_x">–</span> <span class="NLM_lpage">39695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=39684-39695&author=G.+Pandiniauthor=F.+Frascaauthor=R.+Mineoauthor=L.+Sciaccaauthor=R.+Vigneriauthor=A.+Belfiore&title=Insulin%2Finsulin-like+growth+factor+I+hybrid+receptors+have+different+biological+characteristics+depending+on+the+insulin+receptor+isoform+involved"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%252Finsulin-like%2520growth%2520factor%2520I%2520hybrid%2520receptors%2520have%2520different%2520biological%2520characteristics%2520depending%2520on%2520the%2520insulin%2520receptor%2520isoform%2520involved%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D39684%26epage%3D39695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medico, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">42178</span><span class="NLM_x">–</span> <span class="NLM_lpage">42189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=42178-42189&author=G.+Pandiniauthor=E.+Medicoauthor=E.+Conteauthor=L.+Sciaccaauthor=R.+Vigneriauthor=A.+Belfiore&title=Differential+gene+expression+induced+by+insulin+and+insulin-like+growth+factor-II+through+the+insulin+receptor+isoform+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMedico%26aufirst%3DE.%26aulast%3DConte%26aufirst%3DE.%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DDifferential%2520gene%2520expression%2520induced%2520by%2520insulin%2520and%2520insulin-like%2520growth%2520factor-II%2520through%2520the%2520insulin%2520receptor%2520isoform%2520A%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D42178%26epage%3D42189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbraccia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2471</span><span class="NLM_x">–</span> <span class="NLM_lpage">2479</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=2471-2479&author=L.+Sciaccaauthor=A.+Costantinoauthor=G.+Pandiniauthor=R.+Mineoauthor=F.+Frascaauthor=P.+Scaliaauthor=P.+Sbracciaauthor=I.+D.+Goldfineauthor=R.+Vigneriauthor=A.+Belfiore&title=Insulin+receptor+activation+by+IGF-II+in+breast+cancers%3A+evidence+for+a+new+autocrine%2Fparacrine+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DScalia%26aufirst%3DP.%26aulast%3DSbraccia%26aufirst%3DP.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%2520receptor%2520activation%2520by%2520IGF-II%2520in%2520breast%2520cancers%253A%2520evidence%2520for%2520a%2520new%2520autocrine%252Fparacrine%2520mechanism%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D2471%26epage%3D2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Sciacca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mineo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8240</span><span class="NLM_x">–</span> <span class="NLM_lpage">8250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=8240-8250&author=L.+Sciaccaauthor=R.+Mineoauthor=G.+Pandiniauthor=A.+Murabitoauthor=R.+Vigneriauthor=A.+Belfiore&title=In+IGF-I+receptor-deficient+leiomyosarcoma+cells+autocrine+IGF-II+induces+cell+invasion+and+protection+from+apoptosis+via+the+insulin+receptor+isoform+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSciacca%26aufirst%3DL.%26aulast%3DMineo%26aufirst%3DR.%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DMurabito%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DIn%2520IGF-I%2520receptor-deficient%2520leiomyosarcoma%2520cells%2520autocrine%2520IGF-II%2520induces%2520cell%2520invasion%2520and%2520protection%2520from%2520apoptosis%2520via%2520the%2520insulin%2520receptor%2520isoform%2520A%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D8240%26epage%3D8250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">686</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F138161207780249173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17346183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=671-686&author=A.+Belfiore&title=The+role+of+insulin+receptor+isoforms+and+hybrid+insulin%2FIGF-I+receptors+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer</span></div><div class="casAuthors">Belfiore, Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-686</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review will focus on the emerging role of the insulin receptor (IR) in cancer.  Several epidemiol. studies have shown that insulin resistance states, characterized by hyperinsulinemia, are assocd. with an increased risk for a no. of malignancies, including carcinomas of the breast, prostate, colon and kidney.  Recent data have elucidated some mol. mechanisms by which IR is involved in cancer.  First, IR is overexpressed in several human malignancies.  Interestingly, one of the two IR isoform (IR-A) is esp. overexpressed in cancer.  IR-A is the IR fetal isoform and has the peculiar characteristic to bind not only insulin but also IGF-II.  Second, IR forms hybrid receptors with the homologous IGF-IR, which is also commonly overexpressed in cancer.  These hybrid receptors contg. IR-A hemidimers have broad binding specificity as they bind IGF-I and also IGF-II and insulin.  By binding to hybrid receptors, insulin may stimulate specific IGF-IR signaling pathways.  Overexpression of IR-A is, therefore, a major mechanism of IGF system overactivation in cancer.  These findings may have important implications for both the prevention and treatment of common human malignancies.  They underline the concept that hyperinsulinemia, assocd. with insulin resistance and obesity, should be treated by changes in life style and/or pharmachol. approaches to avoid an increased risk for cancer.  IR-A isoform and hybrid receptors should be regarded, therefore, as potential mol. targets for novel anti-cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzOXo5usLgbVg90H21EOLACvtfcHk0lj21BUu4_53Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVagtr8%253D&md5=7f35c91393d0c0fd34b62467121b1f6e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F138161207780249173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161207780249173%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520insulin%2520receptor%2520isoforms%2520and%2520hybrid%2520insulin%252FIGF-I%2520receptors%2520in%2520human%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2007%26volume%3D13%26spage%3D671%26epage%3D686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Pandini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita-Yamaguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siddle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span> </span><span class="NLM_article-title">Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1935</span><span class="NLM_x">–</span> <span class="NLM_lpage">1944</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10430101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXltVCqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1999&pages=1935-1944&author=G.+Pandiniauthor=R.+Vigneriauthor=A.+Costantinoauthor=F.+Frascaauthor=A.+Ippolitoauthor=Y.+Fujita-Yamaguchiauthor=K.+Siddleauthor=I.+D.+Goldfineauthor=A.+Belfiore&title=Insulin+and+insulin-like+growth+factor-I+%28IGF-I%29+receptor+overexpression+in+breast+cancers+leads+to+insulin%2FIGF-I+hybrid+receptor+overexpression%3A+evidence+for+a+second+mechanism+of+IGF-I+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling</span></div><div class="casAuthors">Pandini, Giuseppe; Vigneri, Riccardo; Costantino, Angela; Frasca, Francesco; Ippolito, Antonio; Fujita-Yamaguchi, Yoko; Siddle, Kenneth; Goldfine, Ira D.; Belfiore, Antonino</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1935-1944</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin receptor (IR) form hybrids with the closely related insulin-like growth factor-I (IGF-I) receptor (IGF-I-R).  Because most human breast carcinomas overexpress both the IR and the IGF-I-R, we evaluated whether the insulin/IGF-I hybrid receptor (Hybrid-R) is also overexpressed in these tumors and what role it plays in breast cancer biol.  Using specific ELISAs and Western blots, we measured Hybrid-R content and function in 8 human cultured breast cancer cell lines and 39 human breast cancer specimens.  Hybrid-R content and function were also compared to the content and function of the IR and the IGF-I-R.  Hybrid-R content exceeded the IGF-I-R content in >75% of breast cancer specimens and was directly related to the molar ratio of both the IR and IGF-I-R content, suggesting that Hybrid-R formation occurred by random assembly of IR and IGF-I-R half-receptors.  Hybrid-Rs became tyrosine autophosphorylated when breast cancer cells were exposed to IGF-I but not when they were exposed to insulin.  In cells with an elevated Hybrid-R content, Hybrid-R autophosphorylation in response to IGF-I exceeded IGF-I-R autophosphorylation, suggesting that most of the IGF-I effect occurred via the Hybrid-R.  Furthermore, Hybrid-Rs mediated growth in response to IGF-I, as indicated by expts. with blocking antibodies to the IGF-I-R.  These data indicated therefore that: (a) Hybrid-Rs are present and play a major role in mediating the IGF-I signal in breast cancer; (b) their expression is directly related to IR overexpression; and (c) potential therapies designed to block IGF-I actions in breast cancer must take into account the role of these Hybrid-Rs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGFXal6HPgLVg90H21EOLACvtfcHk0lj21BUu4_53Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVCqtL8%253D&md5=f685d7d1d496c8a08df18da522c719d1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPandini%26aufirst%3DG.%26aulast%3DVigneri%26aufirst%3DR.%26aulast%3DCostantino%26aufirst%3DA.%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DIppolito%26aufirst%3DA.%26aulast%3DFujita-Yamaguchi%26aufirst%3DY.%26aulast%3DSiddle%26aufirst%3DK.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DBelfiore%26aufirst%3DA.%26atitle%3DInsulin%2520and%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520overexpression%2520in%2520breast%2520cancers%2520leads%2520to%2520insulin%252FIGF-I%2520hybrid%2520receptor%2520overexpression%253A%2520evidence%2520for%2520a%2520second%2520mechanism%2520of%2520IGF-I%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1999%26volume%3D5%26spage%3D1935%26epage%3D1944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Heuson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legros, N.</span><span> </span><span class="NLM_article-title">Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1972</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">226</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1972&pages=226-232&author=J.+C.+Heusonauthor=N.+Legros&title=Influence+of+insulin+deprivation+on+growth+of+the+7%2C12-dimethylbenz%28a%29anthracene-induced+mammary+carcinoma+in+rats+subjected+to+alloxan+diabetes+and+food+restriction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeuson%26aufirst%3DJ.%2BC.%26aulast%3DLegros%26aufirst%3DN.%26atitle%3DInfluence%2520of%2520insulin%2520deprivation%2520on%2520growth%2520of%2520the%25207%252C12-dimethylbenz%2528a%2529anthracene-induced%2520mammary%2520carcinoma%2520in%2520rats%2520subjected%2520to%2520alloxan%2520diabetes%2520and%2520food%2520restriction%26jtitle%3DCancer%2520Res.%26date%3D1972%26volume%3D32%26spage%3D226%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Osborne, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monaco, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, M. E.</span><span> </span><span class="NLM_article-title">Hormone responsive human breast cancer in long-term tissue culture: effect of insulin</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">4536</span><span class="NLM_x">–</span> <span class="NLM_lpage">4540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4536-4540&author=C.+K.+Osborneauthor=G.+Bolanauthor=M.+E.+Monacoauthor=M.+E.+Lippman&title=Hormone+responsive+human+breast+cancer+in+long-term+tissue+culture%3A+effect+of+insulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DBolan%26aufirst%3DG.%26aulast%3DMonaco%26aufirst%3DM.%2BE.%26aulast%3DLippman%26aufirst%3DM.%2BE.%26atitle%3DHormone%2520responsive%2520human%2520breast%2520cancer%2520in%2520long-term%2520tissue%2520culture%253A%2520effect%2520of%2520insulin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4536%26epage%3D4540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Arcaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doepfner, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerreiro, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalaby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span> </span><span class="NLM_article-title">Novel role for insulin as an autocrine growth factor for malignant brain tumour cells</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2007&pages=57-66&author=A.+Arcaroauthor=K.+T.+Doepfnerauthor=D.+Bollerauthor=A.+S.+Guerreiroauthor=T.+Shalabyauthor=S.+P.+Jacksonauthor=S.+M.+Schoenwaelderauthor=O.+Delattreauthor=M.+A.+Grotzerauthor=B.+Fischer&title=Novel+role+for+insulin+as+an+autocrine+growth+factor+for+malignant+brain+tumour+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DArcaro%26aufirst%3DA.%26aulast%3DDoepfner%26aufirst%3DK.%2BT.%26aulast%3DBoller%26aufirst%3DD.%26aulast%3DGuerreiro%26aufirst%3DA.%2BS.%26aulast%3DShalaby%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSchoenwaelder%26aufirst%3DS.%2BM.%26aulast%3DDelattre%26aufirst%3DO.%26aulast%3DGrotzer%26aufirst%3DM.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26atitle%3DNovel%2520role%2520for%2520insulin%2520as%2520an%2520autocrine%2520growth%2520factor%2520for%2520malignant%2520brain%2520tumour%2520cells%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D406%26spage%3D57%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Cox, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gleave, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakikhani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin receptor expression by human prostate cancers</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=33-40&author=M.+E.+Coxauthor=M.+E.+Gleaveauthor=M.+Zakikhaniauthor=R.+H.+Bellauthor=E.+Piuraauthor=E.+Vickersauthor=M.+Cunninghamauthor=O.+Larssonauthor=L.+Fazliauthor=M.+Pollak&title=Insulin+receptor+expression+by+human+prostate+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DM.%2BE.%26aulast%3DGleave%26aufirst%3DM.%2BE.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DR.%2BH.%26aulast%3DPiura%26aufirst%3DE.%26aulast%3DVickers%26aufirst%3DE.%26aulast%3DCunningham%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DFazli%26aufirst%3DL.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin%2520receptor%2520expression%2520by%2520human%2520prostate%2520cancers%26jtitle%3DProstate%26date%3D2009%26volume%3D69%26spage%3D33%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Hede, K.</span><span> </span><span class="NLM_article-title">Doctors seek to prevent breast cancer recurrence by lowering insulin levels</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2Fdjn119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18398091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1c3lt1Wntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=530-532&author=K.+Hede&title=Doctors+seek+to+prevent+breast+cancer+recurrence+by+lowering+insulin+levels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Doctors seek to prevent breast cancer recurrence by lowering insulin levels</span></div><div class="casAuthors">Hede Karyn</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">530-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRs6BohTJeTws-crCu0nI_sfW6udTcc2ebWepo6t3YNmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3lt1Wntw%253D%253D&md5=a54d69fb501a454e5a9e740888f31386</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjn119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjn119%26sid%3Dliteratum%253Aachs%26aulast%3DHede%26aufirst%3DK.%26atitle%3DDoctors%2520seek%2520to%2520prevent%2520breast%2520cancer%2520recurrence%2520by%2520lowering%2520insulin%2520levels%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D530%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Law, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habibi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, S. E.</span><span> </span><span class="NLM_article-title">Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">10238</span><span class="NLM_x">–</span> <span class="NLM_lpage">10246</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=10238-10246&author=J.+H.+Lawauthor=G.+Habibiauthor=K.+Huauthor=H.+Masoudiauthor=M.+Y.+Wangauthor=A.+L.+Stratfordauthor=E.+Parkauthor=J.+M.+Geeauthor=P.+Finlayauthor=H.+E.+Jonesauthor=R.+I.+Nicholsonauthor=J.+Carboniauthor=M.+Gottardisauthor=M.+Pollakauthor=S.+E.+Dunn&title=Phosphorylated+insulin-like+growth+factor-i%2Finsulin+receptor+is+present+in+all+breast+cancer+subtypes+and+is+related+to+poor+survival"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaw%26aufirst%3DJ.%2BH.%26aulast%3DHabibi%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DMasoudi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%2BY.%26aulast%3DStratford%26aufirst%3DA.%2BL.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DFinlay%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DH.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DPollak%26aufirst%3DM.%26aulast%3DDunn%26aufirst%3DS.%2BE.%26atitle%3DPhosphorylated%2520insulin-like%2520growth%2520factor-i%252Finsulin%2520receptor%2520is%2520present%2520in%2520all%2520breast%2520cancer%2520subtypes%2520and%2520is%2520related%2520to%2520poor%2520survival%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D10238%26epage%3D10246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Ohsugi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cras-Meneur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernal-Mizrachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luciani, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polonsky, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Permutt, M. A.</span><span> </span><span class="NLM_article-title">Reduced expression of the insulin receptor in mouse insulinoma (MIN6) cells reveals multiple roles of insulin signaling in gene expression, proliferation, insulin content, and secretion</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">4992</span><span class="NLM_x">–</span> <span class="NLM_lpage">5003</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=4992-5003&author=M.+Ohsugiauthor=C.+Cras-Meneurauthor=Y.+Zhouauthor=E.+Bernal-Mizrachiauthor=J.+D.+Johnsonauthor=D.+S.+Lucianiauthor=K.+S.+Polonskyauthor=M.+A.+Permutt&title=Reduced+expression+of+the+insulin+receptor+in+mouse+insulinoma+%28MIN6%29+cells+reveals+multiple+roles+of+insulin+signaling+in+gene+expression%2C+proliferation%2C+insulin+content%2C+and+secretion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOhsugi%26aufirst%3DM.%26aulast%3DCras-Meneur%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DBernal-Mizrachi%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DJ.%2BD.%26aulast%3DLuciani%26aufirst%3DD.%2BS.%26aulast%3DPolonsky%26aufirst%3DK.%2BS.%26aulast%3DPermutt%26aufirst%3DM.%2BA.%26atitle%3DReduced%2520expression%2520of%2520the%2520insulin%2520receptor%2520in%2520mouse%2520insulinoma%2520%2528MIN6%2529%2520cells%2520reveals%2520multiple%2520roles%2520of%2520insulin%2520signaling%2520in%2520gene%2520expression%252C%2520proliferation%252C%2520insulin%2520content%252C%2520and%2520secretion%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D4992%26epage%3D5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Venkateswaran, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, A. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleshner, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">1793</span><span class="NLM_x">–</span> <span class="NLM_lpage">1800</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2Fdjm231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18042933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2sjit1SgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2007&pages=1793-1800&author=V.+Venkateswaranauthor=A.+Q.+Haddadauthor=N.+E.+Fleshnerauthor=R.+Fanauthor=L.+M.+Sugarauthor=R.+Namauthor=L.+H.+Klotzauthor=M.+Pollak&title=Association+of+diet-induced+hyperinsulinemia+with+accelerated+growth+of+prostate+cancer+%28LNCaP%29+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts</span></div><div class="casAuthors">Venkateswaran Vasundara; Haddad Ahmed Q; Fleshner Neil E; Fan Rong; Sugar Linda M; Nam Rob; Klotz Laurence H; Pollak Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1793-800</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Prior research suggested that energy balance and fat intake influence prostate cancer progression, but the influence of dietary carbohydrate on prostate cancer progression has not been well characterized.  We hypothesized that hyperinsulinemia resulting from high intake of refined carbohydrates would lead to more rapid growth of tumors in the murine LNCaP xenograft model of prostate cancer.  METHODS:  Athymic mice were injected subcutaneously with LNCaP human prostate cancer cells and, when tumors were palpable, were randomly assigned (n = 20 per group) to high carbohydrate-high fat or low carbohydrate-high fat diets.  Body weight and tumor volume were measured weekly.  After 9 weeks, serum levels of insulin and insulin-like growth factor 1 (IGF-1) were measured by enzyme immunoassay.  AKT activation and the levels of the insulin receptor in tumor cells were determined by immunoblotting.  The in vitro growth response of LNCaP cells to serum from mice in the two treatment groups was measured based on tetrazolium compound reduction.  All statistical tests were two-sided.  RESULTS:  After 9 weeks on the experimental diets, mice on the high carbohydrate-high fat diet were heavier (mean body weight of mice on the high carbohydrate-high fat diet = 34 g versus 29.1 g on the low carbohydrate-high fat diet, difference = 4.9 g, 95% CI = 3.8 to 6.0 g; P = .003), experienced increased tumor growth (mean tumor volume in mice on high carbohydrate-high fat diet = 1695 versus 980 mm3 on low carbohydrate-high fat diet, difference = 715 mm3, 95% CI = 608 to 822 mm3; P<.001), and experienced a statistically significant increase in serum insulin and IGF-1 levels.  Tumors from mice on the high carbohydrate-high fat diet had higher levels of activated AKT and modestly higher insulin receptor levels than tumors from mice on the low carbohydrate-high fat diet.  Serum from mice on the high carbohydrate-high fat diet was more mitogenic for LNCaP cells in vitro than serum from mice fed the low carbohydrate-high fat diet.  CONCLUSION:  A diet high in refined carbohydrates is associated with increased tumor growth and with activation of signaling pathways distal to the insulin receptor in a murine model of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYgSZZbgBO8kQ0lWbKiCflfW6udTcc2ebWepo6t3YNmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjit1SgtQ%253D%253D&md5=be414eb149b66cd784d81dbc3f04e80a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm231%26sid%3Dliteratum%253Aachs%26aulast%3DVenkateswaran%26aufirst%3DV.%26aulast%3DHaddad%26aufirst%3DA.%2BQ.%26aulast%3DFleshner%26aufirst%3DN.%2BE.%26aulast%3DFan%26aufirst%3DR.%26aulast%3DSugar%26aufirst%3DL.%2BM.%26aulast%3DNam%26aufirst%3DR.%26aulast%3DKlotz%26aufirst%3DL.%2BH.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520diet-induced%2520hyperinsulinemia%2520with%2520accelerated%2520growth%2520of%2520prostate%2520cancer%2520%2528LNCaP%2529%2520xenografts%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2007%26volume%3D99%26spage%3D1793%26epage%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">11118</span><span class="NLM_x">–</span> <span class="NLM_lpage">11128</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-04-3841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16322262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=11118-11128&author=R.+Nahtaauthor=L.+X.+Yuanauthor=B.+Zhangauthor=R.+Kobayashiauthor=F.+J.+Esteva&title=Insulin-like+growth+factor-I+receptor%2Fhuman+epidermal+growth+factor+receptor+2+heterodimerization+contributes+to+trastuzumab+resistance+of+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells</span></div><div class="casAuthors">Nahta, Rita; Yuan, Linda X. H.; Zhang, Bing; Kobayashi, Ryuji; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11118-11128</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of breast cancer patients who achieve an initial therapeutic response to the human epidermal growth factor receptor 2 (HER-2)-targeted antibody trastuzumab will show disease progression within 1 yr.  The authors previously reported the characterization of SKBR3-derived trastuzumab-resistant pools.  In the current study, the authors show that HER-2 interacts with insulin-like growth factor-I receptor (IGF-IR) uniquely in these resistant cells and not in the parental trastuzumab-sensitive cells.  The occurrence of cross talk between IGF-IR and HER-2 exclusively in resistant cells is evidenced by the IGF-I stimulation resulting in increased phosphorylation of HER-2 in resistant cells, but not in parental cells, and by the inhibition of IGF-IR tyrosine kinase activity leading to decreased HER-2 phosphorylation only in resistant cells.  In addn., inhibition of IGF-IR tyrosine kinase activity by I-OMe-AG538 increased sensitivity of resistant cells to trastuzumab.  HER-2/IGF-IR interaction was disrupted on exposure of resistant cells to the anti-IGF-IR antibody α-IR3 and, to a lesser extent, when exposed to the anti-HER-2 antibody pertuzumab.  Heterodimer disruption by α-IR3 dramatically restored sensitivity to trastuzumab and resistant cells showed a slightly increased sensitivity to pertuzumab vs. parental cells.  Neither α-IR3 nor pertuzumab decreased HER-2 phosphorylation, suggesting that addnl. sources of phosphorylation other than IGF-IR exist when HER-2 and IGF-IR are not phys. bound.  Our data support a unique interaction between HER-2 and IGF-IR in trastuzumab-resistant cells such that cross talk occurs between IGF-IR and HER-2.  These data suggest that the IGF-IR/HER-2 heterodimer contributes to trastuzumab resistance and justify the need for further studies examg. this complex as a potential therapeutic target in breast cancers that have progressed while on trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYXv8m9As-bVg90H21EOLACvtfcHk0liZIEKewXI1oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KjsrrI&md5=305f51b308dbb62d5f7b7de48fecbcea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3841%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DKobayashi%26aufirst%3DR.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%252Fhuman%2520epidermal%2520growth%2520factor%2520receptor%25202%2520heterodimerization%2520contributes%2520to%2520trastuzumab%2520resistance%2520of%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D11118%26epage%3D11128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Firth, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, R. C.</span><span> </span><span class="NLM_article-title">Cellular actions of the insulin-like growth factor binding proteins</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2001-0033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12466191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVSntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=824-854&author=S.+M.+Firthauthor=R.+C.+Baxter&title=Cellular+actions+of+the+insulin-like+growth+factor+binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular actions of the insulin-like growth factor binding proteins</span></div><div class="casAuthors">Firth, Sue M.; Baxter, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">824-854</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In addn. to their roles in IGF transport, the 6 IGF-binding proteins (IGFBPs) regulate cell activity in various ways.  By sequestering IGFs away from the type I IGF receptor, they may inhibit mitogenesis, differentiation, survival, and other IGF-stimulated events.  IGFBP proteolysis can reverse this inhibition or generate IGFBP fragments with novel bioactivity.  Alternatively, IGFBP interaction with cell or matrix components may conc. IGFs near their receptor, enhancing IGF activity.  IGF receptor-independent IGFBP actions are also increasingly recognized.  IGFBP-1 interacts with α5β1 integrin, influencing cell adhesion and migration.  IGFBP-2, -3, -5, and -6 have heparin-binding domains and can bind glycosaminoglycans.  IGFBP-3 and -5 have C-terminal basic motifs incorporating heparin-binding and addnl. basic residues that interact with the cell surface and matrix, the nuclear transporter importin-β, and other proteins.  Serine/threonine kinase receptors are proposed for IGFBP-3 and -5, but their signaling functions are poorly understood.  Other cell surface IGFBP-interacting proteins are uncharacterized as functional receptors.  However, IGFBP-3 binds and modulates the retinoid X receptor-α, interacts with TGFβ signaling through Smad proteins, and influences other signaling pathways.  These interactions can modulate cell cycle and apoptosis.  Because IGFBPs regulate cell functions by diverse mechanisms, manipulation of IGFBP-regulated pathways is speculated to offer therapeutic opportunities in cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm_E7z_51hwLVg90H21EOLACvtfcHk0liZIEKewXI1oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVSntb8%253D&md5=9d90c6ce160d4ad7d2f8babdd036b6f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1210%2Fer.2001-0033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2001-0033%26sid%3Dliteratum%253Aachs%26aulast%3DFirth%26aufirst%3DS.%2BM.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26atitle%3DCellular%2520actions%2520of%2520the%2520insulin-like%2520growth%2520factor%2520binding%2520proteins%26jtitle%3DEndocr.%2520Rev.%26date%3D2002%26volume%3D23%26spage%3D824%26epage%3D854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Rosenfeld, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Bermejo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckway, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minniti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, Y.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor binding protein superfamily: new perspectives</span> <span class="citation_source-journal">Pediatrics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=1018-1021&author=R.+G.+Rosenfeldauthor=V.+Hwaauthor=L.+Wilsonauthor=A.+Lopez-Bermejoauthor=C.+Buckwayauthor=C.+Burrenauthor=W.+K.+Choiauthor=G.+Deviauthor=A.+Ingermannauthor=D.+Grahamauthor=G.+Minnitiauthor=A.+Spagnoliauthor=Y.+Oh&title=The+insulin-like+growth+factor+binding+protein+superfamily%3A+new+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenfeld%26aufirst%3DR.%2BG.%26aulast%3DHwa%26aufirst%3DV.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DLopez-Bermejo%26aufirst%3DA.%26aulast%3DBuckway%26aufirst%3DC.%26aulast%3DBurren%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DW.%2BK.%26aulast%3DDevi%26aufirst%3DG.%26aulast%3DIngermann%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DMinniti%26aufirst%3DG.%26aulast%3DSpagnoli%26aufirst%3DA.%26aulast%3DOh%26aufirst%3DY.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520binding%2520protein%2520superfamily%253A%2520new%2520perspectives%26jtitle%3DPediatrics%26date%3D1999%26volume%3D104%26spage%3D1018%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiojima, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umezawa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komuro, I.</span><span> </span><span class="NLM_article-title">IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=345-349&author=W.+Zhuauthor=I.+Shiojimaauthor=Y.+Itoauthor=Z.+Liauthor=H.+Ikedaauthor=M.+Yoshidaauthor=A.+T.+Naitoauthor=J.+Nishiauthor=H.+Uenoauthor=A.+Umezawaauthor=T.+Minaminoauthor=T.+Nagaiauthor=A.+Kikuchiauthor=M.+Asashimaauthor=I.+Komuro&title=IGFBP-4+is+an+inhibitor+of+canonical+Wnt+signalling+required+for+cardiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DShiojima%26aufirst%3DI.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DA.%2BT.%26aulast%3DNishi%26aufirst%3DJ.%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DUmezawa%26aufirst%3DA.%26aulast%3DMinamino%26aufirst%3DT.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DAsashima%26aufirst%3DM.%26aulast%3DKomuro%26aufirst%3DI.%26atitle%3DIGFBP-4%2520is%2520an%2520inhibitor%2520of%2520canonical%2520Wnt%2520signalling%2520required%2520for%2520cardiogenesis%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Kooijman, R.</span><span> </span><span class="NLM_article-title">Regulation of apoptosis by insulin-like growth factor (IGF)-I</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.cytogfr.2006.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16621671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=305-323&author=R.+Kooijman&title=Regulation+of+apoptosis+by+insulin-like+growth+factor+%28IGF%29-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of apoptosis by insulin-like growth factor (IGF)-I</span></div><div class="casAuthors">Kooijman, Ron</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">305-323</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  IGF-I is important for fetal and post-natal development, but it also controls tissue homeostasis throughout life via regulation of cell proliferation and apoptosis.  This review summarizes our current understanding of how IGF-I receptor signaling interferes with the apoptotic machinery of the cell.  IGF-I acts at different control points of apoptosis, including the Bcl-2 family proteins, inhibitors of caspases and signaling of death-inducing receptors.  The main focal point of IGF-I is the regulation of Bcl-2 family proteins.  Several signaling pathways converge to both the phosphorylation and transcriptional regulation of these proteins.  This phenomenon may explain the efficacy of IGF-I as an inhibitor of apoptosis in many different cell types and in the presence of different apoptogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmTBNxQwZr7Vg90H21EOLACvtfcHk0lh2SAYkdLOdzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSgsbk%253D&md5=02828dfebc553f75dc5b08b5a24ade3b</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2006.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2006.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DKooijman%26aufirst%3DR.%26atitle%3DRegulation%2520of%2520apoptosis%2520by%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529-I%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2006%26volume%3D17%26spage%3D305%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span> </span><span class="NLM_article-title">Protein tyrosine kinase structure and function</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">398</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1146%2Fannurev.biochem.69.1.373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10966463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2000&pages=373-398&author=S.+R.+Hubbardauthor=J.+H.+Till&title=Protein+tyrosine+kinase+structure+and+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine kinase structure and function</span></div><div class="casAuthors">Hubbard, Stevan R.; Till, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-398</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 116 refs.  Tyr-phosphorylation is one of the key covalent modifications that occurs in multicellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues.  The enzymes that carry out this modification are the protein tyrosine kinases (PTKs), which catalyze the transfer of the γ-phosphate of ATP to Tyr residues on protein substrates.  Phosphorylation of Tyr residues modulates enzymic activity and creates binding sites for the recruitment of downstream signaling proteins.  Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs.  Because PTKs are crit. components of cellular signaling pathways, their catalytic activity is strictly regulated.  Over the past several years, high-resoln. structural studies of PTKs have provided a mol. basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated.  This review highlights the important results that have emerged from these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogx8K1IKwbKLVg90H21EOLACvtfcHk0lh2SAYkdLOdzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D&md5=2aae3e0c121c9e6652be99030af36af1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.69.1.373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.69.1.373%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26atitle%3DProtein%2520tyrosine%2520kinase%2520structure%2520and%2520function%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2000%26volume%3D69%26spage%3D373%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resnicoff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Effect of mutations at serines 1280−1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">12254</span><span class="NLM_x">–</span> <span class="NLM_lpage">12260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=12254-12260&author=S.+Liauthor=M.+Resnicoffauthor=R.+Baserga&title=Effect+of+mutations+at+serines+1280%E2%88%921283+on+the+mitogenic+and+transforming+activities+of+the+insulin-like+growth+factor+I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DResnicoff%26aufirst%3DM.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DEffect%2520of%2520mutations%2520at%2520serines%25201280%25E2%2588%25921283%2520on%2520the%2520mitogenic%2520and%2520transforming%2520activities%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D12254%26epage%3D12260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Dews, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prisco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peruzzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrione, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1300</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2000&pages=1289-1300&author=M.+Dewsauthor=M.+Priscoauthor=F.+Peruzziauthor=G.+Romanoauthor=A.+Morrioneauthor=R.+Baserga&title=Domains+of+the+insulin-like+growth+factor+I+receptor+required+for+the+activation+of+extracellular+signal-regulated+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDews%26aufirst%3DM.%26aulast%3DPrisco%26aufirst%3DM.%26aulast%3DPeruzzi%26aufirst%3DF.%26aulast%3DRomano%26aufirst%3DG.%26aulast%3DMorrione%26aufirst%3DA.%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DDomains%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520required%2520for%2520the%2520activation%2520of%2520extracellular%2520signal-regulated%2520kinases%26jtitle%3DEndocrinology%26date%3D2000%26volume%3D141%26spage%3D1289%26epage%3D1300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tartare-Deckert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawka-Verhelle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdaca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van, O. E.</span><span> </span><span class="NLM_article-title">Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">23456</span><span class="NLM_x">–</span> <span class="NLM_lpage">23460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=23456-23460&author=S.+Tartare-Deckertauthor=D.+Sawka-Verhelleauthor=J.+Murdacaauthor=O.+E.+Van&title=Evidence+for+a+differential+interaction+of+SHC+and+the+insulin+receptor+substrate-1+%28IRS-1%29+with+the+insulin-like+growth+factor-I+%28IGF-I%29+receptor+in+the+yeast+two-hybrid+system"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTartare-Deckert%26aufirst%3DS.%26aulast%3DSawka-Verhelle%26aufirst%3DD.%26aulast%3DMurdaca%26aufirst%3DJ.%26aulast%3DVan%26aufirst%3DO.%2BE.%26atitle%3DEvidence%2520for%2520a%2520differential%2520interaction%2520of%2520SHC%2520and%2520the%2520insulin%2520receptor%2520substrate-1%2520%2528IRS-1%2529%2520with%2520the%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520in%2520the%2520yeast%2520two-hybrid%2520system%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D23456%26epage%3D23460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Chang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navolanic, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blalock, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span> </span><span class="NLM_article-title">Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12579299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslKrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=469-480&author=F.+Changauthor=L.+S.+Steelmanauthor=J.+G.+Sheltonauthor=J.+T.+Leeauthor=P.+M.+Navolanicauthor=W.+L.+Blalockauthor=R.+Franklinauthor=J.+A.+McCubrey&title=Regulation+of+cell+cycle+progression+and+apoptosis+by+the+Ras%2FRaf%2FMEK%2FERK+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review)</span></div><div class="casAuthors">Chang, Fumin; Steelman, Linda S.; Shelton, John G.; Lee, John T.; Navolanic, Patrick M.; Blalock, William L.; Franklin, Richard; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">469-480</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">A review.  The Ras/Raf/MEK/ERK signal transduction pathway regulates cell cycle progression and apoptosis in diverse types of cells.  Mutations in this pathway are often obsd. in transformed cell lines and frequently linked with human cancers.  The Ras/Raf/MEK/ERK pathway can induce events both assocd. with cell proliferation and cell cycle arrest.  The particular course chosen may depend on the strength and the particular Raf gene activated by Ras.  This pathway also is involved in maintaining cell survival by modulating the activity of apoptotic mols. including Bad and Bcl-2.  This review will discuss the regulation of the Ras/Raf/MEK/ERK pathway and how it modulates cell cycle progression and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkNzwwNV5N1LVg90H21EOLACvtfcHk0lhepyoqSEP-nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslKrtbo%253D&md5=7edac4057b0506e100b773af70378a3a</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DF.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DNavolanic%26aufirst%3DP.%2BM.%26aulast%3DBlalock%26aufirst%3DW.%2BL.%26aulast%3DFranklin%26aufirst%3DR.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DRegulation%2520of%2520cell%2520cycle%2520progression%2520and%2520apoptosis%2520by%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2003%26volume%3D22%26spage%3D469%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">White, M. F.</span><span> </span><span class="NLM_article-title">The IRS-signalling system: a network of docking proteins that mediate insulin action</span> <span class="citation_source-journal">Mol. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">182</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=1998&pages=3-11&author=M.+F.+White&title=The+IRS-signalling+system%3A+a+network+of+docking+proteins+that+mediate+insulin+action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DM.%2BF.%26atitle%3DThe%2520IRS-signalling%2520system%253A%2520a%2520network%2520of%2520docking%2520proteins%2520that%2520mediate%2520insulin%2520action%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D1998%26volume%3D182%26spage%3D3%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x"> (</span><span class="NLM_issue">Part 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=289-305&issue=Part+2&author=W.+Kolch&title=Meaningful+relationships%3A+the+regulation+of+the+Ras%2FRaf%2FMEK%2FERK+pathway+by+protein+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMeaningful%2520relationships%253A%2520the%2520regulation%2520of%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%2520by%2520protein%2520interactions%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26issue%3DPart%25202%26spage%3D289%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Allan, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrice, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. R.</span><span> </span><span class="NLM_article-title">Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncb1005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12792650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFeru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=647-654&author=L.+A.+Allanauthor=N.+Morriceauthor=S.+Bradyauthor=G.+Mageeauthor=S.+Pathakauthor=P.+R.+Clarke&title=Inhibition+of+caspase-9+through+phosphorylation+at+Thr+125+by+ERK+MAPK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK</span></div><div class="casAuthors">Allan, Lindsey A.; Morrice, Nick; Brady, Suzanne; Magee, Gareth; Pathak, Shalini; Clarke, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">647-654</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many pro-apoptotic signals activate caspase-9, an initiator protease that activates caspase-3 and downstream caspases to initiate cellular destruction.  However, survival signals can impinge on this pathway and suppress apoptosis.  Activation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway is assocd. with protection of cells from apoptosis and inhibition of caspase-3 activation, although the targets are unknown.  Here, the authors show that the ERK MAPK pathway inhibits caspase-9 activity by direct phosphorylation.  In mammalian cell exts., cytochrome c-induced activation of caspases-9 and -3 requires okadaic acid-sensitive protein phosphatase activity.  The opposing protein kinase activity is overcome by treatment with the broad-specificity kinase inhibitor staurosporine or with inhibitors of MEK1/2.  Caspase-9 is phosphorylated at Thr 125, a conserved MAPK consensus site targeted by ERK2 in vitro, in a MEK-dependent manner in cells stimulated with epidermal growth factor (EGF) or 12-O-tetradecanoylphorbol-13-acetate (TPA).  Phosphorylation at Thr 125 is sufficient to block caspase-9 processing and subsequent caspase-3 activation.  The authors suggest that phosphorylation and inhibition of caspase-9 by ERK promotes cell survival during development and tissue homeostasis.  This mechanism may also contribute to tumorigenesis when the ERK MAPK pathway is constitutively activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAxPQ4IB8G17Vg90H21EOLACvtfcHk0lhepyoqSEP-nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFeru7Y%253D&md5=360d7b1ddf1c1fcee2f958577ac89256</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fncb1005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1005%26sid%3Dliteratum%253Aachs%26aulast%3DAllan%26aufirst%3DL.%2BA.%26aulast%3DMorrice%26aufirst%3DN.%26aulast%3DBrady%26aufirst%3DS.%26aulast%3DMagee%26aufirst%3DG.%26aulast%3DPathak%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DP.%2BR.%26atitle%3DInhibition%2520of%2520caspase-9%2520through%2520phosphorylation%2520at%2520Thr%2520125%2520by%2520ERK%2520MAPK%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2003%26volume%3D5%26spage%3D647%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Yan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apolloni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, J. F.</span><span> </span><span class="NLM_article-title">Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">24052</span><span class="NLM_x">–</span> <span class="NLM_lpage">24056</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=24052-24056&author=J.+Yanauthor=S.+Royauthor=A.+Apolloniauthor=A.+Laneauthor=J.+F.+Hancock&title=Ras+isoforms+vary+in+their+ability+to+activate+Raf-1+and+phosphoinositide+3-kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DApolloni%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DA.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26atitle%3DRas%2520isoforms%2520vary%2520in%2520their%2520ability%2520to%2520activate%2520Raf-1%2520and%2520phosphoinositide%25203-kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D24052%26epage%3D24056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Galmiche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fueller, J.</span><span> </span><span class="NLM_article-title">RAF kinases and mitochondria</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1773</span><span class="NLM_x">, </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1773&publication_year=2007&pages=1256-1262&author=A.+Galmicheauthor=J.+Fueller&title=RAF+kinases+and+mitochondria"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalmiche%26aufirst%3DA.%26aulast%3DFueller%26aufirst%3DJ.%26atitle%3DRAF%2520kinases%2520and%2520mitochondria%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2007%26volume%3D1773%26spage%3D1256%26epage%3D1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Dhillon, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rath, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3279</span><span class="NLM_x">–</span> <span class="NLM_lpage">3290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lh9qMECKCnZ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Macdonald, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, J. L.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbruzzese, J. L.</span><span> </span><span class="NLM_article-title">A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=485-487&author=J.+S.+Macdonaldauthor=S.+McCoyauthor=R.+P.+Whiteheadauthor=S.+Iqbalauthor=J.+L.+Wadeauthor=J.+K.+Giguereauthor=J.+L.+Abbruzzese&title=A+phase+II+study+of+farnesyl+transferase+inhibitor+R115777+in+pancreatic+cancer%3A+a+Southwest+oncology+group+%28SWOG+9924%29+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DJ.%2BS.%26aulast%3DMcCoy%26aufirst%3DS.%26aulast%3DWhitehead%26aufirst%3DR.%2BP.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DWade%26aufirst%3DJ.%2BL.%26aulast%3DGiguere%26aufirst%3DJ.%2BK.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520pancreatic%2520cancer%253A%2520a%2520Southwest%2520oncology%2520group%2520%2528SWOG%25209924%2529%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2005%26volume%3D23%26spage%3D485%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Rosenberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von der, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigne, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardiak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahasrabudhe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Ruixo, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, E. J.</span><span> </span><span class="NLM_article-title">A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">2035</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2005&pages=2035-2041&author=J.+E.+Rosenbergauthor=M.+H.+von+derauthor=J.+D.+Seigneauthor=J.+Mardiakauthor=D.+J.+Vaughnauthor=M.+Mooreauthor=D.+Sahasrabudheauthor=P.+A.+Palmerauthor=J.+J.+Perez-Ruixoauthor=E.+J.+Small&title=A+phase+II+trial+of+R115777%2C+an+oral+farnesyl+transferase+inhibitor%2C+in+patients+with+advanced+urothelial+tract+transitional+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DJ.%2BE.%26aulast%3Dvon%2Bder%26aufirst%3DM.%2BH.%26aulast%3DSeigne%26aufirst%3DJ.%2BD.%26aulast%3DMardiak%26aufirst%3DJ.%26aulast%3DVaughn%26aufirst%3DD.%2BJ.%26aulast%3DMoore%26aufirst%3DM.%26aulast%3DSahasrabudhe%26aufirst%3DD.%26aulast%3DPalmer%26aufirst%3DP.%2BA.%26aulast%3DPerez-Ruixo%26aufirst%3DJ.%2BJ.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520R115777%252C%2520an%2520oral%2520farnesyl%2520transferase%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520urothelial%2520tract%2520transitional%2520cell%2520carcinoma%26jtitle%3DCancer%26date%3D2005%26volume%3D103%26spage%3D2035%26epage%3D2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlabach, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yunus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVore, R. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1187</span><span class="NLM_x">–</span> <span class="NLM_lpage">1193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fannonc%2Fmdh315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15277257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2cznt1Wmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=1187-1193&author=J.+V.+Heymachauthor=D.+H.+Johnsonauthor=F.+R.+Khuriauthor=H.+Safranauthor=L.+L.+Schlabachauthor=F.+Yunusauthor=R.+F.+DeVoreauthor=P.+M.+De+Porreauthor=H.+M.+Richardsauthor=X.+Jiaauthor=S.+Zhangauthor=B.+E.+Johnson&title=Phase+II+study+of+the+farnesyl+transferase+inhibitor+R115777+in+patients+with+sensitive+relapse+small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer</span></div><div class="casAuthors">Heymach J V; Johnson D H; Khuri F R; Safran H; Schlabach L L; Yunus F; DeVore R F 3rd; De Porre P M; Richards H M; Jia X; Zhang S; Johnson B E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1187-93</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  R115777 (tipifarnib, Zarnestra) is a farnesyl transferase inhibitor that blocks the farnesylation of proteins involved in signal transduction pathways critical for cell proliferation and survival.  This multicenter phase II study was conducted to determine the efficacy, tolerability and pharmacokinetics of R115777 in patients with relapsed small-cell lung cancer (SCLC).  PATIENTS AND METHODS:  Patients who had a partial or complete response to their initial chemotherapy regimen, followed by at least 3 months off treatment before relapse (sensitive relapse) were eligible.  R115777 was administered in 3-week cycles at a dose of 400 mg orally twice daily for 14 consecutive days followed by 7 days off treatment.  RESULTS:  Twenty-two patients were enrolled.  The median progression-free survival was 1.4 months and median overall survival was 6.8 months.  Non-hematological toxicities were predominantly grade 1-2 and included nausea (64%) and fatigue (60%).  Grade 3-4 granulocytopenia and thrombocytopenia occurred in 27% and 23% of patients, respectively.  Febrile neutropenia was not observed.  Pharmacokinetic studies demonstrated peak plasma concentrations of R115777 2.6-4.5 h after oral dosing and no significant drug accumulation.  The trial was terminated because no objective responses were observed in 20 patients evaluable for response.  CONCLUSIONS:  R115777 showed no significant antitumor activity as a single agent in sensitive-relapse SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRIDYFtJj-b8IYPsCkJIw00fW6udTcc2eYopg3OsBzoUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cznt1Wmtg%253D%253D&md5=087c6ab3c1c27b87f6fe7d4d77281d24</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdh315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdh315%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSafran%26aufirst%3DH.%26aulast%3DSchlabach%26aufirst%3DL.%2BL.%26aulast%3DYunus%26aufirst%3DF.%26aulast%3DDeVore%26aufirst%3DR.%2BF.%26aulast%3DDe%2BPorre%26aufirst%3DP.%2BM.%26aulast%3DRichards%26aufirst%3DH.%2BM.%26aulast%3DJia%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DPhase%2520II%2520study%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520patients%2520with%2520sensitive%2520relapse%2520small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2004%26volume%3D15%26spage%3D1187%26epage%3D1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced clear-cell renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowski&title=Sorafenib+in+advanced+clear-cell+renal-cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0lhvxNdSC4zj5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26atitle%3DSorafenib%2520in%2520advanced%2520clear-cell%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Elser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agulnik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pond, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheiken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elting, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrenciuc, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. X.</span><span> </span><span class="NLM_article-title">Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3766</span><span class="NLM_x">–</span> <span class="NLM_lpage">3773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2006.10.2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17704426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqtL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=3766-3773&author=C.+Elserauthor=L.+L.+Siuauthor=E.+Winquistauthor=M.+Agulnikauthor=G.+R.+Pondauthor=S.+F.+Chinauthor=P.+Francisauthor=R.+Cheikenauthor=J.+Eltingauthor=A.+McNabolaauthor=D.+Wilkieauthor=O.+Petrenciucauthor=E.+X.+Chen&title=Phase+II+trial+of+sorafenib+in+patients+with+recurrent+or+metastatic+squamous+cell+carcinoma+of+the+head+and+neck+or+nasopharyngeal+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma</span></div><div class="casAuthors">Elser, Christine; Siu, Lillian L.; Winquist, Eric; Agulnik, Mark; Pond, Gregory R.; Chin, Soo F.; Francis, Peggy; Cheiken, Robin; Elting, James; McNabola, Angela; Wilkie, Dean; Petrenciuc, Oana; Chen, Eric X.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3766-3773</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To det. the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC).  Patients and Methods: In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles.  Patients had ≤ one line of chemotherapy for recurrent and/or metastatic disease, Eastern Cooperative Oncol. Group performance status of ≤ 2, and adequate organ function.  At the end of stage 1, efficacy criteria for further accrual were not met, but the study was amended to enroll an addnl. five patients for paired tumor biopsies.  Results: Twenty-seven and 26 patients were eligible for toxicity and efficacy evaluations, resp.  One patient (3.7%; 95% CI, 0.1% to 19.0%) achieved a partial response.  Disease stabilization was maintained in 10 patients (37.0%; 95% CI, 22.4% to 61.2%).  The median time to progression was 1.8 mo (95% CI, 1.6 to 3.4 mo), and median overall survival time was 4.2 mo (95% CI, 3.6 to 8.7 mo).  Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities.  Biomarker anal. of paired tumor samples before and after treatment with sorafenib revealed a decrease of pERK in all five patients, with a decrease in Ki67 in four patients, consistent with a disruption of ERK signaling.  The antiapoptotic protein Mcl-1 was downregulated in four patients, and there was also evidence of antiangiogenic activity.  Conclusion: Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients.  Further development in combination with radiation or other agents may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XKfUu9hLG7Vg90H21EOLACvtfcHk0lhvxNdSC4zj5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqtL7N&md5=f250b63e9c01bee09330dacafa96d9a2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.10.2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.10.2871%26sid%3Dliteratum%253Aachs%26aulast%3DElser%26aufirst%3DC.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DPond%26aufirst%3DG.%2BR.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DCheiken%26aufirst%3DR.%26aulast%3DElting%26aufirst%3DJ.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DPetrenciuc%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DE.%2BX.%26atitle%3DPhase%2520II%2520trial%2520of%2520sorafenib%2520in%2520patients%2520with%2520recurrent%2520or%2520metastatic%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%2520or%2520nasopharyngeal%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D3766%26epage%3D3773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Kopec, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamowicz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esdaile, J. M.</span><span> </span><span class="NLM_article-title">Randomized discontinuation trials: utility and efficiency</span> <span class="citation_source-journal">J. Clin. Epidemiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2F0895-4356%2893%2990163-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8263581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaK2c%252FoslaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1993&pages=959-971&author=J.+A.+Kopecauthor=M.+Abrahamowiczauthor=J.+M.+Esdaile&title=Randomized+discontinuation+trials%3A+utility+and+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized discontinuation trials: utility and efficiency</span></div><div class="casAuthors">Kopec J A; Abrahamowicz M; Esdaile J M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical epidemiology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">959-71</span>
        ISSN:<span class="NLM_cas:issn">0895-4356</span>.
    </div><div class="casAbstract">The randomized discontinuation trial (RDT) is a two-phase trial.  In phase I all patients are openly treated with the medication being evaluated.  In phase II, those who have responded are randomly assigned to continue the same treatment or switch to placebo.  Usually, non-compliers and "adverse reactors" identified in phase I are excluded from phase II.  To investigate the value of this design, we reviewed the advantages and limitations of discontinuation studies, and compared the RDT design to the classic randomized clinical trial design in terms of clinical utility and efficiency (sample size).  A computer model was used to study the efficiency of the two designs under a broad range of assumptions.  The RDT design is particularly useful in studying the effect of long-term, non-curative therapies, especially when the clinically important effect is relatively small, and the use of placebo should be minimized for ethical or feasibility reasons.  However, its use is limited if the objective of an investigation is to estimate the magnitude of absolute treatment effects and toxic effects in the source population, or to evaluate a potentially curative treatment.  Our results indicate that selecting responders prior to randomization has a very strong effect on the relative efficiency of the trial.  Further improvement may be achieved by excluding non-compliers and adverse reactors.  Under the assumptions tested in our model, the sample size required in phase II of an RDT was only 20-50% of that in a classic trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG5rK8JeajGJ0d-O_J5C0AfW6udTcc2eZly8MwnmBcm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252FoslaksA%253D%253D&md5=605cf138d3b553ea9b8fc4464528b4a2</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0895-4356%2893%2990163-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0895-4356%252893%252990163-U%26sid%3Dliteratum%253Aachs%26aulast%3DKopec%26aufirst%3DJ.%2BA.%26aulast%3DAbrahamowicz%26aufirst%3DM.%26aulast%3DEsdaile%26aufirst%3DJ.%2BM.%26atitle%3DRandomized%2520discontinuation%2520trials%253A%2520utility%2520and%2520efficiency%26jtitle%3DJ.%2520Clin.%2520Epidemiol.%26date%3D1993%26volume%3D46%26spage%3D959%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Bertrand, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steelman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappell, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span> </span><span class="NLM_article-title">Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1254</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1254-1260&author=F.+E.+Bertrandauthor=L.+S.+Steelmanauthor=W.+H.+Chappellauthor=S.+L.+Abramsauthor=J.+G.+Sheltonauthor=E.+R.+Whiteauthor=D.+L.+Ludwigauthor=J.+A.+McCubrey&title=Synergy+between+an+IGF-1R+antibody+and+Raf%2FMEK%2FERK+and+PI3K%2FAkt%2FmTOR+pathway+inhibitors+in+suppressing+IGF-1R-mediated+growth+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DF.%2BE.%26aulast%3DSteelman%26aufirst%3DL.%2BS.%26aulast%3DChappell%26aufirst%3DW.%2BH.%26aulast%3DAbrams%26aufirst%3DS.%2BL.%26aulast%3DShelton%26aufirst%3DJ.%2BG.%26aulast%3DWhite%26aufirst%3DE.%2BR.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DSynergy%2520between%2520an%2520IGF-1R%2520antibody%2520and%2520Raf%252FMEK%252FERK%2520and%2520PI3K%252FAkt%252FmTOR%2520pathway%2520inhibitors%2520in%2520suppressing%2520IGF-1R-mediated%2520growth%2520in%2520hematopoietic%2520cells%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D1254%26epage%3D1260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT pathway for cancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+pathway+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0ljhl3H1d3znaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520pathway%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Osaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oshimura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, H.</span><span> </span><span class="NLM_article-title">PI3K-Akt pathway: its functions and alterations in human cancer</span> <span class="citation_source-journal">Apoptosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=667-676&author=M.+Osakiauthor=M.+Oshimuraauthor=H.+Ito&title=PI3K-Akt+pathway%3A+its+functions+and+alterations+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsaki%26aufirst%3DM.%26aulast%3DOshimura%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26atitle%3DPI3K-Akt%2520pathway%253A%2520its%2520functions%2520and%2520alterations%2520in%2520human%2520cancer%26jtitle%3DApoptosis%26date%3D2004%26volume%3D9%26spage%3D667%26epage%3D676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span> </span><span class="NLM_article-title">Regulation of protein kinases in insulin, growth factor and Wnt signalling</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0959-440X%2802%2900386-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12504681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XpslSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=761-767&author=L.+H.+Pearlauthor=D.+Barford&title=Regulation+of+protein+kinases+in+insulin%2C+growth+factor+and+Wnt+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases in insulin, growth factor and Wnt signalling</span></div><div class="casAuthors">Pearl, Laurence H.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">761-767</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinase cascades provide the regulatory mechanisms for many of the essential processes in eukaryotic cells.  Recent structural and biochem. work has revealed the basis of phosphorylation regulation of three consecutive protein kinases - phosphoinositide-dependent kinase 1 (PDK1), protein kinase B (PKB)/Akt and glycogen synthase kinase 3β (GSK3β) - which transduce signals generated by insulin and/or growth factors binding to cell surface receptors.  PDK1 and PKB are both AGC family kinases.  Whereas PKB is pos. regulated via its phosphorylated C-terminal hydrophobic motif, the activity and specificity of PDK1 are detd. by equiv. hydrophobic motifs of substrate AGC kinases.  In a contrasting mechanism, GSK3β is neg. regulated by competitive autoinhibition by its phosphorylated N terminus.  GSK3β also functions in the developmental Wnt signaling pathway, but without cross-talk with the PDK1-PKB/Akt pathway.  Structural studies of GSK3β complexes are contributing to our understanding of the phosphorylation-independent mechanism that insulates the Wnt and insulin/growth factor pathways.  Structural studies of three consecutive protein kinases in insulin/growth factor signaling (PDK1, PKB/Akt and GSK3b) are revealing complex regulatory mechanisms and beginning to explain how GSK3b also participates in Wnt signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa4IaywapaqbVg90H21EOLACvtfcHk0ljhl3H1d3znaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpslSksL8%253D&md5=b0aab1728b44477af6a2b8bdf2a6d565</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0959-440X%2802%2900386-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0959-440X%252802%252900386-X%26sid%3Dliteratum%253Aachs%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520protein%2520kinases%2520in%2520insulin%252C%2520growth%2520factor%2520and%2520Wnt%2520signalling%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D12%26spage%3D761%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Mamane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petroulakis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeBacquer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">mTOR, translation initiation and cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6416</span><span class="NLM_x">–</span> <span class="NLM_lpage">6422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6416-6422&author=Y.+Mamaneauthor=E.+Petroulakisauthor=O.+LeBacquerauthor=N.+Sonenberg&title=mTOR%2C+translation+initiation+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamane%26aufirst%3DY.%26aulast%3DPetroulakis%26aufirst%3DE.%26aulast%3DLeBacquer%26aufirst%3DO.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DmTOR%252C%2520translation%2520initiation%2520and%2520cancer%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6416%26epage%3D6422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Marygold, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leevers, S. J.</span><span> </span><span class="NLM_article-title">Growth signaling: TSC takes its place</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">R785</span><span class="NLM_x">–</span> <span class="NLM_lpage">R787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=R785-R787&author=S.+J.+Marygoldauthor=S.+J.+Leevers&title=Growth+signaling%3A+TSC+takes+its+place"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarygold%26aufirst%3DS.%2BJ.%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26atitle%3DGrowth%2520signaling%253A%2520TSC%2520takes%2520its%2520place%26jtitle%3DCurr.%2520Biol.%26date%3D2002%26volume%3D12%26spage%3DR785%26epage%3DR787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Growing roles for the mTOR pathway</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">603</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ceb.2005.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16226444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyksL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=596-603&author=D.+D.+Sarbassovauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Growing+roles+for+the+mTOR+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Growing roles for the mTOR pathway</span></div><div class="casAuthors">Sarbassov, Dos D.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">596-603</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian TOR (mTOR; mammalian target of rapamycin) pathway is a key regulator of cell growth and proliferation and increasing evidence suggests that its deregulation is assocd. with human diseases, including cancer and diabetes.  The mTOR pathway integrates signals from nutrients, energy status, and growth factors to regulate many processes, including autophagy, ribosome biogenesis, and metab.  Recent work identifying 2 structurally and functionally distinct mTOR-contg. multiprotein complexes, and TSC1/2, rheb, and AMPK as upstream regulators of mTOR, is beginning to reveal how mTOR can sense diverse signals and produce a myriad of responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMOIIVMYJG0LVg90H21EOLACvtfcHk0lh8tJ07jxtIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyksL7F&md5=e24e27de16bd9f8e7219b684c7242f8e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DGrowing%2520roles%2520for%2520the%2520mTOR%2520pathway%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26spage%3D596%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span> </span><span class="NLM_article-title">Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=977-980&author=X.+Baiauthor=D.+Maauthor=A.+Liuauthor=X.+Shenauthor=Q.+J.+Wangauthor=Y.+Liuauthor=Y.+Jiang&title=Rheb+activates+mTOR+by+antagonizing+its+endogenous+inhibitor%2C+FKBP38"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DY.%26atitle%3DRheb%2520activates%2520mTOR%2520by%2520antagonizing%2520its%2520endogenous%2520inhibitor%252C%2520FKBP38%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D977%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Saucedo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarelli, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edgar, B. A.</span><span> </span><span class="NLM_article-title">Rheb promotes cell growth as a component of the insulin/TOR signalling network</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">566</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fncb996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12766776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlWnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=566-571&author=L.+J.+Saucedoauthor=X.+Gaoauthor=D.+A.+Chiarelliauthor=L.+Liauthor=D.+Panauthor=B.+A.+Edgar&title=Rheb+promotes+cell+growth+as+a+component+of+the+insulin%2FTOR+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Rheb promotes cell growth as a component of the insulin/TOR signalling network</span></div><div class="casAuthors">Saucedo, Leslie J.; Gao, Xinsheng; Chiarelli, Dominic A.; Li, Ling; Pan, Duoija; Edgar, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">566-571</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insulin signaling is a potent inhibitor of cell growth and has been proposed to function, at least in part, through the conserved protein kinase TOR (target of rapamycin).  Recent studies suggest a that the tuberous sclerosis complex Tsc1-Tsc2 may couple insulin signaling to Tor activity.  However, the regulatory mechanism involved remains unclear, and addnl. components are most probably involved.  In a screen for novel regulators of growth, we identified Rheb (Ras homolog enriched in brain), a member of the Ras superfamily of GTP-binding proteins.  Increased levels of Rheb in D. melanogaster promote cell growth and alter cell cycle kinetics in multiple tissues.  In mitotic tissues, overexpression of Rheb accelerates passage through G1-S phase without affecting rates of cell division, whereas in endoreplicating tissues, Rheb increases DNA ploidy.  Mutation of Rheb suspends larval growth and prevents progression from 1st to 2nd instar.  Genetic and biochem. tests indicate that Rheb functions in the insulin signaling pathway downstream of Tsc1-Tsc2 and upstream of TOR.  Levels of rheb mRNA are rapidly induced in response to protein starvation, and overexpressed Rheb can drive cell growth in starved animals, suggesting a role for Rheb in the nutritional control of cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8DM_KyEMljLVg90H21EOLACvtfcHk0lh8tJ07jxtIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlWnsro%253D&md5=f1b291a45a362c0dfe5e92e3212f84ee</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fncb996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb996%26sid%3Dliteratum%253Aachs%26aulast%3DSaucedo%26aufirst%3DL.%2BJ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChiarelli%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DD.%26aulast%3DEdgar%26aufirst%3DB.%2BA.%26atitle%3DRheb%2520promotes%2520cell%2520growth%2520as%2520a%2520component%2520of%2520the%2520insulin%252FTOR%2520signalling%2520network%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2003%26volume%3D5%26spage%3D566%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Tee, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blenis, J.</span><span> </span><span class="NLM_article-title">Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1259</span><span class="NLM_x">–</span> <span class="NLM_lpage">1268</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0960-9822%2803%2900506-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12906785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1Kitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=1259-1268&author=A.+R.+Teeauthor=B.+D.+Manningauthor=P.+P.+Rouxauthor=L.+C.+Cantleyauthor=J.+Blenis&title=Tuberous+sclerosis+complex+gene+products%2C+tuberin+and+hamartin%2C+control+mTOR+signaling+by+acting+as+a+GTPase-activating+protein+complex+toward+Rheb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb</span></div><div class="casAuthors">Tee, Andrew R.; Manning, Brendan D.; Roux, Philippe P.; Cantley, Lewis C.; Blenis, John</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Background: Tuberous Sclerosis Complex (TSC) is a genetic disorder that occurs through the loss of heterozygosity of either TSC1 or TSC2, which encode Hamartin or Tuberin, resp.  Tuberin and Hamartin form a tumor suppressor heterodimer that inhibits the mammalian target of rapamycin (mTOR) nutrient signaling input, but how this occurs is unclear.  Results: We show that the small G protein Rheb (Ras homolog enriched in brain) is a mol. target of TSC1/TSC2 that regulates mTOR signaling.  Overexpression of Rheb activates 40S ribosomal protein S6 kinase 1 (S6K1) but not p90 ribosomal S6 kinase 1 (RSK1) or Akt.  Furthermore, Rheb induces phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and causes 4E-BP1 to dissoc. from eIF4E.  This dissocn. is completely sensitive to rapamycin (an mTOR inhibitor) but not wortmannin (a phosphoinositide 3-kinase [PI3K] inhibitor).  Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.  Moreover, Rheb does not activate a S6K1 mutant that is unresponsive to mTOR-mediated signals, confirming that Rheb functions upstream of mTOR.  Overexpression of the Tuberin-Hamartin heterodimer inhibits Rheb-mediated S6K1 activation, suggesting that Tuberin functions as a Rheb GTPase activating protein (GAP).  Supporting this notion, TSC patient-derived Tuberin GAP domain mutants were unable to inactivate Rheb in vivo.  Moreover, in vitro studies reveal that Tuberin, when assocd. with Hamartin, acts as a Rheb GTPase-activating protein.  Finally, we show that membrane localization of Rheb is important for its biol. activity because a farnesylation-defective mutant of Rheb stimulated S6K1 activation less efficiently.  Conclusions: We show that Rheb acts as a novel mediator of the nutrient signaling input to mTOR and is the mol. target of TSC1 and TSC2 within mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKz47uqJPZrVg90H21EOLACvtfcHk0lh8tJ07jxtIhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1Kitr0%253D&md5=96bcd417af27ed57a88046ff4f7b78de</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2803%2900506-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252803%252900506-2%26sid%3Dliteratum%253Aachs%26aulast%3DTee%26aufirst%3DA.%2BR.%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DTuberous%2520sclerosis%2520complex%2520gene%2520products%252C%2520tuberin%2520and%2520hamartin%252C%2520control%2520mTOR%2520signaling%2520by%2520acting%2520as%2520a%2520GTPase-activating%2520protein%2520complex%2520toward%2520Rheb%26jtitle%3DCurr.%2520Biol.%26date%3D2003%26volume%3D13%26spage%3D1259%26epage%3D1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Lazaris-Karatzas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">547</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1990&pages=544-547&author=A.+Lazaris-Karatzasauthor=K.+S.+Montineauthor=N.+Sonenberg&title=Malignant+transformation+by+a+eukaryotic+initiation+factor+subunit+that+binds+to+mRNA+5%E2%80%B2+cap"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DMontine%26aufirst%3DK.%2BS.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DMalignant%2520transformation%2520by%2520a%2520eukaryotic%2520initiation%2520factor%2520subunit%2520that%2520binds%2520to%2520mRNA%25205%25E2%2580%25B2%2520cap%26jtitle%3DNature%26date%3D1990%26volume%3D345%26spage%3D544%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Lazaris-Karatzas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonenberg, N.</span><span> </span><span class="NLM_article-title">The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1234</span><span class="NLM_x">–</span> <span class="NLM_lpage">1238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=1532049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK38XhslWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=1234-1238&author=A.+Lazaris-Karatzasauthor=N.+Sonenberg&title=The+mRNA+5%E2%80%B2+cap-binding+protein%2C+eIF-4E%2C+cooperates+with+v-myc+or+E1A+in+the+transformation+of+primary+rodent+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts</span></div><div class="casAuthors">Lazaris-Karatzas, Anthoula; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1234-8</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The authors present evidence that eIF-4E, the mRNA 5' cap-binding protein, cooperates with 2 immortalizing oncogenes, v-myc and E1A, to cause transformation of rat embryo fibroblasts.  EIF-4E alone can transform rat embryo fibroblasts when selection is applied.  The pattern of transformation by eIF-4E is similar to that of p21 Ras, raising the possibility that eIF-4E shares a common signal transduction pathway with p21 Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KEuy5sCzprVg90H21EOLACvtfcHk0lgMBVpuvX3ucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhslWhtL0%253D&md5=59004e6953eea6bf997626b6d2b6a98b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLazaris-Karatzas%26aufirst%3DA.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DThe%2520mRNA%25205%25E2%2580%25B2%2520cap-binding%2520protein%252C%2520eIF-4E%252C%2520cooperates%2520with%2520v-myc%2520or%2520E1A%2520in%2520the%2520transformation%2520of%2520primary%2520rodent%2520fibroblasts%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1992%26volume%3D12%26spage%3D1234%26epage%3D1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Ruvinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyuhas, O.</span><span> </span><span class="NLM_article-title">Ribosomal protein S6 phosphorylation: from protein synthesis to cell size</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=342-348&author=I.+Ruvinskyauthor=O.+Meyuhas&title=Ribosomal+protein+S6+phosphorylation%3A+from+protein+synthesis+to+cell+size"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuvinsky%26aufirst%3DI.%26aulast%3DMeyuhas%26aufirst%3DO.%26atitle%3DRibosomal%2520protein%2520S6%2520phosphorylation%253A%2520from%2520protein%2520synthesis%2520to%2520cell%2520size%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2006%26volume%3D31%26spage%3D342%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Averous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proud, C. G.</span><span> </span><span class="NLM_article-title">When translation meets transformation: the mTOR story</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6423</span><span class="NLM_x">–</span> <span class="NLM_lpage">6435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.onc.1209887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17041627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6423-6435&author=J.+Averousauthor=C.+G.+Proud&title=When+translation+meets+transformation%3A+the+mTOR+story"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">When translation meets transformation: The mTOR story</span></div><div class="casAuthors">Averous, J.; Proud, C. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6423-6435</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is currently a high level of interest in signaling through the mammalian target of rapamycin (mTOR).  This reflects both its key role in many cell functions and its involvement in disease states such as cancers.  The best understood targets for mTOR signalling are proteins involved in controlling the translational machinery, including the ribosomal protein S6 kinases and proteins that regulate the initiation and elongation phases of translation.  Indeed, there is compelling evidence that at least one of these targets of mTOR (eukaryotic initiation factor eIF4E) plays a key role in tumorigenesis.  It is regulated through the mTOR-dependent phosphorylation of inhibitory proteins such as eIF4E-binding protein 1.  Thus, targeting mTOR signalling may be an effective anticancer strategy, in at least a significant subset of tumors.  Not all effects of mTOR are sensitive to the classical anti-mTOR drug rapamycin, and this compd. also interferes with other processes besides eIF4E function.  Developing new approaches to targeting mTOR for cancer therapy requires more detailed knowledge of signalling downstream of mTOR.  Such advances are likely to come from further work to understand the regulation of mTOR targets such as components of the translational app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsNfzV_sznY7Vg90H21EOLACvtfcHk0lgMBVpuvX3ucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOlsrrO&md5=4b175aaae5494507cbc43ec08f8da1ac</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209887%26sid%3Dliteratum%253Aachs%26aulast%3DAverous%26aufirst%3DJ.%26aulast%3DProud%26aufirst%3DC.%2BG.%26atitle%3DWhen%2520translation%2520meets%2520transformation%253A%2520the%2520mTOR%2520story%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6423%26epage%3D6435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Dancey, J. E.</span><span> </span><span class="NLM_article-title">Therapeutic targets: MTOR and related pathways</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.4161%2Fcbt.5.9.3175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16969122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1065-1073&author=J.+E.+Dancey&title=Therapeutic+targets%3A+MTOR+and+related+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targets. MTOR and related pathways</span></div><div class="casAuthors">Dancey, Janet E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR), a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, has a central role in controlling malignant cellular growth.  As a result, mTOR is viewed as an important target for anticancer drug development.  Inhibitors of mTOR currently under evaluation in cancer clin. trials are rapamycin (also known as sirolimus, Wyeth) and derivs. temsirolimus (CCI-779, Wyeth), everolimus, (RAD001, Novartis Pharma AG), and AP23573 (Ariad Pharmaceuticals).  Preclin. studies suggest that sensitivity to mTOR inhibitors may correlate with activation of the PI3K pathway and/or with aberrant expression of cell cycle regulatory or anti-apoptotic proteins.  Clin. trial results show that mTOR inhibitors are well tolerated and may induce prolonged stable disease and tumor regressions in cancer patients.  Future research should evaluate optimal, schedule, patient selection, and combination strategies for this novel class of agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz_taiC5i3ALVg90H21EOLACvtfcHk0lgMBVpuvX3ucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlejsQ%253D%253D&md5=be06e2ae7e26fcb0dfe54c3f38011c5e</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.4161%2Fcbt.5.9.3175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.5.9.3175%26sid%3Dliteratum%253Aachs%26aulast%3DDancey%26aufirst%3DJ.%2BE.%26atitle%3DTherapeutic%2520targets%253A%2520MTOR%2520and%2520related%2520pathways%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1065%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Easton, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">mTOR and cancer therapy</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6436</span><span class="NLM_x">–</span> <span class="NLM_lpage">6446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6436-6446&author=J.+B.+Eastonauthor=P.+J.+Houghton&title=mTOR+and+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEaston%26aufirst%3DJ.%2BB.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DmTOR%2520and%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6436%26epage%3D6446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroemer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Current development of mTOR inhibitors as anticancer agents</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">688</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrd2062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16883305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=671-688&author=S.+Faivreauthor=G.+Kroemerauthor=E.+Raymond&title=Current+development+of+mTOR+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Current development of mTOR inhibitors as anticancer agents</span></div><div class="casAuthors">Faivre, Sandrine; Kroemer, Guido; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">671-688</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch between catabolic and anabolic metab. and as such is a target for the design of anticancer agents.  The most established mTOR inhibitors - rapamycin and its derivs. - showed long-lasting objective tumor responses in clin. trials, with CCI-779 being a first-in-class mTOR inhibitor that improved the survival of patients with advanced renal cell carcinoma.  This heralded the beginning of extensive clin. programs to further evaluate mTOR inhibitors in several tumor types.  Here we review the clin. development of this drug class and look at future prospects for incorporating these agents into multitarget or multimodality strategies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajgc4JNPmPrVg90H21EOLACvtfcHk0ljrdq8K7pCHxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkurk%253D&md5=3fe58d7e26bff7c311437ca516584882</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1038%2Fnrd2062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2062%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DCurrent%2520development%2520of%2520mTOR%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D671%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basch, E.</span><span> </span><span class="NLM_article-title">Targeted drugs for metastatic renal cell carcinoma</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=2071-2073&author=R.+J.+Motzerauthor=E.+Basch&title=Targeted+drugs+for+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DBasch%26aufirst%3DE.%26atitle%3DTargeted%2520drugs%2520for%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D2071%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">O'Reilly, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rojo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1500</span><span class="NLM_x">–</span> <span class="NLM_lpage">1508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%27Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0ljrdq8K7pCHxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%2527Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Masiello, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neel, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bubley, G. J.</span><span> </span><span class="NLM_article-title">Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17218776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=195-201&author=D.+Masielloauthor=M.+G.+Mohiauthor=N.+C.+McKnightauthor=B.+Smithauthor=B.+G.+Neelauthor=S.+P.+Balkauthor=G.+J.+Bubley&title=Combining+an+mTOR+antagonist+and+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer</span></div><div class="casAuthors">Masiello, David; Mohi, M. Golam; McKnight, Nicole C.; Smith, Bradley; Neel, Ben G.; Balk, Steven P.; Bubley, Glenn J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-201</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway is a potentially useful therapeutic strategy in the treatment of advanced prostate cancer.  However mTOR antagonists used as single agents are not likely to result in dramatic clin. responses, so that it is useful to identify prospective agents that might be useful in combination.  We treated CWR22Rv1 and LNCaP prostate cancer cells with an mTOR inhibitor, rapamycin, alone, or in combination with either of two receptor protein kinase (RTK) inhibitors.  We assessed the effects of these treatments on cell survival and activation of down-stream mTOR target proteins.  Treatment with either PD16839, an EGFr antagonist, or imatinib mesylate (Gleevec), a PDGFr, c-kit and bcr/abl antagonist, enhanced the anti-proliferative effects of rapamycin.  We therefore assessed the effects of treatment with the RTK antagonist alone and in combination with rapamycin on mTOR targeted proteins.  RTK antagonists alone had no effect or paradoxically increased phosphorylation of the mTOR targeted proteins, p70 S6 kinase and ribosomal S6.  In contrast, when these cells were treated with either RTK antagonist in the presence of rapamycin, there was a dramatic decrease in phosphorylation of these two mTOR-targeted proteins.  These effects were not mediated through phospho-AKT.  Since two sep. RTK antagonists had additive antiproliferative effects in combination with an mTOR antagonist and were assocd. with a dramatic decrease in mTOR targeted proteins in cells with or without PTEN expression, the strategy deserves further evaluation for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfa9_zd3h8drVg90H21EOLACvtfcHk0ljrdq8K7pCHxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsbzK&md5=5c99f14560ab6c1d7ab8a3ed419a19f4</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasiello%26aufirst%3DD.%26aulast%3DMohi%26aufirst%3DM.%2BG.%26aulast%3DMcKnight%26aufirst%3DN.%2BC.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DNeel%26aufirst%3DB.%2BG.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DBubley%26aufirst%3DG.%2BJ.%26atitle%3DCombining%2520an%2520mTOR%2520antagonist%2520and%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D195%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Buck, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyzaguirre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, G.</span><span> </span><span class="NLM_article-title">Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2676</span><span class="NLM_x">–</span> <span class="NLM_lpage">2684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17121914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1els7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2676-2684&author=E.+Buckauthor=A.+Eyzaguirreauthor=E.+Brownauthor=F.+Pettiauthor=S.+McCormackauthor=J.+D.+Haleyauthor=K.+K.+Iwataauthor=N.+W.+Gibsonauthor=G.+Griffin&title=Rapamycin+synergizes+with+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+in+non-small-cell+lung%2C+pancreatic%2C+colon%2C+and+breast+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors</span></div><div class="casAuthors">Buck, Elizabeth; Eyzaguirre, Alexandra; Brown, Eric; Petti, Filippo; McCormack, Siobhan; Haley, John D.; Iwata, Kenneth K.; Gibson, Neil W.; Griffin, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2676-2684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers.  One important signaling pathway regulated by EGFR is the phosphatidylinositol 3'-kinase (PI3K)-phosphoinositide-dependent kinase 1-Akt pathway.  Activation of Akt leads to the stimulation of antiapoptotic pathways, promoting cell survival.  Akt also regulates the mammalian target of rapamycin (mTOR)-S6K-S6 pathway to control cell growth in response to growth factors and nutrients.  Recent reports have shown that the sensitivity of non-small-cell lung cancer cell lines to EGFR inhibitors such as erlotinib (Tarceva, OSI Pharmaceuticals) is dependent on inhibition of the phosphatidylinositol 3'-kinase-phosphoinositide-dependent kinase 1-Akt-mTOR pathway.  There can be multiple inputs to this pathway as activity can be regulated by other receptors or upstream mutations.  Therefore, inhibiting EGFR alone may not be sufficient for substantial inhibition of all tumor cells, highlighting the need for multipoint intervention.  Herein, we sought to det. if rapamycin, an inhibitor of mTOR, could enhance erlotinib sensitivity for cell lines derived from a variety of tissue types (non-small-cell lung, pancreatic, colon, and breast).  Erlotinib could inhibit extracellular signal-regulated kinase, Akt, and S6 only in cell lines that were the most sensitive.  Rapamycin could fully inhibit S6 in all cell lines, but this was accompanied by activation of Akt phosphorylation.  However, combination with erlotinib could down-modulate rapamycin-stimulated Akt activity.  Therefore, in select cell lines, inhibition of both S6 and Akt was achieved only with the combination of erlotinib and rapamycin.  This produced a synergistic effect on cell growth inhibition, observations that extended in vivo using xenograft models.  These results suggest that combining rapamycin with erlotinib might be clin. useful to enhance response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrywRO-to2xnbVg90H21EOLACvtfcHk0lgmzCiMDTuyIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1els7nP&md5=ac5ac416f697a06090869a47975b1f4a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0166%26sid%3Dliteratum%253Aachs%26aulast%3DBuck%26aufirst%3DE.%26aulast%3DEyzaguirre%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DPetti%26aufirst%3DF.%26aulast%3DMcCormack%26aufirst%3DS.%26aulast%3DHaley%26aufirst%3DJ.%2BD.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26aulast%3DGriffin%26aufirst%3DG.%26atitle%3DRapamycin%2520synergizes%2520with%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520in%2520non-small-cell%2520lung%252C%2520pancreatic%252C%2520colon%252C%2520and%2520breast%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2676%26epage%3D2684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaghlul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=81-93&author=D.+Liauthor=T.+Shimamuraauthor=H.+Jiauthor=L.+Chenauthor=H.+J.+Haringsmaauthor=K.+McNamaraauthor=M.+C.+Liangauthor=S.+A.+Pereraauthor=S.+Zaghlulauthor=C.+L.+Borgmanauthor=S.+Kuboauthor=M.+Takahashiauthor=Y.+Sunauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=N.+I.+Lindemanauthor=P.+A.+Janneauthor=R.+K.+Thomasauthor=M.+L.+Meyersonauthor=M.+J.+Eckauthor=J.+A.+Engelmanauthor=G.+I.+Shapiroauthor=K.+K.+Wong&title=Bronchial+and+peripheral+murine+lung+carcinomas+induced+by+T790M-L858R+mutant+EGFR+respond+to+HKI-272+and+rapamycin+combination+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DM.%2BC.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DZaghlul%26aufirst%3DS.%26aulast%3DBorgman%26aufirst%3DC.%2BL.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DLindeman%26aufirst%3DN.%2BI.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%2BL.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBronchial%2520and%2520peripheral%2520murine%2520lung%2520carcinomas%2520induced%2520by%2520T790M-L858R%2520mutant%2520EGFR%2520respond%2520to%2520HKI-272%2520and%2520rapamycin%2520combination%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D81%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurie, J. M.</span><span> </span><span class="NLM_article-title">Drugging the bad “AKT-TOR” to overcome TKI-resistant lung cancer</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=6-8&author=J.+Settlemanauthor=J.+M.+Kurie&title=Drugging+the+bad+%E2%80%9CAKT-TOR%E2%80%9D+to+overcome+TKI-resistant+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DKurie%26aufirst%3DJ.%2BM.%26atitle%3DDrugging%2520the%2520bad%2520%25E2%2580%259CAKT-TOR%25E2%2580%259D%2520to%2520overcome%2520TKI-resistant%2520lung%2520cancer%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D12%26spage%3D6%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efstratiadis, A.</span><span> </span><span class="NLM_article-title">Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1993&pages=59-72&author=J.+P.+Liuauthor=J.+Bakerauthor=A.+S.+Perkinsauthor=E.+J.+Robertsonauthor=A.+Efstratiadis&title=Mice+carrying+null+mutations+of+the+genes+encoding+insulin-like+growth+factor+I+%28Igf-1%29+and+type+1+IGF+receptor+%28Igf1r%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DPerkins%26aufirst%3DA.%2BS.%26aulast%3DRobertson%26aufirst%3DE.%2BJ.%26aulast%3DEfstratiadis%26aufirst%3DA.%26atitle%3DMice%2520carrying%2520null%2520mutations%2520of%2520the%2520genes%2520encoding%2520insulin-like%2520growth%2520factor%2520I%2520%2528Igf-1%2529%2520and%2520type%25201%2520IGF%2520receptor%2520%2528Igf1r%2529%26jtitle%3DCell%26date%3D1993%26volume%3D75%26spage%3D59%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Powell-Braxton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warburton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts-Meek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. A.</span><span> </span><span class="NLM_article-title">IGF-I is required for normal embryonic growth in mice</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2609</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=2609-2617&author=L.+Powell-Braxtonauthor=P.+Hollingsheadauthor=C.+Warburtonauthor=M.+Dowdauthor=S.+Pitts-Meekauthor=D.+Daltonauthor=N.+Gillettauthor=T.+A.+Stewart&title=IGF-I+is+required+for+normal+embryonic+growth+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPowell-Braxton%26aufirst%3DL.%26aulast%3DHollingshead%26aufirst%3DP.%26aulast%3DWarburton%26aufirst%3DC.%26aulast%3DDowd%26aufirst%3DM.%26aulast%3DPitts-Meek%26aufirst%3DS.%26aulast%3DDalton%26aufirst%3DD.%26aulast%3DGillett%26aufirst%3DN.%26aulast%3DStewart%26aufirst%3DT.%2BA.%26atitle%3DIGF-I%2520is%2520required%2520for%2520normal%2520embryonic%2520growth%2520in%2520mice%26jtitle%3DGenes%2520Dev.%26date%3D1993%26volume%3D7%26spage%3D2609%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Woods, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camacho-Hubner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, A. J.</span><span> </span><span class="NLM_article-title">Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJM199610313351805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8857020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaK2s%252FhtFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=1996&pages=1363-1367&author=K.+A.+Woodsauthor=C.+Camacho-Hubnerauthor=M.+O.+Savageauthor=A.+J.+Clark&title=Intrauterine+growth+retardation+and+postnatal+growth+failure+associated+with+deletion+of+the+insulin-like+growth+factor+I+gene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene</span></div><div class="casAuthors">Woods K A; Camacho-Hubner C; Savage M O; Clark A J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1363-7</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT01tsIhtZ4o6cY7HFp97qMfW6udTcc2eZ5dfdC8tbmYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FhtFSnsw%253D%253D&md5=479ba9dbc5bf5f11db26ea67a8d4531b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1056%2FNEJM199610313351805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199610313351805%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DK.%2BA.%26aulast%3DCamacho-Hubner%26aufirst%3DC.%26aulast%3DSavage%26aufirst%3DM.%2BO.%26aulast%3DClark%26aufirst%3DA.%2BJ.%26atitle%3DIntrauterine%2520growth%2520retardation%2520and%2520postnatal%2520growth%2520failure%2520associated%2520with%2520deletion%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520gene%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D335%26spage%3D1363%26epage%3D1367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Abuzzahab, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorescu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiess, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klammt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratzsch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osgood, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfaffle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raile, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chernausek, S. D.</span><span> </span><span class="NLM_article-title">IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">2211</span><span class="NLM_x">–</span> <span class="NLM_lpage">2222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa010107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14657428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Whs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=2211-2222&author=M.+J.+Abuzzahabauthor=A.+Schneiderauthor=A.+Goddardauthor=F.+Grigorescuauthor=C.+Lautierauthor=E.+Kellerauthor=W.+Kiessauthor=J.+Klammtauthor=J.+Kratzschauthor=D.+Osgoodauthor=R.+Pfaffleauthor=K.+Raileauthor=B.+Seidelauthor=R.+J.+Smithauthor=S.+D.+Chernausek&title=IGF-I+receptor+mutations+resulting+in+intrauterine+and+postnatal+growth+retardation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation</span></div><div class="casAuthors">Abuzzahab, M. Jennifer; Schneider, Anke; Goddard, Audrey; Grigorescu, Florin; Lautier, Corinne; Keller, Eberhard; Kiess, Wieland; Klammt, Juergen; Kratzsch, Juergen; Osgood, Doreen; Pfaeffle, Roland; Raile, Klemens; Seidel, Berthold; Smith, Robert J.; Chernausek, Steven D.; Frank, G. R.; Kaplowitz, P. B.; Pescovitz, O. H.; Smith, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2211-2222</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND-Approx. 10 percent of infants with intrauterine growth retardation remain small, and the causes of their growth deficits are often unclear.  We postulated that mutations in the gene for the insulin-like growth factor I receptor (IGF-IR) might underlie some cases of prenatal and postnatal growth failure.  METHODS-We screened two groups of children for abnormalities in the IGF-IR gene.  In one group of 42 patients with unexplained intrauterine growth retardation and subsequent short stature, we used single-strand conformation polymorphism anal., followed by direct DNA sequencing of any abnormalities found.  A second cohort consisted of 50 children with short stature who had elevated circulating IGF-I concns.  Complete sequencing of the IGF-IR gene was performed with DNA from nine children.  We also studied a control group of 43 children with normal birth wts.  RESULTS-In the first cohort, we identified one girl who was a compd. heterozygote for point mutations in exon 2 of the IGF-IR gene that altered the amino acid sequence to Arg108Gln in one allele and Lys115Asn in the other.  Fibroblasts cultured from the patient had decreased IGF-I-receptor function, as compared with that in control fibroblasts.  No such mutations were found in the 43 controls.  In the second group, we identified one boy with a nonsense mutation (Arg59stop) that reduced the no. of IGF-I receptors on fibroblasts.  Both children had intrauterine growth retardation and poor postnatal growth.  CONCLUSIONS-Mutations in the IGF-IR gene that lead to abnormalities in the function or no. of IGF-I receptors may also retard intrauterine and subsequent growth in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9hG0FbEOBCrVg90H21EOLACvtfcHk0lgTzm51w4f6cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Whs7w%253D&md5=4292bf2089b400b84d78b640177b67e2</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa010107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa010107%26sid%3Dliteratum%253Aachs%26aulast%3DAbuzzahab%26aufirst%3DM.%2BJ.%26aulast%3DSchneider%26aufirst%3DA.%26aulast%3DGoddard%26aufirst%3DA.%26aulast%3DGrigorescu%26aufirst%3DF.%26aulast%3DLautier%26aufirst%3DC.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DKiess%26aufirst%3DW.%26aulast%3DKlammt%26aufirst%3DJ.%26aulast%3DKratzsch%26aufirst%3DJ.%26aulast%3DOsgood%26aufirst%3DD.%26aulast%3DPfaffle%26aufirst%3DR.%26aulast%3DRaile%26aufirst%3DK.%26aulast%3DSeidel%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DR.%2BJ.%26aulast%3DChernausek%26aufirst%3DS.%2BD.%26atitle%3DIGF-I%2520receptor%2520mutations%2520resulting%2520in%2520intrauterine%2520and%2520postnatal%2520growth%2520retardation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D2211%26epage%3D2222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Laursen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiansen, J. S.</span><span> </span><span class="NLM_article-title">The management of adult growth hormone deficiency syndrome</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2435</span><span class="NLM_x">–</span> <span class="NLM_lpage">2450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F14656566.9.14.2435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18778182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVygtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=2435-2450&author=T.+Laursenauthor=J.+O.+Jorgensenauthor=J.+S.+Christiansen&title=The+management+of+adult+growth+hormone+deficiency+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The management of adult growth hormone deficiency syndrome</span></div><div class="casAuthors">Laursen, Torben; Jorgensen, Jens Otto Lunde; Christiansen, Jens Sandahl</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2435-2450</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  In patients with hypopituitarism, growth hormone deficiency (GHD) is almost inevitably present.  Lack of other pituitary hormones may require prompt replacement, but lack of growth hormone (GH) is also assocd. with several abnormalities.  Growth hormone treatment safely improves or normalizes many of these deviations.  The aberrations include low bone mass and increased risk of fractures, abnormal body compn. in terms of increased fat mass, and reduced lean body mass resulting in reduced muscle mass and strength.  The decreased exercise capacity in GHD may be influenced by impaired cardiac performance and heat intolerance.  Increased abdominal fat results in metabolic disturbancies such as reduced insulin sensitivity and hyperlipidemia, leading to an increased risk of cardiovascular diseases.  Patients with hypopituitarism who have had relevant hormones replaced except GH have increased mortality due to, for example, cardiovascular diseases.  Thus, it is important to diagnose GHD, which requires precise diagnostic criteria and methods.  Dynamic testing of GH secretion with insulin tolerance test or arginine + GH releasing hormone can be used.  Patients with childhood onset GHD should be re-evaluated if GH therapy is maintained into adulthood.  Although GH replacement therapy improves the patophysiol. manifestations of GHD and quality of life, it is unclear whether mortality is reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCGpMjMp3097Vg90H21EOLACvtfcHk0lgTzm51w4f6cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVygtb7N&md5=c90ef5321de25c0e74ccebcf45526db0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1517%2F14656566.9.14.2435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.9.14.2435%26sid%3Dliteratum%253Aachs%26aulast%3DLaursen%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DJ.%2BO.%26aulast%3DChristiansen%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520management%2520of%2520adult%2520growth%2520hormone%2520deficiency%2520syndrome%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2008%26volume%3D9%26spage%3D2435%26epage%3D2450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Baylink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span> </span><span class="NLM_article-title">The role of IGF system in the rise and fall in bone density with age</span> <span class="citation_source-journal">J. Musculoskeletal Neuronal Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18094484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2sjls1Wjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=304-305&author=D.+Baylinkauthor=K.+H.+Lauauthor=S.+Mohan&title=The+role+of+IGF+system+in+the+rise+and+fall+in+bone+density+with+age"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The role of IGF system in the rise and fall in bone density with age</span></div><div class="casAuthors">Baylink D; Lau K H-W; Mohan S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of musculoskeletal & neuronal interactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-5</span>
        ISSN:<span class="NLM_cas:issn">1108-7161</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIV8rkcnqV_9FxYDaSSP8XfW6udTcc2ebtDo2U7lZf9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjls1Wjug%253D%253D&md5=dee29ba0bf022715dce665e093147d7a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaylink%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DK.%2BH.%26aulast%3DMohan%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520IGF%2520system%2520in%2520the%2520rise%2520and%2520fall%2520in%2520bone%2520density%2520with%2520age%26jtitle%3DJ.%2520Musculoskeletal%2520Neuronal%2520Interact.%26date%3D2007%26volume%3D7%26spage%3D304%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Niu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, C. J.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I gene and osteoporosis: a critical appraisal</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2005&pages=38-56&author=T.+Niuauthor=C.+J.+Rosen&title=The+insulin-like+growth+factor-I+gene+and+osteoporosis%3A+a+critical+appraisal"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520gene%2520and%2520osteoporosis%253A%2520a%2520critical%2520appraisal%26jtitle%3DGene%26date%3D2005%26volume%3D361%26spage%3D38%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Perrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalicchio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laviola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cignarelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccioppoli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonardini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martemucci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belsanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciampolillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrado, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantatore, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, F.</span><span> </span><span class="NLM_article-title">Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2008&pages=1302-1313&author=S.+Perriniauthor=A.+Natalicchioauthor=L.+Laviolaauthor=A.+Cignarelliauthor=M.+Melchiorreauthor=S.+F.+Deauthor=C.+Caccioppoliauthor=A.+Leonardiniauthor=S.+Martemucciauthor=G.+Belsantiauthor=S.+Miccoliauthor=A.+Ciampolilloauthor=A.+Corradoauthor=F.+P.+Cantatoreauthor=R.+Giorginoauthor=F.+Giorgino&title=Abnormalities+of+insulin-like+growth+factor-I+signaling+and+impaired+cell+proliferation+in+osteoblasts+from+subjects+with+osteoporosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerrini%26aufirst%3DS.%26aulast%3DNatalicchio%26aufirst%3DA.%26aulast%3DLaviola%26aufirst%3DL.%26aulast%3DCignarelli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DS.%2BF.%26aulast%3DCaccioppoli%26aufirst%3DC.%26aulast%3DLeonardini%26aufirst%3DA.%26aulast%3DMartemucci%26aufirst%3DS.%26aulast%3DBelsanti%26aufirst%3DG.%26aulast%3DMiccoli%26aufirst%3DS.%26aulast%3DCiampolillo%26aufirst%3DA.%26aulast%3DCorrado%26aufirst%3DA.%26aulast%3DCantatore%26aufirst%3DF.%2BP.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DGiorgino%26aufirst%3DF.%26atitle%3DAbnormalities%2520of%2520insulin-like%2520growth%2520factor-I%2520signaling%2520and%2520impaired%2520cell%2520proliferation%2520in%2520osteoblasts%2520from%2520subjects%2520with%2520osteoporosis%26jtitle%3DEndocrinology%26date%3D2008%26volume%3D149%26spage%3D1302%26epage%3D1313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Feldman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, J. W.</span><span> </span><span class="NLM_article-title">Insulin-like growth factors regulate neuronal differentiation and survival</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1006%2Fnbdi.1997.0156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9361296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK2sXnsVWjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=201-214&author=E.+L.+Feldmanauthor=K.+A.+Sullivanauthor=B.+Kimauthor=J.+W.+Russell&title=Insulin-like+growth+factors+regulate+neuronal+differentiation+and+survival"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factors regulate neuronal differentiation and survival</span></div><div class="casAuthors">Feldman, Eva L.; Sullivan, Kelli A.; Kim, Bhumsoo; Russell, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3 & 4</span>),
    <span class="NLM_cas:pages">201-214</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review, with ∼130 refs.  Insulin-like growth factor I (IGF-I) and IGF-II are potent trophic factors for motor and sensory neurons and glial cells.  The actions of IGF-I and IGF-II are mediated via the IGF-I receptor (IGF-IR).  IGF:IGF-IR binding activates distinct signaling cascades, which in turn mediate the trophic-effects of the IGFs.  The authors discuss three main IGF coupled events: growth cone motility, long-term neurite outgrowth, and neuroprotection.  Our data suggest that IGF-I enhances growth cone motility by promoting reorganization of actin and activation of focal adhesion proteins via the phosphatidylinositol-3 kinase (PI-3K) pathway.  Long-term treatment with IGF-I activates the mitogen-activated protein (MAP) kinase cascade and promotes neurite outgrowth.  A separable, but likely linked, action of the IGFs via PI-3K is protection of neurons from apoptosis.  These pleotrophic effects of IGFs suggest that this family of growth factors may have potential clin. utility in the treatment of neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd0EWytNh4nbVg90H21EOLACvtfcHk0lh7v93p4VHhcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsVWjtLg%253D&md5=7142a4124534e413723781f442bbfc65</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1006%2Fnbdi.1997.0156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fnbdi.1997.0156%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DE.%2BL.%26aulast%3DSullivan%26aufirst%3DK.%2BA.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DRussell%26aufirst%3DJ.%2BW.%26atitle%3DInsulin-like%2520growth%2520factors%2520regulate%2520neuronal%2520differentiation%2520and%2520survival%26jtitle%3DNeurobiol.%2520Dis.%26date%3D1997%26volume%3D4%26spage%3D201%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Garcia-Segura, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardona-Gomez, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azcoitia, I.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection</span> <span class="citation_source-journal">J. Neurocytol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1023%2FA%3A1007125626308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11424959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFWqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2000&pages=425-437&author=L.+M.+Garcia-Seguraauthor=G.+P.+Cardona-Gomezauthor=J.+A.+Chowenauthor=I.+Azcoitia&title=Insulin-like+growth+factor-I+receptors+and+estrogen+receptors+interact+in+the+promotion+of+neuronal+survival+and+neuroprotection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection</span></div><div class="casAuthors">Garcia-Segura, Luis Miguel; Cardona-Gomez, Gloria Patricia; Chowen, Julie Ann; Azcoitia, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurocytology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">425-437</span>CODEN:
                <span class="NLM_cas:coden">JNCYA2</span>;
        ISSN:<span class="NLM_cas:issn">0300-4864</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 120 refs.  Several in vitro and in vivo studies have shown that estrogen has neuroprotective properties.  The neuroprotective effects of estrogen are probably exerted through several mechanisms.  It is established that estrogen can provide neuroprotection by actions that are independent of estrogen receptor activation.  In addn., in several exptl. models, activation of estrogen receptors appears to be indispensable for neuroprotection.  This review focuses on neuroprotection mediated by estrogen receptors.  The interaction of estrogen with growth factor receptor signaling to induce neuroprotection is discussed.  Evidence is presented that estrogen receptors and insulin-like growth factor-I receptors interact in the promotion of neuronal survival and neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEZigIWZjH0rVg90H21EOLACvtfcHk0lh7v93p4VHhcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFWqtLs%253D&md5=5027b37a334b3d98b7f2458ab3e1431f</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1023%2FA%3A1007125626308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1007125626308%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Segura%26aufirst%3DL.%2BM.%26aulast%3DCardona-Gomez%26aufirst%3DG.%2BP.%26aulast%3DChowen%26aufirst%3DJ.%2BA.%26aulast%3DAzcoitia%26aufirst%3DI.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptors%2520and%2520estrogen%2520receptors%2520interact%2520in%2520the%2520promotion%2520of%2520neuronal%2520survival%2520and%2520neuroprotection%26jtitle%3DJ.%2520Neurocytol.%26date%3D2000%26volume%3D29%26spage%3D425%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Russo, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gluckman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werther, G. A.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor system and its pleiotropic functions in brain</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fer.2004-0024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16131630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=916-943&author=V.+C.+Russoauthor=P.+D.+Gluckmanauthor=E.+L.+Feldmanauthor=G.+A.+Werther&title=The+insulin-like+growth+factor+system+and+its+pleiotropic+functions+in+brain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor system and its pleiotropic functions in brain</span></div><div class="casAuthors">Russo, V. C.; Gluckman, P. D.; Feldman, E. L.; Werther, G. A.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">916-943</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  In recent years, much interest has been devoted to defining the role of the IGF system in the nervous system.  The ubiquitous IGFs, their cell membrane receptors, and their carrier binding proteins, the IGFBPs, are expressed early in the development of the nervous system and are therefore considered to play a key role in these processes.  In vitro studies have demonstrated that the IGF system promotes differentiation and proliferation and sustains survival, preventing apoptosis of neuronal and brain derived cells.  Furthermore, studies of transgenic mice overexpressing components of the IGF system or mice with disruptions of the same genes have clearly shown that the IGF system plays a key role in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK9cGpbNqt_rVg90H21EOLACvtfcHk0liCmbXjDOz92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVygtA%253D%253D&md5=c907190467d50427aae4136067525c6f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1210%2Fer.2004-0024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2004-0024%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DV.%2BC.%26aulast%3DGluckman%26aufirst%3DP.%2BD.%26aulast%3DFeldman%26aufirst%3DE.%2BL.%26aulast%3DWerther%26aufirst%3DG.%2BA.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%2520system%2520and%2520its%2520pleiotropic%2520functions%2520in%2520brain%26jtitle%3DEndocr.%2520Rev.%26date%3D2005%26volume%3D26%26spage%3D916%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Guan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gluckman, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunn, A. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-1 and post-ischemic brain injury</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14568359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVequ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2003&pages=443-462&author=J.+Guanauthor=L.+Bennetauthor=P.+D.+Gluckmanauthor=A.+J.+Gunn&title=Insulin-like+growth+factor-1+and+post-ischemic+brain+injury"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-1 and post-ischemic brain injury</span></div><div class="casAuthors">Guan, J.; Bennet, L.; Gluckman, P. D.; Gunn, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">443-462</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor-1 (IGF-1) is a naturally occurring neurotrophic factor that plays an important role in promoting cell proliferation and differentiation during normal brain development and maturation.  The present review examines recent evidence that endogenous IGF-1 also plays a significant role in recovery from insults such as hypoxia-ischemia and that giving addnl. exogenous IGF-1 can actively ameliorate damage.  It is now well established that neurons and other cell types die many hours or even days after initial injury due to activation of programmed cell death pathways.  IGF-1 and its binding proteins and receptors are intensely induced within damaged brain regions following brain injury, suggesting a possible a role for IGF-1 in brain recovery.  Exogenous administration of IGF-1 within a few hours after brain injury is now known to be protective in both gray and white matter and leads to improved somatic function.  In contrast, pre-treatment is ineffective, likely reflecting limited intracerebral penetration of IGF-1 into the uninjured brain.  The neuroprotective effects of IGF-1 are mediated by IGF-1 receptors and its binding proteins and are specific to particular cellular phenotypes and brain regions.  The window of opportunity for treatment with IGF-1 is limited to a few hours after normothermic brain injury, reflecting its specific actions on early, intracellular events in the apoptotic cascade.  However, injury-assocd. mild post-hypoxic hypothermia, which delays the development of cell death, can shift and dramatically extend the window of opportunity for delayed treatment with IGF-1.  Such a combined approach is likely to be essential for any clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjRH5SsgSwErVg90H21EOLACvtfcHk0liCmbXjDOz92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVequ7c%253D&md5=159e576706662df782578610bbd7b68d</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DBennet%26aufirst%3DL.%26aulast%3DGluckman%26aufirst%3DP.%2BD.%26aulast%3DGunn%26aufirst%3DA.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor-1%2520and%2520post-ischemic%2520brain%2520injury%26jtitle%3DProg.%2520Neurobiol.%26date%3D2003%26volume%3D70%26spage%3D443%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Carro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trejo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Isla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Aleman, I.</span><span> </span><span class="NLM_article-title">Serum insulin-like growth factor I regulates brain amyloid-beta levels</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1390</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12415260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XptVSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1390-1397&author=E.+Carroauthor=J.+L.+Trejoauthor=T.+Gomez-Islaauthor=D.+LeRoithauthor=I.+Torres-Aleman&title=Serum+insulin-like+growth+factor+I+regulates+brain+amyloid-beta+levels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Serum insulin-like growth factor I regulates brain amyloid-β levels</span></div><div class="casAuthors">Carro, E.; Trejo, J. L.; Gomez-Isla, T.; LeRoith, D.; Torres-Aleman, I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1390-1397</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Levels of insulin-like growth factor I (IGF-I), a neuroprotective hormone, decrease in serum during aging, whereas amyloid-β (Aβ), which is involved in the pathogenesis of Alzheimer disease, accumulates in the brain.  High brain Aβ levels are found at an early age in mutant mice with low circulating IGF-I, and Aβ burden can be reduced in aging rats by increasing serum IGF-I.  This opposing relation between serum IGF-I and brain Aβ levels reflects the ability of IGF-I to induce clearance of brain Aβ, probably by enhancing transport of Aβ carrier proteins such as albumin and transthyretin into the brain.  This effect is antagonized by tumor necrosis factor-α, a pro-inflammatory cytokine putatively involved in dementia and aging.  Because IGF-I treatment of mice overexpressing mutant amyloid markedly reduces their brain Aβ burden, the authors consider that circulating IGF-I is a physiol. regulator of brain amyloid levels with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPwbC1nIXq7Vg90H21EOLACvtfcHk0liCmbXjDOz92A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptVSgsb0%253D&md5=6546487471edc218c63de56606548280</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnm793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm793%26sid%3Dliteratum%253Aachs%26aulast%3DCarro%26aufirst%3DE.%26aulast%3DTrejo%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Isla%26aufirst%3DT.%26aulast%3DLeRoith%26aufirst%3DD.%26aulast%3DTorres-Aleman%26aufirst%3DI.%26atitle%3DSerum%2520insulin-like%2520growth%2520factor%2520I%2520regulates%2520brain%2520amyloid-beta%2520levels%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D1390%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarnavski, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisping, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">4782</span><span class="NLM_x">–</span> <span class="NLM_lpage">4793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=4782-4793&author=J.+R.+McMullenauthor=T.+Shioiauthor=W.+Y.+Huangauthor=L.+Zhangauthor=O.+Tarnavskiauthor=E.+Bispingauthor=M.+Schinkeauthor=S.+Kongauthor=M.+C.+Sherwoodauthor=J.+Brownauthor=L.+Riggiauthor=P.+M.+Kangauthor=S.+Izumo&title=The+insulin-like+growth+factor+1+receptor+induces+physiological+heart+growth+via+the+phosphoinositide+3-kinase%28p110alpha%29+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DShioi%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTarnavski%26aufirst%3DO.%26aulast%3DBisping%26aufirst%3DE.%26aulast%3DSchinke%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DS.%26aulast%3DSherwood%26aufirst%3DM.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DRiggi%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DP.%2BM.%26aulast%3DIzumo%26aufirst%3DS.%26atitle%3DThe%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520induces%2520physiological%2520heart%2520growth%2520via%2520the%2520phosphoinositide%25203-kinase%2528p110alpha%2529%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D4782%26epage%3D4793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Suleiman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, C. E.</span><span> </span><span class="NLM_article-title">Apoptosis and the cardiac action of insulin-like growth factor I</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.pharmthera.2007.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17499363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=278-294&author=M.+S.+Suleimanauthor=R.+J.+Singhauthor=C.+E.+Stewart&title=Apoptosis+and+the+cardiac+action+of+insulin-like+growth+factor+I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis and the cardiac action of insulin-like growth factor I</span></div><div class="casAuthors">Suleiman, M.-S.; Singh, R. J. R.; Stewart, C. E. H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">278-294</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In both cardiac surgical and cardiol. settings, clin. interventions used to reperfuse the ischemic heart are assocd. with myocardial damage that is likely to influence long-term functional recovery.  Ischemia and reperfusion trigger cardiomyocyte death by necrosis and apoptosis.  Therefore identifying potent cardioprotective agents remains an important goal in cardiac research.  In a variety of tissues, insulin-like growth factor I (IGF-I) stimulates cellular proliferation, somatic growth, and differentiation.  In addn., IGF-I inhibits apoptotic cell death and therefore plays an important role as a cell survival factor.  This characteristic would provide an opportunity to both protect (rescue) the cardiac myocytes during (after) cardiac insults.  In this review, we shall (i) describe the characteristics of apoptotic cell death with particular emphasis on the heart, (ii) discuss the IGF system with emphasis on the cardiac actions of IGF-I under normal and pathol. conditions, (iii) elaborate on the potential role of IGF-I in myocardial protection, and finally (iv) describe how an improved understanding of the cardiac actions of IGF-I may lead to better protective clin. strategies in the future.  We discuss work by ourselves and others in these areas and also consider recent work describing the cellular signaling assocd. with the IGF-I receptor (IGF-IR) in the heart and its potential role in regulating excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9w-l5jxvPrVg90H21EOLACvtfcHk0liMr3lCwRbFPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVantrg%253D&md5=c029fdc356b0549a21c0ef7ae0318395</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2007.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2007.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DSuleiman%26aufirst%3DM.%2BS.%26aulast%3DSingh%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DC.%2BE.%26atitle%3DApoptosis%2520and%2520the%2520cardiac%2520action%2520of%2520insulin-like%2520growth%2520factor%2520I%26jtitle%3DPharmacol.%2520Ther.%26date%3D2007%26volume%3D114%26spage%3D278%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Delafontaine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brink, M.</span><span> </span><span class="NLM_article-title">The growth hormone and insulin-like growth factor 1 axis in heart failure</span> <span class="citation_source-journal">Ann. Endocrinol. (Paris)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10790588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvV2rtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2000&pages=22-26&author=P.+Delafontaineauthor=M.+Brink&title=The+growth+hormone+and+insulin-like+growth+factor+1+axis+in+heart+failure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The growth hormone and insulin-like growth factor 1 axis in heart failure</span></div><div class="casAuthors">Delafontaine, P.; Brink, M.</div><div class="citationInfo"><span class="NLM_cas:title">Annales d'Endocrinologie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-26</span>CODEN:
                <span class="NLM_cas:coden">ANENAG</span>;
        ISSN:<span class="NLM_cas:issn">0003-4266</span>.
    
            (<span class="NLM_cas:orgname">Masson Editeur</span>)
        </div><div class="casAbstract">A review is given with 53 refs.  Exptl. data suggests that growth hormone and IGF-1 have beneficial effects on myocardial function in animal models of heart failure.  Preliminary evidence suggests an abnormality in the growth hormone-IGF-1 axis in heart failure with relative growth hormone resistance.  Beneficial effects of growth hormone and IGF-1 include vasodilation, stimulation of cardiac hypertrophy, increase in calcium sensitivity of cardiac myofilaments and prevention of apoptosis.  Recently, cardiac cachexia was shown to be a powerful neg. predictive factor in heart failure.  Cachectic patients have higher angiotensin II levels.  In the rat there is an important interaction between the renin-angiotensin system and IGF-1.  Thus, angiotensin II infusion causes wt. loss in part through a catabolic effect.  This effect results from increased protein degrdn.  Angiotensin II reduces circulating and skeletal muscle IGF-1 but increases IGF-1 and the IGF-IR expression in cardiac muscle.  Preliminary data suggest a potential beneficial effect of growth hormone in heart failure.  Further trials are necessary to test the potential beneficial effect of growth hormone and/or IGF-1 in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOWZZgJOxQbVg90H21EOLACvtfcHk0liMr3lCwRbFPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvV2rtbY%253D&md5=ba65b135f7cf197ae6403aba49414017</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDelafontaine%26aufirst%3DP.%26aulast%3DBrink%26aufirst%3DM.%26atitle%3DThe%2520growth%2520hormone%2520and%2520insulin-like%2520growth%2520factor%25201%2520axis%2520in%2520heart%2520failure%26jtitle%3DAnn.%2520Endocrinol.%2520%2528Paris%2529%26date%3D2000%26volume%3D61%26spage%3D22%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span> </span><span class="NLM_article-title">Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy</span> <span class="citation_source-journal">Novartis Found. Symp.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F0470029331.ch7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17019808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslGktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=2006&pages=90-111&author=J.+R.+McMullenauthor=S.+Izumo&title=Role+of+the+insulin-like+growth+factor+1+%28IGF1%29%2Fphosphoinositide-3-kinase+%28PI3K%29+pathway+mediating+physiological+cardiac+hypertrophy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway mediating physiological cardiac hypertrophy</span></div><div class="casAuthors">McMullen, Julie R.; Izumo, Seigo</div><div class="citationInfo"><span class="NLM_cas:title">Novartis Foundation Symposium</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">Heart Failure</span>),
    <span class="NLM_cas:pages">90-117</span>CODEN:
                <span class="NLM_cas:coden">NFSYF7</span>;
        ISSN:<span class="NLM_cas:issn">1528-2511</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Growth of the heart can be induced by physiol. stimuli (e.g. postnatal development or chronic exercise training: 'the athlete's heart') or pathol. stimuli (e.g. pressure or vol. overload).  Physiol. hypertrophy is characterized by the normal organization of sarcomeres and fibers, normal or enhanced cardiac function and a relatively normal pattern of cardiac gene expression; whereas pathol. hypertrophy is assocd. with an altered pattern of cardiac gene expression, fibrosis, cardiac dysfunction and increased mortality.  Previously, an unresolved question in cardiac biol. was whether distinct signalling pathways are responsible for the development of pathol. and physiol. cardiac hypertrophy.  Recent studies have identified several signalling pathways that play unique roles in the regulation of pathol. and physiol. cardiac hypertrophy.  This review focuses largely on the role of the insulin-like growth factor 1 (IGF1)/phosphoinositide-3-kinase (PI3K) pathway in mediating physiol. cardiac growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohMnEb_Yxq8rVg90H21EOLACvtfcHk0liMr3lCwRbFPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslGktb4%253D&md5=9716197e9623c254e32105de5377b5fb</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1002%2F0470029331.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0470029331.ch7%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DIzumo%26aufirst%3DS.%26atitle%3DRole%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520%2528IGF1%2529%252Fphosphoinositide-3-kinase%2520%2528PI3K%2529%2520pathway%2520mediating%2520physiological%2520cardiac%2520hypertrophy%26jtitle%3DNovartis%2520Found.%2520Symp.%26date%3D2006%26volume%3D274%26spage%3D90%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Neri Serneri, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boddi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modesti, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecioni, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coppo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeletti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanti, G.</span><span> </span><span class="NLM_article-title">Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">977</span><span class="NLM_x">–</span> <span class="NLM_lpage">982</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2001&pages=977-982&author=G.+G.+Neri+Serneriauthor=M.+Boddiauthor=P.+A.+Modestiauthor=I.+Cecioniauthor=M.+Coppoauthor=L.+Padelettiauthor=A.+Michelucciauthor=A.+Colellaauthor=G.+Galanti&title=Increased+cardiac+sympathetic+activity+and+insulin-like+growth+factor-I+formation+are+associated+with+physiological+hypertrophy+in+athletes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeri%2BSerneri%26aufirst%3DG.%2BG.%26aulast%3DBoddi%26aufirst%3DM.%26aulast%3DModesti%26aufirst%3DP.%2BA.%26aulast%3DCecioni%26aufirst%3DI.%26aulast%3DCoppo%26aufirst%3DM.%26aulast%3DPadeletti%26aufirst%3DL.%26aulast%3DMichelucci%26aufirst%3DA.%26aulast%3DColella%26aufirst%3DA.%26aulast%3DGalanti%26aufirst%3DG.%26atitle%3DIncreased%2520cardiac%2520sympathetic%2520activity%2520and%2520insulin-like%2520growth%2520factor-I%2520formation%2520are%2520associated%2520with%2520physiological%2520hypertrophy%2520in%2520athletes%26jtitle%3DCirc.%2520Res.%26date%3D2001%26volume%3D89%26spage%3D977%26epage%3D982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Scheinowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler-Icekson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freimann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaper, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golomb, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savion, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldar, M.</span><span> </span><span class="NLM_article-title">Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression</span> <span class="citation_source-journal">Growth Horm. IGF. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS1096-6374%2802%2900137-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12550078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Gkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=19-25&author=M.+Scheinowitzauthor=G.+Kessler-Iceksonauthor=S.+Freimannauthor=R.+Zimmermannauthor=W.+Schaperauthor=E.+Golombauthor=N.+Savionauthor=M.+Eldar&title=Short-+and+long-term+swimming+exercise+training+increases+myocardial+insulin-like+growth+factor-I+gene+expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression</span></div><div class="casAuthors">Scheinowitz, M.; Kessler-Icekson, G.; Freimann, S.; Zimmermann, R.; Schaper, W.; Golomb, E.; Savion, N.; Eldar, M.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Hormone & IGF Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">GHIRF9</span>;
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors investigated the effect of short- and long-term swimming exercise, with or without insulin-like growth factor (IGF)-I administration, on the expression of myocardial IGFs and contractile proteins.  Sprague-Dawley male rats were subjected to swimming exercise for 2 or 6 wk.  IGF-I (0.5 mg/rat) was administered continuously for 1 wk, using Alzet osmotic pumps.  Control groups remained sedentary.  IGF-I, IGF-I receptor (IGF-IR), IGF-II, skeletal α-actin (sk-actin), and β myosin heavy chain (βMHC) mRNAs were measured using Northern blot anal. and RT-PCR.  A significant 2-fold increase in myocardial IGF-I mRNA was found after 2 and 6 wk of swimming in both IGF-I treated and untreated rats.  IGF-IR mRNA was significantly increased after 6 wk of training only in the IGF-I treated animals.  IGF-II mRNA remained unchanged at all time points.  While βMHC mRNA was significantly decreased at 2 and 6 wk, sk-actin mRNA remained unchanged.  Thus, short- and long-term swimming exercise training increase myocardial expression of IGF-I mRNA.  Exogenous administration of IGF-I, during the first week of the exercise session, did not produce any effect on myocardial IGF-I but was assocd. with increased IGF-IR signal after the long-term exercise training.  These data suggest a relationship between IGF-I expression and cardiac adaptation to exercise training.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ3sX-mnwzwLVg90H21EOLACvtfcHk0lg52gNQBEUZsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Gkuw%253D%253D&md5=405c770630c671b8eb6a156f4e4457a4</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS1096-6374%2802%2900137-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1096-6374%252802%252900137-5%26sid%3Dliteratum%253Aachs%26aulast%3DScheinowitz%26aufirst%3DM.%26aulast%3DKessler-Icekson%26aufirst%3DG.%26aulast%3DFreimann%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DR.%26aulast%3DSchaper%26aufirst%3DW.%26aulast%3DGolomb%26aufirst%3DE.%26aulast%3DSavion%26aufirst%3DN.%26aulast%3DEldar%26aufirst%3DM.%26atitle%3DShort-%2520and%2520long-term%2520swimming%2520exercise%2520training%2520increases%2520myocardial%2520insulin-like%2520growth%2520factor-I%2520gene%2520expression%26jtitle%3DGrowth%2520Horm.%2520IGF.%2520Res.%26date%3D2003%26volume%3D13%26spage%3D19%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Verdecchia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reboldi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schillaci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgioni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telera, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santeusanio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcellati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, P.</span><span> </span><span class="NLM_article-title">Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1802</span><span class="NLM_x">–</span> <span class="NLM_lpage">1807</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=1999&pages=1802-1807&author=P.+Verdecchiaauthor=G.+Reboldiauthor=G.+Schillaciauthor=C.+Borgioniauthor=A.+Ciucciauthor=M.+P.+Teleraauthor=F.+Santeusanioauthor=C.+Porcellatiauthor=P.+Brunetti&title=Circulating+insulin+and+insulin+growth+factor-1+are+independent+determinants+of+left+ventricular+mass+and+geometry+in+essential+hypertension"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerdecchia%26aufirst%3DP.%26aulast%3DReboldi%26aufirst%3DG.%26aulast%3DSchillaci%26aufirst%3DG.%26aulast%3DBorgioni%26aufirst%3DC.%26aulast%3DCiucci%26aufirst%3DA.%26aulast%3DTelera%26aufirst%3DM.%2BP.%26aulast%3DSanteusanio%26aufirst%3DF.%26aulast%3DPorcellati%26aufirst%3DC.%26aulast%3DBrunetti%26aufirst%3DP.%26atitle%3DCirculating%2520insulin%2520and%2520insulin%2520growth%2520factor-1%2520are%2520independent%2520determinants%2520of%2520left%2520ventricular%2520mass%2520and%2520geometry%2520in%2520essential%2520hypertension%26jtitle%3DCirculation%26date%3D1999%26volume%3D100%26spage%3D1802%26epage%3D1807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Kuo, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueng, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. Y.</span><span> </span><span class="NLM_article-title">Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats</span> <span class="citation_source-journal">Cell Biochem. Funct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fcbf.1244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15996002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVCgt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=325-331&author=W.+W.+Kuoauthor=C.+Y.+Chuauthor=C.+H.+Wuauthor=J.+A.+Linauthor=J.+Y.+Liuauthor=Y.+H.+Hsiehauthor=K.+C.+Uengauthor=S.+D.+Leeauthor=D.+J.+Hsiehauthor=H.+H.+Hsuauthor=L.+M.+Chenauthor=C.+Y.+Huang&title=Impaired+IGF-I+signalling+of+hypertrophic+hearts+in+the+developmental+phase+of+hypertension+in+genetically+hypertensive+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Impaired IGF-I signalling of hypertrophic hearts in the developmental phase of hypertension in genetically hypertensive rats</span></div><div class="casAuthors">Kuo, Wei-Wen; Chu, Chia-Yih; Wu, Chieh-Hsi; Lin, James A.; Liu, Jer-Yuh; Hsieh, Yi-Hsien; Ueng, Kwo-Chang; Lee, Shin-Da; Hsieh, Dennis Jine-Yuan; Hsu, His-Hsien; Chen, Li-Mien; Huang, Chih-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biochemistry and Function</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">325-331</span>CODEN:
                <span class="NLM_cas:coden">CBFUDH</span>;
        ISSN:<span class="NLM_cas:issn">0263-6484</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) signaling is reported to contribute to the modulation of blood pressure and set survival and hypertrophic responses in cardiac tissue.  However, whether IGF-I signaling normally acts in cardiac tissues of hypertensive rats is unknown.  In this study, using spontaneously hypertensive rats (SHR) and stroke-prone spontaneously hypertensive rats (SPSHR), both with early blood pressure increases, and Wistar-Kyoto (WKY) rats as controls, we measured the hypertrophic and IGF-I signaling activity changes in rat hearts at 4, 6 and 12 wk of age.  Both SHR and SPSHR were found to have significantly increased blood pressures and ratios of heart- and left ventricle- to body wt. at 12 wk of age.  However, IGF-IR and its downstream signaling, including the protein levels of phosphatidylinositol 3-kinase and phosphorylated Akt, known to maintain physiol. cardiac hypertrophy and cardiomyocyte survival, were downregulated.  The results of dot blotting showed that cardiac mRNA levels of IGF-I in hypertensive rats were higher than those in controls starting from the age of 4 wk.  This difference suggests the increased ligand IGF-I mRNA levels may be a compensatory response caused by the impaired IGF-I signaling.  Moreover, enhanced cardiac cytosolic cytochrome-c, a mitochondria-dependent apoptotic pathway component, tended to occur in both hypertensive rats, although it did not reach a significant level.  These findings indicate that impaired IGF-IR signaling occurs at early stages, and it may contribute, at least partially, to the development of hypertension and pathol. cardiac hypertrophy and to cardiomyocyte apoptosis at later stages in SHR and SPSHR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpbx5jMKI6LVg90H21EOLACvtfcHk0lg52gNQBEUZsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVCgt7vE&md5=c7c7f67feeb4919d6cddcef877ee5e9f</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1002%2Fcbf.1244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbf.1244%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DW.%2BW.%26aulast%3DChu%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DLin%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DHsieh%26aufirst%3DY.%2BH.%26aulast%3DUeng%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DS.%2BD.%26aulast%3DHsieh%26aufirst%3DD.%2BJ.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DHuang%26aufirst%3DC.%2BY.%26atitle%3DImpaired%2520IGF-I%2520signalling%2520of%2520hypertrophic%2520hearts%2520in%2520the%2520developmental%2520phase%2520of%2520hypertension%2520in%2520genetically%2520hypertensive%2520rats%26jtitle%3DCell%2520Biochem.%2520Funct.%26date%3D2005%26volume%3D23%26spage%3D325%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Laustsen, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Entingh-Pearsall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzenberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span> </span><span class="NLM_article-title">Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1664</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.01110-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17189427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1WgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1649-1664&author=P.+G.+Laustsenauthor=S.+J.+Russellauthor=L.+Cuiauthor=A.+Entingh-Pearsallauthor=M.+Holzenbergerauthor=R.+Liaoauthor=C.+R.+Kahn&title=Essential+role+of+insulin+and+insulin-like+growth+factor+1+receptor+signaling+in+cardiac+development+and+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function</span></div><div class="casAuthors">Laustsen, Palle G.; Russell, Steven J.; Cui, Lei; Entingh-Pearsall, Amelia; Holzenberger, Martin; Liao, Ronglih; Kahn, C. Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1649-1664</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cardiovascular disease is the leading cause of death in people with type 2 diabetes and is linked to insulin resistance even in the absence of diabetes.  Here we show that mice with combined deficiency of the insulin receptor and insulin-like growth factor 1 (IGF-1) receptor in cardiac and skeletal muscle develop early-onset dilated cardiomyopathy and die from heart failure within the first month of life despite having a normal glucose homeostasis.  Mice lacking the insulin receptor show impaired cardiac performance at 6 mo, and mice lacking the insulin receptor plus one Igf1r allele have slightly increased mortality.  By contrast, mice lacking the IGF-1 receptor or the IGF-1 receptor plus one Ir allele appear normal.  Morphol. characterization and oligonucleotide array anal. of gene expression demonstrate that prior to development of these physiol. defects, mice with combined deficiency of both insulin and IGF-1 receptors have a coordinated down-regulation of genes encoding components of the electron transport chain and mitochondrial fatty acid β-oxidn. pathways and altered expression of contractile proteins.  Thus, while neither the insulin receptor nor IGF-1 receptor in muscle is crit. for glucose homeostasis during the first month of life, signaling from these receptors, particularly the insulin receptor, is required for normal cardiac metab. and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGD8CFWIVweLVg90H21EOLACvtfcHk0lhHQiDSYwWfqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1WgtLc%253D&md5=8c56605c83ace76198ae8b4533d14a10</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1128%2FMCB.01110-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01110-06%26sid%3Dliteratum%253Aachs%26aulast%3DLaustsen%26aufirst%3DP.%2BG.%26aulast%3DRussell%26aufirst%3DS.%2BJ.%26aulast%3DCui%26aufirst%3DL.%26aulast%3DEntingh-Pearsall%26aufirst%3DA.%26aulast%3DHolzenberger%26aufirst%3DM.%26aulast%3DLiao%26aufirst%3DR.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26atitle%3DEssential%2520role%2520of%2520insulin%2520and%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signaling%2520in%2520cardiac%2520development%2520and%2520function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D1649%26epage%3D1664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Crone, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minamisawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Condorelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. F.</span><span> </span><span class="NLM_article-title">ErbB2 is essential in the prevention of dilated cardiomyopathy</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm0502-459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11984589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Kgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=459-465&author=S.+A.+Croneauthor=Y.+Y.+Zhaoauthor=L.+Fanauthor=Y.+Guauthor=S.+Minamisawaauthor=Y.+Liuauthor=K.+L.+Petersonauthor=J.+Chenauthor=R.+Kahnauthor=G.+Condorelliauthor=J.+Rossauthor=K.+R.+Chienauthor=K.+F.+Lee&title=ErbB2+is+essential+in+the+prevention+of+dilated+cardiomyopathy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">ErbB2 is essential in the prevention of dilated cardiomyopathy</span></div><div class="casAuthors">Crone, S. A.; Zhao, Y.-Y.; Fan, L.; Gu, Y.; Minamisawa, S.; Liu, Y.; Peterson, K. L.; Chen, J.; Kahn, R.; Condorelli, G.; Ross, J., Jr.; Chien, K. R.; Lee, K.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-465</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is crit. for the progression of several forms of breast cancer.  In a large-scale clin. trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival.  However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure.  To investigate the physiol. role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2.  These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype.  However, physiol. anal. revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility.  Addnl., cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity.  ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-I76RZDQLVg90H21EOLACvtfcHk0lhHQiDSYwWfqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Kgtbs%253D&md5=902e85bf249c10dfd6540c533ceb267a</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fnm0502-459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0502-459%26sid%3Dliteratum%253Aachs%26aulast%3DCrone%26aufirst%3DS.%2BA.%26aulast%3DZhao%26aufirst%3DY.%2BY.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DMinamisawa%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKahn%26aufirst%3DR.%26aulast%3DCondorelli%26aufirst%3DG.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DChien%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DK.%2BF.%26atitle%3DErbB2%2520is%2520essential%2520in%2520the%2520prevention%2520of%2520dilated%2520cardiomyopathy%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D459%26epage%3D465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Kerkela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacobi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iliescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patten, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shevtsov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clubb, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alroy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">908</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnm1446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16862153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=908-916&author=R.+Kerkelaauthor=L.+Grazetteauthor=R.+Yacobiauthor=C.+Iliescuauthor=R.+Pattenauthor=C.+Beahmauthor=B.+Waltersauthor=S.+Shevtsovauthor=S.+Pesantauthor=F.+J.+Clubbauthor=A.+Rosenzweigauthor=R.+N.+Salomonauthor=R.+A.+Van+Ettenauthor=J.+Alroyauthor=J.+B.+Durandauthor=T.+Force&title=Cardiotoxicity+of+the+cancer+therapeutic+agent+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxicity of the cancer therapeutic agent imatinib mesylate</span></div><div class="casAuthors">Kerkela Risto; Grazette Luanda; Yacobi Rinat; Iliescu Cezar; Patten Richard; Beahm Cara; Walters Brian; Shevtsov Sergei; Pesant Stephanie; Clubb Fred J; Rosenzweig Anthony; Salomon Robert N; Van Etten Richard A; Alroy Joseph; Durand Jean-Bernard; Force Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">908-16</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.  Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction.  Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco- (endo-) plasmic reticulum, findings suggestive of a toxic myopathy.  With imatinib treatment, cardiomyocytes in culture show activation of the endoplasmic reticulum (ER) stress response, collapse of the mitochondrial membrane potential, release of cytochrome c into the cytosol, reduction in cellular ATP content and cell death.  Retroviral gene transfer of an imatinib-resistant mutant of c-Abl, alleviation of ER stress or inhibition of Jun amino-terminal kinases, which are activated as a consequence of ER stress, largely rescues cardiomyocytes from imatinib-induced death.  Thus, cardiotoxicity is an unanticipated side effect of inhibition of c-Abl by imatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGHOTag-dpJhjv2lLSLOxFfW6udTcc2eaYIxoh2EaNIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rhtlKrtg%253D%253D&md5=4012ddd42a942f1441abb54df1894db8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnm1446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1446%26sid%3Dliteratum%253Aachs%26aulast%3DKerkela%26aufirst%3DR.%26aulast%3DGrazette%26aufirst%3DL.%26aulast%3DYacobi%26aufirst%3DR.%26aulast%3DIliescu%26aufirst%3DC.%26aulast%3DPatten%26aufirst%3DR.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DB.%26aulast%3DShevtsov%26aufirst%3DS.%26aulast%3DPesant%26aufirst%3DS.%26aulast%3DClubb%26aufirst%3DF.%2BJ.%26aulast%3DRosenzweig%26aufirst%3DA.%26aulast%3DSalomon%26aufirst%3DR.%2BN.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26aulast%3DAlroy%26aufirst%3DJ.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DCardiotoxicity%2520of%2520the%2520cancer%2520therapeutic%2520agent%2520imatinib%2520mesylate%26jtitle%3DNat.%2520Med.%26date%3D2006%26volume%3D12%26spage%3D908%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Perez, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodeheffer, R.</span><span> </span><span class="NLM_article-title">Clinical cardiac tolerability of trastuzumab</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1200%2FJCO.2004.01.120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14722042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=322-329&author=E.+A.+Perezauthor=R.+Rodeheffer&title=Clinical+cardiac+tolerability+of+trastuzumab"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical cardiac tolerability of trastuzumab</span></div><div class="casAuthors">Perez, Edith A.; Rodeheffer, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">This review provides an update on the current understanding of the clin. cardiac tolerability of trastuzumab, a humanized monoclonal antibody effective in the treatment of patients with advanced breast cancer overexpressing or amplifying HER2.  We produced a summary of currently available information regarding the incidence and natural history of trastuzumab-assocd. cardiac dysfunction.  Data from new, prospective clin. studies that incorporate close cardiac monitoring and standardized follow-up in patients with either advanced or earlier stages of breast cancer are also presented, and hypotheses regarding potential mechanisms of trastuzumab-related cardiotoxicity are discussed.  Patients treated with trastuzumab in the pivotal trials were found to have increased risk for cardiac dysfunction, mostly when used concurrent with anthracyclines.  Recent trials have required more stringent and consistent cardiac monitoring criteria and excluded patients with abnormal cardiac function, pre-existing heart disease, and/or high cumulative doses of anthracyclines.  Decreases of ejection fraction and a few cases of congestive heart failure (CHF) requiring medical therapy have been detected.  Improvements in ejection fraction and the symptoms of CHF have been subsequently noted in a significant no. of these patients.  Trastuzumab is assocd. with an increased risk of asymptomatic decreases in ejection fraction, and, in a small no. of patients, CHF that is almost always responsive to medical management.  This risk is greatest in patients receiving concurrent anthracyclines.  More data are needed to help elucidate the pathophysiol. of this syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4w4tmYBRz27Vg90H21EOLACvtfcHk0lgzd8IS6zo5gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKitLY%253D&md5=7666bf56fb54a5994af2e7a70a9146a6</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.01.120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.01.120%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DRodeheffer%26aufirst%3DR.%26atitle%3DClinical%2520cardiac%2520tolerability%2520of%2520trastuzumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amirahmadi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodcock, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinke-Braun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouwman, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollica, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buerger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, G. L.</span><span> </span><span class="NLM_article-title">Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=612-617&author=J.+R.+McMullenauthor=F.+Amirahmadiauthor=E.+A.+Woodcockauthor=M.+Schinke-Braunauthor=R.+D.+Bouwmanauthor=K.+A.+Hewittauthor=J.+P.+Mollicaauthor=L.+Zhangauthor=Y.+Zhangauthor=T.+Shioiauthor=A.+Buergerauthor=S.+Izumoauthor=P.+Y.+Jayauthor=G.+L.+Jennings&title=Protective+effects+of+exercise+and+phosphoinositide+3-kinase%28p110alpha%29+signaling+in+dilated+and+hypertrophic+cardiomyopathy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DAmirahmadi%26aufirst%3DF.%26aulast%3DWoodcock%26aufirst%3DE.%2BA.%26aulast%3DSchinke-Braun%26aufirst%3DM.%26aulast%3DBouwman%26aufirst%3DR.%2BD.%26aulast%3DHewitt%26aufirst%3DK.%2BA.%26aulast%3DMollica%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShioi%26aufirst%3DT.%26aulast%3DBuerger%26aufirst%3DA.%26aulast%3DIzumo%26aufirst%3DS.%26aulast%3DJay%26aufirst%3DP.%2BY.%26aulast%3DJennings%26aufirst%3DG.%2BL.%26atitle%3DProtective%2520effects%2520of%2520exercise%2520and%2520phosphoinositide%25203-kinase%2528p110alpha%2529%2520signaling%2520in%2520dilated%2520and%2520hypertrophic%2520cardiomyopathy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2007%26volume%3D104%26spage%3D612%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">McMullen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jay, P. Y.</span><span> </span><span class="NLM_article-title">PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=910-913&author=J.+R.+McMullenauthor=P.+Y.+Jay&title=PI3K%28p110alpha%29+inhibitors+as+anti-cancer+agents%3A+minding+the+heart"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcMullen%26aufirst%3DJ.%2BR.%26aulast%3DJay%26aufirst%3DP.%2BY.%26atitle%3DPI3K%2528p110alpha%2529%2520inhibitors%2520as%2520anti-cancer%2520agents%253A%2520minding%2520the%2520heart%26jtitle%3DCell%2520Cycle%26date%3D2007%26volume%3D6%26spage%3D910%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Butler, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1688</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=1685-1688&author=A.+A.+Butlerauthor=D.+LeRoith&title=Minireview%3A+tissue-specific+versus+generalized+gene+targeting+of+the+igf1+and+igf1r+genes+and+their+roles+in+insulin-like+growth+factor+physiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DA.%2BA.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DMinireview%253A%2520tissue-specific%2520versus%2520generalized%2520gene%2520targeting%2520of%2520the%2520igf1%2520and%2520igf1r%2520genes%2520and%2520their%2520roles%2520in%2520insulin-like%2520growth%2520factor%2520physiology%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26spage%3D1685%26epage%3D1688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Yakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stannard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluzik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouxsein, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice</span> <span class="citation_source-journal">J. Clin. Invest</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1172%2FJCI200417763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14702113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=96-105&author=S.+Yakarauthor=J.+Setserauthor=H.+Zhaoauthor=B.+Stannardauthor=M.+Haluzikauthor=V.+Glattauthor=M.+L.+Bouxseinauthor=J.+J.+Kopchickauthor=D.+LeRoith&title=Inhibition+of+growth+hormone+action+improves+insulin+sensitivity+in+liver+IGF-1-deficient+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice</span></div><div class="casAuthors">Yakar, Shoshana; Setser, Jennifer; Zhao, Hong; Stannard, Bethel; Haluzik, Martin; Glatt, Vaida; Bouxsein, Mary L.; Kopchick, John J.; LeRoith, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-105</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Liver IGF-1-deficient (LID) mice have a 75% redn. in circulating IGF-1 levels and, as a result, a fourfold increase in growth hormone (GH) secretion.  To block GH action, LID mice were crossed with GH antagonist (GHa) transgenic mice.  Inactivation of GH action in the resulting LID + GHa mice led to decreased blood glucose and insulin levels and improved peripheral insulin sensitivity.  Hyperinsulinemic-euglycemic clamp studies showed that LID mice exhibit severe insulin resistance.  In contrast, expression of the GH antagonist transgene in LID + GHa mice led to enhanced insulin sensitivity and increased insulin-stimulated glucose uptake in muscle and white adipose tissue.  Interestingly, LID + GHa mice exhibit a twofold increase in white adipose tissue mass, as well as increased levels of serum-free fatty acids and triglycerides, but no increase in the triglyceride content of liver and muscle.  In conclusion, these results show that despite low levels of circulating IGF-1, insulin sensitivity in LID mice could be improved by inactivating GH action, suggesting that chronic elevation of GH levels plays a major role in insulin resistance.  These results suggest that IGF-1 plays a role in maintaining a fine balance between GH and insulin to promote normal carbohydrate and lipid metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSUCGSZalz7Vg90H21EOLACvtfcHk0lgzd8IS6zo5gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVGlsQ%253D%253D&md5=dbd6b50304640304707ad2c6b36c0cfa</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1172%2FJCI200417763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200417763%26sid%3Dliteratum%253Aachs%26aulast%3DYakar%26aufirst%3DS.%26aulast%3DSetser%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DStannard%26aufirst%3DB.%26aulast%3DHaluzik%26aufirst%3DM.%26aulast%3DGlatt%26aufirst%3DV.%26aulast%3DBouxsein%26aufirst%3DM.%2BL.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DInhibition%2520of%2520growth%2520hormone%2520action%2520improves%2520insulin%2520sensitivity%2520in%2520liver%2520IGF-1-deficient%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest%26date%3D2004%26volume%3D113%26spage%3D96%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Kulkarni, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winnay, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruning, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flier, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, C. R.</span><span> </span><span class="NLM_article-title">Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">R69</span><span class="NLM_x">–</span> <span class="NLM_lpage">R75</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=R69-R75&author=R.+N.+Kulkarniauthor=J.+N.+Winnayauthor=M.+Danielsauthor=J.+C.+Bruningauthor=S.+N.+Flierauthor=D.+Hanahanauthor=C.+R.+Kahn&title=Altered+function+of+insulin+receptor+substrate-1-deficient+mouse+islets+and+cultured+beta-cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWinnay%26aufirst%3DJ.%2BN.%26aulast%3DDaniels%26aufirst%3DM.%26aulast%3DBruning%26aufirst%3DJ.%2BC.%26aulast%3DFlier%26aufirst%3DS.%2BN.%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DKahn%26aufirst%3DC.%2BR.%26atitle%3DAltered%2520function%2520of%2520insulin%2520receptor%2520substrate-1-deficient%2520mouse%2520islets%2520and%2520cultured%2520beta-cell%2520lines%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1999%26volume%3D104%26spage%3DR69%26epage%3DR75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Withers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burks, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towery, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamuro, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flint, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, M. F.</span><span> </span><span class="NLM_article-title">Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10471495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1999&pages=32-40&author=D.+J.+Withersauthor=D.+J.+Burksauthor=H.+H.+Toweryauthor=S.+L.+Altamuroauthor=C.+L.+Flintauthor=M.+F.+White&title=Irs-2+coordinates+Igf-1+receptor-mediated+beta-cell+development+and+peripheral+insulin+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signalling</span></div><div class="casAuthors">Withers, Dominic J.; Burks, Deborah J.; Towery, Heather H.; Altamuro, Shari L.; Flint, Carrie L.; White, Morris F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-40</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Insulin receptor substrates (Irs proteins) mediate the pleiotropic effects of insulin and Igf-1 (insulin-like growth factor-1), including regulation of glucose homeostasis and cell growth and survival.  The authors intercrossed mice heterozygous for two null alleles (Irs1+/- and Irs2+/-) and investigated growth and glucose metab. in mice with viable genotypes.  The authors' expts. revealed that Irs-1 and Irs-2 are crit. for embryonic and post-natal growth, with Irs-1 having the predominant role.  By contrast, both Irs-1 and Irs-2 function in peripheral carbohydrate metab., but Irs-2 has the major role in β-cell development and compensation for peripheral insulin resistance.  To establish a role for the Igf-1 receptor in β-cells, the authors intercrossed mice heterozygous for null alleles of Igf1r and Irs2.  The authors' results reveal that Igf-1 receptors promote β-cell development and survival through the Irs-2 signaling pathway.  Thus, Irs-2 integrates the effects of insulin in peripheral target tissues with Igf-1 in pancreatic β-cells to maintain glucose homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc_S0y68m6qLVg90H21EOLACvtfcHk0li8ys7NtFy4cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWhsL0%253D&md5=f0ef4c50a968001252813c325b9740eb</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWithers%26aufirst%3DD.%2BJ.%26aulast%3DBurks%26aufirst%3DD.%2BJ.%26aulast%3DTowery%26aufirst%3DH.%2BH.%26aulast%3DAltamuro%26aufirst%3DS.%2BL.%26aulast%3DFlint%26aufirst%3DC.%2BL.%26aulast%3DWhite%26aufirst%3DM.%2BF.%26atitle%3DIrs-2%2520coordinates%2520Igf-1%2520receptor-mediated%2520beta-cell%2520development%2520and%2520peripheral%2520insulin%2520signalling%26jtitle%3DNat.%2520Genet.%26date%3D1999%26volume%3D23%26spage%3D32%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berggren, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tally, M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1677%2Fjoe.0.1560573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9582514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXitVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1998&pages=573-581&author=Q.+Zhangauthor=P.+O.+Berggrenauthor=A.+Hanssonauthor=M.+Tally&title=Insulin-like+growth+factor-I-induced+DNA+synthesis+in+insulin-secreting+cell+line+RINm5F+is+associated+with+phosphorylation+of+the+insulin-like+growth+factor-I+receptor+and+the+insulin+receptor+substrate-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2</span></div><div class="casAuthors">Zhang, Q.; Berggren, P. -O.; Hansson, A.; Tally, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-581</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Journal of Endocrinology</span>)
        </div><div class="casAbstract">A proliferative effect of insulin-like growth factor-I (IGF-I) was previously shown in pancreatic islets.  However, the mechanism under which IGF-I actions are exerted in insulin-secreting cells is not clear.  The rat insulinoma cell line, RINm5F, was shown to have both IGF-I receptors and IGF-II/mannose-6-phosphate receptors.  IGF-I binding to cell surface receptors stimulated phosphorylation of 97 kDa and 93 kDa subunits of the IGF-I receptor and incorporation of [3H]thymidine into RINm5F cells.  Both the IGF-I-induced protein phosphorylation and [3H]thymidine incorporation were abolished in the presence of the tyrosine kinase inhibitor, genistein.  Under basal conditions, IGF-I did not induce insulin release or changes in cytosolic free Ca2+ concn.  Immunopptn. of proteins from RINm5F cells, using phosphotyrosine antibodies, followed by western blotting using antibody against IRS-1 revealed no distinct band of phosphorylated insulin receptor substrate (IRS)-1.  Instead, tyrosine-phosphorylated IRS-2 was detected and stimulated by IGF-I when western blotting was performed using antibody against IRS-2.  These results indicate that IRS-1 is not likely to be involved in IGF-I signaling in RINm5F cells.  Hence, IGF-I stimulated DNA synthesis in RINm5F cells was assocd. with phosphorylation of IGF-I receptors and IRS-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyrc6rzKGzhbVg90H21EOLACvtfcHk0li8ys7NtFy4cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVWjsrw%253D&md5=b342f79145ef08a8e22c70684981062a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1677%2Fjoe.0.1560573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.0.1560573%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DBerggren%26aufirst%3DP.%2BO.%26aulast%3DHansson%26aufirst%3DA.%26aulast%3DTally%26aufirst%3DM.%26atitle%3DInsulin-like%2520growth%2520factor-I-induced%2520DNA%2520synthesis%2520in%2520insulin-secreting%2520cell%2520line%2520RINm5F%2520is%2520associated%2520with%2520phosphorylation%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520and%2520the%2520insulin%2520receptor%2520substrate-2%26jtitle%3DJ.%2520Endocrinol.%26date%3D1998%26volume%3D156%26spage%3D573%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">del Rincon, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaylinn, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leitner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbour, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopchick, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draznin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorner, M. O.</span><span> </span><span class="NLM_article-title">Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1638</span><span class="NLM_x">–</span> <span class="NLM_lpage">1646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=1638-1646&author=J.+P.+del+Rinconauthor=K.+Iidaauthor=B.+D.+Gaylinnauthor=C.+E.+McCurdyauthor=J.+W.+Leitnerauthor=L.+A.+Barbourauthor=J.+J.+Kopchickauthor=J.+E.+Friedmanauthor=B.+Drazninauthor=M.+O.+Thorner&title=Growth+hormone+regulation+of+p85alpha+expression+and+phosphoinositide+3-kinase+activity+in+adipose+tissue%3A+mechanism+for+growth+hormone-mediated+insulin+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BRincon%26aufirst%3DJ.%2BP.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DGaylinn%26aufirst%3DB.%2BD.%26aulast%3DMcCurdy%26aufirst%3DC.%2BE.%26aulast%3DLeitner%26aufirst%3DJ.%2BW.%26aulast%3DBarbour%26aufirst%3DL.%2BA.%26aulast%3DKopchick%26aufirst%3DJ.%2BJ.%26aulast%3DFriedman%26aufirst%3DJ.%2BE.%26aulast%3DDraznin%26aufirst%3DB.%26aulast%3DThorner%26aufirst%3DM.%2BO.%26atitle%3DGrowth%2520hormone%2520regulation%2520of%2520p85alpha%2520expression%2520and%2520phosphoinositide%25203-kinase%2520activity%2520in%2520adipose%2520tissue%253A%2520mechanism%2520for%2520growth%2520hormone-mediated%2520insulin%2520resistance%26jtitle%3DDiabetes%26date%3D2007%26volume%3D56%26spage%3D1638%26epage%3D1646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Kahn, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flier, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorden, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, J.</span><span> </span><span class="NLM_article-title">The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=176581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADyaE287kvFylug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=739-745&author=C.+R.+Kahnauthor=J.+S.+Flierauthor=R.+S.+Barauthor=J.+A.+Archerauthor=P.+Gordenauthor=M.+M.+Martinauthor=J.+Roth&title=The+syndromes+of+insulin+resistance+and+acanthosis+nigricans.+Insulin-receptor+disorders+in+man"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man</span></div><div class="casAuthors">Kahn C R; Flier J S; Bar R S; Archer J A; Gorden P; Martin M M; Roth J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">739-45</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">In six patients with acanthosis nigricans variable degrees of glucose intolerance, hyperinsulinemia and marked resistance to exogenous insulin were found.  Studies of insulin receptors on circulating monocytes suggest that the insulin resistance in these patients was due to a marked decrease in insulin binding to its membrane receptors.  When these patients were fasted, there was a fall in plasma insulin but no increase in insulin binding, suggesting that the receptor defect was not secondary to the hyperinsulinemia.  The clinical features shared by these cases and several similar ones previously reported may be divided into two unique clinical syndromes: Type A, a syndrome in younger females with signs of virilization or accelerated growth, in whom the receptor defect may be primary, and Type B, a syndrome in older females with signs of an immunologic disease, in whom circulating antibodies to the insulin receptor are found.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK5kqY8sDhzDToTC3aBaesfW6udTcc2ebPirEA3QIL2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287kvFylug%253D%253D&md5=6bf5e66c471a9e12cdc82066430add9e</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKahn%26aufirst%3DC.%2BR.%26aulast%3DFlier%26aufirst%3DJ.%2BS.%26aulast%3DBar%26aufirst%3DR.%2BS.%26aulast%3DArcher%26aufirst%3DJ.%2BA.%26aulast%3DGorden%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DM.%2BM.%26aulast%3DRoth%26aufirst%3DJ.%26atitle%3DThe%2520syndromes%2520of%2520insulin%2520resistance%2520and%2520acanthosis%2520nigricans.%2520Insulin-receptor%2520disorders%2520in%2520man%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D739%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Railo, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pekonen, F.</span><span> </span><span class="NLM_article-title">The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">30A</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30A&publication_year=1994&pages=307-311&author=M.+J.+Railoauthor=S.+K.+vonauthor=F.+Pekonen&title=The+prognostic+value+of+insulin-like+growth+factor-I+in+breast+cancer+patients.+Results+of+a+follow-up+study+on+126+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRailo%26aufirst%3DM.%2BJ.%26aulast%3Dvon%26aufirst%3DS.%2BK.%26aulast%3DPekonen%26aufirst%3DF.%26atitle%3DThe%2520prognostic%2520value%2520of%2520insulin-like%2520growth%2520factor-I%2520in%2520breast%2520cancer%2520patients.%2520Results%2520of%2520a%2520follow-up%2520study%2520on%2520126%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D1994%26volume%3D30A%26spage%3D307%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Ueda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigekawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsubara, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiraide, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mochizuki, H.</span><span> </span><span class="NLM_article-title">Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1111%2Fj.1349-7006.2006.00228.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16827799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=597-604&author=S.+Uedaauthor=H.+Tsudaauthor=K.+Satoauthor=H.+Takeuchiauthor=T.+Shigekawaauthor=O.+Matsubaraauthor=H.+Hiraideauthor=H.+Mochizuki&title=Alternative+tyrosine+phosphorylation+of+signaling+kinases+according+to+hormone+receptor+status+in+breast+cancer+overexpressing+the+insulin-like+growth+factor+receptor+type+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1</span></div><div class="casAuthors">Ueda, Shigeto; Tsuda, Hitoshi; Sato, Kazuhiko; Takeuchi, Hideki; Shigekawa, Takashi; Matsubara, Osamu; Hiraide, Hoshio; Mochizuki, Hidetaka</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">597-604</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">The insulin-like growth factor receptor type 1 (IGF1R) is suggested to play important roles in cancer cell growth through cross-talk with hormone receptors and growth factor receptors.  However, its clin. significance in breast cancers in vivo is still unclear.  We examd. immunohistochem. the expression of IGF1R, phosphorylated-AKT (pAKT) and phosphorylated-ERK1/2 (pERK1/2) using tissue microarray slides contg. 150 cases of primary breast carcinoma.  Their mutual correlation and correlation with the status of hormone receptors epidermal growth factor receptor and human epidermal growth factor receptor type 2 were also investigated.  IGF1R overexpression was detected in 71 cases (47%), and was correlated with lower nuclear grade (P = 0.03), pos. estrogen receptor (ER) and/or progesterone receptor status (P = 0.002).  PERK1/2 expression, detected in 53 cases (35%), was correlated with pos. ER (P < 0.0001) and lower nuclear grade (P = 0.014).  PAKT expression, detected in 88 cases (59%), was not correlated with nuclear grade, hormone receptors status or other clin. parameters.  Of the 71 IGF1R-overexpressing tumors, pERK1/2 expression was detected in 27 (56%) of 48 ER-pos. cases but in only four (17%) of 23 ER-neg. cases (P = 0.022).  In contrast, pAKT expression was constantly (64% or higher) detected irresp. of hormone receptor status in IGF1R-overexpressing breast cancers.  Taken together, these findings suggest that IGF1R overexpression might activate pERK1/2 and pAKT in hormone receptor-pos. breast cancer, but activate only pAKT in hormone receptor-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaQKDT0pleprVg90H21EOLACvtfcHk0lgddNxsVr5JTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOnt7c%253D&md5=035f51edd2bbecfe143a6c6b9d6c7663</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00228.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00228.x%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DShigekawa%26aufirst%3DT.%26aulast%3DMatsubara%26aufirst%3DO.%26aulast%3DHiraide%26aufirst%3DH.%26aulast%3DMochizuki%26aufirst%3DH.%26atitle%3DAlternative%2520tyrosine%2520phosphorylation%2520of%2520signaling%2520kinases%2520according%2520to%2520hormone%2520receptor%2520status%2520in%2520breast%2520cancer%2520overexpressing%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520type%25201%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D597%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Shimizu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsumata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, Y.</span><span> </span><span class="NLM_article-title">Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1537</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.humpath.2004.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15619214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyku7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=1537-1542&author=C.+Shimizuauthor=T.+Hasegawaauthor=Y.+Taniauthor=F.+Takahashiauthor=M.+Takeuchiauthor=T.+Watanabeauthor=M.+Andoauthor=N.+Katsumataauthor=Y.+Fujiwara&title=Expression+of+insulin-like+growth+factor+1+receptor+in+primary+breast+cancer%3A+immunohistochemical+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis</span></div><div class="casAuthors">Shimizu, Chikako; Hasegawa, Tadashi; Tani, Yoichi; Takahashi, Fumiaki; Takeuchi, Masahiro; Watanabe, Toru; Ando, Masashi; Katsumata, Noriyuki; Fujiwara, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Human Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1537-1542</span>CODEN:
                <span class="NLM_cas:coden">HPCQA4</span>;
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-1 receptor (IGF-1R) has been implicated in regulation in tumor growth.  The results of previous studies performed by RIA are conflicting, and the prognostic significance of IGF-1R expression in primary breast cancer is still controversial.  IGF-1R expression was evaluated in formalin-fixed, paraffin-embedded tissue of 210 primary breast cancer patients by using anti-IGF-1R antibody.  The clinicopathol. variables and 5-yr disease-free survival were studied, and their correlations between IGF-1R expressions were investigated.  IGF-1R overexpression was obsd. in 43.8% of tumors.  IGF-1R overexpression had no correlation with prognosis or with other clinicopathol. parameters, such as age, tumor size, nodal status, histol. grade, hormone receptor status, and human epidermal growth factor 2 status.  Though its prognostic value in breast cancer is limited, immunohistochem. evaluation of IGF-1R by using this monoclonal antibody may be useful in translational research using archived material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7qcH_clPsYLVg90H21EOLACvtfcHk0lgddNxsVr5JTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyku7%252FE&md5=eb0bf648fd0edec48803632abb0ab1cd</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.humpath.2004.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.humpath.2004.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DC.%26aulast%3DHasegawa%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DTakeuchi%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DKatsumata%26aufirst%3DN.%26aulast%3DFujiwara%26aufirst%3DY.%26atitle%3DExpression%2520of%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520in%2520primary%2520breast%2520cancer%253A%2520immunohistochemical%2520analysis%26jtitle%3DHum.%2520Pathol.%26date%3D2004%26volume%3D35%26spage%3D1537%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Hellawell, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewster, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macaulay, V. M.</span><span> </span><span class="NLM_article-title">Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">2942</span><span class="NLM_x">–</span> <span class="NLM_lpage">2950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=2942-2950&author=G.+O.+Hellawellauthor=G.+D.+Turnerauthor=D.+R.+Daviesauthor=R.+Poulsomauthor=S.+F.+Brewsterauthor=V.+M.+Macaulay&title=Expression+of+the+type+1+insulin-like+growth+factor+receptor+is+up-regulated+in+primary+prostate+cancer+and+commonly+persists+in+metastatic+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHellawell%26aufirst%3DG.%2BO.%26aulast%3DTurner%26aufirst%3DG.%2BD.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DPoulsom%26aufirst%3DR.%26aulast%3DBrewster%26aufirst%3DS.%2BF.%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26atitle%3DExpression%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520is%2520up-regulated%2520in%2520primary%2520prostate%2520cancer%2520and%2520commonly%2520persists%2520in%2520metastatic%2520disease%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D2942%26epage%3D2950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Tennant, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrasher, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twomey, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drivdahl, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plymate, S. R.</span><span> </span><span class="NLM_article-title">Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">3774</span><span class="NLM_x">–</span> <span class="NLM_lpage">3782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1210%2Fjc.81.10.3774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8855837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK28XmtlCmu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1996&pages=3774-3782&author=M.+K.+Tennantauthor=J.+B.+Thrasherauthor=P.+A.+Twomeyauthor=R.+H.+Drivdahlauthor=R.+S.+Birnbaumauthor=S.+R.+Plymate&title=Protein+and+messenger+ribonucleic+acid+%28mRNA%29+for+the+type+1+insulin-like+growth+factor+%28IGF%29+receptor+is+decreased+and+IGF-II+mRNA+is+increased+in+human+prostate+carcinoma+compared+to+benign+prostate+epithelium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium</span></div><div class="casAuthors">Tennant, Marie K.; Thrasher, J. Brantley; Twomey, Patrick A.; Drivdahl, Rolf H.; Birnbaum, R. S.; Plymate, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3774-3782</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Insulin-like growth factors (IGFs) and the type 1 IGF receptor (IGF-R) are involved in normal growth and development of the human prostate.  Changes in levels of IGF-R and IGFs have been shown for several malignancies.  Immunohistochem. and in situ hybridization were performed to compare the expression of IGF-R and IGF-II in vivo in prostate tissue contg. benign epithelium, high grade prostate intraepithelial neoplasia (PIN), and adenocarcinoma.  The mRNA hybridization signals and immunoreactivity for IGF-R were localized primarily to epithelial cells, with less signal in stroma.  IGF-R mRNA was significantly decreased by 42% in PIN and 35% in cancer cells compared to that in benign epithelium.  IGF-R immunostaining was significantly decreased by 32% in PIN and by 42% in malignant epithelium compared to that in benign epithelium.  IGF-II mRNA was also localized primarily to epithelial cells.  IGF-II mRNA was significantly increased by 30% in adenocarcinoma compared to that in benign epithelium.  Immunoreactivity for IGF-II was localized to both stroma and epithelium.  Protein levels for IGF-II were not significantly increased in cancer cells compared to those in benign epithelium.  The decrease in the type 1 IGF receptor and increase in IGF-II mRNA may affect prostate cancer proliferation and differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4SAaiVAizUbVg90H21EOLACvtfcHk0li2zWr9nUFyew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlCmu7k%253D&md5=d0052fb7132b0136e4713734505baae6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1210%2Fjc.81.10.3774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.81.10.3774%26sid%3Dliteratum%253Aachs%26aulast%3DTennant%26aufirst%3DM.%2BK.%26aulast%3DThrasher%26aufirst%3DJ.%2BB.%26aulast%3DTwomey%26aufirst%3DP.%2BA.%26aulast%3DDrivdahl%26aufirst%3DR.%2BH.%26aulast%3DBirnbaum%26aufirst%3DR.%2BS.%26aulast%3DPlymate%26aufirst%3DS.%2BR.%26atitle%3DProtein%2520and%2520messenger%2520ribonucleic%2520acid%2520%2528mRNA%2529%2520for%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520%2528IGF%2529%2520receptor%2520is%2520decreased%2520and%2520IGF-II%2520mRNA%2520is%2520increased%2520in%2520human%2520prostate%2520carcinoma%2520compared%2520to%2520benign%2520prostate%2520epithelium%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab%26date%3D1996%26volume%3D81%26spage%3D3774%26epage%3D3782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Figueroa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speights, V. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rinehart, J. J.</span><span> </span><span class="NLM_article-title">Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters</span> <span class="citation_source-journal">Cancer Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=28-34&author=J.+A.+Figueroaauthor=R.+S.+Deauthor=V.+O.+Speightsauthor=J.+J.+Rinehart&title=Gene+expression+of+insulin-like+growth+factors+and+receptors+in+neoplastic+prostate+tissues%3A+correlation+with+clinico-pathological+parameters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFigueroa%26aufirst%3DJ.%2BA.%26aulast%3DDe%26aufirst%3DR.%2BS.%26aulast%3DSpeights%26aufirst%3DV.%2BO.%26aulast%3DRinehart%26aufirst%3DJ.%2BJ.%26atitle%3DGene%2520expression%2520of%2520insulin-like%2520growth%2520factors%2520and%2520receptors%2520in%2520neoplastic%2520prostate%2520tissues%253A%2520correlation%2520with%2520clinico-pathological%2520parameters%26jtitle%3DCancer%2520Invest.%26date%3D2001%26volume%3D19%26spage%3D28%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Miyata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanetake, H.</span><span> </span><span class="NLM_article-title">Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2003&pages=125-132&author=Y.+Miyataauthor=H.+Sakaiauthor=T.+Hayashiauthor=H.+Kanetake&title=Serum+insulin-like+growth+factor+binding+protein-3%2Fprostate-specific+antigen+ratio+is+a+useful+predictive+marker+in+patients+with+advanced+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyata%26aufirst%3DY.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DKanetake%26aufirst%3DH.%26atitle%3DSerum%2520insulin-like%2520growth%2520factor%2520binding%2520protein-3%252Fprostate-specific%2520antigen%2520ratio%2520is%2520a%2520useful%2520predictive%2520marker%2520in%2520patients%2520with%2520advanced%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D2003%26volume%3D54%26spage%3D125%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Shariat, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slawin, K. M.</span><span> </span><span class="NLM_article-title">Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer</span> <span class="citation_source-journal">Urology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=359-364&author=S.+F.+Shariatauthor=J.+Kimauthor=C.+Nguyenauthor=T.+M.+Wheelerauthor=S.+P.+Lernerauthor=K.+M.+Slawin&title=Correlation+of+preoperative+levels+of+IGF-I+and+IGFBP-3+with+pathologic+parameters+and+clinical+outcome+in+patients+with+bladder+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShariat%26aufirst%3DS.%2BF.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DWheeler%26aufirst%3DT.%2BM.%26aulast%3DLerner%26aufirst%3DS.%2BP.%26aulast%3DSlawin%26aufirst%3DK.%2BM.%26atitle%3DCorrelation%2520of%2520preoperative%2520levels%2520of%2520IGF-I%2520and%2520IGFBP-3%2520with%2520pathologic%2520parameters%2520and%2520clinical%2520outcome%2520in%2520patients%2520with%2520bladder%2520cancer%26jtitle%3DUrology%26date%3D2003%26volume%3D61%26spage%3D359%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Giovannucci, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platz, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majeed, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speizer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankinson, S. E.</span><span> </span><span class="NLM_article-title">A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=345-349&author=E.+Giovannucciauthor=M.+N.+Pollakauthor=E.+A.+Platzauthor=W.+C.+Willettauthor=M.+J.+Stampferauthor=N.+Majeedauthor=G.+A.+Colditzauthor=F.+E.+Speizerauthor=S.+E.+Hankinson&title=A+prospective+study+of+plasma+insulin-like+growth+factor-1+and+binding+protein-3+and+risk+of+colorectal+neoplasia+in+women"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannucci%26aufirst%3DE.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DPlatz%26aufirst%3DE.%2BA.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DMajeed%26aufirst%3DN.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DSpeizer%26aufirst%3DF.%2BE.%26aulast%3DHankinson%26aufirst%3DS.%2BE.%26atitle%3DA%2520prospective%2520study%2520of%2520plasma%2520insulin-like%2520growth%2520factor-1%2520and%2520binding%2520protein-3%2520and%2520risk%2520of%2520colorectal%2520neoplasia%2520in%2520women%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2000%26volume%3D9%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortolero-Luna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phatak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitz, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Follen, M.</span><span> </span><span class="NLM_article-title">Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3356</span><span class="NLM_x">–</span> <span class="NLM_lpage">3361</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12960122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=3356-3361&author=X.+Wuauthor=G.+Tortolero-Lunaauthor=H.+Zhaoauthor=D.+Phatakauthor=M.+R.+Spitzauthor=M.+Follen&title=Serum+levels+of+insulin-like+growth+factor+I+and+risk+of+squamous+intraepithelial+lesions+of+the+cervix"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix</span></div><div class="casAuthors">Wu, Xifeng; Tortolero-Luna, Guillermo; Zhao, Hua; Phatak, Deepali; Spitz, Margaret R.; Follen, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3356-3361</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Squamous intraepithelial lesions (SILs) are areas of precancerous growth in the cervix that can be indicative of future cervical cancer.  Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) have been implicated in cancer development.  Recent studies have demonstrated that elevated plasma IGF-I levels are assocd. with increased risk of prostate, lung, colon, and breast cancers.  In this case-control study, we analyzed the relationship between serum levels of IGF-I and IGFBP-3, and SILs of the cervix.  The case patients were comprised of 267 women treated at The University of Texas M. D. Anderson Cancer Center Colposcopy Clinic in Houston, Texas for abnormal Pap smears.  The clinic serves minority and economically disadvantaged women referred from the County Health Department clinics of Harris County, Texas.  The control subjects were 238 healthy women receiving family planning and screening services at two Harris County Health Department clinics.  Case patients with either high-grade or low-grade SILs had significantly higher serum levels of IGF-I, IGFBP-3, and molar ratios of IGF-I:IGFBP-3 than the control subjects did.  IGF-I levels in the highest quartile were assocd. with significantly higher risk of SILs compared with the lowest quartile, independent of IGFBP-3 levels.  The odds ratio for the fourth quartile of IGF-I level, relative to the first quartile, was 8.54 (95% confidence interval, 4.15-17.60; P < 0.0001) after adjustment for age, ethnicity, smoking status, and IGFBP-3 level.  There was a dose-response relationship between risk of SILs and the level of IGF-I: as the level of IGF-I increased, so did the risk of SILs.  In addn., the serum level of IGFBP-3 was significantly higher in case patients than in control subjects.  However, after adjustment for IGF-I, no relationship was evident between IGFBP-3 level and risk of SILs.  Serum levels of IGF-I may be a useful biomarker for assessing risk of SIL development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZcqscFE_2T7Vg90H21EOLACvtfcHk0lgWFCmnxJaATQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCksb0%253D&md5=6e4e50dae429cdad259a2ef61464f903</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DTortolero-Luna%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPhatak%26aufirst%3DD.%26aulast%3DSpitz%26aufirst%3DM.%2BR.%26aulast%3DFollen%26aufirst%3DM.%26atitle%3DSerum%2520levels%2520of%2520insulin-like%2520growth%2520factor%2520I%2520and%2520risk%2520of%2520squamous%2520intraepithelial%2520lesions%2520of%2520the%2520cervix%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D3356%26epage%3D3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Chao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Amore, P. A.</span><span> </span><span class="NLM_article-title">IGF2: epigenetic regulation and role in development and disease</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.cytogfr.2008.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18308616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Wjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=111-120&author=W.+Chaoauthor=P.+A.+D%27Amore&title=IGF2%3A+epigenetic+regulation+and+role+in+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">IGF2: Epigenetic regulation and role in development and disease</span></div><div class="casAuthors">Chao, Wendy; D'Amore, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-120</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor II (IGF2) is perhaps the most intricately regulated of all growth factors characterized to date.  Its gene is imprinted - only one allele is active, depending on parental origin - and this pattern of expression is maintained epigenetically in almost all tissues.  IGF2 activity is further controlled through differential expression of receptors and IGF-binding proteins (IGFBPs) that det. protein availability.  This complex and multifaceted regulation emphasizes the importance of accurate IGF2 expression and activity.  This review will examine the regulation of the IGF2 gene and what it has revealed about the phenomenon of imprinting, which is frequently disrupted in cancer.  IGF2 protein function will be discussed, along with diseases that involve IGF2 overexpression.  Roles for IGF2 in sonic hedgehog (Shh) signaling and angiogenesis will also be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSZuk6DOp4vrVg90H21EOLACvtfcHk0lihdTvjgU6pwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Wjtrc%253D&md5=a54a762e44d514fba6e6f0c9795c7425</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2008.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2008.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DW.%26aulast%3DD%2527Amore%26aufirst%3DP.%2BA.%26atitle%3DIGF2%253A%2520epigenetic%2520regulation%2520and%2520role%2520in%2520development%2520and%2520disease%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2008%26volume%3D19%26spage%3D111%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Cui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Correa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giardiello, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutcheon, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafonek, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandenburg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powe, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, A. P.</span><span> </span><span class="NLM_article-title">Loss of IGF2 imprinting: a potential marker of colorectal cancer risk</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=1753-1755&author=H.+Cuiauthor=M.+Cruz-Correaauthor=F.+M.+Giardielloauthor=D.+F.+Hutcheonauthor=D.+R.+Kafonekauthor=S.+Brandenburgauthor=Y.+Wuauthor=X.+Heauthor=N.+R.+Poweauthor=A.+P.+Feinberg&title=Loss+of+IGF2+imprinting%3A+a+potential+marker+of+colorectal+cancer+risk"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DCruz-Correa%26aufirst%3DM.%26aulast%3DGiardiello%26aufirst%3DF.%2BM.%26aulast%3DHutcheon%26aufirst%3DD.%2BF.%26aulast%3DKafonek%26aufirst%3DD.%2BR.%26aulast%3DBrandenburg%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DPowe%26aufirst%3DN.%2BR.%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26atitle%3DLoss%2520of%2520IGF2%2520imprinting%253A%2520a%2520potential%2520marker%2520of%2520colorectal%2520cancer%2520risk%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D1753%26epage%3D1755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Sakatani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobuzio-Donahue, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boom, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinberg, A. P.</span><span> </span><span class="NLM_article-title">Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1976-1978&author=T.+Sakataniauthor=A.+Kanedaauthor=C.+A.+Iacobuzio-Donahueauthor=M.+G.+Carterauthor=W.+S.+de+Boomauthor=H.+Okanoauthor=M.+S.+Koauthor=R.+Ohlssonauthor=D.+L.+Longoauthor=A.+P.+Feinberg&title=Loss+of+imprinting+of+Igf2+alters+intestinal+maturation+and+tumorigenesis+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakatani%26aufirst%3DT.%26aulast%3DKaneda%26aufirst%3DA.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26aulast%3DCarter%26aufirst%3DM.%2BG.%26aulast%3Dde%2BBoom%26aufirst%3DW.%2BS.%26aulast%3DOkano%26aufirst%3DH.%26aulast%3DKo%26aufirst%3DM.%2BS.%26aulast%3DOhlsson%26aufirst%3DR.%26aulast%3DLongo%26aufirst%3DD.%2BL.%26aulast%3DFeinberg%26aufirst%3DA.%2BP.%26atitle%3DLoss%2520of%2520imprinting%2520of%2520Igf2%2520alters%2520intestinal%2520maturation%2520and%2520tumorigenesis%2520in%2520mice%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1976%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span> </span><span class="NLM_article-title">Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program</span> <span class="citation_source-journal">Pediatr. Blood Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1197</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fpbc.21450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18260118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1c3jtFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=1190-1197&author=E.+A.+Kolbauthor=R.+Gorlickauthor=P.+J.+Houghtonauthor=C.+L.+Mortonauthor=R.+Lockauthor=H.+Carolauthor=C.+P.+Reynoldsauthor=J.+M.+Marisauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+a+monoclonal+antibody+%28SCH+717454%29+against+the+IGF-1+receptor+by+the+pediatric+preclinical+testing+program"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program</span></div><div class="casAuthors">Kolb E Anders; Gorlick Richard; Houghton Peter J; Morton Christopher L; Lock Richard; Carol Hernan; Reynolds C Patrick; Maris John M; Keir Stephen T; Billups Catherine A; Smith Malcolm A</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1190-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  SCH 717454 (19D12) is a fully human antibody directed against the insulin-like growth factor 1 receptor (IGF-1R), which is implicated in the growth and metastatic phenotype of a broad range of malignancies.  The activity of SCH 717454 was evaluated against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP).  PROCEDURES:  SCH 717454 was tested against the PPTP in vitro panel at concentrations ranging from 0.01 to 100 nM and was tested against the PPTP in vivo panel at a dose of 0.5 mg per mouse administered twice weekly for 4 weeks via intraperitoneal injection.  RESULTS:  SCH 717454 was ineffective at retarding growth of cell lines in the in vitro panel.  In vivo, SCH 717454 significantly increased event-free survival in 20 of 35 (57%) solid tumor xenograft models with tumor regressions in one Ewing sarcoma model (complete response) and 2 osteosarcoma models (maintained complete responses).  Using the time to event activity measure, SCH 717454 had intermediate (n = 9) or high (n = 1) activity against 31 evaluable solid tumor xenografts, including xenografts from the rhabdoid tumor, Ewing, rhabdomyosarcoma, glioblastoma, neuroblastoma, and osteosarcoma panels.  SCH 717454 showed little activity against the 8 xenografts of the acute lymphoblastic leukemia panel.  CONCLUSIONS:  SCH 717454 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels.  Further characterization of the molecular predictors of response and of the activity of combinations of SCH 717454 with other anticancer agents are anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlbcF-p4rZLBLDWw4HIq2sfW6udTcc2eZGjjs4nbPTArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3jtFaqtw%253D%253D&md5=32f7605ecdaba71e9fb978b05d0f10f1</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fpbc.21450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.21450%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DMorton%26aufirst%3DC.%2BL.%26aulast%3DLock%26aufirst%3DR.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520a%2520monoclonal%2520antibody%2520%2528SCH%2520717454%2529%2520against%2520the%2520IGF-1%2520receptor%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2008%26volume%3D50%26spage%3D1190%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Gil-Ad, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtaif, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weizman, A.</span><span> </span><span class="NLM_article-title">Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture</span> <span class="citation_source-journal">Growth Horm. IGF Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fghir.1999.0130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10629167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFSrtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=458-464&author=I.+Gil-Adauthor=B.+Shtaifauthor=D.+Luriaauthor=L.+Karpauthor=Y.+Fridmanauthor=A.+Weizman&title=Insulin-like-growth-factor-I+%28IGF-I%29+antagonizes+apoptosis+induced+by+serum+deficiency+and+doxorubicin+in+neuronal+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture</span></div><div class="casAuthors">Gil-Ad, I.; Shtaif, B.; Luria, D.; Karp, L.; Fridman, Y.; Weizman, A.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Hormone & IGF Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458-464</span>CODEN:
                <span class="NLM_cas:coden">GHIRF9</span>;
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">The authors evaluated the effect of insulin-like growth factor (IGF)-I on neuronal cell viability and apoptosis induced by exposure to serum-free (SF) medium and to doxorubicin.  In primary neuronal culture, IGF-I (0.5-2.0 μg/mL) slightly increased basal cell viability; SF medium tended to decrease viability (20-27%), and addn. of IGF-I significantly antagonized this decrease (P < 0.05).  In neuroblastoma (NB) SK-N-SH cell culture, IGF-I significantly increased viability (0.05-1.25 μg/mL) (P < 0.005); SF medium decreased it by 75%, and this decrease was prevented by IGF-I (0.5-1.0 μg/mL) (P < 0.005).  Flow cytometry studies showed an increased apoptosis on exposure to SF medium (88.8 vs 10.2%), which was suppressed to 38.3% by addn. of IGF-I.  Growth hormone (1-10 μU/mL) did not modify basal cell viability in either culture, and SF-induced cell death in NB cells.  Doxorubicin (1-100 μM) caused neurotoxicity in primary and NB cultures (66-39% and 39-10% of controls, resp.), and increased apoptosis in NB cells (73.8 vs 20.1%).  IGF-I antagonized these neurotoxic/apoptotic effects (P < 0.05).  This study suggests that IGF-I possesses a potent neuroprotective activity which may be involved in the resistance to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCVaXdSB62_bVg90H21EOLACvtfcHk0lhhOu05vwq9Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFSrtrk%253D&md5=57d8ac98d56a7027c134532313c13978</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1054%2Fghir.1999.0130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fghir.1999.0130%26sid%3Dliteratum%253Aachs%26aulast%3DGil-Ad%26aufirst%3DI.%26aulast%3DShtaif%26aufirst%3DB.%26aulast%3DLuria%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DL.%26aulast%3DFridman%26aufirst%3DY.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DInsulin-like-growth-factor-I%2520%2528IGF-I%2529%2520antagonizes%2520apoptosis%2520induced%2520by%2520serum%2520deficiency%2520and%2520doxorubicin%2520in%2520neuronal%2520cell%2520culture%26jtitle%3DGrowth%2520Horm.%2520IGF%2520Res.%26date%3D1999%26volume%3D9%26spage%3D458%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Gooch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Berg, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death—proliferative and anti-apoptotic effects</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1023%2FA%3A1006208721167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10517338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=1-10&author=J.+L.+Goochauthor=C.+L.+Van+Den+Bergauthor=D.+Yee&title=Insulin-like+growth+factor+%28IGF%29-I+rescues+breast+cancer+cells+from+chemotherapy-induced+cell+death%E2%80%94proliferative+and+anti-apoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death - proliferative and anti-apoptotic effects</span></div><div class="casAuthors">Gooch, Jennifer L.; Van Den Berg, Carla L.; Yee, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">IGF-I protects many cell types from apoptosis.  As a result, it is possible that IGF-I-responsive cancer cells may be resistant to apoptosis-inducing chemotherapies.  Therefore, the authors examd. the effects of IGF-I on paclitaxel- and doxorubicin-induced apoptosis in the IGF-I-responsive breast cancer cell line MCF-7.  Both drugs caused DNA laddering in a dose-dependent fashion, and IGF-I reduced the formation of ladders.  The authors next examd. the effects of IGF-I and estradiol on cell survival following drug treatment in monolayer culture.  IGF-I, but not estradiol, increased survival of MCF-7 cells in the presence of either drug.  Cell cycle progression and counting of trypan-blue stained cells showed that IGF-I was inducing proliferation in paclitaxel-treated but not doxorubicin-treated cells.  However, IGF-I decreased the fraction of apoptotic cells in doxorubicin- but not paclitaxel-treated cells.  Recent work has shown that mitogen-activated protein kinase (MAPK) and phosphotidylinositol-3 (PI-3) kinase are activated by IGF-I in these cells.  PI-3 kinase activation has been linked to anti-apoptotic functions while MAPK activation is assocd. with proliferation.  The authors found that IGF-I rescue of doxorubicin-induced apoptosis required PI-3 kinase but not MAPK function, suggesting that IGF-I inhibited apoptosis.  In contrast, IGF-I rescue of paclitaxel-induced apoptosis required both PI-3 kinase and MAPK, suggesting that IGF-I-mediated protection was due to enhancement of proliferation.  Therefore, IGF-I attenuated the response of breast cancer cells to doxorubicin and paclitaxel by at least two mechanisms: induction of proliferation and inhibition of apoptosis.  Thus, inhibition of IGF-I action could be a useful adjuvant to cytotoxic chemotherapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppJ62Chyw-grVg90H21EOLACvtfcHk0lhhOu05vwq9Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVyns7s%253D&md5=dd8d743e2d55006d4c702971eb66ec17</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006208721167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006208721167%26sid%3Dliteratum%253Aachs%26aulast%3DGooch%26aufirst%3DJ.%2BL.%26aulast%3DVan%2BDen%2BBerg%26aufirst%3DC.%2BL.%26aulast%3DYee%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520%2528IGF%2529-I%2520rescues%2520breast%2520cancer%2520cells%2520from%2520chemotherapy-induced%2520cell%2520death%25E2%2580%2594proliferative%2520and%2520anti-apoptotic%2520effects%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1999%26volume%3D56%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span> </span><span class="NLM_article-title">Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6077</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=6071-6077&author=Y.+Jiangauthor=W.+N.+Romauthor=T.+A.+Yieauthor=C.+X.+Chiauthor=K.+M.+Tchou-Wong&title=Induction+of+tumor+suppression+and+glandular+differentiation+of+A549+lung+carcinoma+cells+by+dominant-negative+IGF-I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DChi%26aufirst%3DC.%2BX.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26atitle%3DInduction%2520of%2520tumor%2520suppression%2520and%2520glandular%2520differentiation%2520of%2520A549%2520lung%2520carcinoma%2520cells%2520by%2520dominant-negative%2520IGF-I%2520receptor%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D6071%26epage%3D6077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurwitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spandau, D. F.</span><span> </span><span class="NLM_article-title">Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F%28SICI%291097-0215%2819990129%2980%3A3%3C431%3A%3AAID-IJC16%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9935186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1MXovF2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1999&pages=431-438&author=C.+Kuhnauthor=S.+A.+Hurwitzauthor=M.+G.+Kumarauthor=J.+Cottonauthor=D.+F.+Spandau&title=Activation+of+the+insulin-like+growth+factor-1+receptor+promotes+the+survival+of+human+keratinocytes+following+ultraviolet+B+irradiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation</span></div><div class="casAuthors">Kuhn, Christine; Hurwitz, Steven A.; Kumar, Manish G.; Cotton, Jenny; Spandau, Dan F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The UVB component of sunlight causes non-melanoma skin cancers due to the damage it inflicts on genomic DNA.  The response of epidermal keratinocytes to sunlight depends on the dose of UVB received and the severity of the damage to the DNA.  Mild DNA damage typically induces DNA-repair pathways and cell survival, while severe DNA damage provokes apoptosis.  Primary human keratinocytes grown in serum-free media respond in a similar manner to UVB irradn.  However, we obsd. that keratinocytes are exquisitely more susceptible to UVB-induced apoptosis if the growth medium is depleted of exogenous growth factors.  Therefore, an exogenous growth factor could provide protection from UVB-induced apoptosis.  We found that the only growth factor that provided protection from UVB-induced apoptosis was insulin and that the protective effect elicited by insulin was not due to binding the insulin receptor but, rather, to activation of the insulin-like growth factor-1 (IGF-1) receptor.  Addnl., activation of the IGF-1 receptor in combination with UVB irradn. induced keratinocytes to become post-mitotic.  This survival function of the IGF-1 receptor in response to UVB irradn. was influenced by activation of phosphatidylinositol-3 kinase and MAP kinase.  Prior to UVB irradn., insulin or IGF-1 had little to no effect on cell growth or viability.  Therefore, activation of the IGF-1 receptor in conjunction with UVB irradn. promotes keratinocyte survival at the expense of cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3FXjbqmldcrVg90H21EOLACvtfcHk0lhhOu05vwq9Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXovF2isw%253D%253D&md5=1026f3a33bcfc2fb0a6fff730a5ef47a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819990129%2980%3A3%3C431%3A%3AAID-IJC16%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819990129%252980%253A3%253C431%253A%253AAID-IJC16%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DHurwitz%26aufirst%3DS.%2BA.%26aulast%3DKumar%26aufirst%3DM.%2BG.%26aulast%3DCotton%26aufirst%3DJ.%26aulast%3DSpandau%26aufirst%3DD.%2BF.%26atitle%3DActivation%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520promotes%2520the%2520survival%2520of%2520human%2520keratinocytes%2520following%2520ultraviolet%2520B%2520irradiation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D80%26spage%3D431%26epage%3D438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payne, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, R.</span><span> </span><span class="NLM_article-title">Expression of the insulin-like growth factor I receptor C terminus as a myristylated protein leads to induction of apoptosis in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">570</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=570-576&author=Y.+Liuauthor=S.+Leharauthor=C.+Corviauthor=G.+Payneauthor=R.+O%27Connor&title=Expression+of+the+insulin-like+growth+factor+I+receptor+C+terminus+as+a+myristylated+protein+leads+to+induction+of+apoptosis+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLehar%26aufirst%3DS.%26aulast%3DCorvi%26aufirst%3DC.%26aulast%3DPayne%26aufirst%3DG.%26aulast%3DO%2527Connor%26aufirst%3DR.%26atitle%3DExpression%2520of%2520the%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520C%2520terminus%2520as%2520a%2520myristylated%2520protein%2520leads%2520to%2520induction%2520of%2520apoptosis%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D570%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Peters, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsark, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, L. M.</span><span> </span><span class="NLM_article-title">Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">722</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2307%2F3579363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=8643832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK28XjsVWgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=1996&pages=722-729&author=J.+M.+Petersauthor=E.+C.+Tsarkauthor=L.+M.+Wiley&title=Radiosensitive+target+in+the+mouse+embryo+chimera+assay%3A+implications+that+the+target+involves+autocrine+growth+factor+function"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitive target in the mouse embryo chimera assay: implications that the target involves autocrine growth factor function</span></div><div class="casAuthors">Peters, Jeffrey M.; Tsark, Eleanor C.; Wiley, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-729</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    
            (<span class="NLM_cas:orgname">Kluge Carden Jennings Publishing</span>)
        </div><div class="casAbstract">Mouse preimplantation embryos express at least two functional cell surface growth factor receptors that are radiosensitive in other cell types, the epidermal growth factor I receptor (IGF-I receptor).  These embryos also express ligands that bind to and activate these receptors, including transforming growth factor alpha (TGF-α) and insulin-like growth factor II (IGF-II), which bind to the EGF receptor and IGF-I receptor, resp.  Embryo-expressed IGF-II and TGF-α increase embryo cell no. - a measure of proliferation rate - and stimulate blastocoele formation - a measure of cell differentiation - allowing the embryo to self-modulate cell proliferation and morphogenesis into a blastocyst (Paria and Dey, Proc. Natl. Acad. Sci. USA 87, 4756-4760, 1990; Dardik and Schultz, Development 113, 919-930, 1991; Rappolee et al., Genes Dev. 6, 939-952, 1992).  In this work, we tested the hypothesis that IGF-I receptor and/or EGF receptor function may be impaired to produce the radiation-induced competitive cell proliferation disadvantage that is expressed by irradiated embryos that are aggregated with nonirradiated embryos in chimeras.  Cleavage-stage embryos were irradiated with 137Cs γ rays (0.5 or 1.0 Gy) and paired with nonirradiated same-stage embryos to form groups of chimeras that were cultured in control medium or medium contg. IGF-II, insulin, EGF or TGF-α.  The cell proliferation disadvantage expressed by the irradiated embryos within chimeras was completely eliminated by IGF-II or insulin.  In contrast to the rescue action of IGF-II or insulin in chimeras, neither EGF nor TGF-α could prevent the cell proliferation disadvantage exhibited by irradiated embryos paired with nonirradiated embryos in chimeras.  For irradiated conventionally cultured zona-enclosed embryos, IGF-II and TGF-α did not increase mean embryo cell no. significantly, although both IGF-II and TGF-α did increase blastocoele formation significantly.  Collectively, these results support the following conclusions: (1) ligands for the IGF-I receptor can rescue irradiated embryos from competitive cell proliferation disadvantage in Chimeras, while ligands for the EGF receptor cannot; (2) IGF-I receptor function and EGF receptor function are affected differently by ionizing radiation with respect to competitive cell proliferation and are affected with respect to competitive cell proliferation and are affected similarly by ionizing radiation with respect to blastocoele formation; (3) EGF receptor-dependent stimulation of competitive cell proliferation and cell differentiation are affected differently by ionizing radiation in preimplantation embryos.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ30aDi2mMTrVg90H21EOLACvtfcHk0lgaoJn-Q7EGyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVWgt7c%253D&md5=0df98ee022ed28c0bb6e353173619e39</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2307%2F3579363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3579363%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26aulast%3DTsark%26aufirst%3DE.%2BC.%26aulast%3DWiley%26aufirst%3DL.%2BM.%26atitle%3DRadiosensitive%2520target%2520in%2520the%2520mouse%2520embryo%2520chimera%2520assay%253A%2520implications%2520that%2520the%2520target%2520involves%2520autocrine%2520growth%2520factor%2520function%26jtitle%3DRadiat.%2520Res.%26date%3D1996%26volume%3D145%26spage%3D722%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Yu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, M.</span><span> </span><span class="NLM_article-title">Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">6702</span><span class="NLM_x">–</span> <span class="NLM_lpage">6709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=6702-6709&author=D.+Yuauthor=H.+Watanabeauthor=H.+Shibuyaauthor=M.+Miura&title=Redundancy+of+radioresistant+signaling+pathways+originating+from+insulin-like+growth+factor+I+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DMiura%26aufirst%3DM.%26atitle%3DRedundancy%2520of%2520radioresistant%2520signaling%2520pathways%2520originating%2520from%2520insulin-like%2520growth%2520factor%2520I%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D6702%26epage%3D6709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Heron-Milhavet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">15600</span><span class="NLM_x">–</span> <span class="NLM_lpage">15606</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=15600-15606&author=L.+Heron-Milhavetauthor=D.+LeRoith&title=Insulin-like+growth+factor+I+induces+MDM2-dependent+degradation+of+p53+via+the+p38+MAPK+pathway+in+response+to+DNA+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeron-Milhavet%26aufirst%3DL.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520induces%2520MDM2-dependent%2520degradation%2520of%2520p53%2520via%2520the%2520p38%2520MAPK%2520pathway%2520in%2520response%2520to%2520DNA%2520damage%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D15600%26epage%3D15606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Guo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan-Sanders, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyn-Cook, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamae, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khaletskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weydert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longmate, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitz, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oberley, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span> </span><span class="NLM_article-title">Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2362</span><span class="NLM_x">–</span> <span class="NLM_lpage">2378</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.23.7.2362-2378.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12640121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisFensbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=2362-2378&author=G.+Guoauthor=Y.+Yan-Sandersauthor=B.+D.+Lyn-Cookauthor=T.+Wangauthor=D.+Tamaeauthor=J.+Ogiauthor=A.+Khaletskiyauthor=Z.+Liauthor=C.+Weydertauthor=J.+A.+Longmateauthor=T.+T.+Huangauthor=D.+R.+Spitzauthor=L.+W.+Oberleyauthor=J.+J.+Li&title=Manganese+superoxide+dismutase-mediated+gene+expression+in+radiation-induced+adaptive+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses</span></div><div class="casAuthors">Guo, Guozheng; Yan-Sanders, Yan; Lyn-Cook, Beverly D.; Wang, Tieli; Tamae, Daniel; Ogi, Julie; Khaletskiy, Alexander; Li, Zhongkui; Weydert, Christine; Longmate, Jeffrey A.; Huang, Ting-Ting; Spitz, Douglas R.; Oberley, Larry W.; Li, Jian Jian</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2362-2378</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Antioxidant enzymes are crit. in oxidative stress responses.  Radioresistant variants isolated from MCF-7 human carcinoma cells following fractionated ionizing radiation (MCF+FIR cells) or overexpression of manganese superoxide dismutase (MCF+SOD cells) demonstrated dose-modifying factors at 10% isosurvival of 1.8 and 2.3, resp.  MCF+FIR and MCF-7 cells (exposed to single-dose radiation) demonstrated 5- to 10-fold increases in MnSOD activity, mRNA, and immunoreactive protein.  Radioresistance in MCF+FIR and MCF+SOD cells was reduced following expression of antisense MnSOD.  DNA microarray anal. and immunoblotting identified p21, Myc, 14-3-3 zeta, cyclin A, cyclin B1, and GADD153 as genes constitutively overexpressed (2- to 10-fold) in both MCF+FIR and MCF+SOD cells.  Radiation-induced expression of these six genes was suppressed in fibroblasts from Sod2 knockout mice (-/-) as well as in MCF+FIR and MCF+SOD cells expressing antisense MnSOD.  Inhibiting NF-κB transcriptional activity in MCF+FIR cells, by using mutant IκBα, inhibited radioresistance as well as reducing steady-state levels of MnSOD, 14-3-3 zeta, GADD153, cyclin A, and cyclin B1 mRNA.  In contrast, mutant IκBα was unable to inhibit radioresistance or reduce 14-3-3 zeta, GADD153, cyclin A, and cyclin B1 mRNAs in MCF+SOD cells, where MnSOD overexpression was independent of NF-κB.  These results support the hypothesis that NF-κB is capable of regulating the expression of MnSOD, which in turn is capable of increasing the expression of genes that participate in radiation-induced adaptive responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBpxTkCZEHfbVg90H21EOLACvtfcHk0lgaoJn-Q7EGyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisFensbg%253D&md5=bc288e5cd223e7e431a3db25629a893a</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1128%2FMCB.23.7.2362-2378.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.23.7.2362-2378.2003%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DG.%26aulast%3DYan-Sanders%26aufirst%3DY.%26aulast%3DLyn-Cook%26aufirst%3DB.%2BD.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DTamae%26aufirst%3DD.%26aulast%3DOgi%26aufirst%3DJ.%26aulast%3DKhaletskiy%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWeydert%26aufirst%3DC.%26aulast%3DLongmate%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DSpitz%26aufirst%3DD.%2BR.%26aulast%3DOberley%26aufirst%3DL.%2BW.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26atitle%3DManganese%2520superoxide%2520dismutase-mediated%2520gene%2520expression%2520in%2520radiation-induced%2520adaptive%2520responses%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2003%26volume%3D23%26spage%3D2362%26epage%3D2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Guo, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houston, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, C. M.,  Jr.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2F%28SICI%291097-4652%28199805%29175%3A2%3C141%3A%3AAID-JCP3%3E3.0.CO%3B2-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=9525472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADyaK1cXit1Srt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1998&pages=141-148&author=Y.+S.+Guoauthor=G.+F.+Jinauthor=C.+W.+Houstonauthor=J.+C.+Thompsonauthor=C.+M.+Townsend&title=Insulin-like+growth+factor-I+promotes+multidrug+resistance+in+MCLM+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells</span></div><div class="casAuthors">Guo, Yan-Shi; Jin, Gui-Fang; Houston, Clifford W.; Thompson, James C.; Townsend, Courtney M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-148</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is known as a potent mitogen for a variety of cell types, including colon cancer cell lines.  The objective of this study was to det. the effect of IGF-I on cell death induced by cytotoxic agents actinomycin D (Act-D), lovastatin (LOV), and doxorubicin (DOX) in the MCLM mouse colon cancer cell line, and the mechanisms involved.  Subconfluent monolayer MCLM cells were treated with IGF-I (25 ng/mL) for 12 h in serum-free media.  Various concns. of cytotoxic agents then were added to the cells that were incubated continually at 370C for 24 h.  Cell survival was detd. with the MTT (3-[4-5-dimenthylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, which assesses mitochondrial function in living cells.  The mRNA expression for multidrug resistance gene-I (mdr-I), c-H-ras, and manganese superoxide dismutase (MnSOD) in cells treated with IGF-I was examd. by Northern blot or RNase protection assays.  The levels of p-glycoprotein, a drug efflux pump encoded by the mdr-I gene, were assessed by Western immunoblotting.  Results demonstrated that (1) IGF-I significantly inhibited the cell death and apoptosis of MCLM cells treated with Act-D, LOV, or DOX; (2) IGF-I increased mRNA expression for mdr-I, c-H-ras, and MnSOD; (3) the p-glycoproteins in cells treated with IGF-I or stably transfected with c-H-ras were elevated when compared with control.  These results suggest that IGF-I protects MCLM cells against death induced by cytotoxic agents; this acquired drug resistance may be mediated by multiple mechanisms, including promoting expression of mdr-I, c-H-ras, and MnSOD; whereas, the p-glycoprotein level stimulated by IGF-I may result partly from the increase of c-H-ras in the cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpefmohYIBQQbVg90H21EOLACvtfcHk0lgdpOHuburf2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXit1Srt7s%253D&md5=06f728d108d2c61b04f9687fade0482b</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-4652%28199805%29175%3A2%3C141%3A%3AAID-JCP3%3E3.0.CO%3B2-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-4652%2528199805%2529175%253A2%253C141%253A%253AAID-JCP3%253E3.0.CO%253B2-O%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%2BS.%26aulast%3DJin%26aufirst%3DG.%2BF.%26aulast%3DHouston%26aufirst%3DC.%2BW.%26aulast%3DThompson%26aufirst%3DJ.%2BC.%26aulast%3DTownsend%26aufirst%3DC.%2BM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520promotes%2520multidrug%2520resistance%2520in%2520MCLM%2520colon%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D1998%26volume%3D175%26spage%3D141%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Dunn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kari, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2687</span><span class="NLM_x">–</span> <span class="NLM_lpage">2693</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=2687-2693&author=S.+E.+Dunnauthor=R.+A.+Hardmanauthor=F.+W.+Kariauthor=J.+C.+Barrett&title=Insulin-like+growth+factor+1+%28IGF-1%29+alters+drug+sensitivity+of+HBL100+human+breast+cancer+cells+by+inhibition+of+apoptosis+induced+by+diverse+anticancer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DS.%2BE.%26aulast%3DHardman%26aufirst%3DR.%2BA.%26aulast%3DKari%26aufirst%3DF.%2BW.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26atitle%3DInsulin-like%2520growth%2520factor%25201%2520%2528IGF-1%2529%2520alters%2520drug%2520sensitivity%2520of%2520HBL100%2520human%2520breast%2520cancer%2520cells%2520by%2520inhibition%2520of%2520apoptosis%2520induced%2520by%2520diverse%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D2687%26epage%3D2693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Dunn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrlich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span> </span><span class="NLM_article-title">A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3353</span><span class="NLM_x">–</span> <span class="NLM_lpage">3361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=3353-3361&author=S.+E.+Dunnauthor=M.+Ehrlichauthor=N.+J.+Sharpauthor=K.+Reissauthor=G.+Solomonauthor=R.+Hawkinsauthor=R.+Basergaauthor=J.+C.+Barrett&title=A+dominant+negative+mutant+of+the+insulin-like+growth+factor-I+receptor+inhibits+the+adhesion%2C+invasion%2C+and+metastasis+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DS.%2BE.%26aulast%3DEhrlich%26aufirst%3DM.%26aulast%3DSharp%26aufirst%3DN.%2BJ.%26aulast%3DReiss%26aufirst%3DK.%26aulast%3DSolomon%26aufirst%3DG.%26aulast%3DHawkins%26aufirst%3DR.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26atitle%3DA%2520dominant%2520negative%2520mutant%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520inhibits%2520the%2520adhesion%252C%2520invasion%252C%2520and%2520metastasis%2520of%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D3353%26epage%3D3361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Macaulay, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salisbury, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohula, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Playford, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smorodinsky, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiloh, Y.</span><span> </span><span class="NLM_article-title">Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">4029</span><span class="NLM_x">–</span> <span class="NLM_lpage">4040</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=4029-4040&author=V.+M.+Macaulayauthor=A.+J.+Salisburyauthor=E.+A.+Bohulaauthor=M.+P.+Playfordauthor=N.+I.+Smorodinskyauthor=Y.+Shiloh&title=Downregulation+of+the+type+1+insulin-like+growth+factor+receptor+in+mouse+melanoma+cells+is+associated+with+enhanced+radiosensitivity+and+impaired+activation+of+Atm+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMacaulay%26aufirst%3DV.%2BM.%26aulast%3DSalisbury%26aufirst%3DA.%2BJ.%26aulast%3DBohula%26aufirst%3DE.%2BA.%26aulast%3DPlayford%26aufirst%3DM.%2BP.%26aulast%3DSmorodinsky%26aufirst%3DN.%2BI.%26aulast%3DShiloh%26aufirst%3DY.%26atitle%3DDownregulation%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520receptor%2520in%2520mouse%2520melanoma%2520cells%2520is%2520associated%2520with%2520enhanced%2520radiosensitivity%2520and%2520impaired%2520activation%2520of%2520Atm%2520kinase%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D4029%26epage%3D4040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Peretz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1676-1681&author=S.+Peretzauthor=R.+Jensenauthor=R.+Basergaauthor=P.+M.+Glazer&title=ATM-dependent+expression+of+the+insulin-like+growth+factor-I+receptor+in+a+pathway+regulating+radiation+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeretz%26aufirst%3DS.%26aulast%3DJensen%26aufirst%3DR.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DATM-dependent%2520expression%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520in%2520a%2520pathway%2520regulating%2520radiation%2520response%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D1676%26epage%3D1681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Shahrabani-Gargir, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandita, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, H.</span><span> </span><span class="NLM_article-title">Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">5679</span><span class="NLM_x">–</span> <span class="NLM_lpage">5687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2004&pages=5679-5687&author=L.+Shahrabani-Gargirauthor=T.+K.+Panditaauthor=H.+Werner&title=Ataxia-telangiectasia+mutated+gene+controls+insulin-like+growth+factor+I+receptor+gene+expression+in+a+deoxyribonucleic+acid+damage+response+pathway+via+mechanisms+involving+zinc-finger+transcription+factors+Sp1+and+WT1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShahrabani-Gargir%26aufirst%3DL.%26aulast%3DPandita%26aufirst%3DT.%2BK.%26aulast%3DWerner%26aufirst%3DH.%26atitle%3DAtaxia-telangiectasia%2520mutated%2520gene%2520controls%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520gene%2520expression%2520in%2520a%2520deoxyribonucleic%2520acid%2520damage%2520response%2520pathway%2520via%2520mechanisms%2520involving%2520zinc-finger%2520transcription%2520factors%2520Sp1%2520and%2520WT1%26jtitle%3DEndocrinology%26date%3D2004%26volume%3D145%26spage%3D5679%26epage%3D5687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Cosaceanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carapancea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekedahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewensohn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dricu, A.</span><span> </span><span class="NLM_article-title">Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">222</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.canlet.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15863266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2005&pages=173-181&author=D.+Cosaceanuauthor=M.+Carapanceaauthor=J.+Castroauthor=J.+Ekedahlauthor=L.+Kanterauthor=R.+Lewensohnauthor=A.+Dricu&title=Modulation+of+response+to+radiation+of+human+lung+cancer+cells+following+insulin-like+growth+factor+1+receptor+inactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation</span></div><div class="casAuthors">Cosaceanu, Daria; Carapancea, Mia; Castro, Juan; Ekedahl, Jessica; Kanter, Lena; Lewensohn, Rolf; Dricu, Anica</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">173-181</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeted disruption of the insulin-like growth factor 1 receptor (IGF-1R) restricts proliferation of tumor cells and enhances their in vitro radiosensitivity.  However, there is little information regarding the effect of IGF-1R expression and function on the lung cancer response to radiotherapy.  In this study, we evaluated the cell surface expression of IGF-1R and the antitumoral effect of IGF-1R blockade in combination with irradn. in 6 non-small cell lung cancer (NSCLC) cell lines.  All cell lines showed specific IGF-1 binding with an affinity ranging from 0.95×10-9 to 2.3×10-9 M, which was evaluated by competitive binding assay.  The amt. of binding sites ranged from 118 to 377 fmol/mg protein.  In one cell line (U1810), the combined treatment led to synergistic cell death and was assocd. with an accumulation of cells in the G2 phase.  IGF-1R activation was able to obstruct serum starvation/radiation-induced cell death in U1810 cell line.  Additive interactions were found for four cell lines (A549, H157, H23 and H125) whereas only subadditive effects were obsd. in U1752 cell line.  Our results indicate that the IGF-1R is present on NSCLC cells and thereby its involvement in the modulation of radiosensitivity in lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf3SUeT-rLxbVg90H21EOLACvtfcHk0lguZ70zgOn7nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Ghs7g%253D&md5=eba00fbbc5900722c550c238d99de8e1</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCosaceanu%26aufirst%3DD.%26aulast%3DCarapancea%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEkedahl%26aufirst%3DJ.%26aulast%3DKanter%26aufirst%3DL.%26aulast%3DLewensohn%26aufirst%3DR.%26aulast%3DDricu%26aufirst%3DA.%26atitle%3DModulation%2520of%2520response%2520to%2520radiation%2520of%2520human%2520lung%2520cancer%2520cells%2520following%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520inactivation%26jtitle%3DCancer%2520Lett.%26date%3D2005%26volume%3D222%26spage%3D173%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">Min, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imsumran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinoda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadaf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=591-600&author=Y.+Minauthor=Y.+Adachiauthor=H.+Yamamotoauthor=A.+Imsumranauthor=Y.+Arimuraauthor=T.+Endoauthor=Y.+Hinodaauthor=C.+T.+Leeauthor=S.+Nadafauthor=D.+P.+Carboneauthor=K.+Imai&title=Insulin-like+growth+factor+I+receptor+blockade+enhances+chemotherapy+and+radiation+responses+and+inhibits+tumour+growth+in+human+gastric+cancer+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DImsumran%26aufirst%3DA.%26aulast%3DArimura%26aufirst%3DY.%26aulast%3DEndo%26aufirst%3DT.%26aulast%3DHinoda%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DC.%2BT.%26aulast%3DNadaf%26aufirst%3DS.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DImai%26aufirst%3DK.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520blockade%2520enhances%2520chemotherapy%2520and%2520radiation%2520responses%2520and%2520inhibits%2520tumour%2520growth%2520in%2520human%2520gastric%2520cancer%2520xenografts%26jtitle%3DGut%26date%3D2005%26volume%3D54%26spage%3D591%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Perer, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shurin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakris, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romeguera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, D. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells</span> <span class="citation_source-journal">J. Surg. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1006%2Fjsre.2000.5923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11038295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlKrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2000&pages=1-5&author=E.+S.+Pererauthor=A.+K.+Madanauthor=A.+Shurinauthor=E.+Zakrisauthor=K.+Romegueraauthor=Y.+Pangauthor=D.+J.+Beech&title=Insulin-like+growth+factor+I+receptor+antagonism+augments+response+to+chemoradiation+therapy+in+colon+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells</span></div><div class="casAuthors">Perer, Elise S.; Madan, Atul K.; Shurin, Autumn; Zakris, Ellen; Romeguera, Keith; Pang, Ying; Beech, Derrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The frequent overexpression of insulin-like growth factor I receptor (IGF-I-R) in rectal adenocarcinoma suggests that inhibition of the signal transduction pathway may be a novel approach to enhance tumor response.  This work investigated the role of IGF-I-R antagonism, by monoclonal antibody α-IR3, in augmenting cytotoxicity to adjuvant chemoradiation therapy of adenocarcinoma of the rectum.  SW 480 colon cancer cells were cultured to semiconfluent conditions with dose titrns. performed for 5-fluorouracil (5-FU) to det. that the IC50 was 0.5 μg/mL.  The IC50 for 5-FU was reassessed in the presence of IGF-I. Exptl. groups included colon cancer cells treated with 5-FU; 6-MeV external beam radiation (100-500 cGy); and α-IR-3.  The addn. of 100 ng IGF-I/mL 1 h prior to 5-FU or radiation blunted the expected cytotoxicity, resulting in a 10-fold increase in the IC50 (from 0.5 to 5 μg/mL).  Receptor antagonism by the monoclonal antibody α-IR-3 (100-400 ng/mL) produced a concn.-dependent increase in cytotoxicity compared with that from 5-FU alone.  The use of radiation produced synergistic amplification of this response.  IGF-I-R activation blocks the expected cytotoxic effects of 5-FU and external beam radiation.  Receptor antagonism increased the cytotoxic response of chemoradiation therapy.  These data suggest the utility of inhibiting IGF-I-R signal transduction in the treatment of rectal adenocarcinoma.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqqRhgENJEFLVg90H21EOLACvtfcHk0lguZ70zgOn7nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlKrt74%253D&md5=56096aaf5aa2a6ca23e763bb6b826db9</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1006%2Fjsre.2000.5923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjsre.2000.5923%26sid%3Dliteratum%253Aachs%26aulast%3DPerer%26aufirst%3DE.%2BS.%26aulast%3DMadan%26aufirst%3DA.%2BK.%26aulast%3DShurin%26aufirst%3DA.%26aulast%3DZakris%26aufirst%3DE.%26aulast%3DRomeguera%26aufirst%3DK.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DBeech%26aufirst%3DD.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520antagonism%2520augments%2520response%2520to%2520chemoradiation%2520therapy%2520in%2520colon%2520cancer%2520cells%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2000%26volume%3D94%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Turner, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haffty, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havre, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gumbs, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgaud, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baserga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glazer, P. M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3079</span><span class="NLM_x">–</span> <span class="NLM_lpage">3083</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3079-3083&author=B.+C.+Turnerauthor=B.+G.+Hafftyauthor=L.+Narayananauthor=J.+Yuanauthor=P.+A.+Havreauthor=A.+A.+Gumbsauthor=L.+Kaplanauthor=J.+L.+Burgaudauthor=D.+Carterauthor=R.+Basergaauthor=P.+M.+Glazer&title=Insulin-like+growth+factor-I+receptor+overexpression+mediates+cellular+radioresistance+and+local+breast+cancer+recurrence+after+lumpectomy+and+radiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DB.%2BC.%26aulast%3DHaffty%26aufirst%3DB.%2BG.%26aulast%3DNarayanan%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DHavre%26aufirst%3DP.%2BA.%26aulast%3DGumbs%26aufirst%3DA.%2BA.%26aulast%3DKaplan%26aufirst%3DL.%26aulast%3DBurgaud%26aufirst%3DJ.%2BL.%26aulast%3DCarter%26aufirst%3DD.%26aulast%3DBaserga%26aufirst%3DR.%26aulast%3DGlazer%26aufirst%3DP.%2BM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520overexpression%2520mediates%2520cellular%2520radioresistance%2520and%2520local%2520breast%2520cancer%2520recurrence%2520after%2520lumpectomy%2520and%2520radiation%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3079%26epage%3D3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Wen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marangoni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frascona, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggiorella, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdulkarim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavaudra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourhis, J.</span><span> </span><span class="NLM_article-title">Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2017</span><span class="NLM_x">–</span> <span class="NLM_lpage">2021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1054%2Fbjoc.2001.2171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11747348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=2017-2021&author=B.+Wenauthor=E.+Deutschauthor=E.+Marangoniauthor=V.+Frasconaauthor=L.+Maggiorellaauthor=B.+Abdulkarimauthor=N.+Chavaudraauthor=J.+Bourhis&title=Tyrphostin+AG+1024+modulates+radiosensitivity+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells</span></div><div class="casAuthors">Wen, B.; Deutsch, E.; Marangoni, E.; Frascona, V.; Maggiorella, L.; Abdulkarim, B.; Chavaudra, N.; Bourhis, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2017-2021</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor-1 (IGF-1) plays an important growth-promoting effect by activating the PI3K/Akt signalling pathway, inhibiting apoptotic pathways and mediating mitogenic actions.  Tyrphostin AG 1024, one selective inhibitor of IGF-1R, was used to evaluate effects on proliferation, radiosensitivity, and radiation-induced cell apoptosis in a human breast cancer cell line MCF-7.  Exposure to Tyrphostin AG 1024 inhibited proliferation and induced apoptosis in a time-dependent manner, and the degree of growth inhibition for IC20 plus irradn. (4 Gy) was up to 50% compared to the control.  Examn. of Tyrphostin AG 1024 effects on radiation response demonstrated a marked enhancement in radiosensitivity and amplification of radiation-induced apoptosis.  Western blot anal. indicated that Tyrphostin AG 1024-induced apoptosis was assocd. with a downregulation of expression of phospho-Akt1, increased expression of Bax, p53 and p21, and a decreased expression of bcl-2 expression, esp. when combined with irradn.  To our knowledge, this is the first report showing that an IGF-1 inhibitor was able to markedly increase the response of tumor cells to ionizing radiation.  These results suggest that Tyrphostin AG 1024 could be used as a potential therapeutic agent in combination with irradn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpARXRmECvMb7Vg90H21EOLACvtfcHk0lgf4K3OuPEscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWmsr0%253D&md5=8d27001da364c6bcdbae0fb202179bbc</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2171%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DB.%26aulast%3DDeutsch%26aufirst%3DE.%26aulast%3DMarangoni%26aufirst%3DE.%26aulast%3DFrascona%26aufirst%3DV.%26aulast%3DMaggiorella%26aufirst%3DL.%26aulast%3DAbdulkarim%26aufirst%3DB.%26aulast%3DChavaudra%26aufirst%3DN.%26aulast%3DBourhis%26aufirst%3DJ.%26atitle%3DTyrphostin%2520AG%25201024%2520modulates%2520radiosensitivity%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D2017%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Chakravarti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyson, N. J.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=200-207&author=A.+Chakravartiauthor=J.+S.+Loefflerauthor=N.+J.+Dyson&title=Insulin-like+growth+factor+receptor+I+mediates+resistance+to+anti-epidermal+growth+factor+receptor+therapy+in+primary+human+glioblastoma+cells+through+continued+activation+of+phosphoinositide+3-kinase+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DA.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26atitle%3DInsulin-like%2520growth%2520factor%2520receptor%2520I%2520mediates%2520resistance%2520to%2520anti-epidermal%2520growth%2520factor%2520receptor%2520therapy%2520in%2520primary%2520human%2520glioblastoma%2520cells%2520through%2520continued%2520activation%2520of%2520phosphoinositide%25203-kinase%2520signaling%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D200%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cichowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">3788</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=3788-3793&author=J.+A.+Engelmanauthor=P.+A.+Janneauthor=C.+Mermelauthor=J.+Pearlbergauthor=T.+Mukoharaauthor=C.+Fleetauthor=K.+Cichowskiauthor=B.+E.+Johnsonauthor=L.+C.+Cantley&title=ErbB-3+mediates+phosphoinositide+3-kinase+activity+in+gefitinib-sensitive+non-small+cell+lung+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DPearlberg%26aufirst%3DJ.%26aulast%3DMukohara%26aufirst%3DT.%26aulast%3DFleet%26aufirst%3DC.%26aulast%3DCichowski%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DErbB-3%2520mediates%2520phosphoinositide%25203-kinase%2520activity%2520in%2520gefitinib-sensitive%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D3788%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Jones, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiscox, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowlden, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeling, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, R. I.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=793-814&author=H.+E.+Jonesauthor=L.+Goddardauthor=J.+M.+Geeauthor=S.+Hiscoxauthor=M.+Rubiniauthor=D.+Barrowauthor=J.+M.+Knowldenauthor=S.+Williamsauthor=A.+E.+Wakelingauthor=R.+I.+Nicholson&title=Insulin-like+growth+factor-I+receptor+signalling+and+acquired+resistance+to+gefitinib+%28ZD1839%3B+Iressa%29+in+human+breast+and+prostate+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DH.%2BE.%26aulast%3DGoddard%26aufirst%3DL.%26aulast%3DGee%26aufirst%3DJ.%2BM.%26aulast%3DHiscox%26aufirst%3DS.%26aulast%3DRubini%26aufirst%3DM.%26aulast%3DBarrow%26aufirst%3DD.%26aulast%3DKnowlden%26aufirst%3DJ.%2BM.%26aulast%3DWilliams%26aufirst%3DS.%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520signalling%2520and%2520acquired%2520resistance%2520to%2520gefitinib%2520%2528ZD1839%253B%2520Iressa%2529%2520in%2520human%2520breast%2520and%2520prostate%2520cancer%2520cells%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2004%26volume%3D11%26spage%3D793%26epage%3D814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lgf4K3OuPEscw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas-Kogan, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dia, E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chute, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horvath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavenee, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beroukhim, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prados, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span> </span><span class="NLM_article-title">Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">2012</span><span class="NLM_x">–</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa051918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16282176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SrtrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2012-2024&author=I.+K.+Mellinghoffauthor=M.+Y.+Wangauthor=I.+Vivancoauthor=D.+A.+Haas-Koganauthor=S.+Zhuauthor=E.+Q.+Diaauthor=K.+V.+Luauthor=K.+Yoshimotoauthor=J.+H.+Huangauthor=D.+J.+Chuteauthor=B.+L.+Riggsauthor=S.+Horvathauthor=L.+M.+Liauauthor=W.+K.+Caveneeauthor=P.+N.+Raoauthor=R.+Beroukhimauthor=T.+C.+Peckauthor=J.+C.+Leeauthor=W.+R.+Sellersauthor=D.+Stokoeauthor=M.+Pradosauthor=T.+F.+Cloughesyauthor=C.+L.+Sawyersauthor=P.+S.+Mischel&title=Molecular+determinants+of+the+response+of+glioblastomas+to+EGFR+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors</span></div><div class="casAuthors">Mellinghoff, Ingo K.; Wang, Maria Y.; Vivanco, Igor; Haas-Kogan, Daphne A.; Zhu, Shaojun; Dia, Ederlyn Q.; Lu, Kan V.; Yoshimoto, Koji; Huang, Julie H. Y.; Chute, Dennis J.; Riggs, Bridget L.; Horvath, Steve; Liau, Linda M.; Cavenee, Webster K.; Rao, P. Nagesh; Beroukhim, Rameen; Peck, Timothy C.; Lee, Jeffrey C.; Sellers, William R.; Stokoe, David; Prados, Michael; Cloughesy, Timothy F.; Sawyers, Charles L.; Mischel, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2012-2024</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but only 10 to 20 % of patients have a response to EGFR kinase inhibitors.  The mechanism of responsiveness of glioblastomas to these inhibitors is unknown.  We sequenced kinase domains in the EGFR and human EGFR type 2 (Her21neu) genes and analyzed the expression of EGFR, EGFR deletion mutantvariant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients who had received EGFR kinase inhibitors.  We detd. the mol. correlates of clin. response, validated them in an independent data set, and identified effects of the mol. abnormalities in vitro.  Of 49 patients with recurrent malignant glioma who were treated with EGFR kinase inhibitors, 9 had tumor shrinkage of at least 25 %.  Pretreatment tissue was available for mol. anal. from 26 patients, 7 of whom had a response and 19 of whom had rapid progression during therapy.  No mutations in EGFR or Her2/neu kinase domains were detected in the tumors.  Coexpression of EGFRvIII and PTEN was significantly assocd. with a clin. response (P <0.001; odds ratio, 51; 95 % confidence interval, 4 to 669).  These findings were validated in 33 patients who received similar treatment for glioblastoma at a different institution (P = 0.001; odds ratio, 40; 95 % confidence interval, 3 to 468).  In vitro, coexpression of EGFRvIII and PTEN sensitized glioblastoma cells to erlotinib.  Coexpression of EGFRvIII and PTEN by glioblastoma cells is assocd. with responsiveness to EGFR kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowUwTSK9-yL7Vg90H21EOLACvtfcHk0liyVFBFY3mFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SrtrrE&md5=e19cb1d6924c5019a7ed5d5f1ccdb6d0</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051918%26sid%3Dliteratum%253Aachs%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DWang%26aufirst%3DM.%2BY.%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DDia%26aufirst%3DE.%2BQ.%26aulast%3DLu%26aufirst%3DK.%2BV.%26aulast%3DYoshimoto%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DJ.%2BH.%26aulast%3DChute%26aufirst%3DD.%2BJ.%26aulast%3DRiggs%26aufirst%3DB.%2BL.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DPeck%26aufirst%3DT.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DPrados%26aufirst%3DM.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26atitle%3DMolecular%2520determinants%2520of%2520the%2520response%2520of%2520glioblastomas%2520to%2520EGFR%2520kinase%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2012%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0liyVFBFY3mFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">She, Q. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M. M.</span><span> </span><span class="NLM_article-title">Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4340</span><span class="NLM_x">–</span> <span class="NLM_lpage">4346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14555504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=4340-4346&author=Q.+B.+Sheauthor=D.+Solitauthor=A.+Bassoauthor=M.+M.+Moasser&title=Resistance+to+gefitinib+in+PTEN-null+HER-overexpressing+tumor+cells+can+be+overcome+through+restoration+of+PTEN+function+or+pharmacologic+modulation+of+constitutive+phosphatidylinositol+3%E2%80%B2-kinase%2FAkt+pathway+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling</span></div><div class="casAuthors">She, Qing-Bai; Solit, David; Basso, Andrea; Moasser, Mark M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4340-4346</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tyrosine kinase (TK) inhibitors are emerging as a promising new approach to the treatment of HER overexpressing tumors, however optimal use of these agents awaits further definition of the downstream signaling pathways that mediate their effects.  We reported previously that both EGFR- and Her2-overexpressing tumors are sensitive to the new EGFR-selective TK inhibitor gefitinib (ZD 1839, "Iressa"), and sensitivity to this agent correlated with its ability to down-regulate Akt.  However, EGFR-overexpressing MDA-468 cells, which lack PTEN function, are resistant to ZD 1839, and ZD 1839 is unable to down-regulate Akt activity in these cells.  To study the role of PTEN function, we generated MDA468 cells with tet-inducible PTEN expression.  We show here that the resistance of MDA-468 cells to ZD 1839 is attributable to EGFR-independent constitutive Akt activation caused by loss of PTEN function in these cells.  Reconstitution of PTEN function through tet-inducible expression restores ZD 1839 sensitivity to these cells and reestablishes EGFR-stimulated Akt signaling.  Although restoration of PTEN function to tumors is difficult to implement clin., much of the effects of PTEN loss are attributable to overactive phosphatidylinositol 3'-kinase (PI3K)/Akt pathway signaling, and this overactivity can be modulated by pharmacol. approaches.  We show here that pharmacol. down-regulation of constitutive PI3K/Akt pathway signaling using the PI3K inhibitor LY294002 similarly restores EGFR-stimulated Akt signaling and sensitizes MDA-468 cells to ZD 1839.  Sensitivity to ZD 1839 requires intact growth factor receptor-stimulated Akt signaling activity.  PTEN loss leads to uncoupling of this signaling pathway and results in ZD 1839 resistance, which can be reversed with reintroduction of PTEN or pharmacol. down-regulation of constitutive PI3K/Akt pathway activity.  These data have important predictive and therapeutic clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL23ncra0tHbVg90H21EOLACvtfcHk0linjseuScRoQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVShsLg%253D&md5=0fab02229bea07fa6c580ff8f2abbb08</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DResistance%2520to%2520gefitinib%2520in%2520PTEN-null%2520HER-overexpressing%2520tumor%2520cells%2520can%2520be%2520overcome%2520through%2520restoration%2520of%2520PTEN%2520function%2520or%2520pharmacologic%2520modulation%2520of%2520constitutive%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%252FAkt%2520pathway%2520signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D4340%26epage%3D4346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Tonra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makhoul, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtrum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finnerty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrick, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span> </span><span class="NLM_article-title">Synergistic anti-tumor effects of anti-EGFR monoclonal antibody Erbitux combined with antibodies targeting IGF1R or VEGFR-2</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">5053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2009&pages=5053&author=J.+R.+Tonraauthor=E.+Corcoranauthor=G.+Makhoulauthor=D.+Burtrumauthor=B.+Finnertyauthor=J.+Huberauthor=F.+E.+Carrickauthor=D.+L.+Ludwigauthor=D.+J.+Hicklin&title=Synergistic+anti-tumor+effects+of+anti-EGFR+monoclonal+antibody+Erbitux+combined+with+antibodies+targeting+IGF1R+or+VEGFR-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTonra%26aufirst%3DJ.%2BR.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DMakhoul%26aufirst%3DG.%26aulast%3DBurtrum%26aufirst%3DD.%26aulast%3DFinnerty%26aufirst%3DB.%26aulast%3DHuber%26aufirst%3DJ.%26aulast%3DCarrick%26aufirst%3DF.%2BE.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26atitle%3DSynergistic%2520anti-tumor%2520effects%2520of%2520anti-EGFR%2520monoclonal%2520antibody%2520Erbitux%2520combined%2520with%2520antibodies%2520targeting%2520IGF1R%2520or%2520VEGFR-2%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2009%26volume%3D2005%26spage%3D5053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lh0eznBd29Wsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Camirand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakikhani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">R570</span><span class="NLM_x">–</span> <span class="NLM_lpage">R579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=R570-R579&author=A.+Camirandauthor=M.+Zakikhaniauthor=F.+Youngauthor=M.+Pollak&title=Inhibition+of+insulin-like+growth+factor-1+receptor+signaling+enhances+growth-inhibitory+and+proapoptotic+effects+of+gefitinib+%28Iressa%29+in+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamirand%26aufirst%3DA.%26aulast%3DZakikhani%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DF.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520signaling%2520enhances%2520growth-inhibitory%2520and%2520proapoptotic%2520effects%2520of%2520gefitinib%2520%2528Iressa%2529%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2005%26volume%3D7%26spage%3DR570%26epage%3DR579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burtrum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">2856</span><span class="NLM_x">–</span> <span class="NLM_lpage">2865</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=2856-2865&author=D.+Luauthor=H.+Zhangauthor=D.+Ludwigauthor=A.+Persaudauthor=X.+Jimenezauthor=D.+Burtrumauthor=P.+Balderesauthor=M.+Liuauthor=P.+Bohlenauthor=L.+Witteauthor=Z.+Zhu&title=Simultaneous+blockade+of+both+the+epidermal+growth+factor+receptor+and+the+insulin-like+growth+factor+receptor+signaling+pathways+in+cancer+cells+with+a+fully+human+recombinant+bispecific+antibody"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DPersaud%26aufirst%3DA.%26aulast%3DJimenez%26aufirst%3DX.%26aulast%3DBurtrum%26aufirst%3DD.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSimultaneous%2520blockade%2520of%2520both%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520signaling%2520pathways%2520in%2520cancer%2520cells%2520with%2520a%2520fully%2520human%2520recombinant%2520bispecific%2520antibody%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D2856%26epage%3D2865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Lu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balderes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prewett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangalampalli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anselma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">19665</span><span class="NLM_x">–</span> <span class="NLM_lpage">19672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=19665-19672&author=D.+Luauthor=H.+Zhangauthor=H.+Kooauthor=J.+Tonraauthor=P.+Balderesauthor=M.+Prewettauthor=E.+Corcoranauthor=V.+Mangalampalliauthor=R.+Bassiauthor=D.+Anselmaauthor=D.+Patelauthor=X.+Kangauthor=D.+L.+Ludwigauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=L.+Witteauthor=Z.+Zhu&title=A+fully+human+recombinant+IgG-like+bispecific+antibody+to+both+the+epidermal+growth+factor+receptor+and+the+insulin-like+growth+factor+receptor+for+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DH.%26aulast%3DTonra%26aufirst%3DJ.%26aulast%3DBalderes%26aufirst%3DP.%26aulast%3DPrewett%26aufirst%3DM.%26aulast%3DCorcoran%26aufirst%3DE.%26aulast%3DMangalampalli%26aufirst%3DV.%26aulast%3DBassi%26aufirst%3DR.%26aulast%3DAnselma%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DWitte%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DA%2520fully%2520human%2520recombinant%2520IgG-like%2520bispecific%2520antibody%2520to%2520both%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520for%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D19665%26epage%3D19672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Albanell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1830</span><span class="NLM_x">–</span> <span class="NLM_lpage">1832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2F93.24.1830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11752000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FgtlKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1830-1832&author=J.+Albanellauthor=J.+Baselga&title=Unraveling+resistance+to+trastuzumab+%28Herceptin%29%3A+insulin-like+growth+factor-I+receptor%2C+a+new+suspect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect</span></div><div class="casAuthors">Albanell J; Baselga J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1830-2</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRD5HLDjTaioFMGsG_HTXYFfW6udTcc2eaKQ9FBUJA3SLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FgtlKrtA%253D%253D&md5=786ffccb7aa0661a54823768b051f64e</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.24.1830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.24.1830%26sid%3Dliteratum%253Aachs%26aulast%3DAlbanell%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DUnraveling%2520resistance%2520to%2520trastuzumab%2520%2528Herceptin%2529%253A%2520insulin-like%2520growth%2520factor-I%2520receptor%252C%2520a%2520new%2520suspect%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1830%26epage%3D1832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Camirand, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells</span> <span class="citation_source-journal">Med. Sci. Monit.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">BR521</span><span class="NLM_x">–</span> <span class="NLM_lpage">BR526</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=BR521-BR526&author=A.+Camirandauthor=Y.+Luauthor=M.+Pollak&title=Co-targeting+HER2%2FErbB2+and+insulin-like+growth+factor-1+receptors+causes+synergistic+inhibition+of+growth+in+HER2-overexpressing+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamirand%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DCo-targeting%2520HER2%252FErbB2%2520and%2520insulin-like%2520growth%2520factor-1%2520receptors%2520causes%2520synergistic%2520inhibition%2520of%2520growth%2520in%2520HER2-overexpressing%2520breast%2520cancer%2520cells%26jtitle%3DMed.%2520Sci.%2520Monit.%26date%3D2002%26volume%3D8%26spage%3DBR521%26epage%3DBR526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Chakraborty, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiGiovanna, M. P.</span><span> </span><span class="NLM_article-title">Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1538</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1538-1545&author=A.+K.+Chakrabortyauthor=K.+Liangauthor=M.+P.+DiGiovanna&title=Co-targeting+insulin-like+growth+factor+I+receptor+and+HER2%3A+dramatic+effects+of+HER2+inhibitors+on+nonoverexpressing+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DLiang%26aufirst%3DK.%26aulast%3DDiGiovanna%26aufirst%3DM.%2BP.%26atitle%3DCo-targeting%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520and%2520HER2%253A%2520dramatic%2520effects%2520of%2520HER2%2520inhibitors%2520on%2520nonoverexpressing%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1538%26epage%3D1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1852</span><span class="NLM_x">–</span> <span class="NLM_lpage">1857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1093%2Fjnci%2F93.24.1852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11752009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVWluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1852-1857&author=Y.+Luauthor=X.+Ziauthor=Y.+Zhaoauthor=D.+Mascarenhasauthor=M.+Pollak&title=Insulin-like+growth+factor-I+receptor+signaling+and+resistance+to+trastuzumab+%28Herceptin%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptor signaling and resistance to Trastuzumab (herceptin)</span></div><div class="casAuthors">Lu, Yuhong; Zi, Xiaolin; Zhao, Yunhua; Mascarenhas, Desmond; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1852-1857</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Trastuzumab (Herceptin), an anti-HER2/neu receptor monoclonal antibody that inhibits growth of ErbB2-overexpressing breast cancer, is used to treat such cancers.  Development of resistance to Trastuzumab, however, is common.  The authors investigated whether insulin-like growth factor-I (IGF-I), which activates cell survival signals, interferes with the growth-inhibitory action of Trastuzumab.  MCF-7/HER2-18 and SKBR3 human breast cancer models were used to assess cell proliferation, colony formation in soft agar, and cell cycle parameters.  Throughout, the authors used Trastuzumab at a dose of 10 μg/mL and IGF-I at a dose of 40 ng/mL.  All statistical tests were two-sided.  Trastuzumab inhibited the growth of MCF-7/HER2-18 cells, which overexpress HER2/neu receptors and express IGF-I receptors (IGF-IRs), only when IGF-IR signaling was minimized.  For example, in 1% fetal bovine serum (FBS), Trastuzumab reduced cell proliferation by 42%; however, in 10% FBS or IGF-I, Trastuzumab had no effect on proliferation.  In SKBR3 cells, which overexpress HER2/neu receptor but express few IGF-IRs, Trastuzumab reduced proliferation by 42% regardless of IGF-I concn.  When SKBR3 cells were genetically altered to overexpress IGF-IRs and cultured with IGF-I, Trastuzumab had no effect on proliferation.  However, the addn. of IGF-binding protein-3, which decreased IGF-IR signaling, restored Trastuzumab-induced growth inhibition.  In breast cancer cell models that overexpress HER2/neu, an increased level of IGF-IR signaling appears to interfere with the action of Trastuzumab.  Thus, strategies that target IGF-IR signaling may prevent or delay development of resistance to Trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQ9Lp7VRj9LVg90H21EOLACvtfcHk0licWBn1n-iq-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVWluw%253D%253D&md5=dab7e32075ddd55ee081a1eccb991a72</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.24.1852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.24.1852%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMascarenhas%26aufirst%3DD.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520signaling%2520and%2520resistance%2520to%2520trastuzumab%2520%2528Herceptin%2529%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1852%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fijc.11445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14648698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSmu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2004&pages=334-341&author=Y.+Luauthor=X.+Ziauthor=M.+Pollak&title=Molecular+mechanisms+underlying+IGF-I-induced+attenuation+of+the+growth-inhibitory+activity+of+trastuzumab+%28Herceptin%29+on+SKBR3+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (herceptin) on SKBR3 breast cancer cells</span></div><div class="casAuthors">Lu, Yuhong; Zi, Xiaolin; Pollak, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-341</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The clin. usefulness of trastuzumab (Herceptin; Genentech, San Francisco, CA) in breast cancer treatment is limited by the rapid development of resistance.  We previously reported that IGF-I signaling confers resistance to the growth-inhibitory actions of trastuzumab in a model system, but the underlying mol. mechanism remains unknown.  We used SKBR3/neo cells (expressing few IGF-I receptors) and SKBR3/IGF-IR cells (overexpressing IGF-I receptor) as our exptl. model.  IGF-I antagonized the trastuzumab-induced increase in the level of the Cdk inhibitor p27Kip1.  This resulted in decreased assocn. of p27Kip1 with Cdk2, restoration of Cdk2 activity and attenuation of cell-cycle arrest in G1 phase, all of which had been induced by trastuzumab treatment in SKBR3/IGF-IR cells.  We also found that the decrease in p27Kip1 induced by IGF-I was accompanied by an increase in expression of Skp2, which is a ubiquitin ligase for p27Kip1, and by increased Skp2 assocn. with p27Kip1.  A specific proteasome inhibitor (LLnL) completely blocked the ability of IGF-I to reduce the p27Kip1 protein level, while IGF-I increased p27Kip1 ubiquitination.  This suggests that the action of IGF-I in conferring resistance to trastuzumab involves targeting of p27Kip1 to the ubiquitin/proteasome degrdn. machinery.  Finally, specific inhibitors of MAPK and PI3K suggest that the IGF-I-mediated redn. in p27Kip1 protein level by increased degrdn. predominantly involves the PI3K pathway.  Our results provide an example of resistance to an antineoplastic therapy that targets one tyrosine kinase receptor by increased signal transduction through an alternative pathway in a complex regulatory network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFa-Tpiak-QbVg90H21EOLACvtfcHk0lh-UHt7vtqQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSmu7fI&md5=10074839f031c006c512b7b0e9be5373</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1002%2Fijc.11445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.11445%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZi%26aufirst%3DX.%26aulast%3DPollak%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520underlying%2520IGF-I-induced%2520attenuation%2520of%2520the%2520growth-inhibitory%2520activity%2520of%2520trastuzumab%2520%2528Herceptin%2529%2520on%2520SKBR3%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D108%26spage%3D334%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Martins, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackintosh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordonez, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de, A. E.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-05-1778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16740780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFyisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=3532-3540&author=A.+S.+Martinsauthor=C.+Mackintoshauthor=D.+H.+Martinauthor=M.+Camposauthor=T.+Hernandezauthor=J.+L.+Ordonezauthor=A.+E.+de&title=Insulin-like+growth+factor+I+receptor+pathway+inhibition+by+ADW742%2C+alone+or+in+combination+with+imatinib%2C+doxorubicin%2C+or+vincristine%2C+is+a+novel+therapeutic+approach+in+Ewing+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor</span></div><div class="casAuthors">Martins, Ana S.; Mackintosh, Carlos; Martin, David Herrero; Campos, Maria; Hernandez, Teresa; Ordonez, Jose-Luis; de Alava, Enrique</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11, Pt. 1</span>),
    <span class="NLM_cas:pages">3532-3540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ewing tumor cell survival and proliferation depends on several autocrine loops.  Targeting these loops is a promising therapeutic approach.  We recently showed the cytostatic role of imatinib, an inhibitor of the SCF-KIT loop, on Ewing tumor cells, and in this study, we intend to analyze the inhibition of the insulin-like growth factor I receptor (IGF1R) loop.  Exptl. Design: We analyzed IGF1R blockade by ADW742, a small mol. specific for this receptor, alone and in combination with imatinib, vincristine, and doxorubicin on Ewing tumor cell lines.  We studied the effect on proliferation, apoptosis, cell cycle, pathway phosphorylation, soft-agar growth, motility, and vascular endothelial growth factor expression levels.  Results: Treatment with ADW742 induced down-regulation of IGF1R/AKT/mammalian target of rapamycin (mTOR) phosphorylation, which was deeper in cell lines having higher IGF1R activation levels.  Treatment also induced dose-dependent inhibition of cell proliferation (IC50 = 0.55-1.4 μmol/L), inducing a G1 phase blockage and apoptosis.  Addn. of imatinib to ADW742 synergistically augmented these effects and was esp. effective in inhibiting AKT/mTOR phosphorylation and reducing vascular endothelial growth factor expression in cell lines having high IGF1R activation levels.  Combination with usual chemotherapeutic agents vincristine and doxorubicin showed synergistic interactions.  Conclusions: Inhibition of Ewing tumor cell proliferation by ADW742 is mediated through blockade of IGF1R signaling.  Combination of ADW742 with imatinib, vincristine, and doxorubicin induces a significant redn. of tumor cell growth, mainly by the increase in apoptosis with a pattern depending on IGF1R activation levels.  This study supports a potential role for ADW742 in the treatment of Ewing tumor and AKT/mTOR as a possible surrogate marker of response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI9m11e83OubVg90H21EOLACvtfcHk0lh-UHt7vtqQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFyisb0%253D&md5=0023acfdf1cc972003ac3d1f9d2c4252</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1778%26sid%3Dliteratum%253Aachs%26aulast%3DMartins%26aufirst%3DA.%2BS.%26aulast%3DMackintosh%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DD.%2BH.%26aulast%3DCampos%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DT.%26aulast%3DOrdonez%26aufirst%3DJ.%2BL.%26aulast%3Dde%26aufirst%3DA.%2BE.%26atitle%3DInsulin-like%2520growth%2520factor%2520I%2520receptor%2520pathway%2520inhibition%2520by%2520ADW742%252C%2520alone%2520or%2520in%2520combination%2520with%2520imatinib%252C%2520doxorubicin%252C%2520or%2520vincristine%252C%2520is%2520a%2520novel%2520therapeutic%2520approach%2520in%2520Ewing%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D3532%26epage%3D3540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenstein, A.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1533</span><span class="NLM_x">–</span> <span class="NLM_lpage">1540</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-05-0068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16227402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWhtLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=1533-1540&author=Y.+Shiauthor=H.+Yanauthor=P.+Frostauthor=J.+Geraauthor=A.+Lichtenstein&title=Mammalian+target+of+rapamycin+inhibitors+activate+the+AKT+kinase+in+multiple+myeloma+cells+by+up-regulating+the+insulin-like+growth+factor+receptor%2Finsulin+receptor+substrate-1%2Fphosphatidylinositol+3-kinase+cascade"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade</span></div><div class="casAuthors">Shi, Yijiang; Yan, Huajun; Frost, Patrick; Gera, Joseph; Lichtenstein, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1533-1540</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have shown preclin. potential as therapy for multiple myeloma.  By inhibiting expression of cell cycle proteins, these agents induce G1 arrest.  However, by also inhibiting an mTOR-dependent serine phosphorylation of insulin receptor substrate-1 (IRS-1), they may enhance insulin-like growth factor-I (IGF-I) signaling and downstream phosphatidylinositol 3-kinase (PI3K)/AKT activation.  This may be a particular problem in multiple myeloma where IGF-I-induced activation of AKT is an important antiapoptotic cascade.  We, therefore, studied AKT activation in multiple myeloma cells treated with mTOR inhibitors.  Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.  CCI-779, used in a xenograft model, also resulted in multiple myeloma cell AKT activation in vivo.  Blockade of IGF-I receptor function prevented rapamycin's activation of AKT.  Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 assocn. with IGF-I receptors, and prevented IRS-1 degrdn.  Although similarly blocking IRS-1 degrdn., proteasome inhibitors did not activate AKT.  Thus, mTOR inhibitors activate PI3-K/AKT in multiple myeloma cells; activation depends on basal IGF-R signaling; and enhanced IRS-1/IGF-I receptor interactions secondary to inhibited IRS-1 serine phosphorylation may play a role in activation of the cascade.  In cotreatment expts., rapamycin inhibited myeloma cell apoptosis induced by PS-341.  These results provide a caveat for future use of mTOR inhibitors in myeloma patients if they are to be combined with apoptosis-inducing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB4Wab6SFXtbVg90H21EOLACvtfcHk0lh-UHt7vtqQEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWhtLjE&md5=27833984d72f3bfa2da5d106604113aa</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0068%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DGera%26aufirst%3DJ.%26aulast%3DLichtenstein%26aufirst%3DA.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520inhibitors%2520activate%2520the%2520AKT%2520kinase%2520in%2520multiple%2520myeloma%2520cells%2520by%2520up-regulating%2520the%2520insulin-like%2520growth%2520factor%2520receptor%252Finsulin%2520receptor%2520substrate-1%252Fphosphatidylinositol%25203-kinase%2520cascade%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D1533%26epage%3D1540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Tamburini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapuis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sujobert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willems, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ifrah, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouscary, D.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=379-382&author=J.+Tamburiniauthor=N.+Chapuisauthor=V.+Bardetauthor=S.+Parkauthor=P.+Sujobertauthor=L.+Willemsauthor=N.+Ifrahauthor=F.+Dreyfusauthor=P.+Mayeuxauthor=C.+Lacombeauthor=D.+Bouscary&title=Mammalian+target+of+rapamycin+%28mTOR%29+inhibition+activates+phosphatidylinositol+3-kinase%2FAkt+by+up-regulating+insulin-like+growth+factor-1+receptor+signaling+in+acute+myeloid+leukemia%3A+rationale+for+therapeutic+inhibition+of+both+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamburini%26aufirst%3DJ.%26aulast%3DChapuis%26aufirst%3DN.%26aulast%3DBardet%26aufirst%3DV.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DSujobert%26aufirst%3DP.%26aulast%3DWillems%26aufirst%3DL.%26aulast%3DIfrah%26aufirst%3DN.%26aulast%3DDreyfus%26aufirst%3DF.%26aulast%3DMayeux%26aufirst%3DP.%26aulast%3DLacombe%26aufirst%3DC.%26aulast%3DBouscary%26aufirst%3DD.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibition%2520activates%2520phosphatidylinositol%25203-kinase%252FAkt%2520by%2520up-regulating%2520insulin-like%2520growth%2520factor-1%2520receptor%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%253A%2520rationale%2520for%2520therapeutic%2520inhibition%2520of%2520both%2520pathways%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D379%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Wan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harkavy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span> </span><span class="NLM_article-title">Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1932</span><span class="NLM_x">–</span> <span class="NLM_lpage">1940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1932-1940&author=X.+Wanauthor=B.+Harkavyauthor=N.+Shenauthor=P.+Groharauthor=L.+J.+Helman&title=Rapamycin+induces+feedback+activation+of+Akt+signaling+through+an+IGF-1R-dependent+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DX.%26aulast%3DHarkavy%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DN.%26aulast%3DGrohar%26aufirst%3DP.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DRapamycin%2520induces%2520feedback%2520activation%2520of%2520Akt%2520signaling%2520through%2520an%2520IGF-1R-dependent%2520mechanism%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1932%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe-Fukunaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukunaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. Y.</span><span> </span><span class="NLM_article-title">Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">7405</span><span class="NLM_x">–</span> <span class="NLM_lpage">7413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1128%2FMCB.00760-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17724079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GltrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=7405-7413&author=X.+Wangauthor=P.+Yueauthor=C.+B.+Chanauthor=K.+Yeauthor=T.+Uedaauthor=R.+Watanabe-Fukunagaauthor=R.+Fukunagaauthor=H.+Fuauthor=F.+R.+Khuriauthor=S.+Y.+Sun&title=Inhibition+of+mammalian+target+of+rapamycin+induces+phosphatidylinositol+3-kinase-dependent+and+Mnk-mediated+eukaryotic+translation+initiation+factor+4E+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation</span></div><div class="casAuthors">Wang, Xuerong; Yue, Ping; Chan, Chi-Bun; Ye, Keqiang; Ueda, Takeshi; Watanabe-Fukunaga, Rie; Fukunaga, Rikiro; Fu, Haian; Khuri, Fadlo R.; Sun, Shi-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7405-7413</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The initiation factor eukaryotic translation initiation factor 4E (eIF4E) plays a crit. role in initiating translation of mRNAs, including those encoding oncogenic proteins.  Therefore, eIF4E is considered a survival protein involved in cell cycle progression, cell transformation, and apoptotic resistance.  Phosphorylation of eIF4E (usually at Ser209) increases its binding affinity for the cap of mRNA and may also favor its entry into initiation complexes.  Mammalian target of rapamycin (mTOR) inhibitors suppress cap-dependent translation through inhibition of the phosphorylation of eIF4E-binding protein 1.  Paradoxically, we have shown that inhibition of mTOR signaling increases eIF4E phosphorylation in human cancer cells.  In this study, we focused on revealing the mechanism by which mTOR inhibition increases eIF4E phosphorylation.  Silencing of either mTOR or raptor could mimic mTOR inhibitors' effects to increase eIF4E phosphorylation.  Moreover, knockdown of mTOR, but not rictor or p70S6K, abrogated rapamycin's ability to increase eIF4E phosphorylation.  These results indicate that mTOR inhibitor-induced eIF4E phosphorylation is secondary to mTOR/raptor inhibition and independent of p70S6K.  Importantly, mTOR inhibitors lost their ability to increase eIF4E phosphorylation only in cells where both Mnk1 and Mnk2 were knocked out, indicating that mTOR inhibitors increase eIF4E phosphorylation through a Mnk-dependent mechanism.  Given that mTOR inhibitors failed to increase Mnk and eIF4E phosphorylation in phosphatidylinositol 3-kinase (PI3K)-deficient cells, we conclude that mTOR inhibition increases eIF4E phosphorylation through a PI3K-dependent and Mnk-mediated mechanism.  In addn., we also suggest an effective therapeutic strategy for enhancing mTOR-targeted cancer therapy by cotargeting mTOR signaling and Mnk/eIF4E phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquXolS5uYp0LVg90H21EOLACvtfcHk0ljPZfD0bRx4vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GltrzE&md5=2dec230f38b5dc7cd95ddd8986f374e5</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1128%2FMCB.00760-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00760-07%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DChan%26aufirst%3DC.%2BB.%26aulast%3DYe%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DWatanabe-Fukunaga%26aufirst%3DR.%26aulast%3DFukunaga%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DSun%26aufirst%3DS.%2BY.%26atitle%3DInhibition%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520induces%2520phosphatidylinositol%25203-kinase-dependent%2520and%2520Mnk-mediated%2520eukaryotic%2520translation%2520initiation%2520factor%25204E%2520phosphorylation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2007%26volume%3D27%26spage%3D7405%26epage%3D7413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Blume-Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">Oncogenic kinase signalling</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2F35077225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11357143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2001&pages=355-365&author=P.+Blume-Jensenauthor=T.+Hunter&title=Oncogenic+kinase+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic kinase signaling</span></div><div class="casAuthors">Blume-Jensen, Peter; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">6835</span>),
    <span class="NLM_cas:pages">355-365</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 93 refs.  Protein-tyrosine kinases (PTKs) are important regulators of intracellular signal-transduction pathways mediating development and multicellular communication in metazoans.  Their activity is normally tightly controlled and regulated.  Perturbation of PTK signaling by mutations and other genetic alterations results in deregulated kinase activity and malignant transformation.  The lipid kinase phosphoinositide 3-OH kinase (PI(3)K) and some of its downstream targets, such as the protein-serine/threonine kinases Akt and p70 S6 kinase (p70S6K), are crucial effectors in oncogenic PTK signaling.  This review emphasizes how oncogenic conversion of protein kinases results from perturbation of the normal autoinhibitory constraints on kinase activity and provides an update on our knowledge about the role of deregulated PI(3)K/Akt and mammalian target of rapamycin/p70S6K signaling in human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJiBzQk4vjZbVg90H21EOLACvtfcHk0ljPZfD0bRx4vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktVSjsr0%253D&md5=cd1bce803c2daadb98cbdba8550be43b</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2F35077225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35077225%26sid%3Dliteratum%253Aachs%26aulast%3DBlume-Jensen%26aufirst%3DP.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DOncogenic%2520kinase%2520signalling%26jtitle%3DNature%26date%3D2001%26volume%3D411%26spage%3D355%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griswold, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underwood, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Votta, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase as a therapeutic strategy</span> <span class="citation_source-journal">Immunopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">185</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2FS0162-3109%2800%2900206-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=10878289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=185-201&author=J.+C.+Leeauthor=S.+Kumarauthor=D.+E.+Griswoldauthor=D.+C.+Underwoodauthor=B.+J.+Vottaauthor=J.+L.+Adams&title=Inhibition+of+p38+MAP+kinase+as+a+therapeutic+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase as a therapeutic strategy</span></div><div class="casAuthors">Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">185-201</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with ∼200 refs.  Since the discovery of p38 MAP kinase in 1994, our understanding of its biol. has progressed dramatically.  The key advances include (1) identification of p38 MAP kinase homologs and protein kinases that act upstream and downstream from p38 MAP kinase, (2) identification of interesting and potentially important substrates, (3) elucidation of the role of p38 MAP kinase in cellular processes and (4) the establishment of the mechanism by which the pyridinylimidazole p38 MAP kinase inhibitors inhibit enzyme activity.  It is now known that there are four members of the p38 MAP kinase family.  They differ in their tissue distribution, regulation of kinase activation and subsequent phosphorylation of downstream substrates.  They also differ in terms of their sensitivities toward the p38 MAP kinase inhibitors.  The best-studied isoform is p38 alpha, whose activation has been obsd. in many hematopoietic and non-hematopoietic cell types upon treatment with appropriate stimuli.  The pyridinylimidazole compds., exemplified by SB 203580, were originally prepd. as inflammatory cytokine synthesis inhibitors that subsequently were selective inhibitors of p38 MAP kinase.  SB 203580 inhibits the catalytic activity of p38 MAP kinase by competitive binding in the ATP pocket.  X-ray crystallog. studies of the target enzyme complexed with inhibitor reinforce the observations made from site-directed mutagenesis studies, thereby providing a mol. basis for understanding the kinase selectivity of these inhibitors.  The p38 MAP kinase inhibitors are efficacious in several disease models, including inflammation, arthritis and other joint diseases, septic shock, and myocardial injury.  In all cases, p38 activation in key cell types correlated with disease initiation and progression.  Treatment with p38 MAP kinase inhibitors attenuated both p38 activation and disease severity.  Structurally diverse p38 MAP kinase inhibitors have been tested extensively in preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWDqUQeNxhwbVg90H21EOLACvtfcHk0ljPZfD0bRx4vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7Y%253D&md5=3d566c9a46952830fd4fca6692fb863b</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900206-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900206-X%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DUnderwood%26aufirst%3DD.%2BC.%26aulast%3DVotta%26aufirst%3DB.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D185%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Goepfert, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkley, B. R.</span><span> </span><span class="NLM_article-title">The centrosome-associated Aurora/Ipl-like kinase family</span> <span class="citation_source-journal">Curr. Top. Dev. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=331-342&author=T.+M.+Goepfertauthor=B.+R.+Brinkley&title=The+centrosome-associated+Aurora%2FIpl-like+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoepfert%26aufirst%3DT.%2BM.%26aulast%3DBrinkley%26aufirst%3DB.%2BR.%26atitle%3DThe%2520centrosome-associated%2520Aurora%252FIpl-like%2520kinase%2520family%26jtitle%3DCurr.%2520Top.%2520Dev.%2520Biol.%26date%3D2000%26volume%3D49%26spage%3D331%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Winder, W. W.</span><span> </span><span class="NLM_article-title">AMP-activated protein kinase: possible target for treatment of type 2 diabetes</span> <span class="citation_source-journal">Diabetes Technol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1089%2F15209150050194305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11467346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXos1SgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=441-448&author=W.+W.+Winder&title=AMP-activated+protein+kinase%3A+possible+target+for+treatment+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase: Possible target for treatment of type 2 diabetes</span></div><div class="casAuthors">Winder, W. W.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Technology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">DTTHFH</span>;
        ISSN:<span class="NLM_cas:issn">1520-9156</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review with 49 refs.  A considerable amt. of data have accumulated showing that contraction of muscle has an acute insulin-like effect, triggering the uptake of glucose.  Chronic muscle contraction, as seen in endurance training has effects on insulin sensitivity, enhancing the effect of insulin on glucose uptake.  Endurance training results in an increase in levels of GLUT4 in the muscle.  This increase in GLUT4 is thought to be responsible in part for the enhancement of insulin sensitivity.  Recent expts. have demonstrated that acute and chronic effects of muscle contraction on glucose uptake and the increase in GLUT4 may be due to activation of a protein kinase, AMP-activated protein kinase (AMPK).  This kinase is activated by the increase in 5'-AMP and the decline in creatine phosphate that occur during muscle contraction.  Phosphorylated AMPK then presumably phosphorylates undefined target proteins, which in turn increase glucose uptake and transcription of the GLUT4 gene.  Expts. have demonstrated that this kinase, normally activated during exercise, can be activated artificially in muscle by injecting non-exercising rats with 5-aminoimidazole-4-carboxamide-riboside (AICAR), an adenosine analog.  AICAR is taken up into muscle and phosphorylated to form an analog of 5'-AMP.  Acute (stimulation of glucose uptake into muscle) and chronic (increase in GLUT4) effects of exercise can be reproduced by injection of this drug.  These observations open the door to the possibility of treatment of patients with type 2 diabetes with AMPK activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4RkPNzHUbbVg90H21EOLACvtfcHk0ljdcoOnmOYSuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXos1SgsLs%253D&md5=64494f4ee3515880bc0b5dac35b4f002</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1089%2F15209150050194305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F15209150050194305%26sid%3Dliteratum%253Aachs%26aulast%3DWinder%26aufirst%3DW.%2BW.%26atitle%3DAMP-activated%2520protein%2520kinase%253A%2520possible%2520target%2520for%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DDiabetes%2520Technol.%2520Ther.%26date%3D2000%26volume%3D2%26spage%3D441%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Wagman, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span> </span><span class="NLM_article-title">Current therapies and emerging targets for the treatment of diabetes</span> <span class="citation_source-journal">Curr. Pharm. Des</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F1381612013397915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11281851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=417-450&author=A.+S.+Wagmanauthor=J.+M.+Nuss&title=Current+therapies+and+emerging+targets+for+the+treatment+of+diabetes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Current therapies and emerging targets for the treatment of diabetes</span></div><div class="casAuthors">Wagman, Allan S.; Nuss, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-450</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 275 refs.  Concurrent with the spread of the western lifestyle, the prevalence of all types of diabetes is on the rise in the world's population.  The no. of diabetics is increasing by 4-5% per yr with an estd. 40-45% of individual's over the age of 65 yr having either type II diabetes or impaired glucose tolerance.  Since the signs of diabetes are not immediately obvious, diagnosis can be preceded by an extended period of impaired glucose tolerance resulting in the prevalence of beta-cell dysfunction and macrovascular complications.  In addn. to increased medical vigilance, diabetes is being combated through aggressive treatment directed at lowering circulating blood glucose and inhibiting postprandial hyperglycemic spikes.  Current strategies to treat diabetes include reducing insulin resistance using glitazones, supplementing insulin supplies with exogenous insulin, increasing endogenous insulin prodn. with sulfonylureas and meglitinides, reducing hepatic glucose prodn. through biguanides, and limiting postprandial glucose absorption with alpha-glucosidase inhibitors.  In all of these areas, new generations of small mols. are being investigated which exhibit improved efficacy and safety profiles.  Promising biol. targets are also emerging such as (1) insulin sensitizers including protein tyrosine phosphatase-1B (PTP-1B) and glycogen synthase kinase 3 (GSK3), (2) inhibitors of gluconeogenesis like pyruvate dehydrogenase kinase (PDH) inhibitors, (3) lipolysis inhibitors, (4) fat oxidn. including carnitine palmitoyltransferase (CPT) I and II inhibitors, and (5) energy expenditure by beta 3-adrenoceptor agonists.  Also important are alternative routes of glucose disposal such as Na+-glucose cotransporter (SGLT) inhibitors, combination therapies, and the treatment of diabetic complications (eg. retinopathy, nephropathy, and neuropathy).  With may new opportunities for drug discovery, the prospects are excellent for development of innovative therapies to effectively manage diabetes and prevent its long term complications.  This review highlights recent (1997-2000) advances in diabetes therapy and research with an emphasis on small mol. drug design (275 refs.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEKavClISK_bVg90H21EOLACvtfcHk0ljdcoOnmOYSuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOjt74%253D&md5=c3b89d3fb630d6dbafdb9e42e014463f</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.2174%2F1381612013397915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397915%26sid%3Dliteratum%253Aachs%26aulast%3DWagman%26aufirst%3DA.%2BS.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26atitle%3DCurrent%2520therapies%2520and%2520emerging%2520targets%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DCurr.%2520Pharm.%2520Des%26date%3D2001%26volume%3D7%26spage%3D417%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group">Kirschenbaum, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, J. V.</span><span> </span><span class="NLM_article-title">Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">30701</span><span class="NLM_x">–</span> <span class="NLM_lpage">30707</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=30701-30707&author=F.+Kirschenbaumauthor=S.+C.+Hsuauthor=B.+Cordellauthor=J.+V.+McCarthy&title=Glycogen+synthase+kinase-3beta+regulates+presenilin+1+C-terminal+fragment+levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKirschenbaum%26aufirst%3DF.%26aulast%3DHsu%26aufirst%3DS.%2BC.%26aulast%3DCordell%26aufirst%3DB.%26aulast%3DMcCarthy%26aufirst%3DJ.%2BV.%26atitle%3DGlycogen%2520synthase%2520kinase-3beta%2520regulates%2520presenilin%25201%2520C-terminal%2520fragment%2520levels%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D30701%26epage%3D30707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sali, A.</span><span> </span><span class="NLM_article-title">Comparative protein structure modeling. Introduction and practical examples with modeller</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11084904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVehtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2000&pages=97-129&author=R.+Sanchezauthor=A.+Sali&title=Comparative+protein+structure+modeling.+Introduction+and+practical+examples+with+modeller"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative protein structure modeling - introduction and practical examples with MODELLER</span></div><div class="casAuthors">Sanchez, Roberto; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, New Jersey)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">Protein Structure Prediction</span>),
    <span class="NLM_cas:pages">97-129</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review with 75 refs.  Topics discussed include the usefulness of comparative modeling, steps in comparative modeling, and examples of typical comparative modeling cases using the program MODELLER and other freely available software.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1LXDmFwRarVg90H21EOLACvtfcHk0ljdcoOnmOYSuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVehtbc%253D&md5=57872474e6a98bb003a27e8100619e89</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparative%2520protein%2520structure%2520modeling.%2520Introduction%2520and%2520practical%2520examples%2520with%2520modeller%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2000%26volume%3D143%26spage%3D97%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Zheng, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirion, R.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway</span> <span class="citation_source-journal">J. Neural Transm., Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11205145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gt1OitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=261-272&author=W.+H.+Zhengauthor=S.+Karauthor=S.+Doreauthor=R.+Quirion&title=Insulin-like+growth+factor-1+%28IGF-1%29%3A+a+neuroprotective+trophic+factor+acting+via+the+Akt+kinase+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway</span></div><div class="casAuthors">Zheng W H; Kar S; Dore S; Quirion R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neural transmission. Supplementum</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">60</span>),
    <span class="NLM_cas:pages">261-72</span>
        ISSN:<span class="NLM_cas:issn">0303-6995</span>.
    </div><div class="casAbstract">Insulin-like growth factor-I (IGF-I) is a pleiotropic polypeptide with a wide range of actions in both central and peripheral nervous sytems.  Over the past few years, we studied the trophic as well as neuromodulatory roles of IGF-I in the brain.  Accumulated evidence indicates that IGF-I, apart from regulating growth and development, protects neurons against cell death induced by amyloidogenic derivatives, glucose or serum deprivation via the activation of intracellular pathways implicating phosphatidylinositide 3/Akt kinase, winged-helix family of transcription factor FKHRL1 phosphorylation or production of free radicals.  The effects of IGF-I on neuroprotection, glucose metabolism and activity-dependent plasticity suggest the potential usefulness of this growth factor or related mimetics in the treatment of Alzheimer's disease and other neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj2Aw68nvLXcULxIEhxUjPfW6udTcc2ebtHDE9xLs1R7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gt1OitA%253D%253D&md5=d5004c17799f1d3b14ab846dd0d57532</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DW.%2BH.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DDore%26aufirst%3DS.%26aulast%3DQuirion%26aufirst%3DR.%26atitle%3DInsulin-like%2520growth%2520factor-1%2520%2528IGF-1%2529%253A%2520a%2520neuroprotective%2520trophic%2520factor%2520acting%2520via%2520the%2520Akt%2520kinase%2520pathway%26jtitle%3DJ.%2520Neural%2520Transm.%252C%2520Suppl.%26date%3D2000%26spage%3D261%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2001</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">37</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2002</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">267</span>− <span class="NLM_lpage">268</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=267-268&author=A.+M.+Dohertyauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942001%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2002%26spage%3D267%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group">Doherty, A. M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2002</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">38</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">358</span>− <span class="NLM_lpage">359</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=358-359&author=A.+M.+Dohertyauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942002%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2003%26spage%3D358%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2004</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">40</span>th ed.; <span class="NLM_contrib-group">Doherty, A. M.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">454</span>− <span class="NLM_lpage">455</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=454-455&author=S.+Hegde&author=M.+Schmidtauthor=A.+M.+Doherty&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942004%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26pub%3DAcademic%2520Press%26date%3D2005%26spage%3D454%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.</span><span> </span><span class="NLM_article-title">To Market, to Market—2005</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>, <span class="NLM_edition">41</span>st ed.; <span class="NLM_contrib-group">Wood, A.</span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">466</span>− <span class="NLM_lpage">467</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=466-467&author=S.+Hegde&author=M.+Schmidtauthor=A.+Wood&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520to%2520Market%25E2%2580%25942005%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26aulast%3DWood%26aufirst%3DA.%26pub%3DAcademic%2520Press%26date%3D2006%26spage%3D466%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group">Liao, J. J.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&author=J.+J.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0ljg63T5LRJlzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span>FDA News. FDA Approves Tykerb for Advanced Breast Cancer Patients. <a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html" class="extLink">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01586.html</a>. Mar 13,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News.+FDA+Approves+Tykerb+for+Advanced+Breast+Cancer+Patients.+http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FNEWS%2F2007%2FNEW01586.html.+Mar+13%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span>FDA News. FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia. <a href="http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html" class="extLink">http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html</a>. Oct 13,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News.+FDA+Approves+Tasigna+for+Treatment+of+Philadelphia+Chromosome+Positive+Chronic+Myeloid+Leukemia.+http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FNEWS%2F2007%2FNEW01734.html.+Oct+13%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span><span> </span><span class="NLM_article-title">Kinase Inhibitor Drugs</span>. In  <span class="citation_source-book">Drug Discovery and Development</span>; <span class="NLM_contrib-group">Wang, B.</span>, Ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>; in press.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Li%2C+R.%3B+Stafford%2C+J.+A.+Kinase+Inhibitor+Drugs.+In+Drug+Discovery+and+Development%3B+Wang%2C+B.%2C+Ed.%3B+John+Wiley+%26+Sons%2C+Inc.%3A+Hoboken%2C+NJ%3B+in+press."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26atitle%3DKinase%2520Inhibitor%2520Drugs%26btitle%3DDrug%2520Discovery%2520and%2520Development%26aulast%3DWang%26aufirst%3DB.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liB6cAynUgNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">Hubbard, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsbacher, J. L.</span><span> </span><span class="NLM_article-title">Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR)</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=41-46&author=R.+D.+Hubbardauthor=J.+L.+Wilsbacher&title=Advances+towards+the+development+of+ATP-competitive+small-molecule+inhibitors+of+the+insulin-like+growth+factor+receptor+%28IGF-IR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DR.%2BD.%26aulast%3DWilsbacher%26aufirst%3DJ.%2BL.%26atitle%3DAdvances%2520towards%2520the%2520development%2520of%2520ATP-competitive%2520small-molecule%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-IR%2529%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D41%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1041</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1041-1047&author=F.+Hofmannauthor=C.+Garcia-Echeverria&title=Blocking+the+insulin-like+growth+factor-I+receptor+as+a+strategy+for+targeting+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DBlocking%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520as%2520a%2520strategy%2520for%2520targeting%2520cancer%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D1041%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span> </span><span class="NLM_article-title">Role of insulin-like growth factor 1 receptor signalling in cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">2097</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fsj.bjc.6602627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15956962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltVygtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2005&pages=2097-2101&author=O.+Larssonauthor=A.+Girnitaauthor=L.+Girnita&title=Role+of+insulin-like+growth+factor+1+receptor+signalling+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Role of insulin-like growth factor 1 receptor signalling in cancer</span></div><div class="casAuthors">Larsson, O.; Girnita, A.; Girnita, L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2097-2101</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor (IGF-1) signalling is highly implicated in cancer.  In this signalling the IGF-1 receptor (IGF-1R) is unquestionable, the predominating single factor.  IGF-1R is crucial for tumor transformation and survival of malignant cell, but is only partially involved in normal cell growth.  This is in part due to the interactions with oncogenes.  Recent findings suggest a close interplay with the p53/MDM2 pathway.  Disturbances in components in the p53/MDM2/IGF-1R network may cause IGF-1R upregulation and growth advantage for the cancer cell.  Targeting of IGF-1R is more and more seen as a promising option for future cancer therapy.  Single chain antibodies and small mols. with selective effects on IGF-1R dependent malignant growth are of particular interest.  Forthcoming clin. trials are welcome and will indeed be the only way to evaluate the impact of IGF-1R targeting in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqurCbuWDX67Vg90H21EOLACvtfcHk0liB6cAynUgNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltVygtL0%253D&md5=c767b37b998115faed09101c57096238</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6602627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6602627%26sid%3Dliteratum%253Aachs%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DGirnita%26aufirst%3DL.%26atitle%3DRole%2520of%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520signalling%2520in%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2005%26volume%3D92%26spage%3D2097%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group">Saxena, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hari Narayana Moorthy, N. S.</span><span> </span><span class="NLM_article-title">Insulin like growth factor-1 receptor: an anticancer target waiting for hit</span> <span class="citation_source-journal">Int. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.3923%2Fijcr.2007.54.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotl2mtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=54-73&author=V.+Saxenaauthor=N.+S.+Hari+Narayana+Moorthy&title=Insulin+like+growth+factor-1+receptor%3A+an+anticancer+target+waiting+for+hit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin like growth factor-1 receptor: an anticancer target waiting for hit</span></div><div class="casAuthors">Saxena, Vipin; Moorthy, N. S. Hari Narayana</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-73</span>CODEN:
                <span class="NLM_cas:coden">IJCRCC</span>;
        ISSN:<span class="NLM_cas:issn">1811-9727</span>.
    
            (<span class="NLM_cas:orgname">Academic Journals</span>)
        </div><div class="casAbstract">A review.  The Insulin like Growth Factor-1 (IGF-1) receptors are members of the super family of Receptor Tyrosine Kinase (RTKs) implicated in human cancers due to amplification, overexpression or somatic mutation of the gene.  The type-1 insulin like growth receptors (IGF-1R) is overexpressed by many tumors and mediates proliferation, motility and apoptosis protection.  Tumor growth and metastasis can be blocked by agents that inhibit IGF-1R expression or function, suggesting that the IGF-1R is a promising treatment target.  The strategies to block IGF-1R function employed anti-IGF-1R antibodies, small-mol. inhibitors of the IGF-1R tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant neg. mutant and various compds. reducing ligand availability.  Studies show that antisense IGF-1R expression in melanoma cells leads to enhanced radio sensitivity and impaired activation of ATM, required for DNA double strand break repair.  Antisense and dominant neg. strategies also enhance tumor cell chemosensitivity induced by tumor cells and killed in vivo by IGF-1R antisense.  However, antisense agents cause only modest IGF-1R down regulation and can affect the insulin receptor.  Specificity is an important issue for the development of both kinase inhibitors and mol. reagents.  Using an array-based screen to identify accessible region of IGF-1R mRNA, are designed small interfering RNAs (siRNAs) that induce potent IGF-1R gene silencing without affecting the insulin receptor.  These siRNAs block IGF-signaling, enhancing radio and chemosensitivity and show a genuine therapeutic potential.  The clin. efficacy of IGF-1R targeting will be detd. by key factors including the role of receptors in established tumors.  The potency of inhibition achieved in vivo and the extent to which other signaling pathways compensate for IGF-1R loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVvZOf269Y0rVg90H21EOLACvtfcHk0liB6cAynUgNTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotl2mtb4%253D&md5=d8acac03ab8ca18442f9b15fe8adf971</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.3923%2Fijcr.2007.54.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3923%252Fijcr.2007.54.73%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DV.%26aulast%3DHari%2BNarayana%2BMoorthy%26aufirst%3DN.%2BS.%26atitle%3DInsulin%2520like%2520growth%2520factor-1%2520receptor%253A%2520an%2520anticancer%2520target%2520waiting%2520for%2520hit%26jtitle%3DInt.%2520J.%2520Cancer%2520Res.%26date%3D2007%26volume%3D3%26spage%3D54%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachter, J. A.</span><span> </span><span class="NLM_article-title">Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches</span> <span class="citation_source-journal">Recent Results Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2F978-3-540-31209-3_5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17607936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsleitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2007&pages=59-76&author=Y.+Wangauthor=Q.+S.+Jiauthor=M.+Mulvihillauthor=J.+A.+Pachter&title=Inhibition+of+the+IGF-I+receptor+for+treatment+of+cancer.+Kinase+inhibitors+and+monoclonal+antibodies+as+alternative+approaches"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches</span></div><div class="casAuthors">Wang, Yan; Ji, Qun-sheng; Mulvihill, Mark; Pachter, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">Targeted Interference with Signal Transduction Events</span>),
    <span class="NLM_cas:pages">59-76</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">0080-0015</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review on the role of insulin-like growth factor receptor in cancer and therapeutic approaches targeting the IGF-IR that have been developed for the treatment of cancer.  The normal physiol. of IGF action is discussed, along with IGF signaling in cancer, targeting of IGF-IR for treatment of human cancer, and small-mol. IGF-IR kinase inhibitors with selectivity vs. IR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLNmWdg_q-CLVg90H21EOLACvtfcHk0lgxi-Xr3iVyiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsleitr8%253D&md5=32a15d51321a529347577669efe42283</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-31209-3_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-31209-3_5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMulvihill%26aufirst%3DM.%26aulast%3DPachter%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520the%2520IGF-I%2520receptor%2520for%2520treatment%2520of%2520cancer.%2520Kinase%2520inhibitors%2520and%2520monoclonal%2520antibodies%2520as%2520alternative%2520approaches%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2007%26volume%3D172%26spage%3D59%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group">Sarma, P. K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tandon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dastidar, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span> </span><span class="NLM_article-title">Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F13543776.17.1.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=25-35&author=P.+K.+S.+Sarmaauthor=R.+Tandonauthor=P.+Guptaauthor=S.+G.+Dastidarauthor=A.+Rayauthor=B.+Dasauthor=I.+A.+Cliffe&title=Progress+in+the+development+of+small+molecule+inhibitors+of+insulin-like+growth+factor-1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase</span></div><div class="casAuthors">Sarma, P. K. S.; Tandon, Ruchi; Gupta, Praful; Dastidar, Sunanda G.; Ray, Abhijit; Das, Biswajit; Cliffe, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase that plays a key role in tumor cell proliferation and in the inhibition of apoptosis, and therefore is a potential target for the treatment of cancer.  The blockade of IGF-1R kinase activity by small mol. binding to the catalytic domain of the receptor offers promise for the future and this review summarizes the patent literature from 2000 to early 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPOksMdgUQ7Vg90H21EOLACvtfcHk0lgxi-Xr3iVyiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitFSktQ%253D%253D&md5=3cb01d7455aaf0707e8e94666fe95961</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1517%2F13543776.17.1.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.17.1.25%26sid%3Dliteratum%253Aachs%26aulast%3DSarma%26aufirst%3DP.%2BK.%2BS.%26aulast%3DTandon%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DDastidar%26aufirst%3DS.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DB.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DProgress%2520in%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2007%26volume%3D17%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group">Yaish, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">242</span><span class="NLM_x">, </span> <span class="NLM_fpage">933</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1988&pages=933-935&author=P.+Yaishauthor=A.+Gazitauthor=C.+Gilonauthor=A.+Levitzki&title=Blocking+of+EGF-dependent+cell+proliferation+by+EGF+receptor+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYaish%26aufirst%3DP.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DBlocking%2520of%2520EGF-dependent%2520cell%2520proliferation%2520by%2520EGF%2520receptor%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D1988%26volume%3D242%26spage%3D933%26epage%3D935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaish, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2344</span><span class="NLM_x">–</span> <span class="NLM_lpage">2352</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00130a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2344-2352&author=A.+Gazitauthor=P.+Yaishauthor=C.+Gilonauthor=A.+Levitzki&title=Tyrphostins+I%3A+synthesis+and+biological+activity+of+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fjm00130a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00130a020%26sid%3Dliteratum%253Aachs%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DYaish%26aufirst%3DP.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DTyrphostins%2520I%253A%2520synthesis%2520and%2520biological%2520activity%2520of%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2344%26epage%3D2352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Tyrphostins—potential antiproliferative agents and novel molecular tools</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=913-918&author=A.+Levitzki&title=Tyrphostins%E2%80%94potential+antiproliferative+agents+and+novel+molecular+tools"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DTyrphostins%25E2%2580%2594potential%2520antiproliferative%2520agents%2520and%2520novel%2520molecular%2520tools%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1990%26volume%3D40%26spage%3D913%26epage%3D918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilon, C.</span><span> </span><span class="NLM_article-title">Tyrphostins as molecular tools and potential antiproliferative drugs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">174</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1991&pages=171-174&author=A.+Levitzkiauthor=C.+Gilon&title=Tyrphostins+as+molecular+tools+and+potential+antiproliferative+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DGilon%26aufirst%3DC.%26atitle%3DTyrphostins%2520as%2520molecular%2520tools%2520and%2520potential%2520antiproliferative%2520drugs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1991%26volume%3D12%26spage%3D171%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibition: an approach to drug development</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">1782</span><span class="NLM_x">–</span> <span class="NLM_lpage">1788</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1995&pages=1782-1788&author=A.+Levitzkiauthor=A.+Gazit&title=Tyrosine+kinase+inhibition%3A+an+approach+to+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibition%253A%2520an%2520approach%2520to%2520drug%2520development%26jtitle%3DScience%26date%3D1995%26volume%3D267%26spage%3D1782%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group">Parrizas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wertheimer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeRoith, D.</span><span> </span><span class="NLM_article-title">Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1997&pages=1427-1433&author=M.+Parrizasauthor=A.+Gazitauthor=A.+Levitzkiauthor=E.+Wertheimerauthor=D.+LeRoith&title=Specific+inhibition+of+insulin-like+growth+factor-1+and+insulin+receptor+tyrosine+kinase+activity+and+biological+function+by+tyrphostins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParrizas%26aufirst%3DM.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DWertheimer%26aufirst%3DE.%26aulast%3DLeRoith%26aufirst%3DD.%26atitle%3DSpecific%2520inhibition%2520of%2520insulin-like%2520growth%2520factor-1%2520and%2520insulin%2520receptor%2520tyrosine%2520kinase%2520activity%2520and%2520biological%2520function%2520by%2520tyrphostins%26jtitle%3DEndocrinology%26date%3D1997%26volume%3D138%26spage%3D1427%26epage%3D1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group">Jaleel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visweswariah, S. S.</span><span> </span><span class="NLM_article-title">Tyrphostins are inhibitors of guanylyl and adenylyl cyclases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">8247</span><span class="NLM_x">–</span> <span class="NLM_lpage">8255</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi036234n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=8247-8255&author=M.+Jaleelauthor=A.+R.+Shenoyauthor=S.+S.+Visweswariah&title=Tyrphostins+are+inhibitors+of+guanylyl+and+adenylyl+cyclases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fbi036234n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036234n%26sid%3Dliteratum%253Aachs%26aulast%3DJaleel%26aufirst%3DM.%26aulast%3DShenoy%26aufirst%3DA.%2BR.%26aulast%3DVisweswariah%26aufirst%3DS.%2BS.%26atitle%3DTyrphostins%2520are%2520inhibitors%2520of%2520guanylyl%2520and%2520adenylyl%2520cyclases%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D8247%26epage%3D8255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group">Kamath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buolamwini, J. K.</span><span> </span><span class="NLM_article-title">Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4657</span><span class="NLM_x">–</span> <span class="NLM_lpage">4668</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030065n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4657-4668&author=S.+Kamathauthor=J.+K.+Buolamwini&title=Receptor-guided+alignment-based+comparative+3D-QSAR+studies+of+benzylidene+malonitrile+tyrphostins+as+EGFR+and+HER-2+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1021%2Fjm030065n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030065n%26sid%3Dliteratum%253Aachs%26aulast%3DKamath%26aufirst%3DS.%26aulast%3DBuolamwini%26aufirst%3DJ.%2BK.%26atitle%3DReceptor-guided%2520alignment-based%2520comparative%25203D-QSAR%2520studies%2520of%2520benzylidene%2520malonitrile%2520tyrphostins%2520as%2520EGFR%2520and%2520HER-2%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4657%26epage%3D4668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group">Meydan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dadi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arpaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidot, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeder, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roifman, C. M.</span><span> </span><span class="NLM_article-title">Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">648</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=1996&pages=645-648&author=N.+Meydanauthor=T.+Grunbergerauthor=H.+Dadiauthor=M.+Shaharauthor=E.+Arpaiaauthor=Z.+Lapidotauthor=J.+S.+Leederauthor=M.+Freedmanauthor=A.+Cohenauthor=A.+Gazitauthor=A.+Levitzkiauthor=C.+M.+Roifman&title=Inhibition+of+acute+lymphoblastic+leukaemia+by+a+Jak-2+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeydan%26aufirst%3DN.%26aulast%3DGrunberger%26aufirst%3DT.%26aulast%3DDadi%26aufirst%3DH.%26aulast%3DShahar%26aufirst%3DM.%26aulast%3DArpaia%26aufirst%3DE.%26aulast%3DLapidot%26aufirst%3DZ.%26aulast%3DLeeder%26aufirst%3DJ.%2BS.%26aulast%3DFreedman%26aufirst%3DM.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26aulast%3DRoifman%26aufirst%3DC.%2BM.%26atitle%3DInhibition%2520of%2520acute%2520lymphoblastic%2520leukaemia%2520by%2520a%2520Jak-2%2520inhibitor%26jtitle%3DNature%26date%3D1996%26volume%3D379%26spage%3D645%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors as a therapeutic modality</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar0201207" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=462-469&author=A.+Levitzki&title=Protein+kinase+inhibitors+as+a+therapeutic+modality"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Far0201207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far0201207%26sid%3Dliteratum%253Aachs%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DProtein%2520kinase%2520inhibitors%2520as%2520a%2520therapeutic%2520modality%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D462%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group">Warshamana-Greene, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krystal, G. W.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">535</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15141010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=527-535&author=G.+S.+Warshamana-Greeneauthor=J.+Litzauthor=E.+Buchdungerauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=G.+W.+Krystal&title=The+insulin-like+growth+factor-I+%28IGF-I%29+receptor+kinase+inhibitor+NVP-ADW742%2C+in+combination+with+STI571%2C+delineates+a+spectrum+of+dependence+of+small+cell+lung+cancer+on+IGF-I+and+stem+cell+factor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling</span></div><div class="casAuthors">Warshamana-Greene, G. Sakuntala; Litz, Julie; Buchdunger, Elisabeth; Hofmann, Francesco; Garcia-Echeverria, Carlos; Krystal, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">527-536</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stem cell factor (SCF)/Kit and insulin-like growth factor-I (IGF-I)/IGF-I receptor (IGF-IR) autocrine loops play a prominent role in the growth of small cell lung cancer (SCLC).  Previous data suggested that IGF-I protects cells from apoptosis induced by STI571, an efficient inhibitor of Kit signal transduction, by activating the crit. phosphatidylinositol 3-kinase-Akt pathway.  To det. if inhibition of IGF-IR signaling would be therapeutically relevant in SCLC, the activity of a novel kinase inhibitor of IGF-IR, NVP-ADW742 (Novartis Pharma AG, Basel, Switzerland), was characterized.  Pretreatment of the H526 cell line with NVP-ADW742 inhibited IGF-IR signaling and growth with IC50 values between 0.1 and 0.4 μM.  SCF-mediated Kit phosphorylation and Akt activation were inhibited with IC50 values in the 1-5 μM range.  However, NVP-ADW742 affected neither hepatocyte growth factor-mediated Akt activation nor activity of constitutively active Akt.  The therapeutic potential of NVP-ADW742 was assessed by detg. its effect on growth of several SCLC cell lines in serum.  These studies clearly delineated two populations of cell lines as detd. by differential sensitivity to NVP-ADW742.  One population, which lacks active SCF/Kit autocrine loops, was inhibited with IC50 values between 0.1 and 0.5 μM.  A second population, which has active SCF/Kit autocrine loops, was inhibited with IC50 values in the 4-7 μM range.  When these cell lines were treated with a combination of STI571 and NVP-ADW742, no advantage was seen in the former group, whereas, in the latter group, a clearly synergistic response to the combination was seen when growth, apoptosis, or Akt activation was assessed.  These data demonstrate that NVP-ADW742 is a potent and selective IGF-IR kinase inhibitor that can efficiently inhibit the growth of cells that are highly dependent on IGF-I signaling.  However, for optimal growth inhibition of SCLC cells with an active SCF/Kit autocrine loop, a combination of a Kit inhibitor (STI571) and an IGF-IR inhibitor (NVP-ADW742) appears to be necessary.  These observations suggest that, in tumors in which crit. signal transduction pathways can be activated by alternative receptors, optimal therapy may require inhibition of multiple receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7Sxl-483BrVg90H21EOLACvtfcHk0ljMYns32G1ujw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVKntLY%253D&md5=7751c83d0080df2177e096c0874cc5a0</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWarshamana-Greene%26aufirst%3DG.%2BS.%26aulast%3DLitz%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DKrystal%26aufirst%3DG.%2BW.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520%2528IGF-I%2529%2520receptor%2520kinase%2520inhibitor%2520NVP-ADW742%252C%2520in%2520combination%2520with%2520STI571%252C%2520delineates%2520a%2520spectrum%2520of%2520dependence%2520of%2520small%2520cell%2520lung%2520cancer%2520on%2520IGF-I%2520and%2520stem%2520cell%2520factor%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D527%26epage%3D535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group">Favelyukis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span> </span><span class="NLM_article-title">Structure and autoregulation of the insulin-like growth factor 1 receptor kinase</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=1058-1063&author=S.+Favelyukisauthor=J.+H.+Tillauthor=S.+R.+Hubbardauthor=W.+T.+Miller&title=Structure+and+autoregulation+of+the+insulin-like+growth+factor+1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFavelyukis%26aufirst%3DS.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DStructure%2520and%2520autoregulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%2520kinase%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2001%26volume%3D8%26spage%3D1058%26epage%3D1063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group">Capraro, H. G.; Furet, P.; Garcia-Echeverria, C.; Manley, P. W.</span><span> </span><span class="NLM_article-title">4-Amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-<i>d</i>]pyrimidine Derivatives</span>. PCT Int. Pat. Appl. WO02/92599,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=H.+G.+Capraro&author=P.+Furet&author=C.+Garcia-Echeverria&author=P.+W.+Manley&title=4-Amino-5-phenyl-7-cyclobutyl-pyrrolo%5B2%2C3-d%5Dpyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCapraro%26aufirst%3DH.%2BG.%26atitle%3D4-Amino-5-phenyl-7-cyclobutyl-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520Derivatives%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group">Tanno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancuso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominici, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschella, G.</span><span> </span><span class="NLM_article-title">Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">6772</span><span class="NLM_x">–</span> <span class="NLM_lpage">6780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-06-1479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17121898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1elsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=6772-6780&author=B.+Tannoauthor=C.+Manciniauthor=R.+Vitaliauthor=M.+Mancusoauthor=H.+P.+McDowellauthor=C.+Dominiciauthor=G.+Raschella&title=Down-regulation+of+insulin-like+growth+factor+I+receptor+activity+by+NVP-AEW541+has+an+antitumor+effect+on+neuroblastoma+cells+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of insulin-like growth gactor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo</span></div><div class="casAuthors">Tanno, Barbara; Mancini, Camillo; Vitali, Roberta; Mancuso, Mariateresa; McDowell, Heather P.; Dominici, Carlo; Raschella, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6772-6780</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through insulin-like growth factor I receptor (IGF-IR) is important for growth and survival of many tumor types.  Neuroblastoma is sensitive to IGF.  We assessed the ability of NVP-AEW541, a recently developed small mol. that selectively inhibits IGF-IR activity, for neuroblastoma growth effects in vitro and in vivo.  The data showed that, in a panel of 10 neuroblastoma cell lines pos. for IGF-IR expression, NVP-AEW541 inhibited in vitro proliferation in a submicromolar/micromolar (0.4-6.8) range of concns.  As expected, NVP-AEW541 inhibited IGF-II-mediated stimulation of IGF-IR and Akt.  In addn. to growth inhibition, the drug also induced apoptosis in vitro.  Oral administration of NVP-AEW541 (50 mg/kg twice daily) inhibited tumor growth of neuroblastoma xenografts in nude mice.  Anal. of tumors from the drug-treated animals revealed a marked apoptotic pattern and a decrease in microvascularization compared with controls.  Interestingly, quant. real-time PCR detected both in vitro and in vivo a significant down-regulation of mRNA for vascular endothelial growth factor (VEGF) caused by NVP-AEW541.  In addn., in Matrigel-coated chambers and in severe combined immunodeficient mice tail vein injected with neuroblastoma cells, tumor invasiveness was significantly reduced by this agent.  Anal. of IGF-IR expression in a series of 43 neuroblastoma primary tumors revealed IGF-IR positivity in 86% of cases.  Taken together, these data indicate that NVP-AEW541 can be considered as a novel promising candidate for treatment of neuroblastoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_GfBCaanIDrVg90H21EOLACvtfcHk0liTxEZoQlbjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1elsLzI&md5=b84ea9d198ce7f8ac18d2fb947eb46dd</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1479%26sid%3Dliteratum%253Aachs%26aulast%3DTanno%26aufirst%3DB.%26aulast%3DMancini%26aufirst%3DC.%26aulast%3DVitali%26aufirst%3DR.%26aulast%3DMancuso%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DH.%2BP.%26aulast%3DDominici%26aufirst%3DC.%26aulast%3DRaschella%26aufirst%3DG.%26atitle%3DDown-regulation%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520activity%2520by%2520NVP-AEW541%2520has%2520an%2520antitumor%2520effect%2520on%2520neuroblastoma%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D6772%26epage%3D6780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group">Manara, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landuzzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lollini, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nanni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotlandi, K.</span><span> </span><span class="NLM_article-title">Preclinical in vivo study of new insulin-like growth factor-I receptor—specific inhibitor in Ewing's sarcoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1322</span><span class="NLM_x">–</span> <span class="NLM_lpage">1330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-06-1518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17317844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1322-1330&author=M.+C.+Manaraauthor=L.+Landuzziauthor=P.+Nanniauthor=G.+Nicolettiauthor=D.+Zambelliauthor=P.+L.+Lolliniauthor=C.+Nanniauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=P.+Picciauthor=K.+Scotlandi&title=Preclinical+in+vivo+study+of+new+insulin-like+growth+factor-I+receptor%E2%80%94specific+inhibitor+in+Ewing%27s+sarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma</span></div><div class="casAuthors">Manara, Maria C.; Landuzzi, Lorena; Nanni, Patrizia; Nicoletti, Giordano; Zambelli, Diana; Lollini, Pier Luigi; Nanni, Cristina; Hofmann, Francesco; Garcia-Echeverria, Carlos; Picci, Piero; Scotlandi, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1322-1330</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Small-mol. insulin-like growth factor-I receptor (IGF-IR)-specific tyrosine kinase inhibitors have been recently proposed as clin. viable approaches to impair IGF-IR functions.  NVP-AEW541 seems one of the most promising agents.  In this article, we point out its effects against migration, metastasis, vasculogenicity, and angiogenesis of Ewing's sarcoma cells.  Exptl. Design: In vivo NVP-AEW541 effectiveness was analyzed against TC-71 Ewing's sarcoma growth and bone metastasis after cell inoculation in athymic mice.  Activity of the compd. against angiogenesis as well as vasculogenesis properties was also considered both in vitro and in xenografts.  Serum glucose, urea, transaminase levels, as well as other signs of distress were checked in mice treated with the IGF-IR inhibitor.  Results: Significant inhibition of migration, metastasis, vasculogenicity, and angiogenesis was recorded after treatment of Ewing's sarcoma cells with NVP-AEW541.  In view of its application and the similarity of insulin receptor and IGF-IR, diabetogenic side effects were considered.  We obsd. a significant decrease of glucose blood serum due to increased glucose uptake at cellular level and an increase in urea concn.  Moreover, an initial wt. loss was obsd. in mice bearing tumors.  All these side effects were similarly detected in mice treated with vincristine.  After the first days of treatment, all the animals started to grow again.  Conclusions: Our results globally reinforce the idea that IGF-IR inhibitor NVP-AEW541 could have a role in future combined therapies and suggest to pursue a thorough mol. anal. of the metabolic activity of IGF-IR to avoid possible side effects of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3OEZmWhDvprVg90H21EOLACvtfcHk0liTxEZoQlbjYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2htrc%253D&md5=8c6941407541059ab78d0ac91685c467</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1518%26sid%3Dliteratum%253Aachs%26aulast%3DManara%26aufirst%3DM.%2BC.%26aulast%3DLanduzzi%26aufirst%3DL.%26aulast%3DNanni%26aufirst%3DP.%26aulast%3DNicoletti%26aufirst%3DG.%26aulast%3DZambelli%26aufirst%3DD.%26aulast%3DLollini%26aufirst%3DP.%2BL.%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DScotlandi%26aufirst%3DK.%26atitle%3DPreclinical%2520in%2520vivo%2520study%2520of%2520new%2520insulin-like%2520growth%2520factor-I%2520receptor%25E2%2580%2594specific%2520inhibitor%2520in%2520Ewing%2527s%2520sarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1322%26epage%3D1330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group">Tazzari, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabellini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bortul, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelisti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grafone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCubrey, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, A. M.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">886</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=886-896&author=P.+L.+Tazzariauthor=G.+Tabelliniauthor=R.+Bortulauthor=V.+Papaauthor=C.+Evangelistiauthor=T.+Grafoneauthor=G.+Martinelliauthor=J.+A.+McCubreyauthor=A.+M.+Martelli&title=The+insulin-like+growth+factor-I+receptor+kinase+inhibitor+NVP-AEW541+induces+apoptosis+in+acute+myeloid+leukemia+cells+exhibiting+autocrine+insulin-like+growth+factor-I+secretion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTazzari%26aufirst%3DP.%2BL.%26aulast%3DTabellini%26aufirst%3DG.%26aulast%3DBortul%26aufirst%3DR.%26aulast%3DPapa%26aufirst%3DV.%26aulast%3DEvangelisti%26aufirst%3DC.%26aulast%3DGrafone%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520inhibitor%2520NVP-AEW541%2520induces%2520apoptosis%2520in%2520acute%2520myeloid%2520leukemia%2520cells%2520exhibiting%2520autocrine%2520insulin-like%2520growth%2520factor-I%2520secretion%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D886%26epage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group">Maiso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocio, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garayoa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandiella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, J. F.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1111%2Fj.1365-2141.2008.07049.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18341634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1eis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=470-482&author=P.+Maisoauthor=E.+M.+Ocioauthor=M.+Garayoaauthor=J.+C.+Monteroauthor=F.+Hofmannauthor=C.+Garcia-Echeverriaauthor=J.+Zimmermannauthor=A.+Pandiellaauthor=J.+F.+San+Miguel&title=The+insulin-like+growth+factor-I+receptor+inhibitor+NVP-AEW541+provokes+cell+cycle+arrest+and+apoptosis+in+multiple+myeloma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</span></div><div class="casAuthors">Maiso, Patricia; Ocio, Enrique M.; Garayoa, Mercedes; Montero, Juan C.; Hofmann, Francesco; Garcia-Echeverria, Carlos; Zimmermann, Johann; Pandiella, Atanasio; San Miguel, Jesus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">470-482</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is a B-cell malignancy characterized by accumulation of monoclonal plasma cells in the bone marrow (BM).  Despite recent advances in the treatment, MM represents an incurable disease for which development of new therapies is required.  We report the antimyeloma effect of NVP-AEW541, a small mol. that belongs to the pyrrolo[2,3-d]pyrimidine class, identified as a selective inhibitor of the insulin-like growth factor-I receptor (IGF-IR) in vitro kinase activity.  NVP-AEW541 had a potent cytotoxic effect on fresh cells and in a murine MM model.  NVP-AEW541 partially abrogated the proliferative advantage conferred by the coculture with BM stromal cells and the presence of growth factors produced by the BM microenvironment.  In addn., NVP-AEW541 potentiated the action of drugs, such as bortezomib, lenalidomide, dexamethasone or melphalan.  Moreover the triple combination of NVP-AEW541, dexamethasone and bortezomib resulted in a significant increase in growth inhibition.  Mechanistic studies indicated that NVP-AEW541 provoked a marked cell cycle blockade accompanied by pRb downregulation.  Interestingly, NVP-AEW541 increased the levels of p27 assocd. with a redn. in the CDK2 activity.  Finally, NVP-AEW541 induced cell death through caspase-dependent and -independent mechanisms.  All these data, suggest the potential effect of IGF-IR kinase inhibitors as therapeutic agents for MM patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVpl109zeOZrVg90H21EOLACvtfcHk0lgxJWW6HTg7Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1eis7c%253D&md5=970e997f2c02e4f206a6738223366133</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07049.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07049.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaiso%26aufirst%3DP.%26aulast%3DOcio%26aufirst%3DE.%2BM.%26aulast%3DGarayoa%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DJ.%2BC.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DPandiella%26aufirst%3DA.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520inhibitor%2520NVP-AEW541%2520provokes%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D470%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group">Moser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schachtschneider, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlitt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeltzing, O.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1577</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=1577-1586&author=C.+Moserauthor=P.+Schachtschneiderauthor=S.+A.+Langauthor=A.+Gaumannauthor=A.+Moriauthor=J.+Zimmermannauthor=H.+J.+Schlittauthor=E.+K.+Geisslerauthor=O.+Stoeltzing&title=Inhibition+of+insulin-like+growth+factor-I+receptor+%28IGF-IR%29+using+NVP-AEW541%2C+a+small+molecule+kinase+inhibitor%2C+reduces+orthotopic+pancreatic+cancer+growth+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DC.%26aulast%3DSchachtschneider%26aufirst%3DP.%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DGaumann%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStoeltzing%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor-I%2520receptor%2520%2528IGF-IR%2529%2520using%2520NVP-AEW541%252C%2520a%2520small%2520molecule%2520kinase%2520inhibitor%252C%2520reduces%2520orthotopic%2520pancreatic%2520cancer%2520growth%2520and%2520angiogenesis%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D1577%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group">Piao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imsumran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maehata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-07-2395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18566219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVSktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1483-1493&author=W.+Piaoauthor=Y.+Wangauthor=Y.+Adachiauthor=H.+Yamamotoauthor=R.+Liauthor=A.+Imsumranauthor=H.+Liauthor=T.+Maehataauthor=M.+Iiauthor=Y.+Arimuraauthor=C.+T.+Leeauthor=Y.+Shinomuraauthor=D.+P.+Carboneauthor=K.+Imai&title=Insulin-like+growth+factor-I+receptor+blockade+by+a+specific+tyrosine+kinase+inhibitor+for+human+gastrointestinal+carcinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas</span></div><div class="casAuthors">Piao, Wenhua; Wang, Yu; Adachi, Yasushi; Yamamoto, Hiroyuki; Li, Rong; Imsumran, Arisa; Li, Hua; Maehata, Tadateru; Ii, Masanori; Arimura, Yoshiaki; Lee, Choon-Taek; Shinomura, Yasuhisa; Carbone, David P.; Imai, Kohzoh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1483-1493</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers.  In this study, we sought to evaluate the effect of a new tyrosine kinase inhibitor of IGF-IR, NVP-AEW541, on the signal transduction and the progression of GI carcinomas.  We assessed the effect of NVP-AEW541 on signal transduction, proliferation, survival, and migration in four GI cancer cells: colorectal adenocarcinoma HT29, pancreatic adenocarcinoma BxPC3, esophageal squamous cell carcinoma TE1, and hepatoma PLC/PRF/5.  The effects of NVP-AEW541 alone and with chemotherapy were studied in vitro and in nude mouse xenografts.  We also analyzed the effects of NVP-AEW541 on insulin signals and hybrid receptor formation between IGF-IR and insulin receptor.  NVP-AEW541 blocked autophosphorylation of IGF-IR and both Akt and extracellular signal-regulated kinase activation by IGF but not by insulin.  NVP-AEW541 suppressed proliferation and tumorigenicity in vitro in a dose-dependent manner in all cell lines.  The drug inhibited tumor as a single agent and, when combined with stressors, up-regulated apoptosis in a dose-dependent fashion and inhibited mobility.  NVP-AEW541 augmented the effects of chemotherapy on in vitro growth and induction of apoptosis.  Moreover, the combination of NVP-AEW541 and chemotherapy was highly effective against tumors in mice.  This compd. did not influence hybrid receptor formation.  Thus, NVP-AEW541 may have significant therapeutic utility in human GI carcinomas both alone and in combination with chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PW2tBfNRSrVg90H21EOLACvtfcHk0lgxJWW6HTg7Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVSktL8%253D&md5=61b8dc8245368720b70fcd486e170bfb</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2395%26sid%3Dliteratum%253Aachs%26aulast%3DPiao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DImsumran%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMaehata%26aufirst%3DT.%26aulast%3DIi%26aufirst%3DM.%26aulast%3DArimura%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DC.%2BT.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DCarbone%26aufirst%3DD.%2BP.%26aulast%3DImai%26aufirst%3DK.%26atitle%3DInsulin-like%2520growth%2520factor-I%2520receptor%2520blockade%2520by%2520a%2520specific%2520tyrosine%2520kinase%2520inhibitor%2520for%2520human%2520gastrointestinal%2520carcinomas%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1483%26epage%3D1493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favelyukis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span> </span><span class="NLM_article-title">Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6−5 ring-fused compounds</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=145-154&author=W.+Liauthor=S.+Favelyukisauthor=J.+Yangauthor=Y.+Zengauthor=J.+Yuauthor=A.+Gangjeeauthor=W.+T.+Miller&title=Inhibition+of+insulin-like+growth+factor+I+receptor+autophosphorylation+by+novel+6%E2%88%925+ring-fused+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFavelyukis%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26atitle%3DInhibition%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520autophosphorylation%2520by%2520novel%25206%25E2%2588%25925%2520ring-fused%2520compounds%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D145%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, S.</span><span> </span><span class="NLM_article-title">Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-<i>d</i>]pyrimidines as inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5155</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5155-5170&author=A.+Gangjeeauthor=J.+Yangauthor=M.+A.+Ihnatauthor=S.+Kamat&title=Antiangiogenic+and+antitumor+agents.+Design%2C+synthesis%2C+and+evaluation+of+novel+2-amino-4-%283-bromoanilino%29-6-benzylsubstituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKamat%26aufirst%3DS.%26atitle%3DAntiangiogenic%2520and%2520antitumor%2520agents.%2520Design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202-amino-4-%25283-bromoanilino%2529-6-benzylsubstituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5155%26epage%3D5170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesnitzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowand, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span> </span><span class="NLM_article-title">Optimization of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=360-364&author=S.+D.+Chamberlainauthor=A.+M.+Redmanauthor=J.+W.+Wilsonauthor=F.+Deandaauthor=J.+B.+Shotwellauthor=R.+Gerdingauthor=H.+Leiauthor=B.+Yangauthor=K.+L.+Stevensauthor=A.+M.+Hassellauthor=L.+M.+Shewchukauthor=M.+A.+Leesnitzerauthor=J.+L.+Smithauthor=P.+Sabbatiniauthor=C.+Atkinsauthor=A.+Groyauthor=J.+L.+Rowandauthor=R.+Kumarauthor=R.+A.+Mookauthor=G.+Moorthyauthor=S.+Patnaik&title=Optimization+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidine+IGF-1R+tyrosine+kinase+inhibitors+towards+JNK+selectivity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DLeesnitzer%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DPatnaik%26aufirst%3DS.%26atitle%3DOptimization%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520IGF-1R%2520tyrosine%2520kinase%2520inhibitors%2520towards%2520JNK%2520selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D360%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brickhouse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chew, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brad, S. J.</span><span> </span><span class="NLM_article-title">Optimization of a series of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=373-377&author=S.+D.+Chamberlainauthor=A.+M.+Redmanauthor=S.+Patnaikauthor=K.+Brickhouseauthor=Y.+C.+Chewauthor=F.+Deandaauthor=R.+Gerdingauthor=H.+Leiauthor=G.+Moorthyauthor=M.+Patrickauthor=K.+L.+Stevensauthor=J.+W.+Wilsonauthor=S.+J.+Brad&title=Optimization+of+a+series+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidine+inhibitors+of+IGF-1R%3A+elimination+of+an+acid-mediated+decomposition+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DPatnaik%26aufirst%3DS.%26aulast%3DBrickhouse%26aufirst%3DK.%26aulast%3DChew%26aufirst%3DY.%2BC.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DPatrick%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DBrad%26aufirst%3DS.%2BJ.%26atitle%3DOptimization%2520of%2520a%2520series%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520inhibitors%2520of%2520IGF-1R%253A%2520elimination%2520of%2520an%2520acid-mediated%2520decomposition%2520pathway%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D373%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deanda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbatini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leesnitzer, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowand, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shotwell, J. B.</span><span> </span><span class="NLM_article-title">Discovery of 4,6-bis-anilino-1<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=469-473&author=S.+D.+Chamberlainauthor=J.+W.+Wilsonauthor=F.+Deandaauthor=S.+Patnaikauthor=A.+M.+Redmanauthor=B.+Yangauthor=L.+Shewchukauthor=P.+Sabbatiniauthor=M.+A.+Leesnitzerauthor=A.+Groyauthor=C.+Atkinsauthor=R.+Gerdingauthor=A.+M.+Hassellauthor=H.+Leiauthor=R.+A.+Mookauthor=G.+Moorthyauthor=J.+L.+Rowandauthor=K.+L.+Stevensauthor=R.+Kumarauthor=J.+B.+Shotwell&title=Discovery+of+4%2C6-bis-anilino-1H-pyrrolo%5B2%2C3-d%5Dpyrimidines%3A+potent+inhibitors+of+the+IGF-1R+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26aulast%3DDeanda%26aufirst%3DF.%26aulast%3DPatnaik%26aufirst%3DS.%26aulast%3DRedman%26aufirst%3DA.%2BM.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DSabbatini%26aufirst%3DP.%26aulast%3DLeesnitzer%26aufirst%3DM.%2BA.%26aulast%3DGroy%26aufirst%3DA.%26aulast%3DAtkins%26aufirst%3DC.%26aulast%3DGerding%26aufirst%3DR.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DMoorthy%26aufirst%3DG.%26aulast%3DRowand%26aufirst%3DJ.%2BL.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DShotwell%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%25204%252C6-bis-anilino-1H-pyrrolo%255B2%252C3-d%255Dpyrimidines%253A%2520potent%2520inhibitors%2520of%2520the%2520IGF-1R%2520receptor%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D469%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brassil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eummer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frennesson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnananthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery of a (1<i>H</i>-benzoimidazol-2-yl)-1<i>H</i>-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5639</span><span class="NLM_x">–</span> <span class="NLM_lpage">5643</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050392q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5639-5643&author=M.+Wittmanauthor=J.+Carboniauthor=R.+Attarauthor=B.+Balasubramanianauthor=P.+Balimaneauthor=P.+Brassilauthor=F.+Beaulieuauthor=C.+Changauthor=W.+Clarkeauthor=J.+Dellauthor=J.+Eummerauthor=D.+Frennessonauthor=M.+Gottardisauthor=A.+Greerauthor=S.+Hanselauthor=W.+Hurlburtauthor=B.+Jacobsonauthor=S.+Krishnananthanauthor=F.+Y.+Leeauthor=A.+Liauthor=T.+A.+Linauthor=P.+Liuauthor=C.+Ouelletauthor=X.+Sangauthor=M.+G.+Saulnierauthor=K.+Stoffanauthor=Y.+Sunauthor=U.+Velaparthiauthor=H.+Wongauthor=Z.+Yangauthor=K.+Zimmermannauthor=M.+Zoecklerauthor=D.+Vyas&title=Discovery+of+a+%281H-benzoimidazol-2-yl%29-1H-pyridin-2-one+%28BMS-536924%29+inhibitor+of+insulin-like+growth+factor+I+receptor+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1021%2Fjm050392q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050392q%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DBeaulieu%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DDell%26aufirst%3DJ.%26aulast%3DEummer%26aufirst%3DJ.%26aulast%3DFrennesson%26aufirst%3DD.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DHansel%26aufirst%3DS.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DKrishnananthan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DT.%2BA.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DOuellet%26aufirst%3DC.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DSaulnier%26aufirst%3DM.%2BG.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520%25281H-benzoimidazol-2-yl%2529-1H-pyridin-2-one%2520%2528BMS-536924%2529%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5639%26epage%3D5643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group">Wittman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnanathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D. M.</span><span> </span><span class="NLM_article-title">Novel 1<i>H</i>-(benzimidazol-2-yl)-1<i>H</i>-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">974</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=974-977&author=M.+D.+Wittmanauthor=B.+Balasubramanianauthor=K.+Stoffanauthor=U.+Velaparthiauthor=P.+Liuauthor=S.+Krishnanathanauthor=J.+Carboniauthor=A.+Liauthor=A.+Greerauthor=R.+Attarauthor=M.+Gottardisauthor=C.+Changauthor=B.+Jacobsonauthor=Y.+Sunauthor=S.+Hanselauthor=M.+Zoecklerauthor=D.+M.+Vyas&title=Novel+1H-%28benzimidazol-2-yl%29-1H-pyridin-2-one+inhibitors+of+insulin-like+growth+factor+I+%28IGF-1R%29+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DKrishnanathan%26aufirst%3DS.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJacobson%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHansel%26aufirst%3DS.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DVyas%26aufirst%3DD.%2BM.%26atitle%3DNovel%25201H-%2528benzimidazol-2-yl%2529-1H-pyridin-2-one%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520I%2520%2528IGF-1R%2529%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D974%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of 3-(1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2317</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2317-2321&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=K.+Stoffanauthor=K.+Zimmermannauthor=X.+Sangauthor=J.+Carboniauthor=A.+Liauthor=R.+Attarauthor=M.+Gottardisauthor=A.+Greerauthor=C.+Y.+Changauthor=B.+L.+Jacobsenauthor=J.+S.+Sackauthor=Y.+Sunauthor=D.+R.+Langleyauthor=B.+Balasubramanianauthor=D.+Vyas&title=Discovery+and+initial+SAR+of+3-%281H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-ones+as+inhibitors+of+insulin-like+growth+factor+1-receptor+%28IGF-1R%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DStoffan%26aufirst%3DK.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DSang%26aufirst%3DX.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DJacobsen%26aufirst%3DB.%2BL.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%25203-%25281H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-ones%2520as%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%25201-receptor%2520%2528IGF-1R%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2317%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balasubramanian, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoeckler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Imidazole moiety replacements in the 3-(1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)pyridin-2(1<i>H</i>)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3072</span><span class="NLM_x">–</span> <span class="NLM_lpage">3076</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3072-3076&author=U.+Velaparthiauthor=P.+Liuauthor=B.+Balasubramanianauthor=J.+Carboniauthor=R.+Attarauthor=M.+Gottardisauthor=A.+Liauthor=A.+Greerauthor=M.+Zoecklerauthor=M.+D.+Wittmanauthor=D.+Vyas&title=Imidazole+moiety+replacements+in+the+3-%281H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+inhibitors+of+insulin-like+growth+factor+receptor-1+%28IGF-1R%29+to+improve+cytochrome+P450+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBalasubramanian%26aufirst%3DB.%26aulast%3DCarboni%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DZoeckler%26aufirst%3DM.%26aulast%3DWittman%26aufirst%3DM.%2BD.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DImidazole%2520moiety%2520replacements%2520in%2520the%25203-%25281H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor-1%2520%2528IGF-1R%2529%2520to%2520improve%2520cytochrome%2520P450%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3072%26epage%3D3076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group">Velaparthi, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carboni, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurlburt, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discenza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saulnier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, D.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of 4-(2-(4-chloro-1<i>H</i>-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperid in-4-yl)-4-methyl-1<i>H</i>-benzo[d]imidazol-2-yl)pyridin-2(1<i>H</i>)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5897</span><span class="NLM_x">–</span> <span class="NLM_lpage">5900</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800832q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5897-5900&author=U.+Velaparthiauthor=M.+Wittmanauthor=P.+Liuauthor=J.+M.+Carboniauthor=F.+Y.+Leeauthor=R.+Attarauthor=P.+Balimaneauthor=W.+Clarkeauthor=M.+W.+Sinzauthor=W.+Hurlburtauthor=K.+Patelauthor=L.+Discenzaauthor=S.+Kimauthor=M.+Gottardisauthor=A.+Greerauthor=A.+Liauthor=M.+Saulnierauthor=Z.+Yangauthor=K.+Zimmermannauthor=G.+Trainorauthor=D.+Vyas&title=Discovery+and+evaluation+of+4-%282-%284-chloro-1H-pyrazol-1-yl%29ethylamino%29-3-%286-%281-%283-fluoropropyl%29piperid+in-4-yl%29-4-methyl-1H-benzo%5Bd%5Dimidazol-2-yl%29pyridin-2%281H%29-one+%28BMS-695735%29%2C+an+orally+efficacious+inhibitor+of+insulin-like+growth+factor-1+receptor+kinase+with+broad+spectrum+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1021%2Fjm800832q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800832q%26sid%3Dliteratum%253Aachs%26aulast%3DVelaparthi%26aufirst%3DU.%26aulast%3DWittman%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCarboni%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAttar%26aufirst%3DR.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DW.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DHurlburt%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DGottardis%26aufirst%3DM.%26aulast%3DGreer%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZimmermann%26aufirst%3DK.%26aulast%3DTrainor%26aufirst%3DG.%26aulast%3DVyas%26aufirst%3DD.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%25204-%25282-%25284-chloro-1H-pyrazol-1-yl%2529ethylamino%2529-3-%25286-%25281-%25283-fluoropropyl%2529piperid%2520in-4-yl%2529-4-methyl-1H-benzo%255Bd%255Dimidazol-2-yl%2529pyridin-2%25281H%2529-one%2520%2528BMS-695735%2529%252C%2520an%2520orally%2520efficacious%2520inhibitor%2520of%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520with%2520broad%2520spectrum%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5897%26epage%3D5900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesario, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saroglou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sujka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkes, R.</span><span> </span><span class="NLM_article-title">1,3-Disubstituted-imidazo[1,5-<i>a</i>]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1091</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1091-1097&author=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=D.+Wernerauthor=P.+Beckauthor=C.+Cesarioauthor=A.+Cookeauthor=M.+Coxauthor=A.+Crewauthor=H.+Dongauthor=L.+Fengauthor=K.+W.+Foremanauthor=G.+Makauthor=A.+Nigroauthor=M.+O%27Connorauthor=L.+Saroglouauthor=K.+M.+Stolzauthor=I.+Sujkaauthor=B.+Volkauthor=Q.+Wengauthor=R.+Wilkes&title=1%2C3-Disubstituted-imidazo%5B1%2C5-a%5Dpyrazines+as+insulin-like+growth-factor-I+receptor+%28IGF-IR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DWerner%26aufirst%3DD.%26aulast%3DBeck%26aufirst%3DP.%26aulast%3DCesario%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DCox%26aufirst%3DM.%26aulast%3DCrew%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DForeman%26aufirst%3DK.%2BW.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DNigro%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DSaroglou%26aufirst%3DL.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DSujka%26aufirst%3DI.%26aulast%3DVolk%26aufirst%3DB.%26aulast%3DWeng%26aufirst%3DQ.%26aulast%3DWilkes%26aufirst%3DR.%26atitle%3D1%252C3-Disubstituted-imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520insulin-like%2520growth-factor-I%2520receptor%2520%2528IGF-IR%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1091%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group">Volk, B.; Mulvihill, M. J.; Buck, E.; Cooke, A.; Crew, A.; Dong, H.; Eyzaguirre, A.; Franklin, M.; Feng, L.; Foreman, K. W.; Ji, Q.-S.; Landfair, D.; Mao, Y.; O'Connor, M.; Pirritt, C.; Silva, S.; Siu, K.; Steinig, A.; Stolz, K.; Tavares, P.; Werner, D.</span><span> </span><span class="NLM_article-title">Identification of Clinical Candidate OSI-906 as a Potent, Selective and Orally Bioavailable IGF-1R Inhibitor</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 40th Middle Atlantic Regional Meeting of the American Chemical Society,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span><span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>MRM-313, p  <span class="NLM_fpage">313</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=313&author=B.+Volk&author=M.+J.+Mulvihill&author=E.+Buck&author=A.+Cooke&author=A.+Crew&author=H.+Dong&author=A.+Eyzaguirre&author=M.+Franklin&author=L.+Feng&author=K.+W.+Foreman&author=Q.-S.+Ji&author=D.+Landfair&author=Y.+Mao&author=M.+O%27Connor&author=C.+Pirritt&author=S.+Silva&author=K.+Siu&author=A.+Steinig&author=K.+Stolz&author=P.+Tavares&author=D.+Werner&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520Clinical%2520Candidate%2520OSI-906%2520as%2520a%2520Potent%252C%2520Selective%2520and%2520Orally%2520Bioavailable%2520IGF-1R%2520Inhibitor%26btitle%3DAbstracts%2520of%2520Papers%26date%3D2008%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2008%26spage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craddock, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubbard, S. R.</span><span> </span><span class="NLM_article-title">Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1985</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1985-1994&author=J.+Wuauthor=W.+Liauthor=B.+P.+Craddockauthor=K.+W.+Foremanauthor=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=W.+T.+Millerauthor=S.+R.+Hubbard&title=Small-molecule+inhibition+and+activation-loop+trans-phosphorylation+of+the+IGF1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DCraddock%26aufirst%3DB.%2BP.%26aulast%3DForeman%26aufirst%3DK.%2BW.%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26atitle%3DSmall-molecule%2520inhibition%2520and%2520activation-loop%2520trans-phosphorylation%2520of%2520the%2520IGF1%2520receptor%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D1985%26epage%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group">Mulvihill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Q. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coate, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenfeld-Franklin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulvihill, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigro, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirrit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinig, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stolz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, N. W.</span><span> </span><span class="NLM_article-title">Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-<i>a</i>]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=1359-1375&author=M.+J.+Mulvihillauthor=Q.+S.+Jiauthor=H.+R.+Coateauthor=A.+Cookeauthor=H.+Dongauthor=L.+Fengauthor=K.+Foremanauthor=M.+Rosenfeld-Franklinauthor=A.+Hondaauthor=G.+Makauthor=K.+M.+Mulvihillauthor=A.+I.+Nigroauthor=M.+O%27Connorauthor=C.+Pirritauthor=A.+G.+Steinigauthor=K.+Siuauthor=K.+M.+Stolzauthor=Y.+Sunauthor=P.+A.+Tavaresauthor=Y.+Yaoauthor=N.+W.+Gibson&title=Novel+2-phenylquinolin-7-yl-derived+imidazo%5B1%2C5-a%5Dpyrazines+as+potent+insulin-like+growth+factor-I+receptor+%28IGF-IR%29+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMulvihill%26aufirst%3DM.%2BJ.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DCoate%26aufirst%3DH.%2BR.%26aulast%3DCooke%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DForeman%26aufirst%3DK.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DHonda%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%26aulast%3DMulvihill%26aufirst%3DK.%2BM.%26aulast%3DNigro%26aufirst%3DA.%2BI.%26aulast%3DO%2527Connor%26aufirst%3DM.%26aulast%3DPirrit%26aufirst%3DC.%26aulast%3DSteinig%26aufirst%3DA.%2BG.%26aulast%3DSiu%26aufirst%3DK.%26aulast%3DStolz%26aufirst%3DK.%2BM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTavares%26aufirst%3DP.%2BA.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DGibson%26aufirst%3DN.%2BW.%26atitle%3DNovel%25202-phenylquinolin-7-yl-derived%2520imidazo%255B1%252C5-a%255Dpyrazines%2520as%2520potent%2520insulin-like%2520growth%2520factor-I%2520receptor%2520%2528IGF-IR%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D1359%26epage%3D1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group">Bandiera, T.; Perrone, E.; Lombardi Borgia, A.; Varasi, M.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo[4,3-<i>c</i>]pyridine Derivatives as IGF-1R Inhibitors</span>. PCT Int. Appl. WO 2007099166,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=E.+Perrone&author=A.+Lombardi+Borgia&author=M.+Varasi&title=Preparation+of+Pyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+IGF-1R+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Pyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520IGF-1R%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group">Bandiera, T.; Lombardi Borgia, A.; Polucci, P.; Villa, M.; Nesi, M.; Angiolini, M.; Varasi, M.</span><span> </span><span class="NLM_article-title">Substituted Pyrazolo[4,3-<i>c</i>]pyridine Derivatives as Tyrosine Kinase Inhibitors, Particularly IGF-1R Inhibitors, Their Preparation, Pharmaceutical Compositions, and Use in Therapy</span>. PCT Int. Appl. WO 2007068619,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=A.+Lombardi+Borgia&author=P.+Polucci&author=M.+Villa&author=M.+Nesi&author=M.+Angiolini&author=M.+Varasi&title=Substituted+Pyrazolo%5B4%2C3-c%5Dpyridine+Derivatives+as+Tyrosine+Kinase+Inhibitors%2C+Particularly+IGF-1R+Inhibitors%2C+Their+Preparation%2C+Pharmaceutical+Compositions%2C+and+Use+in+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DSubstituted%2520Pyrazolo%255B4%252C3-c%255Dpyridine%2520Derivatives%2520as%2520Tyrosine%2520Kinase%2520Inhibitors%252C%2520Particularly%2520IGF-1R%2520Inhibitors%252C%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%252C%2520and%2520Use%2520in%2520Therapy%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group">Bandiera, T.; Bertrand, J. A.; Pevarello, P.; Perrone, E.; Lombardi Borgia, A.; Orrenius, S. C.; Angiolini, M.; Fancelli, D.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolo[3,4-<i>c</i>]pyrazole Derivatives as IGF-1R Inhibitors</span>. PCT Int. Appl. WO 2007099171,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Bandiera&author=J.+A.+Bertrand&author=P.+Pevarello&author=E.+Perrone&author=A.+Lombardi+Borgia&author=S.+C.+Orrenius&author=M.+Angiolini&author=D.+Fancelli&title=Preparation+of+Pyrrolo%5B3%2C4-c%5Dpyrazole+Derivatives+as+IGF-1R+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBandiera%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Pyrrolo%255B3%252C4-c%255Dpyrazole%2520Derivatives%2520as%2520IGF-1R%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ermakova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogozin, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Z.</span><span> </span><span class="NLM_article-title">Direct inhibition of insulin-like growth factor-I receptor kinase activity by (−)-epigallocatechin-3-gallate regulates cell transformation</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">598</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=598-605&author=M.+Liauthor=Z.+Heauthor=S.+Ermakovaauthor=D.+Zhengauthor=F.+Tangauthor=Y.+Y.+Choauthor=F.+Zhuauthor=W.+Y.+Maauthor=Y.+Shamauthor=E.+A.+Rogozinauthor=A.+M.+Bodeauthor=Y.+Caoauthor=Z.+Dong&title=Direct+inhibition+of+insulin-like+growth+factor-I+receptor+kinase+activity+by+%28%E2%88%92%29-epigallocatechin-3-gallate+regulates+cell+transformation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DErmakova%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DCho%26aufirst%3DY.%2BY.%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DW.%2BY.%26aulast%3DSham%26aufirst%3DY.%26aulast%3DRogozin%26aufirst%3DE.%2BA.%26aulast%3DBode%26aufirst%3DA.%2BM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DDirect%2520inhibition%2520of%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520activity%2520by%2520%2528%25E2%2588%2592%2529-epigallocatechin-3-gallate%2520regulates%2520cell%2520transformation%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2007%26volume%3D16%26spage%3D598%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirdivant, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darke, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakas, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kett, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornienko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quigley, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxman, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zartman, C. B.</span><span> </span><span class="NLM_article-title">Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">9430</span><span class="NLM_x">–</span> <span class="NLM_lpage">9440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0500628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=9430-9440&author=I.+M.+Bellauthor=S.+M.+Stirdivantauthor=J.+Ahernauthor=J.+C.+Culbersonauthor=P.+L.+Darkeauthor=C.+J.+Dinsmoreauthor=R.+A.+Drakasauthor=S.+N.+Gallicchioauthor=S.+L.+Grahamauthor=D.+C.+Heimbrookauthor=D.+L.+Hallauthor=J.+Huaauthor=N.+R.+Kettauthor=A.+S.+Kimauthor=M.+Kornienkoauthor=L.+C.+Kuoauthor=S.+K.+Munshiauthor=A.+G.+Quigleyauthor=J.+C.+Reidauthor=B.+W.+Trotterauthor=L.+H.+Waxmanauthor=T.+M.+Williamsauthor=C.+B.+Zartman&title=Biochemical+and+structural+characterization+of+a+novel+class+of+inhibitors+of+the+type+1+insulin-like+growth+factor+and+insulin+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1021%2Fbi0500628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0500628%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DStirdivant%26aufirst%3DS.%2BM.%26aulast%3DAhern%26aufirst%3DJ.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDarke%26aufirst%3DP.%2BL.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDrakas%26aufirst%3DR.%2BA.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHall%26aufirst%3DD.%2BL.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DKuo%26aufirst%3DL.%2BC.%26aulast%3DMunshi%26aufirst%3DS.%2BK.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DWaxman%26aufirst%3DL.%2BH.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26atitle%3DBiochemical%2520and%2520structural%2520characterization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%2520of%2520the%2520type%25201%2520insulin-like%2520growth%2520factor%2520and%2520insulin%2520receptor%2520kinases%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D9430%26epage%3D9440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group">Miller, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">62</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.bmcl.2008.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19041240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvF2h" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=62-66&author=L.+M.+Millerauthor=S.+C.+Mayerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=F.+Boschelliauthor=L.+Diauthor=X.+Duauthor=M.+Dutiaauthor=M.+B.+Floydauthor=M.+Johnsonauthor=C.+H.+Kennyauthor=G.+Krishnamurthyauthor=F.+Moyauthor=S.+Petuskyauthor=D.+Tkachauthor=N.+Torresauthor=B.+Wuauthor=W.+Xu&title=Lead+identification+to+generate+3-cyanoquinoline+inhibitors+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+for+potential+use+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span></div><div class="casAuthors">Miller, Lori M.; Mayer, Scott C.; Berger, Dan M.; Boschelli, Diane H.; Boschelli, Frank; Di, Li; Du, Xuemei; Dutia, Minu; Floyd, Middleton B.; Johnson, Mark; Kenny, Cynthia Hess; Krishnamurthy, Girija; Moy, Franklin; Petusky, Susan; Tkach, Diane; Torres, Nancy; Wu, Biqi; Xu, Weixin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-66</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a crit. mediator of cell proliferation and survival.  Inhibitors of this receptor are believed to provide a new target in cancer therapy.  We previously reported an isoquinolinedione series of IGF-1R inhibitors.  Now we have identified a series of 3-cyanoquinoline compds. that are low nanomolar inhibitors of IGF-1R.  The strategies, synthesis, and SAR behind the cyanoquinoline scaffold will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoDq9AfF4LrVg90H21EOLACvtfcHk0liQb5va3nigYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvF2h&md5=71e5721385a22c44586f9e86841c7d2a</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DL.%2BM.%26aulast%3DMayer%26aufirst%3DS.%2BC.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKenny%26aufirst%3DC.%2BH.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DMoy%26aufirst%3DF.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DTorres%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DLead%2520identification%2520to%2520generate%25203-cyanoquinoline%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520for%2520potential%2520use%2520in%2520cancer%2520treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D62%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group">Mayer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnamurthy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutterer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tkach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3641</span><span class="NLM_x">–</span> <span class="NLM_lpage">3645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.bmcl.2008.04.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18501599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvFSntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3641-3645&author=S.+C.+Mayerauthor=A.+L.+Bankerauthor=F.+Boschelliauthor=L.+Diauthor=M.+Johnsonauthor=C.+H.+Kennyauthor=G.+Krishnamurthyauthor=K.+Kuttererauthor=F.+Moyauthor=S.+Petuskyauthor=M.+Raviauthor=D.+Tkachauthor=H.+R.+Tsouauthor=W.+Xu&title=Lead+identification+to+generate+isoquinolinedione+inhibitors+of+insulin-like+growth+factor+receptor+%28IGF-1R%29+for+potential+use+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment</span></div><div class="casAuthors">Mayer, Scott C.; Banker, Annette L.; Boschelli, Frank; Di, Li; Johnson, Mark; Kenny, Cynthia Hess; Krishnamurthy, Girija; Kutterer, Kristina; Moy, Franklin; Petusky, Susan; Ravi, Malini; Tkach, Diane; Tsou, Hwei-Ru; Xu, Weixin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3641-3645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a crit. mediator of cell proliferation and survival.  This receptor is over-expressed or activated in tumor cells and is emerging as a novel target in cancer therapy.  Efforts in our "Hit to Lead" group have generated a novel series of submicromolar IGF-1R inhibitors based on a isoquinolinedione template originating from a Lance enzyme HTS screen.  Chem. triage and parallel synthesis incorporating focused library arrays were instrumental in moving these investigations through the Wyeth exploratory medicinal chem. process.  The strategies, synthesis, and SAR behind this interesting kinase scaffold will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRW-BDE6Ykw7Vg90H21EOLACvtfcHk0liQb5va3nigYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvFSntbw%253D&md5=0784e3b99a08161dec437f7ef0ee456f</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.044%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DS.%2BC.%26aulast%3DBanker%26aufirst%3DA.%2BL.%26aulast%3DBoschelli%26aufirst%3DF.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DKenny%26aufirst%3DC.%2BH.%26aulast%3DKrishnamurthy%26aufirst%3DG.%26aulast%3DKutterer%26aufirst%3DK.%26aulast%3DMoy%26aufirst%3DF.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DRavi%26aufirst%3DM.%26aulast%3DTkach%26aufirst%3DD.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DLead%2520identification%2520to%2520generate%2520isoquinolinedione%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520receptor%2520%2528IGF-1R%2529%2520for%2520potential%2520use%2520in%2520cancer%2520treatment%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3641%26epage%3D3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolazzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span> </span><span class="NLM_article-title">Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F0008-5472.CAN-03-2522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=14729630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslyltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=236-242&author=A.+Girnitaauthor=L.+Girnitaauthor=P.+F.+delauthor=A.+Bartolazziauthor=O.+Larssonauthor=M.+Axelson&title=Cyclolignans+as+inhibitors+of+the+insulin-like+growth+factor-1+receptor+and+malignant+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit266R"><div class="casContent"><span class="casTitleNuber">266</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth</span></div><div class="casAuthors">Girnita, Ada; Girnita, Leonard; Del Prete, Fabrizio; Bartolazzi, Armando; Larsson, Olle; Axelson, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">236-242</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The insulin-like growth factor-1 receptor (IGF-1R) plays a pivotal role in transformation, growth, and survival of malignant cells, and has emerged as a general and promising target for cancer treatment.  However, no fully selective IGF-1R inhibitors have thus far been found.  This is explained by the fact that IGF-1R is highly homologous to the insulin receptor, coinhibition of which may cause diabetic response.  The receptors are both tyrosine kinases, and their ATP binding sites are identical, implying that ATP inhibitors cannot discriminate between them.  Therefore, the current strategy has been to identify compds. interfering with receptor autophosphorylation at the substrate level.  In this study we investigated the effects of cyclolignans and related mols. on IGF-1R activity.  We report that certain cyclolignans are potent and selective inhibitors of tyrosine phosphorylation of the IGF-1R.  Of particular interest was picropodophyllin (PPP), which is almost nontoxic (LD50 >500 mg/kg in rodents).  PPP efficiently blocked IGF-1R activity, reduced pAkt and phosphorylated extracellular signal regulated kinase 1 and 2 (pErk1/2), induced apoptosis in cultured IGF-1R-pos. tumor cells, and caused complete tumor regression in xenografted and allografted mice.  PPP did not affect the insulin receptor or compete with ATP in an in vitro kinase assay, suggesting that it may inhibit IGF-1R autophosphorylation at the substrate level.  This is also in agreement with our mol. model of how the cyclolignans may act on the IGF-1R kinase.  Our results open the possibility to use PPP or related compds. with inhibitory effects on IGF-1R as lead compds. in development of anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvDfY_KrOXw7Vg90H21EOLACvtfcHk0liQb5va3nigYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslyltA%253D%253D&md5=4008ab5c134757fea02a17b0ccc761d2</span></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2522%26sid%3Dliteratum%253Aachs%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DGirnita%26aufirst%3DL.%26aulast%3Ddel%26aufirst%3DP.%2BF.%26aulast%3DBartolazzi%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DAxelson%26aufirst%3DM.%26atitle%3DCyclolignans%2520as%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520and%2520malignant%2520cell%2520growth%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D236%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group">Vasilcanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weng, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lui, W. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilcanu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">3186</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=3186-3195&author=D.+Vasilcanuauthor=W.+H.+Wengauthor=A.+Girnitaauthor=W.+O.+Luiauthor=R.+Vasilcanuauthor=M.+Axelsonauthor=O.+Larssonauthor=C.+Larssonauthor=L.+Girnita&title=The+insulin-like+growth+factor-1+receptor+inhibitor+PPP+produces+only+very+limited+resistance+in+tumor+cells+exposed+to+long-term+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVasilcanu%26aufirst%3DD.%26aulast%3DWeng%26aufirst%3DW.%2BH.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DLui%26aufirst%3DW.%2BO.%26aulast%3DVasilcanu%26aufirst%3DR.%26aulast%3DAxelson%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26aulast%3DLarsson%26aufirst%3DC.%26aulast%3DGirnita%26aufirst%3DL.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-1%2520receptor%2520inhibitor%2520PPP%2520produces%2520only%2520very%2520limited%2520resistance%2520in%2520tumor%2520cells%2520exposed%2520to%2520long-term%2520selection%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D3186%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group">Vasilcanu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasilcanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosengren, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natalishvili, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girnita, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1629</span><span class="NLM_x">–</span> <span class="NLM_lpage">1638</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=1629-1638&author=R.+Vasilcanuauthor=D.+Vasilcanuauthor=L.+Rosengrenauthor=N.+Natalishviliauthor=B.+Sehatauthor=S.+Yinauthor=A.+Girnitaauthor=M.+Axelsonauthor=L.+Girnitaauthor=O.+Larsson&title=Picropodophyllin+induces+downregulation+of+the+insulin-like+growth+factor+1+receptor%3A+potential+mechanistic+involvement+of+Mdm2+and+beta-arrestin1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVasilcanu%26aufirst%3DR.%26aulast%3DVasilcanu%26aufirst%3DD.%26aulast%3DRosengren%26aufirst%3DL.%26aulast%3DNatalishvili%26aufirst%3DN.%26aulast%3DSehat%26aufirst%3DB.%26aulast%3DYin%26aufirst%3DS.%26aulast%3DGirnita%26aufirst%3DA.%26aulast%3DAxelson%26aufirst%3DM.%26aulast%3DGirnita%26aufirst%3DL.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DPicropodophyllin%2520induces%2520downregulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%253A%2520potential%2520mechanistic%2520involvement%2520of%2520Mdm2%2520and%2520beta-arrestin1%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D1629%26epage%3D1638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">The insulin-like growth factor-I receptor as a target for cancer therapy</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">753</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1517%2F14728222.9.4.753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16083341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFels7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=753-768&author=R.+Baserga&title=The+insulin-like+growth+factor-I+receptor+as+a+target+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">The insulin-like growth factor-I receptor as a target for cancer therapy</span></div><div class="casAuthors">Baserga, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">753-768</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">This review examines the rationale for targeting the insulin-like growth factor (IGF)-I receptor in the therapy of human tumors and their metastases.  The rationale is based on two crucial findings: (1) in exptl. animals, normal cells are only partially affected by the deletion of the IGF-I receptor, whereas tumor cells undergo apoptosis when the IGF-I receptor is downregulated; and (2) cells with a deleted IGF-I receptor are refractory to transformation by viral and cellular oncogenes.  This review focuses on the mechanisms underlying the exptl. findings, and discusses the possibility of extrapolating the results obtained in animals to the cure of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpjOKN3IsjbVg90H21EOLACvtfcHk0lhTrJhPYu_HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFels7w%253D&md5=f07d91258f90130e9cb023e9d7a79e03</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1517%2F14728222.9.4.753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.9.4.753%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DThe%2520insulin-like%2520growth%2520factor-I%2520receptor%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2005%26volume%3D9%26spage%3D753%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Substrate competitive inhibitors of IGF-1 receptor kinase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">15705</span><span class="NLM_x">–</span> <span class="NLM_lpage">15712</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi001516y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=15705-15712&author=G.+Blumauthor=A.+Gazitauthor=A.+Levitzki&title=Substrate+competitive+inhibitors+of+IGF-1+receptor+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1021%2Fbi001516y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi001516y%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DSubstrate%2520competitive%2520inhibitors%2520of%2520IGF-1%2520receptor%2520kinase%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D15705%26epage%3D15712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">40442</span><span class="NLM_x">–</span> <span class="NLM_lpage">40454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=40442-40454&author=G.+Blumauthor=A.+Gazitauthor=A.+Levitzki&title=Development+of+new+insulin-like+growth+factor-1+receptor+kinase+inhibitors+using+catechol+mimics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DGazit%26aufirst%3DA.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520new%2520insulin-like%2520growth%2520factor-1%2520receptor%2520kinase%2520inhibitors%2520using%2520catechol%2520mimics%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D40442%26epage%3D40454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group">Steiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedmann, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">562</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ejphar.2007.01.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17376430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjslSksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=562&publication_year=2007&pages=1-11&author=L.+Steinerauthor=G.+Blumauthor=Y.+Friedmannauthor=A.+Levitzki&title=ATP+non-competitive+IGF-1+receptor+kinase+inhibitors+as+lead+anti-neoplastic+and+anti-papilloma+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents</span></div><div class="casAuthors">Steiner, Lilach; Blum, Galia; Friedmann, Yael; Levitzki, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">562</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The insulin-like growth factor-1 receptor (IGF-1 receptor) is a receptor tyrosine kinase, highly homologous to the insulin receptor.  In contrast to the insulin receptor, which is mostly involved in metabolic pathways, the IGF-1 system plays a pivotal role in normal and neoplastic cell growth through anti-apoptotic, proliferative and metastatic pathways.  Furthermore, IGF-1 receptor over-activation is found to correlate with a variety of tumors, such as breast cancer, prostate cancer, hematol. malignancies, colorectal cancer and other proliferative diseases, such as psoriasis and papilloma.  In addn., accumulating evidence implies that blockade of IGF-1 receptor activity causes reversal of tumor progression in cell lines as well as in animal tumor models.  Because of the central role the IGF-1 receptor plays in oncogenic maintenance and metastatic processes, it is a highly appropriate target for anti-cancer agents.  Here we report on a novel substrate-mimic family of IGF-1 receptor inhibitors.  These compds. are tertiary arom. amines, non-competitive with ATP and possess high affinity towards the IGF-1 receptor.  The most potent compd., SBL02 inhibited the IGF-1 receptor with an IC50 of 170 nM in a cell-free kinase assay and was found to inhibit IGF-1 receptor auto-phosphorylation and substrate phosphorylation at the low micromolar range in cellular assays.  SBL02 also blocks the formation of colonies in soft agar by cancer cells and inhibits the growth of keratinocytes and of HPV16 immortalized keratinocytes.  This new family of non-ATP competitive, IGF-1 receptor inhibitors can serve as a lead for the development of anti-cancer, anti-psoriatic and anti-papilloma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE62emXLYfP7Vg90H21EOLACvtfcHk0lhTrJhPYu_HAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjslSksLc%253D&md5=ef00cdacf5de58a183641e5d32dd6cc2</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2007.01.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2007.01.052%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DG.%26aulast%3DFriedmann%26aufirst%3DY.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DATP%2520non-competitive%2520IGF-1%2520receptor%2520kinase%2520inhibitors%2520as%2520lead%2520anti-neoplastic%2520and%2520anti-papilloma%2520agents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D562%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group">Gable, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schow, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span> </span><span class="NLM_article-title">Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-05-0397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16648580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1079-1086&author=K.+L.+Gableauthor=B.+A.+Madduxauthor=C.+Penarandaauthor=M.+Zavodovskayaauthor=M.+J.+Campbellauthor=M.+Loboauthor=L.+Robinsonauthor=S.+Schowauthor=J.+A.+Kernerauthor=I.+D.+Goldfineauthor=J.+F.+Youngren&title=Diarylureas+are+small-molecule+inhibitors+of+insulin-like+growth+factor+I+receptor+signaling+and+breast+cancer+cell+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth</span></div><div class="casAuthors">Gable, Karissa L.; Maddux, Betty A.; Penaranda, Cristina; Zavodovskaya, Marianna; Campbell, Michael J.; Lobo, Margaret; Robinson, Louise; Schow, Steven; Kerner, John A.; Goldfine, Ira D.; Youngren, Jack F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1079-1086</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In breast and certain other cancers, receptor tyrosine kinases, including the insulin-like growth factor I receptor (IGF-IR), play an important role in promoting the oncogenic process.  The IGF-IR is therefore an important target for developing new anti-breast cancer therapies.  An initial screening of a chem. library against the IGF-IR in breast cancer cells identified a diaryl urea compd. as a potent inhibitor of IGF-IR signaling.  This class of compds. has not been studied as inhibitors of the IGF-IR.  We studied the effectiveness of one diaryl urea compd., PQ401, at antagonizing IGF-IR signaling and inhibiting breast cancer cell growth in culture and in vivo.  PQ401 inhibited autophosphorylation of the IGF-IR in cultured human MCF-7 cells with an IC50 of 12 μmol/L and autophosphorylation of the isolated kinase domain of the IGF-IR with an IC50 <1 μmol/L.  In addn., PQ401 inhibited the growth of cultured breast cancer cells in serum at 10 μmol/L.  PQ401 was even more effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μmol/L).  Treatment of MCF-7 cells with PQ401 was assocd. with a decrease in IGF-I-mediated signaling through the Akt antiapoptotic pathway.  Twenty-four hours of treatment with 15 μmol/L PQ401 induced caspase-mediated apoptosis.  In vivo, treatment with PQ401 (i.p. injection thrice a week) reduced the growth rate of MCNeuA cells implanted into mice.  These studies indicate that diaryl urea compds. are potential new agents to test in the treatment of breast and other IGF-I-sensitive cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyXFuJfg99m7Vg90H21EOLACvtfcHk0lj-_-TTDWa9XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCksb4%253D&md5=93934fa4704b46bb1a7734fae8be5b46</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0397%26sid%3Dliteratum%253Aachs%26aulast%3DGable%26aufirst%3DK.%2BL.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26aulast%3DLobo%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DL.%26aulast%3DSchow%26aufirst%3DS.%26aulast%3DKerner%26aufirst%3DJ.%2BA.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26atitle%3DDiarylureas%2520are%2520small-molecule%2520inhibitors%2520of%2520insulin-like%2520growth%2520factor%2520I%2520receptor%2520signaling%2520and%2520breast%2520cancer%2520cell%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1079%26epage%3D1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+kinase+by+utilizing+a+novel+allosteric+binding+site"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lj-_-TTDWa9XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitfelder, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klaus, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span> </span><span class="NLM_article-title">Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2994</span><span class="NLM_x">–</span> <span class="NLM_lpage">3008</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020057r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFagt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2994-3008&author=J.+Reganauthor=S.+Breitfelderauthor=P.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=B.+Klausauthor=J.+Madwedauthor=M.+Moriakauthor=N.+Mossauthor=C.+Pargellisauthor=S.+Pavauthor=A.+Protoauthor=A.+Swinamerauthor=L.+Tongauthor=C.+Torcellini&title=Pyrazole+urea-based+inhibitors+of+p38+MAP+kinase%3A+from+lead+compound+to+clinical+candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate</span></div><div class="casAuthors">Regan, John; Breitfelder, Steffen; Cirillo, Pier; Gilmore, Thomas; Graham, Anne G.; Hickey, Eugene; Klaus, Bernhard; Madwed, Jeffrey; Moriak, Monica; Moss, Neil; Pargellis, Chris; Pav, Sue; Proto, Alfred; Swinamer, Alan; Tong, Liang; Torcellini, Carol</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2994-3008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase.  Importantly, a key binding domain that is distinct from the ATP (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein.  We describe the correlation of the structure-activity relationships and crystallog. structures of these inhibitors with p38.  In addn., we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site.  This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of Compd. 45 (BIRB 796) as a clin. candidate for the treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotOOfLV3xRbVg90H21EOLACvtfcHk0lj-_-TTDWa9XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFagt7k%253D&md5=e473f514179c8fe24ab3efccc292b6c6</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1021%2Fjm020057r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020057r%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DBreitfelder%26aufirst%3DS.%26aulast%3DCirillo%26aufirst%3DP.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKlaus%26aufirst%3DB.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DProto%26aufirst%3DA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DTorcellini%26aufirst%3DC.%26atitle%3DPyrazole%2520urea-based%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%253A%2520from%2520lead%2520compound%2520to%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2994%26epage%3D3008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group">Nahta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-06-0423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17308062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVWrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=667-674&author=R.+Nahtaauthor=L.+X.+Yuanauthor=Y.+Duauthor=F.+J.+Esteva&title=Lapatinib+induces+apoptosis+in+trastuzumab-resistant+breast+cancer+cells%3A+effects+on+insulin-like+growth+factor+I+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling</span></div><div class="casAuthors">Nahta, Rita; Yuan, Linda X. H.; Du, Yi; Esteva, Francisco J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">667-674</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of breast cancer patients who achieve an initial therapeutic response to the HER2-targeted antibody trastuzumab will show disease progression within 1 yr.  Thus, the identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab is crit.  In the current study, we show that the dual epidermal growth factor receptor (EGFR)/human EGFR-2 (HER2) kinase inhibitor lapatinib induces apoptosis in trastuzumab-resistant cells derived from the HER2-overexpressing SKBR3 breast cancer line.  Lapatinib inhibited EGFR and HER2 signaling in resistant cells, blocking activation of downstream Akt, mitogen-activated protein kinase, and S6 kinases and inducing expression of p27kip1.  Importantly, lapatinib also inhibited insulin-like growth factor I (IGF-I) signaling and growth-promoting effects in parental and resistant cells, and the cytotoxic effects of lapatinib were further enhanced by the IGF-I receptor-blocking antibody αIR3.  As increased IGF-I receptor signaling has been implicated in trastuzumab resistance, our data strongly support further study of lapatinib as a potential therapeutic in breast cancers that have progressed on trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgA2XSBOQGErVg90H21EOLACvtfcHk0lhDGYtn5ylUvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVWrsbc%253D&md5=4bee464a1d992a25a4c5f832cb4b0086</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0423%26sid%3Dliteratum%253Aachs%26aulast%3DNahta%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DL.%2BX.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DLapatinib%2520induces%2520apoptosis%2520in%2520trastuzumab-resistant%2520breast%2520cancer%2520cells%253A%2520effects%2520on%2520insulin-like%2520growth%2520factor%2520I%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D667%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhDGYtn5ylUvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteva, F. J.</span><span> </span><span class="NLM_article-title">Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer</span> <span class="citation_source-journal">J. Mammary Gland Biol. Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2Fs10911-008-9107-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19034632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD1cjns1Grtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=485-498&author=Q.+Jinauthor=F.+J.+Esteva&title=Cross-talk+between+the+ErbB%2FHER+family+and+the+type+I+insulin-like+growth+factor+receptor+signaling+pathway+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer</span></div><div class="casAuthors">Jin Quanri; Esteva Francisco J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of mammary gland biology and neoplasia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">485-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Understanding the molecular mechanisms involved in tumorigenesis and their influence on clinical outcome is providing specific molecular markers for targeted therapy.  Activation of tyrosine kinase receptors from the human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) and the insulin-like growth factor receptor I (IGF-IR) plays a key role in the initiation and progression of breast cancer.  HER2 overexpression is a validated therapeutic target, as shown by the clinical efficacy of trastuzumab and lapatinib.  However, only 25-30% of patients with HER2-overexpressing tumors respond to single-agent trastuzumab or lapatinib, and resistance develops even in responding patients.  Therefore, to optimize therapeutic efficacy, it is urgent to elucidate the complex network of signaling pathways that develop in breast cancer cells.  Signaling interactions have been reported between ErbB/HER family members and IGF-IR.  As increased IGF-IR signaling has been implicated in trastuzumab resistance, agents targeting HER2, and IGF-IR could be potential therapeutic tools in breast cancers that develop resistance to HER2-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTY4qBC_Z7VX5agfuraLLzSfW6udTcc2eZag4xY_n4Zdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjns1Grtw%253D%253D&md5=3d72938ec12e8b4cbb1d7695f7b528df</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1007%2Fs10911-008-9107-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10911-008-9107-3%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26atitle%3DCross-talk%2520between%2520the%2520ErbB%252FHER%2520family%2520and%2520the%2520type%2520I%2520insulin-like%2520growth%2520factor%2520receptor%2520signaling%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DJ.%2520Mammary%2520Gland%2520Biol.%2520Neoplasia%26date%3D2008%26volume%3D13%26spage%3D485%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group">Saxena, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliaferro-Smith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anania, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Regan, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, D.</span><span> </span><span class="NLM_article-title">Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9712</span><span class="NLM_x">–</span> <span class="NLM_lpage">9722</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9712-9722&author=N.+K.+Saxenaauthor=L.+Taliaferro-Smithauthor=B.+B.+Knightauthor=D.+Merlinauthor=F.+A.+Ananiaauthor=R.+M.+O%27Reganauthor=D.+Sharma&title=Bidirectional+crosstalk+between+leptin+and+insulin-like+growth+factor-I+signaling+promotes+invasion+and+migration+of+breast+cancer+cells+via+transactivation+of+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaxena%26aufirst%3DN.%2BK.%26aulast%3DTaliaferro-Smith%26aufirst%3DL.%26aulast%3DKnight%26aufirst%3DB.%2BB.%26aulast%3DMerlin%26aufirst%3DD.%26aulast%3DAnania%26aufirst%3DF.%2BA.%26aulast%3DO%2527Regan%26aufirst%3DR.%2BM.%26aulast%3DSharma%26aufirst%3DD.%26atitle%3DBidirectional%2520crosstalk%2520between%2520leptin%2520and%2520insulin-like%2520growth%2520factor-I%2520signaling%2520promotes%2520invasion%2520and%2520migration%2520of%2520breast%2520cancer%2520cells%2520via%2520transactivation%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9712%26epage%3D9722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gable, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1007%2Fs10549-005-6939-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16142439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=37-46&author=J.+F.+Youngrenauthor=K.+Gableauthor=C.+Penarandaauthor=B.+A.+Madduxauthor=M.+Zavodovskayaauthor=M.+Loboauthor=M.+Campbellauthor=J.+Kernerauthor=I.+D.+Goldfine&title=Nordihydroguaiaretic+acid+%28NDGA%29+inhibits+the+IGF-1+and+c-erbB2%2FHER2%2Fneu+receptors+and+suppresses+growth+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Nordihydroguaiaretic Acid (NDGA) Inhibits the IGF-1 and c-erbB2/HER2/neu Receptors and Suppresses Growth in Breast Cancer Cells</span></div><div class="casAuthors">Youngren, Jack F.; Gable, Karissa; Penaranda, Cristina; Maddux, Betty A.; Zavodovskaya, Marianna; Lobo, Margaret; Campbell, Michael; Kerner, John; Goldfine, Ira D.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-46</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Nordihydroguaiaretic acid (NDGA) is a phenolic compd. isolated from the creosote bush Larrea divaricata that has anti-cancer activities both in vitro and in vivo.  We can now attribute certain of these anti-cancer properties in breast cancer cells to the ability of NDGA to directly inhibit the function of two receptor tyrosine kinases (RTKs), the insulin-like growth factor receptor (IGF-1R) and the c-erbB2/HER2/neu (HER2/neu) receptor.  In MCF-7 human breast cancer cells, low micromolar concns. of NDGA inhibited activation of the IGF-1R, and downstream phosphorylation of both the Akt/PKB serine kinase and the pro-apoptotic protein BAD.  In mouse MCNeuA cells, NDGA also inhibited ligand independent phosphorylation of HER2/neu.  To study whether this inhibitory effect in cells was due to a direct action on these receptors, we studied the IGF-1-stimulated tyrosine kinase activity of isolated IGF-1R, which was inhibited by NDGA at 10 μM or less.  NDGA was also effective at inhibiting autophosphorylation of the isolated HER2/neu receptor at similar concns.  In addn., NDGA inhibited IGF-1 specific growth of cultured breast cancer cells with an IC50 of approx. 30 μM.  NDGA treatment (i.p. injection 3 times per wk) also decreased the activity of the IGF-1R and the HER2/neu receptor in MCNeuA cells implanted into mice.  This inhibition of RTK activity was assocd. with decreased growth rates of MCNeuA cells in vivo.  These studies indicate that the anti-breast cancer properties of NDGA are related to the inhibition of two important RTKs.  Agents of this class may therefore provide new insights into potential therapies for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreUxoBHJItcrVg90H21EOLACvtfcHk0lhyKUIJ_lg_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVyltbjN&md5=2c2d27fd3d500655dd32a568b62e2938</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-6939-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-6939-z%26sid%3Dliteratum%253Aachs%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DGable%26aufirst%3DK.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DLobo%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DKerner%26aufirst%3DJ.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26atitle%3DNordihydroguaiaretic%2520acid%2520%2528NDGA%2529%2520inhibits%2520the%2520IGF-1%2520and%2520c-erbB2%252FHER2%252Fneu%2520receptors%2520and%2520suppresses%2520growth%2520in%2520breast%2520cancer%2520cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D94%26spage%3D37%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group">Blecha, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guevarra, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pender, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaranda, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berkman, C. E.</span><span> </span><span class="NLM_article-title">Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4026</span><span class="NLM_x">–</span> <span class="NLM_lpage">4029</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=4026-4029&author=J.+E.+Blechaauthor=M.+O.+Andersonauthor=J.+M.+Chowauthor=C.+C.+Guevarraauthor=C.+Penderauthor=C.+Penarandaauthor=M.+Zavodovskayaauthor=J.+F.+Youngrenauthor=C.+E.+Berkman&title=Inhibition+of+IGF-1R+and+lipoxygenase+by+nordihydroguaiaretic+acid+%28NDGA%29+analogs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlecha%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DChow%26aufirst%3DJ.%2BM.%26aulast%3DGuevarra%26aufirst%3DC.%2BC.%26aulast%3DPender%26aufirst%3DC.%26aulast%3DPenaranda%26aufirst%3DC.%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DBerkman%26aufirst%3DC.%2BE.%26atitle%3DInhibition%2520of%2520IGF-1R%2520and%2520lipoxygenase%2520by%2520nordihydroguaiaretic%2520acid%2520%2528NDGA%2529%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D4026%26epage%3D4029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group">Zavodovskaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddux, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngren, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldfine, I. D.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">624</span><span class="NLM_x">–</span> <span class="NLM_lpage">635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2008&pages=624-635&author=M.+Zavodovskayaauthor=M.+J.+Campbellauthor=B.+A.+Madduxauthor=L.+Shiryauthor=G.+Allanauthor=L.+Hodgesauthor=P.+Kushnerauthor=J.+A.+Kernerauthor=J.+F.+Youngrenauthor=I.+D.+Goldfine&title=Nordihydroguaiaretic+acid+%28NDGA%29%2C+an+inhibitor+of+the+HER2+and+IGF-1+receptor+tyrosine+kinases%2C+blocks+the+growth+of+HER2-overexpressing+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZavodovskaya%26aufirst%3DM.%26aulast%3DCampbell%26aufirst%3DM.%2BJ.%26aulast%3DMaddux%26aufirst%3DB.%2BA.%26aulast%3DShiry%26aufirst%3DL.%26aulast%3DAllan%26aufirst%3DG.%26aulast%3DHodges%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%26aulast%3DKerner%26aufirst%3DJ.%2BA.%26aulast%3DYoungren%26aufirst%3DJ.%2BF.%26aulast%3DGoldfine%26aufirst%3DI.%2BD.%26atitle%3DNordihydroguaiaretic%2520acid%2520%2528NDGA%2529%252C%2520an%2520inhibitor%2520of%2520the%2520HER2%2520and%2520IGF-1%2520receptor%2520tyrosine%2520kinases%252C%2520blocks%2520the%2520growth%2520of%2520HER2-overexpressing%2520human%2520breast%2520cancer%2520cells%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2008%26volume%3D103%26spage%3D624%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group">Rowe, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozbay, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahta, R.</span><span> </span><span class="NLM_article-title">Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1900</span><span class="NLM_x">–</span> <span class="NLM_lpage">1908</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-08-0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18645000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1900-1908&author=D.+L.+Roweauthor=T.+Ozbayauthor=L.+M.+Benderauthor=R.+Nahta&title=Nordihydroguaiaretic+acid%2C+a+cytotoxic+insulin-like+growth+factor-I+receptor%2FHER2+inhibitor+in+trastuzumab-resistant+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer</span></div><div class="casAuthors">Rowe, Danica L.; Ozbay, Tuba; Bender, Laura M.; Nahta, Rita</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1900-1908</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The majority of patients with HER2-overexpressing metastatic breast cancer who initially respond to the HER2-targeted antibody trastuzumab show disease progression within 1 yr.  The identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab is crit. for improving outcome for this patient population.  In the current study, we show that the phenolic compd. nordihydroguaiaretic acid (NDGA) promoted cell death of trastuzumab-naive and trastuzumab-refractory HER2-overexpressing breast cancer cells.  NDGA induced DNA fragmentation, cleavage of poly(ADP-ribose) polymerase and caspase-3, and inhibition of colony formation.  In addn., NDGA inhibited insulin-like growth factor-I and HER2 signaling in trastuzumab-refractory cells, with reduced downstream phosphatidylinositol-3 kinase/Akt signaling.  Importantly, combination treatment with NDGA and trastuzumab suppressed proliferation and survival of trastuzumab-refractory cells to a greater degree than either agent alone, suggesting that NDGA increases the sensitivity of refractory cells to trastuzumab.  Derivs. of NDGA are currently in clin. trial for other solid tumors.  Our data strongly support further study of NDGA as a potential therapeutic against breast cancers that have progressed on trastuzumab. [Mol Cancer Ther 2008;7(7):1900-8].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5znLMBtcqLrVg90H21EOLACvtfcHk0lhnkUofC7cWRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtbs%253D&md5=5521436204e960f408f4f29700a1a780</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0012%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DD.%2BL.%26aulast%3DOzbay%26aufirst%3DT.%26aulast%3DBender%26aufirst%3DL.%2BM.%26aulast%3DNahta%26aufirst%3DR.%26atitle%3DNordihydroguaiaretic%2520acid%252C%2520a%2520cytotoxic%2520insulin-like%2520growth%2520factor-I%2520receptor%252FHER2%2520inhibitor%2520in%2520trastuzumab-resistant%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1900%26epage%3D1908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group">Carlberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dricu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blegen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjertman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zickert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoog, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">17453</span><span class="NLM_x">–</span> <span class="NLM_lpage">17462</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=17453-17462&author=M.+Carlbergauthor=A.+Dricuauthor=H.+Blegenauthor=M.+Wangauthor=M.+Hjertmanauthor=P.+Zickertauthor=A.+Hoogauthor=O.+Larsson&title=Mevalonic+acid+is+limiting+for+N-linked+glycosylation+and+translocation+of+the+insulin-like+growth+factor-1+receptor+to+the+cell+surface.+Evidence+for+a+new+link+between+3-hydroxy-3-methylglutaryl-coenzyme+a+reductase+and+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarlberg%26aufirst%3DM.%26aulast%3DDricu%26aufirst%3DA.%26aulast%3DBlegen%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHjertman%26aufirst%3DM.%26aulast%3DZickert%26aufirst%3DP.%26aulast%3DHoog%26aufirst%3DA.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DMevalonic%2520acid%2520is%2520limiting%2520for%2520N-linked%2520glycosylation%2520and%2520translocation%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520to%2520the%2520cell%2520surface.%2520Evidence%2520for%2520a%2520new%2520link%2520between%25203-hydroxy-3-methylglutaryl-coenzyme%2520a%2520reductase%2520and%2520cell%2520growth%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D17453%26epage%3D17462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group">Schenk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waechter, C. J.</span><span> </span><span class="NLM_article-title">The ins(ide) and out(side) of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum</span> <span class="citation_source-journal">Glycobiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">61R</span><span class="NLM_x">–</span> <span class="NLM_lpage">70R</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=61R-70R&author=B.+Schenkauthor=F.+Fernandezauthor=C.+J.+Waechter&title=The+ins%28ide%29+and+out%28side%29+of+dolichyl+phosphate+biosynthesis+and+recycling+in+the+endoplasmic+reticulum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchenk%26aufirst%3DB.%26aulast%3DFernandez%26aufirst%3DF.%26aulast%3DWaechter%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520ins%2528ide%2529%2520and%2520out%2528side%2529%2520of%2520dolichyl%2520phosphate%2520biosynthesis%2520and%2520recycling%2520in%2520the%2520endoplasmic%2520reticulum%26jtitle%3DGlycobiology%26date%3D2001%26volume%3D11%26spage%3D61R%26epage%3D70R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group">Dricu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjertman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malec, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blegen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wejde, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, O.</span><span> </span><span class="NLM_article-title">Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc</span> <span class="citation_source-journal">Glycobiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=625-633&author=A.+Dricuauthor=M.+Wangauthor=M.+Hjertmanauthor=M.+Malecauthor=H.+Blegenauthor=J.+Wejdeauthor=M.+Carlbergauthor=O.+Larsson&title=Mevalonate-regulated+mechanisms+in+cell+growth+control%3A+role+of+dolichyl+phosphate+in+expression+of+the+insulin-like+growth+factor-1+receptor+%28IGF-1R%29+in+comparison+to+Ras+prenylation+and+expression+of+c-myc"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDricu%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DHjertman%26aufirst%3DM.%26aulast%3DMalec%26aufirst%3DM.%26aulast%3DBlegen%26aufirst%3DH.%26aulast%3DWejde%26aufirst%3DJ.%26aulast%3DCarlberg%26aufirst%3DM.%26aulast%3DLarsson%26aufirst%3DO.%26atitle%3DMevalonate-regulated%2520mechanisms%2520in%2520cell%2520growth%2520control%253A%2520role%2520of%2520dolichyl%2520phosphate%2520in%2520expression%2520of%2520the%2520insulin-like%2520growth%2520factor-1%2520receptor%2520%2528IGF-1R%2529%2520in%2520comparison%2520to%2520Ras%2520prenylation%2520and%2520expression%2520of%2520c-myc%26jtitle%3DGlycobiology%26date%3D1997%26volume%3D7%26spage%3D625%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kataoka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohtsubo, Y.</span><span> </span><span class="NLM_article-title">Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner</span> <span class="citation_source-journal">J. Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2131%2Fjts.32.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17327694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFWltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=57-67&author=T.+Oguraauthor=Y.+Tanakaauthor=T.+Nakataauthor=T.+Namikawaauthor=H.+Kataokaauthor=Y.+Ohtsubo&title=Simvastatin+reduces+insulin-like+growth+factor-1+signaling+in+differentiating+C2C12+mouse+myoblast+cells+in+an+HMG-CoA+reductase+inhibition-independent+manner"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">Simvastatin reduced insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner</span></div><div class="casAuthors">Ogura, Takeharu; Tanaka, Yoshiyuki; Nakata, Tetsushi; Namikawa, Tomoko; Kataoka, Hirofumi; Ohtsubo, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">JTSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0388-1350</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicology</span>)
        </div><div class="casAbstract">Inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase occasionally cause myopathy characterized by weakness, pain, and elevated serum creatine phosphokinase (CK).  In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells.  Simvastatin decreased cell viability and CK activity, a marker of myogenesis, in differentiating cells in a dose-dependent manner.  Although the simvastatin-induced decrease in viability in proliferating and differentiated cells was completely abolished by mevalonate or geranylgeranyl-pyrophosphate, the inhibitory effects of simvastatin in differentiating cells were not abolished by mevalonate or isoprenoid derivs. of mevalonate.  Moreover, the sensitivity of differentiating cells to simvastatin regarding cell viability was about 7 times higher than that of proliferating cells.  After induction of differentiation in the presence of 1 μM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased.  Although mRNA expression of the IGF-1 receptor β-chain (IGF-1Rβ) did not change, protein level of the 200 kDa IGF-1Rβ precursor was significantly increased by simvastatin in a dose-dependent manner.  Mevalonate did not abolish the effect of simvastatin on IGF-1Rβ expression.  These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rβ in an HMG-CoA reductase inhibition-independent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBqO3pZyucrVg90H21EOLACvtfcHk0lhnkUofC7cWRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFWltLo%253D&md5=a999a54d44ce7f88ea1102a2ca7eac57</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.2131%2Fjts.32.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2131%252Fjts.32.57%26sid%3Dliteratum%253Aachs%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNakata%26aufirst%3DT.%26aulast%3DNamikawa%26aufirst%3DT.%26aulast%3DKataoka%26aufirst%3DH.%26aulast%3DOhtsubo%26aufirst%3DY.%26atitle%3DSimvastatin%2520reduces%2520insulin-like%2520growth%2520factor-1%2520signaling%2520in%2520differentiating%2520C2C12%2520mouse%2520myoblast%2520cells%2520in%2520an%2520HMG-CoA%2520reductase%2520inhibition-independent%2520manner%26jtitle%3DJ.%2520Toxicol.%2520Sci.%26date%3D2007%26volume%3D32%26spage%3D57%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><span class="NLM_contrib-group">Sekine, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuya, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, K.</span><span> </span><span class="NLM_article-title">Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">361</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=356-361&author=Y.+Sekineauthor=Y.+Furuyaauthor=M.+Nishiiauthor=H.+Koikeauthor=H.+Matsuiauthor=K.+Suzuki&title=Simvastatin+inhibits+the+proliferation+of+human+prostate+cancer+PC-3+cells+via+down-regulation+of+the+insulin-like+growth+factor+1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSekine%26aufirst%3DY.%26aulast%3DFuruya%26aufirst%3DY.%26aulast%3DNishii%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DMatsui%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26atitle%3DSimvastatin%2520inhibits%2520the%2520proliferation%2520of%2520human%2520prostate%2520cancer%2520PC-3%2520cells%2520via%2520down-regulation%2520of%2520the%2520insulin-like%2520growth%2520factor%25201%2520receptor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2008%26volume%3D372%26spage%3D356%26epage%3D361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref289"><div class="reference"><strong class="refLabel"><a href="#ref289" class="rightTabRefNumLink">289</a></strong><div class="NLM_citation" id="rightTab-cit289"><span><span class="NLM_contrib-group">Schmitt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gehrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multhoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, C.</span><span> </span><span class="NLM_article-title">Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy</span> <span class="citation_source-journal">J. Leukocyte Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1189%2Fjlb.0306167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16931602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=15-27&author=E.+Schmittauthor=M.+Gehrmannauthor=M.+Brunetauthor=G.+Multhoffauthor=C.+Garrido&title=Intracellular+and+extracellular+functions+of+heat+shock+proteins%3A+repercussions+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy</span></div><div class="casAuthors">Schmitt, E.; Gehrmann, M.; Brunet, M.; Multhoff, G.; Garrido, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-27</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Stress or heat shock proteins (HSPs) are the most conserved proteins present in both prokaryotes and eukaryotes.  Their expression is induced in response to a wide variety of physiol. and environmental insults.  These proteins play an essential role as mol. chaperones by assisting the correct folding of nascent and stress-accumulated misfolded proteins, and preventing their aggregation.  HSPs have a dual function depending on their intracellular or extracellular location.  Intracellular HSPs have a protective function.  They allow the cells to survive lethal conditions.  Various mechanisms have been proposed to account for the cytoprotective functions of HSPs.  Several HSPs have also been demonstrated to directly interact with various components of the tightly regulated programmed cell death machinery, upstream and downstream of the mitochondrial events.  On the other hand, extracellular located or membrane-bound HSPs mediate immunol. functions.  They can elicit an immune response modulated either by the adaptive or innate immune system.  This review will focus on HSP27, HSP70, and HSP90.  We will discuss the dual role of these HSPs, protective vs. immunogenic properties, making a special emphasis in their utility as targets in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5_zxS3nMjgLVg90H21EOLACvtfcHk0lgO-O4i5la55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVaisA%253D%253D&md5=df40eb312cf127833e028c7cc26c00b5</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1189%2Fjlb.0306167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.0306167%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DGehrmann%26aufirst%3DM.%26aulast%3DBrunet%26aufirst%3DM.%26aulast%3DMulthoff%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DC.%26atitle%3DIntracellular%2520and%2520extracellular%2520functions%2520of%2520heat%2520shock%2520proteins%253A%2520repercussions%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2007%26volume%3D81%26spage%3D15%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref290"><div class="reference"><strong class="refLabel"><a href="#ref290" class="rightTabRefNumLink">290</a></strong><div class="NLM_citation" id="rightTab-cit290"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S. L.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit290R"><div class="casContent"><span class="casTitleNuber">290</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lgO-O4i5la55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref291"><div class="reference"><strong class="refLabel"><a href="#ref291" class="rightTabRefNumLink">291</a></strong><div class="NLM_citation" id="rightTab-cit291"><span><span class="NLM_contrib-group">Saetrum, O. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P. H.</span><span> </span><span class="NLM_article-title">IGF-I is a matter of heart</span> <span class="citation_source-journal">Growth Horm. IGF Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.ghir.2005.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=15809013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A280%3ADC%252BD2M7ns1WjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=89-94&author=O.+O.+Saetrumauthor=P.+H.+Wang&title=IGF-I+is+a+matter+of+heart"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-I is a matter of heart</span></div><div class="casAuthors">Saetrum Opgaard Ole; Wang Ping H</div><div class="citationInfo"><span class="NLM_cas:title">Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-94</span>
        ISSN:<span class="NLM_cas:issn">1096-6374</span>.
    </div><div class="casAbstract">An intriguing relationship between IGF-I action and cardiac function has been noted for some time, but exactly how IGF-I modulates myocardial function remained obscure.  Recent research shed novel insight into potential mechanisms of IGF-I actions in cardiac muscle.  New discoveries help elucidate the role of IGF-I signaling in protecting cardiac muscle against injuries, and support potential therapeutic roles for IGF-I in cardiomyopathy.  Multiple actions of IGF-I has been described in cardiac muscle cells, including the well-documented anti-apoptosis effect and the newly emerged action on cardiac muscle regeneration.  Furthermore, interplay between heat shock protein and IGF-I receptor signaling has been identified and this new paradigm might be involved in the development of diabetic cardiomyopathy.  This article reviews recent research findings and outlines potential therapeutic implications of IGF-I in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0dmtylvE3VkwlCcfExbvbfW6udTcc2ebuxCE9FtbBtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7ns1WjsA%253D%253D&md5=dd48a632ec0d2d6fbd76c36c1869ceb5</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.1016%2Fj.ghir.2005.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ghir.2005.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DSaetrum%26aufirst%3DO.%2BO.%26aulast%3DWang%26aufirst%3DP.%2BH.%26atitle%3DIGF-I%2520is%2520a%2520matter%2520of%2520heart%26jtitle%3DGrowth%2520Horm.%2520IGF%2520Res.%26date%3D2005%26volume%3D15%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref292"><div class="reference"><strong class="refLabel"><a href="#ref292" class="rightTabRefNumLink">292</a></strong><div class="NLM_citation" id="rightTab-cit292"><span><span class="NLM_contrib-group">Lang, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glockzin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlke, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlitt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geissler, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoeltzing, O.</span><span> </span><span class="NLM_article-title">Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">6459</span><span class="NLM_x">–</span> <span class="NLM_lpage">6468</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1078-0432.CCR-07-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17975158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CgtbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=6459-6468&author=S.+A.+Langauthor=C.+Moserauthor=A.+Gaumannauthor=D.+Kleinauthor=G.+Glockzinauthor=F.+C.+Poppauthor=M.+H.+Dahlkeauthor=P.+Pisoauthor=H.+J.+Schlittauthor=E.+K.+Geisslerauthor=O.+Stoeltzing&title=Targeting+heat+shock+protein+90+in+pancreatic+cancer+impairs+insulin-like+growth+factor-I+receptor+signaling%2C+disrupts+an+interleukin-6%2Fsignal-transducer+and+activator+of+transcription+3%2Fhypoxia-inducible+factor-1alpha+autocrine+loop%2C+and+reduces+orthotopic+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/Signal-Transducer and Activator of Transcription 3/Hypoxia-Inducible Factor-1α Autocrine Loop, and Reduces Orthotopic Tumor Growth</span></div><div class="casAuthors">Lang, Sven A.; Moser, Christian; Gaumann, Andreas; Klein, Dagmar; Glockzin, Gabriel; Popp, Felix C.; Dahlke, Marc H.; Piso, Pompiliu; Schlitt, Hans J.; Geissler, Edward K.; Stoeltzing, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6459-6468</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inhibitors of heat-shock protein 90 (Hsp90) may interfere with oncogenic signaling pathways, including Erk, Akt, and hypoxia-inducible factor-1α (HIF-1α).  Because insulin-like growth factor-I receptor (IGF-IR) and signal transducer and activator of transcription 3 (STAT3) signaling pathways are implicated in the progression of pancreatic cancer, we hypothesized that blocking Hsp90 with geldanamycin derivates [17-allylamino-geldanamycin (17-AAG), 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG)] would impair IGF-I- and interleukin-6-mediated signaling and thus reduce pancreatic tumor growth and angiogenesis in vivo.  Exptl. Design: Human pancreatic cancer cells (HPAF-II, L3.6pl) were used for expts.  Changes in signaling pathway activation upon Hsp90 blockade were investigated by Western blotting.  Effects of Hsp90 inhibition (17-AAG) on vascular endothelial growth factor were detd. by ELISA and real-time PCR.  Effects of 17-DMAG (25 mg/kg; thrice a week; i.p.) on tumor growth and vascularization were investigated in a s.c. xenograft model and in an orthotopic model of pancreatic cancer.  Results: 17-AAG inhibited IGF-IR signaling by down-regulating IGF-IRβ and directly impairing IGF-IR phosphorylation.  Hypoxia- and IL-6-mediated activation of HIF-1α or STAT3/STAT5 were substantially inhibited by 17-AAG.  Moreover, a novel IL-6/STAT3/HIF-1α autocrine loop was effectively disrupted by Hsp90 blockade.  In vivo, 17-DMAG significantly reduced s.c. tumor growth and diminished STAT3 phosphorylation and IGF-IRβ expression in tumor tissues.  In an orthotopic model, pancreatic tumor growth and vascularization were both significantly reduced upon Hsp90 inhibition, as reflected by final tumor wts. and CD31 staining, resp.  Conclusions: Blocking Hsp90 disrupts IGF-I and IL-6-induced proangiogenic signaling cascades by targeting IGF-IR and STAT3 in pancreatic cancer, leading to significant growth-inhibitory effects.  Therefore, we suggest that Hsp90 inhibitors could prove to be valuable in the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJOAQLw4Ir7Vg90H21EOLACvtfcHk0liP9qDkC-D6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CgtbzE&md5=0504e4a34116c70b17dd9e0dd03c8d2b</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1104%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DMoser%26aufirst%3DC.%26aulast%3DGaumann%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DD.%26aulast%3DGlockzin%26aufirst%3DG.%26aulast%3DPopp%26aufirst%3DF.%2BC.%26aulast%3DDahlke%26aufirst%3DM.%2BH.%26aulast%3DPiso%26aufirst%3DP.%26aulast%3DSchlitt%26aufirst%3DH.%2BJ.%26aulast%3DGeissler%26aufirst%3DE.%2BK.%26aulast%3DStoeltzing%26aufirst%3DO.%26atitle%3DTargeting%2520heat%2520shock%2520protein%252090%2520in%2520pancreatic%2520cancer%2520impairs%2520insulin-like%2520growth%2520factor-I%2520receptor%2520signaling%252C%2520disrupts%2520an%2520interleukin-6%252Fsignal-transducer%2520and%2520activator%2520of%2520transcription%25203%252Fhypoxia-inducible%2520factor-1alpha%2520autocrine%2520loop%252C%2520and%2520reduces%2520orthotopic%2520tumor%2520growth%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D6459%26epage%3D6468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref293"><div class="reference"><strong class="refLabel"><a href="#ref293" class="rightTabRefNumLink">293</a></strong><div class="NLM_citation" id="rightTab-cit293"><span><span class="NLM_contrib-group">Boehm, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayr, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortier, L. A.</span><span> </span><span class="NLM_article-title">Hsp90 mediates insulin-like growth factor 1 and interleukin-1beta signaling in an age-dependent manner in equine articular chondrocytes</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2343</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1002%2Fart.22664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=17599753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref293/cit293&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFSgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=2335-2343&author=A.+K.+Boehmauthor=M.+Sethauthor=K.+G.+Mayrauthor=L.+A.+Fortier&title=Hsp90+mediates+insulin-like+growth+factor+1+and+interleukin-1beta+signaling+in+an+age-dependent+manner+in+equine+articular+chondrocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit293R"><div class="casContent"><span class="casTitleNuber">293</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 mediates insulin-like growth factor 1 and interleukin-1β signaling in an age-dependent manner in equine articular chondrocytes</span></div><div class="casAuthors">Boehm, Amber K.; Seth, Mayank; Mayr, Karen G.; Fortier, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2335-2343</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Many metabolic processes in chondrocytes thought to contribute to age-related changes in the extracellular matrix are influenced by known roles of Hsp90.  Age-related decreases in the level of Hsp90 have been documented in numerous cell types and could contribute to cartilage degeneration.  The aim of this study was to investigate the roles of age and Hsp90 in insulin-like growth factor 1 (IGF-1) and interleukin-1β (IL-1β) signaling in chondrocytes.  Methods: Levels of Hsp90 mRNA (mRNA) and protein, with respect to age, were detd. by quant. real-time polymerase chain reaction (PCR) and Western blot anal., resp.  The Hsp90 inhibitor geldanamycin (50 nM, 100 nM, or 500 nM) was used to assess age-related responses to Hsp90 with concurrent IGF-1 or IL-1β stimulation of chondrocytes.  Quant. real-time PCR was used to measure COL2A1 and matrix metalloproteinase 13 (MMP13) gene expression; Western blot anal. was performed to det. the phosphorylation status of p42/44 and Akt/protein kinase B.  Results: The effects of Hsp90 inhibition with geldanamycin were concn. dependent.  Inhibition of Hsp90 with 100 nM or 500 nM geldanamycin blocked IGF-1-induced cell proliferation, Akt and p42/44 activation, and COL2A1 expression.  Basal and IL-1β-induced up-regulation of MMP13 mRNA was blocked by all concns. of geldanamycin tested.  Gain-of-function assays with Hsp90 resulted in increased expression of MMP13 mRNA.  Conclusion: These results suggest that Hsp90 is involved in opposing signaling pathways of cartilage homeostasis, and that catabolic responses are more sensitive to Hsp90 inhibition than are anabolic responses.  Further studies are needed to det. the role of Hsp90 inhibition in osteoarthritis in order to assess its potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozztUun13iBLVg90H21EOLACvtfcHk0liP9qDkC-D6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFSgtbk%253D&md5=776b22b27ef0cfa0215aa5c878087b47</span></div><a href="/servlet/linkout?suffix=cit293&amp;dbid=16384&amp;doi=10.1002%2Fart.22664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.22664%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DA.%2BK.%26aulast%3DSeth%26aufirst%3DM.%26aulast%3DMayr%26aufirst%3DK.%2BG.%26aulast%3DFortier%26aufirst%3DL.%2BA.%26atitle%3DHsp90%2520mediates%2520insulin-like%2520growth%2520factor%25201%2520and%2520interleukin-1beta%2520signaling%2520in%2520an%2520age-dependent%2520manner%2520in%2520equine%2520articular%2520chondrocytes%26jtitle%3DArthritis%2520Rheum.%26date%3D2007%26volume%3D56%26spage%3D2335%26epage%3D2343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref294"><div class="reference"><strong class="refLabel"><a href="#ref294" class="rightTabRefNumLink">294</a></strong><div class="NLM_citation" id="rightTab-cit294"><span><span class="NLM_contrib-group">Fattori, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squarcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartoli, S.</span><span> </span><span class="NLM_article-title">Fragment-based approach to drug lead discovery: overview and advances in various techniques</span> <span class="citation_source-journal">Drugs R&D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2165%2F00126839-200809040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18588353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref294/cit294&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=217-227&author=D.+Fattoriauthor=A.+Squarciaauthor=S.+Bartoli&title=Fragment-based+approach+to+drug+lead+discovery%3A+overview+and+advances+in+various+techniques"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit294R"><div class="casContent"><span class="casTitleNuber">294</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based approach to drug lead discovery: overview and advances in various techniques</span></div><div class="casAuthors">Fattori, Daniela; Squarcia, Antonella; Bartoli, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chem., has produced new tools for the discovery of biol. active mols.  In the past decade, fragment-based drug discovery has emerged as a more rational and focused approach that concs. on the quality, rather than the quantity, of hits and leads.  The principles behind this strategy are different from those that represented the basis of conventional HTS.  The starting point of this approach is always a small chem. entity (typically MW 150-200), a fragment, with low affinity for the selected target.  Fragments should satisfy key features such as diversity, reduced structural complexity, aq. soly. and availability.  Because of their small size, they occupy a smaller region of chem. space if compared with classical HTS compds.; hence, fragment libraries provide a good diversity with a relatively low no. of compds.  Classical biochem. assays are often not suitable to detect the low binding affinities involved, so some well known biophys. techniques, such as NMR and x-ray, have been opportunely modified in order to render them able to perform the task.  When selecting fragments suitable for subsequent optimization, a useful parameter has been introduced, the ligand efficiency, which is defined as the free energy of binding divided by the non-hydrogen atom count.  Once selected, a fragment must undergo a heavy elaboration to improve binding affinity, at the same time acquiring drug-like properties.  There are two main ways to go on at this point.  The most common one is the so-called 'fragment evolution', consisting of a stepwise and systematic addn. of chem. functionalities to the starting fragment core, together with a continuous feedback for pharmacol. and physicochem. properties.  The second one, less common but with great potential, is 'fragment linking': when two or more fragment hits are found to bind in adjacent regions of the target protein, they can be linked through appropriate spacers to rapidly produce a single mol. with much higher binding affinity.  Two representative case histories are described: Abbott's ABT 518, an MMP (matrix metalloproteinase) inhibitor, and Eli-Lilly's LY-517717, an inhibitor of factor Xa serine protease.  In addn., a list of mols. claimed to be derived from fragment approach and currently undergoing clin. trials is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobrVRjDoPS8LVg90H21EOLACvtfcHk0liP9qDkC-D6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt7w%253D&md5=db1cfcf0f9320e95c5dcf4a713c2c2e1</span></div><a href="/servlet/linkout?suffix=cit294&amp;dbid=16384&amp;doi=10.2165%2F00126839-200809040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00126839-200809040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DFattori%26aufirst%3DD.%26aulast%3DSquarcia%26aufirst%3DA.%26aulast%3DBartoli%26aufirst%3DS.%26atitle%3DFragment-based%2520approach%2520to%2520drug%2520lead%2520discovery%253A%2520overview%2520and%2520advances%2520in%2520various%2520techniques%26jtitle%3DDrugs%2520R%2526D%26date%3D2008%26volume%3D9%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref295"><div class="reference"><strong class="refLabel"><a href="#ref295" class="rightTabRefNumLink">295</a></strong><div class="NLM_citation" id="rightTab-cit295"><span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Structure-based design of molecular cancer therapeutics</span> <span class="citation_source-journal">Trends Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=315-328&issue=5&author=R.+L.+van+Montfortauthor=P.+Workman&title=Structure-based+design+of+molecular+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit295&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DStructure-based%2520design%2520of%2520molecular%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Biotechnol.%26date%3D2009%26volume%3D27%26issue%3D5%26spage%3D315%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref296"><div class="reference"><strong class="refLabel"><a href="#ref296" class="rightTabRefNumLink">296</a></strong><div class="NLM_citation" id="rightTab-cit296"><span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">Recent developments in fragment-based drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3661</span><span class="NLM_x">–</span> <span class="NLM_lpage">3680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8000373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3661-3680&author=M.+Congreveauthor=G.+Chessariauthor=D.+Tisiauthor=A.+J.+Woodhead&title=Recent+developments+in+fragment-based+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit296&amp;dbid=16384&amp;doi=10.1021%2Fjm8000373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8000373%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DRecent%2520developments%2520in%2520fragment-based%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3661%26epage%3D3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref297"><div class="reference"><strong class="refLabel"><a href="#ref297" class="rightTabRefNumLink">297</a></strong><div class="NLM_citation" id="rightTab-cit297"><span><span class="NLM_contrib-group">Ghoreschi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Shea, J. J.</span><span> </span><span class="NLM_article-title">Selectivity and therapeutic inhibition of kinases: To be or not to be?</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">356</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1038%2Fni.1701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19295632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref297/cit297&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=356-360&author=K.+Ghoreschiauthor=A.+Laurenceauthor=J.+J.+O%27Shea&title=Selectivity+and+therapeutic+inhibition+of+kinases%3A+To+be+or+not+to+be%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit297R"><div class="casContent"><span class="casTitleNuber">297</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity and therapeutic inhibition of kinases: to be or not to be?</span></div><div class="casAuthors">Ghoreschi, Kamran; Laurence, Arian; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases, which serve crit. functions in signaling pathways in all cells, are popular therapeutic targets.  At present, eight kinase inhibitors have been approved in the United States, each of which shows nanomolar potency.  Although the initial goal was to generate inhibitors with a high degree of selectivity, recent experience has revealed that many of these approved compds. target more than one kinase.  Surprisingly, this promiscuity is less problematic than one would have imagined; indeed, it opens new therapeutic opportunities.  In this Perspective, we discuss the present status of Janus kinase inhibitors-a new class of immunosuppressive drugs-and the advantages and disadvantages of selectively inhibiting this class of kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU0w6t4jgqirVg90H21EOLACvtfcHk0ljgLrzr7dj8rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtlyms78%253D&md5=64dd47e897181d00e5dce6be3bc5db6e</span></div><a href="/servlet/linkout?suffix=cit297&amp;dbid=16384&amp;doi=10.1038%2Fni.1701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.1701%26sid%3Dliteratum%253Aachs%26aulast%3DGhoreschi%26aufirst%3DK.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ.%26atitle%3DSelectivity%2520and%2520therapeutic%2520inhibition%2520of%2520kinases%253A%2520To%2520be%2520or%2520not%2520to%2520be%253F%26jtitle%3DNat.%2520Immunol.%26date%3D2009%26volume%3D10%26spage%3D356%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref298"><div class="reference"><strong class="refLabel"><a href="#ref298" class="rightTabRefNumLink">298</a></strong><div class="NLM_citation" id="rightTab-cit298"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balbas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bleickardt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicaise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=485-493&author=N.+P.+Shahauthor=C.+Kasapauthor=C.+Weierauthor=M.+Balbasauthor=J.+M.+Nicollauthor=E.+Bleickardtauthor=C.+Nicaiseauthor=C.+L.+Sawyers&title=Transient+potent+BCR-ABL+inhibition+is+sufficient+to+commit+chronic+myeloid+leukemia+cells+irreversibly+to+apoptosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit298&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DWeier%26aufirst%3DC.%26aulast%3DBalbas%26aufirst%3DM.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DBleickardt%26aufirst%3DE.%26aulast%3DNicaise%26aufirst%3DC.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DTransient%2520potent%2520BCR-ABL%2520inhibition%2520is%2520sufficient%2520to%2520commit%2520chronic%2520myeloid%2520leukemia%2520cells%2520irreversibly%2520to%2520apoptosis%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref299"><div class="reference"><strong class="refLabel"><a href="#ref299" class="rightTabRefNumLink">299</a></strong><div class="NLM_citation" id="rightTab-cit299"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">Customizing the targeting of IGF-1 receptor</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2217%2F14796694.5.1.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=19243297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref299/cit299&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=43-50&author=R.+Baserga&title=Customizing+the+targeting+of+IGF-1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit299R"><div class="casContent"><span class="casTitleNuber">299</span><div class="casTitle"><span class="NLM_cas:atitle">Customizing the targeting of IGF-1 receptor</span></div><div class="casAuthors">Baserga, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-50</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiol. concns.  It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clin. trials.  Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors.  This review focuses on the optimization of IGF-IR targeting in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2U7de1wk-FrVg90H21EOLACvtfcHk0ljgLrzr7dj8rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyltLw%253D&md5=a976e08ec9ba87222cd55d8c5f8c4ada</span></div><a href="/servlet/linkout?suffix=cit299&amp;dbid=16384&amp;doi=10.2217%2F14796694.5.1.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14796694.5.1.43%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DCustomizing%2520the%2520targeting%2520of%2520IGF-1%2520receptor%26jtitle%3DFuture%2520Oncol.%26date%3D2009%26volume%3D5%26spage%3D43%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref300"><div class="reference"><strong class="refLabel"><a href="#ref300" class="rightTabRefNumLink">300</a></strong><div class="NLM_citation" id="rightTab-cit300"><span><span class="NLM_contrib-group">Baserga, R.</span><span> </span><span class="NLM_article-title">The insulin receptor substrate-1: a biomarker for cancer?</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">315</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">732</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1016%2Fj.yexcr.2008.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref300/cit300&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18851963" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2008&pages=727-732&author=R.+Baserga&title=The+insulin+receptor+substrate-1%3A+a+biomarker+for+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit300&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2008.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2008.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DBaserga%26aufirst%3DR.%26atitle%3DThe%2520insulin%2520receptor%2520substrate-1%253A%2520a%2520biomarker%2520for%2520cancer%253F%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2008%26volume%3D315%26spage%3D727%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref301"><div class="reference"><strong class="refLabel"><a href="#ref301" class="rightTabRefNumLink">301</a></strong><div class="NLM_citation" id="rightTab-cit301"><span><span class="NLM_contrib-group">Hewish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, D.</span><span> </span><span class="NLM_article-title">Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=54-72&author=M.+Hewishauthor=I.+Chauauthor=D.+Cunningham&title=Insulin-like+growth+factor+1+receptor+targeted+therapeutics%3A+novel+compounds+and+novel+treatment+strategies+for+cancer+medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit301&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHewish%26aufirst%3DM.%26aulast%3DChau%26aufirst%3DI.%26aulast%3DCunningham%26aufirst%3DD.%26atitle%3DInsulin-like%2520growth%2520factor%25201%2520receptor%2520targeted%2520therapeutics%253A%2520novel%2520compounds%2520and%2520novel%2520treatment%2520strategies%2520for%2520cancer%2520medicine%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2009%26volume%3D4%26spage%3D54%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref302"><div class="reference"><strong class="refLabel"><a href="#ref302" class="rightTabRefNumLink">302</a></strong><div class="NLM_citation" id="rightTab-cit302"><span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toretsky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helman, L. J.</span><span> </span><span class="NLM_article-title">The role of IGF-1R in pediatric malignancies</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=83-91&author=S.+Y.+Kimauthor=J.+A.+Toretskyauthor=D.+Scherauthor=L.+J.+Helman&title=The+role+of+IGF-1R+in+pediatric+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit302&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DToretsky%26aufirst%3DJ.%2BA.%26aulast%3DScher%26aufirst%3DD.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DThe%2520role%2520of%2520IGF-1R%2520in%2520pediatric%2520malignancies%26jtitle%3DOncologist%26date%3D2009%26volume%3D14%26spage%3D83%26epage%3D91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref303"><div class="reference"><strong class="refLabel"><a href="#ref303" class="rightTabRefNumLink">303</a></strong><div class="NLM_citation" id="rightTab-cit303"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasap, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinilla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clary, D. O.</span><span> </span><span class="NLM_article-title">Targeting drug-resistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=474&author=N.+P.+Shahauthor=C.+Kasapauthor=R.+Paquetteauthor=J.+Cortesauthor=J.+Pinillaauthor=M.+Talpazauthor=L.+A.+Buiauthor=D.+O.+Clary&title=Targeting+drug-resistant+CML+and+Ph%2B-ALL+with+the+spectrum+selective+protein+kinase+inhibitor+XL228"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit303&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DKasap%26aufirst%3DC.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DPinilla%26aufirst%3DJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DBui%26aufirst%3DL.%2BA.%26aulast%3DClary%26aufirst%3DD.%2BO.%26atitle%3DTargeting%2520drug-resistant%2520CML%2520and%2520Ph%252B-ALL%2520with%2520the%2520spectrum%2520selective%2520protein%2520kinase%2520inhibitor%2520XL228%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref304"><div class="reference"><strong class="refLabel"><a href="#ref304" class="rightTabRefNumLink">304</a></strong><div class="NLM_citation" id="rightTab-cit304"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palanki, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref304/cit304&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=M.+S.+Palankiauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit304R"><div class="casContent"><span class="casTitleNuber">304</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lj1nAbRemXT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit304&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DPalanki%26aufirst%3DM.%2BS.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref305"><div class="reference"><strong class="refLabel"><a href="#ref305" class="rightTabRefNumLink">305</a></strong><div class="NLM_citation" id="rightTab-cit305"><span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, R. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2575</span><span class="NLM_x">–</span> <span class="NLM_lpage">2588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=16&amp;doi=10.1021%2Fjm9002395&amp;key=10.1158%2F1535-7163.MCT-08-0265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=8&amp;doi=10.1021%2Fjm9002395&amp;key=18790742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref305/cit305&amp;dbid=32&amp;doi=10.1021%2Fjm9002395&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=2575-2588&author=J.+Rodonauthor=V.+DeSantosauthor=R.+J.+Ferryauthor=R.+Kurzrock&title=Early+drug+development+of+inhibitors+of+the+insulin-like+growth+factor-I+receptor+pathway%3A+lessons+from+the+first+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit305R"><div class="casContent"><span class="casTitleNuber">305</span><div class="casTitle"><span class="NLM_cas:atitle">Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials</span></div><div class="casAuthors">Rodon, Jordi; De Santos, Victoria; Ferry, Robert Jean, Jr.; Kurzrock, Razelle</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2575-2588</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The insulin-like growth factor-I receptor (IGF-IR) was first cloned in 1986.  Since then, intense work has defined classic phosphorelays activated via the IGF-IR, which regulate cell proliferation, apoptosis, motility, and fate.  The understanding of the roles of hormones in cancer and the growth hormone-IGF-IGF-binding protein axis specifically has yield to a second wave of development: the design of specific inhibitors that interrupt the signaling assocd. with this axis.  The ability to manipulate these pathways holds not only significant therapeutic implications but also increase the chance of deeper insight about the role of the axis in carcinogenesis and metastasis.  Nowadays, >25 mols. with the same goal are at different stages of development.  Here, we review the clin. and preclin. experience with the two most-investigated strategies, tyrosine kinase inhibitors and monoclonal antibodies, and the advantages and disadvantages of each strategy, as well as other alternatives and possible drug combinations.  We also review the biomarkers explored in the first clin. trials, the strategies that have been explored thus far, and the clin. trials that are going to explore their role in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDZwaTmwi46rVg90H21EOLACvtfcHk0lgsKo2DAmpcKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSms7jJ&md5=d37e37d3752231ef2c152110c1e85a66</span></div><a href="/servlet/linkout?suffix=cit305&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0265%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDeSantos%26aufirst%3DV.%26aulast%3DFerry%26aufirst%3DR.%2BJ.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DEarly%2520drug%2520development%2520of%2520inhibitors%2520of%2520the%2520insulin-like%2520growth%2520factor-I%2520receptor%2520pathway%253A%2520lessons%2520from%2520the%2520first%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D2575%26epage%3D2588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm9002395&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm9002395%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm9002395" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aae6fbf4322d8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
